<SEC-DOCUMENT>0001628280-21-004654.txt : 20210312
<SEC-HEADER>0001628280-21-004654.hdr.sgml : 20210312
<ACCEPTANCE-DATETIME>20210312171756
ACCESSION NUMBER:		0001628280-21-004654
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210312
DATE AS OF CHANGE:		20210312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		21738529

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cpix-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd,d:510f8c4dc65a401f9689088d17e3694c--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cpix="http://www.cumberlandpharma.com/20201231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8yLTEtMS0xLTA_69547708-367b-4ff4-992b-9247e93016fb">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8zLTEtMS0xLTA_ef0e70a6-8ffa-467a-88a1-8fc8a757d3f6">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF80LTEtMS0xLTA_b02d3f56-ed01-4b35-83f7-b1bd0be016cf">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF82LTEtMS0xLTA_dcf25958-85d7-488f-827b-fc88ae7c5b99">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF84LTEtMS0xLTA_1730597d-fff0-45aa-992f-706ab538e6c7">12/31/2020</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF85LTEtMS0xLTA_077fcbed-fc3d-44f4-92cd-3687f853faf9">2020</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMC0xLTEtMS0w_bb82d37d-f41a-46d5-8e40-e80526c3ec43">FY</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMS0xLTEtMS0w_e651c709-12c3-4863-8d4b-9dd8eb3b99d2">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMi0xLTEtMS0w_71572181-1e61-4aad-93c0-a49309e6002b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMy0xLTEtMS0w_822374ed-7e65-4e11-8064-389953b2800a">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNC0xLTEtMS0w_0fec0eb9-2687-42ff-beb3-f82fe93c4b61">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNi0xLTEtMS0w_abe40342-ea1a-4520-9dfb-e811505afe5f">No</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNy0xLTEtMS0w_2439d961-036b-47c3-b604-4472fed8d3fc">No</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xOC0xLTEtMS0w_06d54ad8-7a20-49e4-b903-f1898f572f9b">Yes</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xOS0xLTEtMS0w_e39d232a-48ec-48a3-bae4-108adf26af4c">Yes</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGV4dHJlZ2lvbjpjNWMwYWI5MDQ5YjI0N2FhYTkwNTBmOTllNTFlNzk4NF80NA_2433f524-40c3-4a32-a1a8-b89602cbed44">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:FinancialConsiderationPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgzNDA_72c8f2e7-a907-47b1-a9cd-8d46f8f9cdb2">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i642116ade18340e99aeefa9e8eaa275e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1afd74e563c247539861253093f00144_I20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4a22c116b6e942bda79f40e91a62534b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d81019dbdfb48579a22e9fb65668453_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6986b113ec4d0998a4d87c9c01c9aa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31230eb23bc348229dd4efb4f08f9b53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67a4367a56c4e6c856f116279449f1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2954ae7b3524c008526b384cd923ae9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03694dc14e8c4bbb93ae06dc4dea9967_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd305c2cee64a88a8f6930ec95cb5c5_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9902b1e772a4972957eb8992b200e37_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61e32dba4b0475d984dfadd6379821d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579acb9f96de41ffba78cca469abf593_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae03170bbe484f15ab0b60e6dbda8bc7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e782a52b4d44329375848c274ec5d1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff3ff90eb944c0dbe11b04ce7b0d7ed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfc004e938140c29692f598f52b5277_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if736d13a5981486b9c4be73116b8d9b3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bb3d0fc63f46a38f73f8e24b9222eb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edfe4448c474b6eaa1f9546a60f6baf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7c45e9e811413cba25b0b270ac8d66_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906c0455495f493dadd51dbdcf6ce33f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b48d6a645042b68c812153d89d701d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25561754ff6f4e2ea07d5a93bb7fc0b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i113acbcb4c7a41f9b06366a217ff041f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dc597efa194fb59a0fb601045119c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72fd6471f1da4426a87a1886db0ae152_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1d88acf1394d319d163e4143882af2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida79e60e9d42460c84903d34b3fd5625_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d15f9eb345d4d64aa801993173c575d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82fdc18596fd4b20999ba80f5d41bd51_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if2a2c29316304015acd330ba1069f0e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3d6f67ab017747e488ce81fe0f2d992e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563ad4ae0b474a93a68d18998539da56_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523a0c1898d94b0d968011937afb9b4c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac26c9d624a4950b3d6b38c45e4b597_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9d8b7bd9c444fd81c867a1f021713b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858b3a2a4199408587b99fe9de451ae9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713b05d7f5bc4937aed96e19605bbd69_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffd3ca73a074170bbcb58ba566f9585_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f0edc4849df4c21910d604bb57d2325_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fc1a3fb3064db1baf227cdf6d18b18_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf84cc8aa13a4c4e9c2848f65593a987_I20181112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3805a80f910745b8ba5901401f43502b_D20181112-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-12</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d4426d3227403fabbfb9d27a6e529f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if526d4a08c254080a221720150e6e894_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9690979d455048e786882dc7d1715d78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25bf3ecd92884fba947bb8fde5284b63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9375d96a8aab42a988665839bfc0db67_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8106a20e864d28bd6d0ef776efb119_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1a0444604f4249b8af8cff8f67e09d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93dbc3e2bb445b79575c990976d088c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f00b78b135497898e49546c1d2f4ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4269e0d435e4dd8af6548e04ee94f28_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932871e9df8745c583acfe2f18eb6df4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cdf7521dab4b328c6824333676f5fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d41290b523433fa5c1c7846ba6fb17_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3738fecb3eaa4c198acc94352adfea94_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0d302dded484788ae6589a0340b9b88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4fb6667544f4f559f12205fcebec85c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf76f0a2b0ed40d8b2b44aebcfae79d7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128821f68ebe4cd097ed7ff95840f048_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff264f92669d449e8bcb64c3d9b88d42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011d9382fa6c4d49bd3e83103b01e17e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21522c7cbff7479c950097c298729560_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379abd9813bb4e449cf04367935a4368_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie836a99c6e9a4ea5b8b4e362f27f61b0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4953695015dc4f6192628e3e06840b93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd71c23cf60e4a89ace2b16705e73a6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05552adfe6bd4b2c9364a3fb0e38115f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11727dca580e45938d1bd2a30fa3b13c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425aa7efcc3d419489434711697897b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a7f8d16fd34d9298c695a5fc27fb15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9075a3fe1d64ddf8f34dc57c4454544_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900aa4346676422fb1898c7d882f8fcb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6fd7af49de249ecb292d30a08cbd4de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b9642648b4446484395a251aeb73e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567a47d8201140e0a6ab9fd8bf24c58c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57a23f2f6ce40868fabc79000f9acc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22150fcc5f674069a6bb7c015e170408_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f7778a12b5457fa1f6664420a75437_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b440537b5d417d8d302cd1bd73dd3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d077df83004e9b9dca31085e2c7dce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b3055ed198427f821e78280855ef22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56325a56faf46d4b05761c86d36d031_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b299fde4ec4bd2b6d62fffe5447170_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19f08d91a2640dba99067b8dbe8c464_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1528e64c010641a68be52125a75832b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff6b1dbcf3c4c8e92b1cdefc3aa7b52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3be021e818547a795f36d1377c9ea4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4713d678174ead99f243c92ec45d16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie005a45bb43941a58835f78c97251e65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0173213b69184c199e2c3ab68e949553_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6724e49269cd4c95a99a8ca277ef19c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e037b70471e490a9f3bd1f848149384_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d622e0a01004a5d9914569d0d5756ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib378884a762c4067ae1b484eca7cbcce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e5a2f67fb448cdac235b8ab69c2e11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f775544b07435aad50e8010203ab2f_I20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id58da084fd084c92baff6faaebe07bce_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd51265d21714c30b785b162b5e9c52b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b442a5827e64fa49e02548ad3d45a60_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ff7e499acb4275a4320c03274a56de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2cf763ce1343ebbb8dcb8ca36ad991_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a65e98565f481a88b31680ce8e66da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4867bf18746745d08a2eb39206ceee78_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-08-09</xbrli:startDate><xbrli:endDate>2009-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de7636956284bbeb962a907482bc027_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367d84ececcc49f0bfbb68634cd626f4_I20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec44f4c9886f4156832890687e6122d3_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-01</xbrli:startDate><xbrli:endDate>2014-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-27</xbrli:startDate><xbrli:endDate>2019-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc74587ea6e4b529a03805961c2bd04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445b6f509473418eb2c8a5237c3bfefd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4313b14cb3a4d8f99fd5c8f9db1107d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6847c5f2fcc44c1580a9549a452c791d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9043384394c24481b001b6c237c321ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe6d71cfdbe4024a8518ad7bd357ab3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac92a1fad73b426db25cdc60a91363c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361f3e2163a24e0599504b3aaa2131ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8201ead17c4f4c9fab01031ebfa723_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c2aba4cd314aabbe1faee299611416_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8a2a14899b4ec1a64b4b7a8ed1abda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236e3d373ccf4b22afd608a82ed75788_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9167ce1de284dc593328aff87ed8bcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5562813807040e1a0e26ee6bf76c4b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4051af70f9c4b60b1d310d19369cccb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db379efa0bc4679a685f33d31ca995f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1831e9cb7e4498bb1e5fac039825fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>cpix:plan</xbrli:measure></xbrli:unit><xbrli:context id="ia24d0d8e81234fb38c59ac70536998b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d13571f70a74cbea8cc3c2e111cf699_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b054a3338614ef4a60b55fb3e0f0983_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39407155449e4cd7b91cf9a0ea955c04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf5204bce4e4cf08f3110023af611f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1083c517cc425bada8b162234c0222_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2761c3aa61481e9ce768736d55283b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if048f68b276d4efaaa2f710dc15c58ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75bc44001e5247da87aaaa6fe49004cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436eb42902d244599c0bc8375f08440b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c8902a15624a57913ab5e23c482d70_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d39a8afd7a4f5485dc0d057ab6de51_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfd07629518431490765805546dcdd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf145f8d53f142ea820e0fca8cf49972_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6739e7f70b46089b224643faa80db4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c4af7e297f4bdb9156fe284ac15e52_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622af044beba4bd281a739b794311672_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6d1b5895064141892cc9e1fa697991_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6a5312e3d74395bd3c1db13869d99c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7aeecc41504677b76f853c9fa184a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbd7aad4f8a44158c186bd69006fa50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b530f82b6fe471b9506787cb064425d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a19579f22c4af496dcb8ed57b17e7f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035fe245e98f4edc8662280dfb190881_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafad14dcd0734e159d5dc98d6debe999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb72fd4e685045b9b3f14ba16be19e8f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id995a6b3c61f46a2916306ecd8f86ea5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0806af42e92d434b8380cece41bef2f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca38735f6bf48f89c09c2c85125ba89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1aaf67bebf341cea9c892fb47997567_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187575b302fb41bd9ee6b605b4f68a30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i419ec7ac9d4f423c8c8f73bf9a5da296_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ce3c4a1d02440f8d5624232436389b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8fefbac99d4eafb16b2bf8a3836ae2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c14abd94304867b117e4fea7e033be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010aee2814cf4f14bce2ff9dacf24d5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6777a90bade44e95aedf63f8638b5d8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053e86b30f9f453cb231c55d294c07a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="supplier"><xbrli:measure>cpix:supplier</xbrli:measure></xbrli:unit><xbrli:context id="ie52ad4b1821b40aeaa322dea12dec215_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a82fe51f4445d5a9623b513f48b606_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60aad94f2f4f44b1a7b8ae65743e96b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:ClinigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1855e705644eb19c43b7bb2e117b81_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40627ef8322d435c8f66224735bfa7b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3fbba7dd4a6485ea115af1a74515fea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053b532230724366b6e9f1045a453663_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf0cdcda3874fbf81f9d06a24caa475_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d578da0f6f43cc8eb4610cda5b0867_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e5f707de404e5784e8284dcb422b96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i510f8c4dc65a401f9689088d17e3694c_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xODc_7ab665cc-3019-45c4-8e0e-7be9a5bd0a44">10-K</ix:nonNumeric></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIx_9d750adf-e0ba-4d2f-9dca-b99cc2c7dea2">December 31, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8zMjc_8780193c-867b-414f-98dc-26253ede7490">CUMBERLAND PHARMACEUTICALS INC</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE0_94e69ad9-9f66-4ae7-b33e-84b1b222ecd7">Tennessee</ix:nonNumeric> Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRS Employer Identification No.  <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIy_3f9b58ee-852b-4b37-8d3a-ec58ebb9967f">62-1765329</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission file number&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIz_71d08292-7e9c-4860-a672-933cd238f7af">001-33637</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDI0_b85aa09f-348a-4c35-a5df-7a368764873b">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE5_ec8e656a-1c09-4b9f-ad34-2d1c8b3e75df">Suite 950</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIw_e919648f-ae36-4762-a934-a23a66b420f3">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE1_4eefc358-6ec8-441d-aac8-fea0fb6b8c43">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE2_df1b8abb-29ce-4790-9146-0fd5312f7f80">37203</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE3_02cb325b-93ce-4b57-b8c1-d4b0c43b3dd7">615</ix:nonNumeric>) <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE4_09562c06-756e-40fe-a05d-f63220f43805">255-0068</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.548%"><tr><td style="width:1.0%"></td><td style="width:37.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTAtMS0xLTA_e34e069e-de7f-4634-b188-7b454e76d71f">Common Stock, $0.00 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTItMS0xLTA_84a2c541-117e-4050-99ce-4a5cc164066f">CPIX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTQtMS0xLTA_3026d7ca-4f1a-47b5-b8b0-c8c2ea293eb8">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">None</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is not a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.  </span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.  Cumberland Pharmaceuticals Inc. (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months, and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</span></div><div style="margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has submitted electronically and posted on its corporate Web site every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months. </span></div><div style="margin-top:3pt;text-indent:72pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is a non-accelerated filer and a smaller reporting company as defined in Rule&#160;12b-2 of the Exchange Act and is not a shell company.</span></div><div style="margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has not filed a report on and attestation to its management's assessment of  the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared and issued its audit report.</span></div><div style="margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i642116ade18340e99aeefa9e8eaa275e_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xNjA1_e80163a0-7645-40e7-ba73-71ec2cbe915a">30,639,333</ix:nonFraction>. The number of shares of the registrant&#8217;s Common Stock, no par value, outstanding as of March&#160;8, 2021 was <ix:nonFraction unitRef="shares" contextRef="i1afd74e563c247539861253093f00144_I20210308" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xNzAz_6fd24c3c-b2aa-4d58-adb1-93f05b5e8ccc">14,920,655</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDEz_73987ea3-cb01-42ed-9995-ca9b73899308" escape="true">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2021 annual meeting of shareholders.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Index</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_10">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_10">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_13">Item&#160;1: Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_13">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_73">Item&#160;1A: Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_73">33</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_94">Item&#160;1B: Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_94">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_97">Item&#160;2: Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_97">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_100">Item&#160;3: Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_100">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_103">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_103">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_106">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_106">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_109">Item 5: Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_109">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_112">Item&#160;6: Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_112">59</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_115">Item&#160;7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_115">60</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_136">Item&#160;7A: Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_136">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_139">Item&#160;8: Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_139">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_142">Item&#160;9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_142">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_145">Item&#160;9A: Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_145">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_148">Item&#160;9B: Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_148">75</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_151">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_151">76</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_154">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_154">77</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_157">Item&#160;15: Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_154">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_160">Item 16: Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_160">82</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_163">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_163">82</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_13"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1. Business.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_16"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE COMPANY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands include:</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a degenerative disease, Systemic Sclerosis (&#8220;SSc&#8221;), a deadly autoimmune condition, and Aspirin-Exacerbated Respiratory Disease ("AERD"), a severe form of asthma. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_19"></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in both product development and commercial capabilities.  We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. and believe we can leverage this existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently feature seven FDA products approved for sale in the United States.  Through our international partners, we are working to bring our medicines to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, through new presentations, and through our support for select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met and unmet medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. CET partners with academic research institutions to identify and progress promising, new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases, other filings and amendments to those reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company managed through the COVID-19 pandemic during 2020, continuing to operate our business - keeping facilities open and our organization intact. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded, pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key products include:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.794%"><tr><td style="width:1.0%"></td><td style="width:30.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetaminophen Poisoning</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain and Fever</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic and Acute Constipation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Pak</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. pylori infection and related Duodenal Ulcer disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euvolemic and Hypervolemic Hyponatremia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serious bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arthritis and psoriasis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td></tr></table></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an intravenous formulation of N-acetylcysteine, indicated for the treatment of the liver toxicity associated with acetaminophen poisoning. Acetadote has been available in the United States since Cumberland's 2004 introduction of the product through our hospital sales force.  Acetadote is typically used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription pain relieving and fever-reducing products. Acetaminophen overdose continues to be a leading cause of poisonings reported by hospital emergency departments in the United States, and Acetadote has become a standard of care for treating this potentially life-threatening condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received U.S. Food and Drug Administration ("FDA") approval as an orphan drug, which provided seven years of marketing exclusivity from the date of approval. In connection with the FDA's approval of Acetadote, we committed to certain post-marketing activities for the product. Completion of our first Phase IV commitment resulted in the FDA's 2006 approval of expanded labeling for the product for use in pediatric patients. Completion of our second Phase IV commitment resulted in further revised labeling for the product with FDA approval of additional safety data in 2008. Completion of our third and final Phase IV commitment in 2010 culminated in the FDA&#8217;s approval of a new formulation for the product. The next generation formulation, contains no ethylene diamine tetracetic acid ("EDTA") or other stabilization agent, chelating agent or preservative. In early 2011, Cumberland introduced this new Acetadote formulation replacing the original form of the product which we no longer manufacture.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, the FDA approved updated labeling for Acetadote revising the product's indication and providing new dosing guidance for specific patient populations.   As a result, dosing guidance is now included for patients weighing over 100 kg, and new language has been added to alert health care providers that, in certain clinical situations, therapy should be extended for some patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2012, the United States Patent and Trademark Office (the "USPTO") issued us a series of patents associated with our Acetadote product.  These patents are discussed in Part I, Item I, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Trademarks and Patents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" of this Form 10-K.  On November 8, 2012, we learned that the FDA approved an abbreviated new drug application (ANDA) filed by InnoPharma, Inc. and referencing Acetadote.  That product, with the old formulation containing EDTA, was subsequently introduced by APP, a division of Fresenius Kabi USA, at the end of 2012. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2013, we entered into an agreement with Perrigo Company resulting in the distribution of our Authorized Generic acetylcysteine injection (our "Authorized Generic") product.  Both Acetadote and our Authorized Generic utilize the new, EDTA-free formulation which accounted for continued significant market share during 2020. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, an Illinois judge issued a final ruling in favor of Cumberland Pharmaceuticals Inc. in a patent case associated with Acetadote. By ruling in Cumberland's favor, the court upheld the validity of the patent which encompasses our EDTA-Free formulation and has a term until August 2025. The court also granted a permanent injunction preventing challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of Cumberland&#8217;s patent in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2017, an Appeals Court affirmed the District Court ruling in the Company's favor upholding Cumberland's Acetadote patent and expressly rejected the validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 we continued to distribute our Acetadote brand and, through Perrigo Company, our Authorized Generic product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our intravenous formulation of ibuprofen, was the first injectable product approved in the U.S. for the treatment of both pain and fever. We conducted a series of clinical studies in over nine hundred adult patients to develop the data to support our FDA submission for the product's registration. The FDA approved Caldolor for marketing in the United States in 2009 following a priority review. A non-steroidal anti-inflammatory drug ("NSAID"), the product was indicated for use in adults as a sole treatment for the management of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics. It was also the first FDA approved intravenous therapy for treating fever. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2009, we launched Caldolor and stocked the product at major wholesalers serving hospitals nationwide. We initially worked to establish a core group of medical facilities approving and purchasing the product and then focused on building more sales volume and treating a broader range of patients within those stocked facilities. We promote Caldolor in the United States through our dedicated hospital sales force. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a series of Phase IV studies to gather additional data to support our Caldolor product. Those clinical trials involved another 1,000 patients, adult and pediatric patients. These studies included data on a shortened infusion time and pre-surgical administration of the product. To address our Phase IV commitment to the FDA, these studies also included evaluation of the product for the reduction of fever in hospitalized children and the treatment of pain in children undergoing tonsillectomy surgeries. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 we received FDA approval for the use of Caldolor in pediatric patients six months of age and older. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug approved for use in children. We then initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to six months of age. Enrollment in that study was completed in 2019. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2018, we completed and filed the application for FDA approval of a next generation Caldolor product featuring an improved presentation and formulation. In April 2018, the FDA determined that the application was complete and notified us of their acceptance of the submission for review. There were then a number of communications with questions addressed through multiple amendments that were submitted to the application. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the FDA approved the application for our next generation Caldolor product. The new, premixed presentation provides healthcare professionals a formulation that is easy to administer, helping manage the treatment of patient pain and fever, while reducing opioid consumption. It is provided in a pre-mixed bag containing 800 mg of ibuprofen in a 200 mL patented low sodium formulation for injection that is ready to use. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the first and only FDA-approved pre-mixed bag of ibuprofen. Caldolor is still available as an 800 mg/8mL single&#8211;dose vial for dilution in addition to the ready-to-use bag. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we began initial shipments of this next generation Caldolor product to select customers. During the third and fourth quarters of 2019, there was a growing demand for the new product from these select accounts. In January 2020, we initiated a full-scale launch of this ready-to-use product. Unfortunately, the launch was impacted by the COVID-19 pandemic and postponement of elective surgeries. Nonetheless, we do expect an improved performance of the product after the pandemic abates as more accounts gain access to the new presentation. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 we distributed both the vial and the ready-to-use premixed bag presentations of Caldolor.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a prescription laxative administered orally for the treatment of acute and chronic constipation. An innovative, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient acceptance and compliance. Kristalose is the only prescription laxative available in pre-measured powder packets.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose dissolves easily in four ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups.  We conducted a preference study which indicated that seventy-seven percent of patients surveyed prefer the taste, consistency and portability of Kristalose over similar products in syrup forms.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired exclusive U.S. commercialization rights to Kristalose in 2006, assembled a dedicated field sales force and re-launched it in September 2006 as a Cumberland brand. We directed our sales efforts to physicians who are the most prolific writers of prescription laxatives, including gastroenterologists and internists. We supplemented this personal promotion with telemarketing campaigns to expand our reach and support of the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2011, through a series of transactions, we entered into an agreement to acquire assets associated with the Kristalose brand including the Kristalose trademark and the FDA registration. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using preference data as a cornerstone of our marketing efforts, we repositioned the brand in early 2014.  The marketing strategy included an enhanced patient coupon program and expanded managed care coverage for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We added a co-promotion partner to provide support for the brand in 2017. Poly Pharmaceuticals is promoting Kristalose to physician targets not covered by our field sales forces. In 2018, we added another partner, Foxland Pharmaceuticals, Inc., who is repackaging Kristalose and featuring it with additional new physician targets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 we continued to support Kristalose through our field sales force as well as our partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">-Pak</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many ulcers of the gastrointestinal tract are caused by an infection from the Helicobacter pylori (&#8220;H. pylori&#8221;) bacterium.   Omeclamox-Pak is a branded prescription product used for the treatment of these infections and the related duodenal ulcer disease. This innovative product combines three well-known and widely prescribed medications: omeprazole, clarithromycin, and amoxicillin.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak was the first FDA approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Clarithromycin and amoxicillin are both antibiotic agents which hinder the growth of the H. pylori bacteria.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interaction of these agents allows the stomach lining to heal effectively.  The medications are packaged together on convenient daily dosing cards, making it simple to follow the twice a day dosing before meals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are competing combination products, Omeclamox-Pak is one of the few actively marketed brands for this condition.  In addition, compared to the competitors, Omeclamox-Pak involves the lowest pill burden and fewest days of therapy.  Our involvement with Omeclamox-Pak began in October 2013, through a co-promotion agreement with Pernix Therapeutics ("Pernix").  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Cumberland entered into an exclusive license and supply agreement with Gastro-Entero Logic, LLC (&#8220;GEL&#8221;), assumed full commercial responsibility for Omeclamox-Pak in the United States, and concluded our agreements with Pernix.  Cumberland became responsible for the distribution, national accounts and all sales promotion of Omeclamox-Pak under the GEL agreement. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we completed an agreement with GEL to acquire all remaining assets associated with Omeclamox-Pak including the product&#8217;s FDA approval as well as the domestic and international trademarks. The closing of this transaction ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL, and we assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our field sales force has promoted Omeclamox-Pak to the gastroenterology market segment, which accounts for the largest component of the prescriber base for this product. We supplemented this personal promotion through telemarketing campaigns to expand the support and use of the product. We have also established a series of contracts to provide managed care coverage for Omeclamox-Pak.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties in 2020 due to the impact of COVID-19, and their operations are currently suspended. We are awaiting resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging. We have notified the FDA that the product is currently not available.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2014, we entered into an agreement with Astellas Pharma US, Inc. ("Astellas") to acquire Vaprisol, including certain product rights, intellectual property and related assets.  Vaprisol is a prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients.  These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is supported by our hospital sales division. Demand for the product increased during the 2020 pandemic, and we worked to ensure availability of the product to hospitals and clinics during the health care crisis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company announced an agreement with Theravance Biopharma ("Theravance") to acquire the Vibativ assets from Theravance and assume global responsibility for the brand including the related marketing, distribution, manufacturing and regulatory activities.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after the closing, we initiated shipments of Vibativ, assumed responsibility for the supply chain and distribution of the product in the U.S. and transitioned the brand's responsibilites from Theravance to Cumberland.  Vibativ is supported by our hospital sales division. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, demand for the product grew, and it was used to treat pneumonia resulting from secondary bacterial infections in hospitalized COVID-19 patients. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, we announced an agreement with Nordic Group B.V. to commercialize their methotrexate product line in the United States. This new line of injectable products is designed for treating patients with arthritis and psoriasis. Cumberland is responsible for the registration and commercialization of these products while Nordic will manage the product supply. Nordic has registered and is selling their methotrexate products in several European countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During late 2018, we completed the submission and filed with the FDA a New Drug Application for our methotrexate products. In December 2019, we received FDA approval for RediTrex and began planning for a launch of this product line. In November 2020, we provided initial shipments of RediTrex to select accounts and began preparing for a national launch in the second half of 2021, once product supplies are assured and market conditions return to normal.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PIPELINE</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development pipeline includes a series of product candidates in Phase II development. During 2020, enrollment in our studies significantly slowed during the pandemic, due to trial suspensions and the decrease in eligible patient admissions to medical centers across the country. We look forward to an improvement as the pandemic subsides and centers begin to reopen with a return of patients eligible for our trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical programs include the evaluation of ifetroban in the following areas:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aspirin-Exacerbated Respiratory Disease ("AERD")</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed the manufacturing and initiated clinical development of an oral formulation of ifetroban under the brand name Boxaban. We are evaluating this candidate for patients suffering from Aspirin-Exacerbated Respiratory Disease ("AERD"), also known as Samter&#8217;s Triad, a chronic medical condition that consists of three clinical features: asthma, sinus disease with nasal polyposis and sensitivity to aspirin. AERD is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Approximately one in twenty asthmatic adults in the U.S. suffer from AERD and awareness of the disease is growing within the medical community. There is no U.S. approved pharmaceutical treatment for AERD.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an initial Phase II clinical study to evaluate the safety and tolerability of Boxaban in AERD patients. The multicenter study involved sixteen patients at several U.S. medical centers led by the Scripps Research Institute. Results indicated that Boxaban was well tolerated with no safety concerns noted in patients with a history of AERD.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2017, the FDA cleared Cumberland&#8217;s IND application for the Company&#8217;s AERD clinical program. Following this clearance, we initiated a follow-on multicenter Phase II efficacy study to evaluate the efficacy of Boxaban in seventy-six patients with symptomatic AERD. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemic Sclerosis ("SSc")</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we announced the addition of Vasculan to our pipeline. Through Cumberland's ifetroban program, Cumberland has initiated the clinical development of ifetroban oral capsules for the treatment of systemic sclerosis. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systemic sclerosis ("SSc"), also called scleroderma, is a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, as well as vascular dysfunction. Preclinical studies have shown that ifetroban prevents and can restore cardiac function in a preclinical model of pulmonary arterial hypertension.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This disease has a high morbidity and the highest case-specific mortality of any rheumatic disorder with 50% of patients dying or developing major internal organ complications within 3 years of diagnosis. Although several medications are used to treat the skin disease associated with SSc, there is no universally effective treatment to improve the function of affected internal organs such as the lungs, heart, and gastrointestinal tract.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has cleared our IND application to evaluate the safety and efficacy of Vasculan in patients with SSc. As a result, we initiated a Phase II multicenter study in thirty-four SSc patients. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duchenne Muscular Dystrophy ("DMD")</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 24, 2019, Cumberland announced an FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;). Based on preclinical findings, the FDA has cleared Cumberland&#8217;s application to study ifetroban in DMD patients, 7 years of age and older. In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support this Phase II DMD clinical study. It is the first DMD clinical study approved for FDA Orphan Product Development funding. During 2020 the FDA awarded a supplemental grant in support of the Phase II study.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Clinical Programs</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway including several investigator-initiated trials. We are awaiting further study results before deciding on the best path for approval for ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Hospital Product Candidate</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and and patient enrollment completed. We have completed the study report, filed it with the FDA and are now determining the next steps for this program.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_22"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRATEGY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market seven FDA approved products for sale in the United States. Through our international partners, we are working to bring our products to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new indications, and select investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address unmet medical needs. Further, we are supplementing these activities with the early stage drug development activities at CET, our majority-owned subsidiary. Specifically, we are seeking long term sustainable growth by executing the following plans:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Support and expand the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.  We will continue to explore opportunities for label expansion to bring our products to new patient populations.  As examples, we have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectively add complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure.  Our acquisition of Vibativ represents the largest product acquisition we have completed.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leverage our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion partnership with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc. allow us to expand the support for Kristalose across the United States.     </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including two sales divisions to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manage our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins, and a strong balance sheet. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_25"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and marketing team has broad industry experience in selling branded pharmaceuticals. Our sales and marketing professionals manage our dedicated hospital and gastroenterology sales forces, including approximately 50 sales representatives and district managers, direct our national marketing campaigns and maintain key national account relationships. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospital market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We promote Caldolor, Vaprisol, Acetadote, and Vibativ through our dedicated hospital sales division. This organization targets key hospitals across the U.S. and is comprised of sales professionals with substantial experience in the hospital market. Independent market data continues to indicate that the majority of pharmaceutical promotional spending is directed toward large, outpatient markets on drugs intended for chronic use rather than short-term, hospital use. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the hospital market is under-served and highly concentrated, and that it can be penetrated effectively by a small, dedicated sales force without large-scale promotional activity.  Our established position in the hospital market provided the rationale for adding Vibativ as our first infectious disease product that complement our hospital product line.  Our strategy has been to increase the focus of our hospital sales team on targeted, high priority accounts. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gastroenterology and rheumatology market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We promote Kristalose, Omeclamox-Pak and RediTrex through a dedicated field sales team addressing a targeted group of physicians who are large prescribers of the products. Because the markets for gastrointestinal and rheumatology diseases are broad in patient scope, yet relatively narrow in physician base, we believe they provide opportunities that can be penetrated with a modest sized sales force.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By investing in our sales and marketing activities we believe that we can increase market share for these products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial executives conduct ongoing analyses to evaluate marketing campaigns and promotional programs in support of our brands. The evaluations include development of product profiles, testing of the profiles against the needs of the market, determining what additional product information or development work is needed to effectively market the products and preparing financial forecasts. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize professional branding and packaging as well as promotional items to support our products, including direct mail, sales brochures, journal advertising, educational and reminder leave-behinds, patient educational pieces, coupons, and product sampling. We also regularly attend select medical meetings and trade shows to expand the awareness of our products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our national accounts function is responsible for key large buyers and related marketing programs. National accounts maintain relationships with our wholesaler customers as well as with third-party payors such as group purchasing organizations, pharmacy benefit managers, hospital buying groups, state and federal government purchasers and health insurance companies. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_28"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CUSTOMERS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary customers are wholesale pharmaceutical distributors in the United States. Total revenue by customer for each customer representing 10% or more of consolidated gross revenues are summarized below for the year ended December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.237%"><tr><td style="width:1.0%"></td><td style="width:64.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_31"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNATIONAL PARTNERSHIPS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established our own capabilities to support the commercialization of our products in the U.S.  Our international strategy is to identify and partner with other companies that have the appropriate capabilities to support our products in their respective countries. We have entered into a series of agreements to establish an international network, which is summarized in the table below and includes information on our primary partners:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:29.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phebra Pty Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia and New Zealand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DB Pharm Korea Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seqirus (a CSL company)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia and New Zealand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandor Medicaids Pvt. Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India, Pakistan, Bangladesh and Nepal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GerminMED</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qutar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R-Pharm JSC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. ETHICA Industri Farmasi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Grifols, S.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain, Portugal and South America</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SciClone Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WinHealth Pharma Group Co.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor &amp; Acetadote</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international commercialization agreements include a license to one or more Cumberland products for a specific territory as noted in the table above. We seek partners who have the local infrastructure to support the registration and commercialization of our products in their territory. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreements our partners are responsible for:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Seeking regulatory approvals for the products;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Launching the brand;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Managing the ongoing marketing, sales and product distribution; </span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Addressing the ongoing regulatory requirements in the international territories;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Remitting any upfront, regulatory and sales milestone payments; </span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Providing the transfer price for supplies of product; and</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Calculating and paying any royalties, as applicable. </span></div><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our responsibilities include:</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Providing a dossier of relevant information to support product registration;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Maintaining our intellectual property associated with the product;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Sharing our marketing strategy, experience and materials for the brand; and</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Manufacturing and providing finished product for sale.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we worked to support our existing international partners and to identify new companies to represent our products in select additional territories. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL AND REGULATORY AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-house capabilities for the management of our clinical, professional and regulatory affairs. Our team develops and manages our clinical trials, prepares regulatory submissions, manages ongoing product-related regulatory responsibilities and manages our medical information call center. Team members have been responsible for devising the regulatory and clinical strategies for all our products as well as obtaining FDA approvals for Acetadote, Caldolor and RediTrex.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development personnel are responsible for: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating clinical development strategies; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">designing, implementing and monitoring our clinical trials; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating case report forms and other study-related documents.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory and quality affairs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal regulatory and quality affairs team is responsible for: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting INDs for clearance to begin patient studies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting NDAs and fulfilling post-approval marketing commitments; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining investigational and marketing applications through the submission of appropriate reports; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submitting supplemental applications for additional label indications, product line extensions and manufacturing improvements;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating regulatory risk profiles for product acquisition candidates, including compliance with manufacturing, labeling, distribution and marketing regulations;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring applicable third-party service providers for quality and compliance with current Good Manufacturing Practices ("GMPs"), Good Laboratory Practices ("GLPs"), and Good Clinical Practices ("GCPs"), and performing periodic audits of such vendors; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining systems for document control, product and process change control, customer complaint handling, product stability studies and annual drug product reviews.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_37"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROFESSIONAL AND MEDICAL AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical team provides in-house, medical information support for our marketed products. This includes interacting directly with healthcare professionals to address any product or medical inquiries through our medical information call center and medical science liaisons. In addition to coordinating the call center, our clinical/regulatory group generates medical information letters, provides informational memos to our sales forces and assists with ongoing training for the sales forces.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_40"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL DEVELOPMENT AND STUDY RESULTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. In November 2018, Cumberland reached an agreement to acquire Vibativ from Theravance Biopharma and assume global responsibility for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, we announced a publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infectious Diseases and Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with study results showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in Phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Additionally, an online publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drugs - Real World Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, detailed the positive clinical outcomes that resulted from treating multiple infection types with Vibativ, including complicated skin infections, bone and joint infections, bacteremia and endocarditis, and lower respiratory tract infections.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Cumberland announced a new study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drugs - Real World Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, detailing the positive clinical outcomes that resulted from treating patients with bacteremia or endocarditis with Vibativ. This publication is a sub analysis of The Telavancin Observational Use Registry (TOUR&#8482;), a study conducted to record population characteristics, prescription information, and real-world clinical outcomes of patients with Gram-positive infections treated with Vibativ. The analysis suggests Vibativ is a promising and viable option for patients with bacteremia or endocarditis, including those with MRSA or another S. aureus pathogen.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in May 2020, we announced the publication of two studies confirming the continued in vitro potency of telavancin. Both publications were part of continued surveillance of telavancin activity since 2011. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first publication tested a global collection of 24,408 Gram-positive clinical isolates, and the second publication tested a U.S. collection of 15,882 S. aureus isolates. Both studies documented the sustained in vitro antimicrobial activity and spectrum of telavancin&#8212;many years after its clinical approval&#8212;against Gram-positive clinical isolates collected worldwide over 7 years, from 2011 through 2017.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Cumberland announced a study published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Orthopedic Trauma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, evaluating the efficacy of Caldolor administration in the management of acute pain in orthopedic trauma patients. The study also measured Caldolor&#8217;s ability in minimizing opioid use. This single-center, randomized, double-blind, placebo-controlled study found that Caldolor (ibuprofen) Injection reduced the quantity of opioids required to manage pain after a traumatic injury with fracture. In addition, the time to first narcotic medication was longer in the Caldolor group than with hospital standard of care. Pain was also managed better in the Caldolor group compared to standard of care narcotics. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2020, we announced the results of a review of nine clinical studies evaluating Caldolor. The comprehensive review was published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Therapeutics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and involved 1,062 adult patients, with 757 receiving Caldolor and 305 receiving placebo or a comparator medication. The data noted that the use of Caldolor improved post-surgery recovery, decreased surgical stress, and reduced the use of opioids and over-the-counter medication. The study determined that patients given Caldolor experienced less postoperative pain and decreased opioid use. Study authors also concluded that the rapid administration and preemptive use of Caldolor should be considered in Enhanced Recovery After Surgery protocols for the management of postoperative pain including that of traumatic origin. </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor Newborn Study</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously received FDA approval for the use of Caldolor in pediatric patients six months of age and older. Caldolor is the first and only injectable NSAID approved for use in children.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to six months of age. Enrollment in that multi-center study was completed in 2019, and topline results were announced in 2020, indicating that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor was well tolerated in this patient population, with no safety concerns noted. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ifetroban Phase II Studies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have three Phase II clinical programs underway evaluating our ifetroban product candidates in 1) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have completed two pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure and 2) patients with Portal Hypertension associated with chronic liver disease.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted during 2020 due to the COVID-19 pandemic. While enrollment of new patients is currently limited, we have worked to ensure that patients already entered into a trial continue to receive their study drug. Many of our clinical study sites have reopened and resumed screening of patients for potential enrollment into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Hospital Product Candidate Study</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase II study has been initiated and patient enrollment completed. We have completed the study report, filed it with the FDA and are now determining the next steps for this product development program.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_43"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS DEVELOPMENT</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have had an active business development program focused on acquiring rights to marketed products and product candidates that fit our strategy and target markets. We source business development opportunities through our international network of advisory firms and individual pharmaceutical industry and medical advisors. A multi-disciplinary internal management team reviews these opportunities on a regular basis using a list of selection criteria. We have historically focused on product opportunities that are a strategic fit with our commercial organization, development expertise and medical focus, employing a variety of transaction structures.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to build a portfolio of complementary, niche products largely through product acquisitions and late-stage product development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary targets are under-promoted, FDA approved drugs with existing brand recognition and late-stage development product candidates that address unmet or poorly met medical needs in the hospital acute care and gastroenterology markets. We believe that by focusing mainly on approved or late-stage products, we can minimize the significant risk, cost and time associated with drug development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, we announced a strategic review of our brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, we felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Partners</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our strategic review, we altered our international arrangements through several new agreements as well as dissolution of prior agreements..</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote brands in China and Hong Kong. Under the terms of the agreement,  WinHealth will provide development milestone payments and purchase supplies of the products following their registration in China.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a Strategic Alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization. Founded in Hangzhou, China and currently headquartered in Hong Kong, WinHealth has developed a wide breadth of capabilities including drug licensing, product development and registration, and has established a strong network of distribution and sales promotional capabilities for the Chinese market. WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer, and Roche, generating approximately $330 million in annual sales in 2018.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we completed the assignment and amendment of a Commercialization Agreement with R-Pharma JSC (&#8220;R Pharma&#8221;) associated with ongoing distribution of Vibativ in Russia and a number of adjacent countries in Eastern Europe. R-Pharma is one of the leading multinational pharmaceutical organizations based in Russia. Headquartered in Moscow and focusing in a wide breadth of therapeutic areas in the specialty and hospital care markets, R-Pharma generated over $1.6 billion in revenues in 2018.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of concluding our Commercialization Agreement with Hikma Pharmaceuticals LLC to register and distribute Vibativ in a number of countries throughout the Middle East, our agreement with Dr. Reddy&#8217;s Laboratories Limited for the registration and distribution of Vibativ in India, and our License and Distribution Agreement with PT. EHTICA Industri Farmasi for the registration and distribution of Caldolor in Indonesia.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Poly Co-Promotion Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a co-promotion arrangement with Poly Pharmaceuticals, Inc. (&#8220;Poly&#8221;) for our Kristalose product in 2017. Poly is a privately held U.S. specialty pharmaceutical company that is featuring Kristalose to an expanded number of physicians. Poly&#8217;s sales organization is more than doubling the number of nationwide physicians that are reached with the Kristalose brand message. During 2019, we extended our co-promotion arrangement with Poly. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nordic License Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, we announced our agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s injectable methotrexate product line. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product line is approved for patient use in various European countries and received FDA approval near the end of 2019. Cumberland has registered and is commercializing the methotrexate products in the United States under the brand name RediTrex.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2R and Foxland Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we entered into another co-promotion arrangement related to our Kristalose product. We have agreements with 2R Investments, LLC and with Foxland Pharmaceuticals, Inc. to package, distribute and promote an authorized generic form of our Kristalose product to physician targets that we do not cover. Cumberland continues to manage the regulatory activities associated with the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinigen Strategic Dissolution Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously entered into a strategic alliance with the Clinigen Group plc ("Clinigen"), an international specialty pharmaceutical and services company, to commercialize select Clinigen products in the U.S. In May 2016, we announced an agreement with Clinigen to acquire an exclusive license and commercialize Ethyol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. We then announced in January 2017, our second agreement with Clinigen to acquire an exclusive license and launch Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, following a strategic review of our partners, products and organization, we entered into a Dissolution Agreement with Clinigen in which Cumberland will return the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the final terms of the amended Dissolution Agreement we transitioned from our current arrangement with Clinigen effective December 31, 2019. Under the terms of the agreement, Cumberland will no longer be involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products. In exchange for the return of these product license rights and not competing with either product, we will receive $5 million in financial consideration paid over the two-years following December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CET University Collaboration Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through CET, we collaborate with a select group of academic research institutions located in the mid-south region of the U.S. to identify, co-develop and seek grant funding for promising biomedical technologies emerging from those research institutions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CET is collaborating with Vanderbilt University, the University of Mississippi, the University of Tennessee Research Foundation, Louisiana State University, and the Medical University of South Carolina to identify, co-develop and seek grant funding for promising biomedical technologies emerging from those research institutions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements enable CET to team with university-based researchers to advance their scientific discoveries and breakthroughs by designing new product candidates to improve patient care and address unmet medical need.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING AND DISTRIBUTION</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with third parties for certain non-core, capital-intensive capabilities, including the manufacturing and distribution of our products. We manage these third-party relationships and are responsible for the quality review and release of each lot of our products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Acetadote we had agreements with two manufacturers, and one manufacturer provided commercial supplies of the product during 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with multiple manufacturers for the supply of Caldolor and during 2020 we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement for the purchase of Kristalose API with an international supplier.  We also have manufacturing relationships with two packagers who provided finished supplies of the product for commercial and sampling purposes during 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our asset purchase agreement with GEL that closed in December 2018, GEL managed the packaging and supply of Omeclamox-Pak commercial and sample units. Following our acquisition of the remaining rights to the brand in late 2018, we assumed responsibility for the packaging and supply of the product.  During 2019 we entered into a new packaging arrangement for this product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the packager for Cumberland&#8217;s Omeclamox-Pak product encountered financial difficulties due to the economic impact of COVID-19, and their operations suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. We informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020, and have not provided a date for the availability of new inventory.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Vaprisol, we purchased a significant existing supply of raw material inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of that transaction, we were assigned a commercial supply agreement with the historical Vaprisol manufacturer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the manufacturer informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is providing us with a multi-year supply. We identified and reached an agreement during 2020 with a new manufacturer to provide us with long term supplies of the product. We subsequently initiated the transfer of the product&#8217;s manufacturing to the new facility in 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the future manufacture of the product and completed the transfer of the product&#8217;s manufacturing activities to a new supplier and received FDA approval for that facility in 2020.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line. In 2019, we received FDA approval for the product and authorization to market them under the RediTrex brand name. Under our agreement with Nordic, they are responsible for providing us the packaged and labeled commercial supply of RediTrex.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many pharmaceutical companies, we engage a third-party with appropriate facilities and logistical expertise to support the U.S. distribution of our products.  Cardinal Health has exclusively handled our U.S. product logistics activities, including warehousing, shipping, and various other customer activities.  Our primary customers are the wholesalers of pharmaceuticals who provide our products to hospitals, clinics and retail pharmacies in the U.S.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_46"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE DEVELOPMENT</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Foundation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as an independent, nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we provided a grant of 50,000 shares of our common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future. The Foundation maintains independent financial statements and its contributions will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2020, we provided approximately $50,000 in cash contributions to the Foundation. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Health and Wellness Political Action Committee</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 we formed the Cumberland Health and Wellness Political Action Committee (PAC). The objective of the PAC is to support candidates and policies that are consistent with Cumberland&#8217;s mission of advancing patient care. The PAC&#8217;s activities will be at the local, state and federal level and conducted in a bi-partisan manner. The initial committee membership is comprised of Cumberland Pharmaceuticals employees. The PAC received initial funding from us and future funding will include voluntary individual contributions from Cumberland Pharmaceuticals directors and employees. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_52"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PATENTS, TRADEMARKS AND OTHER INTELLECTUAL PROPRIETARY RIGHTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the trademarks for each of our branded pharmaceutical products as well as for our corporate name and logo. We have applied for trademark registration for other various names and logos.  Over time, we intend to maintain registrations on trademarks that remain valuable to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our products from competition through a combination of patents, trademarks, trade secrets, FDA exclusivity and contractual restrictions on disclosure. Proprietary rights, including patents, are an important element of our business. We seek to protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute agreements providing for protection of our confidential information upon commencement of their employment or engagement. We also require confidentiality agreements from entities to which we provide our confidential information or materials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed a new formulation of Acetadote (acetylcysteine) Injection as part of a Phase IV commitment in response to a request by the FDA to evaluate the reduction of ethylene diamine tetraacetic acid ("EDTA") from the product's formulation.  In April 2012, the USPTO issued U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to us. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the issuance of the 356 Acetadote Patent, we received separate Paragraph IV certification notices from InnoPharma, Inc. ("InnoPharma"), Paddock Laboratories, LLC (&#8220;Paddock&#8221;), Mylan Institutional LLC (&#8220;Mylan&#8221;), Sagent Agila LLC ("Sagent") and Perrigo Company ("Perrigo") challenging the 356 Acetadote Patent on the basis of non-infringement and/or invalidity. We responded by filing five separate infringement lawsuits, in the appropriate United States District Courts, to contest each of the challenges. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2012, we entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Paddock and Perrigo to resolve the challenges and the pending litigation with those two companies.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2013, the United States District Courts filed opinions granting Sagent&#8217;s and InnoPharma&#8217;s motions to dismiss our suits and we agreed not to file an appeal or motion to reconsider, thereby resolving the challenges and the pending litigation with those two companies. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, Paddock and Perrigo admit that the 356 Acetadote Patent is valid and enforceable and that any Paddock or Perrigo generic version of Acetadote (with or without EDTA) would infringe upon the 356 Acetadote Patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the 356 Acetadote Patent through its expiration currently scheduled for May 2026. On November 12, 2012, in connection with the execution of the Settlement Agreement, we entered into a License and Supply Agreement with Paddock and Perrigo (the &#8220;License and Supply Agreement&#8221;).  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License and Supply Agreement, if a third party  receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party made such generic version available for purchase in commercial quantities in the United States, we are to supply Perrigo with an Authorized Generic version of our Acetadote product.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;18, 2012, we also submitted a Citizen Petition to the FDA requesting that the FDA refrain from approving any applications for acetylcysteine injection that contain EDTA, based in part on the FDA's request that we evaluate the reduction or removal of EDTA from our original Acetadote formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2012, the FDA responded to the Citizen Petition denying our request and on November 8, 2012, we learned that the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. We brought suit against the FDA contesting the FDA's decision to approve the InnoPharma generic on November 13, 2012. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2013, the United States District Court filed an opinion granting a summary judgment in favor of the FDA regarding this suit.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, during 2012 the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. Upon this condition, in accordance with the License and Supply agreement with Perrigo, we began to supply Perrigo with our Authorized Generic.  On January 7, 2013, Perrigo announced initial distribution of our Authorized Generic acetylcysteine injection product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2013, the USPTO issued U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;) which is assigned to us. The claims of the 445 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the 445 Acetadote Patent was listed in the FDA Orange Book. The 445 Acetadote Patent is scheduled to expire in August 2025. Following the issuance of the 445 Acetadote Patent we received separate Paragraph IV certification notices from Perrigo, Sagent Pharmaceuticals, Inc., and Mylan challenging the 445 Acetadote Patent on the basis of non-infringement, unenforceability and/or invalidity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2013, we became aware of a Paragraph IV certification notice from Akorn, Inc. challenging the 445 Acetadote Patent and the 356 Acetadote Patent on the basis of non-infringement. On July 12, 2013, we filed a lawsuit for infringement of the 356 Acetadote Patent against Akorn, Inc. in United States District Court.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2014, the USPTO issued U.S. Patent number 8,653,061 (the &#8220;061 Acetadote Patent&#8221;) which is assigned to us. The claims of the 061 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to treat patients with acetaminophen overdose.  Following its issuance, the 061 Acetadote Patent was listed in the FDA Orange Book. The 061 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2014, the USPTO issued U.S. Patent number 8,722,738 (the &#8220;738 Acetadote Patent&#8221;) which is assigned to us.  The claims of the 738 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 738 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in April 2032.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2014 and March 3, 2015, we became aware of Paragraph IV certification notices from Aurobindo Pharma Limited and Zydus Pharmaceuticals (USA) Inc., respectively, challenging the 356, 445, 061, and 738 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2015, the USPTO issued U.S. Patent number 8,952,065 (the &#8220;065 Acetadote Patent&#8221;) which is assigned to us.  The claims of the 065 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acute liver failure.  The 065 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. &#160;The opinion upheld&#160;our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. &#160; The District Court ruled&#160;that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's&#160;Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court").</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2016, the USPTO issued U.S. Patent number 9,327,028 (the &#8220;028 Acetadote Patent&#8221;) which is assigned to us. The claims of the 028 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 028 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in July 2031.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2017, the Appeals Court affirmed the District Court ruling in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#8217;s ruling upholding our 445 Acetadote Patent and expressly rejected Mylan's validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2017, we became aware of a Paragraph IV certification notice from Exela Pharma Sciences, LLC challenging the 356, 445, 061, 738, and 028 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are considering our legal options and intend to continue to vigorously defend and protect our Acetadote product and related intellectual property rights. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the owner of U.S. Patent No. 6,727,286, which encompasses ibuprofen solution formulations, methods of making the same, and methods of using the same, and which is scheduled to expire in November 2021. This U.S. patent is listed in the FDA Orange Book and is associated with our completed international application No. PCT/US01/42894. We have filed for international patent protection in association with this PCT application in various countries, several of which have been allowed.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive, worldwide license to clinical data for intravenous ibuprofen from Vanderbilt University, in consideration for royalty obligations related to Caldolor.  During 2014, we obtained additional patents for the brand. On May 27, 2014, the USPTO issued U.S. Patent number 8,735,452 (the &#8220;452 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us.  The claims of the 452 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.  Following its issuance, the 452 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2014, the USPTO issued U.S. Patent number 8,871,810 (the &#8220;810 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us.  The claims of the 810 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.   Following its issuance, the 810 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2015, we obtained four additional patents for Caldolor.  On July 7, 2015, the USPTO issued U.S. Patent number&#8217;s 9,072,710 (the &#8220;710 Caldolor Patent&#8221;) and 9,072,661 (the &#8220;661 Caldolor Patent&#8221;) which are assigned to us.  The claims of the 710 Caldolor Patent and the 661 Caldolor Patent include composition and methods of treating pain, inflammation and fever using intravenous ibuprofen.  These Caldolor Patents are listed in the FDA Orange Book and are scheduled to expire in March 2032. On April 21, 2015, the USPTO issued U.S. Patent No. 9,012,508 (the &#8220;508 Caldolor Patent&#8221;) which is assigned to us.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 508 Caldolor Patent include methods of treating pain using intravenous ibuprofen.  Following its issuance, the 508 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2030.  On August 25, 2015, the USPTO issued U.S. Patent number 9,114,068 (the &#8220;068 Caldolor Patent&#8221;) which is assigned to us.  The claims of the 068 Caldolor Patent include methods of treating pain using intravenous ibuprofen.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following its issuance, the 068 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.  On September 22, 2015, the USPTO issued U.S. Patent number 9,138,404 (the &#8220;404 Caldolor Patent&#8221;) which is assigned to us.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 404 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 404 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2016, the USPTO issued U.S. Patent number 9,295,639 (the "639 Caldolor Patent") which is assigned to us.  The claims of the 639 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 639 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2017, the USPTO issued U.S. Patent number 9,649,284 (the "284 Caldolor Patent") which is assigned to us.  The claims of the 284 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 284 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. We also have additional patent applications related to Caldolor which are pending with the USPTO.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own numerous U.S.&#160;patents and related international patents for Vaprisol.  These patents were acquired in our February 2014 acquisition of certain product rights, intellectual property and related assets of Vaprisol from Astellas.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own numerous U.S. patents and related international patents for Vibativ. These patents were acquired in our November 2018 acquisition of certain product rights, intellectual property and related assets of Vibativ from Theravance.  Eleven Vibativ patents are listed in the FDA Orange Book.  U.S. Patent number 7,531,623 (the &#8220;623 Vibativ Patent&#8221;) is scheduled to expire in January 2027 and includes composition of matter claims that encompass the Vibativ drug substance as well as methods for preparing the Vibativ drug substance.        </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Products</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no issued patents for our RediTrex, Omeclamox-Pak and Kristalose products. We have multiple granted patents relating to our ifetroban products and patent applications pending with the USPTO.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by intense competition and rapid innovation. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets. Competitive factors directly affecting our markets include but are not limited to: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product attributes such as efficacy, safety, ease-of-use and cost-effectiveness; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brand awareness and recognition driven by sales, marketing and distribution capabilities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property and other exclusivity rights; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of resources to build and maintain developmental and commercial capabilities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful business development activities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extent of third-party reimbursements, insurance coverage; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advantageous collaborations to conduct development, manufacturing or commercialization efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our competitors possess research and development and sales and marketing capabilities as well as financial resources greater than ours. These competitors, in addition to emerging companies and academic research institutions, may be developing, or in the future could develop, new technologies that could compete with our current and future products or render our products obsolete.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products face competition from other branded products, generics, and alternate medical treatments. Our task is to position each brand to feature its competitive advantages, implement a well thought out marketing plan and provide focused sales and other tactical support. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is our injectable formulation of N-acetylcysteine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NAC") for the treatment of acetaminophen overdose. NAC is accepted worldwide as the standard of care for acetaminophen overdose. Our competitors in the acetaminophen overdose market are those companies selling orally administered NAC including, but not limited to, Geneva Pharmaceuticals, Inc., Bedford Laboratories division of Hikma Pharmaceuticals, Roxane Laboratories, Inc., InnoPharma Inc. and Hospira Inc.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, InnoPharma Inc. was granted approval by the FDA to distribute their generic form of the old formulation of Acetadote containing EDTA.  In late 2012, we entered into the Settlement Agreement with Paddock and Perrigo that included the right to distribute our Authorized Generic Acetadote injection product.  Our branded Acetadote now competes with both the EDTA free Authorized Generic Acetadote distributed by Paddock and Perrigo along with generic Acetadote products that contain EDTA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufactures of the old Acetadote formulation include: Akorn, AuroMedics Pharma, Fresenius Kabi and Sagent Pharmaceuticals. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor is marketed for the treatment of pain and fever, primarily in a hospital or surgery center setting. A variety of other products address the acute pain market:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphine, the most commonly used product for the treatment of acute, post-operative pain, is manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other generic injectable opioids, including fentanyl, meperidine and hydromorphone, address this market;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ketorolac tromethamine (brand name Toradol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an injectable NSAID, is also manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IV acetaminophen (brand name Ofirmev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an injectable analgesic product is sold by Mallinckrodt plc, and there are also generic versions from different manufacturers available;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Bupivacaine injectable suspension (brand name Exparel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold by Pacira Pharmaceuticals, Inc., two additional bupivacaine products, Xaracoll and Posimir, were recently approved;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">IV meloxicam (brand name Anjeso&#8482;), a once a day injectable COX-2 preferential NSAID manufactured by Baudax Bio which was recently approved by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of other product candidates in development to treat acute pain including injectable NSAIDs, novel opioids, new formulations of existing therapies and extended release anesthetics. We believe non-narcotic analgesics for the treatment of post-surgical pain are the primary potential competitors to Caldolor.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the injectable analgesic products above, many companies are developing analgesics for specific indications such as migraine and neuropathic pain, oral extended-release forms of existing narcotic and non-narcotic products, and products with new methods of delivery such as transdermal. We are not aware of any approved injectable products indicated for the treatment of fever in the U.S. other than Caldolor and Ofirmev. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are, however, numerous drugs available to physicians to reduce fevers in hospital settings via oral administration to the patient, including ibuprofen, acetaminophen, and aspirin. These drugs are manufactured by numerous pharmaceutical companies.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a dry powder crystalline prescription formulation of lactulose indicated for the treatment of constipation. The U.S. constipation therapy market includes various prescription and over the counter, or OTC, products. The branded prescription products which we believe are our primary competitors are:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Lubiproston (brand name Amitiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of chronic  idiopathic constipation, irritable bowel syndrome with constipation in adults, is manufactured and sold by Mallinckrodt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Naloxegol (brand name Movantik</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pain and recently acquired by RedHill Biopharma in the first quarter of 2020. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Linaclotide (brand name Linzess</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. It is sold by Allergan, Inc. and Ironwood Pharmaceuticals, Inc.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Plecanatide (brand name Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is sold by Synergy Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Generic and branded liquid lactulose products are marketed by a number of pharmaceutical companies.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Lactitol for oral solution (brand name Pizensy), an oral, osmotic laxative indicated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of chronic idiopathic constipation and distributed by Braintree Laboratories, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was recently approved by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several hundred OTC products used to treat constipation marketed by numerous pharmaceutical and consumer health companies. MiraLax (polyethylene glycol 3350), previously a prescription product, was indicated for the treatment of constipation and manufactured and marketed by Bayer.  MiraLax was converted to an OTC </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product in February 2007 and recently, the FDA rescinded the approval of the generic prescription polyethylene glycol 3350 products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">-Pak</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak is a branded prescription product used for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease.  It combines three well-known and widely prescribed medications packaged in a daily dose pack for patient convenience: omeprazole, clarithromycin, and amoxicillin. The three individual components of Omeclamox-Pak are also available from other suppliers through three separate prescriptions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are several competitor products, Omeclamox-Pak is one of the two actively marketed products for this condition.  In addition, compared to the competing products, Omeclamox-Pak has the lowest pill burden, fewest days of therapy and convenient twice daily dosing. The prescription combination products, indicated for treatment of H. pylori, which we believe are our primary competitors are:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PrevPac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product sold by Takeda Pharmaceutical Company.  There are also approved generic versions of PrevPac;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pylera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product manufactured and sold by Allergan plc; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Talicia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product manufactured by RedHill Biopharma which was recently approved by the FDA.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the first and only intravenously administered branded treatment.  The other competing product is Samsca, an oral product sold by Otsuka Pharmaceutical Company.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 12, 2018, Cumberland acquired the worldwide rights to Vibativ (telavancin) from Theravance Biopharma. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a potent, once-daily, injectable antibiotic for the treatment of certain gram-positive infections. Vibativ is approved for the treatment of complicated skin and skin structure infections and hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. There are several generic and branded antibiotics that compete for these indications. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major generic competitors are vancomycin, linezolid, and daptomycin. Vancomycin is by far the most widely used agent. Newer branded agents are also available including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Ceftaroline fosamil (brand name Teflaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ) an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Dalbavancin (brand name Dalvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Oritavancin (brand name Orbactiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Melinta</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of a number of other novel antibiotics which are currently in development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibiotic drug selection is based both on an empiric and susceptibility proven basis. In the hospital setting, cost is an important factor which favors the use of generic agents as long as they are effective. Newer agents are often reserved for two reasons: they are valuable in the treatment of patients that fail to respond to generics and it is considered good practice to conserve the use of these agents to reduce the risk of resistance. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex was introduced by Cumberland in the fourth quarter of 2020. RediTrex is methotrexate for subcutaneous administration in a unique syringe designed for ease of use, improved accuracy, and enhanced safety. It is indicated for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe, recalcitrant, or disabling psoriasis unresponsive to alternative treatments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This market is highly competitive with drugs from several different therapeutic classes available for treatment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Methotrexate is considered a standard of care especially when patients fail to respond adequately to low dose steroids or non-steroidal anti-inflammatory drugs (NSAIDs). Methotrexate is available in multiple dose forms including oral, subcutaneous, and intra-venous.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Methotrexate may be used alone or in combination with drugs from other therapeutic classes to adequately control patient symptoms.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex competes with other dose forms and delivery systems for methotrexate including, oral tablets, conventional vial and syringe administration, and auto-injector pens.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral tablets and conventional vials are generic and available from many suppliers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two auto-injector pen products available, Rasuvo and Otrexup. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex also competes with or may be used in combination with drugs from other therapeutic classes including, injectable biologics like Humira and Enbrel and oral JAK inhibitors like Xaljanz. These newer agents are more expensive than the methotrexate products but benefit from significant promotion to patients and doctors. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_58"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceutical products can be a long, expensive and risky process. There is no assurance we will obtain successful study results or secure the needed market approvals for our pipeline product candidates.  Governmental authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacturing, distribution, marketing and sale of pharmaceutical products.  In the U.S., the FDA under the Federal Food, Drug, and Cosmetic Act, ("FDCA"), the Public Health Service Act, and other federal statutes and regulations, subjects pharmaceutical products to rigorous review.  Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Application ("NDAs") or biologics license applications, ("BLAs"), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our manufacturers and contract research organizations may also be subject to regulations under other federal, state and local laws, including the Occupational Safety and Health Act, (OSHA), the Resource Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is a regulatory agency within the Department of Health and Human Services. A key responsibility is to regulate the safety and effectiveness of drugs sold in the United States. The FDA manages this responsibility into two phases: pre-approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(premarket) and post approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(post market). The FDA reviews manufacturers' applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. The FDA continues its oversight of drug safety and effectiveness as long as the drug is on the market.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market a prescription drug in the United States, a manufacturer needs FDA approval. To get that approval, the manufacturer must demonstrate the drug's safety and effectiveness according to criteria specified in law and agency regulations, ensure that its manufacturing plant passes FDA inspection, and obtain FDA approval for the drug's labeling, a term that includes all written material about the drug, including, for example, packaging, prescribing information for physicians and patient brochures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression to drug approval begins before FDA involvement. First, scientists work in the laboratory to discover and develop a new compound. Next, basic questions on safety are answered by nonclinical testing with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">animals and then, a drug or biotechnology company develops a prototype drug. That company must seek clearance from the FDA by way of an Investigational New Drug ("IND") application to test the product with human subjects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those tests, called clinical trials, are carried out sequentially in Phase I, II, and III studies, which involve increasing numbers of subjects. The manufacturer then compiles the resulting data and analyses in an NDA. The FDA reviews the NDA with three major concerns: (1) safety and effectiveness in the drug's proposed use; (2) appropriateness of the proposed labeling; and (3) adequacy of manufacturing methods to assure the drug's identity, strength, quality, and purity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA and associated regulations detail the requirements at each step. The FDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition. Those mechanisms include accelerated approval, fast track and priority reviews and the newer designation, breakthrough therapy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsor of the drug typically conducts human clinical trials in three sequential phases, but the phases may overlap. Phase I clinical trials are generally conducted in a small number of healthy volunteers, primarily to collect and assess pharmacokinetics and safety data at one or more dosages prior to proceeding into patients. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Phase II clinical trials, the sponsor evaluates the early efficacy of the product in short term trials on the targeted indication and identifies possible adverse effects and safety risks in a patient population. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase III clinical trials typically involve testing for patients in long term trials examining safety and clinical efficacy in an expanded population at geographically-dispersed test sites.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires that clinical trials be conducted in accordance with the FDA's Good Clinical Practice GCP requirements. The FDA may order the partial, temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The institutional review board ("IRB"), or ethics committee (outside of the U.S.), of each clinical site generally must approve the clinical trial design and patient informed consent and may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the nonclinical and clinical trials, together with detailed information on the manufacturing and composition of the product and proposed labeling, are submitted to the FDA in the form of an NDA for marketing approval. The NDA undergoes a 60-day validation review period before it is accepted for filing. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is found to be incomplete, it will not be accepted.  Once the NDA is validated and accepted for filing, the FDA begins an in-depth review of the NDA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA (currently PDUFA VI - effective October 1, 2017), the FDA has a target timeline of 10 months in which to complete its initial review of a standard NDA and respond to the applicant. The review process and the PDUFA goal date may be extended by two months to address deficiencies, or by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission at any time during the review clock period. If the FDA's evaluations of the NDA and the clinical and manufacturing procedures and facilities are favorable and meet all regulations, the FDA will issue an approval letter. Priority review is reserved for drugs that represent a &#8220;significant improvement in safety or efficacy&#8221; over existing treatments and FDA endeavors to complete these reviews in six months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA meets with FDA approval, a letter will be sent out indicating approval and final labeling recommendations. If not, a complete response letter will be sent to applicants indicating that the review cycle for an application is complete and that the application is not ready for approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complete response letter will describe the specific deficiencies that the agency has identified in an application and what changes must be made before the application can be approved, with no implication regarding whether the application will ultimately be approved.  An approval letter authorizes commercial marketing of the drug for the proposed indication(s) under study. FDA reported that NDAs showed a steadier increase with the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage of first-cycle approval letters for new molecular entities rising from 56% for FY 2009 applications to 89% for FY 2018 applications. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time and cost of completing these steps and obtaining FDA approval can vary dramatically depending on the drug. However, to complete these steps for a novel drug can take many years and cost millions of dollars.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(b) New Drug Applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA may be submitted under different methods, a 505(b)(1), 505(b)(2) or 505(j). Section 505(b) provides for the submission of an NDA to support the approval of a drug. Upon approval, a drug may be marketed only for the FDA-approved indication(s) in the approved dosage form. Further clinical trials may be necessary to gain approval for the use of the product for any additional indications or dosage forms. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also requires post market safety surveillance reporting to monitor the side effects of the drug, which may result in withdrawal of approval after marketing begins if significant adverse safety findings are found.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(1) or the 'full' NDA is used for new chemical entities ("NCEs") and requires full clinical and nonclinical development of a compound. Marketing exclusivity assigned to a 505(b)(1) approval is five years. A 505(b)(2) NDA permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant using previously reported safety and efficacy data, and for which the applicant has not obtained a right of reference. Generally new studies are required to provide data on the proposed change. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs which have a new dosage form, strength, route of administration, formulation or indication or combination drugs. Marketing exclusivity for a 505(b)(2) submission is three years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both 505 (b)(1) and (b)(2) are eligible for seven years of exclusivity for orphan drugs and/or six months for pediatric exclusivity. Any marketing exclusivity is independent of patent exclusivity.  We successfully secured FDA approvals for Acetadote in January 2004, for Caldolor in June 2009 and for RediTrex in 2019 pursuant to the 505(b)(2) pathway. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orphan Drug Act of 1983 (the "Orphan Drug Act") encourages manufacturers to seek approval of products intended to treat &#8220;rare diseases and conditions&#8221; with a prevalence of fewer than 200,000 patients in the U.S. or for which there is no reasonable expectation of recovering the development costs for the product. For products that receive orphan drug designation by the FDA, the Orphan Drug Act provides tax credits for clinical research, FDA assistance with protocol design, eligibility for FDA grants to fund clinical studies, waiver of the FDA application fee, and a period of seven years of marketing exclusivity for the product following FDA marketing approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received Orphan Drug designation in October 2001 and in 2004 the FDA approved the product to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Acetadote was entitled to marketing exclusivity until January 2011 for the treatment of this approved indication.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(j) abbreviated new drug applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ANDA is a type of NDA where approval of a generic drug is based on demonstrating comparability to an innovator drug product (the RLD or Reference Listed Drug). Applications are "abbreviated" because they generally don't include preclinical and clinical data to establish safety and effectiveness. Generics must demonstrate that the product is bioequivalent (i.e., performs in the same manner and is comparable to the 'innovator' product in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics and intended use). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbreviated applications may be submitted for drug products that are the same as a listed drug and must be identical in active ingredient(s), form, strength, route of administration, and identical in conditions of use (non-exclusive uses).  Products are declared suitable based on a suitability petition to the FDA. If the petition is approved, the Sponsor may then submit the ANDA.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act, informally known as the "Hatch-Waxman Act", is a 1984 United States federal law which established the modern system of generic drugs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hatch-Waxman amended the Federal Food, Drug, and Cosmetic Act. Section 505(j) 21 U.S.C. 355(j) sets forth the process by which would-be marketers of generic drugs can file ANDAs to seek FDA approval of the generic. Section 505(j)(2)(A)(vii)(IV), the so-called Paragraph IV, allows 180-day exclusivity to companies that are the "first-to-file" an ANDA against holders of patents for branded counterparts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These Hatch-Waxman amendments grant generic manufacturers the ability to mount a validity challenge without incurring the cost of entry or risking enormous damages flowing from any possible infringement. Hatch-Waxman essentially redistributes the relative risk assessments and explains the flow of settlement funds and their magnitude. Hatch-Waxman gives generics considerable leverage in patent litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care legislation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act, or PPACA. On March 30, 2010, the Health Care and Education Reconciliation Act of 2010, or HCERA, was enacted into law, which modified the revenue provisions of the PPACA. The PPACA as amended by the HCERA constitutes the healthcare reform legislation. The following highlights certain provisions of the legislation that may affect us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Industry Fee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in calendar-year 2011, an annual fee was imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs (e.g., Medicare Part D, Medicare Part B, Medicaid, Department of Veterans Affairs programs, Department of Defense programs and TRICARE). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual fee is allocated to companies based on their previous calendar-year market share using sales data that the government agencies that purchase the pharmaceuticals will provide to the Treasury Department. Although we participate in governmental programs that subject us to this fee, our sales volume in such programs is less than $10 million, with the first $5 million of sales being exempt from the fee. This fee has not had a material impact and is not expected to have a material impact on our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Payments Sunshine Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPACA also includes provisions known as the Physician Payments Sunshine Act, or Sunshine Act, which require manufacturers of pharmaceuticals and medical devices covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services, or CMS, for aggregation and subsequent public disclosure. Under the Sunshine Act, beginning August 1, 2013, we have collected data regarding reportable transfers of value and have reported such data to CMS. Failure to report appropriate data may result in civil or criminal fines and/or penalties.  In addition to the Federal Sunshine Act, similar reporting requirements have also been enacted on the state level requiring transparency of interactions with health care professionals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid Rebate Rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently provide rebates for products sold to Medicaid beneficiaries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Serialization:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November of 2013, the FDA passed the Drug Supply Chain Security Act (DSCSA). The DSCSA was created to strengthen the security of the drug distribution supply chain by adding controls such as a national pharmaceutical track and trace system and establishing national standards for licensing of prescription drug wholesale distributors and third-party logistics providers. DSCSA requires trading partners, including manufacturers, repackagers, wholesale distributors and dispensers to provide transaction information to subsequent purchasers for certain prescription drugs. We have taken necessary steps to implement this program and are in compliance with all requirements by the November 2018 deadline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Century Cures Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently. The law builds on FDA's ongoing work to incorporate the perspectives of patients into the development of drugs, biological products, and devices in FDA's decision-making process. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cures Act enhances FDA's ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Cures Act enables us to work with FDA in the development of new biomarkers, clinical outcome assessments, surrogate endpoints, and patient reported outcomes. It allows for the use of data summaries rather than full clinical trials for approval and the use of real world evidence to support approval of new indications of approved medical products, or to help satisfy post-approval study requirements for marketed products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post Approval Activities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a drug is on the U.S. market (following FDA approval of the NDA), the FDA continues to address drug production, distribution, and use. FDA activities are based on ensuring drug safety and effectiveness, and address product integrity, labeling, reporting of research and adverse events, surveillance, drug studies, risk management, information dissemination, off-label use, physician advertising and direct-to-consumer advertising.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we amend the NDA for an FDA approved product, such as adding safety or efficacy labeling claims, promoting those new claims, making certain manufacturing changes or product enhancements, we will need FDA review and approval before the change can be implemented. While physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication that has not been approved. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing FDA approval for new indications, product enhancements, and manufacturing and labeling changes may require us to conduct additional clinical trials under FDA's IND regulations. Even if such studies are conducted, they are still subject to the same requirements and timelines as an original NDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA continuously gathers information about possible adverse reactions to the products it has approved for use. The FDA requires all manufacturers to report adverse events. It also provides a procedure for consumers and physicians to voluntarily report their concerns about drugs. The agency collects those reports through MedWatch and uses its FDA Adverse Event Reporting System (FAERS) to store and analyze them. Because some events may occur after the use of a drug for reasons unrelated to the product, the FDA reviews the events to assess which ones may indicate a problem with that particular drug. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They then use information gleaned from the surveillance data to determine a course of action. They might recommend a change in drug labeling to alert users to a potential problem, or, perhaps, to require the manufacturer to study the observed association between the drug and the adverse event.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal health care program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid or other federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal health care programs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal False Claims Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of pharmaceutical and other health care companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ICH - International Committee on Harmonization</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., our ability to market our products will depend on receiving marketing authorizations from the appropriate regulatory authorities. The International Committee on Harmonization (ICH) provides a set of standards that most Regulatory Authorities adhere to (e.g. U.S., Europe, and Japan) allowing greater harmonization in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration, thereby reducing or obviating duplication of testing carried out during the research and development of new human medicines. Regulatory harmonization offers many direct benefits to both regulatory authorities and the pharmaceutical industry with beneficial impact for the protection of public health.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_61"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state and local environmental laws and regulations and we believe that our operations comply with such regulations. We anticipate that the effects of compliance with federal, state and local laws and regulations relating to the discharge of materials into the environment will not have any material effect on our capital expenditures, earnings or competitive position.   </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_64"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEASONALITY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no significant seasonal aspects to our business.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_67"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKLOG</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the relatively short lead-time required to fill orders for our products, backlog of orders is not considered material to our business.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_70"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 90 employees.  We believe that our future will depend in part on our continued ability to attract, hire, and retain qualified personnel, including hospital and field sales personnel in particular.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_1236"></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make statements in this Annual Report on Form&#160;10-K that are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statement of historical facts may be forward-looking statements.  In particular, forward-looking statements include, among other things, statements regarding our intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate&#8221; and other comparable terms or the negative thereof. In addition, we, through our senior management, from time to time make forward-looking oral and written public statements concerning our expected future operations and other developments. While forward-looking statements reflect our good-faith beliefs and best judgment based upon current information, they are not guarantees of future performance and are subject to known and unknown risks and uncertainties, including those mentioned in Item&#160;1A, &#8220;Risk Factors,&#8221; Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Form&#160;10-K. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from the expectations contained in the forward-looking statements as a result of various factors. Such factors include, but are not limited to:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The possible or assumed future results of operations, including the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in national or regional economic conditions, including changes in interest rates and the availability and the cost of capital to us;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The extent of the impact of the COVID-19 pandemic, including the duration and any recurrence of the COVID-19 pandemic, the duration and scope of related government orders and restrictions, the impact on our employees, and the extent of the impact of the COVID-19 pandemic on overall demand for our key products; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of the COVID-19 pandemic on our suppliers, including any disruptions and inefficiencies in the supply chain for our products; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitive position and competitors, including the size and growth potential of the markets for our products and product candidates;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success, cost and timing of our product acquisition and development activities and clinical trials; and our ability to successfully commercialize our product candidates;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, resulting in product withdrawals, recalls, regulatory action on the part of the FDA (or international counterparts) or declining sales;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of our third-party suppliers and manufacturers which impacts our supply chain and could create business shutdowns or product shortages; and the retention of key scientific and management personnel;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to our patents and the introduction of generic versions of our products and product candidates, which could negatively impact our ability to commercialize and sell our products and product candidates and decrease sales a result of market exclusivity;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in reimbursement available to us, including changes in Medicare and Medicaid payment levels and availability of third-party insurance coverage and the effects of future legislation or regulations, including changes to regulatory approval of new products, licensing and patent rights, environmental protection and possible drug re-importation legislation;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of our computer and communications systems, and those of our vendors, including computer viruses, hacking and cyber-attacks, that could impair our ability to conduct business and communicate internally and with our customers, or result in the theft of trade secrets or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other misappropriation of assets, or otherwise compromise privacy of sensitive information belonging to us, our customers or other business partners; and </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and the Securities and Exchange Commission. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The list above contains many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1A. Risk Factors.</span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factor Summary</span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Annual Report on Form 10-K prior to investing in our common stock. These risks are discussed more fully in the section titled &#8220;Risk Factors.&#8221; These risks and uncertainties include, but are not limited to, the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">General economic conditions can have a material adverse effect on our business, financial conditions and result of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The ongoing COVID-19 pandemic may adversely affect our revenues, results of operations and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to implement strategies to enhance our performance could have a material adverse effect on our business, results of operations and financial conditions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to perform depends on keeping and hiring exceptionally talented management and employees, and our failure to do so could have a material adverse effect on our business, revenues, results of operations and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our success depends, in part, on our ability to successfully obtain or retain high-performing third-party performers on commercially acceptable terms, and the failure to do so can have a material adverse effect on our business, financial conditions and results of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business is subject to stringent government regulations, it must adhere to numerous complex pieces of legislation, and all of our products face regulatory challenges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business depends on the successful protection of our intellectual property rights and our product candidates becoming approved by regulatory agencies, commercially viable, and accepted by the market.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business faces a serious financial risk if generic products that compete with any of our branded pharmaceutical products are approved and sold because sales of our products will be adversely-affected and our business may not recover the capital costs of bringing that product to market.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business faces an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products, and if we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may attempt to develop internationally and license our products globally, as well as invest in other businesses or joint ventures, all of which may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors described below and throughout this report should be carefully considered and could materially affect our business. There are also risks that are not presently known or not presently material, as well as the other information set forth in this report that could materially affect our business. In addition, in our periodic filings with the SEC, press releases and other statements, we discuss estimates and projections regarding our future performance and business outlook. By their nature, such &#8220;forward-looking statements&#8221; involve known and unknown risks, uncertainties and other factors that in some cases are out of our control. For a further discussion of forward-looking statements, please refer to the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These factors could cause our actual results to differ materially from our historical results or our present expectations and projections. These risk factors and uncertainties include, but are not limited to the following:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business could be adversely affected by natural disasters, public health epidemics, and other events beyond our control.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been adversely impacted by the recent coronavirus (&#8220;COVID-19&#8221;) outbreak which has affected more than 200 countries and has significantly disrupted the day-to-day activities of both individuals and companies. For example, we have been following the recommendations of health authorities to minimize exposure risk for our employees since March 2020, including allowing employees to work remotely to the extent possible. This has included our home office employees and our hospital and field based sales representatives. We rely on individuals and third-party organizations around the world to supply components, manufacture and distribute our products and execute our clinical trials. We are aware of a few instances where these individuals and third-party organizations were adversely impacted by the COVID-19 pandemic. We may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic&#8217;s impact on global markets could affect our future access to liquidity and materially adversely affect our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus has spread throughout much of the world after initially surfacing in Wuhan, China in December 2019. State and local authorities in the United States, like their counterparts in many other countries, have since forced many businesses to temporarily shut down in an attempt to slow the spread of the virus, and Americans are being told by public officials to practice &#8220;social distancing.&#8221; Global stock markets have reacted very negatively, and economists are projecting a sharp economic slowdown, at least in the near term, even as governments take emergency relief measures. While the economic impact brought by, and the duration of, COVID-19 is difficult to assess or predict, the COVID-19 pandemic could result in significant disruption of global financial markets, reducing our ability to access capital in the future, which could negatively affect our liquidity in the future. The situation is constantly evolving, however, so the extent to which the COVID-19 outbreak will impact businesses and the economy is highly uncertain and cannot be predicted. Accordingly, we cannot predict the extent to which our results of operations, financial condition and cash flows will be affected.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An adverse development regarding our products could have a material and adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of factors may impact the effectiveness of our marketing and sales activities and the demand for our products, including:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in intellectual property protection available for our products or competing treatments; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any unfavorable publicity concerning us, our products, or the markets for these products such as information concerning product contamination or other safety issues in any of our product markets, whether or not directly involving our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perception by physicians and other members of the healthcare community of the safety or efficacy of our products or competing products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory developments related to our marketing and promotional practices or the manufacture or continued use of our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The prices of our products relative to other drugs or competing treatments;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of current or additional generic competitors;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability and level of third-party reimbursement for sales of our products;&#160;and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The continued availability of adequate supplies of our products to meet demand.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If demand for our products weaken, our revenues and profitability will likely decline. Known adverse effects of our marketed products are documented in product labeling, including the product package inserts, medical information disclosed to medical professionals and all marketing-related materials. At this time, no unforeseen or serious adverse effects outside of those specified in current product labeling have been directly attributed to our approved products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market and sell seven products: Acetadote, Caldolor, Kristalose, Vaprisol, Omeclamox-Pak, and Vibativ with RediTrex being marketed since late 2020. A product contamination or other safety or regulatory issues, such as a failure to meet certain FDA reporting requirements involving our products could negatively impact us and possibly lead to a product recall. In addition, changes impacting any of our products in areas such as competition, lack of market acceptance or demand, government regulation, intellectual property, reimbursement and manufacturing could have an adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has requested prescribers and manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 milligrams (mg) in each tablet or capsule. The FDA requested this action to protect consumers from the risk of severe liver damage which can result from excess acetaminophen. This category of prescription drugs combines acetaminophen with another ingredient intended to treat pain (most often an opioid), and these products are commonly prescribed to consumers for pain, such as pain from acute injuries, post-operative pain, or pain following dental procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also requires manufacturers to appropriately label all prescription combination acetaminophen products to warn of the potential risk for severe liver injury. The actions the FDA is taking for prescription acetaminophen combination products do not affect over-the-counter acetaminophen products. The FDA's regulation of acetaminophen in prescription combination products and over-the-counter products may reduce the number of acetaminophen overdoses which could result in a lower demand for Acetadote. If the demand for Acetadote decreases, it could have an adverse impact on our future revenues and profitability. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of Caldolor is dependent on many third-parties, including physicians, pharmacists, hospital pharmacy and therapeutics committees, or P&amp;T committees, suppliers and distributors, all of whom we have little or no control over. We expect Caldolor to continue to be administered primarily to hospital and surgery center patients who are unable to receive oral therapies for the treatment of pain or fever. Before we can distribute Caldolor to any new hospital customers, Caldolor must be approved for addition to the hospitals&#8217; formulary lists by their P&amp;T committees. A hospital&#8217;s P&amp;T committee generally governs all matters pertaining to the use of medications within the institution, including review of medication formulary data and recommendations of drugs to the medical staff. We cannot guarantee that we will be successful in getting the approvals we need from enough P&amp;T committees to be able to optimize hospital sales of Caldolor. Even if we obtain hospital approval for Caldolor, we must still convince individual hospital physicians to prescribe Caldolor repeatedly.  The commercial success of Caldolor also depends on our ability to coordinate supply, distribution, marketing, sales and education efforts. As with our other products, if Caldolor is not accepted in the marketplace, it could have an adverse impact on our future revenues and profitability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not manufacture any of our products, and we do not currently plan to develop any capacity to do so. Our dependence upon third parties for the manufacture of our products could adversely affect our profit margins or our ability to develop and deliver products on a timely and competitive basis. If for any reason we are unable to obtain or retain third-party manufacturers on commercially acceptable terms, we may not be able to sell our products as planned. Furthermore, if we encounter delays or difficulties with contract manufacturers in producing our products, the distribution, marketing and subsequent sales of these products could be adversely affected.  A long-term inability to meet demand for our products could result in impairment of our brands overall future and the carrying value of the assets associated with our brands. The recent COVID-19 pandemic may create local issues for our third party-manufacturers and introduce delays in our manufacturing process. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with two manufacturers, and both manufacturers provided commercial supplies of the product during 2020.  If neither of the manufacturers of Acetadote are able to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We have agreements with multiple manufacturers for the supply of Caldolor and during 2020 we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements.  If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The active pharmaceutical ingredient for Kristalose is manufactured at a single facility by an international supplier. We also have manufacturing relationships with two packagers who provided finished supplies of the product for commercial and sampling purposes during 2020.  If these facilities are damaged or destroyed, or if local conditions result in a work stoppage, we could suffer an inability to meet demand for our product. Kristalose is manufactured through a complex process. It would be particularly difficult to find a new manufacturer of Kristalose active pharmaceutical ingredient on an expedited basis. As a result of these factors, our ability to manufacture Kristalose may be substantially impaired if the manufacturer is unable or unwilling to supply sufficient quantities of the product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our asset purchase agreement with GEL that closed in December 2018, GEL managed the packaging and supply of Omeclamox-Pak commercial and sample units. Following our acquisition of the remaining rights to the brand in late 2018, we assumed responsibility for the packaging and supply of the product.  During 2019 we entered into a new packaging arrangement for this product. The Company has been carefully monitoring its supply chain during the pandemic and preparing for its economic impact. The packager for Cumberland&#8217;s Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020, and have not provided a date for the availability of new inventory. Cumberland noted that there is currently some remaining inventory of the product in the distribution channels.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Vaprisol, we purchased an existing supply of raw material inventory.  In addition, as part of this transaction, we were assigned a commercial supply agreement with the historical Vaprisol manufacturer. In 2018, the manufacturer informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is providing us with a multi-year supply. We are currently working with a new manufacturer to provide us with long term supplies of the product.  If we are unable to produce additional marketable inventory in sufficient quantities of Vaprisol, we could suffer an inability to meet demand for our product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the manufacture of the product and completed the transfer of the product&#8217;s manufacturing activities to a new supplier during 2020. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our agreement with Nordic, they are responsible for providing us the packaged and labeled commercial supply of the RediTrex product. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products and product candidates must comply with current good manufacturing practices, ("GMPs"), enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our products may be unable to comply with GMP requirements and with other FDA, state and foreign regulatory requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no control over our manufacturers&#8217; compliance with these regulations and standards. If our third-party manufacturers do not comply with these requirements, we could be subject to:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fines and civil penalties;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension of production or distribution;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or delay in product approval;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or recall;&#160;and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawal of product approval.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on a variety of other third parties. If these third parties fail to perform as we expect, our operations could be disrupted and our financial results could suffer.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a relatively small internal infrastructure. We rely on a variety of third parties, in addition to our manufacturers, to help us operate our business. Other third parties on which we rely include:</span></div><div style="margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cardinal Health Specialty Pharmaceutical Services, a logistics and fulfillment company and business unit of Cardinal, which bills for, collects, warehouses and ships our marketed products;&#160;and</span></div><div style="margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanderbilt University, WinHealth and the Tennessee Technology Development Corporation, co-owners with us of CET, and the universities that collaborate with us in connection with CET's research and development programs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not continue to provide services to us, or collaborate with us, we might not be able to obtain others who can serve these functions. This could disrupt our business operations, increase our operating expenses or otherwise adversely affect our operating results. The recent COVID-19 pandemic may create additional risk and delays at our independent third-party service providers. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive pressures could reduce our revenues and profits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is intensely competitive. Our strategy is to target differentiated products in specialized markets. However, this strategy does not relieve us from competitive pressures and can entail distinct competitive risks. Certain of our competitors do not aggressively promote their products in our markets. An increase in promotional activity in our markets could result in large shifts in market share, adversely impacting us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may sell or develop drugs that are more effective and useful or less costly than ours, and they may be more successful in manufacturing and marketing their products. Many of our competitors have significantly greater financial and marketing resources than we do. Additional competitors may enter our markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by constant and significant investment in new product development, which can result in rapid technological change. The introduction of new products could substantially reduce our market share or render our products obsolete. The selling prices of pharmaceutical products tend to decline as competition increases, through new product introduction or otherwise, which could reduce our revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If generic products that compete with any of our branded pharmaceutical products are approved and sold, sales of our products will be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic equivalents for branded pharmaceutical products are typically sold at lower costs than the branded products. The regulatory approval process in the United States exempts generic products from costly and time-consuming clinical trials to demonstrate their safety and efficacy and rely instead on the safety and efficacy of prior products, manufacturers of generic products can invest far less in research and development.&#160;&#160;After the introduction of a competing generic product, a significant percentage of the prescriptions previously written for the branded product are often written for the generic version.&#160;&#160;In addition, legislation enacted in most U.S. states allows or, in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded product, in the absence of specific instructions from the prescribing physician. Governmental and private </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare payors also emphasize substitution of branded pharmaceuticals with less expensive generic equivalents.&#160;&#160;Pursuant to the provisions of the Hatch-Waxman Act, manufacturers of branded products often bring lawsuits to enforce their patent rights against generic products released prior to the expiration of branded products&#8217; patents, but it is possible for generic manufacturers to offer generic products while such litigation is pending.&#160;&#160;As a result, branded products typically experience a significant loss in revenues following the introduction of a competing generic product, even if subject to an existing patent.&#160;&#160;Our branded pharmaceutical products are or may become subject to competition from generic equivalents because there is no proprietary protection for some of the branded pharmaceutical products we sell, because our patent protection expires or because our patent protection is not sufficiently broad or enforceable.&#160;&#160;In addition, we may not be successful in our efforts to extend the proprietary protection afforded our branded products through the development and commercialization of proprietary product improvements. Competition from generic equivalents could result in a decrease in revenues of our branded pharmaceuticals or result in a material impairment of our intangible assets or the acceleration of amortization on our non-impaired intangible assets and may have a material adverse impact on our revenues, financial condition, results of operations and cash flows.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any attempt by us to expand the potential market for any of our products is subject to limitations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expansion of the market for our products may be subject to certain limitations. In the past, these limitations have included FDA required Phase&#160;IV commitments. We may also experience delays associated with future required Phase&#160;IV clinical studies potentially resulting from, among other factors, difficulty enrolling patients. Such delays could impact our ability to explore opportunities for label expansion and limit our ability to bring our products to new patient populations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have largely obtained regulatory approval to market our products in the United States. Not all foreign jurisdictions may represent attractive opportunities for our products due to pricing, competitive, regulatory or other factors. In certain foreign jurisdictions, we have licensed the right to market some of our products to third parties. These third parties are responsible for seeking and maintaining regulatory approval for the products in their respective jurisdictions. We have no control over these third parties and cannot be sure that marketing approval for our products will be obtained outside the United&#160;States. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends on our ability to identify and acquire rights to products. If we do not successfully identify and acquire rights to products, our growth opportunities may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired rights to our products and our product candidates. Our business strategy is to continue to acquire rights to FDA-approved products as well as pharmaceutical product candidates in the late stages of development. We do not plan to conduct basic research or preclinical product development, except to the extent of our investment in CET. As compared to large multi-national pharmaceutical companies, we have limited resources to acquire third-party products, businesses and technologies and integrate them into our current infrastructure. Many acquisition opportunities involve competition among several potential purchasers including large multi-national pharmaceutical companies and other competitors that have access to greater financial resources than we do. With future acquisitions, we may face financial and operational risks and uncertainties. We may not be able to engage in future product acquisitions, and those we do complete may not be beneficial to us in the long term.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, other products in development may encounter unforeseen issues during their clinical trials. Any unforeseen issues or lack of FDA approval will negatively affect marketing and development plans for those products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends on our ability to successfully integrate acquired product brands into our operations. If we do not successfully integrate acquired product brands into our operations, our growth opportunities may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We added six marketed products to our portfolio of brands, roughly one brand per year, beginning in late 2013 through the launch of RediTrex during late 2020. If we are unable to continue to optimize our sales of our brands or we are unable to successfully integrate the marketing, sale and distribution of any other potential products into our current infrastructure or if they require significantly greater resources than originally anticipated, we may face </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial and operational risks and uncertainties. If we are unable to successfully integrate any acquired brands, both current and future, these product acquisitions may not be beneficial to us in the long term. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Hepatoren, Boxaban, Vasculan, and Portaban product candidates have not been approved for sale and may never be successfully commercialized.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that a portion of our future revenue growth will come from sales of our Hepatoren, Boxaban, Vasculan, and Portaban product candidates. Hepatoren (intravenous ifetroban) is used to treat hepatorenal syndrome ("HRS"), Boxaban (oral ifetroban) is used to treat aspirin exacerbated respiratory disease ("AERD"), Vasculan (oral ifetroban) is for the treatment of systemic sclerosis ("SSc"), and Portaban (injection and oral ifetroban) is for the treatment of portal hypertension associated with liver disease.  However, none of these products have been approved by the FDA for marketing, and these product candidates are still subject to risks associated with their development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has cleared our IND's for the ifetroban product candidates as we evaluate them as treatments for these conditions. Delays in the enrollment and completion of the clinical studies could significantly delay commercial launch and affect our product development costs. Moreover, results from the clinical studies may not be favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if they are eventually developed and approved by the FDA, they may never gain significant acceptance in the marketplace and therefore never generate substantial revenue or profits for us. Physicians may determine that existing drugs are adequate to address patients' needs. The extent to which these product candidates will be reimbursed by the U.S. government or third-party payors is also currently unknown.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing and other factors, we do not know the extent to which our product candidates will contribute to our future growth.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain, train and build an effective sales and marketing infrastructure, we will not be able to commercialize and grow our products and product candidates successfully.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow, we may not be able to secure sales personnel or organizations that are adequate in number or expertise to successfully market and sell our products. This risk would be accentuated if we acquire products in areas outside of our current focus areas since our sales forces specialize in our existing areas. If we are unable to expand our sales and marketing capability, train our sales force effectively or provide any other capabilities necessary to commercialize our products and product candidates, we will need to contract with third parties to market and sell our products. We must train our employees on proper regulatory compliance, including, but not limited to, &#8220;fair balance&#8221; promotion of our products and anti-kickback laws. If we are unable to establish and maintain compliant and adequate sales and marketing capabilities, we may not be able to increase our product revenue, may generate increased expenses and may experience regulatory compliance issues.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If governmental or third-party payors do not provide adequate reimbursement for our products, our revenue and prospects for profitability may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial success depends, in part, on the availability of adequate reimbursement from third-party healthcare payors. Such third-party payors include governmental health programs such as Medicare and Medicaid, managed care providers and private health insurers. Third-party payors are increasingly challenging the pricing of medical products and services, while governments continue to propose and pass legislation designed to reduce the cost of healthcare. Adoption of such legislation could further limit reimbursement for pharmaceuticals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the U.S.&#160;government passed into law the Patient Protection and Affordable Care Act, ("PPACA") along with the Health Care and Education Reconciliation Act of 2010, ("HCERA"), which modified the revenue provisions of the PPACA. The legislation calls for an increase in certain Medicare drug rebates paid by pharmaceutical manufacturers and an industry fee imposed on pharmaceutical manufacturers according to the individual manufacturer&#8217;s relative percentage of total industry sales to specified government programs. At this time no assurances can be given that these measures, or any other measures included in the Healthcare Reform Act, will not have an adverse effect on our revenues in the future. Future cost control initiatives, legislation and regulations could decrease the price that we receive for any products, which would limit our revenue and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, other legislative changes have been proposed and adopted. These changes included aggregate reductions of Medicare payments to providers of up to two percent per fiscal year. Additionally, in January 2013, the American Taxpayer Relief Act of 2012, was signed into law which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, while the healthcare reform agenda and policies of the current administration are not fully known, it is possible that additional regulatory changes may take place. This includes a repeal of all or portions of the PPACA, and Congress could be asked to replace the current legislation of the PPACA. There is uncertainty with respect to the timing and impact of any changes. These changes could have an impact on coverage and reimbursement for healthcare products and services covered by plans that were authorized by the PPACA. At this time, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, reimbursement practices of third-party payors might preclude us from achieving market acceptance for our products or maintaining price levels sufficient to realize an appropriate return on our investment in product acquisition and development. If we cannot obtain adequate reimbursement levels, our business, financial condition and results of operations would be materially and adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees have been trained to submit accurate and correct pricing information to payors. If, despite the training, our employees provide incorrect or fraudulent information, then we will be subject to various administrative and judicial investigations and litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Formulary&#8221; practices of third-party payors could adversely affect our competitive position.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many managed healthcare organizations are now controlling the pharmaceutical products included on their formulary lists. Having products listed on these formulary lists creates competition among pharmaceutical companies which, in turn, has created a trend of downward pricing pressure in our industry. In addition, many managed care organizations are pursuing various ways to reduce pharmaceutical costs and are considering formulary contracts primarily with those pharmaceutical companies that can offer a full line of products for a given therapy sector or disease state. Our products might not be included on the formulary lists of managed care organizations, and downward pricing pressure in our industry generally could negatively impact our operations.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continued consolidation of distributor networks in the pharmaceutical industry as well as increases in retailer concentration may limit our ability to profitably sell our products.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products to large pharmaceutical wholesalers, who in turn sell to hospitals, surgery centers and retail pharmacies. The distribution network for pharmaceutical products has become increasingly consolidated in recent years. Further consolidation or financial difficulties could also cause our customers to reduce the amounts of our products that they purchase, adversely impacting our business, financial condition and results of operations.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CET joint initiative may not result in our gaining access to commercially viable products.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CET joint initiative with Vanderbilt University, WinHealth and Tennessee Technology Development Corporation is designed to help us investigate, in a cost-effective manner, early-stage products and technologies. However, we may never gain access to commercially viable products from CET for a variety of reasons, including:</span></div><div style="margin-top:7pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET investigates early-stage products, which have risk of failure prior to FDA approval and commercialization;</span></div><div style="margin-top:7pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In some programs, we do not have pre-set rights to product candidates developed by CET. We would need to agree with CET and its collaborators on the terms of any product licensed or acquired by us;</span></div><div style="margin-top:7pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely principally on government grants to fund&#160;CET&#8217;s research and development programs. If these grants were no longer available, we or our co-owners might be unable or unwilling to fund&#160;CET operations at current levels or at all;</span></div><div style="margin-top:7pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in disputes with our co-owners regarding CET policy or operations, such as how best to deploy CET assets or which product opportunities to pursue. Disagreement could disrupt or halt product development;&#160;and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:7pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET may disagree with one of the various universities with which CET is collaborating on research. A disagreement could disrupt or halt product development.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our key personnel, the loss of whom would adversely affect our operations. If we fail to attract and retain the talent required for our business, our business will be materially harmed.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a relatively small company, and we depend to a great extent on principal members of our management, scientific staff, and sales representatives and managers. If we lose the services of any key personnel, in particular, A.J. Kazimi, our Chief Executive Officer, or other members of senior management it could have a material adverse effect on our business prospects. Mr.&#160;Kazimi, plays a key role in several operational and strategic decisions such that any loss of his services due to death or disability would adversely impact our day-to-day operations. We have a life insurance policy covering the life of Mr. Kazimi. We have entered into agreements with each of our employees that contain restrictive covenants relating to non-competition and non-solicitation of our customers and suppliers for one year after termination of employment. Nevertheless, each of our officers and key employees may terminate his or her employment at any time without notice and without cause or good reason, and so as a practical matter these agreements do not guarantee the continued service of these employees. Our success depends on our ability to attract and retain highly qualified scientific, technical, sales and managerial personnel and research partners. Competition among pharmaceutical companies for qualified employees is intense, and we may not be able to retain existing personnel or attract and retain qualified staff in the future. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results.  The recent COVID-19 pandemic may introduce additional challenges in the retention and hiring of key personnel.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of our organization and our potential growth may lead to difficulties in managing operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 90 employees. We may need to continue to expand our managerial, operational, financial and other resources in order to increase our marketing efforts with regard to our currently marketed products, continue our business development and product development activities and commercialize our product candidates. We have experienced, and may continue to experience, growth and increased expenses in the scope of our operations in connection with the continued marketing and development of our products. Our financial performance will depend, in part, on our ability to manage any such growth and expenses of the current organization effectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product or product candidate and may have to limit its commercialization.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products. An individual may bring a liability claim against us if one of our product candidates or products causes, or appears to have caused, an injury. If we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities. Liability claims may result in:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased demand for our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injury to our reputation;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawal of clinical trial participants;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant litigation costs;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Substantial monetary awards to or costly settlement with patients;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product recalls;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of revenue;&#160;and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to commercialize our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon medical and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we or our products are subject to negative publicity. We could also be adversely affected if any of our products or any similar products sold by other companies prove to be, or are asserted to be, harmful to patients. Also, because of our dependence upon medical and patient perceptions, any adverse publicity associated with illness or other adverse effects resulting from the use or misuse of our products or any similar products sold by other companies could have a material adverse impact on our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product liability insurance that covers our clinical trials, the marketing and sale of our products up to a $10&#160;million annual aggregate limit, subject to specified deductibles. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S.&#160;generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to suspend or withdraw an approved product from the market, require a recall or payment of fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures, security breaches, including any cybersecurity incidents, adverse events or other disruptions within our information technology infrastructure at our corporate headquarters.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, including those at our corporate headquarters, are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. In the ordinary course of our business, we store sensitive data, including intellectual property, our proprietary business information and that of our customers.  We also maintain personally identifiable information of our employees in our data centers and on our networks. The secure processing and maintenance of this information is critical to our operations. In the event that our corporate headquarters and/or our computer systems are disabled or materially damaged, it would have a substantial and material negative effect on our operations. Furthermore, any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our drug development programs. While we continue to invest in data protection and information technology, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability and the further development of our products or product candidates may be delayed. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may develop internationally and license our products globally; therefore, we may have an increased exposure to foreign regulatory requirements and fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have only obtained regulatory approval to market our products in the United States, in the future we may seek global opportunities for our products and to develop product candidates internationally in the future. Such opportunities and development will inherently subject us to a number of risks and uncertainties, including:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability or sanctions in areas in which we operate;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations related to customs and import/export matters (including sanctions);</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax issues, such as tax law changes and variations in tax laws;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in collecting accounts receivable from customers in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with laws, rules and regulations relating to the manufacturing, marketing, distribution and sale of pharmaceutical products in the jurisdictions in which we do or will operate;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating under regulations in jurisdictions related to obtaining eligibility for government or private payor reimbursement for our products at the wholesale/retail level;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from local, regional and international competitors;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations, including cultural and language differences and additional employment regulations, union workforce negotiations and potential disputes in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with compliance with a variety of laws and regulations governing international trade, including the Foreign Corrupt Practices Act;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. These or other similar risks could adversely affect our revenue and profitability. As we develop internationally, our exposure to these factors will increase.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more capital and time than we are willing to invest. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our drug candidates receives regulatory approval, it could be subject to post-regulatory surveillance, and may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing, and the drug product may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. As a result, we may not continue to commercialize a product even though it has obtained regulatory approval. Further, we may decide not to continue to commercialize a product if the market does not accept the product because it is too expensive or because third parties, such as insurance companies or Medicare, have not approved it for substantial reimbursement. In addition, we may decide not to continue to commercialize a product if competitors develop and commercialize similar or superior products or have proprietary rights that preclude us from ultimately marketing our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in gaining regulatory approval of any of our drug candidates or acquire rights to approved drug products, we may not generate significant product revenues and we may not become profitable if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our drug products until longer-term clinical data or other factors demonstrate the safety and efficacy of our drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third-party payors and the effectiveness of our competitors in marketing their products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness and ability of patients and the healthcare community to use our drug products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manufacture our drug products in sufficient quantities with acceptable quality and to offer our drug products for sale at competitive prices;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our drug products relative to existing treatments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions.  We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business.  Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our shareholders could result.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The acquisitions we have made or make in the future may make us the subject of lawsuits from either an acquired company&#8217;s shareholders, an acquired company&#8217;s previous shareholders, or our current shareholders.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be the subject of lawsuits from either an acquired company&#8217;s shareholders, an acquired company&#8217;s previous shareholders, or our current shareholders. These lawsuits could result from the actions of the acquisition target prior to the date of the acquisition, from the acquisition transaction itself, or from actions after the acquisition. Defending potential lawsuits could cost us significant expense and distract management&#8217;s attention from the operation of the business. Additionally, these lawsuits could result in the cancellation of, or the inability to renew, certain insurance coverage that would be necessary to protect our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to modify our business practices, pay fines and significant expenses or experience other losses due to governmental investigations or other enforcement activities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become subject to litigation or governmental investigations in the United States and foreign jurisdictions that may arise from the conduct of our business. Like many companies in our industry, we have from time to time received inquiries and other types of information requests from government authorities.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the ultimate outcomes of investigations and legal proceedings are difficult to predict, adverse resolutions or settlements of those matters could result in, among other things:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant damage awards, fines, penalties or other payments, and administrative remedies, such as exclusion and/or debarment from government programs, or other rulings that preclude us from operating our business in a certain manner;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes and additional costs to our business operations to avoid risks associated with such litigation or investigations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> reputational damage and decreased demand for our products; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditure of significant time and resources that would otherwise be available for operating our business. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_79"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent government regulation. All of our products face regulatory challenges.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all aspects of our business activities are regulated by government agencies. The manufacturing, processing, formulation, packaging, labeling, distribution, promotion and sampling, advertising of our products, and disposal of waste products arising from such activities are subject to governmental regulation. These activities are regulated by one or more of the FDA, the Federal Trade Commission, ("FTC"), the Consumer Product Safety Commission, the U.S.&#160;Department of Agriculture and the U.S.&#160;Environmental Protection Agency, ("EPA"), as well as by comparable agencies in foreign countries. These activities are also regulated by various agencies of the states and localities in which our products are sold. For more information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like all pharmaceutical manufacturers, we are subject to regulation by the FDA under the Federal Food, Drug and Cosmetic Act ("FDCA"). All new drugs must be the subject of an FDA-approved new drug application, ("NDA"), before they may be marketed in the United States. The FDA has the authority to withdraw existing NDA approvals and to review the regulatory status of products marketed under the enforcement policy. The FDA may require an approved NDA for any drug product marketed under the enforcement policy if new information reveals questions about the drug&#8217;s safety and effectiveness. All drugs must be manufactured in conformity with GMP, and drug products subject to an approved NDA must be manufactured, processed, packaged, held and labeled in accordance with information contained in the NDA. Since we rely on third parties to manufacture our products, GMP requirements directly affect our third party manufacturers and indirectly affect us. The manufacturing facilities of our third-party manufacturers are continually subject to inspection by such governmental agencies, and manufacturing operations could be interrupted or halted in any such facilities if such inspections prove unsatisfactory. Our third-party manufacturers are subject to periodic inspection by the FDA to assure such compliance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after regulatory approval, certain developments may decrease demand for our products, including the following:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the re-review of products that are already marketed;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new scientific information and evolution of scientific theories;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changing government standards or public expectations regarding safety, efficacy or labeling changes; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater scrutiny in advertising and promotion.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, clinical trials and post-marketing surveillance of certain marketed drugs of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products.&#160;&#160;If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of our products, it could significantly reduce demand for the product or require us to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes.&#160;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain health authorities, regulators and agencies have increased their focus on safety when assessing the balance of benefits and risks of drugs.&#160;&#160;Some health authorities appear to have become more cautious when making decisions about approvability of new products and are re-reviewing select products that are already marketed, adding further to the uncertainties in the regulatory processes.&#160;&#160;There is also greater regulatory scrutiny, especially in the U.S., on advertising, and promotion (in particular, direct-to-consumer advertising) and pricing of pharmaceutical products.&#160;&#160;Certain regulatory changes or decisions could make it more difficult for us to sell our products and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and other applicable regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory agency may impose restrictions on that product or the manufacturer, including withdrawal of the product from the market or suspension of manufacturing. If we, our partners or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may take the following actions, among others:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications submitted by us;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in the FDA&#8217;s enforcement policy could have a material adverse effect on our business, financial condition and results of operations.  We cannot determine what effect changes in regulations or statutes or legal interpretation, when and if promulgated or enacted, may have on our business in the future. Such changes, or new legislation, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent COVID-19 pandemic has introduced additional strain on the FDA. We are unable to fully understand the impact this may cause on regulations or the related timeframes pertaining to communication with the FDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed legislation may permit re-importation of drugs from other countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In previous years, legislation has been introduced in Congress that, if enacted, would permit more widespread re-importation of drugs from foreign countries into the U.S.,&#160;which may include re-importation from foreign countries where the drugs are sold at lower prices than in the U.S.&#160;Based on recent election results, there could be a renewed effort for legislation permitting the re-importation of prescription drugs as a means of lowering drug costs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such legislation, or similar regulatory changes, if enacted, could decrease the price we receive for any approved products which, in turn, could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Foreign Corrupt Practices Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Foreign Corrupt Practices Act, which prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business.&#160;Foreign companies, including some of our competitors, are not subject to these prohibitions.&#160;If our competitors engage in these practices, they may receive preferential treatment from officials or agencies in some countries, giving our competitors an advantage in securing business from government officials who might give them priority in obtaining new licenses, which would put us at a disadvantage.&#160;We have established formal policies or procedures for prohibiting or monitoring this conduct, but we cannot assure you that our employees or other agents will not engage in such conduct for which we might be held responsible.&#160;If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Physician Payment Sunshine Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Physician Payment Sunshine Act, which requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to physicians and teaching hospitals.  Manufacturers are required to report this information annually to The Centers for Medicare &amp; Medicaid Services ("CMS").  Cumberland has implemented a series of policies and procedures for every employee involved in the data collection process, and has systems in place to capture the data, which is verified by an outside firm that specializes in reporting the payments.  Cumberland has also established a system to ensure that data was reported completely, in the correct format, and on time.  Despite these policies, procedures and systems, we cannot assure you that we will collect and report all data accurately.  If we fail to accurately report this information, we could suffer severe penalties.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in and have certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we have obligations to report average sales price under the Medicare program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by us on a monthly and quarterly basis to CMS, the federal agency that administers the Medicaid Drug Rebate program. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the US in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthcare Reform Act made significant changes to the Medicaid Drug Rebate program, such as expanding rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well and changing the definition of average manufacturer price. The Healthcare Reform Act also increased the minimum Medicaid rebate; changed the calculation of the rebate for certain innovator products that qualify as line extensions of existing drugs; and capped the total rebate amount at 100% of the average manufacturer price. Finally, the Healthcare Reform Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Healthcare Reform Act. These regulations became effective on April 1, 2016. The issuance of the final regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program has and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we take in our implementation of the final regulations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that any company that participates in the Medicaid Drug Rebate program also participate in the Public Health Service's 340B drug pricing program in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge no more than the 340B "ceiling price" for the manufacturer's covered outpatient drugs to a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The Healthcare Reform Act expanded the list of covered entities to include certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals. The 340B ceiling price is calculated using a statutory formula based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program. Changes to the definition of average manufacturer price and the Medicaid rebate amount under the Healthcare Reform Act and CMS's final regulations implementing those changes also could affect our 340B ceiling price calculations and negatively impact our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthcare Reform Act obligates the Secretary of the Department of Health and Human Services ("HHS") to update the agreement that manufacturers must sign to participate in the 340B program to obligate a manufacturer to offer the 340B price to covered entities if the manufacturer makes the drug available to any other purchaser at any price and to report to the government the ceiling prices for its drugs. The Health Resources and Services Administration ("HRSA"), the federal agency that administers the 340B program, recently updated the agreement with participating manufacturers. The Healthcare Reform Act also obligates the Secretary of the HHS to create regulations and processes to improve the integrity of the 340B program. On January 5, 2017, HRSA issued a final regulation regarding the calculation of 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities. The regulation became effective as of January 1, 2019. Implementation of this final rule and the issuance of any other final regulations and guidance could affect our obligations under the 340B program in ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law also requires that a company that participates in the Medicaid Drug Rebate program report average sales price information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations. Also, the Medicare Part B drug payment methodology is subject to change based on potential demonstration projects undertaken by CMS or potential legislation enacted by Congress.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted any false price information to the government, we may be liable for civil monetary penalties. If we are found to have made a misrepresentation in the reporting of our average sales price, the Medicare statute provides for civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Our failure to submit the required price data on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of Inspector General ("OIG") have pursued manufacturers that were alleged to have failed to report these data to the government in a timely manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs we are required to participate in the VA Federal Supply Schedule ("FSS") pricing program, established under Section 603 of the Veterans Health Care Act of 1992. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and any response to government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent COVID-19 pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_82"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO INTELLECTUAL PROPERTY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy to secure and extend marketing exclusivity or patent rights may provide only limited or no protection from competition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to secure and extend marketing exclusivity for our products through a variety of means, including FDA exclusivity and patent rights. Additional barriers for competitors seeking to enter the market include the time and cost associated with the development, regulatory approval and manufacturing of a similar product formulation. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Part I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Patents, Trademarks, and Other Intellectual Proprietary Rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this report on Form 10-K, we have several patents for formulations of Acetadote, and have previously engaged in litigation to enforce our patent rights.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have additional patent applications relating to Acetadote which are pending with the USPTO and may or may not be issued.  We intend to continue to vigorously defend and protect our Acetadote product and related intellectual property rights. If we are unsuccessful in protecting our Acetadote intellectual property rights, our competitors may be able to introduce products into the marketplace that reduce the sales and market share of our Acetadote product which may require us to take measures such as reducing prices or increasing our marketing expense, any of which may result in a material adverse effect to our financial condition and results of operations. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider patent protection when evaluating product acquisition opportunities, any products we acquire in the future may not have significant patent protection. Neither the USPTO nor the courts have a consistent policy regarding the breadth of claims allowed or the degree of protection afforded under many pharmaceutical patents. Patent applications in the U.S.&#160;and many foreign jurisdictions are typically not published until 18&#160;months following the filing date of the first related application, and in some cases not at all. In addition, publication of discoveries in scientific literature often lags significantly behind actual discoveries. Therefore, neither we nor our licensors can be certain that we or they were the first to make the inventions claimed in our issued patents or pending patent applications, or that we or they were the first to file for protection of the inventions set forth in these patent applications. In addition, changes in either patent laws or in interpretations of patent laws in the U.S.&#160;and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Furthermore, our competitors may independently develop similar technologies or duplicate technology developed by us in a manner that does not infringe our patents or other intellectual property. As a result of these factors, our patent rights may not provide any commercially valuable protection from competing products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon trade secrets, unpatented proprietary know-how and continuing technological innovation where we do not believe patent protection is appropriate or attainable. For example, the manufacturing process for Kristalose involves substantial trade secrets and proprietary know-how. We have entered into confidentiality agreements with certain key employees and consultants pursuant to which such employees and consultants must assign to us any inventions relating to our business if made by them while they are our employees, as well as certain confidentiality agreements relating to the acquisition of rights to products. Confidentiality agreements can be breached, though, and we might not have adequate remedies for any breach. Also, others could acquire or independently develop similar technology.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on certain licensors for the maintenance and enforcement of intellectual property rights and have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we license products, we often depend on our licensors to protect the proprietary rights covering those products. We have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf or the priority they place on maintaining patent or other rights and prosecuting patent applications to our advantage. While any such licensor is expected to be contractually obligated to diligently pursue its patent applications and allow us the opportunity to consult, review and comment on patent office communications, we cannot be sure that it will perform as required. If a licensor does not perform and if we do not assume the maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the use of our technology conflicts with the intellectual property rights of third parties, we may incur substantial liabilities, and we may be unable to commercialize products based on this technology in a profitable manner or at all.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products conflict with the intellectual property rights of others, they could bring legal action against us or our licensors, licensees, manufacturers, customers or collaborators. If we were found to be infringing a patent or other intellectual property rights held by a third party, we could be forced to seek a license to use the patented or otherwise protected technology. We might not be able to obtain such a license on terms acceptable to us or at all. If legal action involving an alleged infringement or misappropriation were to be brought against us or our licensors, we would incur substantial costs in defending the action. If such a dispute were to be resolved against us, we could be subject to significant damages, and the manufacturing or sale of one or more of our products could be enjoined.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be costly and time consuming.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been involved in lawsuits for infringement of the Acetadote Patents as previously described.  Because of their nature, these lawsuits can be costly and time-consuming, and we only experience limited benefits and patent protection.  A significant adverse ruling in any such lawsuit could put our patents at risk of being invalidated or interpreted narrowly and could compromise the issuance of our existing patent applications. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe on our patents or the patents of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patent applications or those of our collaborators or licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management. We may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, some of our confidential information could be disclosed during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we breach any of the agreements under which we license rights to our products and product candidates from others, we could lose the ability to continue commercialization of our products and development and commercialization of our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive licenses for the marketing and sale of certain products and may acquire additional licenses. Such licenses may terminate prior to expiration if we breach our obligations under the license agreement related to these pharmaceutical products. For example, the licenses may terminate if we fail to meet specified quality control standards, including GMP with respect to the products, or commit a material breach of other terms and conditions of the licenses. Such early termination could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or these employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_85"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are likely to fluctuate from period to period.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a company actively seeking to deliver significant growth. As we execute our business strategy of adding new products, increasing market share in our existing growth products and striving to maintain market share in our other products, we anticipate that there may be fluctuations in our future operating results. We may not be able to maintain or improve our current levels of revenue or income. Potential causes of future fluctuations in our operating results may include:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New product launches, which could increase revenues but also increase sales and marketing expenses;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition activity and other charges;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases in research and development expenses resulting from the acquisition of a product candidate that requires significant additional studies and development;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ability to utilize unrecognized federal and state net operating loss carryforwards as a result of the exercise of nonqualified options </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the competitive, regulatory or reimbursement environment, which could drive down revenues or drive up sales and marketing or compliance costs;&#160;and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unexpected product liability or intellectual property claims and lawsuits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8212;Liquidity and capital resources.&#8221; Fluctuation in operating results, particularly if not anticipated by investors and other members of the financial community, could add to volatility in our stock price.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent COVID-19 coronavirus has </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negatively impacted the financial markets and may create additional risk for our customers and their ability to pay for our products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our focus on acquisitions as a growth strategy has created intangible assets whose amortization could negatively affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total assets include intangible assets related to our acquisitions. As of December&#160;31, 2020, intangible assets relating to products, which are being amortized, represented approximately 29% of our total assets. We may never realize the value of these assets. U.S. Generally Accepted Accounting Principles ("GAAP") require that we evaluate on a regular basis whether events and circumstances have occurred that indicate that all or a portion of the carrying amount of the asset may no longer be recoverable, in which case we would write down the value of the asset and take a corresponding charge to earnings. Any determination requiring the write-off of a significant portion of unamortized intangible assets would adversely affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce or eliminate our product development or commercialization and marketing efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional funds in order to meet the capital requirements of running our business and acquiring and developing new pharmaceutical products. If we require additional funding, we may seek to sell common stock or other equity or equity-linked securities, which could result in dilution to our shareholders. We may also seek to raise capital through a debt financing, which would result in ongoing debt-service payments and increased interest expense. Any financings would also likely involve operational and financial restrictions being imposed on us. We might also seek to sell assets or rights in one or more commercial products or product development programs. Additional capital might not be available to us when we need it.  We are unable to predict the impact of global credit market trends, and if economic conditions deteriorate, our business, results of operations and ability to raise needed capital could be materially and adversely affected. If we are unable to raise additional capital when needed due to the reasons listed above and lack of creditworthiness, bank failures, or price decline in market investments, we could be forced to scale back our operations to conserve cash.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls are necessary for us to provide reliable financial reports and mitigate the risk of fraud. We maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, and affected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we will not, in the future, identify areas requiring improvement in our internal control over financial reporting.&#160;We cannot assure you that the measures we will take to improve these controls will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as we continue to expand.&#160;If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain a system of internal controls and provide training to employees designed to provide reasonable assurance that unlawful and fraudulent&#160;activity,&#160;including misappropriation of assets, fraudulent financial reporting, and unauthorized access to sensitive or confidential data is either prevented or timely detected. However, in the event that our employees engage in such fraudulent behavior, we could suffer material adverse consequences.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in, or interpretations of, accounting principles could have a significant impact on our financial position and results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare our consolidated financial statements in accordance with GAAP. These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even retroactively affect previously reported transactions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in recent years, the U.S.-based Financial Accounting Standards Board, ("FASB"), has worked together with the&#160;International&#160;Accounting&#160;Standards&#160;Board, ("IASB"), on several projects to further align accounting principles and facilitate more comparable financial reporting between companies who are required to follow GAAP under SEC regulations and those who are required to follow International Financial Reporting Standards, ("IFRS"), outside of the U.S. These efforts by the FASB and IASB may result in different accounting principles under GAAP that may result in materially different financial results for us in certain areas.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur losses in the future and we may not achieve or maintain profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses in future periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain whether or when we will achieve profitability because of the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing additional drug products, we may incur losses if our drug products do not generate significant revenues. If we achieve profitability, we may not be able to sustain or increase profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to obtain future financing through the issuance of debt or equity, which may have an adverse effect on our shareholders or may otherwise adversely affect our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through the issuance of additional equity, whether through private placements or public offerings, such an issuance would dilute ownership of our current shareholders that do not participate in the issuance. If we are unable to obtain any needed additional funding, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities or to license to third parties the rights to develop and/or commercialize products or technologies that we would otherwise seek to develop and/or commercialize ourselves or on terms that are less attractive than they might otherwise be, any of which could materially harm our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the terms of any additional debt securities we may issue in the future may impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, pay dividends on or repurchase our common shares, or make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our officers, directors, and principal shareholders, acting as a group, could significantly influence corporate actions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our officers and directors control approximately 41 percent of our common stock.  Acting together, these shareholders could significantly influence any matter requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other shareholders and may prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock because many investors perceive disadvantages to owning stock in companies with controlling shareholders.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock may be affected by the reports financial analysts publish about us. If one of the analysts covering us downgrades our stock, its price could decline rapidly and significantly. Securities analysts covering our common stock may discontinue coverage.  A lack of research coverage may adversely affect our stock&#8217;s market price.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_88"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNING OUR STOCK</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may fluctuate substantially.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price for the shares of our common stock sold in our initial public offering was determined by negotiation between the representatives of the underwriters and us. This price may not have reflected the market price of our common stock following our initial public offering. Through March 5, 2021, the closing price of our common stock since our initial public offering has ranged from a low of $2.77 to a high of $17.05 per share. Moreover, the market price of our common stock might decline below current levels. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially. Sales of a substantial number of shares of our common stock in the public market or the perception that these sales may occur could cause the market price of our common stock to decline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of any of the risks described in these &#8220;Risk Factors&#8221; could have a dramatic and material adverse impact on the market price of our common stock. In addition, securities class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such securities litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could negatively impact our business, operating results and financial condition. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent COVID-19 pandemic may cause increased risk to our common stock&#8217;s liquidity and trading price.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market conditions may have serious adverse consequences on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general business strategy may be adversely affected by unpredictable and unstable market conditions. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a radical economic downturn or increase in our expenses could require additional financing on less than attractive rates or on terms that are dilutive to existing shareholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical developments plans. There is a risk that one or more of our current service providers, manufacturers and other partners may encounter difficult economic circumstances, which would directly affect our ability to attain our operating goals on schedule and on budget.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity and lending markets have been and will most likely continue to be negatively impacted for an unknown period of time due to the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We experience costs and regulatory risk as a result of operating as a public company, and our management is required to devote time to compliance initiatives.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and will continue to incur costs as a result of operating as a public company, and our management is required to devote time to compliance initiatives. As a public company, we have and will continue to incur legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and other rules and regulations subsequently implemented by the SEC and Nasdaq, have imposed various requirements on public companies, including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. These rules and regulations have and will continue to result in legal and financial compliance costs and render some activities more time-consuming and costly. Despite the internal controls and procedures put in place to maintain compliance with securities laws and regulations, our employees may still fail to comply with all SEC disclosure and reporting requirements. Such failure could lead to administrative and civil </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penalties, criminal penalties, and private litigation with shareholders. The consequences could have a material effect on our ability to effectively market our products and operate our business. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting. Our testing may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section&#160;404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. Moreover, if we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we identify deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our third amended and restated charter, bylaws and Tennessee law may inhibit potential acquisition bids that you may consider favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents contain provisions that may enable our board of directors to resist a change in control of our company even if a change in control were to be considered favorable by you and other shareholders. These provisions include:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without shareholder approval;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance notice procedures required for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limitations on persons authorized to call a special meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A staggered board of directors;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restriction prohibiting shareholders from removing directors without cause;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A requirement that vacancies in directorships are to be filled by a majority of the directors then in office and the number of directors is to be fixed by the board of directors;&#160;and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No cumulative voting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions contained in our third amended and restated charter and bylaws could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which our shareholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of shareholders to remove our current management or approve transactions that our shareholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to control share acquisitions provisions and affiliated transaction provisions of the Tennessee Business Corporation Act, the applications of which may have the effect of delaying or preventing a merger, takeover or other change in control of us and therefore could discourage attempts to acquire our company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our capital stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our capital stock. The availability of funds for distributions to shareholders will depend on our financial performance and assets. Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DEBT-RELATED RISKS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Revolving Credit Agreement impose restrictive and financial covenants on us. Our failure to comply with these covenants could trigger events that would have a material adverse effect on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. Additionally, our Revolving Credit Agreement contains financial covenants that, for example, require us to maintain certain financial ratios which are measured at the end of each fiscal quarter.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains specified quarterly financial maintenance covenants. As of  December&#160;31, 2020, we were in compliance with the Tangible Capital Ratio financial covenant of the Revolving Credit Agreement and we expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. However, we can make no assurance that we will be able to comply with the restrictive and financial covenants contained in the Revolving Credit Agreement in the future. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lender in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lender under our Revolving Credit Agreement may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, the lender under our Revolving Credit Agreement may accelerate the maturity of the related debt, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our securities to decline. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have risks related to interest rates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit facility bears interest based on variable interest. Thus, a change in the short-term interest rate environment (especially a material change) could have a material adverse effect on our business, financial condition, cash flows and results of operations. As of December&#160;31, 2020, we did not have any outstanding interest rate swap contracts.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_97"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2. Properties.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we leased approximately 25,500 square feet of office space in Nashville, Tennessee for our corporate headquarters. The lease expires in October 2022.  We believe these facilities are adequate to meet our current needs for office space. Manufacturing, packaging or warehousing services are provided to us through contracts with third-party organizations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratory space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. CET leases approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee to operate the CET Life Sciences Center.  Cumberland's product formulation and testing laboratories are located at this facility, along with CET's offices. The CET Life Sciences Center also provides laboratory and office space, equipment and infrastructure to early-stage life sciences companies and university spin-outs.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_100"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;3. Legal Proceedings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Please see the discussion of our Acetadote patent defense legal proceedings contained in Part 1, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business -Patents, Trademarks and Other Intellectual Proprietary Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Form 10-K, which is incorporated by reference herein. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_103"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;4. Mine Safety Disclosures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_106"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, no par value, has been traded on the Nasdaq Global Select Market since August&#160;11, 2009 under the symbol &#8220;CPIX.&#8221; As of March&#160;8, 2021, we had 77 shareholders of record of our common stock.  This excludes shareholders whose shares are held by brokers and other institutions on behalf of shareholders. The closing price of our common stock on the Nasdaq Global Select Market on March&#160;8, 2021 was $3.21 per share.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock.  Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock performance graph below illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2015 to the Nasdaq Composite and a composite of seven Nasdaq Pharmaceutical and Specialty Pharmaceutical Stocks which most closely compare to our Company. The graph assumes an initial investment of $100 on December 31, 2015, and that all dividends were reinvested.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><img src="cpix-20201231_g1.jpg" alt="cpix-20201231_g1.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program to repurchase up to $10.0 million of our common stock pursuant to Rule 10b-18 of the Securities Act of 1934. In January 2019, the Company's Board of Directors established the current $10.0 million repurchase program to replace the prior authorizations.  We repurchased  503,626 shares, 623,478 shares and 443,041 shares of common stock for approximately $1.8 million,  $3.5 million and $2.9 million, and during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the fourth quarter of 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:23.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased as</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number&#160;(or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value) of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)&#160;that&#160;May&#160;Yet&#160;Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased Under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plans or Programs</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,364,741</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,162&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,162</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,270,602</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,280</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,190,118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,943&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Of this amount, 280 shares were repurchased directly in private purchases at the then-current fair market value of common stock.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;6. Selected Financial Data.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected consolidated financial data set forth below should be read in conjunction with the audited consolidated financial statements and related notes and Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and other financial information appearing elsewhere in this Form 10-K. The historical results are not necessarily indicative of the results to be expected for any future periods.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,821)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,848)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,694&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt (including current portion) and other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial position and results of operations should be read together with our audited consolidated financial statements and related notes appearing elsewhere in this Form 10-K. This discussion and analysis may contain forward-looking statements that involve risks and uncertainties &#8211; please refer to the section entitled, &#8220;Special Note Regarding Forward-Looking Statements,&#8221; contained in Part I, Item&#160;1A, &#8220;Risk Factors,&#8221; of this Form 10-K. You should review the &#8220;Risk Factors&#8221; section of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_118"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE SUMMARY </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and</span></div><div style="margin-top:8pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), Systemic Sclerosis (&#8220;SSc&#8221;), and Aspirin-Exacerbated Respiratory Disease ("AERD"). We have also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our approved products through our hospital and gastroenterology sales forces in the United States, which together comprised approximately 40 sales representatives and managers as of December&#160;31, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have both product development and commercial capabilities and believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion opportunities. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and manages our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales professionals </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our 2020 highlights and recent developments. For more information, please see Part I, Item I, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Form 10-K. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Early in 2020, we implemented the national launch of our Next Generation Caldolor product featuring a ready to use formulation in a pre-mixed bag, offering time and cost savings associated with its administration.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We launched several national initiatives during 2020 to help hospitals access our acute care brands during this healthcare emergency. Our Vibativ product was used to help COVID patients who developed bacterial infections in their lungs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We entered into an agreement with Win Health Pharma and formed WHC Biopharmaceuticals, Pte. Ltd &#8211; a joint venture based in Singapore to acquire, develop and commercialize products for China and adjacent Asian markets.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We announced a series of publications featuring important new data associated with our Caldolor and Vibativ brands.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We ended the year with the initial introduction of our FDA-approved RediTrex line of injectable methotrexate products, featuring an innovative delivery system for patients with arthritis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company managed through the COVID-19 pandemic during 2020, continuing to operate our business - keeping facilities open and our organization intact. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded, pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_121"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that are not determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, marketable securities, inventory, intangible assets and goodwill, research and development accounting, contingent consideration liability, provision for income taxes and share-based payments.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the Accounting Standards Codification (ASC) Topic 606. Effective January 1, 2018, we adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived primarily from the product sales of our FDA approved pharmaceutical brands. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 60 days from date of shipment. Our net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, and discounts and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Other revenue, which is a component of net revenues, includes non-refundable upfront payments and milestone payments under licensing agreements along with grant and rental income. Other income was approximately 4.3% percent of net revenues in 2020, 5.8% in 2019, and 1.8% in 2018 respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements reflect accounts receivable allowances of $1.0 million and $0.8 million at December&#160;31, 2020 and 2019, respectively, for chargebacks and early pay discounts for products. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our sales-related accrual activity for the periods indicated below:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:45.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,961,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,081,251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,192,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual product returns and credits issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,983,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,449,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,371,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063,435&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,961,631&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowances for chargebacks and discounts and sales related accruals for rebates, fee for service and product returns are determined on a product-by-product basis. We establish them using our best estimate at the time of sale based on: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The contractual terms with direct and indirect customers;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analyses of historical levels of chargebacks, discounts and returns of product; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Communications with customers;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchased information about the rate of prescriptions being written and the level of inventory remaining in the distribution channel, if known; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expectations about the market for each product, including any anticipated introduction of competitive products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from us based on either negotiated contracts to carry our products or reimbursements for filled prescriptions. These entities are considered our indirect customers. When recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by our estimate of the rebate that may be claimed. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks and accruals for rebates and product returns are the most significant estimates used in the recognition of our revenue from product sales. Of the accounts receivable allowances and our sales related accruals, our accrual for fee for services and product returns represents the majority of the balance. Sales related accrued liabilities for rebates, product returns, service fees, and administrative fees totaled $4.1 million, $4.6 million and $5.0 million as of December&#160;31, 2020, 2019 and 2018, respectively. Of these amounts, our estimated liability for fee for services represented $1.0 million, $1.4 million and $1.8 million, respectively, while our accrual for product returns totaled $1.7 million, $1.9 million and $1.8 million, respectively. If the actual amount of cash discounts, chargebacks, rebates, and product returns differs from the amounts estimated by management, material differences may result from the amount of our revenue recognized from product sales. A change in our rebate estimate of one percentage point would have impacted net sales by approximately $0.4 million for the years ended December&#160;31, 2020, 2019 and 2018.  A change in our product return estimate of one percentage point would have impacted net sales by $0.3 million for the years ended December&#160;31, 2020, 2019 and 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically invested a portion of our cash reserves in short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper in order to maximize our return on cash.  We mark the investments to fair value at the end of each reporting period, with the adjustment being recognized in the statement of income as a component of interest income.  These investments are generally valued using observable market prices by third-party pricing services, or are derived from such services' pricing models. The level of management judgment required in establishing fair value of financial instruments for which there is a quoted price in an active market is minimal. Similarly, there is little subjectivity or judgment required for instruments valued using valuation models that are standard across the industry and where all parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the net realizable value based upon assumptions about remaining shelf life, future demand and market conditions. The estimated inventory obsolescence amounts are calculated based upon specific review of the inventory expiration dates and the quantity on-hand at December&#160;31, 2020 in comparison to our expected inventory usage. The amount of actual inventory obsolescence and unmarketable inventory could differ (either higher or lower) in the near term from the estimated amounts. Changes in our estimates would be recorded in our statement of operations in the period of the change.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to operating loss and tax credit carry-forwards and differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our principal differences are related to the timing of deductibility of certain items such as depreciation, amortization and expense for options issued to nonemployees. Deferred tax assets and liabilities are measured using management&#8217;s estimate of tax rates expected to apply to taxable income in the years in which management believes those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our results of operations in the period that includes the enactment date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all share-based payments based on the fair value of the award on the date of grant. In addition, incremental compensation expense is recognized upon the modification of equity awards. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue restricted stock awards at no cost in lieu of stock options to employees, directors and consultants. Compensation expense for restricted stock granted to employees and directors is generally equal to the fair market value of the underlying common stock on the date of grant. If a sufficient disincentive for nonperformance does not exist at the date of grant, the compensation cost is remeasured at each reporting date at the then-current fair market value of the underlying common stock until the award vests.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for and expense research and development costs based on estimates of work performed, patient enrollment or fixed-fee-for-services. As work is performed and/or invoices are received, we adjust our estimates and accruals. To date, our accruals have not differed materially from our estimates. Total research and development costs are a function of studies being conducted and will increase or decrease based on the level of activity in any particular year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include product rights, license agreements, other identifiable intangible assets and goodwill associated with the Vibativ acquisition. We assess the impairment of goodwill at least annually. We assess the impairment of identifiable intangible assets subject to amortization whenever events or changes in circumstances indicate the carrying value may not be recoverable. In determining the recoverability of our intangible assets, we make assumptions regarding estimated future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets, we must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than the carrying value, an impairment loss will be recognized in an amount equal to the difference. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models, as considered necessary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2020 compared to year ended December&#160;31, 2019</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:39.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,441,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,653,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,765,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,277,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,094,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,196,299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,974,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,915&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,822,729&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,676,477&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,252&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,381,595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,019)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,569,877)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,291,004)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721,127&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,625,779)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585,909&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues for the years presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,567,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,870,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,336,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,950,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580,741)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,441,134&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052,839&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2020 were approximately $37.4 million compared to $34.4 million  for the year ended December&#160;31, 2019, representing an increase of $3.1 million or 8.9%.  As detailed in the table above, net revenue increased during the 2020 for four of our marketed products: Kristalose, Vibativ, Caldolor and Vaprisol.   The improvement was led by largest product, Kristalose which delivered $2.7 million in revenue growth, followed by Vibativ, which delivered an additional $2.2 million during 2020 compared to 2019.  Our newest product, RediTrex, contributed $0.9 million in incremental revenue during the year after its late 2020 soft launch.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by decreased net product sales of Acetadote and Omeclamox-Pak.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The first four installments totaling $3.0 million due from Clinigen was recorded during the year ended December&#160;31, 2020, as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $2.7 million, or 20.7%, compared to December&#160;31, 2019 primarily as a result of improved sales volume for the product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $10.9 million compared to $8.7 million in the prior year.  This $2.2 million or 25.1%  increase in net revenue was a result of improved sales volume for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue experienced a 2.2% increase to $5.3 million during the year ended December 31, 2020 compared to $5.2 million in the same period last year. This increase in Caldolor revenue for the year ended December 31, 2020 w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the result of an increase in international shipments when compared to the prior year, which were partially offset by lower domestic shipments of the product, significantly impacted by COVID-19 and a reduction in elective surgeries.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue increased $0.1 million during the year ended December 31, 2020 compared to the prior year period due primarily to increased sales of the product. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2020, the Acetadote net revenue decreased $2.0 million compared to the prior year due to a reduction in sales volume, primarily impacting the Authorized Generic.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue decreased $0.6 million during the year ended December 31, 2020 compared to the prior year.  The decrease was largely the result of decreased sales volume, which were negatively impacted by COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2020 were $8.7 million compared to $7.4 million in the prior year.  As a percentage of net revenues, cost of products sold were 23.1% compared to 21.6% during the prior year.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ.  The Vibativ inventory sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.  The increase in costs of product sold expense was also the result of a step up in the fair value of the inventory over the cost to Theravance, as required under purchase accounting rules. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the year ended December&#160;31, 2020 were $14.8&#160;million compared to $15.3 million in the prior year, which was a decrease of $0.5 million.  This decrease was primarily a result of decreases in direct promotional spending, meeting costs and travel expenses.  These decreases were partially offset by increases in salaries as well as increases in royalty costs associated with growth in Vibativ sales during the period.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2020 were $5.8&#160;million, compared to $6.9 million last year, representing a decrease of $1.1 million. A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  During 2020, we experienced a decrease in study activity which was partially offset by increases in our annual FDA user fees.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expenses for the year ended December&#160;31, 2020 were $10.2 million compared to $10.0 million last year. The increase resulted from an increase in legal and professional fees partially offset by lower stock based compensation during the period.  A portion of these increased costs were for 2019 expenses related to our acquisition of Vibativ.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,870,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366,198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,552,343&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,365,681&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expenses represent the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for 2020 totaled approximately $4.4&#160;million compared to $4.1 million in the prior year, which was an increase of  $0.3 million over the prior year.  The increase in expense was attributable to the amortization of additional product rights and capitalized patents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income taxes were an expense of  $55,902 for the year ended December&#160;31, 2020 and a benefit of  $79,316 for the year ended December&#160;31, 2019. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2019 compared to year ended December&#160;31, 2018 </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for the years ended December&#160;31, 2019 and 2018:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:39.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,016,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,277,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,004,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,974,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,150,777&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,393)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,676,477&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,517,890&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158,587&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,172,996)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,291,004)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,804,360)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513,356&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609,308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues for the years presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,344,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2019 were approximately $34.4 million compared to $29.3 million for the year ended December&#160;31, 2018, representing an increase of $5.0 million or 17.2%.  Four of our products, Omeclamox-Pak, Kristalose, Caldolor and Vibativ, experienced an increase in revenue during 2019. The 17.2% improvement was led by our newest product, Vibativ, which delivered an additional  $3.6 million during the full year of 2019 compared to a partial year during 2018. These increases were partially offset by decreased net product sales of Acetadote and Vaprisol.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 and 2018 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid over the two-years following the return date.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $0.8 million, or 7.0%, compared to December&#160;31, 2018 primarily as a result of increased wholesale prices. The product's net revenue was also positively impacted by lower managed care rebates, resulting in improved net pricing for the product for the year ended December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue experienced a 4.4% increase to $5.2 million during the year ended December 31, 2019 compared to $5.0 million in during 2018. This increase in Caldolor revenue for the year ended December 31, 2019 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the result of an 11% increase in domestic shipments of the product and improved net pricing. The changes were partially offset by a reduction in international shipments of Caldolor in 2019 over 2018.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue increased $0.2 million or 34.4% during the year ended December 31, 2019 compared to the prior year.  The increase was largely the result of increased sales volume partially offset by higher expired product sales returns. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue decreased $0.8 million during the year ended December 31, 2019 compared to the prior year period due primarily to decreased sales of the product.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year period sales were higher as a result of the arrival of a new lot of the product during April 2018 resolving temporary supply issues associated with the product.    </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2019, the Acetadote net revenue decreased $0.5 million or 10.7% compared to 2018 due to a reduction in sales volume as a result of generic competition.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2019 were $7.4 million, compared to $6.0&#160;million during 2018.  As a percentage of net revenues, cost of products sold were 21.6% compared to 20.5% during 2018.  The change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix during the period compared to 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the year ended December&#160;31, 2019 were $15.3 million, which was an increase of $1.3 million compared to 2018's expense of $14.0 million. This increase was primarily attributable to promotional spending and sales force costs, including salary and benefits for the increased sales force.  The increase in the sales force and promotional spending is due largely to the addition of our newest brand, Vibativ, during the fourth quarter of 2018.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2019 were $6.9 million, compared to $7.6 million during 2018, representing a decrease of $0.7 million. A portion of our research and development costs are variable based on the number of trials, study sites and patients involved in the development of our product candidates. The decrease was primarily the result of the FDA program fee of $1.3 million paid during 2018 associated with the successful RediTrex FDA submission.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the year ended December&#160;31, 2019 was $10.0 million for 2019, compared to $10.2 million during 2018. The $0.2&#160;million or, 1.7%, decrease from the same period for 2018 was primarily driven by a decrease in compensation and benefits, including non-cash stock based compensation and deferred compensation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expenses represent the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for 2019 totaled approximately $4.1 million, which was an increase of $1.4 million over 2018.  The increase in expense was attributable to the amortization of additional product rights and capitalized patents, including those assets associated with the Vibativ acquisition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax benefit for the year ended December&#160;31, 2019 was $79,316. As a percentage of income (loss) before income taxes, income taxes were a benefit of  0.9% for the year ended December&#160;31, 2019 compared to income tax expense as a percentage of loss before income taxes of 0.2% for the year ended December&#160;31, 2018. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_127"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the proceeds from the Paycheck Protection Program loan, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:61.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,302,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:43.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757,789)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297,848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,724,818)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,116,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,080,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash equivalents </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,458,839)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,675&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,473,908)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $3.5 million decrease in cash and cash equivalents for the year ended December&#160;31, 2020 was attributable to cash used by investing and financing activities partially offset by cash provided by operating activities.  Cash provided by operating activities of $5.4 million included non-cash expense add backs for depreciation and amortization and share-based compensation expense totaling $5.8 million and changes in our working capital that provided net cash of $5.4 million.  The cash provided by operating activities included  $3.5 million provided by discontinued operations. This increase was partially offset by a net loss for the period of $6.6 million.  Cash used by investing activities of $1.8 million was the result of additions to intangibles of $2.0 million, which included the payment of $1.0 million for product rights, additions to property and equipment of $0.1 million and partially offset by proceeds from the surrender of life insurance of  $0.5&#160;million.  Our financing activities included a net repayment of  $3.5&#160;million under our line of credit net, $1.9 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of a portion of CET's shares. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we continue to repurchase shares of our common stock, as discussed in Part II, Item&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.3 million increase in cash and cash equivalents for the year ended December&#160;31, 2019 was attributable to cash provided by operating and investing activities offset by cash used in financing activities.  Cash provided by operating activities of $3.1&#160;million included non-cash expense add backs for depreciation and amortization and share-based compensation expense totaling $5.9 million. The cash provided by operating activities included $5.5 million provided by discontinued operations.  These increases were partially offset by a net loss for the period of $3.5 million. Changes in our working capital provided net cash of $1.6 million.  Cash provided by investing activities of  $2.3 million included net sales of marketable securities of $8.3 million, partially offset by the $5 million payment to Theravance as part of the acquisition of Vibativ and the addition to intangibles of $0.8 million.  Our financing activities included a net repayment of  $1.5&#160;million under our line of credit net and $3.5 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $17.5 million decrease in cash and cash equivalents for the year ended December 31, 2018 was attributable to cash used by investing activities offset by cash provided by operating and financing activities.  Cash provided by operating activities of $3.1 million was impacted by a net loss for the period of $7.0 million. This use of operating cash was offset by non-cash expenses of depreciation and amortization and share-based compensation expense totaling $4.3 million. Changes in our working capital provided net cash of $5.2 million.  The cash provided by operating activities included $4.5 million provided by discontinued operations.  Cash used in investing activities included $20 million in cash paid for the acquisition of Vibativ during 2018, the use of cash to complete a net increase in marketable securities of $3.4 million, and the addition to intangibles of $3.8 million.  Our financing activities included  $10.2&#160;million in net cash provided by borrowings under our line of credit net of $2.9 million in cash used to repurchase shares of our common stock. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, we entered into a Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022 and provides for a principal available for borrowing of up to $15 million.  We also have the ability to request an increase of up to an additional $5 million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20 million. On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021, as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 9 to the accompanying notes to the consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018, we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with the Tangible Capital Ratio financial covenant as  of  December&#160;31, 2020 and we expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding we have used the loan amount for such qualifying expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from our PPP loan, we currently do not foresee doing so.  In October 2020, we submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to the SBA for the SBA's review and approval. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum Product Purchase Requirements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and supply agreements do not require minimum annual purchase obligations. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual cash obligations</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual cash obligations as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:22.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Line of credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated interest on debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,239,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046,178&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,275,970&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,033&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,515&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270,680&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The sum of the individual amounts may not agree due to rounding.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The line of credit payments represent the estimated unused line of credit payments and the amount due at maturity. The estimated interest on debt represents the interest on the principal outstanding on the line of credit.  These amounts are based on the $15.0 million line of credit assuming the current $15.0 million balance outstanding on December&#160;31, 2020 is consistently outstanding through maturity of October 2022.  Interest and unused line of credit payments are due and payable quarterly in arrears. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The contingent consideration liability represents the fair value of the royalty payments of up to 20% of future net sales as part of the Vibativ acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Represents minimum purchase obligations under our manufacturing agreements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, we did not engage in any off-balance sheet arrangements.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_133"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. We adopted the standard effective January 1, 2020 with no impact to our consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on our consolidated financial statements. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. Our investment policy focuses on principal preservation and liquidity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments in marketable securities at December&#160;31, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.65% at December&#160;31, 2020).   As of December&#160;31, 2020, we had $15.0 million in borrowings outstanding under our revolving line of credit. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the U.S., we are exposed to foreign currency risk. A portion of our research and development is performed abroad. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange losses were immaterial for 2020, 2019 and 2018. Neither a five percent increase nor decrease from current exchange rates would have had a material effect on our operating results or financial condition.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_139"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See consolidated financial statements, including the reports of the independent registered public accounting firm, starting on page F-1, which is incorporated herein by reference.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_142"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_145"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the year ended  December&#160;31, 2020. Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be included in this Annual Report on Form 10-K has been recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and to ensure that such information was accumulated and communicated to management to allow for timely decisions regarding disclosure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s report on internal control over financial reporting is included on page F-1 of this annual report on Form 10-K, and incorporated herein by reference.  During our fourth quarter of 2020, there were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f) or 15d-15(f)).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_148"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9B. Other Information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 8-K, Item 5.02(e).    Compensatory Arrangements of Certain Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2021, the Company entered into new employment agreements with each of A.J. Kazimi, our Chief Executive Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Kazimi Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Martin Cearnal, our Executive Vice President and Chief Commercial Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cearnal Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Leo Pavliv, our Executive Vice President, Operations and Chief Development Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pavliv Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), James Herman, our Senior Vice President, National Accounts and Chief Compliance Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Herman Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and Michael Bonner, our Senior Director, Finance and Accounting and Chief Financial Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bonner Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and together with the Kazimi Employment Agreement, the Cearnal Employment Agreement, the Pavliv Employment Agreement, and the Herman Employment Agreement, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Employment Agreements were effective as of January 1, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Employment Agreement provides for a salary for services performed, a potential annual bonus and a grant of restricted common shares pursuant to a restricted stock agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of each Employment Agreement, employment is at-will and may be terminated by the Company at any time, with or without notice and with or without cause. Similarly, each of Mr. Kazimi, Mr. Cearnal, Mr. Pavliv, Mr. Bonner, and Mr. Herman may terminate his respective employment with us at any time, with or without notice. The Employment Agreements do not provide for any severance payments in the event employment is terminated for cause nor any severance benefits in the event employment is terminated as a result of death or permanent disability. The Employment Agreements include non-competition, non-solicitation and non-disclosure covenants on the part of employees. The Employment Agreements impose obligations regarding confidential information and state that any discoveries or improvements conceived, developed or otherwise made by the employees, or with others, are deemed our sole property. The Employment Agreements do not contain any termination or change in control provisions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kazimi Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Kazimi Employment Agreement, Mr. Kazimi will serve as the Company&#8217;s Chief Executive Officer and will receive a base salary of $610,132.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Kazimi Employment Agreement are qualified in their entirety by reference to the Kazimi Employment Agreement, which is included as Exhibit 10.11 to this Annual Report on Form 10-K and are incorporated by reference into this Item. The foregoing description of the Kazimi Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cearnal Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cearnal Employment Agreement, Mr. Cearnal will serve as the Company&#8217;s Executive Vice President and Chief Commercial Officer and will receive a base salary of $336,500.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Cearnal Employment Agreement are qualified in their entirety by reference to the Cearnal Employment Agreement, which is included as Exhibit 10.12 to this Annual Report on Form 10-K and are incorporated by reference into this Item. The foregoing description of the Cearnal Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pavliv Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Pavliv Employment Agreement, Mr. Pavliv will serve as the Company&#8217;s Executive Vice President, Operations and Chief Development Officer and will receive a base salary of $437,500.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Pavliv Employment Agreement are qualified in their entirety by reference to the Pavliv Employment Agreement, which is included as Exhibit 10.13 to this Annual Report on Form 10-K and are incorporated by reference into this Item. The foregoing description of the Pavliv Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Herman Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Herman Employment Agreement, Mr. Herman will serve as the Company&#8217;s  Senior Vice President, National Accounts and Chief Compliance Officer and will receive a base salary of $270,000.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Herman Employment Agreement are qualified in their entirety by reference to the Herman Employment Agreement, which is included as Exhibit 10.15 to this Annual Report on Form 10-K and are incorporated by reference into this Item. The foregoing description of the Herman Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bonner Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bonner Employment Agreement, Mr. Bonner will serve as the Company&#8217;s Senior Director, Finance and Accounting and Chief Financial Officer and will receive a base salary of $220,000.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Bonner Employment Agreement are qualified in their entirety by reference to the Bonner Employment Agreement, which is included as Exhibit 10.14 to this Annual Report on Form 10-K and are incorporated by reference into this Item. The foregoing description of the Bonner Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_151"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by Part III of Form 10-K (Item 10 &#8211; Directors, Executive Officers and Corporate Governance, Item&#160;11 &#8211; Executive Compensation, Item&#160;12 &#8211; Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, Item&#160;13 &#8211; Certain Relationships and Related Transactions, and Director Independence, Item&#160;14 &#8211; Principal Accounting Fees and Services), is incorporated by reference from our proxy statement related to our 2021 annual meeting of shareholders, which is expected to be filed with the SEC on or around March&#160;12, 2021.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_157"></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Documents filed as part of this report:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:79.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page&#160;Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_166">Management&#8217;s Report on Internal Control over Financial Reporting</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_166">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_169">Report of Independent Registered Public Accounting Firm &#8211; Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_169">2</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_172">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_172">5</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_178">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_178">6</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_181">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_181">7</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_184">Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_184">9</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_187">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_187">10</a></span></div></td></tr></table></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Financial Statement Schedule</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:79.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_274">Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i510f8c4dc65a401f9689088d17e3694c_274">40</a></span></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b. Exhibits</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w1.htm">Third Amended and Restated Charter of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w2.htm">Second Amended and Restated Bylaws of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407007248/g06286a5exv4w1.htm">Specimen Common Stock Certificate of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on August 6, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517372414/d489256dex42.htm">Preferred Stock Terms, Rights, and Provisions, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on December 19, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv4w5.htm">Form of Option Agreement under 1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit461.htm">Form of Incentive Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit462.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit47.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Directors&#8217; Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012310026333/g22569exv4w8.htm">Warrant to Purchase Common Stock of Cumberland Pharmaceuticals Inc., issued to Bank of America, N.A. on July 22, 2009, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 19, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020q4exhibit411.htm">Description of Cumberland Pharmaceutical's Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993310003084/exhibit1.htm">Exclusive Distribution Agreement, effective as of July 1, 2010, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on August 13, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000108729413000004/exhibit1071amendmenttoexcl.htm">First Amendment to Exclusive Distribution Agreement, dated March 31, 2013, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant's Current Report o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000108729413000004/exhibit1071amendmenttoexcl.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000108729413000004/exhibit1071amendmenttoexcl.htm"> Form 8-K (File No. 001-33637) as filed with the SEC on June 3, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407006504/g06286a3exv10w10.htm">License Agreement, dated May 28, 1999, by and between Vanderbilt University and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 11, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxex1011ajkazimi.htm">Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 .12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1012martincearnal.htm">Employment Agreement dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1012martincearnal.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1012martincearnal.htm">, 2021, effective as of January 1, 2021, by and between Martin E. Cearnal and Cumberland Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxex1013leopavliv.htm">Employment Agreement dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxex1013leopavliv.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxex1013leopavliv.htm">, 2021, effective as of January 1, 2021, by and between Leo B. Pavliv and Cumberland Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1014michaelbonner.htm">Employment Agreement dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1014michaelbonner.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex1014michaelbonner.htm">, 2021, effective as of January 1, 2021, by and between Michael P. Bonner and Cumberland Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxex1015jimherman.htm">Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w17.htm">1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix A of the Registrant&#8217;s Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Directors&#8217; Incentive Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix B of the Registrant's Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w20.htm">Form of Indemnification Agreement between Cumberland Pharmaceuticals Inc. and all members of its Board of Directors, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407006504/g06286a3exv10w21.htm">Lease Agreement, dated September 10, 2005, by and between Nashville Hines Development, LLC and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 11, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014408004306/g06286b1exv10w21w1.htm">First Amendment to Office Lease Agreement, dated April 25, 2008, by and between 2525 West End, LLC (successor in interest to Nashville Hines Development LLC) and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 10 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 21, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012310050308/g23297exv10w21w2.htm">Second Amendment to Office Lease Agreement, dated March 2, 2010, by and between 2525 West End, LLC (successor in interest to Nashville Hines Development LLC) and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 17, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828015008469/q3201510q.htm">Third Amendment to Office Lease Agreement, dated September 29, 2015, by and between 2525 West End, LLC (successor in interest to Nashville Hines Development LLC) and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 6, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w23.htm">Amended and Restated Lease Agreement, dated November 11, 2004, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w24.htm">First Amendment to Amended and Restated Lease Agreement, dated August 23, 2005, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014408004306/g06286b1exv10w24w1.htm">Second Amendment to Amended and Restated Lease Agreement, dated January 9, 2006, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 10 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 21, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512347942/d334181dex10241.htm">Third Amendment to Amended and Restated Lease Agreement, dated July 3, 2012, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 9, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828016012682/a2015-10kxexhibit1025gelli.htm">License and Supply Agreement, dated November 16, 2015, by and between Cumberland Pharmaceuticals Inc. and Gastro-Entero Logic, LLC incorporated herein by reference to the corresponding exhibit of the Registrant's Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 14, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993311003397/exhibit1.htm">Asset Purchase and Royalty Agreement for Kristalose dated November 15, 2011 by and between Mylan Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on November 22, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512247355/d358671dex1030.htm">Supplemental Executive Retirement and Savings Plan, incorporated herein by reference to the corresponding exhibit to the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on May 24, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1031-perrigoxpa.htm">Settlement Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1032-perrigoxpa.htm">License and Supply Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828017011224/loanagreementexhibit1034.htm">Revolving Credit Loan Agreement, dated July 31, 2017, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 8, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Amendment to Revolving Credit Loan Agreement, by and between Pinnacle Bank and Cumberland Pharmaceuticals Inc., dated August 14, 2018, incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement, dated as of October 17, 2018, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on October 19, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828017011224/loanagreementexhibit1034.htm">Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement, dated as of May 10, 2019, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-336371) as filed with the SEC on May 15, 2019.  </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit101-amendment2l.htm">Amendment Number 2 to the Amended and Restated 2007 Long-Term Incentive Plan, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit102-amendment2d.htm">Amendment Number 2 to the Amended and Restated 2007 Directors&#8217; Incentive Compensation Plan, incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit103-form147_716ba.htm">Payment Protection Program Note dated April 20, 2020, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.3 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020016446/a2020q3-exhibit101.htm">Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement, dated as of October 7, 2020, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 13, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv21.htm">Subsidiaries of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May&#160;1, 2007</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex231consentofbdollp.htm">Consent of BDO USA, LLP</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-xex232consentofbkdllp.htm">Consent of BKD, LLP</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxexhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxexhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2020-10kxexhibit321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 16. Form 10-K Summary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div id="i510f8c4dc65a401f9689088d17e3694c_163"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;12, 2021.</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:42.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and CEO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Director)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Michael P. Bonner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and CFO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael P. Bonner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Martin E. Cearnal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin E. Cearnal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Jonathan I. Griggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan I. Griggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ James R. Jones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Jones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Joey A. Jacobs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joey A. Jacobs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Caroline R. Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline R. Young </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of Cumberland Pharmaceuticals Inc. and its subsidiaries (the&#160;"Company") is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Cumberland Pharmaceuticals Inc.&#8217;s internal control system was designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.&#8217;s management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020.&#160;In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its assessment, management has concluded that, as of December&#160;31, 2020, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</span></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders, Board of Directors and Audit Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2020, and the related consolidated statements of operations, equity, and cash flows for the year ended December&#160;31, 2020, and the related notes and schedule listed in the accompanying index (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020, and the results of its operations and its cash flows for the year ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on the Company's financial statements based on our audit.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.  Accordingly, we express no such opinion. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.  The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customer Allowances for Chargebacks, Discounts and Damaged Goods and Accruals for Rebates, Coupons, Product Returns and Certain Fees </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, revenues from product sales are recorded net of estimated allowances for chargebacks, discounts and damaged goods and reflects sales related accruals for rebates, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coupons, product returns and certain fees.  These allowances and accruals are determined on a product-by-product basis, and are established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances.  Management reviews these allowances on an ongoing basis and adjusts them based on the most recent information available, including actual results since the end of the reporting period.  As of December 31, 2020, consolidated allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $1.0 million and consolidated estimated liability for rebates, coupons, product returns and certain fees were $4.1 million. These provisions are recognized concurrently with the sales of products. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers. Provisions are calculated using historical chargeback experience, and/or expected chargeback levels for new products and anticipated pricing changes. Provisions for rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment as well as historical experience for estimated market activity. Provisions for Medicaid are based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels, pricing data and increases or decreases in sales.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal consideration for our determination that performing procedures relating to these allowances and accruals is a critical audit matter was the significant judgment by management to estimate the reserves due to the significant measurement uncertainty involved in developing the reserves. Management tracks the various types of allowances on several different schedules, each of which relates to different contracts agreed to with various customers or the interplay with government payors.  Management exercises judgment in computing the amount of sales subject to the allowances and tracks the amount of allowances taken over time.  All of this in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s significant assumptions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the estimated sales allowances and accruals as a critical audit matter.  The primary procedures we performed to address this critical audit matter included: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the completeness and accuracy of the underlying data used to estimate the accrual by agreeing the sales data used in the calculation to reports that were reconciled to the financial statements, reconciling the various allowance percentages to signed customer contracts, tracing the allowance amounts used by the various customers during the year to supporting documentation and comparing the estimated allowances from the end of 2019 to actual results that occurred during 2020;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the assumptions used by management in the computation of selected allowances to historical results for the related products and any recent changes in factors that could influence the future allowances to be claimed;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comparing actual allowances reported since December 31, 2020 to the estimated reserves and accruals recorded on the December 31, 2020 consolidated balance sheet;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the clerical accuracy of the individual customer allowances computed by management and agreeing the total of all estimated allowances to the respective accounts on the financial statements.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BKD, LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;12, 2021</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders and Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) as of December 31, 2019, the related consolidated statements of operations, equity, and cash flows for each of the two years in the period ended December 31, 2019 and the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of</span><span style="color:#ff00ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We served as the Company's auditor from 2017 to 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 20, 2020, except for the effects of presenting discontinued operations as discussed in Note 20, as to which the date is December 10, 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 and 2019 </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzQtMi0xLTEtMA_56fb70c8-fe6a-4f1c-9493-4f8cbf2adbfc">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzQtNC0xLTEtMA_63ab9f16-15f6-4dae-85fc-845149989f00">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzYtMi0xLTEtMA_b72180e7-c3f8-45a8-806e-f2a6de6d05f7">12,377,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzYtNC0xLTEtMA_e491b55e-607b-4596-8ab2-3f03bd13dc36">7,859,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzctMi0xLTEtMA_c56bd8b6-976e-44fd-86df-5acd9e5d6451">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzctNC0xLTEtMA_f2e32030-080a-486d-850a-4e5557581bda">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzgtMi0xLTEtMA_8c7858cf-726d-4730-83fb-dcaf8735ca7c">2,199,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzgtNC0xLTEtMA_78947ba0-5b3a-4f3f-b483-e035ca9b65e1">2,757,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktMi0xLTEtOTUx_711bdfaa-ed4f-4623-a7cf-e761bace2490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktNC0xLTEtOTU3_1b2743b8-f9ff-4a71-a3a4-5b6917bf0ca7">2,462,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktMi0xLTEtMA_bbae37f8-68ec-484e-9f36-87eef4053e78">49,969,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktNC0xLTEtMA_81d96c31-07c9-4465-b6b8-71395ef71f2e">50,163,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEwLTItMS0xLTA_b794f284-a54c-49c7-8e2b-8121eb69b0cd">11,656,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEwLTQtMS0xLTA_1f4b3a92-9021-48b0-b3cc-bf6495acb54b">15,554,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzExLTItMS0xLTA_51c379c6-e577-48cc-ab81-94fbba3a641e">574,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzExLTQtMS0xLTA_aaf03d7e-5bf9-41ab-999b-09ad5471650d">747,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEyLTItMS0xLTA_791a9ea5-d2e3-4364-8bdb-62288882173c">28,118,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEyLTQtMS0xLTA_a87097f0-952f-4e78-a4c3-0aafd2172f2e">30,920,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEzLTItMS0xLTA_fcaed65f-aee7-425b-901b-a9d7718b31cd">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEzLTQtMS0xLTA_ea7a2c95-f05a-4dc6-9a2f-5ff6b9168ded">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE0LTItMS0xLTA_ec0cd2d8-da6c-4790-a7c0-0793db4c8b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE0LTQtMS0xLTA_9b11dd6d-6046-453c-ab54-49a06fb88998">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE1LTItMS0xLTA_f3d13267-033a-4d0a-bf05-39bb2b7efd63">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE1LTQtMS0xLTA_e03f1096-5d95-441f-9187-60be5c174b4e">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE2LTItMS0xLTA_be16fb28-c579-477e-a700-ffeb09d90e3a">3,234,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE2LTQtMS0xLTA_0f1e86dc-075d-403f-af5a-0a3d3de67855">3,298,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE3LTItMS0xLTA_a7f6e9ec-1b6f-471b-b0a0-5069212d988f">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE3LTQtMS0xLTA_ff48c518-ba53-4c99-9c17-bfe711fc21fe">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIxLTItMS0xLTA_95473f59-462f-4172-9a87-f4edf09ade71">13,396,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIxLTQtMS0xLTA_628af309-4b93-4dc0-9364-b02805b17ae8">9,993,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIyLTItMS0xLTA_e6f87ff0-e1a3-48f8-bb5c-66fab34a8aa6">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIyLTQtMS0xLTA_480e9ef8-13aa-4aac-95a8-2cddc36d1dd5">920,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIzLTItMS0xLTA_349c1ac3-50be-42af-9f2f-55734c8afbe3">11,254,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIzLTQtMS0xLTA_d0bc45e0-f2c9-4b59-b509-7736d3953ed3">11,084,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTItMS0xLTY3OQ_c06c375f-b37a-4f61-9f16-f9d829061313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTQtMS0xLTY3OQ_d68ff128-9cfc-4e27-931c-f2582ed26399">2,151,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTItMS0xLTA_1a5662ea-23ba-46aa-8456-9dffb3d0086d">25,667,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTQtMS0xLTA_0065814f-a052-46ae-a0c4-dd15e80d1ff6">24,150,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI1LTItMS0xLTA_2e22cfc7-fb13-421f-ae40-e34ffdfd4de0">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI1LTQtMS0xLTA_f5d5e254-1c70-4f3c-a0ad-5e9eb991598c">18,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI2LTItMS0xLTA_b882a6e6-2fcc-415f-b22b-630077d50295">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI2LTQtMS0xLTA_66e8d6f2-4759-4d6f-91f0-8cd92a0dea9d">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI3LTItMS0xLTA_fe266b3d-95e3-42fc-994d-c40cf1431c5a">7,862,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI3LTQtMS0xLTA_de79f597-3a43-4ff2-b0d9-b830aed4f3d1">8,737,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI4LTItMS0xLTA_57f4679b-47bb-4ce8-a781-7bc677395d2d">49,589,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI4LTQtMS0xLTA_1cacbd6f-fcf7-488b-ba7c-1d610fb517ac">53,464,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI5LTItMS0xLTA_7a4bd567-05f6-44e9-a21b-91e1c56d1417"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI5LTQtMS0xLTA_ebfe5f23-61db-4e97-87d3-652d4d410720"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzYw_2745e26a-6ed6-4a46-baa0-2fbd70170434"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzYw_6c960a14-55a0-43e5-b436-7023c8577689">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzI5_0809c2b4-94ba-4bfe-a3d4-710c555d2fb6"><ix:nonFraction unitRef="shares" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzI5_29ca9b12-2acc-4580-b12e-cbf13a7b8511">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzQy_71051ed7-00ae-4259-906e-3a6d110cceee"><ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzQy_aa5d4872-4491-4836-a963-645b8427ad65">14,988,429</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzU1_43a64fed-8641-4c4a-ad0f-575cd5a5f93c"><ix:nonFraction unitRef="shares" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzU1_6a3f44f5-115d-4326-9ce9-098457058e32">15,263,555</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTItMS0xLTA_21a44ec2-aa23-49e3-8cdc-1acc4a5f2fb0">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTQtMS0xLTA_9e790e0c-4df0-4799-a76b-ffa62e891e41">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMzLTItMS0xLTA_5d067169-e5df-4d01-b0d2-31eb221e1bdd">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMzLTQtMS0xLTA_69af4901-eeee-4619-a9c6-04e0cd70b0ae">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM0LTItMS0xLTA_76277c4f-390b-4ba1-a1ad-3feb8d6a80da">46,990,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM0LTQtMS0xLTA_589368ff-1160-410e-b2ba-a73369f6fa43">51,122,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM1LTItMS0xLTA_0e35a2b9-4d96-4b57-833d-9d69f77c6b9b">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM1LTQtMS0xLTA_3874e017-4715-4dd5-ae7d-ad08a4d7f6d0">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM2LTItMS0xLTA_6fe3a43d-0751-4c78-accc-0b4751d953a2">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM2LTQtMS0xLTA_e3050540-74ed-403e-8ef8-ba2c1a26cefe">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM3LTItMS0xLTA_7bcfe384-72a2-4017-96fd-a41ccbf31382">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM3LTQtMS0xLTA_725d2b5a-148c-4756-aa48-5195fd1f1a76">104,549,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a22c116b6e942bda79f40e91a62534b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtMi0xLTEtMA_30f7d7eb-f26f-4f03-9cd5-ebec1de7395a">35,840,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d81019dbdfb48579a22e9fb65668453_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtNC0xLTEtMA_4d1c9675-0882-4071-9d66-69cb92f78c4e">32,407,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6986b113ec4d0998a4d87c9c01c9aa_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtNi0xLTEtMA_e600276c-add3-4397-8fb3-80c4d727d7be">28,803,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31230eb23bc348229dd4efb4f08f9b53_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtMi0xLTEtMA_43998301-3a2b-4d12-a2a8-3481f726cbb9">1,600,461</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67a4367a56c4e6c856f116279449f1f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtNC0xLTEtMA_2e943c14-8bf5-40b6-91bf-18b92501316f">1,980,450</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2954ae7b3524c008526b384cd923ae9_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtNi0xLTEtMA_9275706f-1514-4b8c-9e81-c6fd2bd022c7">540,933</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtMi0xLTEtMA_f77721a8-abb7-4d6b-84a0-890cd637528d">37,441,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtNC0xLTEtMA_faf40886-5d87-40c1-b5c8-2227fca094a3">34,388,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtNi0xLTEtMA_3025c447-0074-4a14-b2d1-795470681a71">29,344,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctMi0xLTEtMA_88931093-a112-4a63-a5e9-f1bf85ef660f">8,653,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctNC0xLTEtMA_c53fa168-5468-4144-8106-b6626801340f">7,421,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctNi0xLTEtMA_8625787f-199f-475a-b31b-7bef126418fa">6,016,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtMi0xLTEtMA_fb919d8a-65bd-463c-aba9-d7324e777fba">14,765,465</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtNC0xLTEtMA_40824e23-08a2-4fc4-bd5a-bf7d53d659b7">15,277,740</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtNi0xLTEtMA_11ed8b1f-490e-4288-b5a1-1f4ff4279fa7">14,004,933</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktMi0xLTEtMA_9c58c56b-9d42-4c43-9fb3-3b0f21e44622">5,773,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktNC0xLTEtMA_6d07349a-9eb6-4b38-8cda-3de737db6aba">6,868,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktNi0xLTEtMA_f47554da-7e79-49e6-a7c8-f144f89f89d8">7,575,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTItMS0xLTA_aaef3314-f5c2-4acb-a2e2-6f44b3a8eb21">10,196,299</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTQtMS0xLTA_44e5c373-c5d9-43ce-b5e0-b90debacb012">9,974,384</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTYtMS0xLTA_f570b7c5-f9a1-4ce0-9bf6-18e46fe3bb56">10,150,777</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTItMS0xLTA_7e9429a3-fe66-4708-9ddb-1a393a950885">4,434,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTQtMS0xLTA_2a8d7357-0ea8-4a28-8a35-076687f2c88c">4,134,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTYtMS0xLTA_8e29b8e0-05c6-48ec-b189-c2f9f813bb4f">2,769,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTItMS0xLTA_1654557a-6b5a-439d-ae8a-5a60926a58a8">43,822,729</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTQtMS0xLTA_82e65f7e-4ccc-41e4-97b7-1cb3f42f2a9e">43,676,477</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTYtMS0xLTA_ddce794a-52d4-4461-a5d7-3c441d7366ad">40,517,890</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTItMS0xLTA_de33bcba-dafc-4f13-82ec-ba0f24622034">6,381,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTQtMS0xLTA_f4ff9402-09a8-49b8-8f72-72d5e4033979">9,288,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTYtMS0xLTA_8d3d5c56-1226-4fca-8e12-a3bdbfced3e8">11,172,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTItMS0xLTA_d85cd785-1557-455c-9d70-b23c57e7d345">75,345</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTQtMS0xLTA_b94a4aa0-1a47-4e96-97ef-c174ff61dcbc">243,364</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTYtMS0xLTA_9d0bd210-157f-43bd-81e1-636c7fac2ae4">564,484</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTItMS0xLTA_26beafb7-fbfd-409f-a594-bf43153277a2">263,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTQtMS0xLTA_f1f5da8d-8262-4718-91f4-21b4f27f2aa8">246,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTYtMS0xLTA_13138b0a-5bbc-480b-98ce-dad6f89dc862">195,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTItMS0xLTA_f7b4a439-5174-4e29-a117-9a52f359b15b">6,569,877</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTQtMS0xLTA_290762e8-4035-4482-a9eb-8b919e6e4b9b">9,291,004</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTYtMS0xLTA_aeadf02a-065d-4841-8a30-6e457b52e9b1">10,804,360</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTItMS0xLTA_c0042e23-458b-4719-8b1b-80d24a64a648">55,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTQtMS0xLTA_83624f8b-646e-4f47-a9c9-310066f9526f">79,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTYtMS0xLTA_be0ad9be-a1c4-4034-b2d3-005441a8ffb1">16,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTItMS0xLTc1OQ_81fcc7a5-42fe-45f8-8f03-f6fc5bb74d8e">6,625,779</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTQtMS0xLTc1OA_0caa90b2-49e1-40c7-9396-2f948d717e9c">9,211,688</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTYtMS0xLTU4NzU_2b1c483f-ca89-4cc1-8e21-ca20f78e84cd">10,820,996</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTItMS0xLTE1Mw_838de442-e0e0-4536-ae45-99d0b72560e6">3,206,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTQtMS0xLTE1Mw_ca1363ad-1ec7-4927-a944-6a1125291895">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTYtMS0xLTE2NA_b1adc3a4-2a33-4b61-97aa-32edcd4657be">3,782,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTItMS0xLTA_fd0d0a7d-811d-42f5-88b1-4730666d8201">3,418,904</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTQtMS0xLTA_909753d3-8e1e-48ed-aa70-7a345ece839b">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTYtMS0xLTA_c6f97c53-903d-4771-a5ef-d06563da13ff">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTItMS0xLTA_bdd3461b-c51d-494d-9409-55c8528e905b">79,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTQtMS0xLTA_a8130032-0ce0-431d-bf61-664987595763">8,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTYtMS0xLTA_5920a68b-7443-4cbc-bdfd-dd416a886443">75,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTItMS0xLTA_7c3dbe51-802a-42b9-ace1-3b041ab036d0">3,339,408</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTQtMS0xLTA_c386876c-a1cb-44a8-b2a1-ed2cbc8ae27f">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTYtMS0xLTA_3d936bef-58f3-40b6-83cd-37580493a8fe">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTItMS0xLTEwMTU_12c00d16-8cf9-4f51-9a3e-cbdefcde0ca8">0.43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTQtMS0xLTEwMjA_9b5c9c58-c47a-448e-9f8d-2be95750caa1">0.60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTYtMS0xLTEwMjg_22ed102b-df94-412c-8509-909e662c1b18">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-basic</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTItMS0xLTEwMTU_a0f58115-939d-4f31-b39a-b8e07cdfc4ea">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTQtMS0xLTEwMjA_78140d31-72de-4d67-90d7-86ab9c3c7648">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTYtMS0xLTEwMjg_42ae6df4-7846-4779-a837-bfedc2488192">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTItMS0xLTE3MQ_84ba3c9d-c6df-4031-ae26-902f85a4cc0a">0.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTQtMS0xLTE3MQ_8d97a996-3723-449d-878f-6e0e1363b72e">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTYtMS0xLTE3MQ_17b17dfe-4104-4719-ae01-83d6b2839043">0.45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt 0 25pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTItMS0xLTEwMzQ_b1edbbbe-2e6b-48a1-9753-8668a4552b3c">0.43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTQtMS0xLTEwMzQ_39b6b5c2-2c2c-4fbb-b450-cebaf5d09cde">0.60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTYtMS0xLTEwNTI_9ffbe614-4dc6-4f0c-b96b-caacae397394">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-diluted</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTItMS0xLTA_61fc9b48-1b0e-4324-b957-14ad7ec0ae8d">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTQtMS0xLTA_97fce69c-7d10-4cd3-bedf-fbca6646281e">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTYtMS0xLTA_175eab0f-6e2c-4012-8225-76005bc2327e">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTItMS0xLTA_b7a3ca5a-d9ed-4fdb-9a0c-db8ba218a415">0.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTQtMS0xLTA_30ece14a-23cb-432e-a28a-a6fce49ad439">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTYtMS0xLTA_b2c4ae20-7f57-4445-990c-334500ba4147">0.45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTItMS0xLTA_c215c479-a3eb-4e4a-bd1b-305b7e511fd7">15,162,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTQtMS0xLTA_a3e5bce1-d53a-4d84-b75e-f9a960e59641">15,396,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTYtMS0xLTA_a5ef40f5-9c7c-48ea-96ff-02d96b893240">15,614,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTItMS0xLTA_be14cf47-950c-450f-af55-9b2c5b9cb945">15,162,184</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTQtMS0xLTA_8f6cca09-77d2-4dad-a1de-19a9f9895d67">15,396,098</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTYtMS0xLTA_7543989e-2320-4fe3-96d1-1b22b8b68b25">15,614,052</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_181"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.078%"><tr><td style="width:1.0%"></td><td style="width:57.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtMi0xLTEtMA_7dedd7dd-d9c5-4b5c-b416-c1116d5318da">3,418,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtNC0xLTEtMA_6a8d66e0-d748-4d22-b3eb-a34847d4f9a7">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtNi0xLTEtMA_e026cb26-ee6a-48ae-b445-f9add2eb7091">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtMi0xLTEtMzU0_d49f050d-99bc-4faf-b291-c678e1b266b9">3,206,875</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtNC0xLTEtMzU0_8819d85b-9eae-4ada-835d-66e6fbbd09c9">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtNi0xLTEtMzU0_53bb2058-709d-459f-958e-dfaa289449f8">3,782,224</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtMi0xLTEtMzU0_9245a913-a2d8-4e9f-a979-3091f882076f">6,625,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNC0xLTEtMzU0_7033e7ea-1bce-4671-b31b-10665aa7118f">9,211,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNi0xLTEtMzU0_3b24ef53-0f93-412f-a7d3-a3af275b81fe">10,820,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash flows provided by operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtMi0xLTEtMA_bd5f28e0-d4df-4dc6-8b51-286e17e801fc">4,748,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNC0xLTEtMA_5cde82ae-064e-47b5-9b07-c86f6977b292">4,404,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNi0xLTEtMA_3b16add1-3687-4c0d-ac93-6ca6219a64e2">2,982,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtMi0xLTEtMA_873b81f7-0e61-436f-bcfd-110ae0e50179">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtNC0xLTEtMA_1f2556a8-19af-4d65-a73c-106eb1e37dd6">65,408</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtNi0xLTEtMA_6bf32ef4-900a-4fc1-8066-c8b66f6d7f3b">81,886</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctMi0xLTEtMA_9e01b5a4-8a1f-428d-9e16-cc6614b8bb27">1,046,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctNC0xLTEtMA_ecdce7ab-262f-41b4-b96d-579a158b28b3">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctNi0xLTEtMA_8beea201-f2ff-4cb7-8267-4286da602780">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefit derived from exercise of stock options</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktMi0xLTEtMA_bc1784ce-a7ba-4e40-abec-d90605a5ee44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktNC0xLTEtMA_d78b4982-70b3-41d2-a847-eb376a5872a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktNi0xLTEtMA_0b0e1e47-a859-4c8a-abde-5a96390b6c5a">81,886</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTItMS0xLTA_81c7d7f3-f366-47ea-9665-7f0600348d36">1,160,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTQtMS0xLTA_abb6d010-dc7e-4e4a-a536-7e7e05ca4e5d">804,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTYtMS0xLTA_34c6953d-22d2-4774-bd68-5f4e43d70047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write off of deferred offering costs</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTItMS0xLTUzMjk_9817d1b4-0a26-4eb5-9bea-16ade6cb9b2b">440,091</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTQtMS0xLTUzMjk_4a9ffb47-7370-46b5-81eb-30e3a7541513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTYtMS0xLTUzMjk_5512ddf4-d2ea-4403-8a9a-69768391b087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTItMS0xLTUzMTQ_93724de8-7948-4233-b99b-895f65156153">154,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTQtMS0xLTUzMTQ_2c0d0785-57c5-49cd-b414-22d4b9fe870b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTYtMS0xLTUzMTQ_746c0dab-7741-4c48-8a84-667179219073">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTItMS0xLTA_096ccda5-d4c6-4d80-b178-260f578952bc">47,636</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTQtMS0xLTA_66a55abb-3f4b-4071-8d5d-db6f92124090">47,525</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTYtMS0xLTA_d7f80e5a-8248-484d-8397-c8f9e183f435">99,883</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investment gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTItMS0xLTA_be3ddeab-2df6-4b14-8aea-40e2e9828a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTQtMS0xLTA_5b445fec-4b65-40e3-9c34-5b7f88df700a">26,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTYtMS0xLTA_c0a4e2be-176d-4557-a5cc-4279952f60f7">168,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTItMS0xLTA_940d3017-e09b-434e-950c-1fa458a8742a">4,518,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTQtMS0xLTA_fdf5fbfd-2208-4b42-8689-eba11efd58dd">1,399,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTYtMS0xLTA_b82d06f8-4999-48b0-8f33-8d9de7ee7ddd">47,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTItMS0xLTA_af099755-40bb-4072-b762-82570f3b3344">2,131,347</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTQtMS0xLTA_b62eb063-b84d-438d-9a44-bf43faf55a66">1,106,175</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTYtMS0xLTA_f462fed8-3c0a-40ae-8a50-950c89993c9c">528,153</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTItMS0xLTA_422af2f2-38a2-4792-9d24-4f97ce0f65c0">1,210,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTQtMS0xLTA_d5cfa954-21cd-4eaa-a0b2-4b218ed393b3">615,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTYtMS0xLTA_d1e0d1d2-0e4b-4830-9081-15174615a388">676,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTItMS0xLTA_76e67eb9-9bce-441c-8aca-af0a02372db2">6,569,002</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTQtMS0xLTA_7fe13f2c-a2c4-41cf-99bf-814f327312b2">3,221,780</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTYtMS0xLTA_c04bae6b-7615-4bf4-b35f-76e55c0ea6d9">4,153,287</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTItMS0xLTA_e380f032-4be9-46e2-b743-2515a1203d6f">1,859,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTQtMS0xLTA_a0daab7f-60bf-4086-8ed5-c952f5ba1daf">729,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTYtMS0xLTA_3e42b1cf-4042-404e-b280-b9847c5b958f">159,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTItMS0xLTA_26467ef3-db98-4d6f-8aea-f6dfd45521ba">1,896,819</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTQtMS0xLTA_e8c29268-b3a8-4c69-8039-f82598955042">2,455,240</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTYtMS0xLTA_ef6a3975-d69f-4c53-8e04-bd0735b6aef0">1,390,808</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTItMS0xLTM1MA_3e93cef1-7beb-43f0-a7db-4ff5c8577820">3,518,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTQtMS0xLTM1MA_1b617594-ca9c-4319-805b-832f5cfd6ffe">5,511,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTYtMS0xLTM1MA_688765fd-9914-4a44-b9a3-95419eab374d">4,503,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTItMS0xLTMxMw_3bb988dd-e965-4cf4-b9e8-e253f5e4b3c6">5,415,061</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTQtMS0xLTMxMw_44b10003-5f8d-496d-b744-2f9c514bee81">3,056,356</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTYtMS0xLTMxMw_a664f52b-7899-47c4-a2ea-6a7a9b6abf9d">3,112,737</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTItMS0xLTA_51571b59-560c-4621-a8b0-604fa9f41dc6">140,817</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTQtMS0xLTA_99bc9b33-9088-49fb-9bcb-4b4bcbf27e52">246,202</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTYtMS0xLTA_579786ec-8032-4512-b56c-5604457a6aa8">455,569</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTItMS0xLTA_df0ba42d-58fc-4de4-a09a-53afb0cad7cc">1,973,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTQtMS0xLTA_d65b8b58-188d-496a-a0a9-46902e9bbf1f">772,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTYtMS0xLTA_7f1c9c9a-8e30-4bed-932f-4a315a863e3b">3,819,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from surrender of life insurance policies</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTItMS0xLTk2Nw_eb4054a3-996d-4d82-ad6b-6feb90815df5">460,888</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTQtMS0xLTk2Nw_950733b7-c90e-4cdf-9a95-5a5094c02f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTYtMS0xLTk2Nw_40dc7bde-45e7-4670-a628-c1ffec7f3a71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash surrender value of life insurance policies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTItMS0xLTUzMTg_bc1799af-eb3c-4cfd-a602-fb435a4c4815">104,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTQtMS0xLTUzMTg_4668a01a-1287-4794-88ce-b5387d43c324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTYtMS0xLTUzMTg_b5206a53-ff94-4c9a-8c64-b86e38363f83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTItMS0xLTA_9747348a-b668-4412-9c77-63e4efead6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTQtMS0xLTA_697a60ad-11e8-47c3-8989-92845b5b349e">5,000,000</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTYtMS0xLTA_aed39650-2126-4e2a-8c5e-3537c61c17f8">20,000,000</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTItMS0xLTA_9fb68b1d-4f86-41ec-a6bc-2dfb03d68e5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTQtMS0xLTA_eb150008-5242-4c3a-b5cf-fc18cf931131">20,062,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTYtMS0xLTA_349a1a82-41be-405e-be19-299386b0a8b4">16,122,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTItMS0xLTA_3d0ecdd9-1df9-45aa-8b17-cf4c8568acfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTQtMS0xLTA_14d737ce-c052-4857-a46d-e7da9657df51">11,745,138</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTYtMS0xLTA_b6ad6cad-c6d1-40e2-9c3f-97ad4495fcb1">19,572,139</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTItMS0xLTA_cf150ad2-a582-470b-a633-263b600d7dfd">1,757,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTQtMS0xLTA_7d8315db-acf5-4a55-b4ac-441055816a87">2,297,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTYtMS0xLTA_b4ab12e2-b6d9-4fd1-a135-02db75421605">27,724,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.078%"><tr><td style="width:1.0%"></td><td style="width:57.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtMi0xLTEtMTA5NA_2d341852-801a-481f-bdd0-a7cf1d36180f">59,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtNC0xLTEtMTA5NA_2611e568-cb7e-4c53-a72d-e04ebccaeb26">76,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtNi0xLTEtMTA5NA_d3084c62-6179-459e-96c8-7dd7a11d574d">56,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on line of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItMi0xLTEtMTA5NA_8ac44e64-79fd-4a7b-a7cd-608c45540ef9">62,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItNC0xLTEtMTA5NA_d3678ff4-ad74-484f-8f41-0aeaba8a73eb">77,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItNi0xLTEtMTA5NA_0fa1411f-635d-4711-ba5e-aa778ed07333">45,800,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of shares of common stock, net of offering costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtMi0xLTEtMTA5NA_89a1c150-e283-4d60-8742-f75aaf097ecd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtNC0xLTEtMTA5NA_3cf2ee51-3be6-4638-a20d-8bcf1b93b8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtNi0xLTEtMTA5NA_f70ef9fa-9ef9-4b24-a548-b960bfa9d02b">200,909</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made in connection with repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtMi0xLTEtMTA5NA_eb9c93d5-c444-4720-8def-1af883f43f72">1,851,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtNC0xLTEtMTA5NA_a0c067c7-b139-4e72-b1d3-595023ac7231">3,494,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtNi0xLTEtMTA5NA_0782748f-ca84-4a63-b202-8efbce1a2fe3">2,879,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash settlement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtMi0xLTEtMTA5NA_9c0274fb-05ed-42d3-ba32-09c8082e7fbe">819,180</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtNC0xLTEtMTA5NA_a26d539c-6457-45a0-bd07-6f3913874851">1,033,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtNi0xLTEtMTA5NA_c7ea2569-f746-4de5-8a13-ff1b592c3c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtMi0xLTEtMTA5NA_10be276d-e15d-41b3-b6d5-77fcadbf4337">800,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03694dc14e8c4bbb93ae06dc4dea9967_D20170101-20171231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtNC0xLTEtMTA5NA_d8e26872-4fe4-40de-b5fa-bbbcc5589c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd305c2cee64a88a8f6930ec95cb5c5_D20160101-20161231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtNi0xLTEtMTA5NA_6cb00839-40d2-4546-b5b8-d17049d868b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctMi0xLTEtMTA5NA_b674b8c9-8547-4393-8bbc-cc79c0194bfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctNC0xLTEtMTA5NA_7b60dbca-a989-429f-bb9e-f016ed62a198">1,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctNi0xLTEtMTA5NA_e368766d-eea6-4ec1-838e-129eca25e3fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of deferred equity offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtMi0xLTEtMTA5NA_a29bdb08-9d19-47cd-b743-680cff7261b7">135,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtNC0xLTEtMTA5NA_60219ba6-3052-4754-9d9d-11a0eb0af711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtNi0xLTEtMTA5NA_1295b195-0677-4e57-95ae-0b94a60a3783">383,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of deferred financing costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktMi0xLTEtMTA5NA_6c084359-64cd-4bf7-8a00-03bf077c9231">10,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktNC0xLTEtMTA5NA_b612e612-74a8-46bd-b239-fd0bcb2e57e9">52,500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktNi0xLTEtMTA5NA_21b67cc2-3e32-4a10-a7df-5f7a557b644f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTItMS0xLTEwOTQ_092e1895-f6c9-4554-a877-72bb251aae6a">7,116,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTQtMS0xLTEwOTQ_a1416545-381f-403c-8721-8a3594bd811b">5,080,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTYtMS0xLTEwOTQ_8e274a77-8865-4976-9abc-d59d6688b4aa">7,138,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTItMS0xLTEwOTQ_4c3eb5c3-1df3-42cc-ba58-59109c03ea18">3,458,839</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTQtMS0xLTEwOTQ_38114d14-2771-4d5b-bca5-32ca609ae897">273,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTYtMS0xLTEwOTQ_5c6eb411-72b9-4fa5-8d17-2d46831c0b8e">17,473,908</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTItMS0xLTEwOTQ_de5c763c-112c-44c4-a5fd-a9f632495b4b">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTQtMS0xLTEwOTQ_741a0dec-f072-4f4e-84ee-e759407de5df">27,938,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61e32dba4b0475d984dfadd6379821d_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTYtMS0xLTEwOTQ_a61563c8-73d8-44bc-821c-29cc453885dc">45,412,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTItMS0xLTEwOTQ_627fcfc3-a903-4327-bf3c-239beee10e16">24,753,796</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTQtMS0xLTEwOTQ_200cbf0c-689c-4534-a57b-354c24126611">28,212,635</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTYtMS0xLTEwOTQ_c87b4746-74b4-43f5-88e1-613d18d2ff80">27,938,960</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.358%"><tr><td style="width:1.0%"></td><td style="width:57.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid (refunded) during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItMi0xLTEtMA_5a300b09-a387-4b05-bfe0-5029b4869857">215,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItNC0xLTEtMA_e1d46206-4905-432f-9557-8bf85e4f8bf9">198,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItNi0xLTEtMA_86bf916f-8488-49e4-b137-a7aae28d93c2">95,965</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtMi0xLTEtMA_ae1d9b56-62ab-4127-9f1e-ec97f92be62c">91,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtNC0xLTEtMA_beb858c5-de3d-4f2c-b08b-283032da1238">16,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtNi0xLTEtMA_a2374b43-28ad-4ac4-8aa9-136f3f858457">15,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investing and financing activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for intangible asset additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtMi0xLTEtMA_33633bc2-d75c-4a77-8040-43edcc2c4678">340,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtNC0xLTEtMA_5c81fcd3-07b3-46e3-bf3e-d5e3f83e976a">576,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtNi0xLTEtMA_71dc534c-2aa8-4a1e-b0a8-fcdf1fae4fec">539,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash increase in liabilities related to other asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtMi0xLTEtNTgyMA_af28c306-4a41-499c-8d61-7e2ca8fac2e5">200,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtNC0xLTEtNTgyMA_176d7661-62b4-4757-8964-a644304cd0df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtNi0xLTEtNTgyMA_871d247c-8483-4ba5-bc24-9f55aedd9622">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash increase in liabilities related to acquisition (see Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctMi0xLTEtMA_6855e430-4624-4b21-8664-c92f08cb7d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNC0xLTEtMA_5975e0fe-8c34-4000-8014-ba221f68f602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNi0xLTEtMA_f81a80ac-faf4-4f7f-8038-9187227f2e71">14,034,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzgtMi0xLTEtMA_1dce940e-1db4-42b3-84b1-c61560e80989">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzgtNC0xLTEtODc5_c721e45f-df37-43d6-a743-1b76aaa3a359">3,629,320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNi0xLTEtMTQzMQ_0f30a0ec-9775-430a-8f1f-b5a91584d801">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of shares related to RediTrex approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktMi0xLTEtMA_040d0388-8923-42ab-a47c-680da378ee10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktNC0xLTEtMA_ce060d84-c480-48d1-8d0e-c492450c5c8b">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="cpix:NoncashOrPartNoncashTransactionVestingOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktNi0xLTEtMA_c123549f-e2c0-4229-b80f-0a047fd1d5b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTItMS0xLTA_59ed3b96-26fb-4751-a843-d545577a22e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTQtMS0xLTA_8d2d166d-86be-4159-ae6a-8ad53a826001">800,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTYtMS0xLTA_11006b43-251e-4e94-9879-85b780e69e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets from final purchase price allocation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTItMS0xLTA_033b2dde-c717-4031-966e-e0e8c1f5f129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTQtMS0xLTA_1e921e9a-f24a-49e6-af88-93592e3b6359">148,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTYtMS0xLTA_791f60cf-f6e9-46f7-b1a9-1932f5ebeba7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Equity</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:29.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals Inc. Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i579acb9f96de41ffba78cca469abf593_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTItMS0xLTA_6805c1dc-59c3-4480-a1a4-52d7b937a205">15,723,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579acb9f96de41ffba78cca469abf593_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTQtMS0xLTA_6ecc194e-2c4f-4591-af4f-033eca208680">52,410,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae03170bbe484f15ab0b60e6dbda8bc7_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTYtMS0xLTA_ea566efb-ce2a-4c30-ab97-804a54d71d4f">11,709,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85e782a52b4d44329375848c274ec5d1_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTgtMS0xLTA_44075a2b-f450-41de-a034-597096ad34e4">198,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61e32dba4b0475d984dfadd6379821d_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTEwLTEtMS0w_03ec445f-4da8-48b3-8b77-556c9800cd9f">63,921,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff3ff90eb944c0dbe11b04ce7b0d7ed_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTYtMS0xLTA_7c001600-5e80-47eb-8bbb-512ec2da3290">6,963,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bfc004e938140c29692f598f52b5277_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTgtMS0xLTA_cbcbc978-6cc7-4fa0-bb70-56f2eb958438">75,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTEwLTEtMS0w_55ecb744-8405-4618-9b83-27089bab0dba">7,038,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTItMS0xLTA_24469b5f-0256-4bde-9f7d-f347a322476a">170,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTQtMS0xLTA_e1ae830d-1900-47bd-b155-292f1678ec04">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTEwLTEtMS0w_fac1aab5-6d6c-4a67-a67a-0f5064051d65">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock, net of offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTItMS0xLTA_2735c52d-5970-4df6-bcb8-acc0d399a2eb">30,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTQtMS0xLTA_caf8a966-1d80-4767-9daa-b4dad715481e">200,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTEwLTEtMS0w_ea1b3b79-efa5-4d1a-8485-06274b87fc73">200,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTItMS0xLTA_b93713a1-42e5-4163-9cc7-3d1cdde02da6">443,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTQtMS0xLTA_c2d2facb-7195-4386-86a3-60b5ae8af056">2,877,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTEwLTEtMS0w_0c5698ed-9526-400d-a508-e9303fc99389">2,877,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if736d13a5981486b9c4be73116b8d9b3_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTItMS0xLTA_c3c981c1-0ef0-47d9-9de7-c865b898bcd4">15,481,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if736d13a5981486b9c4be73116b8d9b3_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTQtMS0xLTA_d6835dd1-2d4c-44f0-ac3e-986880df0c00">51,098,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bb3d0fc63f46a38f73f8e24b9222eb_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTYtMS0xLTA_6196ee45-008f-467f-8366-bf750e786abe">4,746,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3edfe4448c474b6eaa1f9546a60f6baf_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTgtMS0xLTA_dea1c436-785f-4bca-b485-aaac40f59a07">274,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTEwLTEtMS0w_bc0b76ff-e0e6-45bd-ba4b-ed0de223cb4d">55,570,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e7c45e9e811413cba25b0b270ac8d66_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTYtMS0xLTA_cbead75f-772f-40f4-87ab-902ea022c6d6">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTgtMS0xLTA_6acffa2a-785c-4413-a774-05afd2a42f1e">8,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTEwLTEtMS0w_44168f74-9f2a-405f-9fd5-d244598780fa">3,546,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTQtMS0xLTA_f589135b-5557-4e6a-bbe3-290bc8a9c408">685,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTgtMS0xLTA_9e1928a0-1830-4676-92c9-72af082457c2">114,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTEwLTEtMS0w_4e908bc5-72a8-45d3-b325-a414d317e158">800,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of subsidiary shares to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTQtMS0xLTA_a225d070-927b-4abf-b7b8-11cdfaa382bc">640,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTgtMS0xLTA_48f794d2-6f40-4cf6-bede-15788709b1e6">359,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTEwLTEtMS0w_41446d42-9a66-4d8d-8a3e-fd8e2bc151b1">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTItMS0xLTA_27c6ebf8-f0ff-4b89-adff-6f8eb83c3bd8">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTQtMS0xLTA_4068eea7-8cee-496d-8076-d668e7d708f6">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTEwLTEtMS0w_07ab167c-9be3-45a9-8f71-364bc200806f">862,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTItMS0xLTA_4c926be5-e8c8-4f26-947a-850aa183971d">225,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTQtMS0xLTA_e58e4cf9-e0ae-493c-8b02-b457f7bdd5fc">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTEwLTEtMS0w_00fff10d-9100-40e6-9944-1d1ad4518f50">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTItMS0xLTA_16c1393e-bd39-4f78-913e-a41d0fb77cb6">623,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTQtMS0xLTA_3adf79e8-711d-43c8-bf2f-a2128a68582e">3,486,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTEwLTEtMS0w_7749867f-fd15-43a1-af69-c706fa59c4aa">3,486,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i906c0455495f493dadd51dbdcf6ce33f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTItMS0xLTA_c06fcc9a-537b-426c-99ce-da75094c16e2">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906c0455495f493dadd51dbdcf6ce33f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTQtMS0xLTA_c18c3f2c-8d0b-430a-a1bc-f0162898b36c">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94b48d6a645042b68c812153d89d701d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTYtMS0xLTA_aacef83b-b95c-4d23-996d-82d7c507d8c9">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25561754ff6f4e2ea07d5a93bb7fc0b8_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTgtMS0xLTA_d50d81b8-c59e-402c-b0e9-e9916b0970ce">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTEwLTEtMS0w_a122760d-6553-460b-8868-fdc66f8c8e2b">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113acbcb4c7a41f9b06366a217ff041f_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTYtMS0xLTE0NDI_56ae8b50-efe1-4bbf-8b99-3f9ec9d81b0d">3,339,408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28dc597efa194fb59a0fb601045119c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTgtMS0xLTE0NDI_c7d3459b-1fb3-4e0d-896a-030b48fde256">79,496</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTEwLTEtMS0xNDQy_e4f217e8-ac35-452d-adee-eb2adc23fed0">3,418,904</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTItMS0xLTE0NDI_42506b81-cf47-4bfd-87c2-bc692181a83b">228,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTQtMS0xLTE0NDI_b5e472f2-a162-40bb-b5d7-e599f330bd62">1,046,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTEwLTEtMS0xNDQy_0575ba44-bfa3-4bb2-9e36-bd49d82c7f91">1,046,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTItMS0xLTE0NDI_97870155-4939-4c1b-8755-d9e4424c4154">503,626</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTQtMS0xLTE0NDI_17958260-4f0c-48ec-8ddc-7980e842251b">1,839,471</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTEwLTEtMS0xNDQy_6047cb4c-d03a-4199-9be9-f2e4f30a9763">1,839,471</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72fd6471f1da4426a87a1886db0ae152_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTItMS0xLTE0NDI_e55d4f5f-e603-49c5-b2f7-40d821e81d36">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fd6471f1da4426a87a1886db0ae152_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTQtMS0xLTE0NDI_4f5d24f9-dd29-4c7e-ba71-13e1612b14de">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1d88acf1394d319d163e4143882af2_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTYtMS0xLTE0NDI_6af5754e-7f7b-4410-bfa0-c57e0817695f">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida79e60e9d42460c84903d34b3fd5625_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTgtMS0xLTE0NDI_742cc6da-450a-448f-9827-700327d048f0">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTEwLTEtMS0xNDQy_ba092da3-9d9e-41ea-965b-1a398c5fb441">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_187"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_190"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)   <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMyOTk_c5ba7350-0b33-4301-8cfc-2ada83113eea" continuedAt="i3b7c4a0783ca4008b7dc3ac3d16ec746" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i3b7c4a0783ca4008b7dc3ac3d16ec746"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d15f9eb345d4d64aa801993173c575d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzE3OTA_66ff5f7a-3096-4782-9d6e-93b32e592b7b">1.0</ix:nonFraction> million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzIwNTY_a2235b48-937a-4ced-940d-59b2fc704280">1.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzIzNDM_bd2999a9-3e35-417f-8807-b529ecbcf48d">1.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="i82fdc18596fd4b20999ba80f5d41bd51_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:ContributionOfCashAdditionalSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI0MzM_ada4aa47-18d5-4ccf-8535-dd2137a9468b">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:IntercompanyLoansPayableConvertedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI0NjQ_11679d4d-7bfb-47c2-82b6-fc350653d352">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzY1OTcwNjk3NzA0NzI_833b46c1-bcea-4b2f-9a5b-058ee28baa06">0.8</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that was funded during 2020.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now <ix:nonFraction unitRef="number" contextRef="if2a2c29316304015acd330ba1069f0e5_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI3MDc_b2e24486-ccf7-4d7a-ad3d-b2faec84f7fb">85</ix:nonFraction>%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwMzA_cafe800d-7f52-4746-81d4-ebe83c539285">79,496</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwMzU_3fb16ff0-9a6b-41dd-8584-694e5250ef28">8,752</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwNDM_82e145c3-a390-4933-9305-fd859033c337">75,704</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_193"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)   <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYz_c32d9f4b-3558-4b2f-bd07-98beaf74fd1d" continuedAt="idc3b5e855f1d4ca69f92e46e7f81d814" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="idc3b5e855f1d4ca69f92e46e7f81d814" continuedAt="ia8bcb5e6b6ec4639be3a0e9756844b70"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ5_00b4c61e-bc4f-4044-8d98-535a27f54584" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ1_37971f80-bd47-404a-9638-ff2caa5901aa" continuedAt="i2ca985c586944cc8b9bb85ce7cefdd7c" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2ca985c586944cc8b9bb85ce7cefdd7c">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</ix:continuation>  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ia8bcb5e6b6ec4639be3a0e9756844b70" continuedAt="i6b83ff08388a4a6dbbcefa63185ac84f"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY4_316a1571-e697-4698-b42e-f63849da2adc" continuedAt="i1295b6c7e51547e7a1e7f4d1670e2c7f" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1295b6c7e51547e7a1e7f4d1670e2c7f">The Company has <ix:nonFraction unitRef="segment" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzEzNzg_f6d89425-2e10-4feb-b915-5962ec0716a0">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation>  Net revenues from customers outside the United States were approximately $<ix:nonFraction unitRef="usd" contextRef="i3d6f67ab017747e488ce81fe0f2d992e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNTA_98331bea-46aa-449e-a0c1-3bc05db4631b">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i563ad4ae0b474a93a68d18998539da56_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNTU_e7719e3a-045e-4239-8965-ecd4322ac414">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i523a0c1898d94b0d968011937afb9b4c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNjM_a5c1281b-9a20-4711-87a4-f8e17f25f8fe">2.1</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYx_99aedfd2-787c-44fb-8995-1a5f5b1622b6" continuedAt="iafa9d966aaa1405ca09ce40154d7a9c7" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i6b83ff08388a4a6dbbcefa63185ac84f" continuedAt="i52cff6d54a6f4bd78fbb56140700f007"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iafa9d966aaa1405ca09ce40154d7a9c7">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</ix:continuation> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYy_cec5fa9a-c310-49b0-8bff-2e83c35daa58" continuedAt="i4f49ca5266e24336a12db6906aede835" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f49ca5266e24336a12db6906aede835">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2020 and 2019, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.</ix:continuation> </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU0_cf143531-1baa-4834-be9c-227081dd5add" continuedAt="i75d88ce877ac4b91814331e2bfa84383" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75d88ce877ac4b91814331e2bfa84383">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2020 and 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.</ix:continuation> </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY0_d39ae0e9-dac8-4b62-ac55-4126c99fe940" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $<ix:nonFraction unitRef="usd" contextRef="i7ac26c9d624a4950b3d6b38c45e4b597_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzgxMDc_2f1e458e-6f13-4e76-8001-946bae5a42cb">1.0</ix:nonFraction> million at December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="icb9d8b7bd9c444fd81c867a1f021713b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzgxMjA_0d8160d2-d719-4292-80f5-8d3d27ad4ef7">0.8</ix:nonFraction> million at December 31, 2019. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU4_64108b25-c47e-4907-ad56-2dc3c1d49562" continuedAt="i1465dcb53e374e6d8854a3a11d802b42" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i52cff6d54a6f4bd78fbb56140700f007" continuedAt="i12ad327895274384ac1f25d0fa6062fc"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1465dcb53e374e6d8854a3a11d802b42">realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.</ix:continuation> </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU5_0f73cb08-dd97-48d8-b83f-97d7cadc973c" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2020 and declared effective in January 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2020, the Company has expensed $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIxOTkwMjMzMDk5NzI_811353b2-e70c-4fe2-a053-b6ad01046024">0.4</ix:nonFraction>&#160;million in deferred offering costs associated with the Shelf Registration that was declared effective in January 2018. </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ2_38ad798e-811b-4b55-b707-51b5287903a2" escape="true"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY1_bcae1f63-bcd8-4a2b-b2b8-aa465d28a639" continuedAt="i67bf262e682d4ce9a6a37c6f7f8168df" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i12ad327895274384ac1f25d0fa6062fc" continuedAt="i00c335f1931c4ac5b733e3ffef4b5b4b"><ix:continuation id="i67bf262e682d4ce9a6a37c6f7f8168df"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ3_b34a507d-000c-4569-9b69-5336f7505cd3" continuedAt="i9c4e10c0041f4ff0b18c54b161fe225c" escape="true">Amortization expense is recognized ratably over the following periods:</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i9c4e10c0041f4ff0b18c54b161fe225c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzAtMi0xLTEtMA_7455c885-39a0-452b-8514-4b4133b3ce14">Estimated economic life</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i858b3a2a4199408587b99fe9de451ae9_D20200101-20201231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzEtMi0xLTEtMA_b9c788be-a6aa-4385-a093-3b8c3e275186">Term of license agreement</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzItMi0xLTEtMA_ca8367f5-4008-42a6-a360-1e2a7e5287ec">Life of patent</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUw_a9ac379c-2949-4bbc-8683-7159c50fc8b4" continuedAt="ie499c50023ae45e5b34127bd7afe9679" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie499c50023ae45e5b34127bd7afe9679">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</ix:continuation>  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2020, 2019 and 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i713b05d7f5bc4937aed96e19605bbd69_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzY1OTcwNjk4MTkwNjE_4c322f2b-1b73-4a72-8eab-2ab15f7dfa8b">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of $<ix:nonFraction unitRef="usd" contextRef="i713b05d7f5bc4937aed96e19605bbd69_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzY1OTcwNjk4MTkxNDI_71d5438f-143d-4cd8-8a52-71599e7fe006">0.2</ix:nonFraction>&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY5_bb99bb23-a070-4017-9ecf-77b13d0f2241" continuedAt="iee242b8e21c646ad903859f7dbd7882f" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span><br/></span></div><ix:continuation id="i00c335f1931c4ac5b733e3ffef4b5b4b" continuedAt="i3c87b60ccf254a9d82aa62e853f1b28b"><ix:continuation id="iee242b8e21c646ad903859f7dbd7882f" continuedAt="i32282d09362c47218a312db8b2c213f4"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32282d09362c47218a312db8b2c213f4">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItMi0xLTEtMA_7057a439-0830-4551-aba1-6af4a770db3e">890,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItNC0xLTEtMA_afaa320b-5991-4812-9c9c-a5d86ee6ab04">613,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProductionAndDistributionCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItNi0xLTEtMA_49efcf36-8126-437d-9660-ffe601ff23b9">457,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i3c87b60ccf254a9d82aa62e853f1b28b" continuedAt="ie03ef74369ac4fe292ed8fa34738a5dd"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY3_959ba076-e8c8-4c03-a085-048f0c02cce0" continuedAt="i90ebf66068614918a920784411adfaff" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90ebf66068614918a920784411adfaff">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItMi0xLTEtMA_3c964001-391e-4722-9bc6-58dae5554e12">2,379,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItNC0xLTEtMA_b3f00b02-5549-4750-89a9-2fff3750d8bf">2,594,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItNi0xLTEtMA_2ba422cf-945b-4844-9046-f14adee8ba9d">2,005,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTcy_c26c034c-d800-4bd0-9e5d-468f1724c15b" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU2_0ebf54e1-233b-49ea-9445-a150fb294d2b" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU3_3205eceb-f41e-4d20-87ce-25e9c4715b31" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUy_c07972db-7d8b-4b1d-9e28-5e4b6e6c8c3e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ie03ef74369ac4fe292ed8fa34738a5dd" continuedAt="i2a163091251c4b9dbfc7a40c7eb76d76"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTcx_3630124c-e700-4dd7-8695-9e0ede42ec33" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 20, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 20, for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUz_ed45e39f-f865-4572-81ca-d6b23714ce9f" continuedAt="i9794e70a9a834116a64d59466b7fe6a4" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i2a163091251c4b9dbfc7a40c7eb76d76"><ix:continuation id="i9794e70a9a834116a64d59466b7fe6a4"><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_199"></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTQ_09f198f4-c180-4440-8b8c-2a0c0bd96774" continuedAt="i087fb15f73d84a4dadb33bcf452ea39a" escape="true">RediTrex</ix:nonNumeric></span><ix:continuation id="i087fb15f73d84a4dadb33bcf452ea39a" continuedAt="i42743034e5e94232b13d830b73e77691"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></ix:continuation></div><ix:continuation id="i42743034e5e94232b13d830b73e77691" continuedAt="iaa8cccfc39044d93afb1575b811b2eb1"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxMDc_a9b1f5fc-720f-4c89-bbdc-189744625ca4">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxNTM_bf1aa0f9-9180-487a-87e0-ba4bcd0f0a10">0.9</ix:nonFraction> million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxODU_26552ec4-7025-4bd1-8ee3-015c32927b1c">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name. The <ix:nonFraction unitRef="shares" contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI2MDg_26552ec4-7025-4bd1-8ee3-015c32927b1c">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI2ODI_5cbab9ad-1fe7-4a3e-8b26-ba8cf13ceefd">0.9</ix:nonFraction> million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI3NjI_68bf37ba-d36e-4cdf-bff8-fa9787f56b47">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  During December 2020 Cumberland launched RediTrex and the launch also resulted in a $<ix:nonFraction unitRef="usd" contextRef="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzY1OTcwNjk3ODA5NDg_68bf37ba-d36e-4cdf-bff8-fa9787f56b47">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="i1ffd3ca73a074170bbcb58ba566f9585_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzE2NDkyNjc0NTIyMTM_5f7517f9-b861-4f44-aaba-bbb552a076ad">2.8</ix:nonFraction> million in net intangible assets related to RediTrex at December&#160;31, 2020.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, Cumberland recognized $<ix:nonFraction unitRef="usd" contextRef="i1f0edc4849df4c21910d604bb57d2325_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzE2NDkyNjc0NTI1MTc_19e49bf1-a14d-4e3b-93be-75c5a05ce5e8">0.5</ix:nonFraction> million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.         </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQwNTY_11d71a51-5139-43e9-8db1-01d23521653c">20.0</ix:nonFraction> million at closing and a $<ix:nonFraction unitRef="usd" contextRef="i60fc1a3fb3064db1baf227cdf6d18b18_D20190308-20190308" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQwNzY_a7c9441b-ac66-46f8-835c-2ff861551c04">5.0</ix:nonFraction> million cash payment during early 2019. In addition, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="iaa8cccfc39044d93afb1575b811b2eb1" continuedAt="ia5b6debb323c4fe28d1a759a20eb79b4"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQxNjg_467929f4-3b42-47f2-a446-bfa5fcb352b6">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTY_96054273-f103-4a48-814d-c750a83c4e37" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:74.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.578%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzItMS0xLTEtMA_407224f2-2796-4245-baf7-95367a5a3612">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzMtMS0xLTEtMA_01d6be53-7551-4966-afd3-e041d6778182">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzQtMS0xLTEtMA_99d0637d-e06c-4e2e-b68e-70c23f2420d4">9,182,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzUtMS0xLTEtMA_6cf12dab-ce68-43a5-8332-e1cedb4e2ea4">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTc_33fe9827-10ab-4ec9-9024-7af981d2d93b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is remeasured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf84cc8aa13a4c4e9c2848f65593a987_I20181112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEtMS0xLTEtMA_ddf43392-f4de-4e80-8dee-fa3f798e5a9a">9,034,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3805a80f910745b8ba5901401f43502b_D20181112-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzItMS0xLTEtMA_4a6f7aca-a2fa-45e0-ab31-f29e44f8385e">40,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3805a80f910745b8ba5901401f43502b_D20181112-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzMtMS0xLTEtMA_0b78817a-7f21-420e-a930-9e5b908b077e">508,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d4426d3227403fabbfb9d27a6e529f_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzQtMS0xLTEtMA_f62124d3-2c83-4d7c-9933-dab3c4eb238f">9,502,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzUtMS0xLTEtMA_7fd60046-5f89-41e8-a421-bb92439e2406">148,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzYtMS0xLTEtMA_344d2d19-edee-4a0e-afaf-bbb144ae1362">1,033,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzctMS0xLTEtMA_c1a0785a-dea4-4bf9-a9b7-f736fa41c5e3">804,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzgtMS0xLTEtMA_42604779-2a4d-40f1-8189-91c10a8392a1">820,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9690979d455048e786882dc7d1715d78_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzktMS0xLTEtMA_6debad4e-cf47-4418-ba30-273fdd932766">8,633,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEwLTEtMS0xLTQzMTg_551e37af-c1dd-4415-abc7-a0d0ba44b0f0">819,180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzExLTEtMS0xLTQzMTg_859dfbd1-faa9-44f2-a465-faf4da36f683">1,160,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEyLTEtMS0xLTQzMTg_879f8b6c-8303-4a7f-b13f-f63a6b835bf8">1,546,346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bf3ecd92884fba947bb8fde5284b63_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEzLTEtMS0xLTQzMTg_bf586340-2cde-4f99-9c62-8e5b60d6e694">8,200,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ia5b6debb323c4fe28d1a759a20eb79b4" continuedAt="ia4f20bf361b144d09d4f0dfc568b1215"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTg_caf94d74-b376-4939-9a91-becbf5b664dd" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzAtMS0xLTEtMA_71eb5148-b0e7-4c50-8467-ce02ddbc3119">6,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzEtMS0xLTEtMA_dfea8572-adea-4e98-ae7b-770495c46abd">3,970,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzItMS0xLTEtMA_04e4a858-bd76-426d-8281-79402f31314b">1,827,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzMtMS0xLTEtMA_719e4fa4-2b13-4157-abc9-7a09917f65d9">9,129,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzQtMS0xLTEtMA_aec66fa7-6bfe-4927-a714-e8629aff259f">21,550,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzYtMS0xLTEtMA_587de83b-f4e7-4e7c-bb4e-3e6e851e313a">11,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzctMS0xLTEtMA_6f29ad2a-3e05-48e2-a190-98dcb0330759">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzgtMS0xLTEtMA_0228b1ae-c70d-4240-81db-313605825699">12,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzktMS0xLTEtMA_c7d2fd08-89fd-415e-a056-ac9c74715a60">34,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4f20bf361b144d09d4f0dfc568b1215">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU3Njc_85cd2246-175c-4ca9-9a13-cded031d7de1">3.3</ix:nonFraction>&#160;million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MDE_be82eaf9-5a75-4393-858f-c5537c142a1d">4.9</ix:nonFraction>&#160;million, as of December&#160;31, 2020.</ix:continuation> </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_202"></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI3NTA_49ba198e-cca7-4045-af64-2b02d3ab04e6" continuedAt="i86849a4c5a9c4b67982adb38621fa697" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i86849a4c5a9c4b67982adb38621fa697" continuedAt="i5c653eba07484991b7a80babff73ff1f"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI3NTI_ba4d84a4-f81e-4a70-aca1-01f0fffe0f56" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8106a20e864d28bd6d0ef776efb119_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItMi0xLTEtMTc1OA_9d4a68eb-465a-477d-87b9-49e12e958cff">15,567,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1a0444604f4249b8af8cff8f67e09d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNC0xLTEtMTc1OA_a50eea67-d519-4986-b385-dfc1d0b72d20">12,895,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93dbc3e2bb445b79575c990976d088c_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNi0xLTEtMTc1OA_036c8386-2162-457a-9af3-4b17cfb3fbef">12,055,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f00b78b135497898e49546c1d2f4ff_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtMi0xLTEtMTc2Mw_c86bdb57-cbb4-47b4-a7ad-5427c6c40143">10,870,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4269e0d435e4dd8af6548e04ee94f28_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNC0xLTEtMTc2Mw_df4e0197-c7d1-409a-a162-153c4d3ec8c1">8,691,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932871e9df8745c583acfe2f18eb6df4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNi0xLTEtMTc2Mw_c8eb0972-d2f1-41c9-aaaa-cdb286bf6b88">5,075,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cdf7521dab4b328c6824333676f5fb_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtMi0xLTEtMTc2OA_068a3d04-c42a-476a-ae7b-24ae7b7a2b66">5,336,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d41290b523433fa5c1c7846ba6fb17_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtNC0xLTEtMTc2OA_2bbaf00b-516a-4e19-8725-934d50d5f63b">5,222,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3738fecb3eaa4c198acc94352adfea94_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtNi0xLTEtMTc2OA_94acb835-431f-40de-ba3b-8db4559d773c">5,001,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d302dded484788ae6589a0340b9b88_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItMi0xLTEtMA_0833088e-21df-4935-88d1-58cf63c81bea">1,874,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fb6667544f4f559f12205fcebec85c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNC0xLTEtMA_391ca38b-0a54-4d5a-ac58-d71f6539b1a7">3,824,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf76f0a2b0ed40d8b2b44aebcfae79d7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNi0xLTEtMA_cf255021-fb2f-4c02-b3dd-99a56e191e38">4,284,111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128821f68ebe4cd097ed7ff95840f048_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtMi0xLTEtMA_c0da71e8-a4cf-4823-84d2-9da2be1ddcd9">257,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff264f92669d449e8bcb64c3d9b88d42_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNC0xLTEtMA_0f40d00f-4b6e-4dfb-8ca9-82bc40a09ee8">837,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011d9382fa6c4d49bd3e83103b01e17e_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNi0xLTEtMA_f8b49a85-1f10-491a-8958-229043b531b2">623,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21522c7cbff7479c950097c298729560_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtMi0xLTEtMA_1ab75dc4-e753-4a54-802b-7abaa5d57282">1,077,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379abd9813bb4e449cf04367935a4368_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtNC0xLTEtMA_fe6740cc-cb36-4199-ba3c-af5ee39f5dc6">936,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie836a99c6e9a4ea5b8b4e362f27f61b0_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtNi0xLTEtMA_4ac84148-4d85-4959-afc8-99caa117c40f">1,763,874</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4953695015dc4f6192628e3e06840b93_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzgtMi0xLTEtMTM1Ng_8e9184fb-55ea-4b33-bc1a-a65fa97fdfae">856,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTItMS0xLTA_8b95f62a-457f-4b05-b2c5-d9795999b3a4">35,840,673</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTQtMS0xLTA_cf4dd806-0f7d-4c8e-b126-28bae14f58bd">32,407,845</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTYtMS0xLTA_17c27800-0ecb-4f8a-9837-d7e1caf0b9e4">28,803,961</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $<ix:nonFraction unitRef="usd" contextRef="icd71c23cf60e4a89ace2b16705e73a6a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzc0Ng_6f0500c5-a1fb-4178-8db1-d35ab295fc6c">0.3</ix:nonFraction>&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019. There were no payments received in 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i5c653eba07484991b7a80babff73ff1f"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The international agreements provide for $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE4NzY_8d8d5468-1089-4b6f-b92a-d3f10e32ded9">1.0</ix:nonFraction> million in non-refundable up-front payments, milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE5NDQ_7c1a28de-c65e-4ebd-9914-0a92db460f3c">2.2</ix:nonFraction> million related to regulatory approvals and up to $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE5ODk_81bea219-f060-4d95-8d14-4cf7c79da44c">4.8</ix:nonFraction> million in payments related to product sales.  From 2012 through December&#160;31, 2020, the Company has recognized a cumulative $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionCumulativeUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzIwOTM_07faf8cd-0765-49c6-b255-60002f712792">1.2</ix:nonFraction> million in upfront payments as other revenue and has recognized $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:RevenueRecognitionMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzIxNTI_34a40f67-b0d1-44dd-85cd-d741e92afea6">0.1</ix:nonFraction>&#160;million in revenue related to the milestone payments associated with these international agreements.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2020, 2019 and 2018 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i05552adfe6bd4b2c9364a3fb0e38115f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2ODY_9f3732e6-840d-4388-baaf-dcb2b18118a4">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i11727dca580e45938d1bd2a30fa3b13c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2OTE_d9f0c37a-edda-448d-9b7c-9cec8052f280">1.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i425aa7efcc3d419489434711697897b5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2OTk_814b32a7-1a2d-490c-b5d2-b2c607fd542b">0.1</ix:nonFraction> million for the years ending December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_205"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE3NjI_2beb20c6-925b-4bd3-869b-5aeaade137af" continuedAt="ia0726dd2495c4ae48d33f65a25142411" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ia0726dd2495c4ae48d33f65a25142411" continuedAt="i0a29f1e9d6c0461e886e3a29cd5a7666"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE3NjM_55eabbf4-57e3-4ee6-ab1d-09623de399c0" escape="true"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:60.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzItMi0xLTEtMA_236c2b70-9cc7-4479-8ee0-0d8d9a1a3e52">16,223,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzItNC0xLTEtMA_8775f4e3-6230-4835-8ec2-1fbb88f1ad0e">19,345,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzMtMi0xLTEtMA_4bfab8ee-8050-4cd9-ac23-dba29a05a09b">128,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzMtNC0xLTEtMA_058cb055-6903-462b-b16e-f25b4da7631a">416,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzQtMi0xLTEtMA_a838ecda-7884-4f0e-877e-a0055ba874ab">5,943,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzQtNC0xLTEtMA_419fd864-a148-4123-bd1e-f4d9f9686bba">4,664,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzUtMi0xLTEtMA_16c49481-383e-4e5a-933d-2db2d00c607c">22,294,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzUtNC0xLTEtMA_a93c99fb-5fec-4585-b3bc-a1abc0bd31f4">24,426,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzYtMi0xLTEtMA_53a0b4a1-0a60-46b9-a0e6-c08409caaf10">11,656,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzYtNC0xLTEtMA_1df3c2fd-a9e3-46a2-b743-53af01c2bdc4">15,554,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzctMi0xLTEtMA_04a861a7-6e25-439f-bb9c-fee5c42b80c4">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzctNC0xLTEtMA_37da5edb-0c4d-4231-b4e2-f43b39fb12f4">8,871,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.  The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At December&#160;31, 2020 and 2019 the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzY1OTcwNjk3NzE5MjU_331e6652-bf69-4e52-952f-9f62603df660">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzY1OTcwNjk3NzIzMTc_11ef7f67-0d1d-4c09-9f14-bfaa62cae41d">0.1</ix:nonFraction>&#160;million, respectively.  </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i0a29f1e9d6c0461e886e3a29cd5a7666"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2020 and 2019. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzEzODE_9c713347-41b9-4201-8c75-e94c86be6fef">15.6</ix:nonFraction> million  that were classified as non-current inventories.  At December&#160;31, 2020, the Vibativ non-current inventory was $<ix:nonFraction unitRef="usd" contextRef="i25bf3ecd92884fba947bb8fde5284b63_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE0ODU_511f3310-8c65-42b1-beea-2af197bc402a">11.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9690979d455048e786882dc7d1715d78_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ4MTM_c2e45fc1-2336-4f22-9be5-5bf3425c052a">15.3</ix:nonFraction> million at December&#160;31, 2019.  The Company had Vibativ finished goods included in the non-current inventories at December&#160;31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i44a7f8d16fd34d9298c695a5fc27fb15_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ2OTE_4f9b5a21-90a8-4238-80ad-cc1704fa1c7d">2.1</ix:nonFraction> million and we did not have any Vibativ finished goods included at December&#160;31, 2019.  At  December&#160;31, 2020 and December&#160;31, 2019, Cumberland had $<ix:nonFraction unitRef="usd" contextRef="ia9075a3fe1d64ddf8f34dc57c4454544_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ2Mjg_b33074f4-b1b4-4abb-8622-645a8474b183">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i900aa4346676422fb1898c7d882f8fcb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDUwMTU_701ea80c-c511-4e77-a367-32e9e4e52809">0.3</ix:nonFraction> million, respectively, in non-current inventory for API related to its ifetroban clinical initiatives.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_208"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM1Ng_ce12fdd0-6881-4cb5-81df-ff2cfe30eff9" continuedAt="i0971db63be874be188b8037db5c065bb" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i0971db63be874be188b8037db5c065bb"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM1OA_c6b97ed4-3bcd-4e54-8004-8c08347c21c5" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:34.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6fd7af49de249ecb292d30a08cbd4de_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItMi0xLTEtMC90ZXh0cmVnaW9uOjIwNWNjNmQ2M2NiYTQzZTk4YWE1N2NmOGU2YmVkMjc2XzIxOTkwMjMyNTU1Njg_e4270ee2-e50f-4d5a-965f-023dc428bdce">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i74b9642648b4446484395a251aeb73e5_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItMi0xLTEtMC90ZXh0cmVnaW9uOjIwNWNjNmQ2M2NiYTQzZTk4YWE1N2NmOGU2YmVkMjc2XzIxOTkwMjMyNTU1NzI_414e52dd-a2f7-4703-81f8-622beb44c22f">5</ix:nonNumeric>&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i567a47d8201140e0a6ab9fd8bf24c58c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItNC0xLTEtMA_490420a1-4227-4298-8007-eff2f94af878">1,275,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57a23f2f6ce40868fabc79000f9acc9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItNi0xLTEtMA_8ecd4a19-9e79-4e59-bd35-64f27808825a">1,260,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22150fcc5f674069a6bb7c015e170408_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmE4ZmQ3NjkzMmUyNDRkOWFhNmIzMTBkYzIyMjllOTcyXzIxOTkwMjMyNTU1Njk_8d14caba-9710-4748-beff-af60660553c0">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i43f7778a12b5457fa1f6664420a75437_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmE4ZmQ3NjkzMmUyNDRkOWFhNmIzMTBkYzIyMjllOTcyXzIxOTkwMjMyNTU1NzQ_f8411523-da69-4e1e-9448-8ff7f15c9d52">15</ix:nonNumeric>&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b440537b5d417d8d302cd1bd73dd3b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtNC0xLTEtMA_cfacb194-b542-44df-a59c-65479ddd2235">806,906</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d077df83004e9b9dca31085e2c7dce_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtNi0xLTEtMA_d037700a-4a84-431f-9d73-7fce36b23f32">878,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61b3055ed198427f821e78280855ef22_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjk3NDM4MDAyNjAyODRjM2JiOWZmODRmNjFiYTNlNmYzXzIxOTkwMjMyNTU1Njk_7586c1d2-262a-47a2-92ce-43f72cb8362b">5</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="ic56325a56faf46d4b05761c86d36d031_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjk3NDM4MDAyNjAyODRjM2JiOWZmODRmNjFiYTNlNmYzXzIxOTkwMjMyNTU1NzQ_92f9df02-32d5-4d43-b70c-9fecc604b8f8">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b299fde4ec4bd2b6d62fffe5447170_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtNC0xLTEtMA_5a13d444-0295-41de-b63f-d842dd13da20">638,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19f08d91a2640dba99067b8dbe8c464_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtNi0xLTEtMA_fc859600-7f0d-41f3-8c36-9984ba70fa07">646,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1528e64c010641a68be52125a75832b1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtMi0xLTEtMC90ZXh0cmVnaW9uOjgzZWEyZTJlZGJlMzRkYWU4OTczNjBkMTQ4NjlmZDkyXzIxOTkwMjMyNTU1OTQ_543c8858-c403-472a-aa2c-2efbb17710aa">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i3ff6b1dbcf3c4c8e92b1cdefc3aa7b52_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtMi0xLTEtMC90ZXh0cmVnaW9uOjgzZWEyZTJlZGJlMzRkYWU4OTczNjBkMTQ4NjlmZDkyXzIxOTkwMjMyNTU1OTk_9328ba5e-24df-4225-926f-8f38feb95973">15</ix:nonNumeric>&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3be021e818547a795f36d1377c9ea4a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtNC0xLTEtMA_ef60a402-f359-4a9b-8474-a9dc2fb08932">1,409,744</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4713d678174ead99f243c92ec45d16_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtNi0xLTEtMA_da451f00-eb57-47f4-8a8f-fd3ec01acf55">1,356,640</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzYtNC0xLTEtMA_e733baa3-8f27-4e17-9987-2cee67082b21">4,131,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzYtNi0xLTEtMA_2fce117b-0dfe-42fb-9960-7d23b474adaa">4,142,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzctNC0xLTEtMA_5876b317-da07-4796-9db8-fe9b6879dd55">3,557,087</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzctNi0xLTEtMA_053d9be3-59fe-4088-b1e4-7966357f8a24">3,394,329</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzgtNC0xLTEtMA_5a400ca7-7081-4b1a-9e65-4bff727a553f">574,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzgtNi0xLTEtMA_c6602464-5b3e-4499-be1e-e4cee8fff930">747,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:ScheduleofDepreciationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM2MA_503b484c-a08b-4cf6-9e61-ed5dee9f3793" continuedAt="id5658cedc525456d904c39529155692a" escape="true">Depreciation expense was as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="id5658cedc525456d904c39529155692a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItMi0xLTEtMA_93a9e166-5f42-475f-a3ca-f3eae7c017df">314,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItNC0xLTEtMA_4d4d1681-11e0-42ef-806a-ee7a5fb69ff8">269,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItNi0xLTEtMA_6593a91a-5fe0-4596-9c8b-63a088cc675f">213,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_214"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNjk_2142d25a-8fd9-4226-ad3a-9de6e436d775" continuedAt="i7d86125d0d4c407bb92ec3ba4c8d8c94" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i7d86125d0d4c407bb92ec3ba4c8d8c94" continuedAt="iad50ba9369404c06bcda827419a2e727"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNzA_16ce33e5-04f6-4414-8e26-58aea477541a" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"></td><td style="width:59.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie005a45bb43941a58835f78c97251e65_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzItMi0xLTEtMA_288e4a7c-0397-4c72-bbc5-0cf8ca16b706">38,543,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0173213b69184c199e2c3ab68e949553_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzItNC0xLTEtMA_e3c9bc4e-ef61-439e-9a8e-ed8c919a6f68">37,400,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie005a45bb43941a58835f78c97251e65_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzMtMi0xLTEtMA_014d970a-3114-4deb-bbb5-34117d37e70f">14,709,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0173213b69184c199e2c3ab68e949553_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzMtNC0xLTEtMA_7e26a0d0-36c3-4564-bf2f-53d4a522b3a7">11,499,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie005a45bb43941a58835f78c97251e65_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzQtMi0xLTEtMA_ca6d3ad7-e3e7-43d5-a393-21513a708832">23,833,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0173213b69184c199e2c3ab68e949553_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzQtNC0xLTEtMA_ee092478-f777-434f-8ef9-abc6c0df6249">25,901,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzUtMi0xLTEtMA_ef79a722-830c-45ca-b4a5-df996c6173ac">10,306,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzUtNC0xLTEtMA_e1e7f889-f0fe-4e8a-8d21-62b4a1abe5fe">9,882,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzYtMi0xLTEtMA_c7eac2aa-1179-42a5-9c12-cf3e0815d548">6,312,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzYtNC0xLTEtMA_ee91b0aa-68e6-4a58-8f53-c6cbb8a43fa4">5,127,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzctMi0xLTEtMA_afb6eb62-6b45-4417-ba61-7e94280127c8">3,994,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzctNC0xLTEtMA_fc4837bf-5e95-421a-962f-a8cb25a3f4ed">4,754,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzgtMi0xLTEtMA_4e88adbf-727d-4d01-976c-46c9b1fb3e12">338,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzgtNC0xLTEtMA_f19d57af-27e1-4122-b87e-419946121d3b">273,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzktMi0xLTEtMA_fd302abc-5aa3-4175-aabf-ffc79897292b">47,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzktNC0xLTEtMA_3c659693-5dd3-4d86-b2b8-c0fe49e14829">9,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEwLTItMS0xLTA_5ceb5473-5008-4366-9de4-d741f9837204">290,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEwLTQtMS0xLTA_99428b74-a1ab-4070-a6e9-ec538b9da24c">264,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzExLTItMS0xLTA_240859ad-922d-4b2d-b535-98d7a62dcaaa">28,118,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzExLTQtMS0xLTA_b9fa78fc-7ca7-4121-b867-d17a2058d285">30,920,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEzLTItMS0xLTA_fcaed65f-aee7-425b-901b-a9d7718b31cd">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEzLTQtMS0xLTA_ea7a2c95-f05a-4dc6-9a2f-5ff6b9168ded">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex and Vibativ. In November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#8217;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $<ix:nonFraction unitRef="usd" contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE5NTU_a9b1f5fc-720f-4c89-bbdc-189744625ca4">100,000</ix:nonFraction> deposit paid at closing, the <ix:nonFraction unitRef="shares" contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE5ODc_26552ec4-7025-4bd1-8ee3-015c32927b1c">180,000</ix:nonFraction> restricted shares valued at $<ix:nonFraction unitRef="usd" contextRef="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIwMTg_5cbab9ad-1fe7-4a3e-8b26-ba8cf13ceefd">0.9</ix:nonFraction> million that vested upon the November 2019 FDA approval, the additional $<ix:nonFraction unitRef="usd" contextRef="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIwODg_bbfb275b-a1b1-4728-a945-0e4fec2f0d33">1.0</ix:nonFraction>&#160;million paid to Nordic during 2020 based on the 2019 FDA approval and the $<ix:nonFraction unitRef="usd" contextRef="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzY1OTcwNjk3NzE3NTg_bbfb275b-a1b1-4728-a945-0e4fec2f0d33">1.0</ix:nonFraction>&#160;million owed to Nordic based on the 2020 product launch.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $<ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIzMjU_2f716c6b-e5cc-4d34-a553-88f28e02b149">11.8</ix:nonFraction> million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIzNDQ_45cf7a96-cb19-4c83-8d92-39f6b908d0c5">0.9</ix:nonFraction> million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $<ix:nonFraction unitRef="usd" contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzI0NjY_078cdbe8-8cba-409b-a27c-17b04f74ed59">0.1</ix:nonFraction>&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE2NDkyNjc0NDQ4NjA_5e7516d3-559e-4c66-9ecd-5ef043219e16">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41e5a2f67fb448cdac235b8ab69c2e11_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE2NDkyNjc0NDQ4NTE_561f82ae-b4a0-4eb2-8bd6-466c4409a566">0.7</ix:nonFraction> million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNzI_466f5166-d950-484f-862d-c47591d1196c" continuedAt="idd5b8a97e39e4cc78ef64b086dc4d123" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"></td><td style="width:38.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.939%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItMi0xLTEtMA_dc485b33-cfdd-4799-a54e-560dc0d7e9b8">4,434,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItNC0xLTEtMA_e27f5d12-0f61-4258-91eb-e7752f8197e2">4,134,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItNi0xLTEtMA_ec52b21f-e191-42c4-949a-df1506cceb40">2,769,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="iad50ba9369404c06bcda827419a2e727"><ix:continuation id="idd5b8a97e39e4cc78ef64b086dc4d123"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"></td><td style="width:72.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzEtMi0xLTEtMA_6ce493bd-d7ef-4331-8cb2-cec4ef237fdb">4,338,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzItMi0xLTEtMA_64c72eaa-c0ea-4db0-9232-f6e9edc0aa59">3,691,293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzMtMi0xLTEtMA_728b8113-f1a0-4330-ba8c-fcebb5f35895">3,629,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzQtMi0xLTEtMA_e4ebaed8-8361-4061-9819-e84ddc6d4c10">3,629,001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzUtMi0xLTEtMA_3a5bfaff-4664-44fa-9659-a2c696148c23">12,830,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzYtMi0xLTEtMA_6a1fb5db-889a-4c29-81e2-3774b1fa177b">28,118,316</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_217"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEzMg_1446c748-25b8-4539-b381-ba2c76823a76" continuedAt="iead37bc3cda647579d37b7b14fcd6982" escape="true">Other Current and Other Long-term Liabilities</ix:nonNumeric></span></div><ix:continuation id="iead37bc3cda647579d37b7b14fcd6982"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEyOA_9f44d144-4444-4f92-8218-2d898e8869f7" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:ProductSalesRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzItMi0xLTEtMA_7e4aa675-d229-4324-b649-82745052431f">4,072,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:ProductSalesRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzItNC0xLTEtMA_298a5566-35fa-43dd-a730-127ef5d900bd">4,593,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzMtMi0xLTEtMA_176dd4ed-dd7d-49d1-9f7d-402133ef9b93">998,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzMtNC0xLTEtMA_c4cec2c6-d2b9-44e7-8f27-80974a897f22">1,295,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzUtMi0xLTEtMA_b96e6a20-0a59-4b7a-ba18-e18d12711ba2">2,787,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzUtNC0xLTEtMA_f4107f80-c92e-41a5-93a6-0e54f3ce7fa9">2,374,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedLiabilitiesInventoryPurchases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzctMi0xLTEtMA_667f16be-27ce-4db2-b7ba-ec538aa8c6f6">294,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedLiabilitiesInventoryPurchases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzctNC0xLTEtMA_3f560d00-870d-4129-91cd-00f579e3464c">829,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="cpix:AccruedPaymentForAssetPurchaseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzgtMi0xLTEtMA_fc6685da-03f4-4949-849d-c496d5eb87bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:AccruedPaymentForAssetPurchaseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzgtNC0xLTEtMA_ca5cad6b-9887-4f7f-b894-25802732d250">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredAcquisitionLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktMi0xLTEtMTUwNg_75baef0a-6a30-4776-be5f-c0ea29291ff8">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:zerodash" name="cpix:DeferredAcquisitionLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktNC0xLTEtMTUwNg_d14d24b2-e895-4a34-8bcf-99632fe3b84c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktMi0xLTEtMA_b4f9a475-dfec-49b1-a2b8-a57ab4df23e7">915,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktNC0xLTEtMA_20f07084-870c-4091-aa9d-257f5757919e">991,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzEwLTItMS0xLTA_b7bafbd9-a838-4757-bdb5-ece7819c3271">11,254,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzEwLTQtMS0xLTA_9d0aa2d6-6dc0-4032-a4bc-797e5550039f">11,084,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEyOQ_251be4ab-2dbd-4d88-9088-2a73a45d000c" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:59.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzItMi0xLTEtMA_88228f28-7a9d-4d7e-b4a4-535d616ef295">4,855,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzItNC0xLTEtMA_e53cead2-bbf1-46d7-a3a9-1341a0a5017f">6,258,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzMtMi0xLTEtMA_f09dc451-c5bf-4ade-aadd-fa1cefe10209">2,702,772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzMtNC0xLTEtMA_130f01b0-4b07-4b9d-9083-cab68e34efcf">2,278,164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzQtMi0xLTEtMA_3cb822ef-45e8-45d1-baec-6c66ed227a4e">304,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzQtNC0xLTEtMA_b55c35b4-91ff-45bc-89d7-b16a628fcbce">200,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzUtMi0xLTEtMA_c010e618-4397-4982-8667-31a9c8f56eea">7,862,772</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzUtNC0xLTEtMA_9fedef26-222e-4e67-b86e-8ed080bfd598">8,737,323</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_220"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzIwODc_c15cd03c-a389-4c82-a73f-1d07d4fc6dfb" continuedAt="ie9df3708f06e40a5bde74c8117e03f53" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ie9df3708f06e40a5bde74c8117e03f53" continuedAt="id52abe9bca03432faf7a6459e3bc561c"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="i70f775544b07435aad50e8010203ab2f_I20201007" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQxMDc_2a406edf-3192-4591-ae16-4643595e2d23">15</ix:nonFraction>&#160;million and Cumberland has the ability to request an increase of up to an additional $<ix:nonFraction unitRef="usd" contextRef="i70f775544b07435aad50e8010203ab2f_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQxODg_bcb738f5-a123-40e0-9f25-3cdf0cdd5354">5</ix:nonFraction>&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="i70f775544b07435aad50e8010203ab2f_I20201007" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQzNzU_5b12300e-416f-48d7-83db-a64fc18c9a06">20</ix:nonFraction>&#160;million, which was also the maximum aggregate principal available for borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in compliance with the Tangible Capital Ratio financial covenant as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzEyMTU_6f9f7214-8e77-4a56-9281-12beb7a82eee">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzEyOTg_d0afc4ae-61ca-4fcf-a4b5-15a486dff1d2">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="id58da084fd084c92baff6faaebe07bce_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE1Mzg_06440619-f6d2-4da9-bd56-413de9c45b40">20.0</ix:nonFraction> million.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $<ix:nonFraction unitRef="usd" contextRef="icd51265d21714c30b785b162b5e9c52b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE1NjE_ce6bb27f-d817-4df7-93d1-7900825a0431">15.0</ix:nonFraction> million in borrowings under the Pinnacle Agreement at December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i8b442a5827e64fa49e02548ad3d45a60_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2MTc_b7ad82e5-5011-4086-b1c2-6aed55ccec45">18.5</ix:nonFraction> million at December&#160;31, 2019.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="ib6ff7e499acb4275a4320c03274a56de_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4MDk_e2f0d8d6-4ee8-4698-b169-a3037fc51c73">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ife2cf763ce1343ebbb8dcb8ca36ad991_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4MTU_af497a4e-be8d-4fe3-bdb3-1a59d6f463f0">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="i55a65e98565f481a88b31680ce8e66da_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQ5OTQ_d47fddeb-479d-4298-8add-d7500dacba42">0.90</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4NTI_1e8fde32-4c0b-4f39-8031-577ef39d898a">3.65</ix:nonFraction>% at December&#160;31, 2020).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i4867bf18746745d08a2eb39206ceee78_D20170731-20170731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4ODY_34a75947-e187-4ada-a240-57427e106d1e">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id52abe9bca03432faf7a6459e3bc561c">Borrowings under the line of credit are collateralized by substantially all of our assets.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzY1OTcwNjk3NzI4MTE_7c8d8dba-7e50-484b-b6f6-5fc05c649596">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").  The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $<ix:nonFraction unitRef="usd" contextRef="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzY1OTcwNjk3NzQxMDY_7c8d8dba-7e50-484b-b6f6-5fc05c649596">2,187,140</ix:nonFraction> as a deferred income liability, which is included as a component of other current liabilities on the consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_223"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUzOTU_826f264d-d80f-426a-8682-79ea5ae87f27" continuedAt="i134004b541264fa792da88fbc89a919c" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i134004b541264fa792da88fbc89a919c" continuedAt="i4560c5a6792245d595c68f4be3d71d0d"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" format="ixt:datemonthdayyearen" name="us-gaap:SaleOfStockTransactionDate" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzYy_2329abb5-b2de-4f6b-a7a8-bee6b1de6756">August&#160;10, 2009</ix:nonNumeric>, the Company completed its initial public offering of <ix:nonFraction unitRef="shares" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzExOQ_0cd58e0c-2334-4059-8ae6-03c596a783c6">5,000,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="INF" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodPricePerShareNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzE2MA_7533466c-2cb0-4177-914a-c87618b04b36">17.00</ix:nonFraction> per share, raising gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwMQ_41dcb1bc-0d39-4fed-904a-6bf5e7b4f3c5">85.0</ix:nonFraction> million. After deducting underwriting discounts of approximately $<ix:nonFraction unitRef="usd" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI2Mg_ff04d356-9bd0-48a2-a3d0-df865c4f5d37">6.0</ix:nonFraction> million and offering costs incurred of approximately $<ix:nonFraction unitRef="usd" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMxMQ_f1b85787-ef62-458d-88c2-908c87d0242d">4.2</ix:nonFraction> million, the net proceeds to the Company were approximately $<ix:nonFraction unitRef="usd" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM2Nw_21aee508-9255-49f0-896d-00fd67ccf269">74.8</ix:nonFraction> million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into <ix:nonFraction unitRef="number" contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810" decimals="INF" format="ixt-sec:numwordsen" name="cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzQ4Mw_7049d1be-df68-4255-89e1-1e65513b2a99">two million</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzU2NQ_c65dd3a4-e593-4d52-a642-a59146f0beb0">20,000,000</ix:nonFraction>&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2020 and 2019, there was <ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzg0Ng_58b38e03-9ed1-43ee-b89a-8f4b53fe5008"><ix:nonFraction unitRef="shares" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzg0Ng_7ca2ea81-51eb-4f7a-aa75-1d2b0cb3db74">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzE2NDkyNjc0NDcwNzc_42506b81-cf47-4bfd-87c2-bc692181a83b">228,500</ix:nonFraction> shares,  <ix:nonFraction unitRef="shares" contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzkzNg_4c926be5-e8c8-4f26-947a-850aa183971d">225,536</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzk0Nw_24469b5f-0256-4bde-9f7d-f347a322476a">170,759</ix:nonFraction> shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2020,  2019 and 2018.  </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i4560c5a6792245d595c68f4be3d71d0d" continuedAt="i0bad90d3a949467dbe332e4f44fe9893"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i1de7636956284bbeb962a907482bc027_D20180101-20180131" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzEzMzU_c2db9a97-879f-4918-82d0-6493b19aa968">100</ix:nonFraction> million in corporate securities.  The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020 or 2019.  The Company issued <ix:nonFraction unitRef="shares" contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzY1OTcwNjk3ODA0NzI_2735c52d-5970-4df6-bcb8-acc0d399a2eb">30,704</ix:nonFraction> shares for proceeds of  <ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIxOTkwMjMyNzE1MTE_d007aa30-ac22-4599-b0e5-f936d02b9708">0.2</ix:nonFraction> million during the year end December 31, 2018.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Warrants</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i367d84ececcc49f0bfbb68634cd626f4_I20091231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwNDQ_c9171410-b1ec-4e44-8b62-33a174a71673">7,500</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i367d84ececcc49f0bfbb68634cd626f4_I20091231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwNzQ_02edce75-2d2e-4290-ab69-8a09fbf87eab">17.00</ix:nonFraction> per share that expired in July 2019.  As of December&#160;31, 2020, there were no outstanding warrants.  </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIyNTM_7ace1496-5d92-47b1-8bb0-76dc9b41f929">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIzOTg_bd164bf3-e69d-4f88-9004-c1412f13ca0e">10</ix:nonFraction> million repurchase program to replace the prior authorizations. The Company repurchased <ix:nonFraction unitRef="shares" contextRef="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI0ODE_f03894bd-7539-45c5-a3ae-51ee08b194f3">503,626</ix:nonFraction> shares, <ix:nonFraction unitRef="shares" contextRef="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI0OTI_b026a0f1-6154-4457-a280-f6cb2bbe31ab">623,478</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1MDY_484f9a37-cbf4-4380-a81f-a126e21af60f">443,041</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NTA_41131e7b-4c55-4277-8322-29db75e6b1d4">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NTQ_28440354-cfc6-4a0a-82a6-b3136744b077">3.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NjI_c933b295-f0cb-49c6-b382-0b13b0c8ffd4">2.9</ix:nonFraction> million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. There remains $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI2MzE_da102a9d-0482-4c2a-b5af-ddf43c323af4">6.2</ix:nonFraction> million available under the current repurchase program available for share repurchases at December&#160;31, 2020.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="iec44f4c9886f4156832890687e6122d3_D20190401-20190430" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI5MTE_5bd0c17b-7373-41d0-908e-47f4079b1b78">1</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMyMDE_bd2999a9-3e35-417f-8807-b529ecbcf48d">1</ix:nonFraction> million investment in CET.  Cumberland </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchased additional CET shares through contribution of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMyOTE_b36b023d-712e-4c67-8b2b-ca2477e87064">0.3</ix:nonFraction> million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430" decimals="-5" format="ixt:numdotdecimal" name="cpix:LoansForgiveninExchangeForShareIssuedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMzMjI_d6f60960-0c70-4894-ae8a-6a06f102b425">0.7</ix:nonFraction> million in intercompany loans payable.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for consideration of  $<ix:nonFraction unitRef="usd" contextRef="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM1MjM_833b46c1-bcea-4b2f-9a5b-058ee28baa06">0.8</ix:nonFraction>&#160;million that was funded during 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the additional investment, the Company&#8217;s ownership in CET is <ix:nonFraction unitRef="number" contextRef="if2a2c29316304015acd330ba1069f0e5_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM2MDM_b2e24486-ccf7-4d7a-ad3d-b2faec84f7fb">85</ix:nonFraction>%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)  &#160;&#160;&#160;&#160;Cumberland Foundation </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of <ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="cpix:SharebasedCompensationCharitableContributionofSharesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzQzOTM_591b7a94-d3af-4120-8b53-9c10f57d7b57">50,000</ix:nonFraction> shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i0bad90d3a949467dbe332e4f44fe9893"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUwNDM_28b26eb4-fcde-42a7-a113-433df2469504">50,000</ix:nonFraction> in cash contributions that were paid to the Foundation during 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Group B.V.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's <ix:nonFraction unitRef="shares" contextRef="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUyODQ_8a65bb6e-f05f-4e37-a60a-22c7373a1333">180,000</ix:nonFraction> shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $<ix:nonFraction unitRef="usd" contextRef="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUzOTM_64cda034-253e-4717-b402-9eff0edcf495">0.9</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_226"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMzMA_212a9c8d-f92b-4523-aa73-3420a689cbe9" continuedAt="i727284fa069c4deea265f1c6778e724f" escape="true">Earnings (Loss) Per Share </ix:nonNumeric></span></div><ix:continuation id="i727284fa069c4deea265f1c6778e724f"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMzMw_00f37542-6e19-45a6-a72e-2d21554192cb" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.012%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtNTYzMw_51d7984f-68ae-4abc-9802-127249d759bf">6,625,779</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNC0xLTEtNTYxNw_329e68fc-7063-49d6-9b26-f30b2b97b406">9,211,688</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNi0xLTEtNTYxNw_99754632-ce1a-4981-8986-36a9cae24f38">10,820,996</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtMi0xLTEtNTYzMw_838de442-e0e0-4536-ae45-99d0b72560e6">3,206,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtNC0xLTEtNTYxNw_ca1363ad-1ec7-4927-a944-6a1125291895">5,665,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtNi0xLTEtNTYxNw_b1adc3a4-2a33-4b61-97aa-32edcd4657be">3,782,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtODg_5937637c-8070-4b7b-b0b8-bedbae675822">3,418,904</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtMA_5ca4855e-3371-44b7-83d8-39988a99719b">3,546,511</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNC0xLTEtMA_b0508f4a-5635-4332-952a-18fd554f5ce4">7,038,772</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtNTYzMw_bdd3461b-c51d-494d-9409-55c8528e905b">79,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNC0xLTEtNTYxNw_a8130032-0ce0-431d-bf61-664987595763">8,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNi0xLTEtNTYxNw_5920a68b-7443-4cbc-bdfd-dd416a886443">75,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtNTYxMQ_5a12e5ec-2b4c-4ce0-9e9e-c8893f35be9d">3,339,408</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNC0xLTEtNTYxMQ_53e79cb7-b1fb-414e-bad0-7dc76fefcd9c">3,537,759</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNi0xLTEtNTYxMQ_c241d0d7-e755-4582-baf9-bf9c8d837305">6,963,068</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtODQ_1ea249d1-52dd-42ab-b826-8c6d2c5516c3">15,162,184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtMA_a3e5bce1-d53a-4d84-b75e-f9a960e59641">15,396,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNC0xLTEtMA_a5ef40f5-9c7c-48ea-96ff-02d96b893240">15,614,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtODQ_97ac3961-dd2c-4247-ba19-49b4c94dcbc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtMA_50802797-1f83-4c1a-ae08-5a4c0a27bd53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNC0xLTEtMA_de2f35d1-c10c-475c-8a8e-1cc3238fad5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtMi0xLTEtODQ_be14cf47-950c-450f-af55-9b2c5b9cb945">15,162,184</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtMi0xLTEtMA_cde171bf-648f-472c-9348-1ab429252670">15,396,098</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtNC0xLTEtMA_7543989e-2320-4fe3-96d1-1b22b8b68b25">15,614,052</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMyOQ_d8bcb149-dc6d-4f2a-a459-204b61a427bb" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:39.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItMi0xLTEtOTk_72ee05c2-9997-4a9b-90db-b86202b4a95b">197,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItMi0xLTEtMA_77b1d132-2aa4-4b9c-bd9b-e2e95d59b654">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItNC0xLTEtMA_1bcb5781-1df0-4a7a-8ac4-d9235dc6fe4d">41,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_229"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1ODA_3586facb-1d44-40f1-b44c-173c2d33d2db" continuedAt="iebba1e0d8b7346db8431b74f81e62d74" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iebba1e0d8b7346db8431b74f81e62d74" continuedAt="i08fcbedc23e84dc682538143f22eb964"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzM_6ff5303c-03a6-4fc8-a0be-e6b8d79b8328" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:61.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzMtMi0xLTEtMA_9ddcf490-0d21-455c-b932-aa2a66fc07f1">16,961,650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzMtNC0xLTEtMA_7f384338-22b1-46f7-aae1-70972552f2f4">16,964,685</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzQtMi0xLTEtMA_1d2877a9-b4e0-4f53-b4cc-f3fae86e619b">227,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzQtNC0xLTEtMA_174e9e7d-c02b-4e6a-ad96-7b7faee54489">227,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzUtMi0xLTEtMA_3d999990-7036-43cb-a416-2982c6fc1899">249,483</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzUtNC0xLTEtMA_87c984cb-c35e-44ef-9898-0aca8eac4238">257,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzYtMi0xLTEtMA_97f57283-eff2-4b31-a161-fa20f91ee6c0">438,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzYtNC0xLTEtMA_b06aca5c-181b-438e-9c4f-6aa7bef52710">469,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzctMi0xLTEtMA_76eaa6dd-e52b-4f14-981b-a7e2e0017665">100,362</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzctNC0xLTEtMA_cccdbb6e-c1b5-484d-b8c5-8b3b9a01609a">35,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzgtMi0xLTEtMA_14aacd4e-834c-4764-ac90-4f1a608c1560">952,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:DeferredTaxAssetsDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzgtNC0xLTEtMA_db9d1a11-ccf8-48c1-8329-c4f8f11565f1">845,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzktMi0xLTEtMA_1c4cac5b-e858-4af1-9e65-7a19361d02d5">928,638</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzktNC0xLTEtMA_49554eb2-e291-4d9c-adb6-60177b075ef3">1,047,149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEwLTItMS0xLTA_b22e48a6-c65c-4d76-8821-36f109b9767a">19,858,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEwLTQtMS0xLTA_b209e9a9-2fbe-4c40-8874-c2f8806063fe">19,846,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEzLTItMS0xLTA_41f2cbbd-011a-4c5f-b7d3-2f715893783e">662,014</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEzLTQtMS0xLTA_be93f4b8-de4a-4635-8fb7-8e251c4d89c0">1,313,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:NetDeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE0LTItMS0xLTA_0ca6d0bd-9fb5-459a-b697-bb8517a6e94c">19,196,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:NetDeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE0LTQtMS0xLTA_ca383436-254b-408b-862f-c7e10146da90">18,532,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE1LTItMS0xLTA_28bf5cbe-5c77-4009-908f-75b042deafb2">19,196,121</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE1LTQtMS0xLTA_bf265110-78c8-46f4-bba0-d15192c9b3a5">18,511,161</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE2LTItMS0xLTA_ef735654-a95e-4a37-892c-bdaea9df34ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE2LTQtMS0xLTA_c32e1456-ae1a-4275-85af-38539af4b485">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzU_7aeff244-ebac-4974-83cd-90ec5f3a4873" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:61.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc74587ea6e4b529a03805961c2bd04_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzItMi0xLTEtMA_df37de93-5b35-4d3a-bd84-6925f2ddd505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445b6f509473418eb2c8a5237c3bfefd_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzItNC0xLTEtMA_94cf9ffb-7b2f-44d4-b6eb-8d8a3266c609">4,342,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4313b14cb3a4d8f99fd5c8f9db1107d_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzMtMi0xLTEtMA_9bb54211-93f5-4fca-9ed8-cd91beb8e040">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6847c5f2fcc44c1580a9549a452c791d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzMtNC0xLTEtMA_040e0b5a-c89c-4df9-a63c-951ee5ee523a">45,045,442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9043384394c24481b001b6c237c321ee_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzQtMi0xLTEtMA_2335833c-92b8-48c1-8618-bdccf3f3afd0">44,153,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6d71cfdbe4024a8518ad7bd357ab3_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzQtNC0xLTEtMA_142af6ac-3fee-4614-ab7e-89242caacc7a">458,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac92a1fad73b426db25cdc60a91363c0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzUtMi0xLTEtMA_dcdb2160-5bbe-457d-bfe5-197afc89f88f">7,534,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361f3e2163a24e0599504b3aaa2131ea_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzUtNC0xLTEtMA_936f77f6-29a0-4ef1-86df-46f66790c813">9,829,212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8201ead17c4f4c9fab01031ebfa723_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzYtMi0xLTEtMA_e1563e00-e304-49cd-b0fa-e0fed2fb2292">4,796,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c2aba4cd314aabbe1faee299611416_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzYtNC0xLTEtMA_219a4a58-1f46-478a-b981-1b47ff131090">263,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8a2a14899b4ec1a64b4b7a8ed1abda_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzgtMi0xLTEtMA_3ad089f2-5d87-4d4f-b917-cf2fe497df08">56,484,494</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236e3d373ccf4b22afd608a82ed75788_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzgtNC0xLTEtMA_be3e5535-983f-4007-818e-cdae79fb17cd">59,939,781</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i08fcbedc23e84dc682538143f22eb964" continuedAt="ie651022dfd68415ebbfe92378e6593ee"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzY_365490eb-5053-4066-bf75-6eb115a5e58b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtMi0xLTEtMA_ae473c09-155a-46c4-aedd-a777ecbbc98c">21,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtNC0xLTEtMA_8c28bbe4-a757-48ce-92c5-b519659a655d">65,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtNi0xLTEtMA_06adb68d-cbc4-408f-8887-00d3257d6c44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtMi0xLTEtMA_348cd3bb-eb71-4c39-b6e8-fe6115e226f3">55,902</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtNC0xLTEtMA_8e5ac50a-009c-41e3-8fd5-b50130a57e70">79,316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtNi0xLTEtMA_1bc65029-fcb0-4088-8eb7-829b49bd9e2b">16,636</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtMi0xLTEtMA_1cdf0e41-b2ee-41b5-998f-4c18efaf3dac">34,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtNC0xLTEtMA_7fddf1fe-c88e-47f5-a730-248e9d6d5cc1">144,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtNi0xLTEtMA_b3eda7db-9c0d-4818-a64f-f3c5bcbb2ff7">16,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtMi0xLTEtMA_ff5d724f-e670-4a3e-93db-392a62404b5e">21,802</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtNC0xLTEtMA_eef80a69-ef3a-4c68-b170-7acd3393a6ea">65,408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtNi0xLTEtMA_b5185362-7670-44b7-80aa-ada871e74779">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktMi0xLTEtMA_1efb999b-b741-42df-a7b1-a123c18f49d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktNC0xLTEtMA_ba25438c-550c-409a-822a-e29d6abe85fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktNi0xLTEtMA_f5312c2f-d0ef-4075-af27-45939ec62d2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTItMS0xLTA_a934a7f6-07bc-4941-aadf-535fe0938115">21,802</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTQtMS0xLTA_c378bb45-462c-46ae-a267-d55b6090c45e">65,408</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTYtMS0xLTA_5bb118a5-e59b-4433-a2e6-ff08a72f0f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTItMS0xLTA_68810260-753b-4320-b664-e0ffe8d6cdf4">55,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTQtMS0xLTA_5287e737-1841-4eff-8abf-463f627ef64e">79,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTYtMS0xLTA_c0323787-d3dd-449c-a00e-d9cee722c823">16,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzE_b776115f-1244-46b8-a44b-f769b7e8d802" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2020, 2019 and 2018 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItMi0xLTEtMA_5ebd3864-6400-41fd-8d94-b8ce9c8f2dbb">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItNC0xLTEtMA_d10ceb49-81bc-47ad-845e-ea070adbf380">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItNi0xLTEtMA_3aa31965-d01d-4358-bdf6-0ed8cc382417">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtMi0xLTEtMA_3699b77a-b766-4689-a3e6-a152fa1817ca">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtNC0xLTEtMA_fc786a51-c975-45d1-a937-78ff31a9bb2e">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtNi0xLTEtMA_bec523d6-5bff-405e-a3c9-5b6525323e57">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtMi0xLTEtMA_25f335c5-7e40-4850-b3e8-b88a39a83801">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtNC0xLTEtMA_fd11cf33-0b97-4fc7-943d-db6bfb877d2e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtNi0xLTEtMA_1fbc3df1-7f91-4dca-b499-6c562aaad7a8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtMi0xLTEtMA_7f987e89-1972-4403-9627-257dffe35005">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtNC0xLTEtMA_adeff1c7-a69f-478d-b80d-b811e192ac93">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtNi0xLTEtMA_9f62475b-22b5-4a36-b44f-12a9ea2e96f0">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctMi0xLTEtMA_d2809e33-4651-462e-89f7-12fe7d7dea99">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctNC0xLTEtMA_b734db82-89fc-44b2-b683-2eb29b860c83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctNi0xLTEtMA_f008bb9b-b7e1-426b-aa73-a82252db43fd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtMi0xLTEtMA_e00bc70a-3934-4021-bcd5-978b70c013f3">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtNC0xLTEtMA_038fdd95-b6ef-45df-a9c7-4707c7d28c3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtNi0xLTEtMA_fe26eec9-226c-4a6c-aa39-19f661255289">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktMi0xLTEtMA_0a6dff25-5146-4232-8344-7c2b2335d555">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktNC0xLTEtMA_5d20861b-de56-46d3-bd2c-e06a754b0598">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktNi0xLTEtMA_1b311e6d-a42a-4b0d-aa16-92441c99e5c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets, with the exception of one noted below, are fully offset with a valuation allowance as of the periods ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019, and December 31, 2018.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only deferred tax asset not offset with a valuation allowance as of the periods ended December 31, 2019 and December 31, 2018 was the Company&#8217;s AMT Credit Carryforward, which became refundable under the Tax Cuts and Jobs Act passed in 2017.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the balance of the refund related to this credit during the period ended December 31, 2020, and as such, the deferred tax asset has been realized and all remaining deferred tax assets are fully offset with a valuation allowance as of December 31, 2020. </span></div></ix:continuation><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ie651022dfd68415ebbfe92378e6593ee"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzIxOTkwMjMyNjIxNzg_f740a14a-682c-4611-961d-c2ee536185c4" escape="true"><div style="margin-top:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company has general business credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ie9167ce1de284dc593328aff87ed8bcc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzIxOTkwMjMyNjIxNjU_dd1e5c37-30b2-499e-8e48-d44c8a44d0a7">1.7</ix:nonFraction>&#160;million.  These credit carryforwards will expire in years 2021 through 2041.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.807%"><tr><td style="width:1.0%"></td><td style="width:73.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5562813807040e1a0e26ee6bf76c4b6_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzEtMi0xLTEtMzg5MA_3e1ee6f2-5fec-4cc7-bdde-62ee75ff0af4">173,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022-2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4051af70f9c4b60b1d310d19369cccb_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzItMi0xLTEtMzg5MA_0b6b75b0-cf26-469c-b33f-ab07abfff167">622,276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db379efa0bc4679a685f33d31ca995f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzMtMi0xLTEtMzg5MA_16d1c849-17fc-488d-b81f-f79d147f550c">836,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1831e9cb7e4498bb1e5fac039825fa_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzQtMi0xLTEtMzg5MA_566f332a-4117-43c6-b497-95460f058904">97,244</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9167ce1de284dc593328aff87ed8bcc_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzUtMi0xLTEtMzg5MA_7ac00299-26af-4cb2-9052-684d6f9dcbd8">1,729,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2017, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2017.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2017 remain subject to examination and adjustment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits in 2020, 2019 and 2018.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_232"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDk_14d479e9-bcb2-4981-a9eb-88c22760c1e9" continuedAt="ic3aae2587c594ede9f441abd774a97bf" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="ic3aae2587c594ede9f441abd774a97bf" continuedAt="ieec0a990d1394edeb2587bdd08291983"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under <ix:nonFraction unitRef="plan" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzgy_f6820fca-5cb0-426e-a4a4-ccf245e4da01">three</ix:nonFraction> equity compensation plans, with <ix:nonFraction unitRef="plan" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzExNw_5671ca67-1699-487a-b132-9e175c8e2e5f">two</ix:nonFraction> of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="ia24d0d8e81234fb38c59ac70536998b1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzczMg_36608d6b-4348-44a2-a9d1-c2e0a75c5382">2.4</ix:nonFraction> million shares of common stock for issuance under the 2007 Plan and <ix:nonFraction unitRef="shares" contextRef="i4d13571f70a74cbea8cc3c2e111cf699_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzc5NQ_1fb2ab28-fcd7-4cfc-8630-7dff76b4168e">250,000</ix:nonFraction> shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally <ix:nonFraction unitRef="number" contextRef="i5b054a3338614ef4a60b55fb3e0f0983_D20200101-20201231" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzg5NA_9fc90c03-a837-4148-a22a-536ece1f2ddf">100</ix:nonFraction>% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is <ix:nonNumeric contextRef="i39407155449e4cd7b91cf9a0ea955c04_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzEwMjE_f16f0258-7896-472e-b3cc-b8e96ccd1641">ten years</ix:nonNumeric> from the date of grant, except for incentive stock options granted to 10% shareholders, which is <ix:nonNumeric contextRef="ifdf5204bce4e4cf08f3110023af611f2_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzExMjA_2dd1e185-0469-4060-8397-2a205d84c34e">five years</ix:nonNumeric>.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the <ix:nonNumeric contextRef="iaa1083c517cc425bada8b162234c0222_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzEzOTQ_4c7231be-89d3-42d0-87a2-e323dc739c88">one year</ix:nonNumeric> anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDU_4bbd152a-1533-484a-a8e8-4429f9e935ba" continuedAt="i73136b58254144b7980cb0ed2b85d9f1" escape="true">Stock compensation expense consisted of the following for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i73136b58254144b7980cb0ed2b85d9f1"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"></td><td style="width:40.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2761c3aa61481e9ce768736d55283b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItMi0xLTEtMA_6e2a1283-a505-4f15-9f3a-6db62f600a45">1,050,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if048f68b276d4efaaa2f710dc15c58ed_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItNC0xLTEtMA_988a811f-86e4-4de1-a132-3db4a69f8507">1,481,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75bc44001e5247da87aaaa6fe49004cd_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItNi0xLTEtMA_41343da2-a398-4b44-bf89-4f9d08cfd5de">1,244,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i436eb42902d244599c0bc8375f08440b_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtMi0xLTEtMA_3ae0f9a3-3feb-4213-87e7-082fae0d02dd">3,663</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c8902a15624a57913ab5e23c482d70_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtNC0xLTEtMA_d84e1d7a-e314-47ac-8bb2-aad4f62e28e9">4,882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d39a8afd7a4f5485dc0d057ab6de51_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtNi0xLTEtMA_31b74ea4-0e61-428e-8232-4b43fec5b5e1">120,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfd07629518431490765805546dcdd3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtMi0xLTEtMA_3c27ab3e-ab65-4786-9e4a-98681e360bc4">1,046,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf145f8d53f142ea820e0fca8cf49972_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtNC0xLTEtMA_c0b1c058-88e0-484a-9ba4-3b81075d5b74">1,485,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6739e7f70b46089b224643faa80db4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtNi0xLTEtMA_411619da-d7d3-4946-ba70-df6f399966d7">1,364,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ieec0a990d1394edeb2587bdd08291983" continuedAt="if3e7fd2ead584295acdc4216b59a6df8"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzE2OTE_e7aec74c-01aa-4a81-bfb9-32176928ac2f">1.7</ix:nonFraction> million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzE4MzA_0012718f-570d-4ca4-bea0-7de5a7fc8655">2.28</ix:nonNumeric> years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MTE_670a9d31-4298-49a6-9817-d130b05254fc" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2020 and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:34.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItMi0xLTEtMA_0c6486ec-5430-44ad-a1c4-44690be2fea1">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItNC0xLTEtMA_fcaa4aab-f80b-47c7-8328-c69a82ea4257">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItNi0xLTEtMA_d6f330cb-3bc7-4744-b4b5-b739d75cef2a">0.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItOC0xLTEtMA_00eaa2cb-28f7-46ae-ad5c-90fe0200094c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzMtMi0xLTEtMA_d93c71d7-f723-4c92-a037-19b0d0c3e6d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzMtNC0xLTEtMA_86da7ffa-3c27-4349-ad71-b53e4aa3fadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzQtMi0xLTEtMA_6721cfa6-ed26-421e-84ca-69864c23d094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzQtNC0xLTEtMA_67b0818e-b253-4f64-be9c-f5c03ddb39b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzUtMi0xLTEtMA_4348cbcb-b119-4382-8df3-db4bacf3a2bf">5,800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzUtNC0xLTEtMA_cb498b98-3299-4c31-bbc4-04b95808f263">13.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtMi0xLTEtMA_41968597-08f1-4bea-b066-e7799fc85bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtNC0xLTEtMA_54328507-5df7-4549-aa84-58d3c3b8364c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtOC0xLTEtMA_35bbcdec-df05-4632-868c-6363b0dd42d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzctMi0xLTEtMA_a767dc8d-b698-4f42-aa01-6727e124ca32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzctNC0xLTEtMA_0177ca75-619a-473e-a2ed-f0a2e2cb1c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzgtMi0xLTEtMA_676c62f6-e541-4325-bdf3-e401bff9a52b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzgtNC0xLTEtMA_72261aef-5031-4ad4-82f4-e4637e02d6ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzktMi0xLTEtMA_b4647b36-2408-4120-aa05-b032f985d814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzktNC0xLTEtMA_b7ca40c5-1041-4ed5-b0ea-49f2d4e1d028">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTItMS0xLTA_8b37f7cc-ae25-4941-9f8c-2f4f9e34732b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTQtMS0xLTA_a36fcc22-27d6-4d5c-9548-fdfe362b3125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTgtMS0xLTA_e26e59dc-a795-4d4b-b5b9-1bf30a608d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTItMS0xLTA_b86cd9a8-69b2-4e80-9daa-959676566304">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTQtMS0xLTA_8189ae41-97a6-43c5-a284-0394e0887822">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTgtMS0xLTA_e01b89c5-951e-49e8-a987-5e6069bbd588">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options and there were no options exercised during 2020, 2019 and 2018.    As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDg_50e8d566-cb1a-427e-917a-6519d26c9772" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"></td><td style="width:50.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18c4af7e297f4bdb9156fe284ac15e52_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzItMi0xLTEtMA_81e44482-ed40-4bf5-aa9c-d31c356bd8bb">833,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18c4af7e297f4bdb9156fe284ac15e52_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzItNC0xLTEtMA_5c0d81f4-01e3-45ac-a01f-3a24ffb99557">6.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzMtMi0xLTEtMA_9f02ba0d-4d52-4735-9066-86e2ca360d91">229,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzMtNC0xLTEtMA_517041af-ef80-42b6-a103-f8a5353052f3">5.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzQtMi0xLTEtMA_b0ad7179-8732-4ebf-a609-1db0b445ab54">225,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzQtNC0xLTEtMA_7f9583fe-a3de-4cad-9b8a-e315016db5d2">6.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzUtMi0xLTEtMA_97d0e043-3a1b-4db4-9bd2-2ffc7aebb777">22,925</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzUtNC0xLTEtMA_68223aae-c858-4190-b154-3480d827ec6f">6.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i622af044beba4bd281a739b794311672_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzYtMi0xLTEtMA_8bf43363-6a9d-4dfa-8098-ddd9fb617bb7">814,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i622af044beba4bd281a739b794311672_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzYtNC0xLTEtMA_b6b050d1-8ba9-4cd4-9865-e4f750393178">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzctMi0xLTEtMA_d8f1abb9-0ec7-42bb-81d1-0a4daf6c0381">231,091</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzctNC0xLTEtMA_b025fb3a-3a55-41e8-a667-ce37b4dfdad3">3.56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzgtMi0xLTEtMA_15890b4a-61d3-4170-b2f9-f886a67a1bda">228,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzgtNC0xLTEtMA_5e828a00-a8b3-4f43-897e-9345c84d0031">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzktMi0xLTEtMA_7735417f-96ee-4dc9-a8f4-a45958b28381">38,125</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzktNC0xLTEtMA_abf49b51-a58b-46b5-8d3f-bb8c76298807">5.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzEwLTItMS0xLTA_5483fcd2-5a19-49c0-9911-4c796346be2d">779,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzEwLTQtMS0xLTA_7a40aa7d-b8c5-48b6-8932-772f7606dbeb">5.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if3e7fd2ead584295acdc4216b59a6df8">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_1268"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8yMTk5MDIzMjU2ODk2_2c2209a7-ad0a-4725-b4f8-b46c191125d2" continuedAt="i3c779fb327534fcb82f14c7723a30ae9" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i3c779fb327534fcb82f14c7723a30ae9"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" format="ixt-sec:duryear" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4MDcz_a3b834a4-951b-4ca5-8fd7-c199dd40bd90">21</ix:nonNumeric>, having been employed by the Company for at least <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4MTI3_67b834dd-94d6-4f3b-b3d8-842c9fe6a7cc">six months</ix:nonNumeric>. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2020, 2019 and 2018, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_162befc8-307c-4fd6-83dc-62bad86ac4f1"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_40749508-5126-41d6-91da-977d1a33c377"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_dea2ee73-00d7-4df7-a335-7416fe5a1904">50,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4ODE5_7597f305-342b-436b-beaa-741a96a33f41">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4ODI3_283994af-c37a-4380-a6df-eb8fefffd69f">2.3</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI5MDc2_d0b11d3e-ab04-4214-b6f7-e04b355813b5">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI5MDg0_f5274362-1fc5-433c-821b-7ef54c2c788d">3.1</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_244"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTI_c93d526e-e933-4ea2-9750-4a66158ab382" continuedAt="i4a5a94769fd543a095333d31fba641cd" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i4a5a94769fd543a095333d31fba641cd" continuedAt="i37e43fe9acc24d46b91932766fabf008"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTU_9de57fbb-d08c-49b2-b7cf-a936bd994a47" continuedAt="i84270fdaa53e4b25b91769c63e6da576" escape="true">Rent expense and sublease income  as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i84270fdaa53e4b25b91769c63e6da576"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:41.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItMi0xLTEtMA_a495c07b-85ad-4bd6-be55-4b7682601b55">1,166,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItNC0xLTEtMA_ce601580-bdb9-4d48-9471-34ed73081890">1,246,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItNi0xLTEtMA_b39f3280-3fc1-448d-bd30-6ae65f4049ad">1,136,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtMi0xLTEtMA_ed0baa1e-b77b-4a06-a3c9-bff257219353">680,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtNC0xLTEtMA_0a57d9e0-5cd1-4c07-900d-f5c152dff071">688,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtNi0xLTEtMA_f4477892-9d03-45aa-b367-837a4c878657">662,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These operating leases resulted in initial ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101" decimals="1" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3NjY_ece1f622-0e63-4f99-a6eb-68353715a017">3.6</ix:nonFraction> million and lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101" decimals="1" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3NzU_e19012c2-bc93-4260-bef6-bbb8e3f04428">3.8</ix:nonFraction> million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i37e43fe9acc24d46b91932766fabf008"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is <ix:nonNumeric contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzMzOTg_1aec31e2-4a56-4fdf-810f-1d1c9c5cbcda">2.0</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3ODQ_d9beaf12-5f58-47bc-acee-47fd08160bfc">7.42</ix:nonFraction>%.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTA_ca786b5e-e601-42f2-98a5-ea18e3b880bc" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company recorded the following on the Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo3NjZjZGQ0NzI3YjE0NjdhYTg3Nzg4ZDM1OWY1Y2E4Zi90YWJsZXJhbmdlOjc2NmNkZDQ3MjdiMTQ2N2FhODc3ODhkMzU5ZjVjYThmXzEtNC0xLTEtMA_47d5e4a3-1618-43f4-8125-53e508e4c057">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo3NjZjZGQ0NzI3YjE0NjdhYTg3Nzg4ZDM1OWY1Y2E4Zi90YWJsZXJhbmdlOjc2NmNkZDQ3MjdiMTQ2N2FhODc3ODhkMzU5ZjVjYThmXzEtNC0xLTEtNDM3NA_a594d16b-9733-4962-a6e9-6feb0e16e671">2,960,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzEtMi0xLTEtNjAwNA_f648d6d7-26d2-4ded-9f8a-189034c10f4e">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzItNC0xLTEtMA_b98f97ba-9f3c-44ce-a0ba-c463e1631f50">920,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzItMi0xLTEtNjAwNA_bf7b082a-7cc9-4e53-971a-de52ea6b162a">1,059,693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzQtNC0xLTEtMA_6fd74cb0-1ed5-4135-a3fa-7c1b7ae0013c">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzMtMi0xLTEtNjAwNA_b77a299c-5d25-4063-bbce-294141ef9d12">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzUtNC0xLTEtMA_66290cc7-895e-4ab7-9554-81bef6a35c7a">2,996,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzM3NTU_93d4f5a9-6027-4f52-b850-016b1aa17e30">0.4</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTc_eb2ab916-68c2-4f29-afca-325c7cbe336f" continuedAt="ie082e131b3564a01b4ca57c8d316106f" escape="true">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><ix:continuation id="ie082e131b3564a01b4ca57c8d316106f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzItMi0xLTEtMA_2e7e2083-e05f-4492-8108-aaa22881cada">1,144,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzMtMi0xLTEtMA_fbc11469-eb06-491a-9b21-2c9b0f8b4ef6">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzQtMi0xLTEtMA_8501c0a9-5fb3-4c7f-b6c4-2f0388040ec5">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzUtMi0xLTEtMA_e63726a0-020f-4c41-8da5-69aaaa01dc2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzYtMi0xLTEtMA_5a05e705-388a-4e7c-9470-216a8971fa1e">2,256,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzctMi0xLTEtMA_c3eb6d28-92a7-499c-a719-54f01f867139">180,208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzgtMi0xLTEtMA_79db6fb9-0a79-417b-9846-75913f9d1fbe">2,076,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_247"></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90ZXh0cmVnaW9uOmRjNjFjZGE5N2MzYTQxNzdhNjAzOGJjNmJkYTQxZTdmXzY4OA_dc6169db-d119-4e8b-9eef-90c4cb955ad0" continuedAt="i3c8dfd23e95b4a4ea838f57fbe4cfde3" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c8dfd23e95b4a4ea838f57fbe4cfde3" continuedAt="i0e26a52d6bf14a0fae160ad28b5f8f32">The Company owns marketable securities that had a maturity date of less than ninety days and are classified as cash and cash equivalents at December&#160;31, 2020 and December 31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. <ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90ZXh0cmVnaW9uOmRjNjFjZGE5N2MzYTQxNzdhNjAzOGJjNmJkYTQxZTdmXzY5MA_79fdfce5-305d-426d-bbfe-fb40efe2afce" continuedAt="ic00a3b8efdba47cdab6453e9b6d1ba0c" escape="true">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:</ix:nonNumeric></ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:center"><ix:continuation id="i0e26a52d6bf14a0fae160ad28b5f8f32" continuedAt="i2bb2201562304cb8b191146f49b80e30"><ix:continuation id="ic00a3b8efdba47cdab6453e9b6d1ba0c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6d1b5895064141892cc9e1fa697991_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMi0xLTEtMA_2d8d4a24-93e1-46a6-9c25-a25e01199dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6a5312e3d74395bd3c1db13869d99c_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktNC0xLTEtMA_6e1a491c-70fc-4e02-8194-f92450792ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7aeecc41504677b76f853c9fa184a6_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktNi0xLTEtMA_4585cc64-a7e2-4493-9504-a2e0659bc567">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbd7aad4f8a44158c186bd69006fa50_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktOC0xLTEtMA_3f8e6ee3-f01d-459a-b6d2-960331838a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b530f82b6fe471b9506787cb064425d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMTAtMS0xLTA_05b05fe5-6f01-4a8e-aec9-50c0a41ea7e4">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a19579f22c4af496dcb8ed57b17e7f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMTItMS0xLTA_5aabcde2-ff7e-41ce-b3fa-cf84d372a2e3">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035fe245e98f4edc8662280dfb190881_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTItMS0xLTA_14387580-63da-435e-9311-66fc1d6e4241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafad14dcd0734e159d5dc98d6debe999_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTQtMS0xLTA_18de4198-c614-4a6b-8421-34023324d9ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTYtMS0xLTA_6a303e57-ef33-4aa5-b506-d970c726d237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb72fd4e685045b9b3f14ba16be19e8f_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTgtMS0xLTA_19f00706-e348-4ad9-928a-feed4f9b60b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id995a6b3c61f46a2916306ecd8f86ea5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTEwLTEtMS0w_269d8d92-9b3c-499d-a8b6-ae660e9a6bfe">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTEyLTEtMS0w_56db1940-17b8-4203-94d6-7489a02a03f9">2,119,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bb2201562304cb8b191146f49b80e30">The fair values of all other financial instruments outstanding as of December&#160;31, 2020 and 2019 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2020 or 2019.</ix:continuation> </span></div><div id="i510f8c4dc65a401f9689088d17e3694c_250"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3XzkwMg_bd8aab4c-d7f4-463f-b850-848a65b7eeb3" continuedAt="ie21f96180b2142808f263b7b83906f00" escape="true">Market Concentrations</ix:nonNumeric></span></div><ix:continuation id="ie21f96180b2142808f263b7b83906f00"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3XzkwNA_17f7931f-c752-4dc7-bcf9-447a21ebc523" continuedAt="iee8921e12739426cbc49a96a67e86390" escape="true">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="iee8921e12739426cbc49a96a67e86390"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"></td><td style="width:39.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0806af42e92d434b8380cece41bef2f1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItMi0xLTEtMA_91f638a1-15bf-4fb4-8fdb-7f45e22341ae">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca38735f6bf48f89c09c2c85125ba89_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItNC0xLTEtMA_04e1c939-1a6a-4c2d-8532-4f561ef0eceb">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1aaf67bebf341cea9c892fb47997567_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItNi0xLTEtMA_930a868e-1feb-4038-8d75-9e5d4b60a257">28</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i187575b302fb41bd9ee6b605b4f68a30_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtMi0xLTEtMA_4f041eb8-0639-4306-abc2-cfbc6a72326d">25</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i419ec7ac9d4f423c8c8f73bf9a5da296_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtNC0xLTEtMA_d9935c0c-d9b0-4961-a5ee-dc7af20079a5">28</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78ce3c4a1d02440f8d5624232436389b_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtNi0xLTEtMA_055eb7de-d723-464c-b4db-5b6d8f2f4f0c">25</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d8fefbac99d4eafb16b2bf8a3836ae2_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtMi0xLTEtMA_14f92925-e1c5-41d1-b39d-7944816c97ee">21</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c14abd94304867b117e4fea7e033be_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtNC0xLTEtMA_9c55cbc7-05f7-4acb-9966-4c3e72beb535">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i010aee2814cf4f14bce2ff9dacf24d5f_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtNi0xLTEtMA_5059b973-96cc-4ecb-893f-9a699e7e4569">26</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was <ix:nonFraction unitRef="number" contextRef="i6777a90bade44e95aedf63f8638b5d8f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3Xzg2Ng_def5e0a8-7675-4fa7-80d5-bd134936a3a8">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i053e86b30f9f453cb231c55d294c07a9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3Xzg3Mw_32cfe51e-774e-46e9-8fed-3cd21dda8f2e">59</ix:nonFraction>% at December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i510f8c4dc65a401f9689088d17e3694c_256"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:ManufacturingAndSupplyAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzYzOQ_a349fa0c-80b9-436a-b65d-291f7dc3d4e1" continuedAt="iacc5d3da2db94cfd8b3ade2a062ddbba" escape="true">Manufacturing and Supply Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iacc5d3da2db94cfd8b3ade2a062ddbba">The Company utilizes <ix:nonFraction unitRef="supplier" contextRef="ie52ad4b1821b40aeaa322dea12dec215_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzY3_b6e93957-9215-4864-b0f1-34b098c7af90">one</ix:nonFraction> or <ix:nonFraction unitRef="supplier" contextRef="ic3a82fe51f4445d5a9623b513f48b606_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzcz_590eca5e-cc47-4991-a0cc-b3557cdae893">two</ix:nonFraction> primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</ix:continuation></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_259"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="cpix:EmploymentAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTkvZnJhZzpkZWJhYTUwOWQ5MmM0YjA5YTEyOTY0NTFhOGY0N2NhZC90ZXh0cmVnaW9uOmRlYmFhNTA5ZDkyYzRiMDlhMTI5NjQ1MWE4ZjQ3Y2FkXzMxMA_aaf77e16-60e5-4425-ac89-8fcd444f47b8" continuedAt="ib6224279515c4ab49a09797ec9afbb78" escape="true">Employment Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib6224279515c4ab49a09797ec9afbb78">The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.</ix:continuation></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_262"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(20)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzIzMzk_bf3ec397-023d-482b-9c5a-a1d453cb7c41" continuedAt="i044214a8f4644b3fb54aa08f32b8a2a0" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="i044214a8f4644b3fb54aa08f32b8a2a0" continuedAt="i4294e7227cae45efbe7f841249d8b4d8"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgyNjk_f1b9a849-0e6b-4960-a28e-30691f3bafc6">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgzNDA_72c8f2e7-a907-47b1-a9cd-8d46f8f9cdb2">two</span>-years following the transition date.  Cumberland recorded the first four quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NTExNzU_efb95933-6e5b-443e-87e5-b22761644e33">3.0</ix:nonFraction> million during the year ended December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzkzNDU4NDg4NDY2NjU_f4e19211-f66f-48cd-afaf-58ee822adfb1" continuedAt="i1c3b3f97c1b3457e9f5e8ee5b7c43255" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItMi0xLTEtNjExNw_52226e24-55a9-4522-af2f-4c3216ad85ec">3,206,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItNC0xLTEtNjExNw_b28138d3-bdc4-41c8-8d27-1eb6609d941e">13,145,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItNi0xLTEtNjExNw_f123d5b3-9335-4ad8-800b-b7166d9bf76e">11,396,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtMi0xLTEtNjExNw_9dcf7010-2fd2-4f1a-ab8b-ea93481811fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtNC0xLTEtNjExNw_db801180-9123-44a3-9669-602acd387d4f">1,330,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtNi0xLTEtNjExNw_2068df5f-0452-45e8-9647-94406d0a2d66">1,361,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtMi0xLTEtNjExNw_62ed0155-c736-448c-ad86-d6282e0f3208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtNC0xLTEtNjExNw_57ef8a7e-e566-4e64-936a-15f9fab68652">6,149,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtNi0xLTEtNjExNw_4ed3c2c9-da2d-4eb1-bbd3-87b3411c9187">6,253,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtMi0xLTEtNjExNw_da161a98-759e-4623-a161-2ba8a77ff2db">3,206,875</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtNC0xLTEtNjExNw_67eb95eb-cc59-4258-8a48-29f568c3f97e">5,665,177</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtNi0xLTEtNjExNw_efdad49f-f778-42df-af7d-14748c1327f1">3,782,224</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets associated with discontinued operations included $<ix:nonFraction unitRef="usd" contextRef="i60aad94f2f4f44b1a7b8ae65743e96b3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzM4NDgyOTA3MDAyODY_2aae81fb-5038-44a8-b5d0-007bbcfbc9ce">0.5</ix:nonFraction>&#160;million in the remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. </span><ix:continuation id="i1c3b3f97c1b3457e9f5e8ee5b7c43255" continuedAt="i65d993cf39fc4737ac2e3bdc92157cf1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   </span></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i4294e7227cae45efbe7f841249d8b4d8"><ix:continuation id="i65d993cf39fc4737ac2e3bdc92157cf1"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"></td><td style="width:61.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzItMi0xLTEtNjA3MA_7619c2bb-0006-4983-a964-946aafdcebad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzItNC0xLTEtNjA3MA_542321e1-8baa-457a-9672-3098e2c7803a">1,922,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzMtMi0xLTEtNjA3MA_a8283ed6-1e6a-441c-9432-be46f8b61f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzMtNC0xLTEtNjA3MA_b1a562c0-fad7-4293-87ab-afb3adb62b51">540,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzQtMi0xLTEtNjA3MA_fa58723a-44fc-4a2e-a1d8-6ec20a37cb7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzQtNC0xLTEtNjA3MA_c87be2e0-9816-4b73-bc64-6f5b6723ceed">2,462,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"></td><td style="width:61.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzItMi0xLTEtNjExNQ_fc0faf4e-b69f-4b54-a37f-b9722a6ad5fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzItNC0xLTEtNjExNQ_9cf958b9-ec80-4c20-84de-0a471ceeac36">1,918,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzMtMi0xLTEtNjExNQ_77016481-57cd-4fa8-9398-e506227faec8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzMtNC0xLTEtNjExNQ_24f8cbd2-01f1-420f-9434-6f1ea3b19981">232,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzQtMi0xLTEtNjExNQ_ed0edae1-b250-4f08-9119-b79d468a9ea1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzQtNC0xLTEtNjExNQ_5c85c22e-1dbe-46df-aae4-5c824ed05fa3">2,151,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i510f8c4dc65a401f9689088d17e3694c_265"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjUvZnJhZzo2NzdlYTRkMGEwOGY0YmJjOGM1YjdkNDE4NzFjMWQwNS90ZXh0cmVnaW9uOjY3N2VhNGQwYTA4ZjRiYmM4YzViN2Q0MTg3MWMxZDA1XzI1MDY_10b4c6b3-1bc9-40fc-8b5c-2257a650027d" continuedAt="i9598249bc8524f60bc8b4fc683c5e056" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i9598249bc8524f60bc8b4fc683c5e056" continuedAt="i9e8a73176e4b417bb1d470790b0bb277"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9e8a73176e4b417bb1d470790b0bb277">The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</ix:continuation>  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_268"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90ZXh0cmVnaW9uOjVhM2FjOTcxNzg2ODRkODI5MTA3ZjFiOTNiY2E3MTcyXzM1Mw_fb149a0c-bcba-471f-bb26-9006f6cb0f71" continuedAt="i8a5c6ccdabbf4297bf7c49bba167cf31" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="i8a5c6ccdabbf4297bf7c49bba167cf31"><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90ZXh0cmVnaW9uOjVhM2FjOTcxNzg2ODRkODI5MTA3ZjFiOTNiY2E3MTcyXzM1NA_9ed9fea0-466c-4a38-8de2-b57a1076b8b8" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtMi0xLTEtMA_07773581-67e9-4db4-9b98-41ceb8ab47f8">8,330,734</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtNC0xLTEtMA_025485b3-0883-47ee-a677-63659bf7d523">9,598,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtNi0xLTEtMA_dbac73af-1e0e-42ab-acfa-9ae4b9ad9aff">9,250,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtOC0xLTEtMA_47205b6b-644a-44a7-8a2b-f97fe0d1386b">10,261,534</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtMTAtMS0xLTA_667df3da-9c40-4d0f-b42d-56497aa738bf">37,441,134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtMi0xLTEtMA_f2facdd3-3fc3-4409-9a9a-451d8023a7b4">1,846,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtNC0xLTEtMA_6c0baff2-7f42-40ae-9877-9de7258f318d">1,580,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtNi0xLTEtMA_24b3ab70-cbd0-4cc1-9d6e-9ebddc7ed079">1,208,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtOC0xLTEtMA_fba9c219-e768-4be6-aac3-f538c91960a9">1,745,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtMTAtMS0xLTA_9ca2ce0d-5454-4ed1-84b1-0a9b23f260c2">6,381,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMi0xLTEtMjEzMg_e2cd01ed-4db3-4b6a-a62b-ffc780156c65">1,883,418</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNC0xLTEtMjEzMg_3cfa0451-c2ee-4391-82ae-33b371926deb">1,679,211</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNi0xLTEtMjEzMg_93577245-b282-435c-89a6-bd4414bf0d66">1,275,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtOC0xLTEtMjEzMg_1ee8cfcb-176d-4b95-ace2-a91873b1e2fc">1,787,530</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMTAtMS0xLTIxMzI_d0e21d43-5ee2-40b9-9066-8a2fe5ffd543">6,625,779</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtMi0xLTEtMjEzMg_2aacf664-9cbe-4b5d-9e29-5937e2e9dad6">818,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtNC0xLTEtMjEzMg_993fdd35-1f62-4521-9258-3aadeeb85a7b">738,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtNi0xLTEtMjEzMg_3932804d-26f4-42a9-ab36-441c44b5fc39">777,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtOC0xLTEtMjEzMg_be8cf7b9-2a2e-4daa-97c9-71d6ea1eb8ab">872,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtMTAtMS0xLTIxMzI_176fe447-24d0-42e9-8865-5b8f281a67eb">3,206,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMi0xLTEtMA_4535b5af-12c3-4f6e-b9b0-e952610f6fbb">1,055,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNC0xLTEtMA_9aa30c86-edea-4b7e-8403-c0e133f3d4c3">918,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNi0xLTEtMA_c6881792-9048-4230-bb7c-ef7d5386f499">481,737</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtOC0xLTEtMA_d4380c0a-82cf-46e5-a88b-a7dfffe00375">883,776</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMTAtMS0xLTA_91ae942d-2ae2-4fb7-a9e0-1672e505d671">3,339,408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktMi0xLTEtMjEzOQ_3aa17cb5-ac14-4bbf-be40-855b3e9e79e0">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktNC0xLTEtMjEzOQ_e869e343-393c-4704-903d-e115b759676e">0.11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktNi0xLTEtMjEzOQ_53057a9e-345f-40d2-8e25-c48ef857a2be">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktOC0xLTEtMjEzOQ_bc1bb264-e015-4636-9779-797286145151">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktMTAtMS0xLTIxMzk_ff6693d6-6780-4075-a7b8-2d333f6c83d3">0.43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTItMS0xLTIxMzk_2d3213a2-bb69-4ad9-b6f0-e07213bbc9ad">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTQtMS0xLTIxMzk_97fc5539-2189-47b0-870d-bd6d6e32a6c4">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTYtMS0xLTIxMzk_435133a9-024a-4983-85e9-65b9c379d5c7">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTgtMS0xLTIxMzk_19ae1a95-f65f-44aa-a55c-516877a9015a">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTEwLTEtMS0yMTM5_7aef39cf-e1ce-4efa-b938-bcbebc48ddab">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctMi0xLTEtMA_00236362-8d99-4cd3-b0f3-4ef1ae7946f8">0.07</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctNC0xLTEtMA_fe157292-900d-4086-a475-e5b7548e35ac">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctNi0xLTEtMA_bd632353-4b5f-4ebd-99e9-2b58bcab1177">0.03</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctOC0xLTEtMA_26132c2d-842f-4b9c-924b-0d50c9bdf9ac">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctMTAtMS0xLTA_e59d002d-4baa-4ebf-bb39-caa3701583b2">0.22</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTItMS0xLTIxNjM_e2678847-e043-4668-b257-53bf1b1e56f1">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTQtMS0xLTIxNjM_cfa747e1-0d2f-4024-ac32-050cef3239d5">0.11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTYtMS0xLTIxNjM_7da412cd-386b-4515-b4be-00e96e5aec24">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTgtMS0xLTIxNjM_443876e8-e7f0-44c7-8128-528021fd3cb9">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTEwLTEtMS0yMTYz_aef18dbf-13f1-4259-a18e-9165d93df969">0.43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTItMS0xLTIxNjM_98db4efe-a656-49bf-bba8-504f154e8cb7">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTQtMS0xLTIxNjM_9fc9a2af-0b36-4858-89d8-efff737c143c">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTYtMS0xLTIxNjM_359e989a-1f26-46a3-ac3f-6064c2c3ef46">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTgtMS0xLTIxNjM_b1d90923-b5c0-48e0-b716-19041079f158">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTEwLTEtMS0yMTYz_4a622a28-56ff-49b2-81de-4306e0659bbc">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtMi0xLTEtMA_138f18c3-1042-46eb-bbda-c95d0301b0ab">0.07</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtNC0xLTEtMA_30b5f984-3163-40fd-a305-8fb09c371c56">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtNi0xLTEtMA_8d5ddee0-a6d2-469e-b5bd-dafa4de97af0">0.03</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtOC0xLTEtMA_45ddbf8f-3db1-4576-af1e-6adb46395484">0.06</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtMTAtMS0xLTA_1388733e-3610-42fc-85ea-e251f6a55c31">0.22</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTItMS0xLTA_9aba2786-6963-4a5f-a894-5e4e233337dc">8,729,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTQtMS0xLTA_39c4acce-9447-4657-a55c-5aa929131c16">9,417,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTYtMS0xLTA_c757080d-92ab-4dcf-ae71-eadfc30130ac">6,935,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTgtMS0xLTA_8f02a879-2fd0-4a4e-978c-036facc51f4e">9,305,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTEwLTEtMS0w_29772dea-58fa-41d8-8fc6-433b639ec241">34,388,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTItMS0xLTA_d171ea52-ef09-46e4-b219-7449c0290bc3">1,323,932</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTQtMS0xLTA_a999d888-2ddf-4b68-803c-3050a383cc82">1,373,424</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTYtMS0xLTA_83552b47-f9f4-43c1-9501-a4c97139bacc">3,196,436</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTgtMS0xLTA_123f0ab2-5b24-4154-90d5-ba3d6b876450">3,394,390</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTEwLTEtMS0w_989dc212-4cbf-4544-a521-50f3155149d9">9,288,182</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTItMS0xLTIwMzc_9a8259fa-0356-4cb1-b8e2-2574e2a81aac">1,187,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTQtMS0xLTIwMzc_19626109-a97d-4476-a653-02b4f8afa94b">1,338,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTYtMS0xLTIwMzc_aa0f9cc6-29b8-4140-9d70-2098a6b08b5d">3,316,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTgtMS0xLTIwMzc_9f4b51f2-3ff2-4c56-b32a-bd727ebecfbf">3,369,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTEwLTEtMS0yMDM3_01f29bd2-ac49-4d64-8573-cb80449aefbe">9,211,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTItMS0xLTIwMzc_dccb5489-b1f1-4684-b3ed-cd0eee008668">1,147,136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTQtMS0xLTIwMzc_dc8e93a9-43c9-42e4-a90b-f9245aa0aa1a">771,709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTYtMS0xLTIwMzc_96470ad6-add8-4288-a588-ab300aa9d7bf">1,349,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTgtMS0xLTIwMzc_9bfa1464-54dd-4e9c-812c-6452f9091b54">2,396,981</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTEwLTEtMS0yMDM3_ebcefb6f-1c12-4a52-9f4e-1fe4667c2660">5,665,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTItMS0xLTA_bb153a1b-eb9d-4036-98dd-68150ae9194e">73,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTQtMS0xLTA_eeeabf47-38b3-4a3c-bc15-554f1dd28b7e">549,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTYtMS0xLTA_ab39bc22-be19-4d0f-8a6f-40bf77488e57">1,953,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTgtMS0xLTA_7925f2de-eeea-46ed-be85-b48190daeced">960,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTEwLTEtMS0w_d452f52d-6546-433a-b0c5-99d09dbe35df">3,537,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTItMS0xLTIwNDM_21484649-f15d-4739-8edf-aaa6ea15f675">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTQtMS0xLTIwNDM_209376a5-d33c-40e1-9348-89bf786fca2a">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTYtMS0xLTIwNDM_ba4e3c41-801e-4f25-af04-3705f108095c">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTgtMS0xLTIwNDM_33c5d6aa-8816-4bd4-b94e-a5962cc525c8">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTEwLTEtMS0yMDQz_8a278cf7-b48e-4df7-90fe-04272d46944e">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTItMS0xLTIwNDM_2ba9715b-982e-4d4e-b2f6-82fbe0eecbf2">0.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTQtMS0xLTIwNDM_1628a0e6-c7c7-4955-a583-9566aa04430a">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTYtMS0xLTIwNDM_e28e64ef-4d1d-4ef1-80a0-c11619a9584c">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTgtMS0xLTIwNDM_45509dca-64e7-47a2-a4e0-966b58c3f4a7">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTEwLTEtMS0yMDQz_bb1c9f28-1316-4abd-a76b-d6216ce966f1">0.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTItMS0xLTA_340d1ff6-11df-4959-81f7-8a8e8c8bdb25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTQtMS0xLTA_bff68dfa-ea22-4115-b082-082030263841">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTYtMS0xLTA_66dc55f0-ec67-4a9e-8b44-a64e1142d4b7">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTgtMS0xLTA_7d11c31f-9a31-4cb5-9ada-2eb776cfb103">0.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTEwLTEtMS0w_3d57dea5-538d-4d95-85d5-44cc19f773f3">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTItMS0xLTIwNDM_013ae205-1877-43a6-b2a2-cc7f9db5a0f6">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTQtMS0xLTIwNDM_83694200-8c0b-4cf2-b2bb-283eb61edbbc">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTYtMS0xLTIwNDM_b336e8a6-0975-422a-abeb-f46e6b750809">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTgtMS0xLTIwNDM_ffd9d97c-64ce-4e3e-b859-d41ae3a15cd4">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTEwLTEtMS0yMDQz_abb14499-f222-4153-94ac-2a9104cf82c1">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTItMS0xLTIwNDM_e956e48a-baa6-4c2d-84ac-0a8c86b8cc18">0.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTQtMS0xLTIwNDM_963204e6-6d29-478f-a990-5ddae4d55491">0.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTYtMS0xLTIwNDM_ea67c7d7-cd49-4b2d-90d3-2099cb2d0b27">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTgtMS0xLTIwNDM_b804a348-fee2-4f8d-a854-8720f9b08734">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTEwLTEtMS0yMDQz_d9b46059-8c49-46b5-a291-48f2bde5a7ff">0.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTItMS0xLTA_4af1926d-9fd0-4684-a71d-03dcb8461640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTQtMS0xLTA_ab4a6e92-d115-416f-b42b-0c6ad24f8dc3">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTYtMS0xLTA_294db78e-09ff-4335-8cd7-ea37828c3b55">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTgtMS0xLTA_9286c71e-cc92-4e07-845e-f45a9d179b58">0.06</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTEwLTEtMS0w_15ca88fb-df2b-481e-8dad-235e6497a9ef">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="i510f8c4dc65a401f9689088d17e3694c_274"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:right"><span><br/></span></div><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><ix:nonNumeric contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90ZXh0cmVnaW9uOmIyODNhYjZhNTUzMDQ1NDRiZGQ1MjdkMTAyYzlkM2VmXzQwMw_c65f37e0-a9c4-4ab1-bc4f-ba3f7d691f6e" escape="true"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1855e705644eb19c43b7bb2e117b81_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtMi0xLTEtMA_07bab6ae-2f78-4d3f-8b98-687a462c7085">326,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtNC0xLTEtMA_f8bfef08-4f79-452b-b008-fa793ca5b75a">4,610,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtNi0xLTEtMA_f69f7070-3e03-49db-9a88-ac25c2a0f8ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtOC0xLTEtMA_907f7092-b70e-4136-9648-34fa9f2aaf22">4,133,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40627ef8322d435c8f66224735bfa7b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtMTAtMS0xLTA_9c906de6-5946-4eee-b38d-77558373eea7">804,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40627ef8322d435c8f66224735bfa7b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtMi0xLTEtMA_e240a066-6b9b-48ef-bcfe-d2d598810174">804,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtNC0xLTEtMA_7c981df7-d959-4dc6-b178-7ffc83f74bbd">5,915,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtNi0xLTEtMA_c3a519e3-0d07-48b2-b5ab-c65bb7433c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtOC0xLTEtMA_3ba9f514-cad4-49d0-b843-2c6adff116e0">5,927,435</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fbba7dd4a6485ea115af1a74515fea_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtMTAtMS0xLTA_9c8f1fd2-1731-4361-84a1-3b0103cbf6cc">792,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fbba7dd4a6485ea115af1a74515fea_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtMi0xLTEtMA_dda4f9b0-e354-4683-a61e-cfe31c890029">792,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtNC0xLTEtMA_db8d09b2-24ca-41f5-8974-8378df242e56">4,940,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtNi0xLTEtMA_a90ea692-8bec-4072-9de9-9ecd7d1b9de6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtOC0xLTEtMA_2603e2da-668d-4258-b034-60b7fadc571e">4,747,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053b532230724366b6e9f1045a453663_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtMTAtMS0xLTA_4e19f175-81c8-4053-b101-addba013f18c">984,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf0cdcda3874fbf81f9d06a24caa475_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTItMS0xLTA_b2b959c4-366b-4e25-85ac-89bd0c751481">15,632,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTQtMS0xLTA_a1a109ac-c9d9-42bb-a478-308c9518c7ad">1,749,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTYtMS0xLTA_d75f1ff1-8c77-49c4-b87d-a99160a58361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTgtMS0xLTA_779e4c89-407a-4269-b390-b18949443dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d578da0f6f43cc8eb4610cda5b0867_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTEwLTEtMS0w_70adbb0b-64dc-4678-b27b-a144f197515d">17,382,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d578da0f6f43cc8eb4610cda5b0867_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTItMS0xLTA_bbdaff61-528b-4c63-bce2-93240a72a7f9">17,382,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTQtMS0xLTA_8a31a254-3ce4-4ef6-b819-057b2121c6c5">1,129,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTYtMS0xLTA_1fa5ddda-aae9-4075-8915-848cacf2b6bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTgtMS0xLTA_1ee8c2ec-c690-4f9a-9a66-4d4f4c8015a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTEwLTEtMS0w_87625c3e-4901-4067-b054-4460dd7d31d1">18,511,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTItMS0xLTA_ebe39d25-6ff6-44cd-90de-71a5f3424ca0">18,511,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTQtMS0xLTA_017d68fa-5235-45e6-9c77-6dbdfbda696f">684,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTYtMS0xLTA_155ee872-66a2-44f3-ae2b-3fd5101bfcbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTgtMS0xLTA_b5fb5e67-0970-4c71-bcd6-97471d25d98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e5f707de404e5784e8284dcb422b96_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTEwLTEtMS0w_032a6f28-292d-4aba-971f-bf7a662cb03e">19,196,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Composed of actual returns and credits for chargebacks and cash discounts.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>a2020q4exhibit411.htm
<DESCRIPTION>EX-4.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib58350ae3f234e9c9988ef0044e04e13_32"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.11</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">DESCRIPTION OF THE REGISTRANT&#8217;S COMMON STOCK </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The common stock of Cumberland Pharmaceuticals, Inc. ( &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221;) is registered under Section 12 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the actual terms and provisions contained in our Third Amended and Restated Charter, as amended (the &#8220;Charter&#8221;), and our Second Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), copies of are filed as an exhibit to this Annual Report on Form 10-K and are incorporated herein, and to the applicable provisions of Tennessee law. We encourage you to read our Charter and Bylaws and the applicable provisions of Tennessee law for additional information.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Authorized Capital </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">We are authorized to issue up to 120,000,000 shares of capital stock, of which 100,000,000 may be shares of common stock, par value $0.00 per share, and 20,000,000 may be shares of preferred stock, par value $0.00 per share. The Company currently has no preferred stock issued and outstanding. All of the Company&#8217;s outstanding shares of common stock are fully paid and nonassessable. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Voting Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of common stock are entitled to one vote for each share registered in his or her name on our books on all matters voted on by our shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock do not have cumulative voting rights. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Dividends </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to any preferences or other rights of any of our preferred stock that may be issued from time to time, each share of our common stock is entitled to share equally with each other share of common stock in dividends from sources legally available therefore, when, as, and if declared by the Board of Directors of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Absence of Other Rights </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Holders of our common stock do not have any preemptive rights to subscribe for or purchase any of our securities of any class or kind. Holders of our common stock do not have any subscription, redemption or conversion privileges. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon our liquidation or dissolution, whether voluntary or involuntary, each share of our common stock is entitled to share equally in the assets that are available for distribution to our shareholders, after payment of all debts and liabilities and subject to the prior rights of nay holders of preferred stock then outstanding. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Listing </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;CPIX.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Transfer Agent and Registrar </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Continental Stock Transfer &#38; Trust Company is the transfer agent and registrar of our common stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Anti-Takeover Effects of our Charter and Bylaws</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws contain certain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions, which are summarized below, could discourage takeovers, coercive or otherwise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Staggered Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter divides our Board of Directors into three separate classes, and directors are assigned to each class in accordance by resolution of the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each class of directors serves for a full term of three years, and the terms of the respective classes expire in succession so that only one class of directors is required to stand for re-election at each annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision prevents our shareholders or a potential acquirer from replacing all of our incumbent directors at a single annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Removal of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Under Tennessee law, a director can be removed by the shareholders with or without cause, unless a corporation&#8217;s charter provides that the director can only be removed for cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter includes this restriction, which could make it more difficult for shareholders to remove incumbent directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice Provisions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Bylaws contain advance notice provisions applicable to shareholder proposals and the nomination of candidates for election as directors by shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These advance notice provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed and may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempt to obtain control of the Company. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that the Board of Directors, by a majority vote of the remaining directors in office, shall fill any vacant directorships caused by the death, resignation, disqualification, removal of a director.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter also gives the Board of Directors the power to fill any vacancies resulting from the increase in the number of directors serving on the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions could make it more difficult for an acquiror to gain control of our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Calling of Special Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Under Tennessee law, a special meeting of a Tennessee corporation&#8217;s shareholders can be called by its board of directors or, unless the charter provides otherwise, the holders of at least 10% of the outstanding voting stock of the corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that a special meeting can be called by our Chairman of the Board or the Chief Executive Officer only when shareholders owning at least two-thirds of the votes entitled to be cast on any issue proposed to be considered at the meeting deliver to the Company a written demand stating the purposes of the special meeting and a certified check in the amount of $50,000.00.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision may make it harder for our shareholders to call special meetings without the consent of the Board of Directors of the Company. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Undesignated Preferred Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Board of Directors has the ability to designate and issue preferred stock without shareholder approval, and such preferred stock could have voting or other rights or preferences that could deter hostile takeovers or delay changes in control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">No Cumulative Voting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws do not allow shareholders to cumulate votes for the election of directors, which may have the effect of deterring our shareholder&#8217;s ability to replace incumbent directors serving on the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tennessee Anti-Takeover Statutes</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the Charter and Bylaws provisions discussed above, Tennessee has adopted a series of statutes which can have an anti-takeover effect and may delay or prevent a tender offer or takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the market price for our capital stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Business Combination Act </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Business Combination Act (the &#8220;TBCA&#8221;) governs all Tennessee corporations. It imposes a five-year standstill on transactions such as mergers, share exchanges, sales of assets, liquidations and other interested party transactions between Tennessee corporations and &#8220;interested shareholders&#8221; and their associates or affiliates, unless the business combination is approved by the board of directors before the interested shareholder goes above the 10% ownership threshold. Thereafter, the transaction either requires a two-thirds vote of the shareholders other than the interested shareholder or satisfaction of certain fair price standards.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The TBCA also provides for additional exculpatory protection for the board of directors in resisting mergers, exchanges and tender offers if a Tennessee corporation&#8217;s charter specifically opts-in to such provisions. In particular, a Tennessee corporation&#8217;s charter may specifically authorize the members of a board of directors, in the exercise of their judgment, to give due consideration to factors other than price and to consider whether a merger, exchange, tender offer or significant disposition of assets would adversely affect the corporation&#8217;s employees, customers, suppliers, the communities in which the corporation operates, or any other relevant factor in the exercise of their fiduciary duty to the shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Charter currently does not opt-in to the additional exculpation provisions available under the TBCA. In the future, if we amend our Charter to opt-in to such provisions, it could have the effect of protecting our management and Board of Directors from hostile takeover bids.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Control Share Acquisition Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Control Share Acquisition Act (the &#8220;TCSA&#8221;) limits the voting rights of shares owned by a person above certain percentage thresholds, unless the non-interested shareholders of the corporation approve the acquisition above the designated threshold. However, the TCSA only applies to corporations whose charter or bylaws contain an express declaration that control share acquisitions are to be governed by the TCSA. In addition, the charter or bylaws must specifically provide for the redemption of control shares or appraisal rights for dissenting shareholders in a control share transaction. Neither our Charter nor our Bylaws make the express declarations necessary to opt into the TCSA. In the future, if we amend our Bylaws or our Charter to opt into the TCSA, it will have the general effect of discouraging, or rendering more difficult, acquisition attempts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Investor Protection Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Investor Protection Act (&#8220;TIPA&#8221;) generally requires the registration, or an exemption from registration, before a person can make a tender offer for shares of a Tennessee corporation which, if successful, will result in the offeror beneficially owning more than 10% of any class of shares. Registration requires the filing with the Tennessee Commissioner of Commerce and Insurance of a registration statement, a copy of which must be sent to the target company, and the public disclosure of the material terms of the proposed offer. Additional requirements are imposed under that act if the offeror beneficially owns 5% or more of any class of equity securities of the target company, any of which was purchased within one year prior to the proposed takeover offer. TIPA also prohibits fraudulent and deceptive practices in connection with takeover offers, and provides remedies for violations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">TIPA does not apply to an offer involving a vote by holders of equity securities of the offeree company, pursuant to its charter, on a share exchange, consolidation or sale of corporate assets in consideration of the issuance of securities of another corporation, or on a sale of its securities in exchange for cash or securities of another corporation. Also exempt from TIPA are tender offers which are open on substantially equal terms to all shareholders, are recommended by the board of directors of the target company, and include full disclosure of all terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Greenmail Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Greenmail Act (&#8220;TGA&#8221;) prohibits us from purchasing or agreeing to purchase any of our securities, at a price higher than fair market value, from a holder of 3% or more of any class of its securities who has beneficially owned the securities for less than two years. We can, however, make this purchase if the majority of the outstanding shares of each class of voting stock issued by us approves the purchase or if we make an offer of at least equal value per share to all holders of shares of the same class of securities as those held by the prospective seller.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>a2020-10kxex1011ajkazimi.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9dd0484094bd41d8989a49f748e1f55e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.11</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 8, 2021</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. A.J. Kazimi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear A.J.&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Effective January 1, 2021, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company agrees to compensate you as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred ten thousand one hundred thirty-two dollars ($610,132.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of each calendar month of 2021.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)        Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 5.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 6.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 16.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 17       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 18.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 19.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 20.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">#   #   #   #</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9dd0484094bd41d8989a49f748e1f55e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; Jean W. Marstiller</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;Jean W. Marstiller</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 8th of March, 2021&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.J. Kazimi</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>4
<FILENAME>a2020-xex1012martincearnal.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i721ba17da68a49fb81be7c02dd334789_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.12</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 8, 2021</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Martin E. Cearnal</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment of Martin E. Cearnal as Executive Vice President, Chief Commercial Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Martin&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Effective January 1, 2021, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Vice President, Chief Commercial Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company agrees to compensate you as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        The Company agrees to pay you on a salary basis for services performed based on an annual rate of three hundred thirty-six thousand five hundred dollars ($336,500.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of each calendar month of 2021.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)        Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 5.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 6.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 16.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 17       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 18.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 19.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 20.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">#   #   #   #</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i721ba17da68a49fb81be7c02dd334789_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 8th of March, 2021&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Martin E. Cearnal</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Martin E. Cearnal</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>5
<FILENAME>a2020-10kxex1013leopavliv.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0b475024e9044f4b91fb3f02ca44516f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.13</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 8, 2021</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Leo Pavliv</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment of Leo Pavliv as Executive Vice President, Operations and Chief Development Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Leo, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Effective January 1, 2021, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Vice President, Chief Development &#38; Operations Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company agrees to compensate you as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        The Company agrees to pay you on a salary basis for services performed based on an annual rate of four hundred thirty-seven thousand five hundred dollars ($437,500.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of each calendar month of 2021.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)        Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 5.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 6.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 16.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 17       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 18.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 19.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 20.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">#   #   #   #</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0b475024e9044f4b91fb3f02ca44516f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 8th of March, 2021&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leo Pavliv</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leo Pavliv</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>a2020-xex1014michaelbonner.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if405b6e7ba17481a8b196651b6c44d4a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.14</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 8, 2021</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Michael Bonner </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment of Michael Bonner as Senior Director, Finance &#38; Accounting&#59; Chief Financial Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Michael&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Effective January 1, 2021, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Director, Finance &#38; Accounting&#59; Chief Financial Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company agrees to compensate you as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred twenty thousand dollars ($220,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of each calendar month of 2021.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)        Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 5.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 6.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you 1to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 16.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 17       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 18.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 19.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 20.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">#   #   #   #</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if405b6e7ba17481a8b196651b6c44d4a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 8th of March, 2021&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Bonner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Bonner</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>7
<FILENAME>a2020-10kxex1015jimherman.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2fb77ade52a84bfd9070b775d99af6e7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.15</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 8, 2021</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. James L. Herman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment of James L. Herman as Senior Vice President, National Accounts and Chief Compliance Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Jim&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Effective January 1, 2021, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Senior Vice President, National Accounts and Chief Compliance Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Company agrees to compensate you as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred seventy thousand dollars ($270,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of each calendar month of 2021.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)       You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)        Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 5.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 6.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 16.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 17       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 18.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 19.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 20.      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">#   #   #   #</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div id="i2fb77ade52a84bfd9070b775d99af6e7_4"></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:12pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">A.J. Kazimi</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 8th of March, 2021&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; James L. Herman</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James L. Herman</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>a2020-xex231consentofbdollp.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iefbc8f808d2744649d6049a7fe0d1d6a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-251308) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated March 20, 2020 (except for the effects of presenting discontinued operations discussed in Note 20, as to which the date is December 10, 2020), relating to the consolidated financial statements and schedule, which appears in this Form 10-K</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;12, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>9
<FILENAME>a2020-xex232consentofbkdllp.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8685291bc9384b06b75c98b194ef3872_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 23.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the registration statement of Cumberland Pharmaceuticals Inc. on Form S-3 (No. 333-251308) and Form S-8 (No. 333-164376) of our report dated March 12, 2021, on our audit of the consolidated financial statements of Cumberland Pharmaceuticals Inc. as of December 31, 2020 and for the year ended December 31, 2020, which report is included in this Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BKD, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;12, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>a2020-10kxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i490053b1877e4ae5ba0c77d5076ec2f5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:30.48pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:40.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.226%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>a2020-10kxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6afa094ed6614ffa805891a19e4e1e3f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael P. Bonner, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30.48pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:30.48pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:41.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.289%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael P. Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael P. Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>a2020-10kxexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i421f953880db466e9bf5151b391f2b88_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the fiscal year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer, and Michael P. Bonner, Senior Director and Chief Financial Officer, of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that, based on my knowledge&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Michael P. Bonner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael P. Bonner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>cpix-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.cumberlandpharma.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Organization (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexandVibativ" roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativ">
        <link:definition>2108103 - Disclosure - RediTrex&#174; and Vibativ&#174;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexandVibativTables" roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativTables">
        <link:definition>2309302 - Disclosure - RediTrex&#174; and Vibativ&#174; (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexandVibativNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails">
        <link:definition>2410404 - Disclosure - RediTrex&#174; and Vibativ&#174; - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexandVibativVibativAcquisitionNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails">
        <link:definition>2411405 - Disclosure - RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails">
        <link:definition>2412406 - Disclosure - RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2113104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2314303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofNetProductRevenuesbyProductDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails">
        <link:definition>2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails">
        <link:definition>2416408 - Disclosure - Revenues (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2117105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2318304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2420410 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment">
        <link:definition>2121106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables">
        <link:definition>2322305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails">
        <link:definition>2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets">
        <link:definition>2125107 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables">
        <link:definition>2326306 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2428414 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilities" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities">
        <link:definition>2130108 - Disclosure - Other Current and Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesTables" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables">
        <link:definition>2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails">
        <link:definition>2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.cumberlandpharma.com/role/Debt">
        <link:definition>2133109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLineofCreditDetails" roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails">
        <link:definition>2434417 - Disclosure - Debt (Line of Credit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity">
        <link:definition>2135110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
        <link:definition>2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityWarrantsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails">
        <link:definition>2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
        <link:definition>2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2139111 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2340308 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails">
        <link:definition>2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails">
        <link:definition>2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2143112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables">
        <link:definition>2344309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails">
        <link:definition>2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails">
        <link:definition>2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
        <link:definition>2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails">
        <link:definition>2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails">
        <link:definition>2450428 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans">
        <link:definition>2151113 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables">
        <link:definition>2352310 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails">
        <link:definition>2453429 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails">
        <link:definition>2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
        <link:definition>2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans">
        <link:definition>2157114 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails">
        <link:definition>2458433 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2159115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2360311 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2461434 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofRentExpenseandSubleaseIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails">
        <link:definition>2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2463436 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails">
        <link:definition>2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments">
        <link:definition>2165116 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2366312 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails">
        <link:definition>2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrations" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations">
        <link:definition>2168117 - Disclosure - Market Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsTables" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables">
        <link:definition>2369313 - Disclosure - Market Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
        <link:definition>2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreements" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements">
        <link:definition>2171118 - Disclosure - Manufacturing and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
        <link:definition>2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmploymentAgreements" roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements">
        <link:definition>2173119 - Disclosure - Employment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations">
        <link:definition>2174120 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables">
        <link:definition>2375314 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>2476441 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsDiscontinuedOperationsDetails" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails">
        <link:definition>2477442 - Disclosure - Discontinued Operations - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>2178121 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2179122 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2380315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2481443 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccounts" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts">
        <link:definition>1106123 - Statement - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccountsDetails" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails">
        <link:definition>2482444 - Disclosure - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsDeferredCharges" abstract="false" name="DeferredTaxAssetsDeferredCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LongTermIncentiveCompensationPlan2007Member" abstract="true" name="LongTermIncentiveCompensationPlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentDomain" abstract="true" name="AccountsReceivableAllowancesByComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PreferredStockAbstract" abstract="true" name="PreferredStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_SharebasedCompensationCharitableContributionofSharesShares" abstract="false" name="SharebasedCompensationCharitableContributionofSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductVibativMember" abstract="true" name="ProductVibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeDomain" abstract="true" name="SharesRepurchaseActivityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsAbstract" abstract="true" name="ManufacturingAndSupplyAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_DirectorsIncentivePlan2007Member" abstract="true" name="DirectorsIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EmploymentAgreementsAbstract" abstract="true" name="EmploymentAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" abstract="false" name="PurchasesOfIntangibleAssetsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SalesRevenueGoodsGrossMember" abstract="true" name="SalesRevenueGoodsGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_NonemployeeMember" abstract="true" name="NonemployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" abstract="true" name="CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LoansForgiveninExchangeForShareIssuedAmount" abstract="false" name="LoansForgiveninExchangeForShareIssuedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ExpirationTermThreeMember" abstract="true" name="ExpirationTermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionUpfrontPayment" abstract="false" name="RevenueRecognitionUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherRevenuesAbstract" abstract="true" name="OtherRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" abstract="false" name="PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentAxis" abstract="true" name="AccountsReceivableAllowancesByComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" abstract="false" name="StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="cpix_NetDeferredTaxAssetsGross" abstract="false" name="NetDeferredTaxAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" abstract="false" name="StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ShareRepurchaseProgramAuthorizedIn2010Member" abstract="true" name="ShareRepurchaseProgramAuthorizedIn2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdDomain" abstract="true" name="WinHealthInvestmentSingaporeLtdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_HarbinGloriaPharmaceuticalsCoMember" abstract="true" name="HarbinGloriaPharmaceuticalsCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" abstract="false" name="DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CumberlandEmergingTechnologiesIncMember" abstract="true" name="CumberlandEmergingTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductAndLicenseRightsMember" abstract="true" name="ProductAndLicenseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodAxis" abstract="true" name="ExpirationTimePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FinishedGoodsMember" abstract="true" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionMilestonePayments" abstract="false" name="RevenueRecognitionMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodPricePerShareNewIssues" abstract="false" name="StockIssuedDuringPeriodPricePerShareNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" abstract="false" name="ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeAxis" abstract="true" name="SharesRepurchaseActivityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IntercompanyLoansPayableConvertedAmount" abstract="false" name="IntercompanyLoansPayableConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductRevenuesAbstract" abstract="true" name="ProductRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" abstract="true" name="SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EmploymentAgreementsTextBlock" abstract="false" name="EmploymentAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_CashPaidDuringYearForAbstract" abstract="true" name="CashPaidDuringYearForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ContributionOfCashAdditionalSharesPurchased" abstract="false" name="ContributionOfCashAdditionalSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RevenueRecognitionCumulativeUpfrontPayment" abstract="false" name="RevenueRecognitionCumulativeUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTermFourMember" abstract="true" name="ExpirationTermFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodDomain" abstract="true" name="ExpirationTimePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementLineItems" abstract="true" name="ManufacturingandSupplyAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" abstract="false" name="DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NoncashOrPartNoncashTransactionVestingOfShares" abstract="false" name="NoncashOrPartNoncashTransactionVestingOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FederalAndStateMember" abstract="true" name="FederalAndStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsTextBlock" abstract="false" name="ManufacturingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementTable" abstract="true" name="ManufacturingandSupplyAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" abstract="false" name="DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_InitialPublicOfferingAbstract" abstract="true" name="InitialPublicOfferingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" abstract="false" name="StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ExpirationTermOneMember" abstract="true" name="ExpirationTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductSalesRelatedLiabilitiesCurrent" abstract="false" name="ProductSalesRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NonprincipalOwnerMember" abstract="true" name="NonprincipalOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AccruedPaymentForAssetPurchaseCurrent" abstract="false" name="AccruedPaymentForAssetPurchaseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesInventoryPurchases" abstract="false" name="AccruedLiabilitiesInventoryPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_CommonStockAbstract" abstract="true" name="CommonStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DeferredAcquisitionLiabilityCurrent" abstract="false" name="DeferredAcquisitionLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" abstract="false" name="ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductRightsMember" abstract="true" name="ProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EmployeeNonemployeeandFoundationContributionMember" abstract="true" name="EmployeeNonemployeeandFoundationContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NordicMember" abstract="true" name="NordicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FinancialConsiderationPaymentPeriod" abstract="false" name="FinancialConsiderationPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofDepreciationExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" abstract="false" name="ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ClinigenMember" abstract="true" name="ClinigenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" abstract="false" name="FiniteLivedIntangibleAssetsUsefulLivesTextual" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ExpirationTermTwoMember" abstract="true" name="ExpirationTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" abstract="true" name="WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ThirdAmendmentMember" abstract="true" name="ThirdAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" abstract="true" name="ChargebacksCashDiscountsAndDamagedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInProceedsFromLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>cpix-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50d3390d-ac72-4e43-9256-03373b1625d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50d3390d-ac72-4e43-9256-03373b1625d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c23a3a7-b9bc-4785-9d72-d8db6965c35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c23a3a7-b9bc-4785-9d72-d8db6965c35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0ac49d54-1ef2-460f-980e-a439d1aeccb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0ac49d54-1ef2-460f-980e-a439d1aeccb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9795a2d1-8a3b-4ff3-ab6b-50886b0c49af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_InventoryNet_9795a2d1-8a3b-4ff3-ab6b-50886b0c49af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cef4981-d9d6-4d0b-98ff-fdbd506fe074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cef4981-d9d6-4d0b-98ff-fdbd506fe074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_4e391827-aac4-4452-ac5b-8ddac4c71685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_4e391827-aac4-4452-ac5b-8ddac4c71685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb3d190-0377-46e3-bc48-6834b4fe1547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb3d190-0377-46e3-bc48-6834b4fe1547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f47eb42f-fd5a-45ce-ba11-f1cde4ce0a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_Liabilities_f47eb42f-fd5a-45ce-ba11-f1cde4ce0a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_caf482e3-c00f-415f-af35-283eea5fd2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_caf482e3-c00f-415f-af35-283eea5fd2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b205986d-60a7-4dec-a863-4ac6ac500973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b205986d-60a7-4dec-a863-4ac6ac500973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9886f72-7349-4ea7-8ff8-9e41ac04dfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:to="loc_us-gaap_StockholdersEquity_d9886f72-7349-4ea7-8ff8-9e41ac04dfcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8f935e5d-3428-4c89-a8b6-8e5916dd2912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:to="loc_us-gaap_MinorityInterest_8f935e5d-3428-4c89-a8b6-8e5916dd2912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e71f291-e8a3-488a-82c8-87e9a74e095e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e71f291-e8a3-488a-82c8-87e9a74e095e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b19c0d7-8c2c-4eb8-83e3-c61769c465d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b19c0d7-8c2c-4eb8-83e3-c61769c465d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8a7bebea-438d-4ca7-ad15-7b2596c2fd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8a7bebea-438d-4ca7-ad15-7b2596c2fd86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_32cbd5f1-a4af-4762-8318-1fa964aa9988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_32cbd5f1-a4af-4762-8318-1fa964aa9988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1a943fae-6759-4db9-86a4-a4e64c317ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_AssetsCurrent_1a943fae-6759-4db9-86a4-a4e64c317ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63ff18bc-1a3f-4743-87a4-a7415fe05695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63ff18bc-1a3f-4743-87a4-a7415fe05695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96462b43-8243-40db-8f56-eeaa52903313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96462b43-8243-40db-8f56-eeaa52903313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8a620dbb-e8d9-413f-bd1c-0936f52d2660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_Goodwill_8a620dbb-e8d9-413f-bd1c-0936f52d2660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7d2c5939-a7fb-4f65-8399-3a4ab89e6d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7d2c5939-a7fb-4f65-8399-3a4ab89e6d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3c960195-76ec-40f2-b23b-22d389bd9e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3c960195-76ec-40f2-b23b-22d389bd9e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_308475a8-d07e-4ca8-bdcb-41d44f1a08a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_InventoryNoncurrent_308475a8-d07e-4ca8-bdcb-41d44f1a08a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f612e500-c4c4-48ae-8713-0696ba570c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f612e500-c4c4-48ae-8713-0696ba570c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44667b02-1db0-4075-807e-607cec33af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_44667b02-1db0-4075-807e-607cec33af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_6ce7c9eb-1f74-482c-9fce-9a8119e21506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_LongTermLineOfCredit_6ce7c9eb-1f74-482c-9fce-9a8119e21506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4bd9eb4c-5945-41c3-9bbe-b71edf1dcdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4bd9eb4c-5945-41c3-9bbe-b71edf1dcdb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deb1a007-76d5-44d3-84c1-b06e08618db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deb1a007-76d5-44d3-84c1-b06e08618db8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b70065a-d3f5-46c9-8237-0e0c0340e459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:to="loc_us-gaap_ProfitLoss_0b70065a-d3f5-46c9-8237-0e0c0340e459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12f1ba4f-479d-4ece-996c-d9025ebbd7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12f1ba4f-479d-4ece-996c-d9025ebbd7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c9f6aeb-ecf8-403b-aeba-9bb3a9095b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c9f6aeb-ecf8-403b-aeba-9bb3a9095b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_572d0ac1-ddbd-4b03-af2d-e0ff4360f335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_572d0ac1-ddbd-4b03-af2d-e0ff4360f335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_20879b4a-cd31-4c17-8bf8-b5dcd9763889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_InterestExpense_20879b4a-cd31-4c17-8bf8-b5dcd9763889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a5e5acf1-f41f-4430-b528-a3d246878062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a5e5acf1-f41f-4430-b528-a3d246878062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_06383d05-7a7a-4546-8747-20c7cd499725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_06383d05-7a7a-4546-8747-20c7cd499725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b9db91b3-de1c-427f-aef2-5ca8ac067e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b9db91b3-de1c-427f-aef2-5ca8ac067e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_93c053c3-c4ad-4349-84a8-8496893b540e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_93c053c3-c4ad-4349-84a8-8496893b540e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c80fc06f-85ed-4f9d-b324-010a3de4141b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c80fc06f-85ed-4f9d-b324-010a3de4141b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eec9622d-7bda-4376-8b29-1ce83dfa21fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eec9622d-7bda-4376-8b29-1ce83dfa21fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_328e41af-4392-4aab-ac60-14bfd5df8376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_328e41af-4392-4aab-ac60-14bfd5df8376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a0e4c2f3-5ef8-4759-9159-2a76e1ce837e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:to="loc_us-gaap_CostsAndExpenses_a0e4c2f3-5ef8-4759-9159-2a76e1ce837e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e031b9b4-5519-4023-9cb5-f0d399f50858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:to="loc_us-gaap_Revenues_e031b9b4-5519-4023-9cb5-f0d399f50858" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2da3fb36-857e-48d6-b71c-85c7e014ab2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2da3fb36-857e-48d6-b71c-85c7e014ab2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b970633-3f36-4087-81c5-8d8b6a46c470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b970633-3f36-4087-81c5-8d8b6a46c470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d368be76-d54e-4d14-a408-b22ba9938270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d368be76-d54e-4d14-a408-b22ba9938270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_22b0f166-da34-4546-8a51-5a56dd834156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_22b0f166-da34-4546-8a51-5a56dd834156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c021b31-7952-4822-b6a7-c9e526065d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c021b31-7952-4822-b6a7-c9e526065d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_26ddba9d-48b0-44c0-abb6-2b52a58bc4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_26ddba9d-48b0-44c0-abb6-2b52a58bc4ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd9820f3-cf09-44f0-bad6-906df4f10a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd9820f3-cf09-44f0-bad6-906df4f10a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_01425d2b-3744-49a5-881e-8808c9808e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_01425d2b-3744-49a5-881e-8808c9808e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfa3b159-efb5-4f84-8270-363f08aadd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfa3b159-efb5-4f84-8270-363f08aadd82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_5cd24e3f-ea1d-4287-9159-0dd5b81a29e8" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_5cd24e3f-ea1d-4287-9159-0dd5b81a29e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e4b8eeff-051a-469a-9316-9ea03c7ff4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e4b8eeff-051a-469a-9316-9ea03c7ff4b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_679f293d-4880-4ad5-a217-2dfb06bb0696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_679f293d-4880-4ad5-a217-2dfb06bb0696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_7050053e-401f-482f-9b9a-e3e9b7c9af79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_7050053e-401f-482f-9b9a-e3e9b7c9af79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_3691f812-6a8c-47a0-90bf-d8af4d05ad1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_3691f812-6a8c-47a0-90bf-d8af4d05ad1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_36ad37e5-b751-4982-80a5-731a61e9d58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_36ad37e5-b751-4982-80a5-731a61e9d58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_6716562a-745b-49a2-aa45-e3f60ef20cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_6716562a-745b-49a2-aa45-e3f60ef20cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7febacfd-c383-48c0-a231-9e0b08609f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7febacfd-c383-48c0-a231-9e0b08609f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f340a796-fc0d-4b36-ba10-617aa5e7f9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f340a796-fc0d-4b36-ba10-617aa5e7f9e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6fed93d1-5e7d-443c-91e5-005057274450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6fed93d1-5e7d-443c-91e5-005057274450" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201231.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OrganizationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativ"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_43e328e3-b167-4b44-a72e-3134c0a82c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_43e328e3-b167-4b44-a72e-3134c0a82c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bc64ec2-829a-411c-8e56-6acb0f97541e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:to="loc_us-gaap_Goodwill_8bc64ec2-829a-411c-8e56-6acb0f97541e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6a3d5f76-556b-492f-ab33-4e74a01baf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6a3d5f76-556b-492f-ab33-4e74a01baf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5167ee1b-3e4d-4f97-bdcd-211686612ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5167ee1b-3e4d-4f97-bdcd-211686612ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_998a923a-88eb-451c-98f7-c6aa2efdcb7f" xlink:href="cpix-20201231.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_cpix_PaymentsForContingentConsideration_998a923a-88eb-451c-98f7-c6aa2efdcb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_31ef310e-8019-41cd-8905-b6a8c8e8932d" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_31ef310e-8019-41cd-8905-b6a8c8e8932d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_afc321e0-21d1-4404-8b19-b09e70d567ca" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_afc321e0-21d1-4404-8b19-b09e70d567ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2d67a76b-737f-4deb-a51d-0ade6f4f591f" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2d67a76b-737f-4deb-a51d-0ade6f4f591f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ebba79cc-547c-4cc4-8352-ab367ce74cf7" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ebba79cc-547c-4cc4-8352-ab367ce74cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_21156942-2696-4890-99ac-5321b1182d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_21156942-2696-4890-99ac-5321b1182d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e7865a1e-61c7-4551-a94a-fe604eff1f12" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e7865a1e-61c7-4551-a94a-fe604eff1f12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201231.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7d655ad3-a3e7-4440-ad81-b3bd728a95a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:to="loc_us-gaap_InventoryGross_7d655ad3-a3e7-4440-ad81-b3bd728a95a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_6bbf7a4e-0d8d-452e-978a-74313d27232f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:to="loc_us-gaap_InventoryNoncurrent_6bbf7a4e-0d8d-452e-978a-74313d27232f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8e287a7-6598-4784-9560-0d42aef7696e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8e287a7-6598-4784-9560-0d42aef7696e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_67503536-5499-433a-9794-d296e62ca929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_67503536-5499-433a-9794-d296e62ca929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da02d0da-4f3c-4fee-8de7-d91f9d91b7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da02d0da-4f3c-4fee-8de7-d91f9d91b7ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_89d8deca-7f4f-46a1-afce-cd9f45919b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_89d8deca-7f4f-46a1-afce-cd9f45919b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5385f80a-46df-44f8-b8e9-dc63b5818474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5385f80a-46df-44f8-b8e9-dc63b5818474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd1cccf5-1380-43c6-a72f-7829385f1ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd1cccf5-1380-43c6-a72f-7829385f1ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4bf8bbcf-13f3-416a-813a-099912fb6d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4bf8bbcf-13f3-416a-813a-099912fb6d28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3040394e-e5ab-428e-a365-5a0ad5f59dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3040394e-e5ab-428e-a365-5a0ad5f59dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fb16f7c-2af3-46fd-858a-7a3e12ccfa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fb16f7c-2af3-46fd-858a-7a3e12ccfa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b255d77-4d23-49fd-aab1-a51eede7d417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b255d77-4d23-49fd-aab1-a51eede7d417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d60f64a4-52b2-4d44-a1e6-09e53b74e973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d60f64a4-52b2-4d44-a1e6-09e53b74e973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_4e809626-f62f-42f4-afba-dced5dd97e58" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_4e809626-f62f-42f4-afba-dced5dd97e58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cb783b2a-44ad-4fdd-8e86-d421706c9a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cb783b2a-44ad-4fdd-8e86-d421706c9a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1b440805-3cd8-4e3c-af06-7661144c1fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1b440805-3cd8-4e3c-af06-7661144c1fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_d986ec68-a140-4525-b6c5-9dc78436e8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_d986ec68-a140-4525-b6c5-9dc78436e8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_bfe2e5e3-3481-462c-81f9-2f238630b8e5" xlink:href="cpix-20201231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_bfe2e5e3-3481-462c-81f9-2f238630b8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52b587fd-52de-4648-a9e9-5c5c51547e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52b587fd-52de-4648-a9e9-5c5c51547e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_5a947476-473f-40eb-9661-ab99e2b1f90f" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_5a947476-473f-40eb-9661-ab99e2b1f90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent_c6befacf-c31c-4f4f-b613-c1f373e8c031" xlink:href="cpix-20201231.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_DeferredAcquisitionLiabilityCurrent_c6befacf-c31c-4f4f-b613-c1f373e8c031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_be71fcfe-a652-4280-b73b-bed9695b774a" xlink:href="cpix-20201231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_be71fcfe-a652-4280-b73b-bed9695b774a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_84663d77-5467-43fb-8df4-48a1e9301b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_84663d77-5467-43fb-8df4-48a1e9301b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_087bb988-8f7e-415f-9fab-1897e7adff58" xlink:href="cpix-20201231.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_087bb988-8f7e-415f-9fab-1897e7adff58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201231.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DebtLineofCreditDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41ec51ec-64e0-4cde-8e27-14947848a49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41ec51ec-64e0-4cde-8e27-14947848a49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d0355ecb-70bd-4956-8a63-96442953ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d0355ecb-70bd-4956-8a63-96442953ef41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0347362b-1f61-4a79-a45d-b288943e4b2b" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0347362b-1f61-4a79-a45d-b288943e4b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_39f52234-6ced-4f76-a83a-f67af67389d7" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_39f52234-6ced-4f76-a83a-f67af67389d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_c16808cc-bec7-4ffb-b8ba-cc9771c59f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_c16808cc-bec7-4ffb-b8ba-cc9771c59f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_002399b2-b65f-4b0e-9318-7718547d298a" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_002399b2-b65f-4b0e-9318-7718547d298a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f0775d4a-79cd-4b19-98c4-570d9cd1012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f0775d4a-79cd-4b19-98c4-570d9cd1012c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_1e27218a-164f-4594-a995-b0ec619fdcc7" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_1e27218a-164f-4594-a995-b0ec619fdcc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87b37c21-84e0-47ec-8d43-33265fecb12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87b37c21-84e0-47ec-8d43-33265fecb12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_06e08a79-9d05-42b5-be57-ed1b32f13061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_06e08a79-9d05-42b5-be57-ed1b32f13061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9a110f43-2642-4e5b-8fd8-64873db4ad28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9a110f43-2642-4e5b-8fd8-64873db4ad28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_f15eb1e6-31ef-447c-8240-eadf5cadc2ca" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_f15eb1e6-31ef-447c-8240-eadf5cadc2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe54ddc8-7c4a-4a21-8058-3affe4fb7df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe54ddc8-7c4a-4a21-8058-3affe4fb7df2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46165f65-f664-434e-97b8-6a52a64fa1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46165f65-f664-434e-97b8-6a52a64fa1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4c0db189-4a07-49b6-b77a-7a65d6e6b4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4c0db189-4a07-49b6-b77a-7a65d6e6b4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65b44545-5501-4602-85cb-5dcca28357c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65b44545-5501-4602-85cb-5dcca28357c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_9062ecab-ff9e-49bd-938c-8bb79df4b728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_9062ecab-ff9e-49bd-938c-8bb79df4b728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_058407e9-755e-4ccd-93b3-5b1ea43c198c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_058407e9-755e-4ccd-93b3-5b1ea43c198c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_faaf2bf4-69ce-4a98-9c54-3ff8d07d486c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_faaf2bf4-69ce-4a98-9c54-3ff8d07d486c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f80eb1d8-529b-49b8-b099-155fa1fdfe4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f80eb1d8-529b-49b8-b099-155fa1fdfe4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dfb0a886-15e0-4300-84e0-57f949ca9610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dfb0a886-15e0-4300-84e0-57f949ca9610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_003b4ebd-53bc-49c5-a9cd-12dcac996cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_003b4ebd-53bc-49c5-a9cd-12dcac996cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_55efc703-e413-4ece-bc2f-b9e1cf579984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_55efc703-e413-4ece-bc2f-b9e1cf579984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_fe6b01de-e242-44cd-a2ee-d78e3c28aabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_fe6b01de-e242-44cd-a2ee-d78e3c28aabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73edc1b5-f60f-4dc9-b7c5-dd6d3949ab81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73edc1b5-f60f-4dc9-b7c5-dd6d3949ab81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:href="cpix-20201231.xsd#cpix_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40aa5226-6e20-4910-aa46-9c6e1bb9317e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40aa5226-6e20-4910-aa46-9c6e1bb9317e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3d9acc2-21a1-493a-bbe7-d53e38330922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3d9acc2-21a1-493a-bbe7-d53e38330922" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a1c1ced5-a161-4fb4-a318-d686f602cb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:to="loc_us-gaap_OperatingLeaseLiability_a1c1ced5-a161-4fb4-a318-d686f602cb53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ff0ac6c-2262-422e-9a46-a1ef86860483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ff0ac6c-2262-422e-9a46-a1ef86860483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmploymentAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_82624170-908c-479f-bcfa-3028fb2c9983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_82624170-908c-479f-bcfa-3028fb2c9983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_899d17bd-ed6b-4800-8a24-244296823c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_899d17bd-ed6b-4800-8a24-244296823c50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccounts"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>cpix-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="i48eea3f1657541b0a3a5bf7b83937fdc_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i1c26c74babcb48ad9306a8377efa7afc_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i121cf6daa8784aabb1298c135513fb9c_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended" id="if132c3797726403dbfa51f2485500620_ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_97028044-3878-4a04-98ce-5484a3f41965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:to="loc_us-gaap_Revenues_97028044-3878-4a04-98ce-5484a3f41965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c39b67cb-a8da-4c33-a7e4-a659a6515fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c39b67cb-a8da-4c33-a7e4-a659a6515fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_e13df349-31fa-422e-a256-be52c8e72bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_SellingAndMarketingExpense_e13df349-31fa-422e-a256-be52c8e72bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a079202b-e9f3-4bc3-9db2-17caf1c2f74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a079202b-e9f3-4bc3-9db2-17caf1c2f74f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a7f29bc-e79c-41b2-9928-2f959e134639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a7f29bc-e79c-41b2-9928-2f959e134639" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_36afdbc1-b79e-459b-938c-fcee9c6adf3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_36afdbc1-b79e-459b-938c-fcee9c6adf3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_00659c01-9975-43ea-ae2a-e441f6ca20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_CostsAndExpenses_00659c01-9975-43ea-ae2a-e441f6ca20c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4a76e62-3d93-460c-bb9b-4501403c59f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_OperatingIncomeLoss_b4a76e62-3d93-460c-bb9b-4501403c59f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d9ae8c0d-f4da-41d0-9ace-51984005d1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d9ae8c0d-f4da-41d0-9ace-51984005d1dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dd3d9bc3-0ed4-47eb-a39e-62f1e256c079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_InterestExpense_dd3d9bc3-0ed4-47eb-a39e-62f1e256c079" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d631107-fd73-43d6-b706-35d84d83cd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d631107-fd73-43d6-b706-35d84d83cd61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ea9e508-83e2-4d7d-a3db-c1e5b8e39deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ea9e508-83e2-4d7d-a3db-c1e5b8e39deb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_776d2b62-958d-4a27-aad5-5cd280b23b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_776d2b62-958d-4a27-aad5-5cd280b23b05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_133cd709-a156-411f-811d-0963dacc647e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_133cd709-a156-411f-811d-0963dacc647e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e11462a-3801-40eb-afd4-28b317b4f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_ProfitLoss_0e11462a-3801-40eb-afd4-28b317b4f50e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_470365f8-4ada-4edf-8d66-d33ad648c398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_470365f8-4ada-4edf-8d66-d33ad648c398" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4e04740-0b7f-49e0-8ffb-e5d6dd45e726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_NetIncomeLoss_b4e04740-0b7f-49e0-8ffb-e5d6dd45e726" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c05c10fd-6fcd-4a59-9463-14f1e1e90b45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c05c10fd-6fcd-4a59-9463-14f1e1e90b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46fd2ff8-09c2-4d37-bb90-0d4ba23846da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46fd2ff8-09c2-4d37-bb90-0d4ba23846da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d08f4623-371d-47c2-bb63-e57d3969b6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_EarningsPerShareBasic_d08f4623-371d-47c2-bb63-e57d3969b6a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_27f834d7-ab27-475a-b914-28e052d3ae59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_27f834d7-ab27-475a-b914-28e052d3ae59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_367972cf-d531-4b2a-bc62-8e6438663173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_367972cf-d531-4b2a-bc62-8e6438663173" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_371c31fe-ab2e-44bd-b490-72dee917cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_371c31fe-ab2e-44bd-b490-72dee917cc4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c908f40a-d8f7-431f-b7cb-9e94ae4676b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c908f40a-d8f7-431f-b7cb-9e94ae4676b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03fe7fce-8fc0-40f9-9271-01947706ee9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03fe7fce-8fc0-40f9-9271-01947706ee9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:to="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87a65223-592d-4e4d-8d14-8f73d4b7a776_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:to="loc_srt_ProductsAndServicesDomain_87a65223-592d-4e4d-8d14-8f73d4b7a776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:to="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_491dd531-3c6e-4434-bf2a-ddf45dae61c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:to="loc_us-gaap_ProductMember_491dd531-3c6e-4434-bf2a-ddf45dae61c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_aaa407b9-b396-4c13-8ba1-0766fbe30172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_aaa407b9-b396-4c13-8ba1-0766fbe30172" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i669a2fa2b0e74c6dbad768bd09ab4a5f_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="ibd843061a090485b9d68232b0ac22daa_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06de9eb5-47f1-44fc-92b0-85e8ebf1f571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06de9eb5-47f1-44fc-92b0-85e8ebf1f571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_96c370d3-696f-4727-a896-9cf04356dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_96c370d3-696f-4727-a896-9cf04356dc82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0034dc54-4981-4f47-b956-49ae83517dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NetIncomeLoss_0034dc54-4981-4f47-b956-49ae83517dff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a9f4507-5e83-48c4-be2c-e1db76b1a37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a9f4507-5e83-48c4-be2c-e1db76b1a37c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9771e75-4f5a-4dbc-a08e-a38748733894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_ProfitLoss_d9771e75-4f5a-4dbc-a08e-a38748733894" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8fabe458-691e-4fcc-83e8-ef354b025ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8fabe458-691e-4fcc-83e8-ef354b025ca1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67002b52-4afb-46d4-8e55-2b413d93631a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67002b52-4afb-46d4-8e55-2b413d93631a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4dd4a21d-e20b-41da-82ee-922451a71627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4dd4a21d-e20b-41da-82ee-922451a71627" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40f10509-ad1d-45cf-9128-a66458d3f99a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40f10509-ad1d-45cf-9128-a66458d3f99a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f5ab239f-9348-40f1-bdea-5a98630dd6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f5ab239f-9348-40f1-bdea-5a98630dd6b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e0fd7a6-151d-4b04-98d0-c5a85e800deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e0fd7a6-151d-4b04-98d0-c5a85e800deb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1fc4e7e5-edfd-4671-ac79-31dbda23a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1fc4e7e5-edfd-4671-ac79-31dbda23a6ca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d1dba8ed-a287-44d1-8503-86cd081a00c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d1dba8ed-a287-44d1-8503-86cd081a00c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_24726095-0d0b-47fb-8b71-d817314585c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_24726095-0d0b-47fb-8b71-d817314585c4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5315d074-eb9e-405d-a811-f535c954e958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5315d074-eb9e-405d-a811-f535c954e958" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038860ca-7be1-43b7-bd2c-cdcd2c929fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8365b24c-7185-4395-aa9a-8b22ea5e606e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:to="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40f7a79a-1c2b-4981-8ebc-38d988beda20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:to="loc_us-gaap_EquityComponentDomain_40f7a79a-1c2b-4981-8ebc-38d988beda20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:to="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d34e8c33-d2fd-4c0d-9716-ae93ad418590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_CommonStockMember_d34e8c33-d2fd-4c0d-9716-ae93ad418590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_990f3020-9e50-446f-bf11-f6b32db681ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_RetainedEarningsMember_990f3020-9e50-446f-bf11-f6b32db681ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6ffc19b3-3c15-4cf7-9bac-2c329f9b6e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6ffc19b3-3c15-4cf7-9bac-2c329f9b6e1f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201231.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended" id="i8373dbbc99ff424581745b17d43ecf57_Organization"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="iadffce1af05f45e6a24566f1068fd0fd_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_f5f67904-da13-4a9a-bfc3-24bb3fbefa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_f5f67904-da13-4a9a-bfc3-24bb3fbefa73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_5fac1281-453e-4d1f-b47f-62cd965d2eb5" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_5fac1281-453e-4d1f-b47f-62cd965d2eb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_46cc4b35-af16-44c3-a91c-34c81ed412ef" xlink:href="cpix-20201231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_46cc4b35-af16-44c3-a91c-34c81ed412ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_a40547e5-b3b8-480d-886a-77a2bab6c1a6" xlink:href="cpix-20201231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_a40547e5-b3b8-480d-886a-77a2bab6c1a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_1e5562eb-2728-47be-8a45-6bb60d4657f6" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_1e5562eb-2728-47be-8a45-6bb60d4657f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0cf5d69f-e1b7-41e6-b508-1a2a320f5797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0cf5d69f-e1b7-41e6-b508-1a2a320f5797" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f275480f-002e-414d-ba70-7d1cda1f5f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f275480f-002e-414d-ba70-7d1cda1f5f79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:to="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2fb26d7-ec55-4ae1-b764-d7f255cffb50_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:to="loc_dei_EntityDomain_e2fb26d7-ec55-4ae1-b764-d7f255cffb50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:to="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_ecb70fa5-1d04-434c-ad4b-294b7f976754" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_ecb70fa5-1d04-434c-ad4b-294b7f976754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b98552f-dd6a-4c8e-8d84-5e95d204fd16_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b98552f-dd6a-4c8e-8d84-5e95d204fd16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c32f6e0e-c65e-41c6-9821-b02d85f579ba" xlink:href="cpix-20201231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c32f6e0e-c65e-41c6-9821-b02d85f579ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_cf5ba650-091d-4a11-b4b9-6c98c84417b4" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_cf5ba650-091d-4a11-b4b9-6c98c84417b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_48ba2c06-cd10-4c53-a85e-badb8e69702a" xlink:href="cpix-20201231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_48ba2c06-cd10-4c53-a85e-badb8e69702a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:to="loc_srt_OwnershipDomain_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:to="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_d746bd84-e07c-4de9-ab21-ebfd2cd60cff" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_d746bd84-e07c-4de9-ab21-ebfd2cd60cff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended" id="i3e595977f89c41ae922d99f077f02652_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i820c05712b194d22a480d8bb144a84b0_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" id="icda0024a9d4c4ef19fc2283923aeb65f_SignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i2b22d6dc74ad499dabc74a5faf5a420d_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3f51f956-ac82-4854-af6f-d1c5de5e4154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3f51f956-ac82-4854-af6f-d1c5de5e4154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_12c45cb4-15f9-458c-a95d-20f6a6fb827f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_Revenues_12c45cb4-15f9-458c-a95d-20f6a6fb827f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2406d255-b41a-4a42-9e48-17e344db4d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2406d255-b41a-4a42-9e48-17e344db4d13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed35ef98-b647-4f49-8bf2-c18ce9241a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed35ef98-b647-4f49-8bf2-c18ce9241a69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b75f9e22-0e99-48cf-9170-689c2438c247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_OperatingLeaseLiability_b75f9e22-0e99-48cf-9170-689c2438c247" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_21cd8b69-ed94-41be-a13e-c4291007c44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_21cd8b69-ed94-41be-a13e-c4291007c44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_fa56b1a5-9a83-45a0-8a47-8d554e0556f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_AdvertisingExpense_fa56b1a5-9a83-45a0-8a47-8d554e0556f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_bfc5ceff-5c3f-48d2-bcde-5d593780c8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_bfc5ceff-5c3f-48d2-bcde-5d593780c8e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a552e9b3-130b-4fa7-abb4-6ea3652bf614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a552e9b3-130b-4fa7-abb4-6ea3652bf614" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b7f90f6-ed25-4ee9-b13e-53d3c0815830_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:to="loc_srt_SegmentGeographicalDomain_3b7f90f6-ed25-4ee9-b13e-53d3c0815830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:to="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bd6d00b9-7957-495e-819d-e764cbf31b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:to="loc_us-gaap_NonUsMember_bd6d00b9-7957-495e-819d-e764cbf31b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_82f487b9-9916-4b1b-bda9-9999f98e017a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_82f487b9-9916-4b1b-bda9-9999f98e017a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda999d7-631f-496d-a7f9-8f448224f5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:to="loc_us-gaap_SubsequentEventMember_dda999d7-631f-496d-a7f9-8f448224f5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8c328f5-1702-416e-97b0-21c258db9eb8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:to="loc_srt_RangeMember_c8c328f5-1702-416e-97b0-21c258db9eb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:to="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0ef0dd45-037f-4521-a11f-f7d37a2e303f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:to="loc_srt_MinimumMember_0ef0dd45-037f-4521-a11f-f7d37a2e303f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b515d902-48b0-44f9-ac03-6e58bdf879db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:to="loc_srt_MaximumMember_b515d902-48b0-44f9-ac03-6e58bdf879db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_f77eb379-db6b-42af-a573-0718e6854035_default" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_f77eb379-db6b-42af-a573-0718e6854035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_9ed91f1b-48f1-4805-a3c4-c86675d5e9f5" xlink:href="cpix-20201231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_9ed91f1b-48f1-4805-a3c4-c86675d5e9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_0388ad1c-8ac0-4287-889f-c11d0a21ee8e" xlink:href="cpix-20201231.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_0388ad1c-8ac0-4287-889f-c11d0a21ee8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended" id="i9f7941fec06e416a9949dafab7d4999a_SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_cba119a2-2ef3-448d-8d49-f7f9ba6c2d65" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_cba119a2-2ef3-448d-8d49-f7f9ba6c2d65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_dd57cd98-6c88-4195-ac99-90b80a17d8ef" xlink:href="cpix-20201231.xsd#cpix_ProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_cpix_ProductRightsMember_dd57cd98-6c88-4195-ac99-90b80a17d8ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_269841f5-7d91-4325-8784-4a60713078bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_us-gaap_LicensingAgreementsMember_269841f5-7d91-4325-8784-4a60713078bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_35338164-af5c-4a49-a12e-149e3ccb9322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_us-gaap_PatentsMember_35338164-af5c-4a49-a12e-149e3ccb9322" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativ"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="extended" id="i3f25ab37895c423cbabf7b354e36193d_RediTrexandVibativ"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="extended" id="i7a5809c54bc04a15bf9209987ed172ea_RediTrexandVibativTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="extended" id="idc99c9b0cb3a45bb98d10ec316759553_RediTrexandVibativNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb03caf-84a6-45a2-836e-1302dddf5e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb03caf-84a6-45a2-836e-1302dddf5e99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2e58f79d-b514-49ed-98e7-2a1a4bb75953" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2e58f79d-b514-49ed-98e7-2a1a4bb75953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_16f69dcd-a18a-4569-89fe-4d304e9f77ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_16f69dcd-a18a-4569-89fe-4d304e9f77ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d062f651-9e73-4ab8-ade7-cbbd5777f316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d062f651-9e73-4ab8-ade7-cbbd5777f316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e91ba94d-74b6-4321-bee4-c8aace86e5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e91ba94d-74b6-4321-bee4-c8aace86e5ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2a873e4e-3a3c-4bb7-a0b5-9c2a19907e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2a873e4e-3a3c-4bb7-a0b5-9c2a19907e06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ad813ed-8af2-4bcf-8e26-18d9480fe380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ad813ed-8af2-4bcf-8e26-18d9480fe380" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20f27c09-cfb7-433c-bd60-e2d788efab82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20f27c09-cfb7-433c-bd60-e2d788efab82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7d6941ba-69c1-4542-996c-8de774c29fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_Revenues_7d6941ba-69c1-4542-996c-8de774c29fc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ac78d6d-447f-41c4-bdc8-64b18663ed18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ac78d6d-447f-41c4-bdc8-64b18663ed18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a798c3f-0c7a-4585-a275-304f08f009eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:to="loc_us-gaap_RestrictedStockMember_7a798c3f-0c7a-4585-a275-304f08f009eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ad07aa6-c644-4b80-943f-4c7221a213ef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:to="loc_srt_ProductsAndServicesDomain_8ad07aa6-c644-4b80-943f-4c7221a213ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:to="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_03e4f925-5ecf-485b-965b-eaf1cee6ab4c" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:to="loc_cpix_OmeclamoxPakMember_03e4f925-5ecf-485b-965b-eaf1cee6ab4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88d29ffb-851d-4586-9313-bf8d502d259c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88d29ffb-851d-4586-9313-bf8d502d259c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_80b3eed6-c14f-449f-b63e-537c4a39b2ce" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:to="loc_cpix_OmeclamoxPakMember_80b3eed6-c14f-449f-b63e-537c4a39b2ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_58f7d913-d3e7-47f3-a09c-a1dfbd949317" xlink:href="cpix-20201231.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:to="loc_cpix_MethotrexateMember_58f7d913-d3e7-47f3-a09c-a1dfbd949317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_888ef674-a0bb-4e97-86a0-1f1b207f389b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:to="loc_srt_RangeMember_888ef674-a0bb-4e97-86a0-1f1b207f389b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:to="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be8f00b3-53b2-4fbe-b999-a70b53e73fe6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:to="loc_srt_MinimumMember_be8f00b3-53b2-4fbe-b999-a70b53e73fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c26828c-c887-49bc-b96c-5becbe6a2762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:to="loc_srt_MaximumMember_9c26828c-c887-49bc-b96c-5becbe6a2762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ac08660f-0e62-484c-abef-03fa7e9164c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:to="loc_us-gaap_SubsequentEventMember_ac08660f-0e62-484c-abef-03fa7e9164c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40932935-527d-4a25-934a-7704b0742eb6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40932935-527d-4a25-934a-7704b0742eb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_c21aa989-2af2-4d66-94a4-e1cb3c62d388" xlink:href="cpix-20201231.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:to="loc_cpix_NordicGroupBVMember_c21aa989-2af2-4d66-94a4-e1cb3c62d388" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended" id="i5b7d0de0fe7b43e58d4a826be4712462_RediTrexandVibativVibativAcquisitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_756945c1-5e0e-4912-9393-f514df77bb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_756945c1-5e0e-4912-9393-f514df77bb9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_2321261a-dec0-46a6-bbe1-87c679099258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_2321261a-dec0-46a6-bbe1-87c679099258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_39a59fdf-a21b-448e-b3a9-ffa9c6e00864" xlink:href="cpix-20201231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_39a59fdf-a21b-448e-b3a9-ffa9c6e00864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_50864fbb-1045-4765-8b5d-cb62b676455d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_50864fbb-1045-4765-8b5d-cb62b676455d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92c0cb70-f8f1-4d22-87d1-b21374c295e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92c0cb70-f8f1-4d22-87d1-b21374c295e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4519204d-efe5-4258-af6d-0766601861ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4519204d-efe5-4258-af6d-0766601861ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6aae4201-6f5e-4278-98f1-3379cf2b6151" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:to="loc_cpix_VIBATIVMember_6aae4201-6f5e-4278-98f1-3379cf2b6151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_22df7686-cccc-498d-94b8-eaad44c9f35e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_22df7686-cccc-498d-94b8-eaad44c9f35e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b7536c4-7523-4f28-ae1a-c03a3080d222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:to="loc_us-gaap_SubsequentEventMember_5b7536c4-7523-4f28-ae1a-c03a3080d222" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended" id="ifce42316dc924f3fa2c07db6fdcc97e7_RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8b3b463-a4a4-48c1-9380-53f312118bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8b3b463-a4a4-48c1-9380-53f312118bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f0734c78-6806-4889-b2f3-b73c2748ab59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f0734c78-6806-4889-b2f3-b73c2748ab59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_cc9d4542-9e69-4fbb-8ff9-61113e08d469" xlink:href="cpix-20201231.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_PaymentsForContingentConsideration_cc9d4542-9e69-4fbb-8ff9-61113e08d469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_303e295e-731a-401f-a7aa-5b09cf276169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_303e295e-731a-401f-a7aa-5b09cf276169" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5143ad08-0cd1-4824-98e2-495fe4c2b478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5143ad08-0cd1-4824-98e2-495fe4c2b478" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74cde330-e01d-47d7-94a0-23352cba1f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74cde330-e01d-47d7-94a0-23352cba1f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7203baf9-0b14-46e7-b9c0-97ec266c7f65" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7203baf9-0b14-46e7-b9c0-97ec266c7f65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_39f5b5ed-fbbb-4807-a021-60d8d446e9dd" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_39f5b5ed-fbbb-4807-a021-60d8d446e9dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_a30eb6c2-3caf-459c-af61-c9789da13012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_PaymentsForRoyalties_a30eb6c2-3caf-459c-af61-c9789da13012" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39de276e-ed68-4420-a6a1-a42123116530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_bb6dd18a-2be2-4d41-8877-9ea302a44948" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_bb6dd18a-2be2-4d41-8877-9ea302a44948" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_49fe1dd5-c427-4d6b-8bb5-ec85701eb242" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_49fe1dd5-c427-4d6b-8bb5-ec85701eb242" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_cd73178f-b602-41a7-98f0-b65872024da8" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_cd73178f-b602-41a7-98f0-b65872024da8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_a8132d3b-cc80-4cac-a834-c1c89020fcb3" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_a8132d3b-cc80-4cac-a834-c1c89020fcb3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7ef9b3-87e5-483d-851c-806f3bfe2800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7ef9b3-87e5-483d-851c-806f3bfe2800" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_df2fb81d-9424-42db-8821-7abcb1357659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_df2fb81d-9424-42db-8821-7abcb1357659" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e2ba3e36-7532-4a3e-9d9e-7ef25e69d57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_Goodwill_e2ba3e36-7532-4a3e-9d9e-7ef25e69d57a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d2a39249-bd60-4ce5-90d6-06c19e1d6f0c" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d2a39249-bd60-4ce5-90d6-06c19e1d6f0c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2e2c243d-0bea-4be8-95f4-5229e6fa6db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2e2c243d-0bea-4be8-95f4-5229e6fa6db1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_629d0587-3009-4c36-ac09-d7532174a6ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_629d0587-3009-4c36-ac09-d7532174a6ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_ddbaaa1d-e78e-46f7-9aa2-25896346ded9" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:to="loc_cpix_VIBATIVMember_ddbaaa1d-e78e-46f7-9aa2-25896346ded9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201231.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="i43963e23ad754f45835616bd0bbfd9d1_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="i2ada64edde3a48d192e649e932121487_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended" id="ib0c2e5ee3b79486daf10d3eb75b7a88d_RevenuesScheduleofNetProductRevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_259a0d4f-27c4-4777-a756-f56188e4fa69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_259a0d4f-27c4-4777-a756-f56188e4fa69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:to="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70f6a2e4-5599-48dc-a85e-559a37a41f91_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:to="loc_srt_ProductsAndServicesDomain_70f6a2e4-5599-48dc-a85e-559a37a41f91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:to="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_9d68b6d4-5789-4baa-a2cc-ef77cdb74a01" xlink:href="cpix-20201231.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_KristaloseMember_9d68b6d4-5789-4baa-a2cc-ef77cdb74a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_8dc8cca8-a0a6-4617-8dfd-1393f83b1536" xlink:href="cpix-20201231.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_CaldolorMember_8dc8cca8-a0a6-4617-8dfd-1393f83b1536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_846e0a99-127c-4799-9e94-9815b312e18e" xlink:href="cpix-20201231.xsd#cpix_ProductVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_ProductVibativMember_846e0a99-127c-4799-9e94-9815b312e18e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_4351fb26-6578-48c7-8c87-6e5fabaac482" xlink:href="cpix-20201231.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_AcetadoteMember_4351fb26-6578-48c7-8c87-6e5fabaac482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_7094a3d9-681b-4bb9-8c98-64ba0acffacf" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_OmeclamoxPakMember_7094a3d9-681b-4bb9-8c98-64ba0acffacf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_6cb095d0-f036-4948-8ed2-50d77789dc7b" xlink:href="cpix-20201231.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_VaprisolMember_6cb095d0-f036-4948-8ed2-50d77789dc7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_8c889ba1-cdea-4dab-9961-112672f892e8" xlink:href="cpix-20201231.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_RediTrexMember_8c889ba1-cdea-4dab-9961-112672f892e8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i33280b2b1dd84e20a6667afd13262f40_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:href="cpix-20201231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:to="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbf10cd4-1547-4d0c-9023-f0c8e57f223e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbf10cd4-1547-4d0c-9023-f0c8e57f223e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:href="cpix-20201231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:to="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_1261edf2-acd7-4ed1-99fa-1090f47eff06" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_1261edf2-acd7-4ed1-99fa-1090f47eff06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_aac1ad49-cab2-4741-8400-41c1519c2b06" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_aac1ad49-cab2-4741-8400-41c1519c2b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_7cb5f455-31fa-4a8e-8214-a57553978651" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_7cb5f455-31fa-4a8e-8214-a57553978651" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_e6ceefdb-11cf-4fde-90b9-a034c85df29f" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_e6ceefdb-11cf-4fde-90b9-a034c85df29f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_ffed4689-31a3-438a-86bf-fb9040cbf152" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_ffed4689-31a3-438a-86bf-fb9040cbf152" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93bb910a-b40b-4d4d-bfe3-90ad714a9249_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93bb910a-b40b-4d4d-bfe3-90ad714a9249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_d70e5384-b312-4d33-b39f-6978d5fb9c25" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_d70e5384-b312-4d33-b39f-6978d5fb9c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d4348ad-deec-4a53-ba16-aa534347d2c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d4348ad-deec-4a53-ba16-aa534347d2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_0ca332ce-aa83-4fe6-b79a-3bf37fbea8da" xlink:href="cpix-20201231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_0ca332ce-aa83-4fe6-b79a-3bf37fbea8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:to="loc_srt_ProductsAndServicesDomain_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:to="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_330d7a8a-01c9-4a06-a43b-176df6cdcb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:to="loc_us-gaap_GrantMember_330d7a8a-01c9-4a06-a43b-176df6cdcb8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201231.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="ib30e916c92f745d6b3d0f447cb2c282f_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i96b7ce281a1d44299c02cbf3e64a9611_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="i0e0a28fa63a941788e6108f21fd5a042_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i014fbb6abef24b9dabb33c368109b4ce_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8c48ccff-e3af-445b-aa6e-a2ffaadb22ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:to="loc_us-gaap_InventoryValuationReserves_8c48ccff-e3af-445b-aa6e-a2ffaadb22ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8d3f6d8f-22e9-4a48-92b2-7b40fec14074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:to="loc_us-gaap_InventoryNoncurrent_8d3f6d8f-22e9-4a48-92b2-7b40fec14074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:to="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99d2e860-4870-4ef7-a274-fa2101060d17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99d2e860-4870-4ef7-a274-fa2101060d17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d980369f-7256-42ec-afec-b04ea131febe" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:to="loc_cpix_VIBATIVMember_d980369f-7256-42ec-afec-b04ea131febe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_147f53ad-9a25-4659-b277-25697f1648d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_147f53ad-9a25-4659-b277-25697f1648d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember_3ba296c2-2241-4e45-93bc-0ab11258714d" xlink:href="cpix-20201231.xsd#cpix_FinishedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:to="loc_cpix_FinishedGoodsMember_3ba296c2-2241-4e45-93bc-0ab11258714d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_520800ef-2519-490c-8d37-79856a0e2638" xlink:href="cpix-20201231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:to="loc_cpix_IfetrobanClinicalMember_520800ef-2519-490c-8d37-79856a0e2638" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended" id="i07a0448c632a43f7bd1bd8e27f32beb5_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i9cc084c392a34207be22dc2a91033036_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="iba152d3d3df1445db471a84e499c5bd6_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f3c5a322-954d-48e6-90ac-856785e3dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f3c5a322-954d-48e6-90ac-856785e3dd8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a495011f-f5e2-48ad-ace3-6f78b7709b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a495011f-f5e2-48ad-ace3-6f78b7709b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e7300c3-2f22-4bae-804f-c7ae6f6f9da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e7300c3-2f22-4bae-804f-c7ae6f6f9da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_598cf832-7aae-4589-b4d2-690fd9888cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_598cf832-7aae-4589-b4d2-690fd9888cfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_115dea45-848c-475f-a4a5-ce405597c52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_115dea45-848c-475f-a4a5-ce405597c52d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_33f06e96-8c8d-4977-9c2e-d4d25ac72e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_OfficeEquipmentMember_33f06e96-8c8d-4977-9c2e-d4d25ac72e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a311ae40-4227-42f3-8a25-2284e89adf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a311ae40-4227-42f3-8a25-2284e89adf77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_175028c8-cdc7-477c-8f4d-d56fef3f6ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_175028c8-cdc7-477c-8f4d-d56fef3f6ea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:to="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26eaa195-9911-476b-849f-f0fd8e237861_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:to="loc_srt_RangeMember_26eaa195-9911-476b-849f-f0fd8e237861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:to="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4461391c-b85a-44af-8dd6-c8c85b3ba387" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:to="loc_srt_MinimumMember_4461391c-b85a-44af-8dd6-c8c85b3ba387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdaa57ac-41ca-4c3a-bdca-1a3070086a03" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:to="loc_srt_MaximumMember_fdaa57ac-41ca-4c3a-bdca-1a3070086a03" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended" id="i11621685d5aa4fa1aab882092f3233c0_PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended" id="i58548be7f1354f7bbb1dd292bf43064d_IntangibleAssets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended" id="i38223046e7e0488288fe5e9bc09e8370_IntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i9b0729782c2e4ebbb0a4a4218fdbb984_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0c87d21f-dcf5-4f1b-b0dd-e2b0dccdf6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0c87d21f-dcf5-4f1b-b0dd-e2b0dccdf6ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f3cbbc4b-c9df-463f-9f14-cb7e1de08e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f3cbbc4b-c9df-463f-9f14-cb7e1de08e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_53379068-d40e-481d-b0f0-b5788e58ef0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_53379068-d40e-481d-b0f0-b5788e58ef0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6b88ebff-7097-4f0e-8dce-70c141a11122_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6b88ebff-7097-4f0e-8dce-70c141a11122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_69cb5bf4-eb6a-4777-942d-18c1497d6132" xlink:href="cpix-20201231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_cpix_ProductAndLicenseRightsMember_69cb5bf4-eb6a-4777-942d-18c1497d6132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a371ad6a-b68f-4dec-ad2d-e0379a2019c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_us-gaap_PatentsMember_a371ad6a-b68f-4dec-ad2d-e0379a2019c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_94eef24e-9611-4307-9206-38d0d983f1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_us-gaap_TrademarksMember_94eef24e-9611-4307-9206-38d0d983f1e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" id="i5e2040aa8b5143cf881c7b3f5b0afc62_IntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8d181565-4bdd-4041-8ebf-ee0c087e1311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_Goodwill_8d181565-4bdd-4041-8ebf-ee0c087e1311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_656eeffb-ea5a-4234-b3bd-cb2bb589e4ba" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_656eeffb-ea5a-4234-b3bd-cb2bb589e4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_34787a69-3e7d-4244-b141-cc03dfa54aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_34787a69-3e7d-4244-b141-cc03dfa54aa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3a9ea5c4-c152-426a-9f0f-0ff3bb5115b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3a9ea5c4-c152-426a-9f0f-0ff3bb5115b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f6fdbb24-8c52-4c16-9b50-7e9a1260db36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f6fdbb24-8c52-4c16-9b50-7e9a1260db36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b709f2db-cb21-4a7b-88cf-34a22cd16df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b709f2db-cb21-4a7b-88cf-34a22cd16df7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2e8f30a2-d065-413b-87c7-824bf3cc3120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2e8f30a2-d065-413b-87c7-824bf3cc3120" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5bc35cb5-846f-414b-b520-a2693f3dc53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5bc35cb5-846f-414b-b520-a2693f3dc53e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_55a606d0-a4b0-450a-a7f8-859d31b97057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_55a606d0-a4b0-450a-a7f8-859d31b97057" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ebdcb60b-db6d-48fd-b320-554408b507ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ebdcb60b-db6d-48fd-b320-554408b507ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:to="loc_dei_EntityDomain_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:to="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_1a3f5e7c-39ea-46a0-b7fe-04d06f056a30" xlink:href="cpix-20201231.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:to="loc_cpix_VaprisolMember_1a3f5e7c-39ea-46a0-b7fe-04d06f056a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84a18ade-5ed6-4922-8d6c-2c0f804fc54b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84a18ade-5ed6-4922-8d6c-2c0f804fc54b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_0d956542-7b57-4b48-a37a-f14bedfe5f5b" xlink:href="cpix-20201231.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:to="loc_cpix_MethotrexateMember_0d956542-7b57-4b48-a37a-f14bedfe5f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_b1c606d1-6c23-437e-9816-99157b6f6709" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:to="loc_cpix_VIBATIVMember_b1c606d1-6c23-437e-9816-99157b6f6709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f4b53af-0980-4502-9f56-e9c4ac8db120_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f4b53af-0980-4502-9f56-e9c4ac8db120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_faba81f5-6268-46ce-a7f2-a06737478e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:to="loc_us-gaap_RestrictedStockMember_faba81f5-6268-46ce-a7f2-a06737478e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24915fde-740c-4589-909b-da0b109a88b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:to="loc_srt_ProductsAndServicesDomain_24915fde-740c-4589-909b-da0b109a88b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:to="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_1e16f118-2770-4839-8c05-ad250c1b4a6f" xlink:href="cpix-20201231.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:to="loc_cpix_KristaloseMember_1e16f118-2770-4839-8c05-ad250c1b4a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_3e11a7ff-2d4d-46c0-9b75-a6e612c32db9" xlink:href="cpix-20201231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:to="loc_cpix_ProductAndLicenseRightsMember_3e11a7ff-2d4d-46c0-9b75-a6e612c32db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_4d8fd007-f86a-49ba-b927-d1a78b5aca0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:to="loc_us-gaap_PatentsMember_4d8fd007-f86a-49ba-b927-d1a78b5aca0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b49c97d2-b844-45a2-ba35-db389bac14f4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b49c97d2-b844-45a2-ba35-db389bac14f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_ff119e59-0565-4908-b147-0d2fb1cd643b" xlink:href="cpix-20201231.xsd#cpix_NordicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:to="loc_cpix_NordicMember_ff119e59-0565-4908-b147-0d2fb1cd643b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended" id="i9c09ccef9bf245d9b9cfc2be57122bf1_IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended" id="i4c2dd374c97745ea8c215c411e1b09c3_OtherCurrentandOtherLongtermLiabilities"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended" id="i420dc46e6fe146a7b652cad53d9fb6c3_OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended" id="ib7f6b9c79063474b81c381ebb5c05a8e_OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201231.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended" id="i3917039079f04252ba48af8792e6edaa_Debt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DebtLineofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended" id="i70194786d06047b986f0a230c882f046_DebtLineofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0a699d70-35ce-4c25-b10c-d4e3aa6cf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0a699d70-35ce-4c25-b10c-d4e3aa6cf387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2db8c3da-d14f-42c9-b844-a253b07102d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2db8c3da-d14f-42c9-b844-a253b07102d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_29ffbfab-3b2a-4dcc-9250-85f7334a5b28" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_29ffbfab-3b2a-4dcc-9250-85f7334a5b28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_1e0c1f53-3200-4220-9393-150e9e889d9c" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_1e0c1f53-3200-4220-9393-150e9e889d9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_a836bda9-d51d-4739-b387-bf2ae1574183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LongTermLineOfCredit_a836bda9-d51d-4739-b387-bf2ae1574183" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05266b4f-ab81-4280-a522-ec47f7afe786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05266b4f-ab81-4280-a522-ec47f7afe786" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ede2c596-dae7-4399-9c1d-faea4fe904b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ede2c596-dae7-4399-9c1d-faea4fe904b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d56af0cc-3b71-49ab-8067-4d9ca736ea89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d56af0cc-3b71-49ab-8067-4d9ca736ea89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_fc6190b9-575a-41fe-969a-e2d531dfcd9c" xlink:href="cpix-20201231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_fc6190b9-575a-41fe-969a-e2d531dfcd9c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9812cbbb-1720-49d4-bd1e-95f182005213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:to="loc_us-gaap_CreditFacilityDomain_9812cbbb-1720-49d4-bd1e-95f182005213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:to="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8914db26-acc9-40c1-b715-71268d42e89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8914db26-acc9-40c1-b715-71268d42e89a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_c745a908-f739-4326-bd17-b8f4dc5def8a" xlink:href="cpix-20201231.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:to="loc_cpix_PinnacleBankMember_c745a908-f739-4326-bd17-b8f4dc5def8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af8b814b-290c-4890-bcba-36c63bf28e96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af8b814b-290c-4890-bcba-36c63bf28e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ThirdAmendmentMember_13937cf6-c84c-40e1-b08b-04f04a4c7880" xlink:href="cpix-20201231.xsd#cpix_ThirdAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_cpix_ThirdAmendmentMember_13937cf6-c84c-40e1-b08b-04f04a4c7880" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_c0838273-c78f-4856-ac47-5422504c43e1" xlink:href="cpix-20201231.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_cpix_SecondAmendmentMember_c0838273-c78f-4856-ac47-5422504c43e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fe00f851-bd60-469f-971f-a749e709c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_us-gaap_LineOfCreditMember_fe00f851-bd60-469f-971f-a749e709c1b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_508b75f9-1a00-49d4-806f-173c111542e1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:to="loc_srt_RangeMember_508b75f9-1a00-49d4-806f-173c111542e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:to="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_484f33ec-eec7-4089-840c-e1c28627bd4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:to="loc_srt_MinimumMember_484f33ec-eec7-4089-840c-e1c28627bd4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d279e190-1303-4775-b1ef-ca2dded3818e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:to="loc_srt_MaximumMember_d279e190-1303-4775-b1ef-ca2dded3818e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_61fce1e0-ed2a-4eb1-8621-d9250e1057a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:to="loc_us-gaap_VariableRateDomain_61fce1e0-ed2a-4eb1-8621-d9250e1057a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:to="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f7ab1591-d6b0-47cc-82b0-0c0f631be765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f7ab1591-d6b0-47cc-82b0-0c0f631be765" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended" id="icd54f803ede544db8e82b08d90bf1ef6_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended" id="ie76028233475479384fc480f1b7d393e_ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:href="cpix-20201231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_ab2aabb8-49e6-4fd4-9003-d97692681f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_ab2aabb8-49e6-4fd4-9003-d97692681f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a688da9-72fd-4485-999b-69eb0276a078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a688da9-72fd-4485-999b-69eb0276a078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_d8e61be9-e88c-4e36-b121-2d31ad197310" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_d8e61be9-e88c-4e36-b121-2d31ad197310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_32902ba9-f948-47b6-9d66-07cf1f87b720" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_32902ba9-f948-47b6-9d66-07cf1f87b720" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a8e96d1c-0ae3-4f3a-bbe3-d62560f608d9" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a8e96d1c-0ae3-4f3a-bbe3-d62560f608d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6c7abd97-47a6-4a88-9445-011a5dc98513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6c7abd97-47a6-4a88-9445-011a5dc98513" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6fd06c0e-7f1b-4b15-8a99-d20a922432a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6fd06c0e-7f1b-4b15-8a99-d20a922432a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1895218c-ea4f-46a2-b72b-3fa67acb8db1" xlink:href="cpix-20201231.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1895218c-ea4f-46a2-b72b-3fa67acb8db1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:href="cpix-20201231.xsd#cpix_PreferredStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bbb3d3d7-4d3e-427a-ab3d-b05786f7dd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bbb3d3d7-4d3e-427a-ab3d-b05786f7dd16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2204ab98-bfcc-452e-b475-e9decbfa8cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2204ab98-bfcc-452e-b475-e9decbfa8cca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:href="cpix-20201231.xsd#cpix_CommonStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ff7ff61-822e-4bbe-8303-1524ab3bea5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ff7ff61-822e-4bbe-8303-1524ab3bea5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_640e5abf-c960-4140-8704-55b8223a65c4" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_640e5abf-c960-4140-8704-55b8223a65c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4506e92a-724f-4184-ac86-9441c4aa3dcd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:to="loc_us-gaap_EquityComponentDomain_4506e92a-724f-4184-ac86-9441c4aa3dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:to="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_09e72ac1-ff5e-4ecb-b193-76b4bbef682c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:to="loc_us-gaap_CommonStockMember_09e72ac1-ff5e-4ecb-b193-76b4bbef682c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8117c230-bd62-4dc9-b421-b4b884bdc62e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:to="loc_us-gaap_ClassOfStockDomain_8117c230-bd62-4dc9-b421-b4b884bdc62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:to="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_98d7801c-f942-46c5-8bc4-2745186bf403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:to="loc_us-gaap_CommonStockMember_98d7801c-f942-46c5-8bc4-2745186bf403" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended" id="idb7a4cb848c64ee384573314e1990873_ShareholdersEquityWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fab284c8-333a-4648-b593-2f11fe5241ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fab284c8-333a-4648-b593-2f11fe5241ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df3a7191-e45e-4527-b14a-6b1097029117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df3a7191-e45e-4527-b14a-6b1097029117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a35ddf53-8a1b-48d2-bcb3-50f8f2378299_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a35ddf53-8a1b-48d2-bcb3-50f8f2378299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_f26d609b-eaf3-4c14-ae26-65c0ca4f9e17" xlink:href="cpix-20201231.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_f26d609b-eaf3-4c14-ae26-65c0ca4f9e17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended" id="icdc9bbd27b7d4a98a21baeb117a9a28f_ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9f9e1581-fc44-4595-a315-0044b17e9e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9f9e1581-fc44-4595-a315-0044b17e9e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ae7c82a0-65c2-4459-a2e2-cb7d39997438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ae7c82a0-65c2-4459-a2e2-cb7d39997438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_8c6bd28b-2bbd-48ce-a075-f3f671004b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_8c6bd28b-2bbd-48ce-a075-f3f671004b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a0ecd296-ef2a-4cf9-a26b-0a6d4c5124e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a0ecd296-ef2a-4cf9-a26b-0a6d4c5124e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_73130a50-9269-4753-9abd-4d219137686d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_73130a50-9269-4753-9abd-4d219137686d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d7a17d5d-d449-47cd-9729-81d4eb5c8132" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d7a17d5d-d449-47cd-9729-81d4eb5c8132" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_96b7695c-7640-4390-8590-041c3045ff93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_96b7695c-7640-4390-8590-041c3045ff93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_057c7b10-28c1-4b8d-a9a5-f142f75299fc" xlink:href="cpix-20201231.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_057c7b10-28c1-4b8d-a9a5-f142f75299fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_891c4970-e2a2-4475-adfc-322d6ac6a052" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_891c4970-e2a2-4475-adfc-322d6ac6a052" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8648c5a2-24bf-4f82-81ec-b89396a543d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8648c5a2-24bf-4f82-81ec-b89396a543d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8cc760a6-0d27-4afb-a226-7da585410bca" xlink:href="cpix-20201231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8cc760a6-0d27-4afb-a226-7da585410bca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_b37c69a4-f628-4011-9d6d-68c7718749ff" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_b37c69a4-f628-4011-9d6d-68c7718749ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_700881e2-f38b-4db8-a17d-9d58bd9c7d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_700881e2-f38b-4db8-a17d-9d58bd9c7d5d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d932133b-6766-4430-8276-375a69499408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d932133b-6766-4430-8276-375a69499408" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_85aabaf0-44d0-477c-8fb7-3ff4818d7075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_85aabaf0-44d0-477c-8fb7-3ff4818d7075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_e25dd2fb-c932-4edb-994d-113d76809d90" xlink:href="cpix-20201231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_e25dd2fb-c932-4edb-994d-113d76809d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_dce8861f-885d-4bdb-a84e-086245c32557_default" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_dce8861f-885d-4bdb-a84e-086245c32557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_3c5fd30f-d2e4-474b-ae8e-cfeb25277465" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_3c5fd30f-d2e4-474b-ae8e-cfeb25277465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d97ad31-6fd2-4ac3-9b27-80154ebec516_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:to="loc_dei_EntityDomain_2d97ad31-6fd2-4ac3-9b27-80154ebec516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:to="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_a0334130-5d4e-43f9-bfe2-06baaf63578a" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_a0334130-5d4e-43f9-bfe2-06baaf63578a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3cce2c4b-8234-4129-9684-7b6259b3d41b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:to="loc_us-gaap_EquityComponentDomain_3cce2c4b-8234-4129-9684-7b6259b3d41b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:to="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dc2ad94-4eb6-4f2f-abbb-cfaf0a2368d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:to="loc_us-gaap_CommonStockMember_3dc2ad94-4eb6-4f2f-abbb-cfaf0a2368d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba62d462-8eee-49ad-9e7b-75facbb6f7dd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba62d462-8eee-49ad-9e7b-75facbb6f7dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_b099ed50-89ca-45e8-9367-4ae9596cbb06" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_b099ed50-89ca-45e8-9367-4ae9596cbb06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_6dfdd403-a8b8-4309-835b-c296622ce5db" xlink:href="cpix-20201231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_6dfdd403-a8b8-4309-835b-c296622ce5db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_98792c72-37a8-4270-a88e-fc1cac7d5752" xlink:href="cpix-20201231.xsd#cpix_NordicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_NordicMember_98792c72-37a8-4270-a88e-fc1cac7d5752" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="i2007bf8844a84faf8296a7e2b13fcbd8_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i4814c562315945fe81816dc34a20c60c_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended" id="i377664054ccb410cab16c3e9b7b928e0_EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended" id="i20e8434a58d04ed4b3ae4fddc00ffca4_EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="ie125eb11f6274532bb0f5f4fb35a2d75_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended" id="i4e64b3a6410a4f32a59abf815a470734_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended" id="i90d6758372654978a5a49fdf513a4076_IncomeTaxesOperatingLossCarryforwardsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89c67fa6-0cd8-4289-89d5-bb967ce0cad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89c67fa6-0cd8-4289-89d5-bb967ce0cad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f78fda4f-34d5-4769-b3aa-4df66a820993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f78fda4f-34d5-4769-b3aa-4df66a820993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_914b8d8c-6af9-4d04-b910-4c41bd198e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_914b8d8c-6af9-4d04-b910-4c41bd198e5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5db58753-8d44-4535-bb5c-6b9d2cdf11dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5db58753-8d44-4535-bb5c-6b9d2cdf11dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6cb41175-a8c7-4659-a80e-4f32bbd4d28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6cb41175-a8c7-4659-a80e-4f32bbd4d28d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_dfba5957-7088-4114-81fa-0e063afbf4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_dfba5957-7088-4114-81fa-0e063afbf4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_299281e1-7878-4a46-837f-c383f7b806eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:to="loc_us-gaap_EquityComponentDomain_299281e1-7878-4a46-837f-c383f7b806eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:to="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a36e09bb-a377-4dad-b56c-ae9a3cd4c379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:to="loc_us-gaap_RetainedEarningsMember_a36e09bb-a377-4dad-b56c-ae9a3cd4c379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9f0aa7ee-0557-448e-b23b-86328d757d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9f0aa7ee-0557-448e-b23b-86328d757d9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended" id="i355becf23ebe4520aa6dff349417df10_IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended" id="iacf7d5974571451ba6daeb36785f8255_IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_704586e3-6826-4417-9286-a386c7301530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:to="loc_us-gaap_OperatingLossCarryforwards_704586e3-6826-4417-9286-a386c7301530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:to="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_8d2b914a-0234-4ec4-9004-f19ae55482eb_default" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_8d2b914a-0234-4ec4-9004-f19ae55482eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_ed07ffdc-b814-40bb-be3f-4c38c1dd480e" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermOneMember_ed07ffdc-b814-40bb-be3f-4c38c1dd480e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_722d2b6b-92ac-4999-897e-bb7c327a0697" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermTwoMember_722d2b6b-92ac-4999-897e-bb7c327a0697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_906b49bd-2c7a-4c9f-858e-08e64ab90415" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermThreeMember_906b49bd-2c7a-4c9f-858e-08e64ab90415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_eaf70f03-14a1-4551-adf5-c8b1fcca58be" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermFourMember_eaf70f03-14a1-4551-adf5-c8b1fcca58be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_94ad387f-fbe0-43b4-843a-51407d082041" xlink:href="cpix-20201231.xsd#cpix_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_IndefiniteMember_94ad387f-fbe0-43b4-843a-51407d082041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25eb08df-767d-40fd-b76c-5af69ed29193_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25eb08df-767d-40fd-b76c-5af69ed29193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b7f7c17d-45ef-43dd-b1ca-d0746935e8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b7f7c17d-45ef-43dd-b1ca-d0746935e8dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f5779b9e-2e93-41c4-b5b8-b7b6a6a68ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f5779b9e-2e93-41c4-b5b8-b7b6a6a68ddb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended" id="ifbaff4e5bbd84939b010c52cabfa9b88_IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" id="idc2c24f40c2247a0958dc63a041c9c98_IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended" id="i7736e923f40e456f93a9cae7352c0aba_IncomeTaxesScheduleoftaxcreditcarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c017261f-f405-43aa-b799-ff685ad3a3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c017261f-f405-43aa-b799-ff685ad3a3da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:to="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_6f73f7f6-2090-4eb0-b60d-6ce903c5a406_default" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:to="loc_cpix_ExpirationTimePeriodDomain_6f73f7f6-2090-4eb0-b60d-6ce903c5a406_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:to="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_14010139-efdf-4a38-bf5b-7318c681bd48" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermOneMember_14010139-efdf-4a38-bf5b-7318c681bd48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_bd27992a-eed6-4413-b027-a7ab1320da65" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermTwoMember_bd27992a-eed6-4413-b027-a7ab1320da65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_02d87369-fbb6-4aa1-8c85-c886e61b7506" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermThreeMember_02d87369-fbb6-4aa1-8c85-c886e61b7506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_748d6576-e9ae-4afa-bb9d-dd5b1823e634" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermFourMember_748d6576-e9ae-4afa-bb9d-dd5b1823e634" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f6338fd8-a5e8-48c5-9db1-13ee75cc7416_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f6338fd8-a5e8-48c5-9db1-13ee75cc7416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_28ef8d0e-c298-4abe-98cf-1b39700fe795" xlink:href="cpix-20201231.xsd#cpix_FederalAndStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:to="loc_cpix_FederalAndStateMember_28ef8d0e-c298-4abe-98cf-1b39700fe795" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlans"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended" id="if66894480f534dc78d8072d5cf1ef089_StockBasedCompensationPlans"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended" id="i782144ea3f6d47ad85df8dced8c3824d_StockBasedCompensationPlansTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="idfe3add19ee74279b2a66a70c72a4493_StockBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_9a506fb5-d193-4456-aad4-6a22e977b882" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_9a506fb5-d193-4456-aad4-6a22e977b882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_418a9885-fd47-4da6-b8a9-5d2935a82f16" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_418a9885-fd47-4da6-b8a9-5d2935a82f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c7d50a43-4665-47e3-a872-ec89ae85ba07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c7d50a43-4665-47e3-a872-ec89ae85ba07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_4fde8ab7-dd77-4f3a-8abf-db2588405bd6" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_4fde8ab7-dd77-4f3a-8abf-db2588405bd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c29f384d-bbb0-4dd9-b707-2866cfcb5a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c29f384d-bbb0-4dd9-b707-2866cfcb5a35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59450a43-c4b5-49ee-b179-a8077ca63f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59450a43-c4b5-49ee-b179-a8077ca63f04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e2648d0-7d98-4ef7-8883-2d024e063622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e2648d0-7d98-4ef7-8883-2d024e063622" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_279cc7cd-8617-4111-9692-07736c45a004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_279cc7cd-8617-4111-9692-07736c45a004" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89779fad-f440-4e14-a248-544f2dfde2e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89779fad-f440-4e14-a248-544f2dfde2e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_626bee0e-6bae-4a9d-b95b-d0bae010e04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_626bee0e-6bae-4a9d-b95b-d0bae010e04a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f713488a-6d6b-41e6-a872-bd23238cde84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:to="loc_us-gaap_RestrictedStockMember_f713488a-6d6b-41e6-a872-bd23238cde84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_95dabdc2-6633-4340-a6e3-891878dd0cf2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:to="loc_us-gaap_PlanNameDomain_95dabdc2-6633-4340-a6e3-891878dd0cf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:to="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_3d82a355-b280-447e-b4c9-bac2884dcf64" xlink:href="cpix-20201231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_3d82a355-b280-447e-b4c9-bac2884dcf64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_457091c5-bda5-4b14-810a-95ec2610672e" xlink:href="cpix-20201231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_457091c5-bda5-4b14-810a-95ec2610672e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4c23f47-45e3-4741-917b-9859ff43e7a8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4c23f47-45e3-4741-917b-9859ff43e7a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_2dc03a5c-b9ae-49e0-a1f6-d992e17f5bdb" xlink:href="cpix-20201231.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_cpix_EmployeeMember_2dc03a5c-b9ae-49e0-a1f6-d992e17f5bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_814d9da2-f5d9-4327-b505-6be0ea9ce5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_us-gaap_PrincipalOwnerMember_814d9da2-f5d9-4327-b505-6be0ea9ce5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_87f7de4d-3f05-4635-922c-876bd0fa3a4a" xlink:href="cpix-20201231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_cpix_NonprincipalOwnerMember_87f7de4d-3f05-4635-922c-876bd0fa3a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_38ab2b86-f75f-4ca5-a891-4cc79486b4fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_srt_DirectorMember_38ab2b86-f75f-4ca5-a891-4cc79486b4fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea81972f-042d-4a39-8f79-fc5fc999a6aa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:to="loc_srt_RangeMember_ea81972f-042d-4a39-8f79-fc5fc999a6aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:to="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e75bed13-f543-41ee-a1f0-528850a12bbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:to="loc_srt_MinimumMember_e75bed13-f543-41ee-a1f0-528850a12bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4135aa0e-100c-4c5b-a3d8-c4fddee21ddd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:to="loc_srt_MaximumMember_4135aa0e-100c-4c5b-a3d8-c4fddee21ddd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended" id="i8f9e9c4af15a40da89c998f7d5ac0280_StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0d72b412-3c58-4d5b-ab37-ed5e89100653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0d72b412-3c58-4d5b-ab37-ed5e89100653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:to="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffa1c967-c6e9-4ade-9687-470d5a3b02bf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ffa1c967-c6e9-4ade-9687-470d5a3b02bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_59e468eb-b0ce-4015-a868-4ceeb7de9654" xlink:href="cpix-20201231.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_EmployeeMember_59e468eb-b0ce-4015-a868-4ceeb7de9654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_bc3921bd-328b-4796-b0ac-6a4ebe908b9a" xlink:href="cpix-20201231.xsd#cpix_NonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_NonemployeeMember_bc3921bd-328b-4796-b0ac-6a4ebe908b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_0fbaa2b5-f87a-44a9-9c47-171ebb09edd2" xlink:href="cpix-20201231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_0fbaa2b5-f87a-44a9-9c47-171ebb09edd2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended" id="i4bbd91df3f294a2eaa32b1a82234e2b7_StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended" id="i7599f304e8034777b11cfe0a213188d5_StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54dac0de-9f51-4fe6-94d3-27de4885ae6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54dac0de-9f51-4fe6-94d3-27de4885ae6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe7562d-cec8-4e30-81aa-6a9a3877f812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe7562d-cec8-4e30-81aa-6a9a3877f812" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af52124f-4570-4543-99a4-60d64cfdc8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af52124f-4570-4543-99a4-60d64cfdc8e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ced2f884-d142-421f-a1e4-4bdf5eb5a1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ced2f884-d142-421f-a1e4-4bdf5eb5a1a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f23244fb-2879-40d5-8f64-d35a60eb330d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_372d6dff-b3d7-4b21-bd14-1561537382db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_372d6dff-b3d7-4b21-bd14-1561537382db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f90335fc-1d5d-4087-8f4b-50fc408396cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f90335fc-1d5d-4087-8f4b-50fc408396cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12173684-4b44-4be7-9e80-bacf8394cf20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12173684-4b44-4be7-9e80-bacf8394cf20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_793cf214-3260-430b-991b-b530f054b605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_793cf214-3260-430b-991b-b530f054b605" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d051518-cef7-4b46-8e8c-357aa7a9111c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:to="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4096dfc9-99dd-40db-9740-23c1edfc9a91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4096dfc9-99dd-40db-9740-23c1edfc9a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0491068e-c2ca-4318-8cc4-c9ebb26cde03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:to="loc_us-gaap_RestrictedStockMember_0491068e-c2ca-4318-8cc4-c9ebb26cde03" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i95b497411dfe4ffb82eca2a314471fcb_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="ib8a472f379ae4d49bc25fe56a5902e20_EmployeeBenefitPlansDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="ibd86fbcbd0f94e49acc7763aeaf09518_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i3660e8a6dfc54ccfb2a1f507f21c4c26_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i0580084c84bd40a6adb36f90c7ee36db_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended" id="iebd05cf0614f43c989f1391c346485fe_LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="i4961a95d84d448a0b924131a36e94f01_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended" id="if8a7b5b410df44b4916e276f5113f44e_LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="i9c76123e49834a05ab8c475537f8ce5e_FairValueofFinancialInstruments"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="ie1810c58e593474597c66c33bcbb0de3_FairValueofFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended" id="ib35698d423584685ae269ac4357f44f8_FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_0feaee07-8ec4-4dc6-9199-6147bad3589f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:to="loc_us-gaap_TradingSecurities_0feaee07-8ec4-4dc6-9199-6147bad3589f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83179f75-d45a-43eb-b516-c5afef0e1869_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83179f75-d45a-43eb-b516-c5afef0e1869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_81db5d5c-9111-4a83-96c1-24bd3596ac39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:to="loc_us-gaap_CommercialPaperMember_81db5d5c-9111-4a83-96c1-24bd3596ac39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa54a8b-009b-4b55-927d-75cd72c6962e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa54a8b-009b-4b55-927d-75cd72c6962e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fd7828ce-2026-4bc0-9130-8a423a286487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fd7828ce-2026-4bc0-9130-8a423a286487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f918cd16-ee1d-4fab-80e0-669cfc0c0c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f918cd16-ee1d-4fab-80e0-669cfc0c0c8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended" id="id30484a8c01543ea8992dabd17c4ea1f_MarketConcentrations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended" id="i562bdc3a880b4194a20d2c65aed843be_MarketConcentrationsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended" id="i51139aeb6f1c47f88f3c19cfd5b2c5ce_MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebb50717-21ee-4138-9350-e2ee3dae9f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebb50717-21ee-4138-9350-e2ee3dae9f48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:to="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d05ad43d-b368-449e-8549-88c552ba0832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d05ad43d-b368-449e-8549-88c552ba0832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10df71b8-e567-4a11-bf43-983233f1a003_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10df71b8-e567-4a11-bf43-983233f1a003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_61ad0c57-bcd6-4e37-ae47-8c77dec474d1" xlink:href="cpix-20201231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_61ad0c57-bcd6-4e37-ae47-8c77dec474d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b65eb85b-dbe9-4b2b-9775-fd35ef8a622b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:to="loc_us-gaap_AccountsReceivableMember_b65eb85b-dbe9-4b2b-9775-fd35ef8a622b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d231f113-f428-462d-8f99-f2d281187f0f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_d231f113-f428-462d-8f99-f2d281187f0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_30d68273-b181-4d17-8101-ba07200d4e73" xlink:href="cpix-20201231.xsd#cpix_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerOneMember_30d68273-b181-4d17-8101-ba07200d4e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_e8117e24-608a-4b94-9e1f-600c2c7832a7" xlink:href="cpix-20201231.xsd#cpix_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerTwoMember_e8117e24-608a-4b94-9e1f-600c2c7832a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_8143dc4b-aa88-409f-b58c-8eaf3f066154" xlink:href="cpix-20201231.xsd#cpix_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerThreeMember_8143dc4b-aa88-409f-b58c-8eaf3f066154" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended" id="ida211ce636bd4d0db62b69bb16e3ec10_ManufacturingandSupplyAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended" id="i1c104eb5db1c48f38d9907612e539265_ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_e6eaadd9-c166-4d34-9607-0d14b20632cc" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_e6eaadd9-c166-4d34-9607-0d14b20632cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:to="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b099ed2-b4c0-402d-9658-dc021fb51e27_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:to="loc_srt_RangeMember_7b099ed2-b4c0-402d-9658-dc021fb51e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:to="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_574d2f7d-306c-49cc-aa38-ac3176df6856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:to="loc_srt_MinimumMember_574d2f7d-306c-49cc-aa38-ac3176df6856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb39a5e4-03ef-4d5a-952e-42452e3a4791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:to="loc_srt_MaximumMember_bb39a5e4-03ef-4d5a-952e-42452e3a4791" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmploymentAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended" id="i0a16256f35f240a0a9e04c5630e49791_EmploymentAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended" id="icb200ee607134b0286c6a9e198702478_DiscontinuedOperations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="extended" id="i1a759fdd1dc34d87894c8ab6da80e06d_DiscontinuedOperationsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended" id="id8f514feb7b748158703a125d9f61e4b_DiscontinuedOperationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_b1b20867-3510-4da7-8745-506719b9c7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_b1b20867-3510-4da7-8745-506719b9c7a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_93563a8a-29a5-403b-8315-74a7d6671168" xlink:href="cpix-20201231.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_93563a8a-29a5-403b-8315-74a7d6671168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3cb6bed7-d38a-40c6-be6a-db843ce59f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3cb6bed7-d38a-40c6-be6a-db843ce59f23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_8890c1de-a065-4d52-8b5e-5ef3c06d126b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_8890c1de-a065-4d52-8b5e-5ef3c06d126b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenMember_777c71da-eb33-4d8a-8f7d-3437bca3b943" xlink:href="cpix-20201231.xsd#cpix_ClinigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:to="loc_cpix_ClinigenMember_777c71da-eb33-4d8a-8f7d-3437bca3b943" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="extended" id="i2a8dd40d20994e0e9c30d4422d19f134_DiscontinuedOperationsDiscontinuedOperationsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="id94fb7a554b4456db653619773e96acb_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" id="ief7e1c1d5e5c465fa9aa9071f22a05d6_QuarterlyFinancialInformationUnaudited"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="i7459e86c98294960b8c38d55b8bd1fdd_QuarterlyFinancialInformationUnauditedTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" id="ifea29b07198643349bd1521d1cb1d0be_QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccounts"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended" id="i0035ef9eee8749bd8fa5b8206d1cfb60_ValuationandQualifyingAccounts"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended" id="i485b9d75b81e4411afb6852e7a13d7e9_ValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_279c2c23-533a-475e-b583-57ae43bf52c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_279c2c23-533a-475e-b583-57ae43bf52c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_01d39f6b-16f2-4416-8e5a-c38d8b19c56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_01d39f6b-16f2-4416-8e5a-c38d8b19c56b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_e68aceb0-89c1-4f0a-82cc-73fa15723350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_e68aceb0-89c1-4f0a-82cc-73fa15723350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1ad72dc8-c3ff-4e10-9b12-35e0c5a746d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1ad72dc8-c3ff-4e10-9b12-35e0c5a746d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bb379402-33de-40c2-b719-69cca2957c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6452bcb3-2360-4052-8f92-83d5787a56ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6452bcb3-2360-4052-8f92-83d5787a56ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_a695d7f9-8238-48d0-a391-01f8bd561cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_a695d7f9-8238-48d0-a391-01f8bd561cbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0b7f7745-2a80-4f83-9848-36e329863281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0b7f7745-2a80-4f83-9848-36e329863281" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>cpix-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cpix_ProductRevenuesAbstract_e5b4eb75-ece8-4d1d-8088-9c2a828f56d8_terseLabel_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_label_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract" xlink:href="cpix-20201231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRevenuesAbstract" xlink:to="lab_cpix_ProductRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8a055394-d941-422b-81a0-b63e97f1af2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1447c149-ea90-40a5-9d2b-d67474efbb6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5d1a5855-ab9b-4366-9e6a-f5de90f0b86a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_0e2335bd-bb86-49cd-84f3-524a38ae1d70_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20201231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_acb8d0c9-aba7-48c1-94f6-4b3d655c9be1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_46b95130-5dbd-4d43-8382-9160b4e7c110_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:to="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_99e67ef5-1d4a-4f38-b7ae-3cf9ad65e601_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_422577fd-4998-4c86-a708-407646a367cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_9e473ad2-9227-48b2-843a-f525b279a28b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution costs</link:label>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_label_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production and Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionAndDistributionCosts" xlink:to="lab_us-gaap_ProductionAndDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1430ef46-f9b4-48f4-acd8-2e5daa50555d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_75d6109b-b45f-4e3d-97f6-becd5f758ebc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f513956e-5fb7-4c76-a481-fc31db12a7d2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d0ef3071-192d-4102-a906-a78063b7b48b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_389adc7d-c4bf-45f7-8c68-58fe5a3d9468_terseLabel_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc (CET)</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_label_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_documentation_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:to="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_33d0ece0-3556-4f77-be58-b7b1928ebe21_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_3def13e2-158a-47a8-94ca-8e9286caade3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ea3dffd8-3190-4e19-a93c-4c37cfad3592_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_6670d797-e0fa-4168-a8fc-0c84a50af958_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20201231.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7e3618ff-baa5-4cfd-b1d7-c2dc43580130_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8a7eb1ff-9801-466e-8a48-ba3f7b944330_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ce0ddeb5-5c35-4071-9c4b-bd4fdbfdb32a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_e1a6f383-b6eb-4b38-bcd0-a4b083812048_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b43c8381-c1fe-49f0-9a59-08008730d8e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_5fe287df-750c-4e14-b94f-2036ddfb6c56_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98e836ae-8605-445a-9bca-d7edec79b322_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6647a185-ca75-4088-9d00-d2ef09dc0981_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_8815490c-5bc3-415a-9b53-ca0fa594f038_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_c1d83d7f-d201-4924-b31e-16f551a0f5ca_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, underwriting discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:to="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_0db1a66b-e1ff-4f0e-83a5-e5bc86ca2277_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_842bcdf4-bf17-4003-8731-0eec9a5bd3aa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8f6401c3-8b3e-4cdd-84ab-8e898f9ec8d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_80a96a50-5081-493f-9bc7-4a308d354ea8_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_label_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_documentation_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:to="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_21d872ca-94b0-494e-b31c-fb8fadf582d2_terseLabel_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, including amortization related to leasehold improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_label_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_documentation_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:href="cpix-20201231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:to="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_43144310-2b1d-40ef-8b02-c2afce509295_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_d69455f8-a060-4a77-8b12-2c93bc7777c9_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_2cabd44a-c11b-455b-9966-c404feaa5e86_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract" xlink:href="cpix-20201231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsAbstract" xlink:to="lab_cpix_EmploymentAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_a01427b1-6c73-4f92-9b76-859bb986c717_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_52921772-f71c-4014-bfa3-b01f5c71f7a2_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b05517f-91b3-4459-a3b8-373406e39518_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_33c19f3a-4aee-4f1b-b566-f5bae005082e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_24fd172b-70ab-4bf1-b9b0-b8ad915a6a35_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_773c7c20-61ca-4e44-a7e1-20ba5410c526_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_edd4c8a7-af1a-4108-add8-a150933e1d52_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:href="cpix-20201231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:to="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_04586324-7f7d-46f5-838a-232da77ea88c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_30b2f68b-ee65-4579-85cf-e422a10c2e4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_af9d6de7-1f2a-4b20-a9c3-d2500bb419ca_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8fc448fe-0cd5-4619-9dd6-525491b84271_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1144d560-cd49-458e-97a9-1bb90648f1e6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8eab8d38-c11c-4f86-80a8-f9f36ab24f6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_42d2f62b-7208-4ff5-927e-739b94ab1b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ba5b71b-c07f-4fe9-b304-621c1f95887a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_36be32d8-0c9e-47e6-ab3e-afe657714a80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_21ef3a74-bbd0-48cc-bbbe-74866eff1923_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a3282af-3d05-4b2e-8aec-0a3f3c82c9bc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, amount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9fe76568-ad3d-4f8c-a936-b8fbe92a9d61_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d50ec630-9bdd-4dd7-afd2-67c9cfea249f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b5917aa-0c81-49d6-8c14-2e355df5e758_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f137b73e-0c3f-4873-8d61-012ef4775f59_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_fbf0a0cc-70b9-4091-a337-6b740397ace7_terseLabel_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_label_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_documentation_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:href="cpix-20201231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:to="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_15312ff6-4910-407d-acb9-3f344eadad6e_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_400045fb-a680-4f77-9fab-ad0585642a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_58283b1c-1bd3-4357-bea1-4002514e37b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_c4bd9e5f-1f0d-4596-8153-dbdac32e1da4_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20201231.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3824a2c0-7cd5-4c2c-a5aa-edb1b10458bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_afdb05eb-dc74-43c9-b7df-1c72d447b4ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermTwoMember_d823d0a0-65a6-44bd-a5c1-43127a8dfe27_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 - 2029</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_label_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermTwoMember" xlink:to="lab_cpix_ExpirationTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d123d263-9eda-4532-909b-9029e3c2515c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenMember_2e90449c-2f87-4fb4-bd08-f2c26a0d7ff6_terseLabel_en-US" xlink:label="lab_cpix_ClinigenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenMember_label_en-US" xlink:label="lab_cpix_ClinigenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen [Member]</link:label>
    <link:label id="lab_cpix_ClinigenMember_documentation_en-US" xlink:label="lab_cpix_ClinigenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenMember" xlink:href="cpix-20201231.xsd#cpix_ClinigenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenMember" xlink:to="lab_cpix_ClinigenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d19ddf2f-6783-47e2-85ff-480c58ce8939_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3e67115-e355-4a7a-9480-4e7c4e78c586_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_bbe35b7d-297a-46f1-b322-694dc7737eff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_512c0d63-0420-4e6b-8034-01c01b83ef1d_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, payment period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_label_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:href="cpix-20201231.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:to="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_6b8cf7e3-dade-41de-a8a2-27e49187d691_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8a83fcf7-5f49-43bc-a1c4-97501a15b984_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_e7461a19-b0b3-4108-9a19-cb21177743e8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_cfda8699-37f7-4674-a271-58fc6a60d413_terseLabel_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unpaid invoices for purchases of intangibles</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_label_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:href="cpix-20201231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:to="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_79a8087d-031c-494c-bfe2-8ef45ed8724f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Continuing operations-diluted</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e7ed2f1a-a541-4218-88ef-cac8d7f86dea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_42934a8c-0bc6-4c41-8d84-287e05d6d284_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Discontinued operations-diluted</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7bcaac6f-facd-40fe-bd03-59832084660c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exerciseable, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_140aff3f-733a-4852-8c32-e39f8e27ad48_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodDomain" xlink:to="lab_cpix_ExpirationTimePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_0c8cdb1d-54c2-4b4b-b64a-6add5f1a1d6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_1ff34dc5-5bd5-4ca4-a6d9-5e1fcb9ff29f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_95424da3-7f64-4457-a008-9b241cce6daa_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ad1c7ea5-4e87-477b-8bee-3adfe35f868e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent, Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_72f98f8b-3eb6-4291-8372-74f1f05099c2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_62a46662-af6b-4a8f-b9bb-9fe5ee92c830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or expired, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_61215e6c-5687-4190-9c92-ca902effbe3d_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_435e5fb1-17a7-4670-a182-da3a52d3aeea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_f22303ae-fd3e-402c-8621-74407e9aa297_terseLabel_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, product returns, administrative fees and service fees</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:href="cpix-20201231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:to="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_9f9eb1a8-9341-47c6-a85b-77db7e2bc121_totalLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20201231.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_d1168b0d-bb95-40e1-aada-652ae23d217a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_db5bef30-5a52-4613-a321-e8a41dbd5a3d_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets, useful lives</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:href="cpix-20201231.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_270692c3-d85a-4da7-b75b-ae2308ff29e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or expired, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherRevenuesAbstract_e1bbb1f9-e48d-417e-9fdc-0b83f7e1c5c4_terseLabel_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_label_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract" xlink:href="cpix-20201231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherRevenuesAbstract" xlink:to="lab_cpix_OtherRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e8e90ccf-1e44-4768-8941-297ced004956_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f4afb79c-5c3a-45a4-a7d5-c9e417ad0cea_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_00e3239e-3da0-4125-a962-244d7667ad01_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2523af6-9cf9-4f8f-b6ca-69024af1e104_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_13834118-845c-4947-b275-fdc042d390df_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_8ad88dd3-01c3-435e-bf7a-1e7755fc8741_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_bf6ad66d-e902-41cf-8382-23125dda2e80_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ce61e1c7-ca68-486f-84c8-f4287aa4f777_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_7ef26629-16d5-4e88-a065-afc73f8da5d0_terseLabel_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_label_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member]</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_documentation_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember" xlink:href="cpix-20201231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SalesRevenueGoodsGrossMember" xlink:to="lab_cpix_SalesRevenueGoodsGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_3e39723d-5caa-4a5c-8ee2-b6f277984503_terseLabel_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid (refunded) during the year for:</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_label_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_documentation_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract" xlink:href="cpix-20201231.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CashPaidDuringYearForAbstract" xlink:to="lab_cpix_CashPaidDuringYearForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_f227313c-4662-4c08-9a3a-b52c9b9da3d2_verboseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20201231.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ce391f5a-0873-4897-8a49-0d63118f815a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_30c2ec91-bd44-417a-8c9c-2be85d2b2101_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8cf3c82b-ef10-4e9b-bc59-6296bcd297a8_verboseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3546259b-e08f-4951-bb22-08f947e321c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e96e7887-0f03-48c1-8be4-34d68d11fe04_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_7e719e7f-5931-42aa-b687-b98f74e1d076_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0a4e548d-f86c-4b10-afeb-b7c7d71568aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d60e1270-d8e0-41dd-88d4-a6c0fdf41e06_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f92501a7-0413-429a-b5c8-aa5601815d66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_cff8a035-f3d9-4569-a0a0-767a706bf7f3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_a3f70eee-0591-49b0-8409-03eaa3ea187b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_6218e06b-d7d1-4379-81c6-6f03f6d28f91_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cd82b460-1b33-4adf-b664-1905bea76b1e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5d02242f-421b-4e5a-8b76-dbc455b5d0a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock, shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_6140a334-3024-4717-bffd-da172f92e0ef_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:href="cpix-20201231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0a791b2c-7541-48f3-9383-af86fce05db2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ce9b1a9c-d2bb-4538-87eb-99c1ccbe6fae_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_1e12ecc9-f24e-4596-9b57-e798baf69bf4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, no par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ac3189fc-d233-45a6-8c67-5438ad6cfe59_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_009cb78e-f21e-4d93-ab75-c6ee18a18701_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_43339213-7335-40ab-ab58-a2d6e645d6a4_verboseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_4230f3f3-f8c2-4d22-b71b-09d692020ed8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_87d0f516-0e73-4438-86f7-b44ed58bac72_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_e55dc1c1-c8d2-4a91-987d-11b5f62ff85d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_79502058-a9f4-4167-9f39-47b8e768747b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ed807093-ee9c-42b9-bc22-311dae93b946_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e25b563f-fe53-45d6-92b5-e375c31f2c2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3fa3f22d-d45f-4524-981f-1b9b12e26f2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cd37d468-f283-4241-a798-83e126a268e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_0946287a-5cec-41b0-b8bd-f17c5c93ac9e_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_588470e0-435f-4982-b179-e7bad8bfadf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_cc423748-2f49-4362-8841-c3e517050f5d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_c59d9cfd-36f1-4ff8-85b8-3ef1aee9941b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_d7f52ba3-1bd1-4a86-8f85-bf02cd3fd130_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_56bcaf98-fcc3-4885-a43c-4b8012b68f58_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_f0970c73-88c5-417c-b72c-8aca47337a19_totalLabel_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets, before valuation allowance</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_label_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_documentation_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NetDeferredTaxAssetsGross" xlink:to="lab_cpix_NetDeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_336ccd33-e885-40a8-b55e-a5ff66150ff9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19b8fb3c-36d6-4143-94de-cc0c1a96b930_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of numerator and denominator in earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_8bf6cf3a-dd2f-49fa-9390-dcc5be14f461_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6d2ec83-f6fb-4d82-9e6c-11999277dcef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerTwoMember_f4d89f9c-a67c-44a1-a552-ce6d722101d1_terseLabel_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_label_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_documentation_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember" xlink:href="cpix-20201231.xsd#cpix_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerTwoMember" xlink:to="lab_cpix_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e8bb82d8-a29a-40fb-bec0-6a955a205b6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of products sold</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_16433e25-7531-4658-b32f-f4fd640ec797_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5be852ab-aac1-42f4-8a90-30c0c547f742_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_fed7406b-cbd0-4c27-8bb9-cb1e75afcd98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5ca1f73a-4f28-4455-bf1c-e1c196e54ddb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_27371696-c860-4618-b858-a2fed44152f8_terseLabel_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payment for asset purchase</link:label>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_label_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment For Asset Purchase, Current</link:label>
    <link:label id="lab_cpix_AccruedPaymentForAssetPurchaseCurrent_documentation_en-US" xlink:label="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment For Asset Purchase, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:href="cpix-20201231.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:to="lab_cpix_AccruedPaymentForAssetPurchaseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_03802c37-6e13-4edb-b8c3-033a51bad53e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_424af882-b54b-4305-b333-8fe54cb6eeef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6a51b388-3b13-4b47-ae28-470c258d88c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_22060c5f-4b2a-448b-9864-5fe6ce69fd23_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_f296d0be-2c81-44a3-9719-e8386c5ae9cb_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, price per share</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:to="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e61d83b7-da02-4cb6-9b75-847ab6699d7a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_17d3e0a5-ce8d-4cd6-a106-7679b73da768_terseLabel_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_label_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_documentation_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:href="cpix-20201231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:to="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_48732237-8dda-4519-8360-34cff483685d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8390519e-30cd-4067-ab11-8ce96c8e0556_verboseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b59c3f6f-dc6d-4730-a656-4c17c16e7155_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_b35e0950-e6af-4a1a-9451-2493a15173fd_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20201231.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9d54d8b7-c632-4f0d-b4ee-d0dbaecc7e0a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_37e3fcd6-b133-4bf2-a4d3-f071c20bb158_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_96db25b2-8c29-444d-be31-850f626de219_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4257c838-fa48-4518-a8e9-1eaca9452f9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CommonStockAbstract_960c6f7b-32c8-4077-8629-dfee472a6f68_terseLabel_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_label_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_documentation_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract" xlink:href="cpix-20201231.xsd#cpix_CommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CommonStockAbstract" xlink:to="lab_cpix_CommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_18fecc4b-39fc-4e2d-b26b-ae34f24d38f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net product revenues by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5415d441-3f49-4506-aef9-7e9aca282355_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38688309-c024-4e88-ad0c-b86863ba4924_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9a529e69-beb2-4fec-8ed7-64f453fbeb16_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ef496ed-9a99-415b-9efd-12661e7f498e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_88e61df2-0695-4a45-8a4b-56158f3cc76a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd98a077-56c3-4b96-af38-ee2bc47ab2c1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_1c08f1b9-81f4-4730-9000-2ecad1300f5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_131bcd91-4b83-44ec-aba6-4fb57a25bd71_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2ddbb516-29c0-49f9-b90f-030575b80a70_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e925b887-d197-4384-9ce7-7e706eff6dc6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_c8b96ca7-05f9-4e80-8663-a6a42a0bce76_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_6d04f036-1ce3-4d35-a975-c9896d89196d_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ab0f70e6-630f-4bb5-84b1-914669699860_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e972a76-14df-44b8-af38-4e00589cf71c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a0388e0d-c240-49f6-b599-1cc2ec364616_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_62e69fce-df19-4b46-81c7-743a11be4e7d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_46ef3026-cb16-433c-9a3c-c592f3bcb775_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ThirdAmendmentMember_cb8391dd-fd39-4fe4-b615-ba7080937d15_terseLabel_en-US" xlink:label="lab_cpix_ThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amendment</link:label>
    <link:label id="lab_cpix_ThirdAmendmentMember_label_en-US" xlink:label="lab_cpix_ThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amendment [Member]</link:label>
    <link:label id="lab_cpix_ThirdAmendmentMember_documentation_en-US" xlink:label="lab_cpix_ThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ThirdAmendmentMember" xlink:href="cpix-20201231.xsd#cpix_ThirdAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ThirdAmendmentMember" xlink:to="lab_cpix_ThirdAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_557411fb-7748-4e37-a3e1-87d01f379083_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_3fe363ff-41c0-48d7-8a64-4f9ee6da99a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8f0d3177-3cff-4b38-a3f8-46131878781b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7599f241-fe08-4489-bdc2-43459c7497c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f309c1ac-411c-44bf-b522-38c916915785_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_435324ff-aab6-4768-9ed6-5f3f050337b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_522d74cb-024b-4850-a4a6-58ce8d3fbbdb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_562dd57f-20d2-4c73-a9e3-8eda807a9b09_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dad47b2a-b831-4dba-8edf-5c2dae9cf88e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_68ab5e54-15ff-48d4-b222-8ccf5b5124b0_terseLabel_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_label_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_documentation_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:href="cpix-20201231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:to="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_5c4f2eb6-0137-4486-9049-192a8ca8ef34_terseLabel_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and other accrued expenses</link:label>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_label_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</link:label>
    <link:label id="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_documentation_en-US" xlink:label="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:href="cpix-20201231.xsd#cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:to="lab_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_05c6df6c-92a6-4032-be60-f2dea70f0458_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_233269f4-4114-48d9-9f18-ac669131ff46_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f053ed49-254a-48cb-982f-fba024da0cc4_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_5929691d-5a32-4eb1-83d6-d5651c7e79be_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductVibativMember_e3969afa-0bf3-4ab3-b65a-08ee3ec5cf82_terseLabel_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_ProductVibativMember_label_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ [Member]</link:label>
    <link:label id="lab_cpix_ProductVibativMember_documentation_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember" xlink:href="cpix-20201231.xsd#cpix_ProductVibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductVibativMember" xlink:to="lab_cpix_ProductVibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5c66702a-aff5-405d-9430-908e5004c7eb_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ccd5baa2-e8e3-4425-bdb2-c45742c78be5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_e7ee96fd-22fc-4465-8a02-6bdfc665283b_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of rent expense and sublease income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20201231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c0135041-d870-4c31-9fed-f76fddcfa050_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bea81482-4830-4600-9fcc-66647e2cfbef_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_0f8d276f-5aa2-41d2-8b7b-f15a4899f344_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:to="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1135850a-c51d-4a56-8b9d-b362350071c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_6f8d50ef-2a63-4d1f-8766-4e559f9fc653_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Proceeds from Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Proceeds from Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7f9d67c9-119f-4871-a533-a0a0856ec58a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_a0b4810a-dcbf-4fa3-a183-280cae3574e1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_faf743f8-d704-402c-8082-2056d888a003_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_539bd096-4838-47c8-8868-ba237dc21d51_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets from final purchase price allocation</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a9dc2268-361a-4d3d-b1ae-076d38ece6ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_ba6c455b-1c58-4fc8-b17a-76516494aff1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6ae9844f-3db1-4e9c-abb9-ceb1ad1fd461_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_ef691073-96b1-4d39-81cd-dc4fdb0081e7_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax (benefit) expense derived from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b0e8987-1610-488a-804d-f025b05f2a01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_20c3fea0-a238-4a12-a925-b0d64ef62354_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a253eac-6fee-4dbf-a8d0-f9a9ce9a24d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e00cd1b2-4c14-4224-ab3d-bc9f6738e8b3_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_1924f6ec-9d18-44bc-be35-902aea6c9418_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e94fcd91-47f8-4ca6-bf45-b15f25562e39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_5f6a69d1-9623-4ef5-a086-b97445da4649_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and related tax benefit</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_f2b07a28-c5d2-49e1-bca5-9c48386f48c7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c8328e12-b976-4e79-81cd-1373b8261d2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f7070238-ac81-4121-a17b-12fd8740024b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quarterly financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_18ec8bb8-1715-448c-af49-e22d8a5002a8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_f4cfc41f-af1f-4c40-b0cd-911b02ce6609_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_719e112d-ef54-4fdd-94a6-b32bddd3446c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8699d9c7-5744-462d-960e-83415646df5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Continuing operations-basic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_e7bd8b84-0bdb-4f3b-a20a-98abfeade590_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_99e19271-6bbd-4ad4-8f2e-781bbecdc181_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_f0916d44-b834-4a59-81c7-9a86673951b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_01184882-4a4c-43f6-9d0c-6ac568c69f8d_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_464951eb-8bde-4f29-a85e-eeb9d1c4c925_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_54c372ed-5a27-4828-9eb6-9cd36a47d7f9_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_997d9430-b621-4ed1-9012-ed3e82f49c1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e20b59be-c286-4d53-b618-bfb013391d50_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef6adbc7-c2cb-4595-ad37-8d3b9da6636e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_dd4030cb-9573-4b1e-85a4-a0065728d3d9_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments associated with international agreements</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_label_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionMilestonePayments" xlink:to="lab_cpix_RevenueRecognitionMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_29f79302-909f-4124-9414-3e4167980ddb_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_32d36971-4287-44bc-91fc-e9dfeec91da2_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_1b1ed7c6-4ff2-4faf-ab3e-99f8dc731874_terseLabel_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock" xlink:href="cpix-20201231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsTextBlock" xlink:to="lab_cpix_EmploymentAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_aca994eb-b10d-4fc1-b217-23a5ec682190_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_237bf671-0d81-4f2a-bc31-6ce6452f0aa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_63130a51-5312-4c0b-b67e-4190e2b9155d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1b532143-9bf0-4662-9f27-44cbe68e8dbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_4b1b0ad6-1d4a-4238-bd64-2cdcbd5bd07e_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:to="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0cc0eae4-9bf7-4135-9c7d-b7599327b6e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_520109df-e831-49e4-8eae-aeb02451d8bc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_ef852232-7943-461c-8d21-169ba1cd001f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_30f29352-abdc-4cf7-a244-6f61f03cd979_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:to="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_99fe847a-1152-4a2b-95ba-e230bb73bb92_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of restricted stock and stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_fe8dad26-9f36-45b4-8e2a-3c57ea5ab258_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6e112c4c-466b-44f4-9bbf-15560f850ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2fcb7573-0f59-4b05-9794-bf8f6427ee9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_362e7469-909e-4ec3-88ed-6f7feaaa9baa_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20201231.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_5f37a67a-30f5-414f-a837-888f268e0751_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodAxis" xlink:to="lab_cpix_ExpirationTimePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_744ff7de-bd29-4ec4-abb2-68547328a696_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_832a766e-66c0-47d2-9b03-fc68172c5aec_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_459c9093-3e50-4119-b744-0fa6e0435935_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_877fbbe0-68fe-470c-82c8-dc81c9ba6494_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, gross proceeds</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:to="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9124ac71-eb00-4342-ba36-b4bd39f13fe0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_26708e23-f265-4051-9ee4-7818c6011504_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f94fcddc-e6d1-46f6-a62a-00e11aee3274_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FederalAndStateMember_61704ca2-25a9-4535-a9fe-7234cc81f1e7_terseLabel_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_label_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State [Member]</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_documentation_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember" xlink:href="cpix-20201231.xsd#cpix_FederalAndStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FederalAndStateMember" xlink:to="lab_cpix_FederalAndStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_ef04db7c-852d-43d4-ac64-8132b2112ccd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_42a988f3-be73-40d7-a9ca-fa5073d4579f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdb214a9-8cf0-4480-94bb-de807b1de770_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a0b907d8-ffa5-456d-ac1a-8924893c42d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_925b4e89-70a7-4407-afd6-fcfb98046f5d_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_4f516088-5f17-4123-9355-94d44b499c50_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ce0993c9-efaf-41ed-b644-40a2573a9738_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences associated with general business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bdd72f48-8017-41bf-862b-e3218e5e283f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_e14a1ccd-2565-4af1-8e4f-8090fa462c4d_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ce810d25-bc03-4fc7-aea6-30180bb53cd3_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b917f459-8aa1-47b7-8c72-de58f60bf27f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_dea8cb12-03c9-45b0-822c-f303f4007b80_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available under current repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_dbaefb1d-63a8-4650-8e13-591389e2be2e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_a72f19fc-98fd-48fb-b5e1-383e31180135_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_7c895fa3-fde2-44a6-92af-75b90f4429fd_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_44f2eb59-8648-46b8-b975-9be1e95e71d4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_86f3110e-d00d-4d3b-b71b-05d68ef313e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_f6cf1663-ebbe-4df5-8fe4-6be0ba79268c_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20201231.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8b313e52-7f8e-4dc7-bbb9-3777a71318e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4ae61201-4135-4ea5-adf5-b43f54fae4ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for accounts receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b978f6cf-41a3-4b09-b0a8-5889ccb8d212_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_943c7939-f24f-4239-bfd6-30be57d30f6a_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b82423b8-caff-4515-9784-736360647dd3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6bbb60eb-cdc5-41b6-8ad2-7e8d4933dc48_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_afd446d3-315d-4122-af61-24c157116988_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, exercise price as percent of weighted-average grant date fair value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_51159585-de09-423b-9659-1e8c41da1fee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d1b3271d-6237-4aa4-a8e8-ac246a589b1e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_91085d07-9ea5-4fa6-b447-6582ebe8619c_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20201231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8a7ddcda-3f16-4674-a06d-5e8c1123c25b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to be paid</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9d1e761d-8aa8-43bc-80cf-6397b0ded76b_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at November 12, 2018</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7739b333-52c4-40ec-9c13-10ba1d087841_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_b662859a-90ac-4b0f-823b-cc3585fe549d_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payment related to product sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_2d6a1e32-6d11-40e8-9870-6b1c0d53a949_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7946ce79-a106-46f7-a3e0-b761effd0a0c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, number of shares authorized to be repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_beb4b7af-5827-4e04-bf69-ec21f280c77f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current and Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b2ea5816-6a3f-43c0-b02f-f7703837ce9e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6ae1d67c-8e2e-41df-86df-ce5f1490ede5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c791bb15-ab46-401e-a17a-ea7d79b617e8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b68effc2-163f-4e4d-945a-8c033a0e24be_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_c58d5ae0-ebb2-45ad-837d-3c0186a4eabf_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c10b68a8-87c9-45bc-8e4d-149ed84e1abb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_75730929-35a8-4265-9963-36e9ae868df5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories, current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_cb29d8e2-4097-4b92-92d1-f8747df334e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_ced02151-1ef0-4bb5-b99e-c66c2502abfb_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_8af29865-9ba1-4f00-b832-96bdd6a7961b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_50eb9956-44a0-4829-bed8-b68b4938f943_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f5a3b607-6b16-4d3b-8931-15270cc807fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_1ee1eadd-022e-4a62-83d4-5ed8c9ab809a_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20201231.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_f25b39a7-66d1-4a98-9387-86893aaeb9a9_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a3e4a628-5144-47a5-922b-5705175778c7_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_5bdc31ff-7cc3-4194-8bae-d73bbdf9b49f_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_75dfd2f3-8b04-4cc1-ac2e-d56d14050be3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_f78701ee-a0cb-4f0e-a606-e868006ce3ff_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_1a4aa64a-ffc2-4c90-901e-9956da131220_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:href="cpix-20201231.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_11010804-8739-4500-86e7-98a3064180ef_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_79b070fa-ce6f-4e00-a1c9-aea99124cf95_terseLabel_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of shares related to RediTrex approval</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_label_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Transaction, Vesting of Shares</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares_documentation_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Transaction, Vesting of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:href="cpix-20201231.xsd#cpix_NoncashOrPartNoncashTransactionVestingOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:to="lab_cpix_NoncashOrPartNoncashTransactionVestingOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_76857248-844b-47ee-b30b-708f4c270e7a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0168ae1d-d7f4-48aa-a175-f595cfaf7564_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_7321dd68-eea7-4776-b1b0-e5775991fdf0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_859940e9-b2a1-41bd-bb7e-a0e1e40c191d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8512425e-a9ba-41f2-aec6-c29d43557774_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_eeba8ccf-8e4c-4c25-8416-3e913c6b4bdc_terseLabel_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contribution of shares, shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_label_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_documentation_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:href="cpix-20201231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:to="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_45892dce-1bc4-4843-a975-fbf0322013f4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_3aa80838-abd5-47ff-92be-b57d2d258533_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1b8f4149-16d1-4151-b135-cf88a62e5206_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_ef23d9d5-651e-4abb-954c-959988c442c3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5da46553-0cc3-49b2-92e9-4194831af819_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_d1a17de3-9f7b-45d1-8792-07692d9058c1_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_733c5a77-91cf-4602-9fa8-ad441050f566_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_52049296-902c-446b-895c-7a006da8ee85_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7bad8615-b026-4758-ab48-b0701dde78bb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d0760aac-cb93-461a-99e9-c875e5b07770_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0acd61e7-2778-490b-9efd-178b75f4fa2b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f1fc61b3-72bd-4aa1-8916-d4dc918461f1_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_0d96382d-fdc6-4180-87f6-781f2b62fb09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2c0c539b-3a86-45d3-af0c-dfa5c400865d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d904ff2c-269f-4149-b7d1-2cd0c5456076_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_bad78715-98c3-4236-ade7-b5558107ef5d_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20201231.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_8057e5fb-b323-4c3e-9cc6-48e99e7ab405_terseLabel_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_label_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_documentation_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:href="cpix-20201231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:to="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_dc48121a-a1e2-4fe5-be1f-60df977d9bed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_da670686-dc11-4fc7-9baa-e2bb225c8c11_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_af2e2cd3-29fb-4b54-bee8-e7ebf27315fa_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f38bae1a-6242-42ae-af9b-d43b27187f6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary allocated to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2060ec4-e085-44d6-8665-8bd3802c214d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5dee1982-fb86-438e-94be-9ee2c2b25d36_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cdd5d3c3-9eea-4b95-8482-6768eb4f0ab6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9efecf4e-7f1e-4f60-bc80-b02b17f5b854_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fd72b121-e0e9-479c-9d7e-4b0ebd62d1a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_0f041788-74d5-4f93-b098-2279b9219d90_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20201231.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fcc701f9-d55d-4334-ba6e-18612a8939a9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_7a77d721-c164-4023-a7d6-5a8adc329bd5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, effective date</link:label>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_label_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Transaction Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_626e010a-637c-4147-975b-e22c5627f1a9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_345b2fdd-32af-4567-aaca-2bf09e695bb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6a58ed64-099f-4415-b360-48e5d59ada33_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9914832f-4265-460f-9bdb-e447f86231fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a0312a17-b882-4130-b4b8-7166585fba1d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_00856171-2126-43c7-ad35-836dae5f2d61_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_6bed2617-2a15-4de4-86aa-fd62b1c77b66_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum increase to line of credit</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_b4680fbc-40ec-44ca-bd8d-0a03011b9ad8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_57099490-97e2-4e6e-8afd-e653cc05e69f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6702c686-ddb7-452e-90ee-262e00d8d34b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b9b840ba-f765-4336-8237-ded3c28c4a87_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_2c88b2b1-d0b0-463e-bca4-d1be4d769ba5_terseLabel_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_label_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]</link:label>
    <link:label id="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_documentation_en-US" xlink:label="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:href="cpix-20201231.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:to="lab_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_61619bfa-6858-40cd-9682-12608c1968c6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermOneMember_ab95fe94-9362-4c8c-94c5-fcd8c0c57cff_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_label_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermOneMember" xlink:to="lab_cpix_ExpirationTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_ca964dc3-0667-4ab4-bfb9-61acca2aa7d8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_aac7fc60-0bf4-43fe-bff4-0e66ca99a937_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_f41dde2e-e4b6-430b-973e-38797462fd6f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ec78b89e-a555-4ef1-8da4-e3fc92b936ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_8345e4a2-ce48-429f-86a5-aec6d6349b46_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to initial fair value of the contingent consideration liability</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_54577431-e987-460e-bd5f-7edbbabfa6f0_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_01db6b5a-449f-40b6-b9ea-6511f2304123_terseLabel_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_label_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_documentation_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:href="cpix-20201231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:to="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_3541bdb2-9a08-4686-acda-525dea67af63_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b6a4d2e8-d2be-4fc2-ab95-514e646d5f86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_41d54dab-1c55-4998-8f09-73d382b6224a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_3e936d6f-b632-416f-bd6e-149e6697c919_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2f036587-896e-4e68-86fe-0dc2c1a01010_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_df77fc9e-ba2a-4d5e-9604-3793e21698ad_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:to="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_e7164eb9-a63b-425c-a463-5ebf9d23f36b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash increase in liabilities related to acquisition (see Note 3)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_73fdae5a-b7e7-465c-9881-21916293f001_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_03d60b43-a101-47f0-a15a-ba2053ac7b55_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0e93e5b2-0a4e-47c8-bfd7-d06d3beae662_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_95017d56-66bd-4dd2-989e-9b63862ee282_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_e2a9344f-1829-447e-98f5-b3b633aa8b48_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_7adb50ef-1491-4b59-9469-a55c094602a8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerOneMember_7e8f2c24-d063-4afe-bcbf-7ab6172eef2a_terseLabel_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_cpix_CustomerOneMember_label_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_cpix_CustomerOneMember_documentation_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember" xlink:href="cpix-20201231.xsd#cpix_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerOneMember" xlink:to="lab_cpix_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_08ca6d48-f1db-4a22-80e4-ff95acb4db69_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_d719203e-232c-4a65-9f24-811892d08ea4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_71a4b2cc-18b7-44c5-b734-8d687c1b89c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_2b747d77-8c06-41ea-85f5-4f81bb22c1fd_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_31c9d2b6-2150-4a68-b3e2-32326e51f52a_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_01fbe94f-0cd4-447d-be68-9c783a8231b4_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_77a2a5a0-d807-4b9c-a05c-6ff269cbb42d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f0a472a2-86a1-4191-8c6c-71059b7d7366_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_baac85a5-eef7-4dda-81aa-4f41f15a7b21_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1bde59ff-3af3-4996-aacd-dc56ff6def4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0f3c867e-4b17-4457-9011-4ffc647319a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_df9796f6-9471-4bda-ada0-5399ea89cec4_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_1d6e167d-364c-4188-a551-9e57f8f5ecc8_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payments related to regulatory approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonemployeeMember_5fc0479b-b07d-4397-8bc5-079ba913dee7_terseLabel_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_cpix_NonemployeeMember_label_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:label id="lab_cpix_NonemployeeMember_documentation_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember" xlink:href="cpix-20201231.xsd#cpix_NonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonemployeeMember" xlink:to="lab_cpix_NonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_54b3bcf0-f133-41e2-9d51-bf70e2b5e715_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_e16576e2-454a-4158-80c9-7157ffc8495a_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for expired product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:to="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_abb0d092-5d10-464c-860d-6db698992c6a_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in CET</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0317b2ea-e90b-4aa5-8cc0-6c0442bdd695_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9a975bc-f731-460d-b959-f664165c7c2e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_8df1ac00-88df-4163-b4a8-6194ca35739e_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20201231.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3fc986a6-9a0f-4dc4-adb4-e62592589721_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6641416e-70ab-40d3-8adf-7cdcf318fb68_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_580461e3-4816-4a68-9a77-eb49f960f8b3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_db7c3c26-e2f1-4227-bdcf-9ad2a27bc0d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Discontinued operations-basic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d966bd5f-077a-4f13-868b-d859b95331c1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc7a4c45-2f31-460f-ad7d-8d095a9b46ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_c78f0c65-85d6-4986-b944-8a3325b62250_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_63448b37-d25c-4a8b-b209-b4d6477bd5b3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bb18dbe8-124a-405a-93e3-0adc5bfef7da_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c1dd13ef-73f4-4b73-98e9-d84b7b74d8e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of expected amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_334da9b9-c18a-4550-945a-f42bc38d5afd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a35c638-9dd5-4ede-9e43-77a6665bbfda_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f64e4c1d-8ec3-4af3-9eb2-ebdacf63562b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of financial instruments by level in hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_738d17cf-09ba-42ce-af6f-49984115ca5a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_fe8f99ab-e38a-4cf8-8bf0-c21abb31c31b_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans available for future grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dc0b407a-daa5-427c-8c52-55e6e74cfe62_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b7dcf691-9616-4140-b2ae-23ff4f11cb80_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf437ea9-f34b-4abe-9fbe-9b3918e483ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_aee33cc6-8702-4569-b2d0-56fec5a2ee0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_ecdd8d53-ce22-4f41-bbbb-154a1e7b5869_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_976bbcb3-604d-48fc-8d7e-38f97ae35ffa_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b9e6adad-992a-4d34-b006-f9d8bd6e8a00_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_c324321e-c8a8-4a59-8a9a-e0aa019379e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,988,429 and 15,263,555 shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_fb78ce31-d6dc-450f-8f47-54115d964d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb113726-fbc7-4a8e-803d-af189ad258b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_cb1b0b8c-47ab-4846-99a1-043c46d2040c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3dae6e18-081b-41f1-ad0d-402f57a2c85a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_6a24de47-5bae-421d-ac7b-c7656537d5be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves, obsolescence and discontinuance</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_90878519-699a-4c5e-8790-15160946d09d_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_2f9104e0-3891-463a-98c3-9c367b0de679_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed cash contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:to="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_34b80c16-759f-45b5-802c-f4ec7ddc07a5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_c9e21dca-b152-4f19-86dd-38b19c1c06a8_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibiilty, minimum employee age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:href="cpix-20201231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_101d468c-c5cc-4969-be87-926104714748_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_401c440d-2310-4ecd-abca-a47bb963be75_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f88a8472-da80-45e5-91fd-3fc4e5770b37_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_725e80ba-3618-46fa-9b83-db59258d024f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8010e1bb-077c-4457-b9c4-4eb25ed7fcfb_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd3aeb7d-164d-4e1b-ac11-7ec484eaa552_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_8e41a8c6-0cae-469f-98dc-0c3fbfc90103_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation assets</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_062a6a24-fc5e-4cfc-96d8-3e3e3917947a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_74be0639-e72c-467f-9138-dbee038a5c71_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation expense</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:href="cpix-20201231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:to="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_c732c758-f136-416b-ad93-004416e79e46_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e0e5e061-4100-4214-895f-6992a313b80b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54b40a45-26cb-4dc7-897c-f7d7b5b0009a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a01a2b1e-3e06-453d-84db-7be6367db490_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ac650c3d-c8c3-4194-9e26-1a35756a6d64_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e9c56ca5-fbfb-4014-8c60-c793057bd039_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_db302bfb-da81-4efe-b83b-91e38103c356_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20201231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerThreeMember_6df33af9-ff11-4eef-9897-7a799fa3b863_terseLabel_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_label_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_documentation_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember" xlink:href="cpix-20201231.xsd#cpix_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerThreeMember" xlink:to="lab_cpix_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e65b172e-b9cb-4f09-b15d-9a5b7654bbe5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b57e827-3bdb-4921-a0e5-59ef4170e14d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3d50d4d1-3bc2-4a7c-8125-ee1e8071f202_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a27baf7-fa73-40b5-a782-fbd42c3152f3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_b84d4ad3-d47d-412c-93d7-01334714bae8_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20201231.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1a136292-0fd2-4270-806b-40287190a93c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_0ff12f91-5966-4e27-a6ce-dbebb2154e11_terseLabel_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_label_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_documentation_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:href="cpix-20201231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:to="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9e1bce47-a42b-4a7b-80c5-da0e77bae8b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_72c61263-9dab-4d28-b7dc-54fca61784fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_eedd2411-8fb9-4c27-b4d6-52f8a4f752dd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_00478712-98e0-44ae-9135-be15153400bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7be22bfc-e5bf-4fd8-b85e-0e0de757910f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a59d1056-bb92-49d1-bc1c-f3b85598163b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_854a49fa-0b6c-417e-a797-236d72a7ff3e_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payments (percentage)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20201231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_66784aeb-8e7f-41fe-8644-4761d7735359_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_12eca1f9-dcfd-44f4-abbd-8b369e601822_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities associated with discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a8221efc-65c1-4dd7-a1e6-e22d9863d137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred equity offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_08f47588-57e5-4ce2-8098-de3d441bcbd1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0d3778c8-15b0-4742-a99d-e28f6606a43c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b3d52694-b1fc-4e7a-8f52-f62f47b0fe33_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_244a9d8b-5404-4951-b7b7-7348f74abbbb_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss and tax credits</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:to="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4576115d-7893-44ef-96a5-a523d958f4c8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e4b34c83-5b19-45cd-9115-3f2ac4335bab_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Marketing and other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_adf509a2-f7a6-4589-b59a-3b5b51e03e2e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e286512a-1731-4cc6-9b4a-eef5268a82ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bb7663bf-4aff-41eb-b2bf-97f397302ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues concentration from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_198c6803-4e59-4b76-a004-58a73c3fb947_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4cd1d8d8-18eb-460c-ba9f-97bd4b47c64e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b2f7bf6-c1ca-49a9-8d42-f1b89d354300_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_93c5cd9f-f19d-4eea-b435-7af059b8f2b5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f10d269a-d8a8-45a4-a054-3738dd98314c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_9f241bc0-41f9-45dc-973c-0b3c56d3270f_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4e7d8a3b-fd77-456c-b6f5-21b789ce3de1_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_861371ac-e8f8-4aae-8ce4-3d81b74be4d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_49a00775-087a-4c36-b640-6dde6e0be7d2_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d52bb74-ea8d-47fc-82c3-1d9616a2e520_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c03ea312-a0d4-4a9f-8d43-f32890ed16cf_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_91d1f676-e6b7-401d-a3bd-bc731a4ba78a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0292cb94-2589-4d59-952d-4056c07d9158_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b07ba434-6035-4ff8-ab19-7e194cac4348_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e38e8cbd-3677-4e95-b7fb-310085003277_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_700d56dd-858d-4630-9a28-2ad75403cf29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_18e0aee3-140b-42ce-9855-6ea374fa7071_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20201231.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bee84fe7-9583-4f97-afc1-ecb3f9064930_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cc59f727-6fe6-402f-8a63-f1f74a14ecb2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PreferredStockAbstract_47bc2fa7-ca74-468a-911f-84380721deca_terseLabel_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_label_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_documentation_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract" xlink:href="cpix-20201231.xsd#cpix_PreferredStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PreferredStockAbstract" xlink:to="lab_cpix_PreferredStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1104b1a0-540b-43da-bd0f-5974872ac545_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3613b6c8-1db9-4e22-8d46-4a790dcb4d4b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7dd0ec3c-9a08-4281-bb90-e2e6b0068dc9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_bd45fa52-40be-4b26-ae85-afbca88ab290_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1bb5804d-0754-408c-9004-abed1ab43b68_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a3b42d4f-4082-4299-ab67-9b3709b7d282_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fb231bf9-feb4-4186-a129-19f8f7137b56_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinishedGoodsMember_dcb704a5-13c4-4835-af5f-2571c509b715_terseLabel_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_cpix_FinishedGoodsMember_label_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_cpix_FinishedGoodsMember_documentation_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember" xlink:href="cpix-20201231.xsd#cpix_FinishedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinishedGoodsMember" xlink:to="lab_cpix_FinishedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfe466f-c52a-43e5-bf20-5681c0038386_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_78fa35f2-5efc-4638-b7d1-ab96b1fed6ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_c3e98a4b-7192-4f5c-bf20-0022bcb085fa_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_e86936f6-cf22-4577-889e-64dae98b7998_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_e7855a02-dc17-4862-862b-783e7c98622c_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balance sheet classification</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20201231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_dc676ece-9eca-4a05-9088-ca9d0b7cb616_totalLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_391df66e-fdac-46ac-af47-25ef610ce548_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b61af1e7-8f6c-43b6-81aa-b2e29a4df20d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c3d08077-5fc5-4e70-82e7-07904f120280_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_30e11e09-4fb6-49ba-bc9c-9a29b9021cf6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7defc63e-9c71-467d-9a9f-5b6d0eecd8d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c19c20d1-3fbd-4d07-8e7f-056e9f6763ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_3faaf53a-8344-448b-9d2a-d95b55c3ae70_terseLabel_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_label_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_documentation_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member" xlink:href="cpix-20201231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DirectorsIncentivePlan2007Member" xlink:to="lab_cpix_DirectorsIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7c99ed23-6453-4dfd-875c-01d7b655895e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (net of federal income tax benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_0327e7ab-635e-4c24-879f-4ca3b851d162_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:to="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonprincipalOwnerMember_18be8eb2-c8df-413d-9999-452989551c06_terseLabel_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_label_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_documentation_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember" xlink:href="cpix-20201231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonprincipalOwnerMember" xlink:to="lab_cpix_NonprincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_042eca7c-0289-4a61-a331-3a7d5b8a2888_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of subsidiary shares to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_752b5f05-1920-459d-bb79-4d8c6ca52efb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_805d48c5-9de3-4b3c-a259-4d398869fbf7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, number of shares called by warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5a04eb49-147a-4d23-a5f2-583161faf06b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_ffe9fc17-391a-4c8c-b7bb-65ee4097d8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d43c4f90-e01a-46f8-a360-461880802fe8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_35f6dbf9-ba0e-4235-916a-846ea997f41c_terseLabel_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_label_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember" xlink:href="cpix-20201231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAndLicenseRightsMember" xlink:to="lab_cpix_ProductAndLicenseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_086e76b2-6f6a-4533-9fa8-87a4bbb43c0a_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_5f18f9ee-c8d5-4921-82e3-b12a980a0681_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductRightsMember_3ea6b80b-dd5c-430c-be3d-3d6214722f3f_verboseLabel_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights</link:label>
    <link:label id="lab_cpix_ProductRightsMember_label_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember" xlink:href="cpix-20201231.xsd#cpix_ProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRightsMember" xlink:to="lab_cpix_ProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2d6e54a4-a80f-4440-83a0-3e101b1a23b3_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7f405c24-a7df-4106-be4e-f586279a73bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b7a6d796-509e-4dd5-8bb4-861517943c0e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_abb284d4-93be-4fc5-904a-ed6ee6e0d649_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6ef772d4-0ea0-4e83-8fcb-3ce9f1ded824_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_92882852-e5f0-45a1-936f-3fe89dafa94d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_31b441c5-e525-4f05-8c93-c08716d202ad_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_84a310bc-ac9a-4160-89cd-546e0b87eaf5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ac389327-51fd-46cc-bf28-839c0301c651_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_ade3e01d-7153-4440-90f8-1c13d767fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_ead978a0-e4b0-4f13-abb2-af5c75321888_terseLabel_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration</link:label>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_label_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:to="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_6f73713c-6b85-46df-9efb-68ec70b676e7_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_0d1be8b3-2903-49dc-89ef-5804871a8a3e_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange for consideration, amount</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_55314f52-7c88-415f-b6a6-7cccfcaf2788_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ebd7cf25-3390-4846-bccb-5e41f792e2d2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81509902-7e60-49b2-b501-902a893a825c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_527997dd-04ab-464b-8d0e-af53cf0a4cf6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cd862a9c-2b66-46c1-8bdd-a51287cb0161_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_ed970c02-97e6-4db6-8ca3-e98ed23316fe_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c7c31861-35f2-46bd-a576-06ef4a8afb03_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_10d99fd7-ccf3-4495-9e65-9b4796ccc963_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_6e900fef-4ea2-4282-819d-4c7dc2577600_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_90341b3a-bcca-4316-aca7-13c41416b3bd_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed324859-357d-4b6c-be4b-3761c2fa0516_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicMember_0d16ab3a-10af-45a7-9ff3-ab715afb72a4_terseLabel_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:label id="lab_cpix_NordicMember_label_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic [Member]</link:label>
    <link:label id="lab_cpix_NordicMember_documentation_en-US" xlink:label="lab_cpix_NordicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember" xlink:href="cpix-20201231.xsd#cpix_NordicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicMember" xlink:to="lab_cpix_NordicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dba3d8a1-ad25-4d4f-960a-eaea0cb85236_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_14def620-3643-4ca0-af07-bfe68bcbe841_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_04f9f51a-d1e7-4783-b44c-3d80d9c9b769_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex&#174; and Vibativ&#174;</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_2693313d-ba86-4ca1-9641-ec7cfb7cad58_terseLabel_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_label_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:label id="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount_documentation_en-US" xlink:label="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Forgiven in Exchange For Share Issued, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:href="cpix-20201231.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:to="lab_cpix_LoansForgiveninExchangeForShareIssuedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_898fa306-8dcf-4775-a386-b686bdb2d8e4_terseLabel_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_label_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_documentation_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:href="cpix-20201231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:to="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c4994f9c-55d6-4440-854e-729857ea8bf3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating lease liability maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4b34f01a-e12d-447c-9d4a-5a32721e3543_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_e7ed091b-3c9c-49fd-9c31-52d139d0afb8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_8d2fe6c2-545a-4228-aacb-6423779e8950_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:href="cpix-20201231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:to="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e5112128-9afb-4880-a40c-bcf6a98c5667_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a74a2d9d-9fca-46c4-938f-413a10fb4857_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b808dffb-aec1-4ac2-a5fd-fec15ea82387_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate with minimum LIBOR</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_89ab8734-4fb6-45e0-897b-f5b33a9dd6c5_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_36b3bead-7fd3-461a-8e25-045daa0c0ccc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment amount</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_6fa0ab5d-faf6-419d-b196-debb4cf3ec6f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_3ebefaa7-bb5e-4f09-83a5-b807e6b8141b_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, number of shares common stock received in exchange for preferred stock</link:label>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_label_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</link:label>
    <link:label id="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:href="cpix-20201231.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:to="lab_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5aa2e3c0-5387-48fa-a232-1b9a8cee7763_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_e2ac4b1f-3a3a-43cd-bfeb-3ddcf6fab62c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3d8515dd-9024-4378-b403-7b1183417798_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeMember_36f22850-fe07-411b-86c5-562d59cb6281_terseLabel_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_cpix_EmployeeMember_label_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_cpix_EmployeeMember_documentation_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember" xlink:href="cpix-20201231.xsd#cpix_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeMember" xlink:to="lab_cpix_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6c76d8b6-2f9f-46ce-b8fa-1461b80dab95_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermFourMember_46aee3b9-94c7-42eb-80f8-1b025409a6d9_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2031 - 2039</link:label>
    <link:label id="lab_cpix_ExpirationTermFourMember_83e7c9cf-3b57-4740-a977-8c985d4c5aac_verboseLabel_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2040</link:label>
    <link:label id="lab_cpix_ExpirationTermFourMember_label_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Four [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermFourMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermFourMember" xlink:to="lab_cpix_ExpirationTermFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3ec1ba46-34c5-43a9-a5cc-539dbb40a347_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_9ef18571-69a3-44a7-a7df-a16edca65385_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0eb940fb-2ff1-453d-a4a6-c8623e2cf8e4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15691df5-0ad7-4593-9e09-6b3e87448896_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a2a9329-3e5e-4102-bcf8-27bdc75b7506_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc31f62d-d537-4fdb-b2e5-2a1c291d5f64_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7d50a437-653e-4921-8f7e-4c1fe1e2f3d7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_73c2b206-8bf9-4b2e-972a-cc1f63799463_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c9279797-ed48-4a94-90a6-f0d8a92a38d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_aae03d2d-884d-4ec9-9029-af28a3e75e09_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_cf2f0a9a-a829-4a54-83a2-1320da1abb6a_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_cd40cd2d-5517-4d90-8d83-e6f4b726003b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from customers outside the United States</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_39ca3b72-8799-4969-8527-1fdb25e218c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_c60cb0dc-192b-497b-be19-690baa15c8c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e91aa8f9-e3de-4001-8cff-9665b381b7b6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_51bc30d3-a511-4ee1-b0be-253a5731c62b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_b6a2d7f4-bb6b-4883-9b66-e941c13b24a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1b8df2a-c422-43ec-8509-9a1f34d419d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ff5a1e9-e586-42f0-99fc-335e385e47bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8b9ff23c-9b79-4035-ba75-58d0b486f866_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ace472ca-692e-4558-8afe-bf43f4b9c46b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_6d5d808b-ac5c-4ea9-bea9-33b18ac41ae7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_96178a75-14d1-4980-b00f-1873c4eefe74_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_efcfcd35-7d75-4b21-a860-f1c86ea235c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9f5ab285-b9ec-46a3-a937-017cac803478_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e2a39607-839d-4b77-a7ad-ad954198fefa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6af878ba-4a9b-4aef-af18-09dac52c6d81_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_ba9ff80f-b34a-438c-b149-c1492e3cd03f_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_bb1a8928-633b-4fe6-9083-9d805ddff0f0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_c1e7892e-583b-43fa-bebe-dd54ea721f5f_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5d6cfe87-ab09-4ee1-b42e-931acce97808_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid at closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_81c73eb1-c969-4638-b723-a4722cabb0c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ea907c3d-eaa5-4a56-b3a4-d22d72e40f41_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d86c1878-b992-47e7-9f22-314219421a53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c00a896-d333-47c4-bd2a-63c86bcc8eda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d4fb1700-0305-4fde-a17e-b96f8a5390ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c6380846-9753-4c8e-abc2-c68a037f1828_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5519b276-8ba8-458f-b256-bebda437366e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_90bec9f4-5626-498e-b99b-54b9b60b6667_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_95c96c58-5e43-4c93-9a8f-3909e28d4ead_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_c4366697-c570-46be-ab0f-08c4d646a676_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during early 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7806a17e-1bce-48a8-9ce5-c01e0ce47fa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_169ed1ff-2d06-48ca-9c47-d25e08a85caf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_ae359dbe-12db-4b26-9c43-d2d810016ab9_terseLabel_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_label_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_documentation_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract" xlink:href="cpix-20201231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InitialPublicOfferingAbstract" xlink:to="lab_cpix_InitialPublicOfferingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_275c8e7f-be35-4ba2-a674-2734794693cb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_ff2d6dc5-473e-4e1c-b68f-d5c83981da54_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a36891e5-4889-43a5-920e-d73cd55e8365_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a58d45c9-dce7-40cd-8b2b-81259af07920_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bea2617c-7d3f-4b3c-90c9-23adf80efd45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8190129d-8ff4-4844-8983-f330c1725878_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_cd3d73a7-a4b7-4ca6-a616-ec9477461f55_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_77ca6219-be7c-45a9-adfb-b917328cb6ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_16646b6f-d2f2-486c-b799-7ec9b936366f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9bc3fa0b-887c-456f-8e60-7f0fe39e5b67_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a8de0559-566b-4456-a78b-c02cca2a022b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative compensation costs incurred on deductible equity awards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9f82d7ce-dd30-4fdf-a17b-1727cb949dff_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IndefiniteMember_277060b9-60ec-4d08-bb19-c47236d1fdda_terseLabel_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Period</link:label>
    <link:label id="lab_cpix_IndefiniteMember_label_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_cpix_IndefiniteMember_documentation_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember" xlink:href="cpix-20201231.xsd#cpix_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IndefiniteMember" xlink:to="lab_cpix_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2714ae4b-3f28-4b77-ac13-397b321da179_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_1900564b-3a7c-442d-a98d-4ba9813c0af0_terseLabel_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:href="cpix-20201231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_43a37ba0-f302-497a-9f74-88c32a35afab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_5fca1366-76a8-43d6-83ed-5474cdba5e6a_terseLabel_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred acquisition liability</link:label>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_label_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Acquisition Liability, Current</link:label>
    <link:label id="lab_cpix_DeferredAcquisitionLiabilityCurrent_documentation_en-US" xlink:label="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Acquisition Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent" xlink:href="cpix-20201231.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredAcquisitionLiabilityCurrent" xlink:to="lab_cpix_DeferredAcquisitionLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9871681c-d325-44d9-b83e-d49af10260ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_875dd63e-8928-4199-aef0-73c9faec9327_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3eaa82b5-0449-4c66-aa89-4e885211a1bc_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7bc72665-fffc-40a4-9998-0c4b7287cfb3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_e8f9b4fd-0a73-4987-9b4f-551f4eeaaf76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_181270a4-4895-48a4-96b9-211d7b158cc9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7c955f5-1d46-4c1f-b097-6adbcad79e43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermThreeMember_190fa5d8-1c6a-4212-b0cf-4e7f036e2fda_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030</link:label>
    <link:label id="lab_cpix_ExpirationTermThreeMember_bfd092c9-c28e-46ca-9278-04419f6380bb_verboseLabel_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030-2039</link:label>
    <link:label id="lab_cpix_ExpirationTermThreeMember_label_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Three [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermThreeMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermThreeMember" xlink:to="lab_cpix_ExpirationTermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_1439f12c-5577-4b33-9a0a-5f8747b17dd5_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment and intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:to="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11abb9cd-f77c-45aa-a9da-90a12d2a4d8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_644bfc9a-ef20-4c9b-981d-479d223e4961_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6e0d069f-6635-484d-96e0-06424bdb241f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_256eb809-edcd-4f2a-8d0b-f6d9afe83dad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d60febb8-4e40-4847-b4c6-30a0230e7e6d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1a315088-ff02-4bc8-a08c-04bae0221c1a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_9694556d-0780-41dc-871d-bff3f39f838d_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3d7cb033-e60e-47e0-bf57-4f892ec6dcbc_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4832bd39-22d4-483e-9187-fc3d36d560ef_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_96d266c3-3ba1-468d-94f7-cbd03286ecc4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_c8094eae-9ffc-4bc6-86a3-6f09704f19fd_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a077d56d-e6f7-40e1-9a26-d6e464036424_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c6bbedf4-6aae-4b99-bd57-8d918760a7b8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7f37f897-bf06-42a5-8f34-74e240d6b56a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>cpix-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_87ba6f6a-8ae2-4c01-bb71-dea97c5d85d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentType_87ba6f6a-8ae2-4c01-bb71-dea97c5d85d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_57364ba5-0ac0-44ae-9286-3df1026f7fa9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentAnnualReport_57364ba5-0ac0-44ae-9286-3df1026f7fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_438a63db-e8e0-42ed-aa38-d69c7712e8e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentPeriodEndDate_438a63db-e8e0-42ed-aa38-d69c7712e8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_758775b8-be7e-4067-9c28-69a7bba3a5cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentTransitionReport_758775b8-be7e-4067-9c28-69a7bba3a5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6fdb4017-7897-4d85-8f68-0733cacd161d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityRegistrantName_6fdb4017-7897-4d85-8f68-0733cacd161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ddcd20b5-03c8-4697-ac96-664019c95ad4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ddcd20b5-03c8-4697-ac96-664019c95ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_50fd4357-8e89-4627-8954-7439fd2bc9eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityTaxIdentificationNumber_50fd4357-8e89-4627-8954-7439fd2bc9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8ddbdc01-f3cd-467b-9b08-ba5f8616b61b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityFileNumber_8ddbdc01-f3cd-467b-9b08-ba5f8616b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fe719af9-4a99-4dd7-b2fd-7cced7042281" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityCentralIndexKey_fe719af9-4a99-4dd7-b2fd-7cced7042281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cff9a564-96cc-44c6-8aa7-d4b24ab399e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_CurrentFiscalYearEndDate_cff9a564-96cc-44c6-8aa7-d4b24ab399e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9133d2da-6a14-4a4c-a0b5-18671465290f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentFiscalYearFocus_9133d2da-6a14-4a4c-a0b5-18671465290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0e5c2b54-a732-4d94-ab79-cc30de17fcf0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0e5c2b54-a732-4d94-ab79-cc30de17fcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_652df507-650e-4f72-af17-d0cfbb8ceda1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_AmendmentFlag_652df507-650e-4f72-af17-d0cfbb8ceda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d42ea225-0eb8-4955-a079-5304c77cfebe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityAddressAddressLine1_d42ea225-0eb8-4955-a079-5304c77cfebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_aea573c4-0fab-4527-8c41-d55784b20e5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityAddressAddressLine2_aea573c4-0fab-4527-8c41-d55784b20e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_65ab319c-c623-4d2b-9157-85a3ebee7426" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityAddressCityOrTown_65ab319c-c623-4d2b-9157-85a3ebee7426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_928c6420-8a0a-4296-88ba-3c08ed2d4159" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityAddressStateOrProvince_928c6420-8a0a-4296-88ba-3c08ed2d4159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4609086d-1348-46dc-b7d6-ce4d6364d10a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityAddressPostalZipCode_4609086d-1348-46dc-b7d6-ce4d6364d10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d804ae2c-e8ad-4623-8678-3be528a7ac62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_CityAreaCode_d804ae2c-e8ad-4623-8678-3be528a7ac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_79e8c890-0b48-4090-bfe3-45cafea08e47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_LocalPhoneNumber_79e8c890-0b48-4090-bfe3-45cafea08e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6df958bc-251f-4bb8-964a-793d948af461" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_Security12bTitle_6df958bc-251f-4bb8-964a-793d948af461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f3b91b0e-57ce-4864-8dc4-e0958aa6c961" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_TradingSymbol_f3b91b0e-57ce-4864-8dc4-e0958aa6c961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_89c610fb-7f5e-4caf-9eae-283d7a9d17ef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_SecurityExchangeName_89c610fb-7f5e-4caf-9eae-283d7a9d17ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ef4d0000-a214-418d-be3f-ee0fca7c8966" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityFilerCategory_ef4d0000-a214-418d-be3f-ee0fca7c8966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b5f92a26-0f7c-4a79-a1d0-21a477d8eb29" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityEmergingGrowthCompany_b5f92a26-0f7c-4a79-a1d0-21a477d8eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a8c32f7e-dfe9-49b7-9f6c-24cad1bfebed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntitySmallBusiness_a8c32f7e-dfe9-49b7-9f6c-24cad1bfebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bcce19a6-3a35-489a-a7b2-0ca5153ee412" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityShellCompany_bcce19a6-3a35-489a-a7b2-0ca5153ee412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c7418683-1af2-4a6b-ad83-c3303b997029" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c7418683-1af2-4a6b-ad83-c3303b997029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_78476493-738b-455e-8754-ca7668001d84" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityVoluntaryFilers_78476493-738b-455e-8754-ca7668001d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_29ee6c19-e9e2-4be8-9b79-5120ba814e11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityCurrentReportingStatus_29ee6c19-e9e2-4be8-9b79-5120ba814e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_143373e4-3ac2-4501-b7ac-24612b3d749c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityInteractiveDataCurrent_143373e4-3ac2-4501-b7ac-24612b3d749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_fe0a4ce9-9062-4fea-82de-ef2edaeb9b47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityPublicFloat_fe0a4ce9-9062-4fea-82de-ef2edaeb9b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6a144105-5c57-4fee-86bc-9a21fa27a376" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6a144105-5c57-4fee-86bc-9a21fa27a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0e0cd9a8-807a-4011-a0df-bb4f79e5a90b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7eb797d-b52c-4f0a-8e2c-fef0a50b7a69" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0e0cd9a8-807a-4011-a0df-bb4f79e5a90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7a4383f6-25db-40e7-b8e6-6a197dcb6387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a4383f6-25db-40e7-b8e6-6a197dcb6387" xlink:to="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_852dae3d-b914-4903-bb12-872ee2318d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_852dae3d-b914-4903-bb12-872ee2318d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e168bdc5-33a0-4762-9872-65f3ec99fecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e168bdc5-33a0-4762-9872-65f3ec99fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4b00ad9c-01a2-40ad-9765-47f6d481eaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_InventoryNet_4b00ad9c-01a2-40ad-9765-47f6d481eaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_727710f9-20d4-4726-82e7-4ece94dade01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_727710f9-20d4-4726-82e7-4ece94dade01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5be769ef-5aaf-41c9-b0a0-9621a5e687d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5be769ef-5aaf-41c9-b0a0-9621a5e687d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cbe51e70-853a-484d-a95b-469494733f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1b51d7bf-0930-4a2d-9e01-7792046b07b9" xlink:to="loc_us-gaap_AssetsCurrent_cbe51e70-853a-484d-a95b-469494733f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ef3da67e-f35a-4eeb-a176-4634d06bea37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_InventoryNoncurrent_ef3da67e-f35a-4eeb-a176-4634d06bea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3e438a7d-a753-4256-b1eb-8a997d0b405b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3e438a7d-a753-4256-b1eb-8a997d0b405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07815d25-b3c9-4ea8-9f7f-d93f45af6743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_07815d25-b3c9-4ea8-9f7f-d93f45af6743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ada2c1a-a7ca-4cf5-b9ae-39fad8187b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_Goodwill_0ada2c1a-a7ca-4cf5-b9ae-39fad8187b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_fb1c7b54-91c5-45ae-b403-ab7f6df35f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_fb1c7b54-91c5-45ae-b403-ab7f6df35f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_db9d9dad-08b2-416e-8e0e-5ba089416f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_db9d9dad-08b2-416e-8e0e-5ba089416f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb3f9a8c-6728-451c-83f6-3d0c3bad85bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb3f9a8c-6728-451c-83f6-3d0c3bad85bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9ca99b72-a86a-49c8-8510-b2bb95cb86b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1709a477-3ba9-44b4-b59e-055019100d57" xlink:to="loc_us-gaap_Assets_9ca99b72-a86a-49c8-8510-b2bb95cb86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a4383f6-25db-40e7-b8e6-6a197dcb6387" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_29f57193-7fa3-471e-beaf-c6e65acae099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:to="loc_us-gaap_AccountsPayableCurrent_29f57193-7fa3-471e-beaf-c6e65acae099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff99fbd2-77fc-4e0f-9775-25ecfe377238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff99fbd2-77fc-4e0f-9775-25ecfe377238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bf624a6d-6838-439a-a00c-ab1e90852071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bf624a6d-6838-439a-a00c-ab1e90852071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_afd57324-135c-4edf-a8e7-eef5aca35c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_afd57324-135c-4edf-a8e7-eef5aca35c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9627913e-ec12-40df-918b-e5e08cdbee4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1744df38-41b8-41b9-a625-40aecba406e6" xlink:to="loc_us-gaap_LiabilitiesCurrent_9627913e-ec12-40df-918b-e5e08cdbee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_98c6d478-5d32-4536-a9ba-ea3298162db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_LongTermLineOfCredit_98c6d478-5d32-4536-a9ba-ea3298162db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3abea10f-b011-4b3e-b5c2-5e9bb581c97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3abea10f-b011-4b3e-b5c2-5e9bb581c97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_03b39dee-de00-464a-9177-eb856174defe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_03b39dee-de00-464a-9177-eb856174defe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fab07b2c-c914-454c-a35f-3f76e608bf90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_Liabilities_fab07b2c-c914-454c-a35f-3f76e608bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b7f2a082-41ca-4446-8b7a-ec7e479d9e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b7f2a082-41ca-4446-8b7a-ec7e479d9e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c979cfcf-4fd8-4738-8484-2cf3acf5db0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c979cfcf-4fd8-4738-8484-2cf3acf5db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_563ae857-5c69-4914-b359-33134d2b2a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c979cfcf-4fd8-4738-8484-2cf3acf5db0b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_563ae857-5c69-4914-b359-33134d2b2a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_37f1a628-8b94-4e9e-a9ed-cdce9d0f001f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_563ae857-5c69-4914-b359-33134d2b2a0f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_37f1a628-8b94-4e9e-a9ed-cdce9d0f001f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d462be7-d642-4bb1-88a2-5d8b677a6547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_563ae857-5c69-4914-b359-33134d2b2a0f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d462be7-d642-4bb1-88a2-5d8b677a6547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d921064-0979-4407-9c22-d8f36e9a3feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_563ae857-5c69-4914-b359-33134d2b2a0f" xlink:to="loc_us-gaap_StockholdersEquity_1d921064-0979-4407-9c22-d8f36e9a3feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_13c8ff46-1874-4e37-be4c-7d3ba1889c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c979cfcf-4fd8-4738-8484-2cf3acf5db0b" xlink:to="loc_us-gaap_MinorityInterest_13c8ff46-1874-4e37-be4c-7d3ba1889c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df85136b-6e79-47f0-954d-52fe68c35e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c979cfcf-4fd8-4738-8484-2cf3acf5db0b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df85136b-6e79-47f0-954d-52fe68c35e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0cf64f38-a747-420a-96ae-37fba5d5a15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a656279-b75c-4be2-824a-5746a186659b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0cf64f38-a747-420a-96ae-37fba5d5a15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ade8d9c6-196f-48e5-bcf3-39ea535530b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_7652fca9-8b82-489f-b6fb-d80af57ffe42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade8d9c6-196f-48e5-bcf3-39ea535530b1" xlink:to="loc_us-gaap_CommonStockNoParValue_7652fca9-8b82-489f-b6fb-d80af57ffe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_41799913-9e65-4cdc-9c2e-20afe1f0f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade8d9c6-196f-48e5-bcf3-39ea535530b1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_41799913-9e65-4cdc-9c2e-20afe1f0f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5ef62991-4016-4380-90a3-dfe1c5b4a46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade8d9c6-196f-48e5-bcf3-39ea535530b1" xlink:to="loc_us-gaap_CommonStockSharesIssued_5ef62991-4016-4380-90a3-dfe1c5b4a46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3ef451b9-37b6-4fc3-97f5-d1c026cd7690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade8d9c6-196f-48e5-bcf3-39ea535530b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3ef451b9-37b6-4fc3-97f5-d1c026cd7690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5893be4f-d194-452c-9a26-0cb7843b431a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5893be4f-d194-452c-9a26-0cb7843b431a" xlink:to="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:to="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87a65223-592d-4e4d-8d14-8f73d4b7a776" xlink:to="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_491dd531-3c6e-4434-bf2a-ddf45dae61c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:to="loc_us-gaap_ProductMember_491dd531-3c6e-4434-bf2a-ddf45dae61c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_aaa407b9-b396-4c13-8ba1-0766fbe30172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21e1b7e0-0353-4999-ba30-7f43beaceeed" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_aaa407b9-b396-4c13-8ba1-0766fbe30172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cde7a9c0-71d9-4e6b-80d7-10b58fc90993" xlink:to="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_97028044-3878-4a04-98ce-5484a3f41965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4c35ad98-4260-4125-a166-25678cfce00a" xlink:to="loc_us-gaap_Revenues_97028044-3878-4a04-98ce-5484a3f41965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c39b67cb-a8da-4c33-a7e4-a659a6515fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c39b67cb-a8da-4c33-a7e4-a659a6515fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_e13df349-31fa-422e-a256-be52c8e72bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_SellingAndMarketingExpense_e13df349-31fa-422e-a256-be52c8e72bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a079202b-e9f3-4bc3-9db2-17caf1c2f74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a079202b-e9f3-4bc3-9db2-17caf1c2f74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a7f29bc-e79c-41b2-9928-2f959e134639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a7f29bc-e79c-41b2-9928-2f959e134639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_36afdbc1-b79e-459b-938c-fcee9c6adf3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_36afdbc1-b79e-459b-938c-fcee9c6adf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_00659c01-9975-43ea-ae2a-e441f6ca20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56feb250-a336-480d-9775-8f543fb9336c" xlink:to="loc_us-gaap_CostsAndExpenses_00659c01-9975-43ea-ae2a-e441f6ca20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4a76e62-3d93-460c-bb9b-4501403c59f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_OperatingIncomeLoss_b4a76e62-3d93-460c-bb9b-4501403c59f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d9ae8c0d-f4da-41d0-9ace-51984005d1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d9ae8c0d-f4da-41d0-9ace-51984005d1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dd3d9bc3-0ed4-47eb-a39e-62f1e256c079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_InterestExpense_dd3d9bc3-0ed4-47eb-a39e-62f1e256c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d631107-fd73-43d6-b706-35d84d83cd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d631107-fd73-43d6-b706-35d84d83cd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ea9e508-83e2-4d7d-a3db-c1e5b8e39deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ea9e508-83e2-4d7d-a3db-c1e5b8e39deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_776d2b62-958d-4a27-aad5-5cd280b23b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_776d2b62-958d-4a27-aad5-5cd280b23b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_133cd709-a156-411f-811d-0963dacc647e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_133cd709-a156-411f-811d-0963dacc647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e11462a-3801-40eb-afd4-28b317b4f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_ProfitLoss_0e11462a-3801-40eb-afd4-28b317b4f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_470365f8-4ada-4edf-8d66-d33ad648c398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_470365f8-4ada-4edf-8d66-d33ad648c398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4e04740-0b7f-49e0-8ffb-e5d6dd45e726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_NetIncomeLoss_b4e04740-0b7f-49e0-8ffb-e5d6dd45e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c05c10fd-6fcd-4a59-9463-14f1e1e90b45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c05c10fd-6fcd-4a59-9463-14f1e1e90b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46fd2ff8-09c2-4d37-bb90-0d4ba23846da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46fd2ff8-09c2-4d37-bb90-0d4ba23846da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d08f4623-371d-47c2-bb63-e57d3969b6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_EarningsPerShareBasic_d08f4623-371d-47c2-bb63-e57d3969b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_27f834d7-ab27-475a-b914-28e052d3ae59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_27f834d7-ab27-475a-b914-28e052d3ae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_367972cf-d531-4b2a-bc62-8e6438663173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_367972cf-d531-4b2a-bc62-8e6438663173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_371c31fe-ab2e-44bd-b490-72dee917cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46c895fa-cc55-4ffd-b7df-ef0d27f9d5de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_371c31fe-ab2e-44bd-b490-72dee917cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6db7b7c-4cb1-4dc7-bc0b-7e2d24e3fb57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c908f40a-d8f7-431f-b7cb-9e94ae4676b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c908f40a-d8f7-431f-b7cb-9e94ae4676b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03fe7fce-8fc0-40f9-9271-01947706ee9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f4deade5-2b01-46bf-90d6-d965ac58f8ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03fe7fce-8fc0-40f9-9271-01947706ee9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_503f1dbe-fe3b-4140-8322-c1fd26433182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_ProfitLoss_503f1dbe-fe3b-4140-8322-c1fd26433182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ccfb69c6-7de9-4cdf-869a-a8f0065bb10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ccfb69c6-7de9-4cdf-869a-a8f0065bb10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_403b659e-47f3-45c8-b979-ed9abe2f0cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_403b659e-47f3-45c8-b979-ed9abe2f0cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_27866c2b-1281-4596-9b10-9fa6fcb36a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_27866c2b-1281-4596-9b10-9fa6fcb36a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c453ca3-fb87-488a-9d07-7ce6eb0b1203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c453ca3-fb87-488a-9d07-7ce6eb0b1203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4469fd26-8520-4f43-9c65-a65459a7de6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_ShareBasedCompensation_4469fd26-8520-4f43-9c65-a65459a7de6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_edc0ce9e-55c2-45fb-8401-e6aed1ddbb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_edc0ce9e-55c2-45fb-8401-e6aed1ddbb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_3318430b-c10a-4bff-86f1-a021f803bdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_3318430b-c10a-4bff-86f1-a021f803bdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_734102f4-fc2e-4428-8b51-b276e99c19e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_734102f4-fc2e-4428-8b51-b276e99c19e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_82ca6852-f51a-427a-b091-e4ec23a1537e" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_82ca6852-f51a-427a-b091-e4ec23a1537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c4191457-b535-4d1b-b2e2-6c3ffd289a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c4191457-b535-4d1b-b2e2-6c3ffd289a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_d6341791-f2a7-412d-a806-c4bce27e6447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_d6341791-f2a7-412d-a806-c4bce27e6447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c4ff93c-b73b-466f-ba95-45c232aaf155" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32d6489f-7e39-4c20-9e5e-9c4a9d242666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32d6489f-7e39-4c20-9e5e-9c4a9d242666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b8ea5eaa-bbee-44a5-a13f-951065e0bf08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b8ea5eaa-bbee-44a5-a13f-951065e0bf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_322e9e08-4367-4e99-b486-7f6d109f7b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_322e9e08-4367-4e99-b486-7f6d109f7b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_844dfd09-6134-4b0d-ac47-55ae51563135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_844dfd09-6134-4b0d-ac47-55ae51563135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94978771-63fa-4f45-b467-37de1a987681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94978771-63fa-4f45-b467-37de1a987681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e201ee8a-ad73-404f-bce7-5500ade0a8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f72f5293-168c-43bf-848e-3569e10567c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e201ee8a-ad73-404f-bce7-5500ade0a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1aacbc23-74cc-419a-b2ca-dd3063833912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1aacbc23-74cc-419a-b2ca-dd3063833912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_979785ee-18c8-47fc-9e7e-eddf50edb226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b688ba6-8c74-40c2-9e31-7c2e874f9479" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_979785ee-18c8-47fc-9e7e-eddf50edb226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_de874e29-6b46-4f49-b199-bc98c39508e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_de874e29-6b46-4f49-b199-bc98c39508e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_afde8f9c-411e-4665-8cfd-84f2f1a44986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_afde8f9c-411e-4665-8cfd-84f2f1a44986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_f1c57e27-6048-4777-85cc-a7dd7f41170c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_f1c57e27-6048-4777-85cc-a7dd7f41170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_3010522c-9566-42b2-88cd-5c241b0f7dc2" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_3010522c-9566-42b2-88cd-5c241b0f7dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2eff8c0a-f172-4a9f-8c31-6c7bcd9ba868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2eff8c0a-f172-4a9f-8c31-6c7bcd9ba868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_906fe48c-dce7-4852-8685-40698af9e287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_906fe48c-dce7-4852-8685-40698af9e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e7b9c02a-e067-4db2-9e37-d5dee923ed5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e7b9c02a-e067-4db2-9e37-d5dee923ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da604e87-9cd0-4ba2-bbb5-4af107095498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1e05528-b892-4aa0-add8-224bb37b080c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da604e87-9cd0-4ba2-bbb5-4af107095498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_c3e6d181-cba2-4547-956a-8182695db1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_c3e6d181-cba2-4547-956a-8182695db1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d9d56e49-cb42-4ce0-84bc-e54c722dec74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d9d56e49-cb42-4ce0-84bc-e54c722dec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_00adac85-4f82-4e56-9eba-a7d975890bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_00adac85-4f82-4e56-9eba-a7d975890bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_484c4b6c-d901-4d6a-aeff-f6e291aea120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_484c4b6c-d901-4d6a-aeff-f6e291aea120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0752d2ec-badb-48d4-8b79-45e71f0cb373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0752d2ec-badb-48d4-8b79-45e71f0cb373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_c32af424-2a8a-4849-ae24-0de963c2035c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_c32af424-2a8a-4849-ae24-0de963c2035c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d29fc946-a746-4f47-b529-75dea117932f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d29fc946-a746-4f47-b529-75dea117932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_6c35a7fa-cfe3-4df2-8edf-c838779ee556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_6c35a7fa-cfe3-4df2-8edf-c838779ee556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_34a5b97d-463c-4fac-a664-9ac6e40d4d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_34a5b97d-463c-4fac-a664-9ac6e40d4d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ae21738a-bc32-49ed-a8d6-561fa33f0529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f673c6b0-2edf-4ccd-b5e6-fa5921ef87f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ae21738a-bc32-49ed-a8d6-561fa33f0529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb85349a-c7ad-48c8-b67d-006bc13383b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb85349a-c7ad-48c8-b67d-006bc13383b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9ecbebc-bc3e-48d3-b586-d293556a58b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9ecbebc-bc3e-48d3-b586-d293556a58b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c22eda09-075f-40d9-bd9a-d45a615e11a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c22eda09-075f-40d9-bd9a-d45a615e11a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e80b776e-fdf1-4cc4-99c0-dc1214947a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c470ce47-f2b3-4bef-96ad-7b5c0b869205" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e80b776e-fdf1-4cc4-99c0-dc1214947a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract_4c7f5ae7-0344-492e-ba17-c3fa9a1418f5" xlink:href="cpix-20201231.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e80b776e-fdf1-4cc4-99c0-dc1214947a55" xlink:to="loc_cpix_CashPaidDuringYearForAbstract_4c7f5ae7-0344-492e-ba17-c3fa9a1418f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f07232ae-3241-48cf-952c-352d1689ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_4c7f5ae7-0344-492e-ba17-c3fa9a1418f5" xlink:to="loc_us-gaap_InterestPaidNet_f07232ae-3241-48cf-952c-352d1689ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_01ca71b6-fe50-42c4-a6c5-da7ca54c8eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_4c7f5ae7-0344-492e-ba17-c3fa9a1418f5" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_01ca71b6-fe50-42c4-a6c5-da7ca54c8eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e80b776e-fdf1-4cc4-99c0-dc1214947a55" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_0eb58c50-cb8a-4868-a236-8cb10f11db71" xlink:href="cpix-20201231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_0eb58c50-cb8a-4868-a236-8cb10f11db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_095eefb9-693c-4089-9287-26b4e5e68b42" xlink:href="cpix-20201231.xsd#cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses_095eefb9-693c-4089-9287-26b4e5e68b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_61b28790-aa11-418e-bad9-108bd1e7c701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_61b28790-aa11-418e-bad9-108bd1e7c701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_acad06b1-31c8-4a45-b663-6bed972b961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_acad06b1-31c8-4a45-b663-6bed972b961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares_d9b51e61-fb63-46a8-a29d-3cce1f30bfee" xlink:href="cpix-20201231.xsd#cpix_NoncashOrPartNoncashTransactionVestingOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_cpix_NoncashOrPartNoncashTransactionVestingOfShares_d9b51e61-fb63-46a8-a29d-3cce1f30bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_97970fa9-8e32-48d2-a35f-9e02da8e3176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_97970fa9-8e32-48d2-a35f-9e02da8e3176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_acb578ed-b5dc-464a-9044-b4621f408b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0249489f-6347-42b6-9f67-de3d791785f5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_acb578ed-b5dc-464a-9044-b4621f408b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb6a80cd-4a2c-4115-93b8-031f66f726be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb6a80cd-4a2c-4115-93b8-031f66f726be" xlink:to="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40f7a79a-1c2b-4981-8ebc-38d988beda20" xlink:to="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d34e8c33-d2fd-4c0d-9716-ae93ad418590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_CommonStockMember_d34e8c33-d2fd-4c0d-9716-ae93ad418590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_990f3020-9e50-446f-bf11-f6b32db681ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_RetainedEarningsMember_990f3020-9e50-446f-bf11-f6b32db681ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6ffc19b3-3c15-4cf7-9bac-2c329f9b6e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc3fc309-83fc-4688-a5e6-685ea643968b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6ffc19b3-3c15-4cf7-9bac-2c329f9b6e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2d34047-b96d-41b3-809f-e6a8be165921" xlink:to="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_413ee7e2-8c1f-4ab0-b218-92ceb0702d0f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06de9eb5-47f1-44fc-92b0-85e8ebf1f571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06de9eb5-47f1-44fc-92b0-85e8ebf1f571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_96c370d3-696f-4727-a896-9cf04356dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_96c370d3-696f-4727-a896-9cf04356dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0034dc54-4981-4f47-b956-49ae83517dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NetIncomeLoss_0034dc54-4981-4f47-b956-49ae83517dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a9f4507-5e83-48c4-be2c-e1db76b1a37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a9f4507-5e83-48c4-be2c-e1db76b1a37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9771e75-4f5a-4dbc-a08e-a38748733894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_ProfitLoss_d9771e75-4f5a-4dbc-a08e-a38748733894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8fabe458-691e-4fcc-83e8-ef354b025ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8fabe458-691e-4fcc-83e8-ef354b025ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67002b52-4afb-46d4-8e55-2b413d93631a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67002b52-4afb-46d4-8e55-2b413d93631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4dd4a21d-e20b-41da-82ee-922451a71627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4dd4a21d-e20b-41da-82ee-922451a71627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40f10509-ad1d-45cf-9128-a66458d3f99a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_40f10509-ad1d-45cf-9128-a66458d3f99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f5ab239f-9348-40f1-bdea-5a98630dd6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f5ab239f-9348-40f1-bdea-5a98630dd6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e0fd7a6-151d-4b04-98d0-c5a85e800deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e0fd7a6-151d-4b04-98d0-c5a85e800deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1fc4e7e5-edfd-4671-ac79-31dbda23a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1fc4e7e5-edfd-4671-ac79-31dbda23a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d1dba8ed-a287-44d1-8503-86cd081a00c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d1dba8ed-a287-44d1-8503-86cd081a00c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_24726095-0d0b-47fb-8b71-d817314585c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_24726095-0d0b-47fb-8b71-d817314585c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5315d074-eb9e-405d-a811-f535c954e958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5315d074-eb9e-405d-a811-f535c954e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038860ca-7be1-43b7-bd2c-cdcd2c929fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038860ca-7be1-43b7-bd2c-cdcd2c929fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8365b24c-7185-4395-aa9a-8b22ea5e606e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5de31a0f-77ac-4b19-82d6-4456dc4d4389" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8365b24c-7185-4395-aa9a-8b22ea5e606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8021c952-727e-40be-9aeb-7704a664d76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d7754291-3e4e-4107-830b-5f75f53fa6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8021c952-727e-40be-9aeb-7704a664d76d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d7754291-3e4e-4107-830b-5f75f53fa6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2284e12f-edac-48b5-a390-d82e15cac48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2284e12f-edac-48b5-a390-d82e15cac48f" xlink:to="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e2fb26d7-ec55-4ae1-b764-d7f255cffb50" xlink:to="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_ecb70fa5-1d04-434c-ad4b-294b7f976754" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e4a675c7-fb55-4ca6-a7c0-e3f70780111c" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_ecb70fa5-1d04-434c-ad4b-294b7f976754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7b98552f-dd6a-4c8e-8d84-5e95d204fd16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c32f6e0e-c65e-41c6-9821-b02d85f579ba" xlink:href="cpix-20201231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c32f6e0e-c65e-41c6-9821-b02d85f579ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_cf5ba650-091d-4a11-b4b9-6c98c84417b4" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_cf5ba650-091d-4a11-b4b9-6c98c84417b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_48ba2c06-cd10-4c53-a85e-badb8e69702a" xlink:href="cpix-20201231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_392df747-852c-4e92-8ac1-7f85791aed64" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_48ba2c06-cd10-4c53-a85e-badb8e69702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f80a96ad-9548-4fb6-8c6b-4f8323fabdf6" xlink:to="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_d746bd84-e07c-4de9-ab21-ebfd2cd60cff" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_91b5d659-0d38-41a7-b6a4-f20f8113dd94" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_d746bd84-e07c-4de9-ab21-ebfd2cd60cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e155b070-b158-4fb0-9307-84f88d1ff929" xlink:to="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_ce7600bd-a668-4cc2-9452-3614f6e94f61" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_f5f67904-da13-4a9a-bfc3-24bb3fbefa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_f5f67904-da13-4a9a-bfc3-24bb3fbefa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_5fac1281-453e-4d1f-b47f-62cd965d2eb5" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_5fac1281-453e-4d1f-b47f-62cd965d2eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_46cc4b35-af16-44c3-a91c-34c81ed412ef" xlink:href="cpix-20201231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_46cc4b35-af16-44c3-a91c-34c81ed412ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_a40547e5-b3b8-480d-886a-77a2bab6c1a6" xlink:href="cpix-20201231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_a40547e5-b3b8-480d-886a-77a2bab6c1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_1e5562eb-2728-47be-8a45-6bb60d4657f6" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_1e5562eb-2728-47be-8a45-6bb60d4657f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0cf5d69f-e1b7-41e6-b508-1a2a320f5797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0cf5d69f-e1b7-41e6-b508-1a2a320f5797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f275480f-002e-414d-ba70-7d1cda1f5f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_747336d8-bf45-4ee6-828f-607807ec00f6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f275480f-002e-414d-ba70-7d1cda1f5f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_157c2fa5-1f28-420d-8ebc-2d54937c88e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8a24b92b-dcb0-4f7a-bb29-19119ffb882c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_157c2fa5-1f28-420d-8ebc-2d54937c88e4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8a24b92b-dcb0-4f7a-bb29-19119ffb882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e46f1c4d-a078-46df-83f4-e4aecd53ff5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e46f1c4d-a078-46df-83f4-e4aecd53ff5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ee6b425d-8208-47ad-8b7c-4f24798b4706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_UseOfEstimates_ee6b425d-8208-47ad-8b7c-4f24798b4706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5af3484a-9cc7-48b7-9c66-befe7094d976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5af3484a-9cc7-48b7-9c66-befe7094d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a2451b9d-e8c5-4f35-bcc1-ad948c4461fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a2451b9d-e8c5-4f35-bcc1-ad948c4461fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cb141171-2b5d-4a8a-a311-a919531c06a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cb141171-2b5d-4a8a-a311-a919531c06a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_b77be8c7-9247-4dac-b3a2-d360f866987d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_b77be8c7-9247-4dac-b3a2-d360f866987d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ab7cb067-6152-4ecf-9d96-09661e7ff3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ab7cb067-6152-4ecf-9d96-09661e7ff3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d4ed4009-f3ce-41ff-9fb6-af694970558c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d4ed4009-f3ce-41ff-9fb6-af694970558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_72cd9f1a-22cc-4401-910a-05d76d9fbf99" xlink:href="cpix-20201231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_72cd9f1a-22cc-4401-910a-05d76d9fbf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0ce03d03-d3f3-4adf-a5ba-93ed9d4ecdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0ce03d03-d3f3-4adf-a5ba-93ed9d4ecdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3caf5f44-cfc4-487f-8ef7-17267d6f3fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3caf5f44-cfc4-487f-8ef7-17267d6f3fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_20e820dd-dd5e-41ad-b005-a00582b195de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_20e820dd-dd5e-41ad-b005-a00582b195de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d337c875-e668-4bf1-80bf-4c37bcf46a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d337c875-e668-4bf1-80bf-4c37bcf46a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7768aa9a-f72f-44ee-a160-9b2a32b8050c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7768aa9a-f72f-44ee-a160-9b2a32b8050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_df468015-726b-4a12-b5ad-ba1143d016a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_df468015-726b-4a12-b5ad-ba1143d016a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c3d6b979-5a54-418d-86ee-94bc8ed7ff17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c3d6b979-5a54-418d-86ee-94bc8ed7ff17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_69f3ca15-22fb-4119-9b58-4e7c82f2789a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_69f3ca15-22fb-4119-9b58-4e7c82f2789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ff886150-0075-44a5-8be9-ff9943268b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ff886150-0075-44a5-8be9-ff9943268b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_12214c95-3b4a-489a-a651-d2687dd3e791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_12214c95-3b4a-489a-a651-d2687dd3e791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_814e4f56-9f4f-4f77-b5be-dbf4da5fa96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c39bc6ee-e179-4adf-b9f2-24b321876cda" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_814e4f56-9f4f-4f77-b5be-dbf4da5fa96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19ad9872-2afd-425d-bbcc-6bff1c32b419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_2d2ab781-8a9c-4951-972f-14d01c7b3ad4" xlink:href="cpix-20201231.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19ad9872-2afd-425d-bbcc-6bff1c32b419" xlink:to="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_2d2ab781-8a9c-4951-972f-14d01c7b3ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dc46381b-8624-4c39-a743-20e2352b08b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dc46381b-8624-4c39-a743-20e2352b08b5" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3b7f90f6-ed25-4ee9-b13e-53d3c0815830" xlink:to="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bd6d00b9-7957-495e-819d-e764cbf31b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7355cf4a-fbd6-4eec-80a5-20ed08254867" xlink:to="loc_us-gaap_NonUsMember_bd6d00b9-7957-495e-819d-e764cbf31b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82f487b9-9916-4b1b-bda9-9999f98e017a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda999d7-631f-496d-a7f9-8f448224f5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d47afa27-1dab-4359-8199-fa551cc2232e" xlink:to="loc_us-gaap_SubsequentEventMember_dda999d7-631f-496d-a7f9-8f448224f5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c8c328f5-1702-416e-97b0-21c258db9eb8" xlink:to="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0ef0dd45-037f-4521-a11f-f7d37a2e303f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:to="loc_srt_MinimumMember_0ef0dd45-037f-4521-a11f-f7d37a2e303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b515d902-48b0-44f9-ac03-6e58bdf879db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e90b9ef-6227-4959-bc1d-9213875ebfe2" xlink:to="loc_srt_MaximumMember_b515d902-48b0-44f9-ac03-6e58bdf879db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:href="cpix-20201231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_f77eb379-db6b-42af-a573-0718e6854035" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_9ed91f1b-48f1-4805-a3c4-c86675d5e9f5" xlink:href="cpix-20201231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_d6b8c190-6c81-4707-b700-727436d8e9f8" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_9ed91f1b-48f1-4805-a3c4-c86675d5e9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f6e7e5d-364f-4d83-9b16-c5aa4ae9ef6f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_0388ad1c-8ac0-4287-889f-c11d0a21ee8e" xlink:href="cpix-20201231.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c57d2e57-648a-4592-92d9-1ab7a93ea3ec" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_0388ad1c-8ac0-4287-889f-c11d0a21ee8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9d8b80fb-69ee-4552-89d1-13368ddc9aea" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3f51f956-ac82-4854-af6f-d1c5de5e4154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3f51f956-ac82-4854-af6f-d1c5de5e4154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_12c45cb4-15f9-458c-a95d-20f6a6fb827f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_Revenues_12c45cb4-15f9-458c-a95d-20f6a6fb827f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2406d255-b41a-4a42-9e48-17e344db4d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2406d255-b41a-4a42-9e48-17e344db4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed35ef98-b647-4f49-8bf2-c18ce9241a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed35ef98-b647-4f49-8bf2-c18ce9241a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b75f9e22-0e99-48cf-9170-689c2438c247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3355bac7-4efb-4280-b23e-df113d73416f" xlink:to="loc_us-gaap_OperatingLeaseLiability_b75f9e22-0e99-48cf-9170-689c2438c247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_21cd8b69-ed94-41be-a13e-c4291007c44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_21cd8b69-ed94-41be-a13e-c4291007c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_fa56b1a5-9a83-45a0-8a47-8d554e0556f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_AdvertisingExpense_fa56b1a5-9a83-45a0-8a47-8d554e0556f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_bfc5ceff-5c3f-48d2-bcde-5d593780c8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_bfc5ceff-5c3f-48d2-bcde-5d593780c8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a552e9b3-130b-4fa7-abb4-6ea3652bf614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_69cda5cf-bf9e-42d2-b6c9-b0a0fa5cac53" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a552e9b3-130b-4fa7-abb4-6ea3652bf614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3fef9451-8ca5-4af6-a9f0-3ae437114da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3fef9451-8ca5-4af6-a9f0-3ae437114da6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba0fdb5b-c779-4f53-93e7-db0b7c4ae873" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_dd57cd98-6c88-4195-ac99-90b80a17d8ef" xlink:href="cpix-20201231.xsd#cpix_ProductRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_cpix_ProductRightsMember_dd57cd98-6c88-4195-ac99-90b80a17d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_269841f5-7d91-4325-8784-4a60713078bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_us-gaap_LicensingAgreementsMember_269841f5-7d91-4325-8784-4a60713078bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_35338164-af5c-4a49-a12e-149e3ccb9322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_29a33e9f-20b0-4142-8eb6-b6641cd9db19" xlink:to="loc_us-gaap_PatentsMember_35338164-af5c-4a49-a12e-149e3ccb9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_125e3bf8-8b03-40f7-8405-22ed02c54397" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_cba119a2-2ef3-448d-8d49-f7f9ba6c2d65" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eef1a1b7-ad66-469a-a1d8-4b0258134a45" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_cba119a2-2ef3-448d-8d49-f7f9ba6c2d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativ"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5356ecc4-20e6-4ddc-80c0-4df785f5ed42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6752b47e-9955-43f4-8e93-01c3529c0719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5356ecc4-20e6-4ddc-80c0-4df785f5ed42" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6752b47e-9955-43f4-8e93-01c3529c0719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_56709fa6-cd97-43f4-8a65-fe990a53e2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_5d276ea0-a031-441d-9d0b-9f81ab25e31c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_56709fa6-cd97-43f4-8a65-fe990a53e2af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_5d276ea0-a031-441d-9d0b-9f81ab25e31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40e7403c-fbb2-4c0c-82a7-0726e0686894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_56709fa6-cd97-43f4-8a65-fe990a53e2af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40e7403c-fbb2-4c0c-82a7-0726e0686894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_26126b13-ceae-4e00-a79c-0870d0117b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_56709fa6-cd97-43f4-8a65-fe990a53e2af" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_26126b13-ceae-4e00-a79c-0870d0117b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_99d6207f-4f1b-4ad2-a4c6-339e09604b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_99d6207f-4f1b-4ad2-a4c6-339e09604b35" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4ac78d6d-447f-41c4-bdc8-64b18663ed18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a798c3f-0c7a-4585-a275-304f08f009eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bccf31-035d-4a8b-9d8f-987561e52fd7" xlink:to="loc_us-gaap_RestrictedStockMember_7a798c3f-0c7a-4585-a275-304f08f009eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8ad07aa6-c644-4b80-943f-4c7221a213ef" xlink:to="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_03e4f925-5ecf-485b-965b-eaf1cee6ab4c" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e82d514f-d7ef-49fe-9a7e-35f8bf541064" xlink:to="loc_cpix_OmeclamoxPakMember_03e4f925-5ecf-485b-965b-eaf1cee6ab4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88d29ffb-851d-4586-9313-bf8d502d259c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_80b3eed6-c14f-449f-b63e-537c4a39b2ce" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:to="loc_cpix_OmeclamoxPakMember_80b3eed6-c14f-449f-b63e-537c4a39b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_58f7d913-d3e7-47f3-a09c-a1dfbd949317" xlink:href="cpix-20201231.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_986fb765-1dd7-4fd3-abfc-8cd30cf66778" xlink:to="loc_cpix_MethotrexateMember_58f7d913-d3e7-47f3-a09c-a1dfbd949317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_888ef674-a0bb-4e97-86a0-1f1b207f389b" xlink:to="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be8f00b3-53b2-4fbe-b999-a70b53e73fe6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:to="loc_srt_MinimumMember_be8f00b3-53b2-4fbe-b999-a70b53e73fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c26828c-c887-49bc-b96c-5becbe6a2762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb920fa8-6966-426a-9858-c3f509a1e7ad" xlink:to="loc_srt_MaximumMember_9c26828c-c887-49bc-b96c-5becbe6a2762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fad8cbd-7fbe-41bc-be32-ee0fed44ab39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ac08660f-0e62-484c-abef-03fa7e9164c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_27b82181-4bc5-48cf-9068-1b63ac18f9f9" xlink:to="loc_us-gaap_SubsequentEventMember_ac08660f-0e62-484c-abef-03fa7e9164c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_40932935-527d-4a25-934a-7704b0742eb6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_c21aa989-2af2-4d66-94a4-e1cb3c62d388" xlink:href="cpix-20201231.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca9347e5-1a24-48e7-be37-ddc19a486bdc" xlink:to="loc_cpix_NordicGroupBVMember_c21aa989-2af2-4d66-94a4-e1cb3c62d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c15cbc78-ea16-4343-967c-30d915ebf5ef" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb03caf-84a6-45a2-836e-1302dddf5e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adb03caf-84a6-45a2-836e-1302dddf5e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2e58f79d-b514-49ed-98e7-2a1a4bb75953" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2e58f79d-b514-49ed-98e7-2a1a4bb75953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_16f69dcd-a18a-4569-89fe-4d304e9f77ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_16f69dcd-a18a-4569-89fe-4d304e9f77ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d062f651-9e73-4ab8-ade7-cbbd5777f316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d062f651-9e73-4ab8-ade7-cbbd5777f316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e91ba94d-74b6-4321-bee4-c8aace86e5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e91ba94d-74b6-4321-bee4-c8aace86e5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2a873e4e-3a3c-4bb7-a0b5-9c2a19907e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2a873e4e-3a3c-4bb7-a0b5-9c2a19907e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ad813ed-8af2-4bcf-8e26-18d9480fe380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ad813ed-8af2-4bcf-8e26-18d9480fe380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20f27c09-cfb7-433c-bd60-e2d788efab82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20f27c09-cfb7-433c-bd60-e2d788efab82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7d6941ba-69c1-4542-996c-8de774c29fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dcb28e2f-332b-4fc7-9323-78b25eb2030a" xlink:to="loc_us-gaap_Revenues_7d6941ba-69c1-4542-996c-8de774c29fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ec7786b4-c576-422e-91eb-1d6654a57a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ec7786b4-c576-422e-91eb-1d6654a57a8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4519204d-efe5-4258-af6d-0766601861ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6aae4201-6f5e-4278-98f1-3379cf2b6151" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ba398220-c53f-4c4e-b0e0-40cdd7b32c35" xlink:to="loc_cpix_VIBATIVMember_6aae4201-6f5e-4278-98f1-3379cf2b6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22df7686-cccc-498d-94b8-eaad44c9f35e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b7536c4-7523-4f28-ae1a-c03a3080d222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_00bc9ae0-6eb2-47e7-a2b7-470741549bbb" xlink:to="loc_us-gaap_SubsequentEventMember_5b7536c4-7523-4f28-ae1a-c03a3080d222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_831ab274-e49c-464e-9af8-724f4d674676" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_756945c1-5e0e-4912-9393-f514df77bb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_756945c1-5e0e-4912-9393-f514df77bb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_2321261a-dec0-46a6-bbe1-87c679099258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_2321261a-dec0-46a6-bbe1-87c679099258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_39a59fdf-a21b-448e-b3a9-ffa9c6e00864" xlink:href="cpix-20201231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_39a59fdf-a21b-448e-b3a9-ffa9c6e00864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_50864fbb-1045-4765-8b5d-cb62b676455d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_50864fbb-1045-4765-8b5d-cb62b676455d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92c0cb70-f8f1-4d22-87d1-b21374c295e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_203c23c0-638f-4397-a021-8f428ebfa04b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_92c0cb70-f8f1-4d22-87d1-b21374c295e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_57d416ce-38b4-4dee-a193-111beb211369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_57d416ce-38b4-4dee-a193-111beb211369" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_629d0587-3009-4c36-ac09-d7532174a6ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_ddbaaa1d-e78e-46f7-9aa2-25896346ded9" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2180a680-6558-4fe1-a868-77a38f39f99f" xlink:to="loc_cpix_VIBATIVMember_ddbaaa1d-e78e-46f7-9aa2-25896346ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_68cc4d63-39b3-4692-9a79-3f6519eb9340" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8b3b463-a4a4-48c1-9380-53f312118bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8b3b463-a4a4-48c1-9380-53f312118bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f0734c78-6806-4889-b2f3-b73c2748ab59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f0734c78-6806-4889-b2f3-b73c2748ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_cc9d4542-9e69-4fbb-8ff9-61113e08d469" xlink:href="cpix-20201231.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_PaymentsForContingentConsideration_cc9d4542-9e69-4fbb-8ff9-61113e08d469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_303e295e-731a-401f-a7aa-5b09cf276169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_303e295e-731a-401f-a7aa-5b09cf276169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5143ad08-0cd1-4824-98e2-495fe4c2b478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5143ad08-0cd1-4824-98e2-495fe4c2b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74cde330-e01d-47d7-94a0-23352cba1f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74cde330-e01d-47d7-94a0-23352cba1f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7203baf9-0b14-46e7-b9c0-97ec266c7f65" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7203baf9-0b14-46e7-b9c0-97ec266c7f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_39f5b5ed-fbbb-4807-a021-60d8d446e9dd" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_39f5b5ed-fbbb-4807-a021-60d8d446e9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_a30eb6c2-3caf-459c-af61-c9789da13012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_PaymentsForRoyalties_a30eb6c2-3caf-459c-af61-c9789da13012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39de276e-ed68-4420-a6a1-a42123116530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39de276e-ed68-4420-a6a1-a42123116530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_bb6dd18a-2be2-4d41-8877-9ea302a44948" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_bb6dd18a-2be2-4d41-8877-9ea302a44948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_49fe1dd5-c427-4d6b-8bb5-ec85701eb242" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_49fe1dd5-c427-4d6b-8bb5-ec85701eb242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_cd73178f-b602-41a7-98f0-b65872024da8" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_cd73178f-b602-41a7-98f0-b65872024da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_a8132d3b-cc80-4cac-a834-c1c89020fcb3" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_a8132d3b-cc80-4cac-a834-c1c89020fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7ef9b3-87e5-483d-851c-806f3bfe2800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7ef9b3-87e5-483d-851c-806f3bfe2800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_df2fb81d-9424-42db-8821-7abcb1357659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_df2fb81d-9424-42db-8821-7abcb1357659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e2ba3e36-7532-4a3e-9d9e-7ef25e69d57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_Goodwill_e2ba3e36-7532-4a3e-9d9e-7ef25e69d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d2a39249-bd60-4ce5-90d6-06c19e1d6f0c" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d2a39249-bd60-4ce5-90d6-06c19e1d6f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2e2c243d-0bea-4be8-95f4-5229e6fa6db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6eb0663e-3bad-486e-a37a-966fa3a9ccd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2e2c243d-0bea-4be8-95f4-5229e6fa6db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_80090b63-f97a-48f2-bfec-d53250df3ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_928cd2d0-0f8e-4a2a-a358-30aeb3a1635f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_80090b63-f97a-48f2-bfec-d53250df3ca3" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_928cd2d0-0f8e-4a2a-a358-30aeb3a1635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b9fe2eaa-a15f-403b-a7d2-fea291a0e12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_83182f97-b3d6-499a-8b5b-8334f4e87a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b9fe2eaa-a15f-403b-a7d2-fea291a0e12c" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_83182f97-b3d6-499a-8b5b-8334f4e87a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5f09021f-dcc8-4124-b1ff-4b3797aff6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5f09021f-dcc8-4124-b1ff-4b3797aff6c3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:to="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_70f6a2e4-5599-48dc-a85e-559a37a41f91" xlink:to="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_9d68b6d4-5789-4baa-a2cc-ef77cdb74a01" xlink:href="cpix-20201231.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_KristaloseMember_9d68b6d4-5789-4baa-a2cc-ef77cdb74a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_8dc8cca8-a0a6-4617-8dfd-1393f83b1536" xlink:href="cpix-20201231.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_CaldolorMember_8dc8cca8-a0a6-4617-8dfd-1393f83b1536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_846e0a99-127c-4799-9e94-9815b312e18e" xlink:href="cpix-20201231.xsd#cpix_ProductVibativMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_ProductVibativMember_846e0a99-127c-4799-9e94-9815b312e18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_4351fb26-6578-48c7-8c87-6e5fabaac482" xlink:href="cpix-20201231.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_AcetadoteMember_4351fb26-6578-48c7-8c87-6e5fabaac482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_7094a3d9-681b-4bb9-8c98-64ba0acffacf" xlink:href="cpix-20201231.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_OmeclamoxPakMember_7094a3d9-681b-4bb9-8c98-64ba0acffacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_6cb095d0-f036-4948-8ed2-50d77789dc7b" xlink:href="cpix-20201231.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_VaprisolMember_6cb095d0-f036-4948-8ed2-50d77789dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_8c889ba1-cdea-4dab-9961-112672f892e8" xlink:href="cpix-20201231.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9273592f-2536-4589-b3b7-4928585f1a09" xlink:to="loc_cpix_RediTrexMember_8c889ba1-cdea-4dab-9961-112672f892e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f75db8c4-1f5c-4a40-9039-4df453ce253f" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_259a0d4f-27c4-4777-a756-f56188e4fa69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98b8c931-c28a-4eba-862b-7117b7abab0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_259a0d4f-27c4-4777-a756-f56188e4fa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8c2fa728-f041-4b21-8822-b481d4de2a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8c2fa728-f041-4b21-8822-b481d4de2a5e" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93bb910a-b40b-4d4d-bfe3-90ad714a9249" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_d70e5384-b312-4d33-b39f-6978d5fb9c25" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9b7b739-9935-41be-84d5-0c3ba72a35d6" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_d70e5384-b312-4d33-b39f-6978d5fb9c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d4348ad-deec-4a53-ba16-aa534347d2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_0ca332ce-aa83-4fe6-b79a-3bf37fbea8da" xlink:href="cpix-20201231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fdf4e5fe-5a54-41c2-a276-74d573449db4" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_0ca332ce-aa83-4fe6-b79a-3bf37fbea8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ff5ef48c-c07c-485f-bc75-09e0b61c4f3f" xlink:to="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_330d7a8a-01c9-4a06-a43b-176df6cdcb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ceee6da-a22d-46ca-a960-ce6c1017f07d" xlink:to="loc_us-gaap_GrantMember_330d7a8a-01c9-4a06-a43b-176df6cdcb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_e1105fbe-918c-47b6-b7ae-85708b502ed5" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:href="cpix-20201231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:to="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbf10cd4-1547-4d0c-9023-f0c8e57f223e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductRevenuesAbstract_f533f9c8-5bab-40f6-8128-840a43738edf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbf10cd4-1547-4d0c-9023-f0c8e57f223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:href="cpix-20201231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_ed12af0f-02ef-447a-8b56-f19e82e7a676" xlink:to="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_1261edf2-acd7-4ed1-99fa-1090f47eff06" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_1261edf2-acd7-4ed1-99fa-1090f47eff06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_aac1ad49-cab2-4741-8400-41c1519c2b06" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_aac1ad49-cab2-4741-8400-41c1519c2b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_7cb5f455-31fa-4a8e-8214-a57553978651" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_7cb5f455-31fa-4a8e-8214-a57553978651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_e6ceefdb-11cf-4fde-90b9-a034c85df29f" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_e6ceefdb-11cf-4fde-90b9-a034c85df29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_ffed4689-31a3-438a-86bf-fb9040cbf152" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_3777bd65-17c8-475b-a9bb-4261115dd123" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_ffed4689-31a3-438a-86bf-fb9040cbf152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e6b51220-6635-4fcc-98a2-e2bd80c1e8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_784abcba-e370-435c-ba2b-7c91cf7d3a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6b51220-6635-4fcc-98a2-e2bd80c1e8f8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_784abcba-e370-435c-ba2b-7c91cf7d3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d9810a76-25db-43e5-9ce7-6f1537983799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ac373914-231d-4181-9b35-be968dccc706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9810a76-25db-43e5-9ce7-6f1537983799" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ac373914-231d-4181-9b35-be968dccc706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e898eb51-62aa-4794-992d-47b09bc8297a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e898eb51-62aa-4794-992d-47b09bc8297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_ab17350d-01a5-4ec2-bcc7-bec3f3148247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_ab17350d-01a5-4ec2-bcc7-bec3f3148247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8c7406f4-98e5-40c8-8c76-94e1406a50ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8c7406f4-98e5-40c8-8c76-94e1406a50ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_94a0dd6b-1d52-4c24-8574-6a45d7c54260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_InventoryGross_94a0dd6b-1d52-4c24-8574-6a45d7c54260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bdf7b458-c680-4ef4-bcb4-9b1c84b2d64d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_InventoryNoncurrent_bdf7b458-c680-4ef4-bcb4-9b1c84b2d64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_63b16a24-fce2-4123-aab4-618cabbbd88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d576f82e-8078-4c19-8404-fd0e5b24e2a5" xlink:to="loc_us-gaap_InventoryNet_63b16a24-fce2-4123-aab4-618cabbbd88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_817e8afc-2506-45ff-b2a3-241ea9229a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_817e8afc-2506-45ff-b2a3-241ea9229a0a" xlink:to="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99d2e860-4870-4ef7-a274-fa2101060d17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d980369f-7256-42ec-afec-b04ea131febe" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32465b63-2c75-4226-ada8-cdeb7b081e3e" xlink:to="loc_cpix_VIBATIVMember_d980369f-7256-42ec-afec-b04ea131febe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_147f53ad-9a25-4659-b277-25697f1648d9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember_3ba296c2-2241-4e45-93bc-0ab11258714d" xlink:href="cpix-20201231.xsd#cpix_FinishedGoodsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:to="loc_cpix_FinishedGoodsMember_3ba296c2-2241-4e45-93bc-0ab11258714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_520800ef-2519-490c-8d37-79856a0e2638" xlink:href="cpix-20201231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1cb882f5-f91b-4fce-9e85-268dd306cc9e" xlink:to="loc_cpix_IfetrobanClinicalMember_520800ef-2519-490c-8d37-79856a0e2638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_409fd6c0-ff79-43b0-9205-364e4f7773c2" xlink:to="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8c48ccff-e3af-445b-aa6e-a2ffaadb22ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:to="loc_us-gaap_InventoryValuationReserves_8c48ccff-e3af-445b-aa6e-a2ffaadb22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8d3f6d8f-22e9-4a48-92b2-7b40fec14074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_70cf8c55-b6ef-4d34-a557-77fd78d5f7a8" xlink:to="loc_us-gaap_InventoryNoncurrent_8d3f6d8f-22e9-4a48-92b2-7b40fec14074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db77be73-c49f-4c13-ba57-ab80db2b36b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6d31dc64-15dd-4da1-983c-3ae76f819f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db77be73-c49f-4c13-ba57-ab80db2b36b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6d31dc64-15dd-4da1-983c-3ae76f819f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35d182ae-5668-4495-9273-d4bdd47b098a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e191c110-0d16-45f5-b561-e54d592bdd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35d182ae-5668-4495-9273-d4bdd47b098a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e191c110-0d16-45f5-b561-e54d592bdd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_99531389-0a33-4bf5-a9c3-d01f2baf8b74" xlink:href="cpix-20201231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35d182ae-5668-4495-9273-d4bdd47b098a" xlink:to="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_99531389-0a33-4bf5-a9c3-d01f2baf8b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_03e8398e-a9a1-45d9-97b6-2700ce3d81a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_03e8398e-a9a1-45d9-97b6-2700ce3d81a1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4e32c3a-565c-4efe-bf3d-697cc94a1fbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_115dea45-848c-475f-a4a5-ce405597c52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_115dea45-848c-475f-a4a5-ce405597c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_33f06e96-8c8d-4977-9c2e-d4d25ac72e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_OfficeEquipmentMember_33f06e96-8c8d-4977-9c2e-d4d25ac72e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a311ae40-4227-42f3-8a25-2284e89adf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a311ae40-4227-42f3-8a25-2284e89adf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_175028c8-cdc7-477c-8f4d-d56fef3f6ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d50854f2-2293-48ad-9db1-68c8fba6d7d8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_175028c8-cdc7-477c-8f4d-d56fef3f6ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:to="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_26eaa195-9911-476b-849f-f0fd8e237861" xlink:to="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4461391c-b85a-44af-8dd6-c8c85b3ba387" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:to="loc_srt_MinimumMember_4461391c-b85a-44af-8dd6-c8c85b3ba387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdaa57ac-41ca-4c3a-bdca-1a3070086a03" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b7bb627-7ac3-4706-9355-73ee31e7e3c8" xlink:to="loc_srt_MaximumMember_fdaa57ac-41ca-4c3a-bdca-1a3070086a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0da05376-579d-4002-9132-311527b1ed55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f3c5a322-954d-48e6-90ac-856785e3dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f3c5a322-954d-48e6-90ac-856785e3dd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a495011f-f5e2-48ad-ace3-6f78b7709b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a495011f-f5e2-48ad-ace3-6f78b7709b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e7300c3-2f22-4bae-804f-c7ae6f6f9da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e7300c3-2f22-4bae-804f-c7ae6f6f9da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_598cf832-7aae-4589-b4d2-690fd9888cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bad0fea2-eff9-49f9-8bed-a205f73990bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_598cf832-7aae-4589-b4d2-690fd9888cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_441e5823-dc0a-402b-886d-0b4522578073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_34b06fb2-e61f-41ca-97df-b605434e04f0" xlink:href="cpix-20201231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_441e5823-dc0a-402b-886d-0b4522578073" xlink:to="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_34b06fb2-e61f-41ca-97df-b605434e04f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42ea0ec7-9098-4460-9a66-e36a56646925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_0917e508-5578-4ac3-a0d6-d65e668788e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42ea0ec7-9098-4460-9a66-e36a56646925" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_0917e508-5578-4ac3-a0d6-d65e668788e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1159075-692b-4598-9cdc-6919749aac38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8cf37376-a9cd-46db-9026-3c546f07fde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1159075-692b-4598-9cdc-6919749aac38" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8cf37376-a9cd-46db-9026-3c546f07fde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f5ff915d-3047-4947-9b4b-df3448f8afbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1159075-692b-4598-9cdc-6919749aac38" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f5ff915d-3047-4947-9b4b-df3448f8afbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3855cf5c-5ba7-4496-a6c0-b7c2fc110599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3855cf5c-5ba7-4496-a6c0-b7c2fc110599" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b88ebff-7097-4f0e-8dce-70c141a11122" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_69cb5bf4-eb6a-4777-942d-18c1497d6132" xlink:href="cpix-20201231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_cpix_ProductAndLicenseRightsMember_69cb5bf4-eb6a-4777-942d-18c1497d6132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a371ad6a-b68f-4dec-ad2d-e0379a2019c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_us-gaap_PatentsMember_a371ad6a-b68f-4dec-ad2d-e0379a2019c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_94eef24e-9611-4307-9206-38d0d983f1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f11d7af9-92c5-4b8b-a06b-c08265f4b710" xlink:to="loc_us-gaap_TrademarksMember_94eef24e-9611-4307-9206-38d0d983f1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4178373-b37c-4277-b832-af84b35c621f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0c87d21f-dcf5-4f1b-b0dd-e2b0dccdf6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0c87d21f-dcf5-4f1b-b0dd-e2b0dccdf6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f3cbbc4b-c9df-463f-9f14-cb7e1de08e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f3cbbc4b-c9df-463f-9f14-cb7e1de08e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_53379068-d40e-481d-b0f0-b5788e58ef0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a1dca7c3-58a1-4acc-b1e0-6e96107892ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_53379068-d40e-481d-b0f0-b5788e58ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_27ac5c59-4e41-4c80-be91-d8ccb4da9dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_27ac5c59-4e41-4c80-be91-d8ccb4da9dee" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7c7915ab-d1ba-4806-a8d9-0c788b4a7f0f" xlink:to="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_1a3f5e7c-39ea-46a0-b7fe-04d06f056a30" xlink:href="cpix-20201231.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ee6c3298-28c4-44d2-ab12-aa755bb3bfcd" xlink:to="loc_cpix_VaprisolMember_1a3f5e7c-39ea-46a0-b7fe-04d06f056a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84a18ade-5ed6-4922-8d6c-2c0f804fc54b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_0d956542-7b57-4b48-a37a-f14bedfe5f5b" xlink:href="cpix-20201231.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:to="loc_cpix_MethotrexateMember_0d956542-7b57-4b48-a37a-f14bedfe5f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_b1c606d1-6c23-437e-9816-99157b6f6709" xlink:href="cpix-20201231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9318e7f0-c513-406e-80a1-a74e44460205" xlink:to="loc_cpix_VIBATIVMember_b1c606d1-6c23-437e-9816-99157b6f6709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3f4b53af-0980-4502-9f56-e9c4ac8db120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_faba81f5-6268-46ce-a7f2-a06737478e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d23f41bd-cfbf-46bb-8362-a291eb29ffcd" xlink:to="loc_us-gaap_RestrictedStockMember_faba81f5-6268-46ce-a7f2-a06737478e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_24915fde-740c-4589-909b-da0b109a88b8" xlink:to="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_1e16f118-2770-4839-8c05-ad250c1b4a6f" xlink:href="cpix-20201231.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ad48e8c2-a7fe-4758-b5dd-734a249834e3" xlink:to="loc_cpix_KristaloseMember_1e16f118-2770-4839-8c05-ad250c1b4a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ab2d344-e41c-42ea-ba5d-d64652e1f2bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_3e11a7ff-2d4d-46c0-9b75-a6e612c32db9" xlink:href="cpix-20201231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:to="loc_cpix_ProductAndLicenseRightsMember_3e11a7ff-2d4d-46c0-9b75-a6e612c32db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_4d8fd007-f86a-49ba-b927-d1a78b5aca0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_022df7a4-e322-4ea8-be3a-0c37c476f8c6" xlink:to="loc_us-gaap_PatentsMember_4d8fd007-f86a-49ba-b927-d1a78b5aca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b49c97d2-b844-45a2-ba35-db389bac14f4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_ff119e59-0565-4908-b147-0d2fb1cd643b" xlink:href="cpix-20201231.xsd#cpix_NordicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b13753db-69d4-455d-97d5-c63761d6ecf6" xlink:to="loc_cpix_NordicMember_ff119e59-0565-4908-b147-0d2fb1cd643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_06209ba0-a61c-4c68-8e2c-db860851e795" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8d181565-4bdd-4041-8ebf-ee0c087e1311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_Goodwill_8d181565-4bdd-4041-8ebf-ee0c087e1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_656eeffb-ea5a-4234-b3bd-cb2bb589e4ba" xlink:href="cpix-20201231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_656eeffb-ea5a-4234-b3bd-cb2bb589e4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_34787a69-3e7d-4244-b141-cc03dfa54aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_34787a69-3e7d-4244-b141-cc03dfa54aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3a9ea5c4-c152-426a-9f0f-0ff3bb5115b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3a9ea5c4-c152-426a-9f0f-0ff3bb5115b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f6fdbb24-8c52-4c16-9b50-7e9a1260db36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f6fdbb24-8c52-4c16-9b50-7e9a1260db36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b709f2db-cb21-4a7b-88cf-34a22cd16df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b709f2db-cb21-4a7b-88cf-34a22cd16df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2e8f30a2-d065-413b-87c7-824bf3cc3120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2e8f30a2-d065-413b-87c7-824bf3cc3120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5bc35cb5-846f-414b-b520-a2693f3dc53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5bc35cb5-846f-414b-b520-a2693f3dc53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_55a606d0-a4b0-450a-a7f8-859d31b97057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_55a606d0-a4b0-450a-a7f8-859d31b97057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ebdcb60b-db6d-48fd-b320-554408b507ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_eb0ec3bb-0173-45a2-b3f0-c77566fd5352" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ebdcb60b-db6d-48fd-b320-554408b507ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b79fa2ef-d122-4a60-9186-bb3544efb83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b79fa2ef-d122-4a60-9186-bb3544efb83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_527cbe5f-1e03-4182-9fdc-f9c89c5d93a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_527cbe5f-1e03-4182-9fdc-f9c89c5d93a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_869b93a3-f91f-46a8-af52-7cb6ada176d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_869b93a3-f91f-46a8-af52-7cb6ada176d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a8506f6d-4ef4-45fa-91f3-d61ec87be7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a8506f6d-4ef4-45fa-91f3-d61ec87be7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_9a563ce6-8668-4cd6-abfd-5b39b4f416f5" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_9a563ce6-8668-4cd6-abfd-5b39b4f416f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0402c407-ce11-4213-b1cc-df6ed6aa9859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_615b0cfa-e69a-4c17-9be5-133d562936b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0402c407-ce11-4213-b1cc-df6ed6aa9859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_d7f6e4bb-83b5-4ba8-b8a1-812c5b0cde54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_e5d89a83-0f79-4783-b033-238b9674f1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_d7f6e4bb-83b5-4ba8-b8a1-812c5b0cde54" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_e5d89a83-0f79-4783-b033-238b9674f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_aade9e94-6e47-4c89-83e4-3aa0c1df4b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b58a1ab1-a68e-4999-a712-8d128e876923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_aade9e94-6e47-4c89-83e4-3aa0c1df4b61" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b58a1ab1-a68e-4999-a712-8d128e876923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_1c5e6acb-a116-4c2b-bcd4-aacef03b9987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_aade9e94-6e47-4c89-83e4-3aa0c1df4b61" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_1c5e6acb-a116-4c2b-bcd4-aacef03b9987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_f49b9366-0a22-487e-b966-d8361f27e89e" xlink:href="cpix-20201231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_f49b9366-0a22-487e-b966-d8361f27e89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_036e91c2-2e89-4a8c-8e1e-c2477d7860b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_036e91c2-2e89-4a8c-8e1e-c2477d7860b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_e1dbfe22-5211-4230-8708-bb9c5d6286c2" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_e1dbfe22-5211-4230-8708-bb9c5d6286c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent_e54d2932-cc8a-4b57-8269-3ade29a9cff6" xlink:href="cpix-20201231.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_cpix_DeferredAcquisitionLiabilityCurrent_e54d2932-cc8a-4b57-8269-3ade29a9cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_8ed3ef72-a6e6-42b2-92b6-79d9937d3ee1" xlink:href="cpix-20201231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_8ed3ef72-a6e6-42b2-92b6-79d9937d3ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_7b1ec2d5-f15e-4827-b1a8-859a169d8dcf" xlink:href="cpix-20201231.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_7b1ec2d5-f15e-4827-b1a8-859a169d8dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7ad6dbd9-4a46-4ec6-9ba8-8bcedf6acf05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7ad6dbd9-4a46-4ec6-9ba8-8bcedf6acf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_23f6f97d-ad24-487f-9a55-675f2369b895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_23f6f97d-ad24-487f-9a55-675f2369b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fcc3bb43-da6c-4cae-a5e5-dac19794c793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fcc3bb43-da6c-4cae-a5e5-dac19794c793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_ecc25c06-b490-4b27-a092-739c0f940a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_ecc25c06-b490-4b27-a092-739c0f940a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_746ee036-62c0-44f8-a544-58f6ba0f3f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_746ee036-62c0-44f8-a544-58f6ba0f3f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d400fbd0-8a40-4b3f-925d-5205c2e83c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_59d1b576-c557-4969-982b-3bea598ea8d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d400fbd0-8a40-4b3f-925d-5205c2e83c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f3de467d-f3bb-46b7-8f22-731a38d8d851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_87e19bf9-393c-4a21-a76d-497758cf6b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f3de467d-f3bb-46b7-8f22-731a38d8d851" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_87e19bf9-393c-4a21-a76d-497758cf6b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DebtLineofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41c7e577-71ba-45c8-b5f7-ea6fc034f97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41c7e577-71ba-45c8-b5f7-ea6fc034f97d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9812cbbb-1720-49d4-bd1e-95f182005213" xlink:to="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8914db26-acc9-40c1-b715-71268d42e89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5afd70fa-c60d-43c8-854e-dac5a12161d7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8914db26-acc9-40c1-b715-71268d42e89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9bcec88-15d5-40d8-8c4e-bd8e1dff97f7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_c745a908-f739-4326-bd17-b8f4dc5def8a" xlink:href="cpix-20201231.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c3717bc0-9998-4162-b3df-cb957de39cda" xlink:to="loc_cpix_PinnacleBankMember_c745a908-f739-4326-bd17-b8f4dc5def8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af8b814b-290c-4890-bcba-36c63bf28e96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ThirdAmendmentMember_13937cf6-c84c-40e1-b08b-04f04a4c7880" xlink:href="cpix-20201231.xsd#cpix_ThirdAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_cpix_ThirdAmendmentMember_13937cf6-c84c-40e1-b08b-04f04a4c7880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_c0838273-c78f-4856-ac47-5422504c43e1" xlink:href="cpix-20201231.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_cpix_SecondAmendmentMember_c0838273-c78f-4856-ac47-5422504c43e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fe00f851-bd60-469f-971f-a749e709c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee684dd4-0670-41e2-aefa-5f436ea1e07b" xlink:to="loc_us-gaap_LineOfCreditMember_fe00f851-bd60-469f-971f-a749e709c1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_508b75f9-1a00-49d4-806f-173c111542e1" xlink:to="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_484f33ec-eec7-4089-840c-e1c28627bd4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:to="loc_srt_MinimumMember_484f33ec-eec7-4089-840c-e1c28627bd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d279e190-1303-4775-b1ef-ca2dded3818e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33de9e82-df19-41a8-9c99-9abbb37f14b9" xlink:to="loc_srt_MaximumMember_d279e190-1303-4775-b1ef-ca2dded3818e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_61fce1e0-ed2a-4eb1-8621-d9250e1057a7" xlink:to="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f7ab1591-d6b0-47cc-82b0-0c0f631be765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0681d596-73e9-42f3-b40f-36167825148b" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f7ab1591-d6b0-47cc-82b0-0c0f631be765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_19573b0b-aab1-4269-a9aa-bb1f98b62a3f" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0a699d70-35ce-4c25-b10c-d4e3aa6cf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0a699d70-35ce-4c25-b10c-d4e3aa6cf387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2db8c3da-d14f-42c9-b844-a253b07102d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2db8c3da-d14f-42c9-b844-a253b07102d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_29ffbfab-3b2a-4dcc-9250-85f7334a5b28" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_29ffbfab-3b2a-4dcc-9250-85f7334a5b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_1e0c1f53-3200-4220-9393-150e9e889d9c" xlink:href="cpix-20201231.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_1e0c1f53-3200-4220-9393-150e9e889d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_a836bda9-d51d-4739-b387-bf2ae1574183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LongTermLineOfCredit_a836bda9-d51d-4739-b387-bf2ae1574183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05266b4f-ab81-4280-a522-ec47f7afe786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05266b4f-ab81-4280-a522-ec47f7afe786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ede2c596-dae7-4399-9c1d-faea4fe904b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ede2c596-dae7-4399-9c1d-faea4fe904b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d56af0cc-3b71-49ab-8067-4d9ca736ea89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d56af0cc-3b71-49ab-8067-4d9ca736ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_fc6190b9-575a-41fe-969a-e2d531dfcd9c" xlink:href="cpix-20201231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fd1eddd2-c820-4eda-8ed6-6036013f006c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_fc6190b9-575a-41fe-969a-e2d531dfcd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f82b8b6c-d9f4-49a6-b682-a6aab14f672e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16e9318e-da0c-439a-9467-097d48c1f6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f82b8b6c-d9f4-49a6-b682-a6aab14f672e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16e9318e-da0c-439a-9467-097d48c1f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_19609cd5-fd10-4ec5-9fbc-11deb4fd638a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19609cd5-fd10-4ec5-9fbc-11deb4fd638a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506e92a-724f-4184-ac86-9441c4aa3dcd" xlink:to="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_09e72ac1-ff5e-4ecb-b193-76b4bbef682c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5cf15efc-915a-4539-aa77-8866757720b2" xlink:to="loc_us-gaap_CommonStockMember_09e72ac1-ff5e-4ecb-b193-76b4bbef682c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8117c230-bd62-4dc9-b421-b4b884bdc62e" xlink:to="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_98d7801c-f942-46c5-8bc4-2745186bf403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_df4d88c3-6b54-419f-b581-c040f5e66c5c" xlink:to="loc_us-gaap_CommonStockMember_98d7801c-f942-46c5-8bc4-2745186bf403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3e256236-ba07-4b05-a86d-1adee95f173e" xlink:to="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:href="cpix-20201231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_ab2aabb8-49e6-4fd4-9003-d97692681f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_ab2aabb8-49e6-4fd4-9003-d97692681f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a688da9-72fd-4485-999b-69eb0276a078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a688da9-72fd-4485-999b-69eb0276a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_d8e61be9-e88c-4e36-b121-2d31ad197310" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_d8e61be9-e88c-4e36-b121-2d31ad197310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_32902ba9-f948-47b6-9d66-07cf1f87b720" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_32902ba9-f948-47b6-9d66-07cf1f87b720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a8e96d1c-0ae3-4f3a-bbe3-d62560f608d9" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a8e96d1c-0ae3-4f3a-bbe3-d62560f608d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6c7abd97-47a6-4a88-9445-011a5dc98513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6c7abd97-47a6-4a88-9445-011a5dc98513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6fd06c0e-7f1b-4b15-8a99-d20a922432a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6fd06c0e-7f1b-4b15-8a99-d20a922432a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1895218c-ea4f-46a2-b72b-3fa67acb8db1" xlink:href="cpix-20201231.xsd#cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_d6cd2f14-b23b-4036-ad0f-7e26ded47b86" xlink:to="loc_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering_1895218c-ea4f-46a2-b72b-3fa67acb8db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:href="cpix-20201231.xsd#cpix_PreferredStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bbb3d3d7-4d3e-427a-ab3d-b05786f7dd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bbb3d3d7-4d3e-427a-ab3d-b05786f7dd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2204ab98-bfcc-452e-b475-e9decbfa8cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_PreferredStockAbstract_68b13250-774b-45b7-aea8-f1badf7cdb97" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2204ab98-bfcc-452e-b475-e9decbfa8cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:href="cpix-20201231.xsd#cpix_CommonStockAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_74fb74ff-7f43-425e-b12e-a2b234aca4d5" xlink:to="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ff7ff61-822e-4bbe-8303-1524ab3bea5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ff7ff61-822e-4bbe-8303-1524ab3bea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_640e5abf-c960-4140-8704-55b8223a65c4" xlink:href="cpix-20201231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_a3db9a2f-e22e-42cb-ab97-5624ae3df158" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_640e5abf-c960-4140-8704-55b8223a65c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_929bb666-ea58-4121-badf-199cafff4617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_929bb666-ea58-4121-badf-199cafff4617" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a35ddf53-8a1b-48d2-bcb3-50f8f2378299" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_f26d609b-eaf3-4c14-ae26-65c0ca4f9e17" xlink:href="cpix-20201231.xsd#cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_146bd422-dfd3-483c-972e-7126c36f931a" xlink:to="loc_cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember_f26d609b-eaf3-4c14-ae26-65c0ca4f9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ea16f7c3-2e7a-4c7e-9725-4469beace270" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fab284c8-333a-4648-b593-2f11fe5241ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fab284c8-333a-4648-b593-2f11fe5241ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df3a7191-e45e-4527-b14a-6b1097029117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3e823b71-f462-4ed7-a518-405f904b858c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df3a7191-e45e-4527-b14a-6b1097029117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1c981af9-e5d4-4253-898f-b0b9b7bd3a80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1c981af9-e5d4-4253-898f-b0b9b7bd3a80" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_85aabaf0-44d0-477c-8fb7-3ff4818d7075" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_e25dd2fb-c932-4edb-994d-113d76809d90" xlink:href="cpix-20201231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_cecb8f31-e737-4451-a80b-e61796f5a58b" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_e25dd2fb-c932-4edb-994d-113d76809d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_dce8861f-885d-4bdb-a84e-086245c32557" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_3c5fd30f-d2e4-474b-ae8e-cfeb25277465" xlink:href="cpix-20201231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_c1ee5695-6360-4d20-9a69-464322724efe" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_3c5fd30f-d2e4-474b-ae8e-cfeb25277465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2d97ad31-6fd2-4ac3-9b27-80154ebec516" xlink:to="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_a0334130-5d4e-43f9-bfe2-06baaf63578a" xlink:href="cpix-20201231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3d143b1d-f7bb-444f-819e-80cdebff7cab" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_a0334130-5d4e-43f9-bfe2-06baaf63578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cce2c4b-8234-4129-9684-7b6259b3d41b" xlink:to="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3dc2ad94-4eb6-4f2f-abbb-cfaf0a2368d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de235cd6-bb72-46f4-a838-3fd4dbbd5d40" xlink:to="loc_us-gaap_CommonStockMember_3dc2ad94-4eb6-4f2f-abbb-cfaf0a2368d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ba62d462-8eee-49ad-9e7b-75facbb6f7dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_b099ed50-89ca-45e8-9367-4ae9596cbb06" xlink:href="cpix-20201231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_b099ed50-89ca-45e8-9367-4ae9596cbb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_6dfdd403-a8b8-4309-835b-c296622ce5db" xlink:href="cpix-20201231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_6dfdd403-a8b8-4309-835b-c296622ce5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicMember_98792c72-37a8-4270-a88e-fc1cac7d5752" xlink:href="cpix-20201231.xsd#cpix_NordicMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72bab3f6-7e68-404a-8720-4c56127bdba3" xlink:to="loc_cpix_NordicMember_98792c72-37a8-4270-a88e-fc1cac7d5752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_79fb3ad0-9d4b-4c00-80ff-8a2af1ab9fdd" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9f9e1581-fc44-4595-a315-0044b17e9e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9f9e1581-fc44-4595-a315-0044b17e9e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ae7c82a0-65c2-4459-a2e2-cb7d39997438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ae7c82a0-65c2-4459-a2e2-cb7d39997438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_8c6bd28b-2bbd-48ce-a075-f3f671004b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_8c6bd28b-2bbd-48ce-a075-f3f671004b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a0ecd296-ef2a-4cf9-a26b-0a6d4c5124e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a0ecd296-ef2a-4cf9-a26b-0a6d4c5124e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_73130a50-9269-4753-9abd-4d219137686d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_73130a50-9269-4753-9abd-4d219137686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d7a17d5d-d449-47cd-9729-81d4eb5c8132" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d7a17d5d-d449-47cd-9729-81d4eb5c8132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_96b7695c-7640-4390-8590-041c3045ff93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_96b7695c-7640-4390-8590-041c3045ff93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_057c7b10-28c1-4b8d-a9a5-f142f75299fc" xlink:href="cpix-20201231.xsd#cpix_LoansForgiveninExchangeForShareIssuedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_LoansForgiveninExchangeForShareIssuedAmount_057c7b10-28c1-4b8d-a9a5-f142f75299fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_891c4970-e2a2-4475-adfc-322d6ac6a052" xlink:href="cpix-20201231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_891c4970-e2a2-4475-adfc-322d6ac6a052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8648c5a2-24bf-4f82-81ec-b89396a543d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8648c5a2-24bf-4f82-81ec-b89396a543d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8cc760a6-0d27-4afb-a226-7da585410bca" xlink:href="cpix-20201231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8cc760a6-0d27-4afb-a226-7da585410bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_b37c69a4-f628-4011-9d6d-68c7718749ff" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_b37c69a4-f628-4011-9d6d-68c7718749ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_700881e2-f38b-4db8-a17d-9d58bd9c7d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_700881e2-f38b-4db8-a17d-9d58bd9c7d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d932133b-6766-4430-8276-375a69499408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_783af78e-ded3-4fc5-b5d0-68c2beaa4757" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d932133b-6766-4430-8276-375a69499408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92b856f9-adf2-458e-85c5-dd66da5defee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d844d136-3cb1-4c6f-9dad-ffdddd80d912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92b856f9-adf2-458e-85c5-dd66da5defee" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d844d136-3cb1-4c6f-9dad-ffdddd80d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cc2b8ec6-dda1-490c-8229-3758d8d64958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_11bc904a-6512-47f8-98a7-53a91f57bae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc2b8ec6-dda1-490c-8229-3758d8d64958" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_11bc904a-6512-47f8-98a7-53a91f57bae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_323f24ef-1632-400b-a3e5-a2d4dd143392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc2b8ec6-dda1-490c-8229-3758d8d64958" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_323f24ef-1632-400b-a3e5-a2d4dd143392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_007518fb-af1d-47c3-9951-56171ee44994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:href="cpix-20201231.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_007518fb-af1d-47c3-9951-56171ee44994" xlink:to="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c8b1ce41-3373-48d6-bdee-5fbef9885001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c8b1ce41-3373-48d6-bdee-5fbef9885001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a4e73edb-243b-43d9-9bfd-dd55b68a5173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a4e73edb-243b-43d9-9bfd-dd55b68a5173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ced54e8c-2c14-4491-b0f0-b8af3e834809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:to="loc_us-gaap_ProfitLoss_ced54e8c-2c14-4491-b0f0-b8af3e834809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cc5a7bd1-fe9b-4f41-b5cf-0a6b52567608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cc5a7bd1-fe9b-4f41-b5cf-0a6b52567608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8da35dd1-097a-43ec-872d-5c4e6b60997d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_a7c9db54-ebc1-40c9-9972-a64467531ac6" xlink:to="loc_us-gaap_NetIncomeLoss_8da35dd1-097a-43ec-872d-5c4e6b60997d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_f0e6137b-a179-4aaf-888d-67c76664d242" xlink:href="cpix-20201231.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_007518fb-af1d-47c3-9951-56171ee44994" xlink:to="loc_cpix_DenominatorAbstract_f0e6137b-a179-4aaf-888d-67c76664d242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_180aad5e-c8f9-4eaa-bd73-d44acf2a778e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_f0e6137b-a179-4aaf-888d-67c76664d242" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_180aad5e-c8f9-4eaa-bd73-d44acf2a778e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ec6b0522-00fa-440e-a017-2ddb311f7acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_f0e6137b-a179-4aaf-888d-67c76664d242" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ec6b0522-00fa-440e-a017-2ddb311f7acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac4980e8-abae-46eb-b3e4-7716985f6186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_f0e6137b-a179-4aaf-888d-67c76664d242" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac4980e8-abae-46eb-b3e4-7716985f6186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_233a01fa-ada9-45db-9f2d-e6717980d0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_855fe514-96e2-401d-89ac-2be6d8d04d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_233a01fa-ada9-45db-9f2d-e6717980d0ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_855fe514-96e2-401d-89ac-2be6d8d04d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1f637ac5-8f69-43b2-85ee-9e6c5b157547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d028d6d-edb6-49a1-b011-c19649dccd6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f637ac5-8f69-43b2-85ee-9e6c5b157547" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d028d6d-edb6-49a1-b011-c19649dccd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_07fbebed-701c-4bf7-989f-8a2c5d97e636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_07fbebed-701c-4bf7-989f-8a2c5d97e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_f9acfd17-b6c1-4bc5-95db-ab21b97ec59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_f9acfd17-b6c1-4bc5-95db-ab21b97ec59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4baf92d0-6c98-4f67-bc8d-49504333edd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4baf92d0-6c98-4f67-bc8d-49504333edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_954952ba-30a5-4687-8242-b656e21ca896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_954952ba-30a5-4687-8242-b656e21ca896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_6ed8fb68-0424-451b-b125-95568df54645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e08262d-58c4-40ec-a145-a2253bb0ee00" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_6ed8fb68-0424-451b-b125-95568df54645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a6e3850a-58fa-45fb-a952-87f975c5c022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a6e3850a-58fa-45fb-a952-87f975c5c022" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5db58753-8d44-4535-bb5c-6b9d2cdf11dd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6cb41175-a8c7-4659-a80e-4f32bbd4d28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6cb41175-a8c7-4659-a80e-4f32bbd4d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_dfba5957-7088-4114-81fa-0e063afbf4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85d373bb-a4a4-4e25-8605-a284b30e8b13" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_dfba5957-7088-4114-81fa-0e063afbf4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_299281e1-7878-4a46-837f-c383f7b806eb" xlink:to="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a36e09bb-a377-4dad-b56c-ae9a3cd4c379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c05dc945-a375-4db3-8aeb-6a401e1bf9bc" xlink:to="loc_us-gaap_RetainedEarningsMember_a36e09bb-a377-4dad-b56c-ae9a3cd4c379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_78e1c074-30e6-4c77-bf4f-dc99cd68b4c1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9f0aa7ee-0557-448e-b23b-86328d757d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf27b042-7a2e-4ec6-b739-1f2357f1c557" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9f0aa7ee-0557-448e-b23b-86328d757d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ba1f20dc-93a4-4dbb-90c9-36a433b16635" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89c67fa6-0cd8-4289-89d5-bb967ce0cad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89c67fa6-0cd8-4289-89d5-bb967ce0cad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f78fda4f-34d5-4769-b3aa-4df66a820993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f78fda4f-34d5-4769-b3aa-4df66a820993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_914b8d8c-6af9-4d04-b910-4c41bd198e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6aa205cf-cf0c-4f77-851c-409b04eade5f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_914b8d8c-6af9-4d04-b910-4c41bd198e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c26d2f33-d92c-47e6-bd9a-c36a95fbac1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c26d2f33-d92c-47e6-bd9a-c36a95fbac1c" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_beb95843-c42b-4230-83bb-f4b088aaac4f" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_beb95843-c42b-4230-83bb-f4b088aaac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_26f5b2d2-e892-44f6-a1c6-c9faae8b74a3" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_26f5b2d2-e892-44f6-a1c6-c9faae8b74a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2a849dbd-8007-4004-b465-4c03ce1e3748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2a849dbd-8007-4004-b465-4c03ce1e3748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_9056fbed-88a3-4939-99dc-92cb3580222c" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_9056fbed-88a3-4939-99dc-92cb3580222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_5856d1df-5899-4fe1-aa91-62a3d99c6c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_5856d1df-5899-4fe1-aa91-62a3d99c6c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_381dda51-db63-4e64-b693-06c9cc1d0354" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_381dda51-db63-4e64-b693-06c9cc1d0354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5cc8f946-210b-45c6-957f-380dbc7ab828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5cc8f946-210b-45c6-957f-380dbc7ab828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_632d5cbe-e520-44cb-a242-9fddfba4983d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7afd15bb-86c5-40ca-829c-494ec797685a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_632d5cbe-e520-44cb-a242-9fddfba4983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c26d2f33-d92c-47e6-bd9a-c36a95fbac1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c837eb67-87ec-4d24-bb4e-da69169b4f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c837eb67-87ec-4d24-bb4e-da69169b4f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_6aaeedeb-585a-48ed-89e3-a2945c9047d2" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_6aaeedeb-585a-48ed-89e3-a2945c9047d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e18da956-b0c3-47da-80f6-222670a53724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e18da956-b0c3-47da-80f6-222670a53724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ecd38199-b57d-476b-9e2c-388a0a023677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_ffa2c3cd-d065-42ee-88ff-294852a80588" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ecd38199-b57d-476b-9e2c-388a0a023677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2c78f8d0-428e-4237-bb33-c81e8de3a108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c78f8d0-428e-4237-bb33-c81e8de3a108" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:to="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_8d2b914a-0234-4ec4-9004-f19ae55482eb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_ed07ffdc-b814-40bb-be3f-4c38c1dd480e" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermOneMember_ed07ffdc-b814-40bb-be3f-4c38c1dd480e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_722d2b6b-92ac-4999-897e-bb7c327a0697" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermTwoMember_722d2b6b-92ac-4999-897e-bb7c327a0697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_906b49bd-2c7a-4c9f-858e-08e64ab90415" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermThreeMember_906b49bd-2c7a-4c9f-858e-08e64ab90415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_eaf70f03-14a1-4551-adf5-c8b1fcca58be" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_ExpirationTermFourMember_eaf70f03-14a1-4551-adf5-c8b1fcca58be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_94ad387f-fbe0-43b4-843a-51407d082041" xlink:href="cpix-20201231.xsd#cpix_IndefiniteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_bf96c5b8-a7ef-4cdb-94ea-b64163d05255" xlink:to="loc_cpix_IndefiniteMember_94ad387f-fbe0-43b4-843a-51407d082041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25eb08df-767d-40fd-b76c-5af69ed29193" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b7f7c17d-45ef-43dd-b1ca-d0746935e8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b7f7c17d-45ef-43dd-b1ca-d0746935e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f5779b9e-2e93-41c4-b5b8-b7b6a6a68ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b20a6539-0cc3-4a48-bfde-b4552988d39d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f5779b9e-2e93-41c4-b5b8-b7b6a6a68ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7c34aaa5-aa6f-4c87-91ad-a27b087d3f5b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_704586e3-6826-4417-9286-a386c7301530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_df9e32ea-0544-4249-bc92-321059cbc6fb" xlink:to="loc_us-gaap_OperatingLossCarryforwards_704586e3-6826-4417-9286-a386c7301530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4db96c1a-73d9-4d44-80e9-f17a2094bde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b97321ce-4537-4385-92fb-37cc1cb22ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4db96c1a-73d9-4d44-80e9-f17a2094bde7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b97321ce-4537-4385-92fb-37cc1cb22ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1d267ae7-f287-494d-bea1-c49228d0313d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b97321ce-4537-4385-92fb-37cc1cb22ef0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1d267ae7-f287-494d-bea1-c49228d0313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_25779ba2-7740-4fd0-97db-1055aead6d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b97321ce-4537-4385-92fb-37cc1cb22ef0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_25779ba2-7740-4fd0-97db-1055aead6d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c54a57e-c419-4e83-8ebd-1ec20bb19a80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b97321ce-4537-4385-92fb-37cc1cb22ef0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c54a57e-c419-4e83-8ebd-1ec20bb19a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5132c1b-e674-4ed0-bbd4-c8a11862795d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4db96c1a-73d9-4d44-80e9-f17a2094bde7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5132c1b-e674-4ed0-bbd4-c8a11862795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_64a8b2ed-e116-4d80-b2af-89b7757c0cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5132c1b-e674-4ed0-bbd4-c8a11862795d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_64a8b2ed-e116-4d80-b2af-89b7757c0cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d462c94a-0865-40fe-943f-8cdbf3a426a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5132c1b-e674-4ed0-bbd4-c8a11862795d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d462c94a-0865-40fe-943f-8cdbf3a426a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_28e0d010-09e5-44f7-8bf1-68ac8df030b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5132c1b-e674-4ed0-bbd4-c8a11862795d" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_28e0d010-09e5-44f7-8bf1-68ac8df030b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a0a44ec2-52e6-4820-865c-5e06d6448446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4db96c1a-73d9-4d44-80e9-f17a2094bde7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a0a44ec2-52e6-4820-865c-5e06d6448446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3eb617d-b2c7-47ec-87f1-87d877017c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d3eb617d-b2c7-47ec-87f1-87d877017c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_735b3e1d-7134-475a-8af4-494a75772721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_735b3e1d-7134-475a-8af4-494a75772721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8f074bf6-354f-4c08-b604-d37e56b7f3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8f074bf6-354f-4c08-b604-d37e56b7f3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_127659d2-0a2a-4e2d-90c3-dbff083abdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_127659d2-0a2a-4e2d-90c3-dbff083abdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_68a182b4-42c1-4b97-8644-f6f93f954e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_68a182b4-42c1-4b97-8644-f6f93f954e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a531880b-c536-423c-97c4-bc0cd300ac8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a531880b-c536-423c-97c4-bc0cd300ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b89dac7-c0f1-4362-8155-e231a174cfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04ecdd23-c564-4e49-a0ed-8c61c2fecbe5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5b89dac7-c0f1-4362-8155-e231a174cfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_1796fed7-3318-44e5-b4bd-cb0dbcd46347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1796fed7-3318-44e5-b4bd-cb0dbcd46347" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:to="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:href="cpix-20201231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_6f73f7f6-2090-4eb0-b60d-6ce903c5a406" xlink:to="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_14010139-efdf-4a38-bf5b-7318c681bd48" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermOneMember_14010139-efdf-4a38-bf5b-7318c681bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_bd27992a-eed6-4413-b027-a7ab1320da65" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermTwoMember_bd27992a-eed6-4413-b027-a7ab1320da65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermThreeMember_02d87369-fbb6-4aa1-8c85-c886e61b7506" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermThreeMember_02d87369-fbb6-4aa1-8c85-c886e61b7506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermFourMember_748d6576-e9ae-4afa-bb9d-dd5b1823e634" xlink:href="cpix-20201231.xsd#cpix_ExpirationTermFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_ed62dbd4-bc59-4788-9e4b-a0142f53d767" xlink:to="loc_cpix_ExpirationTermFourMember_748d6576-e9ae-4afa-bb9d-dd5b1823e634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6338fd8-a5e8-48c5-9db1-13ee75cc7416" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_28ef8d0e-c298-4abe-98cf-1b39700fe795" xlink:href="cpix-20201231.xsd#cpix_FederalAndStateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e09e1c5-cc36-44e0-9373-0e3972144dbb" xlink:to="loc_cpix_FederalAndStateMember_28ef8d0e-c298-4abe-98cf-1b39700fe795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_6b03df54-613e-4e0d-bc62-5411486ddac9" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c017261f-f405-43aa-b799-ff685ad3a3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_dc569d1f-616c-491e-825c-fa1cd95b032f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c017261f-f405-43aa-b799-ff685ad3a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8da7fb6d-709a-40fe-8196-9009ae2422eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_74e06da9-a358-46b1-8f50-882b9d52ed3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8da7fb6d-709a-40fe-8196-9009ae2422eb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_74e06da9-a358-46b1-8f50-882b9d52ed3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6917e29-47d7-438f-8450-fb3cb208065d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eb752389-065d-47ed-bbe5-acb4eee71ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6917e29-47d7-438f-8450-fb3cb208065d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eb752389-065d-47ed-bbe5-acb4eee71ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_048f168a-1af9-4165-ad2d-ae3259bd0417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6917e29-47d7-438f-8450-fb3cb208065d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_048f168a-1af9-4165-ad2d-ae3259bd0417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d1b08811-47d0-4467-9590-65cd0e06222b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6917e29-47d7-438f-8450-fb3cb208065d" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d1b08811-47d0-4467-9590-65cd0e06222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_771408cd-71da-4ae8-b193-26e966377711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_771408cd-71da-4ae8-b193-26e966377711" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_89779fad-f440-4e14-a248-544f2dfde2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_626bee0e-6bae-4a9d-b95b-d0bae010e04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_626bee0e-6bae-4a9d-b95b-d0bae010e04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f713488a-6d6b-41e6-a872-bd23238cde84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae9a535d-0b26-496f-91d7-48b20992eff9" xlink:to="loc_us-gaap_RestrictedStockMember_f713488a-6d6b-41e6-a872-bd23238cde84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_95dabdc2-6633-4340-a6e3-891878dd0cf2" xlink:to="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_3d82a355-b280-447e-b4c9-bac2884dcf64" xlink:href="cpix-20201231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_3d82a355-b280-447e-b4c9-bac2884dcf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_457091c5-bda5-4b14-810a-95ec2610672e" xlink:href="cpix-20201231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be1a91f8-91ce-412b-bfab-435b40c23510" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_457091c5-bda5-4b14-810a-95ec2610672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d4c23f47-45e3-4741-917b-9859ff43e7a8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_2dc03a5c-b9ae-49e0-a1f6-d992e17f5bdb" xlink:href="cpix-20201231.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_cpix_EmployeeMember_2dc03a5c-b9ae-49e0-a1f6-d992e17f5bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_814d9da2-f5d9-4327-b505-6be0ea9ce5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_us-gaap_PrincipalOwnerMember_814d9da2-f5d9-4327-b505-6be0ea9ce5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_87f7de4d-3f05-4635-922c-876bd0fa3a4a" xlink:href="cpix-20201231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_cpix_NonprincipalOwnerMember_87f7de4d-3f05-4635-922c-876bd0fa3a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_38ab2b86-f75f-4ca5-a891-4cc79486b4fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8cfebd2f-4a3a-4c74-b061-35c951e51fb5" xlink:to="loc_srt_DirectorMember_38ab2b86-f75f-4ca5-a891-4cc79486b4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea81972f-042d-4a39-8f79-fc5fc999a6aa" xlink:to="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e75bed13-f543-41ee-a1f0-528850a12bbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:to="loc_srt_MinimumMember_e75bed13-f543-41ee-a1f0-528850a12bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4135aa0e-100c-4c5b-a3d8-c4fddee21ddd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ac2ee61-9690-4301-bbd7-12e03bd1505e" xlink:to="loc_srt_MaximumMember_4135aa0e-100c-4c5b-a3d8-c4fddee21ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a6cc0ee-45f3-4f7a-a99d-c6337b60a998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_9a506fb5-d193-4456-aad4-6a22e977b882" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_9a506fb5-d193-4456-aad4-6a22e977b882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_418a9885-fd47-4da6-b8a9-5d2935a82f16" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_418a9885-fd47-4da6-b8a9-5d2935a82f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c7d50a43-4665-47e3-a872-ec89ae85ba07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c7d50a43-4665-47e3-a872-ec89ae85ba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_4fde8ab7-dd77-4f3a-8abf-db2588405bd6" xlink:href="cpix-20201231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_4fde8ab7-dd77-4f3a-8abf-db2588405bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c29f384d-bbb0-4dd9-b707-2866cfcb5a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c29f384d-bbb0-4dd9-b707-2866cfcb5a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59450a43-c4b5-49ee-b179-a8077ca63f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59450a43-c4b5-49ee-b179-a8077ca63f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e2648d0-7d98-4ef7-8883-2d024e063622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e2648d0-7d98-4ef7-8883-2d024e063622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_279cc7cd-8617-4111-9692-07736c45a004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dddf8e9-f06c-4780-a00e-669419f846fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_279cc7cd-8617-4111-9692-07736c45a004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd9365ea-cfb5-4d1f-8e2f-dedc3d8cc633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd9365ea-cfb5-4d1f-8e2f-dedc3d8cc633" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:to="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ffa1c967-c6e9-4ade-9687-470d5a3b02bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_59e468eb-b0ce-4015-a868-4ceeb7de9654" xlink:href="cpix-20201231.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_EmployeeMember_59e468eb-b0ce-4015-a868-4ceeb7de9654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_bc3921bd-328b-4796-b0ac-6a4ebe908b9a" xlink:href="cpix-20201231.xsd#cpix_NonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_NonemployeeMember_bc3921bd-328b-4796-b0ac-6a4ebe908b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_0fbaa2b5-f87a-44a9-9c47-171ebb09edd2" xlink:href="cpix-20201231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f36038dc-5769-4757-b797-057674677895" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_0fbaa2b5-f87a-44a9-9c47-171ebb09edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d59421-da8f-401f-ae09-85334fe430cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0d72b412-3c58-4d5b-ab37-ed5e89100653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4f463d9-cf7f-49b7-bc8e-421d387e2ca6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0d72b412-3c58-4d5b-ab37-ed5e89100653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_01045339-6a7e-4b03-99ca-45d7eafa32a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_01045339-6a7e-4b03-99ca-45d7eafa32a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c7d193ce-07bc-4ddb-bea8-13a27b11d7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c7d193ce-07bc-4ddb-bea8-13a27b11d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ea2977a-fa10-4ba6-a83f-d7ad6416e1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ea2977a-fa10-4ba6-a83f-d7ad6416e1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ef542a5f-1740-4086-ad9f-5fc5002474b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ef542a5f-1740-4086-ad9f-5fc5002474b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29dd4ace-3a74-4b17-9120-daa0390bfe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e4149335-c2fa-4b21-8d0d-9b8065c8eeda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29dd4ace-3a74-4b17-9120-daa0390bfe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c046b588-d5a1-4472-9fc6-795525c49a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c046b588-d5a1-4472-9fc6-795525c49a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5582524c-9a5b-452b-b258-aa81b4a9802d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5582524c-9a5b-452b-b258-aa81b4a9802d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34c4f074-5c65-47bf-8169-8cf2080f6fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34c4f074-5c65-47bf-8169-8cf2080f6fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3759baff-17ea-494e-98df-212bb8a14106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3759baff-17ea-494e-98df-212bb8a14106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2462f26d-b054-4bf2-bd89-cbf029afb393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2462f26d-b054-4bf2-bd89-cbf029afb393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e98101ca-629b-448a-b2f7-b3ae951fc038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af431f07-8da3-4daa-acd6-10762f49a81f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e98101ca-629b-448a-b2f7-b3ae951fc038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_562ac0fe-8e42-470b-972f-17d203ab8783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_562ac0fe-8e42-470b-972f-17d203ab8783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7fc82f7-dfb0-465a-b148-7cabbf8cfd59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7fc82f7-dfb0-465a-b148-7cabbf8cfd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50255617-9c6e-4715-a953-f70a72ca2532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50255617-9c6e-4715-a953-f70a72ca2532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc579207-7c6e-4c15-8b8a-a23b0a7faf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3704422-8132-40b8-8e75-5531d22b039e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc579207-7c6e-4c15-8b8a-a23b0a7faf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a116f78-52f0-4217-8ccf-0b3859fd59cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a116f78-52f0-4217-8ccf-0b3859fd59cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:to="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4096dfc9-99dd-40db-9740-23c1edfc9a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0491068e-c2ca-4318-8cc4-c9ebb26cde03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bea0bde-6d54-4940-9171-c7395b390395" xlink:to="loc_us-gaap_RestrictedStockMember_0491068e-c2ca-4318-8cc4-c9ebb26cde03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0a452-169e-4a45-af19-9fa70282d39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54dac0de-9f51-4fe6-94d3-27de4885ae6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54dac0de-9f51-4fe6-94d3-27de4885ae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe7562d-cec8-4e30-81aa-6a9a3877f812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe7562d-cec8-4e30-81aa-6a9a3877f812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af52124f-4570-4543-99a4-60d64cfdc8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af52124f-4570-4543-99a4-60d64cfdc8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ced2f884-d142-421f-a1e4-4bdf5eb5a1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ced2f884-d142-421f-a1e4-4bdf5eb5a1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f23244fb-2879-40d5-8f64-d35a60eb330d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eff5c671-692b-4ffd-a8c8-7293a143899c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f23244fb-2879-40d5-8f64-d35a60eb330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6e9c11b-38f8-4fff-96a4-63996505a95b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_372d6dff-b3d7-4b21-bd14-1561537382db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_372d6dff-b3d7-4b21-bd14-1561537382db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f90335fc-1d5d-4087-8f4b-50fc408396cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f90335fc-1d5d-4087-8f4b-50fc408396cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12173684-4b44-4be7-9e80-bacf8394cf20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12173684-4b44-4be7-9e80-bacf8394cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_793cf214-3260-430b-991b-b530f054b605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_793cf214-3260-430b-991b-b530f054b605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d051518-cef7-4b46-8e8c-357aa7a9111c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ef22691a-df71-4b81-8fca-b6e5e5e816dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d051518-cef7-4b46-8e8c-357aa7a9111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_eb99c626-9d3d-4eef-8beb-2351149c264a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4e8f34a2-faab-4992-b09c-fa921612633d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_eb99c626-9d3d-4eef-8beb-2351149c264a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4e8f34a2-faab-4992-b09c-fa921612633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_81affee5-6bd0-4318-852c-2cf95cd5de83" xlink:href="cpix-20201231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_81affee5-6bd0-4318-852c-2cf95cd5de83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_86edfd51-d31f-4c24-aed9-aa0ab12963c2" xlink:href="cpix-20201231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_86edfd51-d31f-4c24-aed9-aa0ab12963c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_20fe6783-aef2-4de3-be4b-b9a60722f246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_20fe6783-aef2-4de3-be4b-b9a60722f246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_082db5a4-83d6-48f8-aec1-63098da52a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_082db5a4-83d6-48f8-aec1-63098da52a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_f2e7306d-e028-4564-96f6-84b1529083b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_6fef99fa-3759-48a5-a1b8-43c5dacc89b3" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_f2e7306d-e028-4564-96f6-84b1529083b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6b8a16b4-30e5-46bf-ae62-f28376fafb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_07cd7d07-aa2f-4d67-a26c-8ce61fdf76a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b8a16b4-30e5-46bf-ae62-f28376fafb07" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_07cd7d07-aa2f-4d67-a26c-8ce61fdf76a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b72d49a2-3357-4280-80a7-ec49d0dfee66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_b67c4371-dedc-4573-a5f4-e1c5e30486ed" xlink:href="cpix-20201231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b72d49a2-3357-4280-80a7-ec49d0dfee66" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_b67c4371-dedc-4573-a5f4-e1c5e30486ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_5d97bdd5-db9a-44c1-af96-694a7c58727e" xlink:href="cpix-20201231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b72d49a2-3357-4280-80a7-ec49d0dfee66" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_5d97bdd5-db9a-44c1-af96-694a7c58727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0920c38f-9cf9-45f2-b2f3-17cf867c2079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b72d49a2-3357-4280-80a7-ec49d0dfee66" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0920c38f-9cf9-45f2-b2f3-17cf867c2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1c331d8c-2cc2-446d-ac7f-28549f2d7be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_22745655-6d15-4ad6-a97b-c0f708011911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c331d8c-2cc2-446d-ac7f-28549f2d7be5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_22745655-6d15-4ad6-a97b-c0f708011911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1b18a5fa-ed90-4558-bc18-a622a036eec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c331d8c-2cc2-446d-ac7f-28549f2d7be5" xlink:to="loc_us-gaap_OperatingLeaseLiability_1b18a5fa-ed90-4558-bc18-a622a036eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4fc1331e-1415-417b-b708-ec1e027dd45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c331d8c-2cc2-446d-ac7f-28549f2d7be5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4fc1331e-1415-417b-b708-ec1e027dd45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_decf24c5-80da-4e04-90a4-7829b56dee00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c331d8c-2cc2-446d-ac7f-28549f2d7be5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_decf24c5-80da-4e04-90a4-7829b56dee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef6cb755-7bc1-42eb-8600-bdf9da79269b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_0fd5a3dc-2161-442e-b8bc-fac6d89ba54c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef6cb755-7bc1-42eb-8600-bdf9da79269b" xlink:to="loc_us-gaap_LeaseAndRentalExpense_0fd5a3dc-2161-442e-b8bc-fac6d89ba54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_c549bab0-51f6-498e-9631-e4d63401b6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef6cb755-7bc1-42eb-8600-bdf9da79269b" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_c549bab0-51f6-498e-9631-e4d63401b6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_ee47b176-0ae4-4282-b5cb-b108d74c9434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef6cb755-7bc1-42eb-8600-bdf9da79269b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_ee47b176-0ae4-4282-b5cb-b108d74c9434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_112bd3c8-1fbd-4533-af7d-b1ecb71d1b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f547cc1c-7ee8-4686-b921-2d097002edad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_112bd3c8-1fbd-4533-af7d-b1ecb71d1b86" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f547cc1c-7ee8-4686-b921-2d097002edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_33af4eb4-c986-4754-ae33-de8e5e76ab10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_112bd3c8-1fbd-4533-af7d-b1ecb71d1b86" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_33af4eb4-c986-4754-ae33-de8e5e76ab10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_310e719f-6011-4a01-ba28-6a58a2aa2039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_112bd3c8-1fbd-4533-af7d-b1ecb71d1b86" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_310e719f-6011-4a01-ba28-6a58a2aa2039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_c8efd6fd-d3b0-4778-996b-95c28bf37640" xlink:href="cpix-20201231.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_112bd3c8-1fbd-4533-af7d-b1ecb71d1b86" xlink:to="loc_cpix_LeaseLiability_c8efd6fd-d3b0-4778-996b-95c28bf37640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4e7b79c7-9e4b-4add-8138-50074c286add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4e7b79c7-9e4b-4add-8138-50074c286add" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d851452d-5736-447e-bc9d-09f1a3566337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d851452d-5736-447e-bc9d-09f1a3566337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2401f096-06e3-4b69-a440-42cb6cc07a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2401f096-06e3-4b69-a440-42cb6cc07a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2be2b539-f9e8-4345-a0c2-219f1a8ddb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2be2b539-f9e8-4345-a0c2-219f1a8ddb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_224e028f-1536-4d49-a753-c7bfa4db2142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_224e028f-1536-4d49-a753-c7bfa4db2142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eaad9049-953c-49b6-a4b0-5d96b4b673d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eaad9049-953c-49b6-a4b0-5d96b4b673d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e0b1a5d6-3ee1-4967-b0f0-2676a0a46642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e0b1a5d6-3ee1-4967-b0f0-2676a0a46642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5fda813a-40f6-4e0e-9043-9150b2b9f326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_455cbad6-cd29-43c4-892e-8ed8189b5e32" xlink:to="loc_us-gaap_OperatingLeaseLiability_5fda813a-40f6-4e0e-9043-9150b2b9f326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_47862771-f27b-4929-880c-de57136cc12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cf8fafb9-8a9e-4480-b3da-0e95928bb6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_47862771-f27b-4929-880c-de57136cc12c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cf8fafb9-8a9e-4480-b3da-0e95928bb6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0ea85587-2d3f-436f-90fb-821a008fe5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_cf9cb81c-3713-43c5-838a-e8d684baab12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0ea85587-2d3f-436f-90fb-821a008fe5dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_cf9cb81c-3713-43c5-838a-e8d684baab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06b2fea2-8ae8-4370-a6ef-f0738366c943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06b2fea2-8ae8-4370-a6ef-f0738366c943" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_83179f75-d45a-43eb-b516-c5afef0e1869" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_81db5d5c-9111-4a83-96c1-24bd3596ac39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06675749-c9ba-43fc-afac-f3ae79347451" xlink:to="loc_us-gaap_CommercialPaperMember_81db5d5c-9111-4a83-96c1-24bd3596ac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1aa54a8b-009b-4b55-927d-75cd72c6962e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fd7828ce-2026-4bc0-9130-8a423a286487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fd7828ce-2026-4bc0-9130-8a423a286487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f918cd16-ee1d-4fab-80e0-669cfc0c0c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7808955-5473-48d2-8c69-afa5cfa5428d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f918cd16-ee1d-4fab-80e0-669cfc0c0c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad20106f-0073-4669-9b13-0a61aef218bb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_0feaee07-8ec4-4dc6-9199-6147bad3589f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf41963d-0eb4-4622-b549-dc8e2b80a280" xlink:to="loc_us-gaap_TradingSecurities_0feaee07-8ec4-4dc6-9199-6147bad3589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_ae8c6ba0-6d53-431a-9e96-ac6cd5de9374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_1aea8e04-827f-478b-96ac-d0198f731b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_ae8c6ba0-6d53-431a-9e96-ac6cd5de9374" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_1aea8e04-827f-478b-96ac-d0198f731b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_51920fd2-e4c0-4ab0-a584-ccb660ca966c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a08063f6-d6ff-450c-9174-54998b5a9b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_51920fd2-e4c0-4ab0-a584-ccb660ca966c" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a08063f6-d6ff-450c-9174-54998b5a9b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_4f66584f-e56f-401d-9b19-6ca6f8eb1f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_4f66584f-e56f-401d-9b19-6ca6f8eb1f91" xlink:to="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3ab46831-29b8-4ab6-8cab-9f40a32ba1ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d05ad43d-b368-449e-8549-88c552ba0832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a27fb942-ed10-4625-a21b-d0f0365f719f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d05ad43d-b368-449e-8549-88c552ba0832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10df71b8-e567-4a11-bf43-983233f1a003" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_61ad0c57-bcd6-4e37-ae47-8c77dec474d1" xlink:href="cpix-20201231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_61ad0c57-bcd6-4e37-ae47-8c77dec474d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b65eb85b-dbe9-4b2b-9775-fd35ef8a622b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_204f3597-765c-4341-ad47-6e395f0eeca2" xlink:to="loc_us-gaap_AccountsReceivableMember_b65eb85b-dbe9-4b2b-9775-fd35ef8a622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d231f113-f428-462d-8f99-f2d281187f0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_30d68273-b181-4d17-8101-ba07200d4e73" xlink:href="cpix-20201231.xsd#cpix_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerOneMember_30d68273-b181-4d17-8101-ba07200d4e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_e8117e24-608a-4b94-9e1f-600c2c7832a7" xlink:href="cpix-20201231.xsd#cpix_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerTwoMember_e8117e24-608a-4b94-9e1f-600c2c7832a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_8143dc4b-aa88-409f-b58c-8eaf3f066154" xlink:href="cpix-20201231.xsd#cpix_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b64912c-15af-408d-aed7-dff81586858a" xlink:to="loc_cpix_CustomerThreeMember_8143dc4b-aa88-409f-b58c-8eaf3f066154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d14fd716-82ec-439f-a235-55326518095f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebb50717-21ee-4138-9350-e2ee3dae9f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2f38d7ca-cf17-432a-a2d0-05fbbae4df4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebb50717-21ee-4138-9350-e2ee3dae9f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_226d11b6-628d-4d25-b804-e9294d4175ac" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_5bb35bac-8f8f-409e-a19c-7e4aba6ba988" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_226d11b6-628d-4d25-b804-e9294d4175ac" xlink:to="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_5bb35bac-8f8f-409e-a19c-7e4aba6ba988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_fe345d2e-e901-4cd9-a353-3b61828c32e2" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_fe345d2e-e901-4cd9-a353-3b61828c32e2" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:to="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b099ed2-b4c0-402d-9658-dc021fb51e27" xlink:to="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_574d2f7d-306c-49cc-aa38-ac3176df6856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:to="loc_srt_MinimumMember_574d2f7d-306c-49cc-aa38-ac3176df6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb39a5e4-03ef-4d5a-952e-42452e3a4791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f96d76f5-2925-4922-bc81-bbc3093ae526" xlink:to="loc_srt_MaximumMember_bb39a5e4-03ef-4d5a-952e-42452e3a4791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:href="cpix-20201231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_6477c1d8-dced-4cf4-be54-d804c93ccba6" xlink:to="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_e6eaadd9-c166-4d34-9607-0d14b20632cc" xlink:href="cpix-20201231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_356c2d67-46d2-4886-9d44-0ad227c3d1fe" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_e6eaadd9-c166-4d34-9607-0d14b20632cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmploymentAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract_80e5552f-10d8-4141-b54f-f8b82265ccb5" xlink:href="cpix-20201231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock_b93785f1-3a42-4750-bafa-1ca1ea7f3be1" xlink:href="cpix-20201231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EmploymentAgreementsAbstract_80e5552f-10d8-4141-b54f-f8b82265ccb5" xlink:to="loc_cpix_EmploymentAgreementsTextBlock_b93785f1-3a42-4750-bafa-1ca1ea7f3be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6a926bc-9b6c-43c0-9dff-f37014c0c7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_680ca52b-2914-4c1b-96ed-022f012d3f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c6a926bc-9b6c-43c0-9dff-f37014c0c7e2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_680ca52b-2914-4c1b-96ed-022f012d3f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f4dda201-871f-4187-b3d2-a55385ea0f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9525baa5-de7d-49da-9464-466b74fef396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f4dda201-871f-4187-b3d2-a55385ea0f63" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9525baa5-de7d-49da-9464-466b74fef396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3a7794bc-f28c-455b-a47e-068464a4875d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3a7794bc-f28c-455b-a47e-068464a4875d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8890c1de-a065-4d52-8b5e-5ef3c06d126b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenMember_777c71da-eb33-4d8a-8f7d-3437bca3b943" xlink:href="cpix-20201231.xsd#cpix_ClinigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6afb653d-df84-4400-999e-b1680b5614ab" xlink:to="loc_cpix_ClinigenMember_777c71da-eb33-4d8a-8f7d-3437bca3b943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ea869b6f-d86c-4369-832d-54732e0201fc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_b1b20867-3510-4da7-8745-506719b9c7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_b1b20867-3510-4da7-8745-506719b9c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_93563a8a-29a5-403b-8315-74a7d6671168" xlink:href="cpix-20201231.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_93563a8a-29a5-403b-8315-74a7d6671168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3cb6bed7-d38a-40c6-be6a-db843ce59f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a3c23776-c240-4792-b557-590eff4607ae" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3cb6bed7-d38a-40c6-be6a-db843ce59f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_fe122f64-79d7-4b7e-8c9c-fae6ed3acb1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_fe122f64-79d7-4b7e-8c9c-fae6ed3acb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_412eb641-b2bb-4bcf-9d24-3693e3e3236c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_412eb641-b2bb-4bcf-9d24-3693e3e3236c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bbcca538-76b1-4bdf-bed8-440043a9b2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bbcca538-76b1-4bdf-bed8-440043a9b2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_630d09cc-5a73-4bc9-ba23-70f7cead5e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_630d09cc-5a73-4bc9-ba23-70f7cead5e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c6932864-f94d-4cfe-95f0-4458a4b38742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c6932864-f94d-4cfe-95f0-4458a4b38742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7bd95c8b-7036-4c22-8bf9-8577e0a9b497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7bd95c8b-7036-4c22-8bf9-8577e0a9b497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8fd5094d-5b48-45ff-903f-bd2abb4a7304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8fd5094d-5b48-45ff-903f-bd2abb4a7304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_f2a46cc1-70de-4261-8068-a758dd846c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_f2a46cc1-70de-4261-8068-a758dd846c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c361a707-944c-47e7-8d0c-f7ad289f4a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c361a707-944c-47e7-8d0c-f7ad289f4a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_012226f3-f987-4368-a9be-62bb7534a6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e1c999da-dcb6-43b4-b605-0c7b2d5fc8a1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_012226f3-f987-4368-a9be-62bb7534a6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4c2a3220-6e44-4d9b-9f0a-5c144395dbf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_530d417c-ed31-4f8c-bc25-d21d842db59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4c2a3220-6e44-4d9b-9f0a-5c144395dbf0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_530d417c-ed31-4f8c-bc25-d21d842db59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_686ec937-efd4-47bc-a572-6489b19b858d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1b0c6f52-3dd2-4387-937e-2f6a1863b7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_686ec937-efd4-47bc-a572-6489b19b858d" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1b0c6f52-3dd2-4387-937e-2f6a1863b7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c3b6df34-aece-47af-9931-7f9bc924dc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_707991ec-72e2-48ed-85de-d3661c006e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c3b6df34-aece-47af-9931-7f9bc924dc5f" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_707991ec-72e2-48ed-85de-d3661c006e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8443df17-4ce7-4674-a118-446f4e477a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c47fa4aa-3c4d-4258-8133-9885a83e1a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8443df17-4ce7-4674-a118-446f4e477a50" xlink:to="loc_us-gaap_Revenues_c47fa4aa-3c4d-4258-8133-9885a83e1a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_409903f1-5a3f-4be4-9f88-17aa09996a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8443df17-4ce7-4674-a118-446f4e477a50" xlink:to="loc_us-gaap_OperatingIncomeLoss_409903f1-5a3f-4be4-9f88-17aa09996a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2dda7318-11dc-4924-8a45-fb6633e9f6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8443df17-4ce7-4674-a118-446f4e477a50" xlink:to="loc_us-gaap_NetIncomeLoss_2dda7318-11dc-4924-8a45-fb6633e9f6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c635e260-9ce1-4f6b-ae72-a1e1af429db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8443df17-4ce7-4674-a118-446f4e477a50" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c635e260-9ce1-4f6b-ae72-a1e1af429db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_303bbb81-625c-49cb-b128-27dcd146aa7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c635e260-9ce1-4f6b-ae72-a1e1af429db4" xlink:to="loc_us-gaap_EarningsPerShareBasic_303bbb81-625c-49cb-b128-27dcd146aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fb060eb8-2a5f-422d-a429-a1a7a388aa3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c635e260-9ce1-4f6b-ae72-a1e1af429db4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fb060eb8-2a5f-422d-a429-a1a7a388aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_53cf2dff-e0a0-4485-8c8e-83d3937b1853" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_46aba2b2-fc1a-45da-8cdd-be9ecc2e248c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_53cf2dff-e0a0-4485-8c8e-83d3937b1853" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_46aba2b2-fc1a-45da-8cdd-be9ecc2e248c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_6f0dd5db-9519-42ce-b342-fa01e6a1ae22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_6f0dd5db-9519-42ce-b342-fa01e6a1ae22" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6452bcb3-2360-4052-8f92-83d5787a56ba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_a695d7f9-8238-48d0-a391-01f8bd561cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_a695d7f9-8238-48d0-a391-01f8bd561cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0b7f7745-2a80-4f83-9848-36e329863281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c8e5fca-761e-4901-a456-eb098ff29233" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0b7f7745-2a80-4f83-9848-36e329863281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5552dd7f-0f1f-4e9a-9771-2edefbdbb8a7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_ba702398-0043-42a6-9f34-93874a2451c9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_279c2c23-533a-475e-b583-57ae43bf52c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_279c2c23-533a-475e-b583-57ae43bf52c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_01d39f6b-16f2-4416-8e5a-c38d8b19c56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_01d39f6b-16f2-4416-8e5a-c38d8b19c56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_e68aceb0-89c1-4f0a-82cc-73fa15723350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_e68aceb0-89c1-4f0a-82cc-73fa15723350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1ad72dc8-c3ff-4e10-9b12-35e0c5a746d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1ad72dc8-c3ff-4e10-9b12-35e0c5a746d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bb379402-33de-40c2-b719-69cca2957c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d1da37e-1141-4901-ba03-859932e0e078" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_bb379402-33de-40c2-b719-69cca2957c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cpix-20201231_g1.jpg
<TEXT>
begin 644 cpix-20201231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?CK\7I_B#\0;Z_NKZ&Y&E+96=I<W&[S9A'O<N^'8*<JJ!N$R%( /L,D*"S$
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MN;5-@X^S^>$&?;S7B_'%<%_P;FW&GM^R%XQM(\?:D^)$[S<\^6VGV(3]5DH
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M]O5^&?\ P5=N;_1_^"N>L:KXXWKIT6K^'I[=IQ^[^Q+:6FXKGC;N67/^T&H
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ME\3_ !OX=UKP+LN-0AT7QGJ,:WNEY(FWH)\,\>X2^8?FV1N"3QCXHUG_ )6
M$_[*]!_Z"E?L]K^@Z/XIT&]\,>(=/BN]/U*TDM;ZTF7*30R*4=&'<%20?8T
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M+XBZJ@6UE1)&B607'F* 7(!#9  YK[1_:D_8;TWQ+X#\6>&OV9OVC_B]X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLP/'S#;/"#R2T\(Z+Q]LZ9IFGZ+IMOHVD645M:6D"0VMM @5(HU4*J*!P
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M:WQD_;KM/BK\<_V>Y? 'PZ\)^#-1MO"UK<>)M.OY[G4;F:U5I9A:3R$.T*2
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MFH27NBQ7\FR&\CD0+-;%\'RV;;&RL>-T8!P&++]544 ?$W[#WQS_ &O?@%\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M10 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M+^W=_P FA^//^P(?_1B5W7PF_P"25^&?^Q?LO_1"5PO[=W_)H?CS_L"'_P!&
M)7=?";_DE?AG_L7[+_T0E '04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5F^,?^18O?\ K@:TJS?&/_(L7O\ UP-
M%S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_^OT_^@FMBL?Q
M+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\
MZ": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+
M_P A?1_^OT_^@FMBN>\2:MIA\6Z1H0OHOM@D\\VV[Y_*.5#X],@C- '0T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_
M 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4
M?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E6;XQ_
MY%B]_P"N!H_X3'PQ_P!!J#_OJL_Q1XH\/WGA^[M;758GD>(A$4\DT ;FG?\
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M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
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M/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :58_B7_ )"^C_\
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!A>([*S35=)5+2(!KPA@(QR-IK7_L[3_\ GQA_[]"LWQ+_ ,A?1_\
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ME_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C
M#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
M$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_
M -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!
M#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% &%9V5F?&=[$;
M2+:+.,A?+& <FM?^SM/_ .?&'_OT*S;+_D=[W_KRB_F:V* (?[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
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MEG;W))K4_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
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MHH **** "BBB@ HHHH **** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +FG?\
M(/@_ZXK_ "%35#IW_(/@_P"N*_R%34 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^
M)?\ D+Z/_P!?I_\ 036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]
M!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S6Q0 4444 %%%
M% !1110 4444 %%%% !117E_QK_:K^'OPA6728)AJ^MJ"!IMI*,1-_TU?D)]
M.6]L<T >CZOK&E:!ILVL:YJ4%I:6Z;I[FYE"(@]23P*^>_B?^V5K?B?5?^$
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M% !1110 4444 %%%% !1110!CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S-;%
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MV!#_ .C$KNOA-_R2OPS_ -B_9?\ HA* .@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\BQ>_]<#6E6;XQ_Y%
MB]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XE_P"0OH__
M %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/_U^G_T$UL5C
M^)?^0OH__7Z?_030!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?'KXRW4=UIMAXSDBM_#ENY(+6TDD5C/<IGG:XG:,-U/D9Z8) /M"]_X+9?\
M!/6Q^))^'+_%F\D5;O[,_B"'19FTT/NVY\T#)3/_ "T"E,?-NV\U](^-OBI\
M.?AS\.;SXN^-O&5AI_AFPL!>W6M2S@P" @%75ESOW94*%R6+*%!) /YF>"?V
M=?A3J'_!O??>,9?!6F/KLUI>:ZVLM9(+E;F'5WC5A)C<,01"+KRI8=Z\V_:;
M^-?C#Q!_P0P^"'AZ[U.9OMWBZXTV_<N?WMM827R6\)]555@X]85]* /OWX'?
M\%@OV&?C]\3[7X2>#_B+?6>K:C<BWTAM<TB2U@U"8G"QQR-D!F/"J^PL2% +
M$ _3]?EC_P %F?@-\-_@O^PU\$O$OP]\(V.BZOX>U6QTRVU#3;5(9RCZ=)*[
M-(@!=O-MT?<23N+-G))/Z7?";Q1>>-_A7X9\::@ +C6/#]E>S@# #RP)(WZL
M: .@HHKC/C-\3?%_PRTRRO\ PA\'=:\8R74[1S6VBR1JUNH7(=MY'!/'% ',
M?MW?\FA^//\ L"'_ -&)7=?";_DE?AG_ +%^R_\ 1"5\S_M9?M'?%?Q;^SEX
MM\.:W^R5XOT.TN]+*3ZM?W$!AM5WJ=[A3G'&./6O?_A+XFU<_"KPR3X/O1_Q
M3]EQN7_G@E '<T5C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\
M)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J
M_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"
M2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO
M_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\
M)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J
M_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"
M2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO
M_P!"A>_]]+0!L5F^,?\ D6+W_K@:A_X275_^A0O?^^EJCXEU[4[G0;J";PQ=
M0JT1!E=EPON: .@T[_D'P?\ 7%?Y"IJPK+Q'JJ6<2+X2O& B4!@RX/'6I?\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
M/$O_ "%]'_Z_3_Z":V*Y37-<U&?4=-DD\-W,9CN2R(S+F0[>@K3_ .$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V*Q_$O_(7T?\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
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M\.OA;X&^%6C#1/!.A16J$#SYS\TLY'\3N>6/Z#/ %6?^$EU?_H4+W_OI:/\
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MQ!W?*>F* .EHHHH **** "BBB@ HHHH **** "BBB@ HHKQG_@H9\8?&_P
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M$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3_P"@F@#8HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 5F^,?^18O?\ K@:TJS?&/_(L7O\ UP-
M%S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_^OT_^@FMBL?Q
M+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\
MZ": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MJKK.N:+X=L'U77]7MK&VC_UEQ=SK&B_5F(%>0_$']N3X2>%-]IX62Y\072Y
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MPF_Y)7X9_P"Q?LO_ $0E '04444 %%%% !1110 4444 %%%% !1110 4444
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MCK/_  JZWU>ZU7Q++#-XF\1>(=8EO;[5I8O,\N29W.W(\V3[BJ#O)(->K44
M%%%% 'YZ_P#!23_@J_\ &+X9^-/&G[/?[(/@HR:KX(TB&]\8^.ITBF31@TD
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MMS%\>/,SU_XJB^./^^HZ\T],^FJ*^9?^%)_MPVO,/Q<\S'&/[?E;CU^9*/\
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MM_8N^(_PRU/X??L1^#+_ $7PYX5E@:\CO-(EMQ/-<>8!)YLK,UQ)^X(=F8L
M$!.,"@#Z1HHHH **** "BBB@ HHHH **** "BBB@#R7]N[_DT/QY_P!@0_\
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MV;OA^Z76D_"S3[RZ3!^VZR&O92W]X&<L%/\ N@5X9\??V2?C!XK_ &@?$_Q
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MB71_BQ^T'\=?C]\%]$N;#X4^*-9TM/#4LEFUM!JVI6]O)'?W\$+ ;%=C&&;
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M]:;IY;2JXJ7_ $Z@VEZR=DEYZG3^*?A3^T)J=A_:WQ\^/VF^&M/D!\R/5O$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZXNO%/BCXEV]QJOB+5YQ+<[)Q=S/!%A56*+>1PJY;:NYFV@CWS]M"_U#3?\
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MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
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M%-GZ[P:7]O\ !N(_WC*>5]X5IK_R5JP?ZO<:X;_=\WYEVJ48/_R9.YY9H/\
MP4Y_9;U?;_:&I:YI6>OV_1V;'U\EI*[70?VT_P!ECQ'M_L_XV:-'NZ?;W>U_
M/SE3%9&O?L1_!#Q'N&H?"WPQ'NZ_8+%[7_T2R8KC=:_X)@_ W5<_88[O3<]/
ML6H2MC_O]OH_XUOB?^@FD_\ N'*/_P D'_&R\-_T#5E_W$A+_P"1/?=!^)OP
MV\4[?^$8^(.AZCN^[]@U:&;/TV,:W*^.]7_X)(^&IL_V#\7;ZV]/M=BD^/\
MOGRZS4_X)L_M(^#ACX:_M)10;/\ 5[;N\L<>G^J+XI_V!P9B/X&;<K[3HS7_
M ),G8/\ 6#C7#?[QE',N].M!_P#DK5S[6K\Q/^'AO[87_17_ /RW]/\ _D>O
M:/\ A2__  5+\"?\B_\ %9M9V?=_XGT5QN_\#4&?QKXNK])\/.$<EI_676J4
M,6GR6LE-P^.]U)>[S:6[\K['YCXC<8YW4^JJA3Q&#:Y[W;@I_!:SC+WN76_;
MF7<]C3]OW]K>.^?4D^+.)I$"._\ 8-AR!T&/(Q4W_#PW]L+_ **__P"6_I__
M ,CUXM17Z5_JMPQ_T T?_!4/_D3\R_UKXI_Z#ZW_ (-G_P#)'[245SFBZCK?
MB33H]7\.^--(O[249BNK("6-_HRD@U;^Q>-_^@W9?^ Q_P :_C*490DXR5FC
M^UXRC.*E%W3-BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:DHV**Q_L7C
M?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z
M#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C
M?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z
M#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C
M?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z
M#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C
M?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V*Q_$O\ R%]'_P"OT_\ H)H^Q>-_
M^@W9?^ Q_P :I7\&NPZSI9UB^@F!O/W8ABVX^4YS0!TM%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?E+_P5:_9S_;7^!FK_%?XO^"/%EWX
MI^$'Q T]!XCLM4UEIF\/E[N&4*D,L@**+A0(VB#*$E*,HP#7O_\ P3__ &3/
MVG-5_:G\3_\ !0']L+0]*\.Z_KN@Q:3X?\):3<)+]EM@D*"65D=U!\J!% WL
MQ,DA8)A5K[0UW0-!\4Z3-H'B;1+34;"Y4+<65_;+-#* 00&1P5;D \CJ!5I5
M5%"(H  P !P!0!\J_P#!8C]FWXT_M4?LEV_PR^ W@S^W=<C\7V=Z]C_:-M:X
M@CBN%=]]Q)&G!=1C=GG@<&O2+S]F^7XI_L'VG[+?Q%0Z;=W_ ,-;31-08%)C
M8W:6<:!QL8K(8YD#<-AMG!P<U['10!^247[,/_!7G0/V8;O_ ()DZ?\  K0[
MCPC<ZPWE^.$U>$1+9-=BZ91(9@5C,P,A!B\W:S+L)(KZC_:/_P""6P\??\$T
M_#?[&_P^UVU/B#P-'!J&B:A= QP7NHJ)3<ACR8TF-Q<8SG:S(3G:37V510!^
M5/B;]EK_ (*B_MZ6GPS_ &9OVGO@YIW@KP5X FB36_%"W\+2WZ11K#YN$GD\
MV8Q*P7RU";Y&9BJD ?JAI]A9Z580:7IUNL-O;0K%!$@X1% "J/8  5-10 5\
M^?MQ_ 'XA_&O6_!FI>!?#@U%-"746NE-Y#%L>7[-Y9_>NN?]6YXS@@5]!T5T
M87%5\%5]I1=I6E&_E*+B_P &SFQ>$H8VE[*LKQO&5O.,E*/XI,^ ?'?[.GQE
M^&?A"_\ 'GC?P=]BTG3(/.OKO^T+>3RDR!G;'(S-R1P 35_2?V3OV@-<TJVU
MO2O /FVMY;I/;2_VK:+OC=0RG!E!&01P1FOI7]N[_DT/QY_V!#_Z,2NZ^$W_
M "2OPS_V+]E_Z(2N<Z3P;]D?]DG5/!M]XS/QJ^'%E]GUI=/:Q2ZE@G(DC^TB
M4J8W8QGYXSG()S[5T_C7]A7X>:PSW7@G7+W19CRL+G[1"/H&(<?7<?I7N5%>
M5Q#D>3\55/:YI0C4GRQCS-6E:$5"/O*TM(Q74\VGE&74J/LHTU:\I?.4G)Z^
MK9\S?\(?^V9\$/F\.:Q)XATV+I#'+]K7:.B^7)B1?HGYUJ>%OVZEL;O^Q_BM
M\/KFPN(SMFEL,Y4^\,N&7_OHGVKZ%K+\4>"/!_C:T^Q>+?#-EJ,8&%%W;JY3
M_=)&5/N"*^0_U.SK*=<DS&<(K_EW5_>P]$W[T5Z79/U#$4/]WJM>4M5_P#)\
M$_&WX5_$,(GA7QK9S3/TM)7\J;/IY;X8_4 BNJKP_P ;_L+?#C6]]SX+UB\T
M28\K$Q^T0#\&(<?]]'Z5RO\ P@?[9'P1^;PGKSZ_IL72"*7[2NWL/*E^=?I'
M^=/_ %FXKR?3-\N<XK>IAWSKU]F_>2[ML/K>-H?QZ5UWCK^&Y]-45\\>&?VZ
M)],N_P"QOBS\.KFQN8SB:6Q!4J?>&7!7_OH_2O6O!'QS^%'Q#V1^&/&EG)._
M2SG?R9L^@1\%OPR*]S*>,^&LZER8;$QY_P"67NROVY96;^5SHH8_"8AVA/7L
M]'^)UM%%%?3G8%%%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]
M_P"N!K2K-\8_\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,?Q+_R%]'_Z_3_Z":V*Q_$O_(7T?_K]/_H)K8H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$O_(7T?\ Z_3_
M .@FMBL?Q+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH
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M,G[;H+?9'!/4[4_=L?=D->(>)/\ @F'\0? NI-XD_9T^.MS9W*<Q17\DEK,
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M71Z-.]KK5WT]#+<RCCDTU:2->BBBOT0]0**** "BBB@ HHHH **** "BBB@
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MWUX>MM/\3^&EN9;B^M[ZUF:^L(H1*L\OV9VB64?O$., A W5C7Y_?M8_L7?
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M'UNW_P"/+XPXV_<_XE3+Q^$QQ1_PQ%\1+;BR^,^ .5_<S)S^#G%>]?8O&_\
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M\-*?M:V_-W\"..@/_"-7Z\_7>:]Z^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:/\ 4[.X_#G%?YJ+_0/J&(6U>7X'@O\ PU?^T;;\WOP-P%X;_B4WB<_B
M3BC_ (;*^,=MQ>_!/&WEOW-PG'XJ<5[U]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XT?ZJ<4Q^'.JGSIP8?4L8ML0_N1X+_P -R^.+?Y;SX,X/4?Z5*O'X
MQF@_\% +V#F[^$&,_=_XG17^<%>]?8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-'^K7&T?@SM_/#TW^H?5,P6V(_\ )4>%Q?\ !06P./.^%<R\<[=8!Y_[
M]"K$7_!0'PTV//\ AQ?+_>V7Z-C_ ,=%>S2Z%XHF&)KW37&<_-8YYJO+X,U.
M?/GQ:*^[KOTM3G]*/["X_CMG$7ZX>"_)A]6S-?\ +]?^ H\IB_;]\"G'G>!=
M67GG;+$>/S%6(_V^/AB0?-\(Z\OIMCA/_M05Z-+\-EGSY^C^'7R,'?HL9R/R
MJO)\'](E.9?"GA5L=-WAZ$_^RT?V3XB1VS*D_6BE^3#V&:+_ )>K_P !.*B_
M;Q^#TAP^@^(DXZM9P?TF->+_ +3OQ\M_C1KME!X<-W#HMC #%;W2!&>=L[G8
M!B.!A1SQSZU]*2? CPI*,-X%\(#']WPY"/Y+7SE^UE\(;KX=>,H-<L=*M8-+
MU2$>5]@M_+ABF089-HX4D -[Y/H:^&\1,-QW0X9F\9B*=2CS1YE"#B[7T;?\
MO-:_G8\[-(9E'"/VDDXW5[*W]:GD]26=W=:?=Q7]C</#/#(LD,L;%61@<A@1
MT(/.:CJ2UM;F^NH[*RMWFFF<)%%&I9G8G   ZDGM7\]1YN9<N_0^75[Z'VI\
M-/VF?AEXB\%Z7>^*O'>F66JO:(-0M[B<1;9@,,>> "02/8BNNL_BI\,-1Q]@
M^(VA39Z"+5X6/Y!J\:T#]AGP]/X;LO\ A(+^2+4&M4-X8)SA9",L!D$<'C\*
M2Y_8%\-ODVOC.]C_ -\(P'_CHK^M,%C_ !+HX.G[3!T:CY8W_>.,GHOBNK<W
M?I<^VIU,VC35X1>G>S/>[/6=(U'_ )!^JVT^>GDSJW\C5FOFVX_X)^EL_9/B
M7L]/,T[=_)Q4:_L2?$_2_P#D _&&-,=,">+_ -!8UU?ZQ\;TOXN2W\XUZ;_"
MUR_K681^+#_=)'TM17S8/V;/VLM)YT?XWAE'1!X@O%S^!0BE_P"%??MU:/\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V*Q_$O_ "%]'_Z_3_Z":Y3XI_%J+X/Z8E_X
MO\6V@EF!^RV-M9[YY\==JY&!_M$@>^:\@O/VX9+[4K>6?PI+Y5M-OCE$JAO3
M.W&#QVW5\QFW&?#&1XGZOC<3&$^VLFO7E3M\[''7Q^#P\^6I.S_KL?45%>??
M"[XK1_%_2WU+P?XNM&DAQ]JLKBSV3P$]-RY/'^T"1[\5U/V+QO\ ]!NR_P#
M8_XU[V#QF$S##1Q&&FIPEJFG=/YG33J0JP4H.Z9L45C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UTEFQ16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M=?";_DE?AG_L7[+_ -$)0!T%%%% !1110 4444 %%%% !1110 4444 %%%%
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M /"#Y_L_X@ZE%Z>=:QR?RVU] 45YE7P\X+K?%@H?+FC^31E+*\OEO31\W/\
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M *_3_P"@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /)?V[O^30_'G_8$/\ Z,2NZ^$W_)*_#/\
MV+]E_P"B$KA?V[O^30_'G_8$/_HQ*[KX3?\ )*_#/_8OV7_HA* .@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\
M8_\ (L7O_7 UI5F^,?\ D6+W_K@: +FG?\@^#_KBO\A4U0Z=_P @^#_KBO\
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M?\FA^//^P(?_ $8E=U\)O^25^&?^Q?LO_1"4 =!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_P"N!K2K
M-\8_\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH
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MN%JWQX&C_P""X?FD9/!8.6]./W(\8N_V%/@S<9\G4M>@]/*O8S_Z%$:S+O\
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M?Y"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z":V* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\ H)H V**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>R_Y'
M>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"MK&BZ1X@TZ72-=TRWO+69<2V]S
M$'1Q[@\5YIKG[,OP+L]?TVYMOA_ IGO")4^U3%&&,XV%]N,]L5ZI6/XE_P"0
MOH__ %^G_P!!->?C,HRK,9J6+P\*C6SE",FO2Z=C*I0HU7><4_5)FAI.D:5H
M.GQZ5HFFP6EK"N(K>VB"(@]@.!5BBBNZ$(TXJ,59+9(T225D%%%%4,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSG]KKXV:A^SE^S-XV^-^CZ
M0E]>^'- FNK&UE!,;SXVQ[\8.P.REL$':#R.M>C5R/QYU/X.Z7\'?$+_ +0.
MJZ99>#+G3GL_$4^LW BMOL]P1 4=R1MW&0(,$'+#'.* /R$^%UK_ ,%(_P!H
M7XS^&_C]\+/VG'U;XF:_\+;WQ#I%K"UO%$EC#K2VCZ5^\Q;H"P,Y1E" H%.2
M=U?>'[;G[;OQT_9 _P""?.D?%?QYX4TS2?BMKOV;1OL,4J7-K9:D\<C2W"A6
M9718X9)%7+*&9%;<,@_"?CO]DCQ?^S!^T-+X[_X)J_M.74VG)\(;_P >Z=J4
M]TG[W2X+Q8Y[,2*ICN0=BN%D158Q@-R :Z3_ (*0?M$^-/VOO^"4_P &OV@/
M&6DQ6^I3>.+FPUMK2(I#)=10W40D4=A(L)?'1264<"@#HO&?QW_X*9_\$\])
M^&'[4WQX_:%_X3OPKX\GA;Q'X2NH%;[$LL2S_9U)0".7RBY5HBJJ\1!#+][]
M6-,U*QUG3;?6-,N%FMKN!)K>9>CHRAE8>Q!!K\W?^"[>M:1?_P#!/KX2FPN(
M]M[XCTZYLXT?=NA&DW'S ]P/,3G_ &A7W]\"=,U#1?@AX-T?5HV2[M/"FG0W
M*-U61;:-6!SWR#0!U=%%<9\9O@9X0^.>F66D^+]4UJUCL9VFA;1=6DM&9BNT
MABGWACL: .8_;N_Y-#\>?]@0_P#HQ*[KX3?\DK\,_P#8OV7_ *(2OFK]JK]B
MOX5?#K]G?Q;XWT'Q/XQDO--TIIK=+WQ5<31%@R_>1CAAST-=/X(_X)__  7U
MWP7I&MWGBOQLLUYI=O/*L/BR9$#/&K$*HX R>!VH ^CJ*\%_X=U? _\ Z&[Q
MW_X5\]'_  [J^!__ $-WCO\ \*^>@#WJBO!?^'=7P/\ ^AN\=_\ A7ST?\.Z
MO@?_ -#=X[_\*^>@#WJBO!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *
M^>@#WJBO!?\ AW5\#_\ H;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>@#WJBO!?^'=
M7P/_ .AN\=_^%?/1_P .ZO@?_P!#=X[_ /"OGH ]ZHKP7_AW5\#_ /H;O'?_
M (5\]'_#NKX'_P#0W>.__"OGH ]ZHKP7_AW5\#_^AN\=_P#A7ST?\.ZO@?\
M]#=X[_\ "OGH ]ZHKP7_ (=U? __ *&[QW_X5\]'_#NKX'_]#=X[_P#"OGH
M]ZHKP7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ />J*\%_X=U?
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M@O\ P[J^!_\ T-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/0![%XE_Y"^C_P#7Z?\
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MAN\=_P#A7ST >]45X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\]
M'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+_P .ZO@?
M_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\ P[J^!_\ T-WCO_PK
MYZ/^'=7P/_Z&[QW_ .%?/0![U17@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\
MH;O'?_A7ST >]45X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/0![U6
M/XE_Y"^C_P#7Z?\ T$UX[_P[J^!__0W>._\ PKYZ\L^/O[''PS\"?$WX7^&]
M$\5>+VM_$OBJ2RU$W/B::1Q$("X\LG[C9'44 ?9M%>"_\.ZO@?\ ]#=X[_\
M"OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U? _\
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M -Q[M67XF\<>"_!2VS^,O%^EZ0MY-Y-H=3U".W$\G]Q-[#<WL.: /@[X;?\
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MJ*EUWQMX,\+ZC8:1XF\6Z9IUWJL_DZ7:WU_'#)>295=D2NP,C9=1A<G+#U%
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MQ)ID.M^'=8M;^RN%W07=E<++%(.F5=201]#5J@ HHHH **** "BBB@ HHHH
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MGVK5+Z.WCW'H-TA S[5:TW4]-UJPBU71]0@N[6= \%S;2K)'(IZ%64D$>XH
MGHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQUXAOO"7@C6?%>F
M:'+J=SIFE7%W;Z; 2'NWCB9UA7"L<L5"C )R>AZ5^+'_  4"\4_MR?$_XM_"
M7XT_M@^%(_"6G>(_$$T?@CP*CLKZ7;P3V1EDEC;YEDD\^,%I")"8CE(U"+7[
M>5^:7_!P)_R5']G'_L/ZO_Z/TB@#ZV_X*,?!']I']HO]FJ]^#_[,GC?2= U;
M5]0A36;W5=0GM1)IH5S+!')!%(P9W$2D8 *>8I.#@_G?_P %&O\ @GG\!?\
M@GI^S+\/_BE\-_'VLZ9\5H];M(7O(M:)-],L#27,\* *T2Q2!"KKC:'56RS
MU^G'[87[57@#]C3X#ZM\<?B CW$=GMM]+TR&0+)J-[(#Y5NA.<9PS,V#M1';
M!VX/YH_LH>*O@C^V7\?#^W#_ ,%*/VI?!5M_9]ZP\'_#6^UV**.V6.3,?F0L
MW[NW1N5C/S3,-\A*G$@!],_\%/OB_P#$*#_@E/X>T;Q);O'XV^)]MX=T:[M(
MTV2&^GCCN;F,*,8SY,L9&,#?CCBK/[4/_!,#4?C/_P *J\*>./C=;Z1\%OA9
MX2@M=?\ #4+R02SFV@827?F\IEE2)2S@%$$K Y<U1_;'\0Z#^U'_ ,%$/V8?
M@KX2U:WU3P_9PR_$&[NK2426]S:JOFV<N1D,C&U8 ]&$X[&O7/VDOV^OV;?A
M5^T!IG[%OQ^\.ZM90>.-&9;CQ#JB00Z(;2X2:+9).9@XW,C1,=@"EP2P&2 #
MXV_X)SZ!X;\$?\%8_$/A']@SQ-JNL?!2/1G_ .$JNVN))[$-]C)C"RN )&6\
M*K&QRY3S=I9=S'T#_@K9\1_V]/B;8?$WX-?"_P"'/_",?"7P7H<=WXI\<74C
MQOXAC:SAN&M8&8#*;Y#$R1!@3&0\BJ2E>=SW7PO^!W_!9WX?>!?^">&MVR:!
MKUK9P^/=$\+ZD;C3&+-<&Z4JK-'\EJL<V!D(XR-K9 ^Z/^"E_P#R8)\6?^Q+
MN_\ T$4 <#_P1%_Y1L> _P#K[UC_ -.EU7"_LP:I/\6?^"HG[2'[34-@^H6G
MPZT*#PCH=LO\<T8S/'&0#\WFV4HR 2/M&,'-=#_P2*\;:3\-?^"2^@?$;7FV
MV/A^Q\0ZE>L3C$4%_>2OSV^534W_  1#\$ZKIW[&LWQA\3J6U?XE^,=3\0WT
MSKAG!E^SKUYP3 [C_KIGO0!^?_\ P4W\=_MV?&>7P)\:_P!K#P.O@CPWJVKW
M$'@CP(69)K18_):2XGC8;_,8.B[I-K?*<1HI&[]5O^"D/Q'/PI_82^*?C%)_
M*D'A"YL;>4'E)KL"TC8>X>=2/>OD#_@XQ_Y ?P9_[&#4_P#T&TK[!_X*"_$#
M]GWX:?LPZQXE_:C^&.J>+?!'VNUBU?2=*LUF?<TR^5(P:6(*HE"?-O&&*T ?
MD;^R;\$O^"1OQ!\ >&=-_:7_ &G/'OAWQWJAE&KPZ:D<.E63FXD6!#-+82A<
MQ")F<N4!8Y90#C]O_A9X*T#X;?##PY\.O"FH37>EZ!H-GINFW5S*DDDUO! D
M4;LR*JLQ5025 !)R !Q7YR_\%"O%'_!-[Q;_ ,$J[;Q#\!=!\%Z9>WHTQ_ ^
MEV,%K'JUE<?:(C<Q2K&S2"18?M"REF8%N2S$JQ^QO^":5EXXT[]@OX66?Q$6
M==37PG =ESG>ML2QM@<\C%N8A@\C&* /<J*** "BBB@ HHHH **** "BBB@
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MNY0TL(<B4!5$0VY+R,J8^Z/^":'_ "8)\)O^Q+M/_037FW_!<O\ Y1Q^+O\
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MAW!?E. #Q?\ X(#'XBV]E\5-+T2^UB\^$EOX@5? 5YJZ,HE?S9Q(T((&"8A
MTH  #E> 2U?//_!6GXD_MY?'GX:0_%GXX?#@^ /A=8>-UTCPKX6GD=+K4;IH
M;IUOI5<!Y ([=PKLL:@2C8K9=S[-_P $B_%8T3_@HC\9/@Q^SIXCNM1^"MG;
MWEUIENMX]Q8VLRW<*0/ [$_>#3JI!_>QH&);8#7??\'%G_)DWA?_ +*G8_\
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M8OBKJ*-)K/Q$UZ\U2_O)B3+)%%*]M$K,>2,Q22#/>=CWK[2H **** "BBB@
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MG^TUX.\:_$?Q#:F[\4:K8:S%++.(4:5XH%SN6WB&]LGYFY=L<*H!4\.K>?M
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M$5;Z_P# 7[9_QO\ V>/A+XUO==^%&AM<2Z3<SW EB6Y2^6&!T91MW20^=ET
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M@ HHHH **** "BBB@ HHHH **** "BBB@ KS2\_8^_9TU#]I&T_:ZN_AWO\
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M9B>>M=!110 4444 %%%% !1110 4444 %%%% !1110 4444 >;>$/V1?V>?
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MXH?\$H_V!OC/\0=6^*?Q,^!#ZIKVN7;76J:@_BS5HS-*< G9'=*BC  "JH
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MKS+Q-_P1Y_X)S^,?$>H>+O$O[/+7>I:K?2WFH73^,-8#33RN7D<@78 )9B>
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MBMGOF\2ZE;CRHQA$$<%RB*!D]%&223DG-8OPY_X),?\ !/SX2^/-(^)OP^^
M/]GZYH6H17NE7W_"5:K+Y$\;!D?9)=,C8(!PRD'N*^C** /&OVH_V _V5OVQ
MKFRU7XZ_#1+_ %/3H?)L]8LKR6UNTBR6\HR1,/,3)8A7W!2S$8))/3_L[?LP
M_ W]E+P*?AW\!_ 5OH6FR3F>ZV2/+-=3$ >9++(S/(V!@9. .  .*[ZB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_PMH-YI=AXBCG>WL=09#-$(KB6 [BA*\F(D8/0BO0J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_8$_;%\5VGBJ^U/17U;X;_$&VL5M7UJVCW&2WN(D^43*L<C9'(\IMQ?>C$
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M\ *YR2 ,YKT;XM?&;X4_ CP?)X^^,?C_ $OPYH\4BQF^U6Z6)7D.2(T!Y=R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPVL*1!%1%'"J%11@=E%?9/[*G[)G_#,GBGXH^)?^$_\ [;_X65\1+[Q3Y/\
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MD5X^LOA1H7B+_@GI\2O"EEX=^(GPXU*XGNTMP0OB.SFDWKJ:,WS2,0\88G^
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MX6_VVQ7WMK.CZ7XATB[T#6[&.ZLKZVDM[RVF7*2Q.I5T8=P5)!^M> ?LS?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K/\6>$_#/COPS?>#?&6A6NIZ3J=J]M
MJ.G7L(DAN(7&&1U/#*1P0:T** *7AOPYH/@[P[8>$?"ND6^GZ7I5E%9Z;86D
M02*VMXD"1Q(HX5550H Z "KM%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%?
M65IJ5E-IVH6R307$31SPR+E71A@J1W!!(J6B@#'\ ?#[P/\ "OPC9^ ?AOX4
ML-#T33U=;'2],MEA@@#.SL%1>!EV9C[L36Q110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>cpix-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20201231.xsd" xlink:type="simple"/>
    <context id="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i642116ade18340e99aeefa9e8eaa275e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1afd74e563c247539861253093f00144_I20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a22c116b6e942bda79f40e91a62534b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d81019dbdfb48579a22e9fb65668453_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a6986b113ec4d0998a4d87c9c01c9aa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i31230eb23bc348229dd4efb4f08f9b53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if67a4367a56c4e6c856f116279449f1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2954ae7b3524c008526b384cd923ae9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb38ed17fae340ce933596e5d361e981_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i03694dc14e8c4bbb93ae06dc4dea9967_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3dd305c2cee64a88a8f6930ec95cb5c5_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ia9902b1e772a4972957eb8992b200e37_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib61e32dba4b0475d984dfadd6379821d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i579acb9f96de41ffba78cca469abf593_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iae03170bbe484f15ab0b60e6dbda8bc7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i85e782a52b4d44329375848c274ec5d1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5ff3ff90eb944c0dbe11b04ce7b0d7ed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3bfc004e938140c29692f598f52b5277_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if736d13a5981486b9c4be73116b8d9b3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id7bb3d0fc63f46a38f73f8e24b9222eb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3edfe4448c474b6eaa1f9546a60f6baf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e7c45e9e811413cba25b0b270ac8d66_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i906c0455495f493dadd51dbdcf6ce33f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94b48d6a645042b68c812153d89d701d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25561754ff6f4e2ea07d5a93bb7fc0b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i113acbcb4c7a41f9b06366a217ff041f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28dc597efa194fb59a0fb601045119c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72fd6471f1da4426a87a1886db0ae152_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f1d88acf1394d319d163e4143882af2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida79e60e9d42460c84903d34b3fd5625_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d15f9eb345d4d64aa801993173c575d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i82fdc18596fd4b20999ba80f5d41bd51_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="if2a2c29316304015acd330ba1069f0e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d6f67ab017747e488ce81fe0f2d992e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i563ad4ae0b474a93a68d18998539da56_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i523a0c1898d94b0d968011937afb9b4c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ac26c9d624a4950b3d6b38c45e4b597_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9d8b7bd9c444fd81c867a1f021713b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i858b3a2a4199408587b99fe9de451ae9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i713b05d7f5bc4937aed96e19605bbd69_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ffd3ca73a074170bbcb58ba566f9585_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f0edc4849df4c21910d604bb57d2325_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i60fc1a3fb3064db1baf227cdf6d18b18_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf84cc8aa13a4c4e9c2848f65593a987_I20181112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-12</instant>
        </period>
    </context>
    <context id="i3805a80f910745b8ba5901401f43502b_D20181112-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i47d4426d3227403fabbfb9d27a6e529f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if526d4a08c254080a221720150e6e894_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9690979d455048e786882dc7d1715d78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25bf3ecd92884fba947bb8fde5284b63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9375d96a8aab42a988665839bfc0db67_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i8b8106a20e864d28bd6d0ef776efb119_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a1a0444604f4249b8af8cff8f67e09d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id93dbc3e2bb445b79575c990976d088c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i41f00b78b135497898e49546c1d2f4ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4269e0d435e4dd8af6548e04ee94f28_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i932871e9df8745c583acfe2f18eb6df4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i76cdf7521dab4b328c6824333676f5fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29d41290b523433fa5c1c7846ba6fb17_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3738fecb3eaa4c198acc94352adfea94_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic0d302dded484788ae6589a0340b9b88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4fb6667544f4f559f12205fcebec85c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf76f0a2b0ed40d8b2b44aebcfae79d7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i128821f68ebe4cd097ed7ff95840f048_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff264f92669d449e8bcb64c3d9b88d42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i011d9382fa6c4d49bd3e83103b01e17e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21522c7cbff7479c950097c298729560_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i379abd9813bb4e449cf04367935a4368_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie836a99c6e9a4ea5b8b4e362f27f61b0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4953695015dc4f6192628e3e06840b93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd71c23cf60e4a89ace2b16705e73a6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05552adfe6bd4b2c9364a3fb0e38115f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11727dca580e45938d1bd2a30fa3b13c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i425aa7efcc3d419489434711697897b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i44a7f8d16fd34d9298c695a5fc27fb15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9075a3fe1d64ddf8f34dc57c4454544_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i900aa4346676422fb1898c7d882f8fcb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6fd7af49de249ecb292d30a08cbd4de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74b9642648b4446484395a251aeb73e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i567a47d8201140e0a6ab9fd8bf24c58c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if57a23f2f6ce40868fabc79000f9acc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22150fcc5f674069a6bb7c015e170408_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43f7778a12b5457fa1f6664420a75437_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15b440537b5d417d8d302cd1bd73dd3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55d077df83004e9b9dca31085e2c7dce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61b3055ed198427f821e78280855ef22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic56325a56faf46d4b05761c86d36d031_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52b299fde4ec4bd2b6d62fffe5447170_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie19f08d91a2640dba99067b8dbe8c464_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1528e64c010641a68be52125a75832b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ff6b1dbcf3c4c8e92b1cdefc3aa7b52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3be021e818547a795f36d1377c9ea4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb4713d678174ead99f243c92ec45d16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie005a45bb43941a58835f78c97251e65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0173213b69184c199e2c3ab68e949553_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6724e49269cd4c95a99a8ca277ef19c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e037b70471e490a9f3bd1f848149384_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d622e0a01004a5d9914569d0d5756ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib378884a762c4067ae1b484eca7cbcce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41e5a2f67fb448cdac235b8ab69c2e11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70f775544b07435aad50e8010203ab2f_I20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:ThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id58da084fd084c92baff6faaebe07bce_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="icd51265d21714c30b785b162b5e9c52b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b442a5827e64fa49e02548ad3d45a60_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6ff7e499acb4275a4320c03274a56de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife2cf763ce1343ebbb8dcb8ca36ad991_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55a65e98565f481a88b31680ce8e66da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4867bf18746745d08a2eb39206ceee78_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-08-09</startDate>
            <endDate>2009-08-10</endDate>
        </period>
    </context>
    <context id="i1de7636956284bbeb962a907482bc027_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i367d84ececcc49f0bfbb68634cd626f4_I20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cpix:WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-12-31</instant>
        </period>
    </context>
    <context id="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-31</instant>
        </period>
    </context>
    <context id="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec44f4c9886f4156832890687e6122d3_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2014-04-01</startDate>
            <endDate>2014-04-30</endDate>
        </period>
    </context>
    <context id="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-27</startDate>
            <endDate>2019-11-27</endDate>
        </period>
    </context>
    <context id="idfc74587ea6e4b529a03805961c2bd04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i445b6f509473418eb2c8a5237c3bfefd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4313b14cb3a4d8f99fd5c8f9db1107d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6847c5f2fcc44c1580a9549a452c791d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9043384394c24481b001b6c237c321ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fe6d71cfdbe4024a8518ad7bd357ab3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac92a1fad73b426db25cdc60a91363c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i361f3e2163a24e0599504b3aaa2131ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a8201ead17c4f4c9fab01031ebfa723_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3c2aba4cd314aabbe1faee299611416_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d8a2a14899b4ec1a64b4b7a8ed1abda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i236e3d373ccf4b22afd608a82ed75788_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9167ce1de284dc593328aff87ed8bcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5562813807040e1a0e26ee6bf76c4b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4051af70f9c4b60b1d310d19369cccb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9db379efa0bc4679a685f33d31ca995f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f1831e9cb7e4498bb1e5fac039825fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia24d0d8e81234fb38c59ac70536998b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d13571f70a74cbea8cc3c2e111cf699_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b054a3338614ef4a60b55fb3e0f0983_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39407155449e4cd7b91cf9a0ea955c04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdf5204bce4e4cf08f3110023af611f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa1083c517cc425bada8b162234c0222_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f2761c3aa61481e9ce768736d55283b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if048f68b276d4efaaa2f710dc15c58ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75bc44001e5247da87aaaa6fe49004cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i436eb42902d244599c0bc8375f08440b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55c8902a15624a57913ab5e23c482d70_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3d39a8afd7a4f5485dc0d057ab6de51_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9cfd07629518431490765805546dcdd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf145f8d53f142ea820e0fca8cf49972_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa6739e7f70b46089b224643faa80db4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i18c4af7e297f4bdb9156fe284ac15e52_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5126864d4086482f8ca3437664a5be84_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i622af044beba4bd281a739b794311672_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i7c6d1b5895064141892cc9e1fa697991_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f6a5312e3d74395bd3c1db13869d99c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa7aeecc41504677b76f853c9fa184a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffbd7aad4f8a44158c186bd69006fa50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b530f82b6fe471b9506787cb064425d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48a19579f22c4af496dcb8ed57b17e7f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i035fe245e98f4edc8662280dfb190881_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafad14dcd0734e159d5dc98d6debe999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb72fd4e685045b9b3f14ba16be19e8f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id995a6b3c61f46a2916306ecd8f86ea5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0806af42e92d434b8380cece41bef2f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idca38735f6bf48f89c09c2c85125ba89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1aaf67bebf341cea9c892fb47997567_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i187575b302fb41bd9ee6b605b4f68a30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i419ec7ac9d4f423c8c8f73bf9a5da296_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78ce3c4a1d02440f8d5624232436389b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4d8fefbac99d4eafb16b2bf8a3836ae2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8c14abd94304867b117e4fea7e033be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i010aee2814cf4f14bce2ff9dacf24d5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6777a90bade44e95aedf63f8638b5d8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i053e86b30f9f453cb231c55d294c07a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie52ad4b1821b40aeaa322dea12dec215_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3a82fe51f4445d5a9623b513f48b606_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60aad94f2f4f44b1a7b8ae65743e96b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:ClinigenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33a485953ea94c868adbce3538277f6b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc1855e705644eb19c43b7bb2e117b81_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i40627ef8322d435c8f66224735bfa7b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3fbba7dd4a6485ea115af1a74515fea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i053b532230724366b6e9f1045a453663_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbf0cdcda3874fbf81f9d06a24caa475_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i61d578da0f6f43cc8eb4610cda5b0867_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9e5f707de404e5784e8284dcb422b96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cpix:segment</measure>
    </unit>
    <unit id="plan">
        <measure>cpix:plan</measure>
    </unit>
    <unit id="supplier">
        <measure>cpix:supplier</measure>
    </unit>
    <dei:DocumentAnnualReport
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8yLTEtMS0xLTA_69547708-367b-4ff4-992b-9247e93016fb">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8zLTEtMS0xLTA_ef0e70a6-8ffa-467a-88a1-8fc8a757d3f6">false</dei:DocumentTransitionReport>
    <dei:EntityCentralIndexKey
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF80LTEtMS0xLTA_b02d3f56-ed01-4b35-83f7-b1bd0be016cf">0001087294</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF82LTEtMS0xLTA_dcf25958-85d7-488f-827b-fc88ae7c5b99">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentPeriodEndDate
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF84LTEtMS0xLTA_1730597d-fff0-45aa-992f-706ab538e6c7">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF85LTEtMS0xLTA_077fcbed-fc3d-44f4-92cd-3687f853faf9">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMC0xLTEtMS0w_bb82d37d-f41a-46d5-8e40-e80526c3ec43">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMS0xLTEtMS0w_e651c709-12c3-4863-8d4b-9dd8eb3b99d2">false</dei:AmendmentFlag>
    <dei:EntityEmergingGrowthCompany
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMi0xLTEtMS0w_71572181-1e61-4aad-93c0-a49309e6002b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xMy0xLTEtMS0w_822374ed-7e65-4e11-8064-389953b2800a">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNC0xLTEtMS0w_0fec0eb9-2687-42ff-beb3-f82fe93c4b61">false</dei:EntityShellCompany>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNi0xLTEtMS0w_abe40342-ea1a-4520-9dfb-e811505afe5f">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xNy0xLTEtMS0w_2439d961-036b-47c3-b604-4472fed8d3fc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xOC0xLTEtMS0w_06d54ad8-7a20-49e4-b903-f1898f572f9b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGFibGU6YWI2NzhlMjEyNjg3NDQ2MTlmNWRkMzFjYWRhMzM0MjgvdGFibGVyYW5nZTphYjY3OGUyMTI2ODc0NDYxOWY1ZGQzMWNhZGEzMzQyOF8xOS0xLTEtMS0w_e39d232a-48ec-48a3-bae4-108adf26af4c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:CurrentFiscalYearEndDate
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y180L2ZyYWc6YzVjMGFiOTA0OWIyNDdhYWE5MDUwZjk5ZTUxZTc5ODQvdGV4dHJlZ2lvbjpjNWMwYWI5MDQ5YjI0N2FhYTkwNTBmOTllNTFlNzk4NF80NA_2433f524-40c3-4a32-a1a8-b89602cbed44">--12-31</dei:CurrentFiscalYearEndDate>
    <cpix:FinancialConsiderationPaymentPeriod
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgzNDA_72c8f2e7-a907-47b1-a9cd-8d46f8f9cdb2">P2Y</cpix:FinancialConsiderationPaymentPeriod>
    <dei:DocumentType
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xODc_7ab665cc-3019-45c4-8e0e-7be9a5bd0a44">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIx_9d750adf-e0ba-4d2f-9dca-b99cc2c7dea2">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8zMjc_8780193c-867b-414f-98dc-26253ede7490">CUMBERLAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE0_94e69ad9-9f66-4ae7-b33e-84b1b222ecd7">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIy_3f9b58ee-852b-4b37-8d3a-ec58ebb9967f">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityFileNumber
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIz_71d08292-7e9c-4860-a672-933cd238f7af">001-33637</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDI0_b85aa09f-348a-4c35-a5df-7a368764873b">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE5_ec8e656a-1c09-4b9f-ad34-2d1c8b3e75df">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDIw_e919648f-ae36-4762-a934-a23a66b420f3">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE1_4eefc358-6ec8-441d-aac8-fea0fb6b8c43">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE2_df1b8abb-29ce-4790-9146-0fd5312f7f80">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE3_02cb325b-93ce-4b57-b8c1-d4b0c43b3dd7">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDE4_09562c06-756e-40fe-a05d-f63220f43805">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTAtMS0xLTA_e34e069e-de7f-4634-b188-7b454e76d71f">Common Stock, $0.00 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTItMS0xLTA_84a2c541-117e-4050-99ce-4a5cc164066f">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGFibGU6MjM4OTI3MTNmMTU5NDhhNGEyMWM4YWNlMGM3Y2NhMTQvdGFibGVyYW5nZToyMzg5MjcxM2YxNTk0OGE0YTIxYzhhY2UwYzdjY2ExNF8xLTQtMS0xLTA_3026d7ca-4f1a-47b5-b8b0-c8c2ea293eb8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityPublicFloat
      contextRef="i642116ade18340e99aeefa9e8eaa275e_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xNjA1_e80163a0-7645-40e7-ba73-71ec2cbe915a"
      unitRef="usd">30639333</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1afd74e563c247539861253093f00144_I20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8xNzAz_6fd24c3c-b2aa-4d58-adb1-93f05b5e8ccc"
      unitRef="shares">14920655</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xL2ZyYWc6ZjAxZTdlNjdkZDAwNGFlYzgxMTg2NTFkM2RhYjkxYmIvdGV4dHJlZ2lvbjpmMDFlN2U2N2RkMDA0YWVjODExODY1MWQzZGFiOTFiYl8yMDEz_73987ea3-cb01-42ed-9995-ca9b73899308">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#x2019;s Proxy Statement for its 2021 annual meeting of shareholders.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzQtMi0xLTEtMA_56fb70c8-fe6a-4f1c-9493-4f8cbf2adbfc"
      unitRef="usd">24753796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzQtNC0xLTEtMA_63ab9f16-15f6-4dae-85fc-845149989f00"
      unitRef="usd">28212635</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzYtMi0xLTEtMA_b72180e7-c3f8-45a8-806e-f2a6de6d05f7"
      unitRef="usd">12377713</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzYtNC0xLTEtMA_e491b55e-607b-4596-8ab2-3f03bd13dc36"
      unitRef="usd">7859006</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzctMi0xLTEtMA_c56bd8b6-976e-44fd-86df-5acd9e5d6451"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzctNC0xLTEtMA_f2e32030-080a-486d-850a-4e5557581bda"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzgtMi0xLTEtMA_8c7858cf-726d-4730-83fb-dcaf8735ca7c"
      unitRef="usd">2199926</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzgtNC0xLTEtMA_78947ba0-5b3a-4f3f-b483-e035ca9b65e1"
      unitRef="usd">2757456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktMi0xLTEtOTUx_711bdfaa-ed4f-4623-a7cf-e761bace2490"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktNC0xLTEtOTU3_1b2743b8-f9ff-4a71-a3a4-5b6917bf0ca7"
      unitRef="usd">2462724</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktMi0xLTEtMA_bbae37f8-68ec-484e-9f36-87eef4053e78"
      unitRef="usd">49969592</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzktNC0xLTEtMA_81d96c31-07c9-4465-b6b8-71395ef71f2e"
      unitRef="usd">50163075</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEwLTItMS0xLTA_b794f284-a54c-49c7-8e2b-8121eb69b0cd"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEwLTQtMS0xLTA_1f4b3a92-9021-48b0-b3cc-bf6495acb54b"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzExLTItMS0xLTA_51c379c6-e577-48cc-ab81-94fbba3a641e"
      unitRef="usd">574169</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzExLTQtMS0xLTA_aaf03d7e-5bf9-41ab-999b-09ad5471650d"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEyLTItMS0xLTA_791a9ea5-d2e3-4364-8bdb-62288882173c"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEyLTQtMS0xLTA_a87097f0-952f-4e78-a4c3-0aafd2172f2e"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEzLTItMS0xLTA_fcaed65f-aee7-425b-901b-a9d7718b31cd"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzEzLTQtMS0xLTA_ea7a2c95-f05a-4dc6-9a2f-5ff6b9168ded"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE0LTItMS0xLTA_ec0cd2d8-da6c-4790-a7c0-0793db4c8b2f"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE0LTQtMS0xLTA_9b11dd6d-6046-453c-ab54-49a06fb88998"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE1LTItMS0xLTA_f3d13267-033a-4d0a-bf05-39bb2b7efd63"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE1LTQtMS0xLTA_e03f1096-5d95-441f-9187-60be5c174b4e"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE2LTItMS0xLTA_be16fb28-c579-477e-a700-ffeb09d90e3a"
      unitRef="usd">3234338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE2LTQtMS0xLTA_0f1e86dc-075d-403f-af5a-0a3d3de67855"
      unitRef="usd">3298725</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE3LTItMS0xLTA_a7f6e9ec-1b6f-471b-b0a0-5069212d988f"
      unitRef="usd">96463305</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzE3LTQtMS0xLTA_ff48c518-ba53-4c99-9c17-bfe711fc21fe"
      unitRef="usd">104549283</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIxLTItMS0xLTA_95473f59-462f-4172-9a87-f4edf09ade71"
      unitRef="usd">13396286</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIxLTQtMS0xLTA_628af309-4b93-4dc0-9364-b02805b17ae8"
      unitRef="usd">9993578</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIyLTItMS0xLTA_e6f87ff0-e1a3-48f8-bb5c-66fab34a8aa6"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIyLTQtMS0xLTA_480e9ef8-13aa-4aac-95a8-2cddc36d1dd5"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIzLTItMS0xLTA_349c1ac3-50be-42af-9f2f-55734c8afbe3"
      unitRef="usd">11254381</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzIzLTQtMS0xLTA_d0bc45e0-f2c9-4b59-b509-7736d3953ed3"
      unitRef="usd">11084869</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTItMS0xLTY3OQ_c06c375f-b37a-4f61-9f16-f9d829061313"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTQtMS0xLTY3OQ_d68ff128-9cfc-4e27-931c-f2582ed26399"
      unitRef="usd">2151357</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTItMS0xLTA_1a5662ea-23ba-46aa-8456-9dffb3d0086d"
      unitRef="usd">25667446</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI0LTQtMS0xLTA_0065814f-a052-46ae-a0c4-dd15e80d1ff6"
      unitRef="usd">24150235</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI1LTItMS0xLTA_2e22cfc7-fb13-421f-ae40-e34ffdfd4de0"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI1LTQtMS0xLTA_f5d5e254-1c70-4f3c-a0ad-5e9eb991598c"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI2LTItMS0xLTA_b882a6e6-2fcc-415f-b22b-630077d50295"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI2LTQtMS0xLTA_66e8d6f2-4759-4d6f-91f0-8cd92a0dea9d"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI3LTItMS0xLTA_fe266b3d-95e3-42fc-994d-c40cf1431c5a"
      unitRef="usd">7862772</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI3LTQtMS0xLTA_de79f597-3a43-4ff2-b0d9-b830aed4f3d1"
      unitRef="usd">8737323</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI4LTItMS0xLTA_57f4679b-47bb-4ce8-a781-7bc677395d2d"
      unitRef="usd">49589911</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI4LTQtMS0xLTA_1cacbd6f-fcf7-488b-ba7c-1d610fb517ac"
      unitRef="usd">53464030</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI5LTItMS0xLTA_7a4bd567-05f6-44e9-a21b-91e1c56d1417"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzI5LTQtMS0xLTA_ebfe5f23-61db-4e97-87d3-652d4d410720"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzYw_2745e26a-6ed6-4a46-baa0-2fbd70170434"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzYw_6c960a14-55a0-43e5-b436-7023c8577689"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzI5_0809c2b4-94ba-4bfe-a3d4-710c555d2fb6"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzI5_29ca9b12-2acc-4580-b12e-cbf13a7b8511"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzQy_71051ed7-00ae-4259-906e-3a6d110cceee"
      unitRef="shares">14988429</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzQy_aa5d4872-4491-4836-a963-645b8427ad65"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzU1_43a64fed-8641-4c4a-ad0f-575cd5a5f93c"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjowZGE5N2NiNDdlYTg0ZWQ0YjQxY2YzZDIzZGExZTAwY18yMTk5MDIzMjU1NzU1_6a3f44f5-115d-4326-9ce9-098457058e32"
      unitRef="shares">15263555</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTItMS0xLTA_21a44ec2-aa23-49e3-8cdc-1acc4a5f2fb0"
      unitRef="usd">49121523</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMyLTQtMS0xLTA_9e790e0c-4df0-4799-a76b-ffa62e891e41"
      unitRef="usd">49914478</us-gaap:CommonStockValueOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMzLTItMS0xLTA_5d067169-e5df-4d01-b0d2-31eb221e1bdd"
      unitRef="usd">-2131013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzMzLTQtMS0xLTA_69af4901-eeee-4619-a9c6-04e0cd70b0ae"
      unitRef="usd">1208395</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM0LTItMS0xLTA_76277c4f-390b-4ba1-a1ad-3feb8d6a80da"
      unitRef="usd">46990510</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM0LTQtMS0xLTA_589368ff-1160-410e-b2ba-a73369f6fa43"
      unitRef="usd">51122873</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM1LTItMS0xLTA_0e35a2b9-4d96-4b57-833d-9d69f77c6b9b"
      unitRef="usd">-117116</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM1LTQtMS0xLTA_3874e017-4715-4dd5-ae7d-ad08a4d7f6d0"
      unitRef="usd">-37620</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM2LTItMS0xLTA_6fe3a43d-0751-4c78-accc-0b4751d953a2"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM2LTQtMS0xLTA_e3050540-74ed-403e-8ef8-ba2c1a26cefe"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM3LTItMS0xLTA_7bcfe384-72a2-4017-96fd-a41ccbf31382"
      unitRef="usd">96463305</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzIvZnJhZzo4MzRkYWMxZTc2Mzc0OTY0YTk5MjVkOWNmMGQzMTNjMi90YWJsZTpmMmNjMWZiZWRkNGM0OWI1YmYzOGI1ZGIxODc2NTFiZC90YWJsZXJhbmdlOmYyY2MxZmJlZGQ0YzQ5YjViZjM4YjVkYjE4NzY1MWJkXzM3LTQtMS0xLTA_725d2b5a-148c-4756-aa48-5195fd1f1a76"
      unitRef="usd">104549283</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i4a22c116b6e942bda79f40e91a62534b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtMi0xLTEtMA_30f7d7eb-f26f-4f03-9cd5-ebec1de7395a"
      unitRef="usd">35840673</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d81019dbdfb48579a22e9fb65668453_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtNC0xLTEtMA_4d1c9675-0882-4071-9d66-69cb92f78c4e"
      unitRef="usd">32407845</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a6986b113ec4d0998a4d87c9c01c9aa_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzMtNi0xLTEtMA_e600276c-add3-4397-8fb3-80c4d727d7be"
      unitRef="usd">28803961</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31230eb23bc348229dd4efb4f08f9b53_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtMi0xLTEtMA_43998301-3a2b-4d12-a2a8-3481f726cbb9"
      unitRef="usd">1600461</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if67a4367a56c4e6c856f116279449f1f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtNC0xLTEtMA_2e943c14-8bf5-40b6-91bf-18b92501316f"
      unitRef="usd">1980450</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2954ae7b3524c008526b384cd923ae9_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzQtNi0xLTEtMA_9275706f-1514-4b8c-9e81-c6fd2bd022c7"
      unitRef="usd">540933</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtMi0xLTEtMA_f77721a8-abb7-4d6b-84a0-890cd637528d"
      unitRef="usd">37441134</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtNC0xLTEtMA_faf40886-5d87-40c1-b5c8-2227fca094a3"
      unitRef="usd">34388295</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzUtNi0xLTEtMA_3025c447-0074-4a14-b2d1-795470681a71"
      unitRef="usd">29344894</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctMi0xLTEtMA_88931093-a112-4a63-a5e9-f1bf85ef660f"
      unitRef="usd">8653020</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctNC0xLTEtMA_c53fa168-5468-4144-8106-b6626801340f"
      unitRef="usd">7421316</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzctNi0xLTEtMA_8625787f-199f-475a-b31b-7bef126418fa"
      unitRef="usd">6016822</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtMi0xLTEtMA_fb919d8a-65bd-463c-aba9-d7324e777fba"
      unitRef="usd">14765465</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtNC0xLTEtMA_40824e23-08a2-4fc4-bd5a-bf7d53d659b7"
      unitRef="usd">15277740</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzgtNi0xLTEtMA_11ed8b1f-490e-4288-b5a1-1f4ff4279fa7"
      unitRef="usd">14004933</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktMi0xLTEtMA_9c58c56b-9d42-4c43-9fb3-3b0f21e44622"
      unitRef="usd">5773825</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktNC0xLTEtMA_6d07349a-9eb6-4b38-8cda-3de737db6aba"
      unitRef="usd">6868480</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzktNi0xLTEtMA_f47554da-7e79-49e6-a7c8-f144f89f89d8"
      unitRef="usd">7575892</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTItMS0xLTA_aaef3314-f5c2-4acb-a2e2-6f44b3a8eb21"
      unitRef="usd">10196299</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTQtMS0xLTA_44e5c373-c5d9-43ce-b5e0-b90debacb012"
      unitRef="usd">9974384</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEwLTYtMS0xLTA_f570b7c5-f9a1-4ce0-9bf6-18e46fe3bb56"
      unitRef="usd">10150777</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTItMS0xLTA_7e9429a3-fe66-4708-9ddb-1a393a950885"
      unitRef="usd">4434120</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTQtMS0xLTA_2a8d7357-0ea8-4a28-8a35-076687f2c88c"
      unitRef="usd">4134557</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzExLTYtMS0xLTA_8e29b8e0-05c6-48ec-b189-c2f9f813bb4f"
      unitRef="usd">2769466</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTItMS0xLTA_1654557a-6b5a-439d-ae8a-5a60926a58a8"
      unitRef="usd">43822729</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTQtMS0xLTA_82e65f7e-4ccc-41e4-97b7-1cb3f42f2a9e"
      unitRef="usd">43676477</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEyLTYtMS0xLTA_ddce794a-52d4-4461-a5d7-3c441d7366ad"
      unitRef="usd">40517890</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTItMS0xLTA_de33bcba-dafc-4f13-82ec-ba0f24622034"
      unitRef="usd">-6381595</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTQtMS0xLTA_f4ff9402-09a8-49b8-8f72-72d5e4033979"
      unitRef="usd">-9288182</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzEzLTYtMS0xLTA_8d3d5c56-1226-4fca-8e12-a3bdbfced3e8"
      unitRef="usd">-11172996</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTItMS0xLTA_d85cd785-1557-455c-9d70-b23c57e7d345"
      unitRef="usd">75345</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTQtMS0xLTA_b94a4aa0-1a47-4e96-97ef-c174ff61dcbc"
      unitRef="usd">243364</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE0LTYtMS0xLTA_9d0bd210-157f-43bd-81e1-636c7fac2ae4"
      unitRef="usd">564484</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTItMS0xLTA_26beafb7-fbfd-409f-a594-bf43153277a2"
      unitRef="usd">263627</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTQtMS0xLTA_f1f5da8d-8262-4718-91f4-21b4f27f2aa8"
      unitRef="usd">246186</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE1LTYtMS0xLTA_13138b0a-5bbc-480b-98ce-dad6f89dc862"
      unitRef="usd">195848</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTItMS0xLTA_f7b4a439-5174-4e29-a117-9a52f359b15b"
      unitRef="usd">-6569877</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTQtMS0xLTA_290762e8-4035-4482-a9eb-8b919e6e4b9b"
      unitRef="usd">-9291004</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE2LTYtMS0xLTA_aeadf02a-065d-4841-8a30-6e457b52e9b1"
      unitRef="usd">-10804360</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTItMS0xLTA_c0042e23-458b-4719-8b1b-80d24a64a648"
      unitRef="usd">55902</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTQtMS0xLTA_83624f8b-646e-4f47-a9c9-310066f9526f"
      unitRef="usd">-79316</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTYtMS0xLTA_be0ad9be-a1c4-4034-b2d3-005441a8ffb1"
      unitRef="usd">16636</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTItMS0xLTc1OQ_81fcc7a5-42fe-45f8-8f03-f6fc5bb74d8e"
      unitRef="usd">-6625779</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTQtMS0xLTc1OA_0caa90b2-49e1-40c7-9396-2f948d717e9c"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE3LTYtMS0xLTU4NzU_2b1c483f-ca89-4cc1-8e21-ca20f78e84cd"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTItMS0xLTE1Mw_838de442-e0e0-4536-ae45-99d0b72560e6"
      unitRef="usd">3206875</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTQtMS0xLTE1Mw_ca1363ad-1ec7-4927-a944-6a1125291895"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTYtMS0xLTE2NA_b1adc3a4-2a33-4b61-97aa-32edcd4657be"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTItMS0xLTA_fd0d0a7d-811d-42f5-88b1-4730666d8201"
      unitRef="usd">-3418904</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTQtMS0xLTA_909753d3-8e1e-48ed-aa70-7a345ece839b"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE4LTYtMS0xLTA_c6f97c53-903d-4771-a5ef-d06563da13ff"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTItMS0xLTA_bdd3461b-c51d-494d-9409-55c8528e905b"
      unitRef="usd">-79496</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTQtMS0xLTA_a8130032-0ce0-431d-bf61-664987595763"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzE5LTYtMS0xLTA_5920a68b-7443-4cbc-bdfd-dd416a886443"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTItMS0xLTA_7c3dbe51-802a-42b9-ace1-3b041ab036d0"
      unitRef="usd">-3339408</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTQtMS0xLTA_c386876c-a1cb-44a8-b2a1-ed2cbc8ae27f"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIwLTYtMS0xLTA_3d936bef-58f3-40b6-83cd-37580493a8fe"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTItMS0xLTEwMTU_12c00d16-8cf9-4f51-9a3e-cbdefcde0ca8"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTQtMS0xLTEwMjA_9b5c9c58-c47a-448e-9f8d-2be95750caa1"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTYtMS0xLTEwMjg_22ed102b-df94-412c-8509-909e662c1b18"
      unitRef="usdPerShare">-0.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTItMS0xLTEwMTU_a0f58115-939d-4f31-b39a-b8e07cdfc4ea"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTQtMS0xLTEwMjA_78140d31-72de-4d67-90d7-86ab9c3c7648"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI1LTYtMS0xLTEwMjg_42ae6df4-7846-4779-a837-bfedc2488192"
      unitRef="usdPerShare">0.24</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTItMS0xLTE3MQ_84ba3c9d-c6df-4031-ae26-902f85a4cc0a"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTQtMS0xLTE3MQ_8d97a996-3723-449d-878f-6e0e1363b72e"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTYtMS0xLTE3MQ_17b17dfe-4104-4719-ae01-83d6b2839043"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTItMS0xLTEwMzQ_b1edbbbe-2e6b-48a1-9753-8668a4552b3c"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTQtMS0xLTEwMzQ_39b6b5c2-2c2c-4fbb-b450-cebaf5d09cde"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI4LTYtMS0xLTEwNTI_9ffbe614-4dc6-4f0c-b96b-caacae397394"
      unitRef="usdPerShare">-0.69</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTItMS0xLTA_61fc9b48-1b0e-4324-b957-14ad7ec0ae8d"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTQtMS0xLTA_97fce69c-7d10-4cd3-bedf-fbca6646281e"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzIzLTYtMS0xLTA_175eab0f-6e2c-4012-8225-76005bc2327e"
      unitRef="usdPerShare">0.24</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTItMS0xLTA_b7a3ca5a-d9ed-4fdb-9a0c-db8ba218a415"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTQtMS0xLTA_30ece14a-23cb-432e-a28a-a6fce49ad439"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI0LTYtMS0xLTA_b2c4ae20-7f57-4445-990c-334500ba4147"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTItMS0xLTA_c215c479-a3eb-4e4a-bd1b-305b7e511fd7"
      unitRef="shares">15162184</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTQtMS0xLTA_a3e5bce1-d53a-4d84-b75e-f9a960e59641"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI2LTYtMS0xLTA_a5ef40f5-9c7c-48ea-96ff-02d96b893240"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTItMS0xLTA_be14cf47-950c-450f-af55-9b2c5b9cb945"
      unitRef="shares">15162184</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTQtMS0xLTA_8f6cca09-77d2-4dad-a1de-19a9f9895d67"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xNzgvZnJhZzpkZTUyMWQzZjgxMTY0ZTliYjdkOTExM2U1NjVkYzdjZC90YWJsZToxNGE2ZTNjOTEwNGQ0NjRmYmVhMDhkZGU2ZTY4MmUxOC90YWJsZXJhbmdlOjE0YTZlM2M5MTA0ZDQ2NGZiZWEwOGRkZTZlNjgyZTE4XzI3LTYtMS0xLTA_7543989e-2320-4fe3-96d1-1b22b8b68b25"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtMi0xLTEtMA_7dedd7dd-d9c5-4b5c-b416-c1116d5318da"
      unitRef="usd">-3418904</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtNC0xLTEtMA_6a8d66e0-d748-4d22-b3eb-a34847d4f9a7"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzMtNi0xLTEtMA_e026cb26-ee6a-48ae-b445-f9add2eb7091"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtMi0xLTEtMzU0_d49f050d-99bc-4faf-b291-c678e1b266b9"
      unitRef="usd">3206875</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtNC0xLTEtMzU0_8819d85b-9eae-4ada-835d-66e6fbbd09c9"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzQtNi0xLTEtMzU0_53bb2058-709d-459f-958e-dfaa289449f8"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtMi0xLTEtMzU0_9245a913-a2d8-4e9f-a979-3091f882076f"
      unitRef="usd">-6625779</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNC0xLTEtMzU0_7033e7ea-1bce-4671-b31b-10665aa7118f"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNi0xLTEtMzU0_3b24ef53-0f93-412f-a7d3-a3af275b81fe"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtMi0xLTEtMA_bd5f28e0-d4df-4dc6-8b51-286e17e801fc"
      unitRef="usd">4748565</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNC0xLTEtMA_5cde82ae-064e-47b5-9b07-c86f6977b292"
      unitRef="usd">4404175</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzUtNi0xLTEtMA_3b16add1-3687-4c0d-ac93-6ca6219a64e2"
      unitRef="usd">2982703</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtMi0xLTEtMA_873b81f7-0e61-436f-bcfd-110ae0e50179"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtNC0xLTEtMA_1f2556a8-19af-4d65-a73c-106eb1e37dd6"
      unitRef="usd">65408</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzYtNi0xLTEtMA_6bf32ef4-900a-4fc1-8066-c8b66f6d7f3b"
      unitRef="usd">81886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctMi0xLTEtMA_9e01b5a4-8a1f-428d-9e16-cc6614b8bb27"
      unitRef="usd">1046516</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctNC0xLTEtMA_ecdce7ab-262f-41b4-b96d-579a158b28b3"
      unitRef="usd">1485898</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzctNi0xLTEtMA_8beea201-f2ff-4cb7-8267-4286da602780"
      unitRef="usd">1364698</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktMi0xLTEtMA_bc1784ce-a7ba-4e40-abec-d90605a5ee44"
      unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktNC0xLTEtMA_d78b4982-70b3-41d2-a847-eb376a5872a3"
      unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzktNi0xLTEtMA_0b0e1e47-a859-4c8a-abde-5a96390b6c5a"
      unitRef="usd">81886</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTItMS0xLTA_81c7d7f3-f366-47ea-9665-7f0600348d36"
      unitRef="usd">1160202</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTQtMS0xLTA_abb6d010-dc7e-4e4a-a536-7e7e05ca4e5d"
      unitRef="usd">804167</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEwLTYtMS0xLTA_34c6953d-22d2-4774-bd68-5f4e43d70047"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTItMS0xLTUzMjk_9817d1b4-0a26-4eb5-9bea-16ade6cb9b2b"
      unitRef="usd">440091</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTQtMS0xLTUzMjk_4a9ffb47-7370-46b5-81eb-30e3a7541513"
      unitRef="usd">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTYtMS0xLTUzMjk_5512ddf4-d2ea-4403-8a9a-69768391b087"
      unitRef="usd">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTItMS0xLTUzMTQ_93724de8-7948-4233-b99b-895f65156153"
      unitRef="usd">154611</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTQtMS0xLTUzMTQ_2c0d0785-57c5-49cd-b414-22d4b9fe870b"
      unitRef="usd">0</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEzLTYtMS0xLTUzMTQ_746c0dab-7741-4c48-8a84-667179219073"
      unitRef="usd">0</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTItMS0xLTA_096ccda5-d4c6-4d80-b178-260f578952bc"
      unitRef="usd">47636</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTQtMS0xLTA_66a55abb-3f4b-4071-8d5d-db6f92124090"
      unitRef="usd">47525</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzExLTYtMS0xLTA_d7f80e5a-8248-484d-8397-c8f9e183f435"
      unitRef="usd">99883</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTItMS0xLTA_be3ddeab-2df6-4b14-8aea-40e2e9828a92"
      unitRef="usd">0</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTQtMS0xLTA_5b445fec-4b65-40e3-9c34-5b7f88df700a"
      unitRef="usd">26315</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzEyLTYtMS0xLTA_c0a4e2be-176d-4557-a5cc-4279952f60f7"
      unitRef="usd">168440</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTItMS0xLTA_940d3017-e09b-434e-950c-1fa458a8742a"
      unitRef="usd">4518707</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTQtMS0xLTA_fdf5fbfd-2208-4b42-8689-eba11efd58dd"
      unitRef="usd">1399012</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE0LTYtMS0xLTA_b82d06f8-4999-48b0-8f33-8d9de7ee7ddd"
      unitRef="usd">47288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTItMS0xLTA_af099755-40bb-4072-b762-82570f3b3344"
      unitRef="usd">-2131347</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTQtMS0xLTA_b62eb063-b84d-438d-9a44-bf43faf55a66"
      unitRef="usd">-1106175</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE1LTYtMS0xLTA_f462fed8-3c0a-40ae-8a50-950c89993c9c"
      unitRef="usd">-528153</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTItMS0xLTA_422af2f2-38a2-4792-9d24-4f97ce0f65c0"
      unitRef="usd">-1210489</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTQtMS0xLTA_d5cfa954-21cd-4eaa-a0b2-4b218ed393b3"
      unitRef="usd">615199</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE2LTYtMS0xLTA_d1e0d1d2-0e4b-4830-9081-15174615a388"
      unitRef="usd">-676750</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTItMS0xLTA_76e67eb9-9bce-441c-8aca-af0a02372db2"
      unitRef="usd">6569002</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTQtMS0xLTA_7fe13f2c-a2c4-41cf-99bf-814f327312b2"
      unitRef="usd">3221780</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE3LTYtMS0xLTA_c04bae6b-7615-4bf4-b35f-76e55c0ea6d9"
      unitRef="usd">4153287</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTItMS0xLTA_e380f032-4be9-46e2-b743-2515a1203d6f"
      unitRef="usd">-1859330</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTQtMS0xLTA_a0daab7f-60bf-4086-8ed5-c952f5ba1daf"
      unitRef="usd">-729820</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE4LTYtMS0xLTA_3e42b1cf-4042-404e-b280-b9847c5b958f"
      unitRef="usd">-159558</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTItMS0xLTA_26467ef3-db98-4d6f-8aea-f6dfd45521ba"
      unitRef="usd">1896819</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTQtMS0xLTA_e8c29268-b3a8-4c69-8039-f82598955042"
      unitRef="usd">-2455240</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzE5LTYtMS0xLTA_ef6a3975-d69f-4c53-8e04-bd0735b6aef0"
      unitRef="usd">-1390808</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTItMS0xLTM1MA_3e93cef1-7beb-43f0-a7db-4ff5c8577820"
      unitRef="usd">3518242</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTQtMS0xLTM1MA_1b617594-ca9c-4319-805b-832f5cfd6ffe"
      unitRef="usd">5511596</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTYtMS0xLTM1MA_688765fd-9914-4a44-b9a3-95419eab374d"
      unitRef="usd">4503545</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTItMS0xLTMxMw_3bb988dd-e965-4cf4-b9e8-e253f5e4b3c6"
      unitRef="usd">5415061</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTQtMS0xLTMxMw_44b10003-5f8d-496d-b744-2f9c514bee81"
      unitRef="usd">3056356</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTYtMS0xLTMxMw_a664f52b-7899-47c4-a2ea-6a7a9b6abf9d"
      unitRef="usd">3112737</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTItMS0xLTA_51571b59-560c-4621-a8b0-604fa9f41dc6"
      unitRef="usd">140817</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTQtMS0xLTA_99bc9b33-9088-49fb-9bcb-4b4bcbf27e52"
      unitRef="usd">246202</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIxLTYtMS0xLTA_579786ec-8032-4512-b56c-5604457a6aa8"
      unitRef="usd">455569</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTItMS0xLTA_df0ba42d-58fc-4de4-a09a-53afb0cad7cc"
      unitRef="usd">1973110</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTQtMS0xLTA_d65b8b58-188d-496a-a0a9-46902e9bbf1f"
      unitRef="usd">772944</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIyLTYtMS0xLTA_7f1c9c9a-8e30-4bed-932f-4a315a863e3b"
      unitRef="usd">3819486</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTItMS0xLTk2Nw_eb4054a3-996d-4d82-ad6b-6feb90815df5"
      unitRef="usd">460888</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTQtMS0xLTk2Nw_950733b7-c90e-4cdf-9a95-5a5094c02f6f"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI3LTYtMS0xLTk2Nw_40dc7bde-45e7-4670-a628-c1ffec7f3a71"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTItMS0xLTUzMTg_bc1799af-eb3c-4cfd-a602-fb435a4c4815"
      unitRef="usd">104750</cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTQtMS0xLTUzMTg_4668a01a-1287-4794-88ce-b5387d43c324"
      unitRef="usd">0</cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI5LTYtMS0xLTUzMTg_b5206a53-ff94-4c9a-8c64-b86e38363f83"
      unitRef="usd">0</cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTItMS0xLTA_9747348a-b668-4412-9c77-63e4efead6e5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTQtMS0xLTA_697a60ad-11e8-47c3-8989-92845b5b349e"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzIzLTYtMS0xLTA_aed39650-2126-4e2a-8c5e-3537c61c17f8"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTItMS0xLTA_9fb68b1d-4f86-41ec-a6bc-2dfb03d68e5e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTQtMS0xLTA_eb150008-5242-4c3a-b5cf-fc18cf931131"
      unitRef="usd">20062132</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI0LTYtMS0xLTA_349a1a82-41be-405e-be19-299386b0a8b4"
      unitRef="usd">16122376</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTItMS0xLTA_3d0ecdd9-1df9-45aa-8b17-cf4c8568acfb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTQtMS0xLTA_14d737ce-c052-4857-a46d-e7da9657df51"
      unitRef="usd">11745138</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI1LTYtMS0xLTA_b6ad6cad-c6d1-40e2-9c3f-97ad4495fcb1"
      unitRef="usd">19572139</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTItMS0xLTA_cf150ad2-a582-470b-a633-263b600d7dfd"
      unitRef="usd">-1757789</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTQtMS0xLTA_7d8315db-acf5-4a55-b4ac-441055816a87"
      unitRef="usd">2297848</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTpkMzViY2VhZTBhNWE0M2Q3YmRiZjUzNzFjZjc4NDI1Yi90YWJsZXJhbmdlOmQzNWJjZWFlMGE1YTQzZDdiZGJmNTM3MWNmNzg0MjViXzI2LTYtMS0xLTA_b4ab12e2-b6d9-4fd1-a135-02db75421605"
      unitRef="usd">-27724818</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtMi0xLTEtMTA5NA_2d341852-801a-481f-bdd0-a7cf1d36180f"
      unitRef="usd">59000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtNC0xLTEtMTA5NA_2611e568-cb7e-4c53-a72d-e04ebccaeb26"
      unitRef="usd">76000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEtNi0xLTEtMTA5NA_d3084c62-6179-459e-96c8-7dd7a11d574d"
      unitRef="usd">56000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItMi0xLTEtMTA5NA_8ac44e64-79fd-4a7b-a7cd-608c45540ef9"
      unitRef="usd">62500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItNC0xLTEtMTA5NA_d3678ff4-ad74-484f-8f41-0aeaba8a73eb"
      unitRef="usd">77500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzItNi0xLTEtMTA5NA_0fa1411f-635d-4711-ba5e-aa778ed07333"
      unitRef="usd">45800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtMi0xLTEtMTA5NA_89a1c150-e283-4d60-8742-f75aaf097ecd"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtNC0xLTEtMTA5NA_3cf2ee51-3be6-4638-a20d-8bcf1b93b8d0"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzMtNi0xLTEtMTA5NA_f70ef9fa-9ef9-4b24-a548-b960bfa9d02b"
      unitRef="usd">200909</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtMi0xLTEtMTA5NA_eb9c93d5-c444-4720-8def-1af883f43f72"
      unitRef="usd">1851526</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtNC0xLTEtMTA5NA_a0c067c7-b139-4e72-b1d3-595023ac7231"
      unitRef="usd">3494921</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzQtNi0xLTEtMTA5NA_0782748f-ca84-4a63-b202-8efbce1a2fe3"
      unitRef="usd">2879426</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtMi0xLTEtMTA5NA_9c0274fb-05ed-42d3-ba32-09c8082e7fbe"
      unitRef="usd">819180</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtNC0xLTEtMTA5NA_a26d539c-6457-45a0-bd07-6f3913874851"
      unitRef="usd">1033108</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzUtNi0xLTEtMTA5NA_c7ea2569-f746-4de5-8a13-ff1b592c3c4d"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtMi0xLTEtMTA5NA_10be276d-e15d-41b3-b6d5-77fcadbf4337"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i03694dc14e8c4bbb93ae06dc4dea9967_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtNC0xLTEtMTA5NA_d8e26872-4fe4-40de-b5fa-bbbcc5589c22"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i3dd305c2cee64a88a8f6930ec95cb5c5_D20160101-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzYtNi0xLTEtMTA5NA_6cb00839-40d2-4546-b5b8-d17049d868b7"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctMi0xLTEtMTA5NA_b674b8c9-8547-4393-8bbc-cc79c0194bfd"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctNC0xLTEtMTA5NA_7b60dbca-a989-429f-bb9e-f016ed62a198"
      unitRef="usd">1000000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzctNi0xLTEtMTA5NA_e368766d-eea6-4ec1-838e-129eca25e3fc"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtMi0xLTEtMTA5NA_a29bdb08-9d19-47cd-b743-680cff7261b7"
      unitRef="usd">135405</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtNC0xLTEtMTA5NA_60219ba6-3052-4754-9d9d-11a0eb0af711"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzgtNi0xLTEtMTA5NA_1295b195-0677-4e57-95ae-0b94a60a3783"
      unitRef="usd">383310</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktMi0xLTEtMTA5NA_6c084359-64cd-4bf7-8a00-03bf077c9231"
      unitRef="usd">10000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktNC0xLTEtMTA5NA_b612e612-74a8-46bd-b239-fd0bcb2e57e9"
      unitRef="usd">52500</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzktNi0xLTEtMTA5NA_21b67cc2-3e32-4a10-a7df-5f7a557b644f"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTItMS0xLTEwOTQ_092e1895-f6c9-4554-a877-72bb251aae6a"
      unitRef="usd">-7116111</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTQtMS0xLTEwOTQ_a1416545-381f-403c-8721-8a3594bd811b"
      unitRef="usd">-5080529</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEwLTYtMS0xLTEwOTQ_8e274a77-8865-4976-9abc-d59d6688b4aa"
      unitRef="usd">7138173</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTItMS0xLTEwOTQ_4c3eb5c3-1df3-42cc-ba58-59109c03ea18"
      unitRef="usd">-3458839</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTQtMS0xLTEwOTQ_38114d14-2771-4d5b-bca5-32ca609ae897"
      unitRef="usd">273675</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzExLTYtMS0xLTEwOTQ_5c6eb411-72b9-4fa5-8d17-2d46831c0b8e"
      unitRef="usd">-17473908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTItMS0xLTEwOTQ_de5c763c-112c-44c4-a5fd-a9f632495b4b"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTQtMS0xLTEwOTQ_741a0dec-f072-4f4e-84ee-e759407de5df"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib61e32dba4b0475d984dfadd6379821d_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEyLTYtMS0xLTEwOTQ_a61563c8-73d8-44bc-821c-29cc453885dc"
      unitRef="usd">45412868</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTItMS0xLTEwOTQ_627fcfc3-a903-4327-bf3c-239beee10e16"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTQtMS0xLTEwOTQ_200cbf0c-689c-4534-a57b-354c24126611"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo1YmI1YWVjYTgzYzQ0YjRkOTY0N2ZlNjM3NTBjN2MzYS90YWJsZXJhbmdlOjViYjVhZWNhODNjNDRiNGQ5NjQ3ZmU2Mzc1MGM3YzNhXzEzLTYtMS0xLTEwOTQ_c87b4746-74b4-43f5-88e1-613d18d2ff80"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItMi0xLTEtMA_5a300b09-a387-4b05-bfe0-5029b4869857"
      unitRef="usd">215991</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItNC0xLTEtMA_e1d46206-4905-432f-9557-8bf85e4f8bf9"
      unitRef="usd">198661</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzItNi0xLTEtMA_86bf916f-8488-49e4-b137-a7aae28d93c2"
      unitRef="usd">95965</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtMi0xLTEtMA_ae1d9b56-62ab-4127-9f1e-ec97f92be62c"
      unitRef="usd">-91486</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtNC0xLTEtMA_beb858c5-de3d-4f2c-b08b-283032da1238"
      unitRef="usd">16694</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzMtNi0xLTEtMA_a2374b43-28ad-4ac4-8aa9-136f3f858457"
      unitRef="usd">15441</us-gaap:IncomeTaxesPaidNet>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtMi0xLTEtMA_33633bc2-d75c-4a77-8040-43edcc2c4678"
      unitRef="usd">-340997</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtNC0xLTEtMA_5c81fcd3-07b3-46e3-bf3e-d5e3f83e976a"
      unitRef="usd">-576837</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzUtNi0xLTEtMA_71dc534c-2aa8-4a1e-b0a8-fcdf1fae4fec"
      unitRef="usd">-539467</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtMi0xLTEtNTgyMA_af28c306-4a41-499c-8d61-7e2ca8fac2e5"
      unitRef="usd">200000</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtNC0xLTEtNTgyMA_176d7661-62b4-4757-8964-a644304cd0df"
      unitRef="usd">0</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzYtNi0xLTEtNTgyMA_871d247c-8483-4ba5-bc24-9f55aedd9622"
      unitRef="usd">0</cpix:DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctMi0xLTEtMA_6855e430-4624-4b21-8664-c92f08cb7d93"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNC0xLTEtMA_5975e0fe-8c34-4000-8014-ba221f68f602"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNi0xLTEtMA_f81a80ac-faf4-4f7f-8038-9187227f2e71"
      unitRef="usd">14034000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzgtMi0xLTEtMA_1dce940e-1db4-42b3-84b1-c61560e80989"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzgtNC0xLTEtODc5_c721e45f-df37-43d6-a743-1b76aaa3a359"
      unitRef="usd">3629320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzctNi0xLTEtMTQzMQ_0f30a0ec-9775-430a-8f1f-b5a91584d801"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktMi0xLTEtMA_040d0388-8923-42ab-a47c-680da378ee10"
      unitRef="usd">0</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktNC0xLTEtMA_ce060d84-c480-48d1-8d0e-c492450c5c8b"
      unitRef="usd">862200</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <cpix:NoncashOrPartNoncashTransactionVestingOfShares
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzktNi0xLTEtMA_c123549f-e2c0-4229-b80f-0a047fd1d5b4"
      unitRef="usd">0</cpix:NoncashOrPartNoncashTransactionVestingOfShares>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTItMS0xLTA_59ed3b96-26fb-4751-a843-d545577a22e3"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTQtMS0xLTA_8d2d166d-86be-4159-ae6a-8ad53a826001"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzEwLTYtMS0xLTA_11006b43-251e-4e94-9879-85b780e69e1f"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTItMS0xLTA_033b2dde-c717-4031-966e-e0e8c1f5f129"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTQtMS0xLTA_1e921e9a-f24a-49e6-af88-93592e3b6359"
      unitRef="usd">148000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODEvZnJhZzo1Yzk5MTEyZDI1ZGQ0ZWQ2YTRjMWI4MGE1M2JiNGJmYy90YWJsZTo3NDRkN2U3Y2EwNDI0YzhlYjBjNmIwZmEyYTRiYmM2MS90YWJsZXJhbmdlOjc0NGQ3ZTdjYTA0MjRjOGViMGM2YjBmYTJhNGJiYzYxXzExLTYtMS0xLTA_791f60cf-f6e9-46f7-b1a9-1932f5ebeba7"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i579acb9f96de41ffba78cca469abf593_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTItMS0xLTA_6805c1dc-59c3-4480-a1a4-52d7b937a205"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i579acb9f96de41ffba78cca469abf593_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTQtMS0xLTA_6ecc194e-2c4f-4591-af4f-033eca208680"
      unitRef="usd">52410941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae03170bbe484f15ab0b60e6dbda8bc7_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTYtMS0xLTA_ea566efb-ce2a-4c30-ab97-804a54d71d4f"
      unitRef="usd">11709222</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85e782a52b4d44329375848c274ec5d1_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTgtMS0xLTA_44075a2b-f450-41de-a034-597096ad34e4"
      unitRef="usd">-198562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib61e32dba4b0475d984dfadd6379821d_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEwLTEwLTEtMS0w_03ec445f-4da8-48b3-8b77-556c9800cd9f"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5ff3ff90eb944c0dbe11b04ce7b0d7ed_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTYtMS0xLTA_7c001600-5e80-47eb-8bbb-512ec2da3290"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3bfc004e938140c29692f598f52b5277_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTgtMS0xLTA_cbcbc978-6cc7-4fa0-bb70-56f2eb958438"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzExLTEwLTEtMS0w_55ecb744-8405-4618-9b83-27089bab0dba"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTItMS0xLTA_24469b5f-0256-4bde-9f7d-f347a322476a"
      unitRef="shares">170759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTQtMS0xLTA_e1ae830d-1900-47bd-b155-292f1678ec04"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEyLTEwLTEtMS0w_fac1aab5-6d6c-4a67-a67a-0f5064051d65"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTItMS0xLTA_2735c52d-5970-4df6-bcb8-acc0d399a2eb"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTQtMS0xLTA_caf8a966-1d80-4767-9daa-b4dad715481e"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzEzLTEwLTEtMS0w_ea1b3b79-efa5-4d1a-8485-06274b87fc73"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTItMS0xLTA_b93713a1-42e5-4163-9cc7-3d1cdde02da6"
      unitRef="shares">443041</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTQtMS0xLTA_c2d2facb-7195-4386-86a3-60b5ae8af056"
      unitRef="usd">2877935</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE0LTEwLTEtMS0w_0c5698ed-9526-400d-a508-e9303fc99389"
      unitRef="usd">2877935</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if736d13a5981486b9c4be73116b8d9b3_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTItMS0xLTA_c3c981c1-0ef0-47d9-9de7-c865b898bcd4"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if736d13a5981486b9c4be73116b8d9b3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTQtMS0xLTA_d6835dd1-2d4c-44f0-ac3e-986880df0c00"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7bb3d0fc63f46a38f73f8e24b9222eb_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTYtMS0xLTA_6196ee45-008f-467f-8366-bf750e786abe"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3edfe4448c474b6eaa1f9546a60f6baf_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTgtMS0xLTA_dea1c436-785f-4bca-b485-aaac40f59a07"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE1LTEwLTEtMS0w_bc0b76ff-e0e6-45bd-ba4b-ed0de223cb4d"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7e7c45e9e811413cba25b0b270ac8d66_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTYtMS0xLTA_cbead75f-772f-40f4-87ab-902ea022c6d6"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTgtMS0xLTA_6acffa2a-785c-4413-a774-05afd2a42f1e"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE2LTEwLTEtMS0w_44168f74-9f2a-405f-9fd5-d244598780fa"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTQtMS0xLTA_f589135b-5557-4e6a-bbe3-290bc8a9c408"
      unitRef="usd">685805</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTgtMS0xLTA_9e1928a0-1830-4676-92c9-72af082457c2"
      unitRef="usd">114195</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE3LTEwLTEtMS0w_4e908bc5-72a8-45d3-b325-a414d317e158"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTQtMS0xLTA_a225d070-927b-4abf-b7b8-11cdfaa382bc"
      unitRef="usd">640407</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ib7c115b568ba442c8a5517c22893cee8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTgtMS0xLTA_48f794d2-6f40-4cf6-bede-15788709b1e6"
      unitRef="usd">359593</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE4LTEwLTEtMS0w_41446d42-9a66-4d8d-8a3e-fd8e2bc151b1"
      unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTItMS0xLTA_27c6ebf8-f0ff-4b89-adff-6f8eb83c3bd8"
      unitRef="shares">180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTQtMS0xLTA_4068eea7-8cee-496d-8076-d668e7d708f6"
      unitRef="usd">862200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzE5LTEwLTEtMS0w_07ab167c-9be3-45a9-8f71-364bc200806f"
      unitRef="usd">862200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTItMS0xLTA_4c926be5-e8c8-4f26-947a-850aa183971d"
      unitRef="shares">225536</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTQtMS0xLTA_e58e4cf9-e0ae-493c-8b02-b457f7bdd5fc"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIwLTEwLTEtMS0w_00fff10d-9100-40e6-9944-1d1ad4518f50"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTItMS0xLTA_16c1393e-bd39-4f78-913e-a41d0fb77cb6"
      unitRef="shares">623478</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTQtMS0xLTA_3adf79e8-711d-43c8-bf2f-a2128a68582e"
      unitRef="usd">3486835</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIxLTEwLTEtMS0w_7749867f-fd15-43a1-af69-c706fa59c4aa"
      unitRef="usd">3486835</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i906c0455495f493dadd51dbdcf6ce33f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTItMS0xLTA_c06fcc9a-537b-426c-99ce-da75094c16e2"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i906c0455495f493dadd51dbdcf6ce33f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTQtMS0xLTA_c18c3f2c-8d0b-430a-a1bc-f0162898b36c"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94b48d6a645042b68c812153d89d701d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTYtMS0xLTA_aacef83b-b95c-4d23-996d-82d7c507d8c9"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25561754ff6f4e2ea07d5a93bb7fc0b8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTgtMS0xLTA_d50d81b8-c59e-402c-b0e9-e9916b0970ce"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIyLTEwLTEtMS0w_a122760d-6553-460b-8868-fdc66f8c8e2b"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i113acbcb4c7a41f9b06366a217ff041f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTYtMS0xLTE0NDI_56ae8b50-efe1-4bbf-8b99-3f9ec9d81b0d"
      unitRef="usd">-3339408</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i28dc597efa194fb59a0fb601045119c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTgtMS0xLTE0NDI_c7d3459b-1fb3-4e0d-896a-030b48fde256"
      unitRef="usd">-79496</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzIzLTEwLTEtMS0xNDQy_e4f217e8-ac35-452d-adee-eb2adc23fed0"
      unitRef="usd">-3418904</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTItMS0xLTE0NDI_42506b81-cf47-4bfd-87c2-bc692181a83b"
      unitRef="shares">228500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTQtMS0xLTE0NDI_b5e472f2-a162-40bb-b5d7-e599f330bd62"
      unitRef="usd">1046516</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI0LTEwLTEtMS0xNDQy_0575ba44-bfa3-4bb2-9e36-bd49d82c7f91"
      unitRef="usd">1046516</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTItMS0xLTE0NDI_97870155-4939-4c1b-8755-d9e4424c4154"
      unitRef="shares">503626</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTQtMS0xLTE0NDI_17958260-4f0c-48ec-8ddc-7980e842251b"
      unitRef="usd">1839471</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI1LTEwLTEtMS0xNDQy_6047cb4c-d03a-4199-9be9-f2e4f30a9763"
      unitRef="usd">1839471</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72fd6471f1da4426a87a1886db0ae152_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTItMS0xLTE0NDI_e55d4f5f-e603-49c5-b2f7-40d821e81d36"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72fd6471f1da4426a87a1886db0ae152_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTQtMS0xLTE0NDI_4f5d24f9-dd29-4c7e-ba71-13e1612b14de"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f1d88acf1394d319d163e4143882af2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTYtMS0xLTE0NDI_6af5754e-7f7b-4410-bfa0-c57e0817695f"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida79e60e9d42460c84903d34b3fd5625_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTgtMS0xLTE0NDI_742cc6da-450a-448f-9827-700327d048f0"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xODQvZnJhZzo2MDg1YzBjNmQ0NjQ0ZGUxYjcyYmIxZTVlOWZkYmNjZS90YWJsZTo4YzgxMDZiODg5YTI0ZDgxYmVhYWFlYTQ2YTkwMDdhNC90YWJsZXJhbmdlOjhjODEwNmI4ODlhMjRkODFiZWFhYWVhNDZhOTAwN2E0XzI2LTEwLTEtMS0xNDQy_ba092da3-9d9e-41ea-965b-1a398c5fb441"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMyOTk_c5ba7350-0b33-4301-8cfc-2ada83113eea">Organization&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#x201c;Gloria&#x201d;).  As a result, Gloria received shares in CET and joined the CET ownership group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;whereby WinHealth made a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.8 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that was funded during 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's ownership in CET is now 85%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $79,496, $8,752 and $75,704 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i1d15f9eb345d4d64aa801993173c575d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzE3OTA_66ff5f7a-3096-4782-9d6e-93b32e592b7b"
      unitRef="usd">1000000.0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzIwNTY_a2235b48-937a-4ced-940d-59b2fc704280"
      unitRef="usd">1000000.0</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzIzNDM_bd2999a9-3e35-417f-8807-b529ecbcf48d"
      unitRef="usd">1000000.0</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:ContributionOfCashAdditionalSharesPurchased
      contextRef="i82fdc18596fd4b20999ba80f5d41bd51_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI0MzM_ada4aa47-18d5-4ccf-8535-dd2137a9468b"
      unitRef="usd">300000</cpix:ContributionOfCashAdditionalSharesPurchased>
    <cpix:IntercompanyLoansPayableConvertedAmount
      contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI0NjQ_11679d4d-7bfb-47c2-82b6-fc350653d352"
      unitRef="usd">700000</cpix:IntercompanyLoansPayableConvertedAmount>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzY1OTcwNjk3NzA0NzI_833b46c1-bcea-4b2f-9a5b-058ee28baa06"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="if2a2c29316304015acd330ba1069f0e5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzI3MDc_b2e24486-ccf7-4d7a-ad3d-b2faec84f7fb"
      unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwMzA_cafe800d-7f52-4746-81d4-ebe83c539285"
      unitRef="usd">-79496</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwMzU_3fb16ff0-9a6b-41dd-8584-694e5250ef28"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTAvZnJhZzplNzcwNmJhOGU2ZGE0ZjNkOGZkNjQ2ZmIzZWU4ZDFiOC90ZXh0cmVnaW9uOmU3NzA2YmE4ZTZkYTRmM2Q4ZmQ2NDZmYjNlZThkMWI4XzMwNDM_82e145c3-a390-4933-9305-fd859033c337"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYz_c32d9f4b-3558-4b2f-bd07-98beaf74fd1d">Significant Accounting Policies&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $2.4 million, $1.5 million and $2.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2020 and 2019, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2020 and 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $1.0 million at December&#160;31, 2020 and $0.8 million at December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2020 and declared effective in January 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2020, the Company has expensed $0.4&#160;million in deferred offering costs associated with the Shelf Registration that was declared effective in January 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) amended guidance in the form of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 20, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 20, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ5_00b4c61e-bc4f-4044-8d98-535a27f54584">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ1_37971f80-bd47-404a-9638-ff2caa5901aa">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY4_316a1571-e697-4698-b42e-f63849da2adc">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzEzNzg_f6d89425-2e10-4feb-b915-5962ec0716a0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Revenues
      contextRef="i3d6f67ab017747e488ce81fe0f2d992e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNTA_98331bea-46aa-449e-a0c1-3bc05db4631b"
      unitRef="usd">2400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i563ad4ae0b474a93a68d18998539da56_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNTU_e7719e3a-045e-4239-8965-ecd4322ac414"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i523a0c1898d94b0d968011937afb9b4c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIyNjM_a5c1281b-9a20-4711-87a4-f8e17f25f8fe"
      unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYx_99aedfd2-787c-44fb-8995-1a5f5b1622b6">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).&lt;/span&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTYy_cec5fa9a-c310-49b0-8bff-2e83c35daa58">Cash and Cash EquivalentsCash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2020 and 2019, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU0_cf143531-1baa-4834-be9c-227081dd5add">Marketable SecuritiesThe Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2020 and 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY0_d39ae0e9-dac8-4b62-ac55-4126c99fe940">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $1.0 million at December&#160;31, 2020 and $0.8 million at December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7ac26c9d624a4950b3d6b38c45e4b597_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzgxMDc_2f1e458e-6f13-4e76-8001-946bae5a42cb"
      unitRef="usd">1000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="icb9d8b7bd9c444fd81c867a1f021713b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzgxMjA_0d8160d2-d719-4292-80f5-8d3d27ad4ef7"
      unitRef="usd">800000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU4_64108b25-c47e-4907-ad56-2dc3c1d49562">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net &lt;/span&gt;&lt;/div&gt;realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.</us-gaap:InventoryPolicyTextBlock>
    <cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU5_0f73cb08-dd97-48d8-b83f-97d7cadc973c">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;</cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzIxOTkwMjMzMDk5NzI_811353b2-e70c-4fe2-a053-b6ad01046024"
      unitRef="usd">400000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ2_38ad798e-811b-4b55-b707-51b5287903a2">&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY1_bcae1f63-bcd8-4a2b-b2b8-aa465d28a639">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTQ3_b34a507d-000c-4569-9b69-5336f7505cd3">Amortization expense is recognized ratably over the following periods:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzAtMi0xLTEtMA_7455c885-39a0-452b-8514-4b4133b3ce14">Estimated economic life</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="i858b3a2a4199408587b99fe9de451ae9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzEtMi0xLTEtMA_b9c788be-a6aa-4385-a093-3b8c3e275186">Term of license agreement</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTo5YTdlODcxNzZlMDk0YjY4OWFlYzQ4MmFhZDg2Y2EyNS90YWJsZXJhbmdlOjlhN2U4NzE3NmUwOTRiNjg5YWVjNDgyYWFkODZjYTI1XzItMi0xLTEtMA_ca8367f5-4008-42a6-a360-1e2a7e5287ec">Life of patent</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUw_a9ac379c-2949-4bbc-8683-7159c50fc8b4">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i713b05d7f5bc4937aed96e19605bbd69_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzY1OTcwNjk4MTkwNjE_4c322f2b-1b73-4a72-8eab-2ab15f7dfa8b"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i713b05d7f5bc4937aed96e19605bbd69_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzY1OTcwNjk4MTkxNDI_71d5438f-143d-4cd8-8a52-71599e7fe006"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY5_bb99bb23-a070-4017-9ecf-77b13d0f2241">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) amended guidance in the form of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItMi0xLTEtMA_7057a439-0830-4551-aba1-6af4a770db3e"
      unitRef="usd">890686</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItNC0xLTEtMA_afaa320b-5991-4812-9c9c-a5d86ee6ab04"
      unitRef="usd">613637</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZToyNWE2OGNlYzUwNDY0ZmYwODZhMzJiYjQ4ZGVhOWFiYy90YWJsZXJhbmdlOjI1YTY4Y2VjNTA0NjRmZjA4NmEzMmJiNDhkZWE5YWJjXzItNi0xLTEtMA_49efcf36-8126-437d-9660-ffe601ff23b9"
      unitRef="usd">457814</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTY3_959ba076-e8c8-4c03-a085-048f0c02cce0">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItMi0xLTEtMA_3c964001-391e-4722-9bc6-58dae5554e12"
      unitRef="usd">2379424</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItNC0xLTEtMA_b3f00b02-5549-4750-89a9-2fff3750d8bf"
      unitRef="usd">2594630</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90YWJsZTplZTUyYmYzYWQzNzM0NjU4OWFjNmViYTY4OGNhYTA4Ni90YWJsZXJhbmdlOmVlNTJiZjNhZDM3MzQ2NTg5YWM2ZWJhNjg4Y2FhMDg2XzItNi0xLTEtMA_2ba422cf-945b-4844-9046-f14adee8ba9d"
      unitRef="usd">2005113</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTcy_c26c034c-d800-4bd0-9e5d-468f1724c15b">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU2_0ebf54e1-233b-49ea-9445-a150fb294d2b">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTU3_3205eceb-f41e-4d20-87ce-25e9c4715b31">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUy_c07972db-7d8b-4b1d-9e28-5e4b6e6c8c3e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTcx_3630124c-e700-4dd7-8695-9e0ede42ec33">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 20, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 20, for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTMvZnJhZzplYTBhZjU0NWEwZTA0YTkzYTcwNDE2NWRkMjU4YjE2MC90ZXh0cmVnaW9uOmVhMGFmNTQ1YTBlMDRhOTNhNzA0MTY1ZGQyNThiMTYwXzMxMTUz_ed45e39f-f865-4572-81ca-d6b23714ce9f">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTQ_09f198f4-c180-4440-8b8c-2a0c0bd96774">RediTrex&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; and Vibativ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  During December 2020 Cumberland launched RediTrex and the launch also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has approximately $2.8 million in net intangible assets related to RediTrex at December&#160;31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, Cumberland recognized $0.5 million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million at closing and a $5.0 million cash payment during early 2019. In addition, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is remeasured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $3.3&#160;million and the non-current portion is $4.9&#160;million, as of December&#160;31, 2020.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxMDc_a9b1f5fc-720f-4c89-bbdc-189744625ca4"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxNTM_bf1aa0f9-9180-487a-87e0-ba4bcd0f0a10"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzIxODU_26552ec4-7025-4bd1-8ee3-015c32927b1c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI2MDg_26552ec4-7025-4bd1-8ee3-015c32927b1c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI2ODI_5cbab9ad-1fe7-4a3e-8b26-ba8cf13ceefd"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzI3NjI_68bf37ba-d36e-4cdf-bff8-fa9787f56b47"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie02e5c124b8f4eb8a49be208c734aa7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzY1OTcwNjk3ODA5NDg_68bf37ba-d36e-4cdf-bff8-fa9787f56b47"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1ffd3ca73a074170bbcb58ba566f9585_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzE2NDkyNjc0NTIyMTM_5f7517f9-b861-4f44-aaba-bbb552a076ad"
      unitRef="usd">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Revenues
      contextRef="i1f0edc4849df4c21910d604bb57d2325_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzE2NDkyNjc0NTI1MTc_19e49bf1-a14d-4e3b-93be-75c5a05ce5e8"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQwNTY_11d71a51-5139-43e9-8db1-01d23521653c"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i60fc1a3fb3064db1baf227cdf6d18b18_D20190308-20190308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQwNzY_a7c9441b-ac66-46f8-835c-2ff861551c04"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i5c16a46beaf24c9480d5671931611d39_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzQxNjg_467929f4-3b42-47f2-a446-bfa5fcb352b6"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTY_96054273-f103-4a48-814d-c750a83c4e37">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzItMS0xLTEtMA_407224f2-2796-4245-baf7-95367a5a3612"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzMtMS0xLTEtMA_01d6be53-7551-4966-afd3-e041d6778182"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzQtMS0xLTEtMA_99d0637d-e06c-4e2e-b68e-70c23f2420d4"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZToyYTQwNDdjZTU3NjM0NjBhOWRhNzhkOTYyN2ViMzAzYS90YWJsZXJhbmdlOjJhNDA0N2NlNTc2MzQ2MGE5ZGE3OGQ5NjI3ZWIzMDNhXzUtMS0xLTEtMA_6cf12dab-ce68-43a5-8332-e1cedb4e2ea4"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTc_33fe9827-10ab-4ec9-9024-7af981d2d93b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is remeasured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icf84cc8aa13a4c4e9c2848f65593a987_I20181112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEtMS0xLTEtMA_ddf43392-f4de-4e80-8dee-fa3f798e5a9a"
      unitRef="usd">9034000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3805a80f910745b8ba5901401f43502b_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzItMS0xLTEtMA_4a6f7aca-a2fa-45e0-ab31-f29e44f8385e"
      unitRef="usd">-40000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i3805a80f910745b8ba5901401f43502b_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzMtMS0xLTEtMA_0b78817a-7f21-420e-a930-9e5b908b077e"
      unitRef="usd">508000</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i47d4426d3227403fabbfb9d27a6e529f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzQtMS0xLTEtMA_f62124d3-2c83-4d7c-9933-dab3c4eb238f"
      unitRef="usd">9502000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment
      contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzUtMS0xLTEtMA_7fd60046-5f89-41e8-a421-bb92439e2406"
      unitRef="usd">148000</cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment>
    <us-gaap:PaymentsForRoyalties
      contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzYtMS0xLTEtMA_344d2d19-edee-4a0e-afaf-bbb144ae1362"
      unitRef="usd">1033108</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzctMS0xLTEtMA_c1a0785a-dea4-4bf9-a9b7-f736fa41c5e3"
      unitRef="usd">-804167</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="if526d4a08c254080a221720150e6e894_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzgtMS0xLTEtMA_42604779-2a4d-40f1-8189-91c10a8392a1"
      unitRef="usd">820864</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9690979d455048e786882dc7d1715d78_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzktMS0xLTEtMA_6debad4e-cf47-4418-ba30-273fdd932766"
      unitRef="usd">8633589</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEwLTEtMS0xLTQzMTg_551e37af-c1dd-4415-abc7-a0d0ba44b0f0"
      unitRef="usd">819180</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzExLTEtMS0xLTQzMTg_859dfbd1-faa9-44f2-a465-faf4da36f683"
      unitRef="usd">-1160202</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEyLTEtMS0xLTQzMTg_879f8b6c-8303-4a7f-b13f-f63a6b835bf8"
      unitRef="usd">1546346</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i25bf3ecd92884fba947bb8fde5284b63_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZDM0Y2NkYjQzY2U0M2FmOGUzMzZhN2Y1YjdlZjdhYy90YWJsZXJhbmdlOjhkMzRjY2RiNDNjZTQzYWY4ZTMzNmE3ZjViN2VmN2FjXzEzLTEtMS0xLTQzMTg_bf586340-2cde-4f99-9c62-8e5b60d6e694"
      unitRef="usd">8200553</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MTg_caf94d74-b376-4939-9a91-becbf5b664dd">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzAtMS0xLTEtMA_71eb5148-b0e7-4c50-8467-ce02ddbc3119"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzEtMS0xLTEtMA_dfea8572-adea-4e98-ae7b-770495c46abd"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzItMS0xLTEtMA_04e4a858-bd76-426d-8281-79402f31314b"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzMtMS0xLTEtMA_719e4fa4-2b13-4157-abc9-7a09917f65d9"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzQtMS0xLTEtMA_aec66fa7-6bfe-4927-a714-e8629aff259f"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzYtMS0xLTEtMA_587de83b-f4e7-4e7c-bb4e-3e6e851e313a"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzctMS0xLTEtMA_6f29ad2a-3e05-48e2-a190-98dcb0330759"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzgtMS0xLTEtMA_0228b1ae-c70d-4240-81db-313605825699"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90YWJsZTo4ZjliOTdiZjYxYTE0ZTFkYjVhNDhhNzE2MDk5MmZmNi90YWJsZXJhbmdlOjhmOWI5N2JmNjFhMTRlMWRiNWE0OGE3MTYwOTkyZmY2XzktMS0xLTEtMA_c7d2fd08-89fd-415e-a056-ac9c74715a60"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU3Njc_85cd2246-175c-4ca9-9a13-cded031d7de1"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xOTkvZnJhZzo1MmE3NzI3NDliZmM0NGU3YjQ4NjcxZTVjN2MzZThhZC90ZXh0cmVnaW9uOjUyYTc3Mjc0OWJmYzQ0ZTdiNDg2NzFlNWM3YzNlOGFkXzU4MDE_be82eaf9-5a75-4393-858f-c5537c142a1d"
      unitRef="usd">4900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI3NTA_49ba198e-cca7-4045-af64-2b02d3ab04e6">Revenues&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,567,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,895,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,055,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,870,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,691,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,336,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,222,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,001,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,824,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,840,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,407,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,803,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#x201c;WinHealth&#x201d;) for our Caldolor and Acetadote&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#x201c;DB Pharm&#x201d;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019. There were no payments received in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The international agreements provide for $1.0 million in non-refundable up-front payments, milestone payments of up to $2.2 million related to regulatory approvals and up to $4.8 million in payments related to product sales.  From 2012 through December&#160;31, 2020, the Company has recognized a cumulative $1.2 million in upfront payments as other revenue and has recognized $0.1&#160;million in revenue related to the milestone payments associated with these international agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues during 2020, 2019 and 2018 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.8 million, $1.3 million, and $0.1 million for the years ending December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI3NTI_ba4d84a4-f81e-4a70-aca1-01f0fffe0f56">&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,567,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,895,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,055,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,870,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,691,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,075,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,336,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,222,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,001,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,824,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,840,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,407,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,803,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b8106a20e864d28bd6d0ef776efb119_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItMi0xLTEtMTc1OA_9d4a68eb-465a-477d-87b9-49e12e958cff"
      unitRef="usd">15567562</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1a0444604f4249b8af8cff8f67e09d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNC0xLTEtMTc1OA_a50eea67-d519-4986-b385-dfc1d0b72d20"
      unitRef="usd">12895120</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id93dbc3e2bb445b79575c990976d088c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNi0xLTEtMTc1OA_036c8386-2162-457a-9af3-4b17cfb3fbef"
      unitRef="usd">12055625</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41f00b78b135497898e49546c1d2f4ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtMi0xLTEtMTc2Mw_c86bdb57-cbb4-47b4-a7ad-5427c6c40143"
      unitRef="usd">10870990</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4269e0d435e4dd8af6548e04ee94f28_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNC0xLTEtMTc2Mw_df4e0197-c7d1-409a-a162-153c4d3ec8c1"
      unitRef="usd">8691550</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i932871e9df8745c583acfe2f18eb6df4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNi0xLTEtMTc2Mw_c8eb0972-d2f1-41c9-aaaa-cdb286bf6b88"
      unitRef="usd">5075057</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76cdf7521dab4b328c6824333676f5fb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtMi0xLTEtMTc2OA_068a3d04-c42a-476a-ae7b-24ae7b7a2b66"
      unitRef="usd">5336943</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29d41290b523433fa5c1c7846ba6fb17_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtNC0xLTEtMTc2OA_2bbaf00b-516a-4e19-8725-934d50d5f63b"
      unitRef="usd">5222282</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3738fecb3eaa4c198acc94352adfea94_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzQtNi0xLTEtMTc2OA_94acb835-431f-40de-ba3b-8db4559d773c"
      unitRef="usd">5001997</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0d302dded484788ae6589a0340b9b88_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItMi0xLTEtMA_0833088e-21df-4935-88d1-58cf63c81bea"
      unitRef="usd">1874206</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4fb6667544f4f559f12205fcebec85c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNC0xLTEtMA_391ca38b-0a54-4d5a-ac58-d71f6539b1a7"
      unitRef="usd">3824449</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf76f0a2b0ed40d8b2b44aebcfae79d7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzItNi0xLTEtMA_cf255021-fb2f-4c02-b3dd-99a56e191e38"
      unitRef="usd">4284111</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i128821f68ebe4cd097ed7ff95840f048_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtMi0xLTEtMA_c0da71e8-a4cf-4823-84d2-9da2be1ddcd9"
      unitRef="usd">257088</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff264f92669d449e8bcb64c3d9b88d42_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNC0xLTEtMA_0f40d00f-4b6e-4dfb-8ca9-82bc40a09ee8"
      unitRef="usd">837829</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i011d9382fa6c4d49bd3e83103b01e17e_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzMtNi0xLTEtMA_f8b49a85-1f10-491a-8958-229043b531b2"
      unitRef="usd">623297</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21522c7cbff7479c950097c298729560_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtMi0xLTEtMA_1ab75dc4-e753-4a54-802b-7abaa5d57282"
      unitRef="usd">1077227</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379abd9813bb4e449cf04367935a4368_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtNC0xLTEtMA_fe6740cc-cb36-4199-ba3c-af5ee39f5dc6"
      unitRef="usd">936615</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie836a99c6e9a4ea5b8b4e362f27f61b0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzUtNi0xLTEtMA_4ac84148-4d85-4959-afc8-99caa117c40f"
      unitRef="usd">1763874</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4953695015dc4f6192628e3e06840b93_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzgtMi0xLTEtMTM1Ng_8e9184fb-55ea-4b33-bc1a-a65fa97fdfae"
      unitRef="usd">856657</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTItMS0xLTA_8b95f62a-457f-4b05-b2c5-d9795999b3a4"
      unitRef="usd">35840673</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTQtMS0xLTA_cf4dd806-0f7d-4c8e-b126-28bae14f58bd"
      unitRef="usd">32407845</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90YWJsZToyODJhY2JlMmNhZmU0MmNkOGNmYWI5NWE2NmE2NjUyMC90YWJsZXJhbmdlOjI4MmFjYmUyY2FmZTQyY2Q4Y2ZhYjk1YTY2YTY2NTIwXzEwLTYtMS0xLTA_17c27800-0ecb-4f8a-9837-d7e1caf0b9e4"
      unitRef="usd">28803961</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd71c23cf60e4a89ace2b16705e73a6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzc0Ng_6f0500c5-a1fb-4178-8db1-d35ab295fc6c"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cpix:RevenueRecognitionUpfrontPayment
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE4NzY_8d8d5468-1089-4b6f-b92a-d3f10e32ded9"
      unitRef="usd">1000000.0</cpix:RevenueRecognitionUpfrontPayment>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE5NDQ_7c1a28de-c65e-4ebd-9914-0a92db460f3c"
      unitRef="usd">2200000</cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzE5ODk_81bea219-f060-4d95-8d14-4cf7c79da44c"
      unitRef="usd">4800000</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <cpix:RevenueRecognitionCumulativeUpfrontPayment
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzIwOTM_07faf8cd-0765-49c6-b255-60002f712792"
      unitRef="usd">1200000</cpix:RevenueRecognitionCumulativeUpfrontPayment>
    <cpix:RevenueRecognitionMilestonePayments
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzIxNTI_34a40f67-b0d1-44dd-85cd-d741e92afea6"
      unitRef="usd">100000</cpix:RevenueRecognitionMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05552adfe6bd4b2c9364a3fb0e38115f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2ODY_9f3732e6-840d-4388-baaf-dcb2b18118a4"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11727dca580e45938d1bd2a30fa3b13c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2OTE_d9f0c37a-edda-448d-9b7c-9cec8052f280"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i425aa7efcc3d419489434711697897b5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDIvZnJhZzoyYWI4YjE1NGNmZGI0ZWE1ODE1NmFhMzZhMzZiZGUxYy90ZXh0cmVnaW9uOjJhYjhiMTU0Y2ZkYjRlYTU4MTU2YWEzNmEzNmJkZTFjXzI2OTk_814b32a7-1a2d-490c-b5d2-b2c607fd542b"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE3NjI_2beb20c6-925b-4bd3-869b-5aeaade137af">Inventories&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.  The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At December&#160;31, 2020 and 2019 the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.2 million and $0.1&#160;million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2020 and 2019. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million  that were classified as non-current inventories.  At December&#160;31, 2020, the Vibativ non-current inventory was $11.2 million and $15.3 million at December&#160;31, 2019.  The Company had Vibativ finished goods included in the non-current inventories at December&#160;31, 2020 of $2.1 million and we did not have any Vibativ finished goods included at December&#160;31, 2019.  At  December&#160;31, 2020 and December&#160;31, 2019, Cumberland had $0.4 million and $0.3 million, respectively, in non-current inventory for API related to its ifetroban clinical initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE3NjM_55eabbf4-57e3-4ee6-ab1d-09623de399c0">&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzItMi0xLTEtMA_236c2b70-9cc7-4479-8ee0-0d8d9a1a3e52"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzItNC0xLTEtMA_8775f4e3-6230-4835-8ec2-1fbb88f1ad0e"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzMtMi0xLTEtMA_4bfab8ee-8050-4cd9-ac23-dba29a05a09b"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzMtNC0xLTEtMA_058cb055-6903-462b-b16e-f25b4da7631a"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzQtMi0xLTEtMA_a838ecda-7884-4f0e-877e-a0055ba874ab"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzQtNC0xLTEtMA_419fd864-a148-4123-bd1e-f4d9f9686bba"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzUtMi0xLTEtMA_16c49481-383e-4e5a-933d-2db2d00c607c"
      unitRef="usd">22294899</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzUtNC0xLTEtMA_a93c99fb-5fec-4585-b3bc-a1abc0bd31f4"
      unitRef="usd">24426246</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzYtMi0xLTEtMA_53a0b4a1-0a60-46b9-a0e6-c08409caaf10"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzYtNC0xLTEtMA_1df3c2fd-a9e3-46a2-b743-53af01c2bdc4"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzctMi0xLTEtMA_04a861a7-6e25-439f-bb9c-fee5c42b80c4"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90YWJsZTo5ODAyMTAyZDg0YWY0MzcwODZlYTJmMDY5NjMyMDUyZi90YWJsZXJhbmdlOjk4MDIxMDJkODRhZjQzNzA4NmVhMmYwNjk2MzIwNTJmXzctNC0xLTEtMA_37da5edb-0c4d-4231-b4e2-f43b39fb12f4"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzY1OTcwNjk3NzE5MjU_331e6652-bf69-4e52-952f-9f62603df660"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzY1OTcwNjk3NzIzMTc_11ef7f67-0d1d-4c09-9f14-bfaa62cae41d"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzEzODE_9c713347-41b9-4201-8c75-e94c86be6fef"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i25bf3ecd92884fba947bb8fde5284b63_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE0ODU_511f3310-8c65-42b1-beea-2af197bc402a"
      unitRef="usd">11200000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i9690979d455048e786882dc7d1715d78_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ4MTM_c2e45fc1-2336-4f22-9be5-5bf3425c052a"
      unitRef="usd">15300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i44a7f8d16fd34d9298c695a5fc27fb15_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ2OTE_4f9b5a21-90a8-4238-80ad-cc1704fa1c7d"
      unitRef="usd">2100000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ia9075a3fe1d64ddf8f34dc57c4454544_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDQ2Mjg_b33074f4-b1b4-4abb-8622-645a8474b183"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i900aa4346676422fb1898c7d882f8fcb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDUvZnJhZzpkOGM2MGE5ZTc3YzQ0NjBhOTExYmFmNzRmZjBhNGY0MS90ZXh0cmVnaW9uOmQ4YzYwYTllNzdjNDQ2MGE5MTFiYWY3NGZmMGE0ZjQxXzE2NDkyNjc0NDUwMTU_701ea80c-c511-4e77-a367-32e9e4e52809"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM1Ng_ce12fdd0-6881-4cb5-81df-ff2cfe30eff9">Property and Equipment&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,557,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,394,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM1OA_c6b97ed4-3bcd-4e54-8004-8c08347c21c5">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,557,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,394,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic6fd7af49de249ecb292d30a08cbd4de_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItMi0xLTEtMC90ZXh0cmVnaW9uOjIwNWNjNmQ2M2NiYTQzZTk4YWE1N2NmOGU2YmVkMjc2XzIxOTkwMjMyNTU1Njg_e4270ee2-e50f-4d5a-965f-023dc428bdce">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i74b9642648b4446484395a251aeb73e5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItMi0xLTEtMC90ZXh0cmVnaW9uOjIwNWNjNmQ2M2NiYTQzZTk4YWE1N2NmOGU2YmVkMjc2XzIxOTkwMjMyNTU1NzI_414e52dd-a2f7-4703-81f8-622beb44c22f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i567a47d8201140e0a6ab9fd8bf24c58c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItNC0xLTEtMA_490420a1-4227-4298-8007-eff2f94af878"
      unitRef="usd">1275703</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if57a23f2f6ce40868fabc79000f9acc9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzItNi0xLTEtMA_8ecd4a19-9e79-4e59-bd35-64f27808825a"
      unitRef="usd">1260630</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i22150fcc5f674069a6bb7c015e170408_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmE4ZmQ3NjkzMmUyNDRkOWFhNmIzMTBkYzIyMjllOTcyXzIxOTkwMjMyNTU1Njk_8d14caba-9710-4748-beff-af60660553c0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i43f7778a12b5457fa1f6664420a75437_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmE4ZmQ3NjkzMmUyNDRkOWFhNmIzMTBkYzIyMjllOTcyXzIxOTkwMjMyNTU1NzQ_f8411523-da69-4e1e-9448-8ff7f15c9d52">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15b440537b5d417d8d302cd1bd73dd3b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtNC0xLTEtMA_cfacb194-b542-44df-a59c-65479ddd2235"
      unitRef="usd">806906</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55d077df83004e9b9dca31085e2c7dce_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzMtNi0xLTEtMA_d037700a-4a84-431f-9d73-7fce36b23f32"
      unitRef="usd">878350</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i61b3055ed198427f821e78280855ef22_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjk3NDM4MDAyNjAyODRjM2JiOWZmODRmNjFiYTNlNmYzXzIxOTkwMjMyNTU1Njk_7586c1d2-262a-47a2-92ce-43f72cb8362b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic56325a56faf46d4b05761c86d36d031_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjk3NDM4MDAyNjAyODRjM2JiOWZmODRmNjFiYTNlNmYzXzIxOTkwMjMyNTU1NzQ_92f9df02-32d5-4d43-b70c-9fecc604b8f8">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i52b299fde4ec4bd2b6d62fffe5447170_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtNC0xLTEtMA_5a13d444-0295-41de-b63f-d842dd13da20"
      unitRef="usd">638903</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie19f08d91a2640dba99067b8dbe8c464_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzQtNi0xLTEtMA_fc859600-7f0d-41f3-8c36-9984ba70fa07"
      unitRef="usd">646505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1528e64c010641a68be52125a75832b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtMi0xLTEtMC90ZXh0cmVnaW9uOjgzZWEyZTJlZGJlMzRkYWU4OTczNjBkMTQ4NjlmZDkyXzIxOTkwMjMyNTU1OTQ_543c8858-c403-472a-aa2c-2efbb17710aa">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3ff6b1dbcf3c4c8e92b1cdefc3aa7b52_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtMi0xLTEtMC90ZXh0cmVnaW9uOjgzZWEyZTJlZGJlMzRkYWU4OTczNjBkMTQ4NjlmZDkyXzIxOTkwMjMyNTU1OTk_9328ba5e-24df-4225-926f-8f38feb95973">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic3be021e818547a795f36d1377c9ea4a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtNC0xLTEtMA_ef60a402-f359-4a9b-8474-a9dc2fb08932"
      unitRef="usd">1409744</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb4713d678174ead99f243c92ec45d16_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzUtNi0xLTEtMA_da451f00-eb57-47f4-8a8f-fd3ec01acf55"
      unitRef="usd">1356640</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzYtNC0xLTEtMA_e733baa3-8f27-4e17-9987-2cee67082b21"
      unitRef="usd">4131256</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzYtNi0xLTEtMA_2fce117b-0dfe-42fb-9960-7d23b474adaa"
      unitRef="usd">4142125</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzctNC0xLTEtMA_5876b317-da07-4796-9db8-fe9b6879dd55"
      unitRef="usd">3557087</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzctNi0xLTEtMA_053d9be3-59fe-4088-b1e4-7966357f8a24"
      unitRef="usd">3394329</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzgtNC0xLTEtMA_5a400ca7-7081-4b1a-9e65-4bff727a553f"
      unitRef="usd">574169</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTpjYTdhZGFkM2Q2ODc0YmYxODQ0YjYyMWRkMWQ1ODBkNS90YWJsZXJhbmdlOmNhN2FkYWQzZDY4NzRiZjE4NDRiNjIxZGQxZDU4MGQ1XzgtNi0xLTEtMA_c6602464-5b3e-4499-be1e-e4cee8fff930"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <cpix:ScheduleofDepreciationExpenseTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90ZXh0cmVnaW9uOmVkZGE4ZDQ0NGUwMzQ0MTBiNGU5NmU3ZTY5Y2VmODU2XzM2MA_503b484c-a08b-4cf6-9e61-ed5dee9f3793">Depreciation expense was as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofDepreciationExpenseTableTextBlock>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItMi0xLTEtMA_93a9e166-5f42-475f-a3ca-f3eae7c017df"
      unitRef="usd">314444</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItNC0xLTEtMA_4d4d1681-11e0-42ef-806a-ee7a5fb69ff8"
      unitRef="usd">269619</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMDgvZnJhZzplZGRhOGQ0NDRlMDM0NDEwYjRlOTZlN2U2OWNlZjg1Ni90YWJsZTphMzdmMDdmMWRlYTY0MTE3OGM3ZThiZWMzMzgzNTAwMi90YWJsZXJhbmdlOmEzN2YwN2YxZGVhNjQxMTc4YzdlOGJlYzMzODM1MDAyXzItNi0xLTEtMA_6593a91a-5fe0-4596-9c8b-63a088cc675f"
      unitRef="usd">213237</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNjk_2142d25a-8fd9-4226-ad3a-9de6e436d775">Intangible Assets and Goodwill&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,543,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,400,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,709,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,499,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,833,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,901,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,306,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,882,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,312,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,127,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,118,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex and Vibativ. In November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#x2019;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $100,000 deposit paid at closing, the 180,000 restricted shares valued at $0.9 million that vested upon the November 2019 FDA approval, the additional $1.0&#160;million paid to Nordic during 2020 based on the 2019 FDA approval and the $1.0&#160;million owed to Nordic based on the 2020 product launch.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $11.8 million and goodwill of $0.9 million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $0.1&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020 and 2019, the Company recorded an additional $0.5 million and $0.7 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,338,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,691,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,830,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,118,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNzA_16ce33e5-04f6-4414-8e26-58aea477541a">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,543,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,400,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,709,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,499,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,833,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,901,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,306,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,882,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,312,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,127,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,118,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,920,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie005a45bb43941a58835f78c97251e65_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzItMi0xLTEtMA_288e4a7c-0397-4c72-bbc5-0cf8ca16b706"
      unitRef="usd">38543542</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0173213b69184c199e2c3ab68e949553_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzItNC0xLTEtMA_e3c9bc4e-ef61-439e-9a8e-ed8c919a6f68"
      unitRef="usd">37400742</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie005a45bb43941a58835f78c97251e65_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzMtMi0xLTEtMA_014d970a-3114-4deb-bbb5-34117d37e70f"
      unitRef="usd">14709824</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0173213b69184c199e2c3ab68e949553_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzMtNC0xLTEtMA_7e26a0d0-36c3-4564-bf2f-53d4a522b3a7"
      unitRef="usd">11499141</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie005a45bb43941a58835f78c97251e65_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzQtMi0xLTEtMA_ca6d3ad7-e3e7-43d5-a393-21513a708832"
      unitRef="usd">23833718</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0173213b69184c199e2c3ab68e949553_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzQtNC0xLTEtMA_ee092478-f777-434f-8ef9-abc6c0df6249"
      unitRef="usd">25901601</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzUtMi0xLTEtMA_ef79a722-830c-45ca-b4a5-df996c6173ac"
      unitRef="usd">10306922</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzUtNC0xLTEtMA_e1e7f889-f0fe-4e8a-8d21-62b4a1abe5fe"
      unitRef="usd">9882511</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzYtMi0xLTEtMA_c7eac2aa-1179-42a5-9c12-cf3e0815d548"
      unitRef="usd">6312460</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzYtNC0xLTEtMA_ee91b0aa-68e6-4a58-8f53-c6cbb8a43fa4"
      unitRef="usd">5127878</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6724e49269cd4c95a99a8ca277ef19c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzctMi0xLTEtMA_afb6eb62-6b45-4417-ba61-7e94280127c8"
      unitRef="usd">3994462</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0e037b70471e490a9f3bd1f848149384_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzctNC0xLTEtMA_fc4837bf-5e95-421a-962f-a8cb25a3f4ed"
      unitRef="usd">4754633</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzgtMi0xLTEtMA_4e88adbf-727d-4d01-976c-46c9b1fb3e12"
      unitRef="usd">338011</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzgtNC0xLTEtMA_f19d57af-27e1-4122-b87e-419946121d3b"
      unitRef="usd">273110</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzktMi0xLTEtMA_fd302abc-5aa3-4175-aabf-ffc79897292b"
      unitRef="usd">47875</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzktNC0xLTEtMA_3c659693-5dd3-4d86-b2b8-c0fe49e14829"
      unitRef="usd">9020</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d622e0a01004a5d9914569d0d5756ee_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEwLTItMS0xLTA_5ceb5473-5008-4366-9de4-d741f9837204"
      unitRef="usd">290136</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib378884a762c4067ae1b484eca7cbcce_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEwLTQtMS0xLTA_99428b74-a1ab-4070-a6e9-ec538b9da24c"
      unitRef="usd">264090</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzExLTItMS0xLTA_240859ad-922d-4b2d-b535-98d7a62dcaaa"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzExLTQtMS0xLTA_b9fa78fc-7ca7-4121-b867-d17a2058d285"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEzLTItMS0xLTA_fcaed65f-aee7-425b-901b-a9d7718b31cd"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmZGMyMzM2MThkY2M0MzgwOWY0NzQ2NmIyMThlMDY4Ni90YWJsZXJhbmdlOmZkYzIzMzYxOGRjYzQzODA5ZjQ3NDY2YjIxOGUwNjg2XzEzLTQtMS0xLTA_ea7a2c95-f05a-4dc6-9a2f-5ff6b9168ded"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic6965a6b62944a7aaeb742134c6fdf52_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE5NTU_a9b1f5fc-720f-4c89-bbdc-189744625ca4"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i3c9232aa96504f6292df3a87cd230e09_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE5ODc_26552ec4-7025-4bd1-8ee3-015c32927b1c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i57d3fa0dc2eb467eb186b690c695ad10_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIwMTg_5cbab9ad-1fe7-4a3e-8b26-ba8cf13ceefd"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIwODg_bbfb275b-a1b1-4728-a945-0e4fec2f0d33"
      unitRef="usd">1000000.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib5b0b7b798bd4f3ea0ddc353036f4d30_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzY1OTcwNjk3NzE3NTg_bbfb275b-a1b1-4728-a945-0e4fec2f0d33"
      unitRef="usd">1000000.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIzMjU_2f716c6b-e5cc-4d34-a553-88f28e02b149"
      unitRef="usd">11800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i9375d96a8aab42a988665839bfc0db67_I20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzIzNDQ_45cf7a96-cb19-4c83-8d92-39f6b908d0c5"
      unitRef="usd">900000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i23f33e7c9b22442bb753954859fb791f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzI0NjY_078cdbe8-8cba-409b-a27c-17b04f74ed59"
      unitRef="usd">100000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE2NDkyNjc0NDQ4NjA_5e7516d3-559e-4c66-9ecd-5ef043219e16"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i41e5a2f67fb448cdac235b8ab69c2e11_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzE2NDkyNjc0NDQ4NTE_561f82ae-b4a0-4eb2-8bd6-466c4409a566"
      unitRef="usd">700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90ZXh0cmVnaW9uOmRhYTUyZTg4NjVhNzRiMTg5MzllOTVkNzg4NzMyODkzXzMxNzI_466f5166-d950-484f-862d-c47591d1196c">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,338,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,691,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,830,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,118,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItMi0xLTEtMA_dc485b33-cfdd-4799-a54e-560dc0d7e9b8"
      unitRef="usd">4434120</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItNC0xLTEtMA_e27f5d12-0f61-4258-91eb-e7752f8197e2"
      unitRef="usd">4134557</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTpmYjViOTRkZjRiYmI0ZWFkODIxNGY3MDMyMmNkNTVhOS90YWJsZXJhbmdlOmZiNWI5NGRmNGJiYjRlYWQ4MjE0ZjcwMzIyY2Q1NWE5XzItNi0xLTEtMA_ec52b21f-e191-42c4-949a-df1506cceb40"
      unitRef="usd">2769466</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzEtMi0xLTEtMA_6ce493bd-d7ef-4331-8cb2-cec4ef237fdb"
      unitRef="usd">4338247</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzItMi0xLTEtMA_64c72eaa-c0ea-4db0-9232-f6e9edc0aa59"
      unitRef="usd">3691293</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzMtMi0xLTEtMA_728b8113-f1a0-4330-ba8c-fcebb5f35895"
      unitRef="usd">3629001</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzQtMi0xLTEtMA_e4ebaed8-8361-4061-9819-e84ddc6d4c10"
      unitRef="usd">3629001</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzUtMi0xLTEtMA_3a5bfaff-4664-44fa-9659-a2c696148c23"
      unitRef="usd">12830774</cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTQvZnJhZzpkYWE1MmU4ODY1YTc0YjE4OTM5ZTk1ZDc4ODczMjg5My90YWJsZTo0NjBkMDg2MWMzYzI0MWQ1ODRkZmU0N2U4YTk0ZGU1MS90YWJsZXJhbmdlOjQ2MGQwODYxYzNjMjQxZDU4NGRmZTQ3ZThhOTRkZTUxXzYtMi0xLTEtMA_6a1fb5db-889a-4c29-81e2-3774b1fa177b"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEzMg_1446c748-25b8-4539-b381-ba2c76823a76">Other Current and Other Long-term Liabilities&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,072,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,787,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payment for asset purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paycheck Protection Program liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,254,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,084,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,862,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEyOA_9f44d144-4444-4f92-8218-2d898e8869f7">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,072,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,787,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payment for asset purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paycheck Protection Program liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,254,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,084,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzItMi0xLTEtMA_7e4aa675-d229-4324-b649-82745052431f"
      unitRef="usd">4072151</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzItNC0xLTEtMA_298a5566-35fa-43dd-a730-127ef5d900bd"
      unitRef="usd">4593167</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzMtMi0xLTEtMA_176dd4ed-dd7d-49d1-9f7d-402133ef9b93"
      unitRef="usd">998064</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzMtNC0xLTEtMA_c4cec2c6-d2b9-44e7-8f27-80974a897f22"
      unitRef="usd">1295905</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzUtMi0xLTEtMA_b96e6a20-0a59-4b7a-ba18-e18d12711ba2"
      unitRef="usd">2787741</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzUtNC0xLTEtMA_f4107f80-c92e-41a5-93a6-0e54f3ce7fa9"
      unitRef="usd">2374776</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzctMi0xLTEtMA_667f16be-27ce-4db2-b7ba-ec538aa8c6f6"
      unitRef="usd">294000</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzctNC0xLTEtMA_3f560d00-870d-4129-91cd-00f579e3464c"
      unitRef="usd">829047</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedPaymentForAssetPurchaseCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzgtMi0xLTEtMA_fc6685da-03f4-4949-849d-c496d5eb87bd"
      unitRef="usd">0</cpix:AccruedPaymentForAssetPurchaseCurrent>
    <cpix:AccruedPaymentForAssetPurchaseCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzgtNC0xLTEtMA_ca5cad6b-9887-4f7f-b894-25802732d250"
      unitRef="usd">1000000</cpix:AccruedPaymentForAssetPurchaseCurrent>
    <cpix:DeferredAcquisitionLiabilityCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktMi0xLTEtMTUwNg_75baef0a-6a30-4776-be5f-c0ea29291ff8"
      unitRef="usd">2187140</cpix:DeferredAcquisitionLiabilityCurrent>
    <cpix:DeferredAcquisitionLiabilityCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktNC0xLTEtMTUwNg_d14d24b2-e895-4a34-8bcf-99632fe3b84c"
      unitRef="usd">0</cpix:DeferredAcquisitionLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktMi0xLTEtMA_b4f9a475-dfec-49b1-a2b8-a57ab4df23e7"
      unitRef="usd">915285</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzktNC0xLTEtMA_20f07084-870c-4091-aa9d-257f5757919e"
      unitRef="usd">991974</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzEwLTItMS0xLTA_b7bafbd9-a838-4757-bdb5-ece7819c3271"
      unitRef="usd">11254381</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZTphMWZhNDdlMjhjMjg0YjNlYjFjZTY5MDBkMmFkNzM0ZC90YWJsZXJhbmdlOmExZmE0N2UyOGMyODRiM2ViMWNlNjkwMGQyYWQ3MzRkXzEwLTQtMS0xLTA_9d0aa2d6-6dc0-4032-a4bc-797e5550039f"
      unitRef="usd">11084869</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90ZXh0cmVnaW9uOjMzZjliNDk2MGE3YTQzNTRiNmRlYWJiZTM0MDY1MjdlXzEyOQ_251be4ab-2dbd-4d88-9088-2a73a45d000c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,862,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,737,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzItMi0xLTEtMA_88228f28-7a9d-4d7e-b4a4-535d616ef295"
      unitRef="usd">4855363</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzItNC0xLTEtMA_e53cead2-bbf1-46d7-a3a9-1341a0a5017f"
      unitRef="usd">6258813</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzMtMi0xLTEtMA_f09dc451-c5bf-4ade-aadd-fa1cefe10209"
      unitRef="usd">2702772</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzMtNC0xLTEtMA_130f01b0-4b07-4b9d-9083-cab68e34efcf"
      unitRef="usd">2278164</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzQtMi0xLTEtMA_3cb822ef-45e8-45d1-baec-6c66ed227a4e"
      unitRef="usd">304637</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzQtNC0xLTEtMA_b55c35b4-91ff-45bc-89d7-b16a628fcbce"
      unitRef="usd">200346</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzUtMi0xLTEtMA_c010e618-4397-4982-8667-31a9c8f56eea"
      unitRef="usd">7862772</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMTcvZnJhZzozM2Y5YjQ5NjBhN2E0MzU0YjZkZWFiYmUzNDA2NTI3ZS90YWJsZToyZmZiM2NjOWZjMjE0YmNmYWE3OWY5Njc3ZDQ1NGQ3NC90YWJsZXJhbmdlOjJmZmIzY2M5ZmMyMTRiY2ZhYTc5Zjk2NzdkNDU0ZDc0XzUtNC0xLTEtMA_9fedef26-222e-4e67-b86e-8ed080bfd598"
      unitRef="usd">8737323</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzIwODc_c15cd03c-a389-4c82-a73f-1d07d4fc6dfb">Debt&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#x201c;Fourth Amendment&#x201d;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#x201c;Pinnacle Agreement&#x201d;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million, which was also the maximum aggregate principal available for borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was in compliance with the Tangible Capital Ratio financial covenant as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company had $15.0 million in borrowings under the Pinnacle Agreement at December&#160;31, 2020 and $18.5 million at December&#160;31, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90% (representing an interest rate of 3.65% at December&#160;31, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  &lt;/span&gt;&lt;/div&gt;Borrowings under the line of credit are collateralized by substantially all of our assets.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i70f775544b07435aad50e8010203ab2f_I20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQxMDc_2a406edf-3192-4591-ae16-4643595e2d23"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="i70f775544b07435aad50e8010203ab2f_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQxODg_bcb738f5-a123-40e0-9f25-3cdf0cdd5354"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i70f775544b07435aad50e8010203ab2f_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQzNzU_5b12300e-416f-48d7-83db-a64fc18c9a06"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzEyMTU_6f9f7214-8e77-4a56-9281-12beb7a82eee"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzEyOTg_d0afc4ae-61ca-4fcf-a4b5-15a486dff1d2"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id58da084fd084c92baff6faaebe07bce_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE1Mzg_06440619-f6d2-4da9-bd56-413de9c45b40"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermLineOfCredit
      contextRef="icd51265d21714c30b785b162b5e9c52b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE1NjE_ce6bb27f-d817-4df7-93d1-7900825a0431"
      unitRef="usd">15000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i8b442a5827e64fa49e02548ad3d45a60_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2MTc_b7ad82e5-5011-4086-b1c2-6aed55ccec45"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib6ff7e499acb4275a4320c03274a56de_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4MDk_e2f0d8d6-4ee8-4698-b169-a3037fc51c73"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ife2cf763ce1343ebbb8dcb8ca36ad991_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4MTU_af497a4e-be8d-4fe3-bdb3-1a59d6f463f0"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i55a65e98565f481a88b31680ce8e66da_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE2NDkyNjc0NDQ5OTQ_d47fddeb-479d-4298-8add-d7500dacba42"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4a1a4cf98104734ac1e6fcb8443b298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4NTI_1e8fde32-4c0b-4f39-8031-577ef39d898a"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i4867bf18746745d08a2eb39206ceee78_D20170731-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzE4ODY_34a75947-e187-4ada-a240-57427e106d1e"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzY1OTcwNjk3NzI4MTE_7c8d8dba-7e50-484b-b6f6-5fc05c649596"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjAvZnJhZzplYjk1ZmE1NjFmNTI0NTM4OWQ1ZTUxOGYwYzgyZjhkNi90ZXh0cmVnaW9uOmViOTVmYTU2MWY1MjQ1Mzg5ZDVlNTE4ZjBjODJmOGQ2XzY1OTcwNjk3NzQxMDY_7c8d8dba-7e50-484b-b6f6-5fc05c649596"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUzOTU_826f264d-d80f-426a-8682-79ea5ae87f27">Shareholders&#x2019; Equity&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into two million shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2020 and 2019, there was no preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019 and 2018, the Company issued 228,500 shares,  225,536 shares and 170,759 shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2020,  2019 and 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities.  The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020 or 2019.  The Company issued 30,704 shares for proceeds of  0.2 million during the year end December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to 7,500 shares of common stock at $17.00 per share that expired in July 2019.  As of December&#160;31, 2020, there were no outstanding warrants.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 503,626 shares, 623,478 shares and 443,041 shares of common stock for approximately $1.8 million, $3.5 million, and $2.9 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. There remains $6.2 million available under the current repurchase program available for share repurchases at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1 million investment in CET.  Cumberland &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchased additional CET shares through contribution of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.3 million in cash and a conversion of $0.7 million in intercompany loans payable.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for consideration of  $0.8&#160;million that was funded during 2020. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; After the additional investment, the Company&#x2019;s ownership in CET is 85%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g)  &#160;&#160;&#160;&#160;Cumberland Foundation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#x2019;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#x2019;s ongoing activities including charitable contributions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#x2019;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions that were paid to the Foundation during 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(h)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nordic Group B.V.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's 180,000 shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $0.9&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzYy_2329abb5-b2de-4f6b-a7a8-bee6b1de6756">2009-08-10</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzExOQ_0cd58e0c-2334-4059-8ae6-03c596a783c6"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cpix:StockIssuedDuringPeriodPricePerShareNewIssues
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzE2MA_7533466c-2cb0-4177-914a-c87618b04b36"
      unitRef="usdPerShare">17.00</cpix:StockIssuedDuringPeriodPricePerShareNewIssues>
    <cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwMQ_41dcb1bc-0d39-4fed-904a-6bf5e7b4f3c5"
      unitRef="usd">85000000.0</cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering>
    <cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI2Mg_ff04d356-9bd0-48a2-a3d0-df865c4f5d37"
      unitRef="usd">6000000.0</cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMxMQ_f1b85787-ef62-458d-88c2-908c87d0242d"
      unitRef="usd">4200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM2Nw_21aee508-9255-49f0-896d-00fd67ccf269"
      unitRef="usd">74800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering
      contextRef="i3ca2c6df99c3462eb93c19d85ca161c1_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzQ4Mw_7049d1be-df68-4255-89e1-1e65513b2a99"
      unitRef="number">2000000</cpix:StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzU2NQ_c65dd3a4-e593-4d52-a642-a59146f0beb0"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzg0Ng_58b38e03-9ed1-43ee-b89a-8f4b53fe5008"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzg0Ng_7ca2ea81-51eb-4f7a-aa75-1d2b0cb3db74"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i758eec7750904adbaeeedc618ec9d4ed_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzE2NDkyNjc0NDcwNzc_42506b81-cf47-4bfd-87c2-bc692181a83b"
      unitRef="shares">228500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id87ed66521d74e45906ce66041ea4edc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzkzNg_4c926be5-e8c8-4f26-947a-850aa183971d"
      unitRef="shares">225536</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzk0Nw_24469b5f-0256-4bde-9f7d-f347a322476a"
      unitRef="shares">170759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i1de7636956284bbeb962a907482bc027_D20180101-20180131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzEzMzU_c2db9a97-879f-4918-82d0-6493b19aa968"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8144e74e9c3e42f5950f36a5116ba2a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzY1OTcwNjk3ODA0NzI_2735c52d-5970-4df6-bcb8-acc0d399a2eb"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIxOTkwMjMyNzE1MTE_d007aa30-ac22-4599-b0e5-f936d02b9708"
      unitRef="usd">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i367d84ececcc49f0bfbb68634cd626f4_I20091231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwNDQ_c9171410-b1ec-4e44-8b62-33a174a71673"
      unitRef="shares">7500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i367d84ececcc49f0bfbb68634cd626f4_I20091231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIwNzQ_02edce75-2d2e-4290-ab69-8a09fbf87eab"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIyNTM_7ace1496-5d92-47b1-8bb0-76dc9b41f929"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i53a25bb778864bbf9b9a148ad3dc6f9c_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzIzOTg_bd164bf3-e69d-4f88-9004-c1412f13ca0e"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI0ODE_f03894bd-7539-45c5-a3ae-51ee08b194f3"
      unitRef="shares">503626</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI0OTI_b026a0f1-6154-4457-a280-f6cb2bbe31ab"
      unitRef="shares">623478</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1MDY_484f9a37-cbf4-4380-a81f-a126e21af60f"
      unitRef="shares">443041</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2eab4e4ce5ca449eb4f35b6f763ca46d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NTA_41131e7b-4c55-4277-8322-29db75e6b1d4"
      unitRef="usd">1800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3c187b9f29cd484d96bb283e0e20ecd1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NTQ_28440354-cfc6-4a0a-82a6-b3136744b077"
      unitRef="usd">3500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i576e17af1e9748bab6c406493051ea0a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI1NjI_c933b295-f0cb-49c6-b382-0b13b0c8ffd4"
      unitRef="usd">2900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI2MzE_da102a9d-0482-4c2a-b5af-ddf43c323af4"
      unitRef="usd">6200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="iec44f4c9886f4156832890687e6122d3_D20190401-20190430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzI5MTE_5bd0c17b-7373-41d0-908e-47f4079b1b78"
      unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ic84c7f5967af4f5e8cef3f19a6b9f14e_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMyMDE_bd2999a9-3e35-417f-8807-b529ecbcf48d"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMyOTE_b36b023d-712e-4c67-8b2b-ca2477e87064"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <cpix:LoansForgiveninExchangeForShareIssuedAmount
      contextRef="i3c1631d946ea4ca287daac2f9ef8d114_D20140401-20140430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzMzMjI_d6f60960-0c70-4894-ae8a-6a06f102b425"
      unitRef="usd">700000</cpix:LoansForgiveninExchangeForShareIssuedAmount>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="ic6b3f2a63eb749e5981937e0ffd912d0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM1MjM_833b46c1-bcea-4b2f-9a5b-058ee28baa06"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="if2a2c29316304015acd330ba1069f0e5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzM2MDM_b2e24486-ccf7-4d7a-ad3d-b2faec84f7fb"
      unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <cpix:SharebasedCompensationCharitableContributionofSharesShares
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzQzOTM_591b7a94-d3af-4120-8b53-9c10f57d7b57"
      unitRef="shares">50000</cpix:SharebasedCompensationCharitableContributionofSharesShares>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUwNDM_28b26eb4-fcde-42a7-a113-433df2469504"
      unitRef="usd">50000</cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUyODQ_8a65bb6e-f05f-4e37-a60a-22c7373a1333"
      unitRef="shares">180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i741ec6ac47574bcf82703da37c1feef6_D20191127-20191127"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjMvZnJhZzpmNDUwNmZlNmE1Mjg0YzQzYjc5MzBhNzU2NTY5OTY3My90ZXh0cmVnaW9uOmY0NTA2ZmU2YTUyODRjNDNiNzkzMGE3NTY1Njk5NjczXzUzOTM_64cda034-253e-4717-b402-9eff0edcf495"
      unitRef="usd">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMzMA_212a9c8d-f92b-4523-aa73-3420a689cbe9">Earnings (Loss) Per Share &lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.012%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,625,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,418,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,546,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,038,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,339,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,162,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,162,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.019%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMzMw_00f37542-6e19-45a6-a72e-2d21554192cb">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.012%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,625,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,820,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,418,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,546,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,038,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,339,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,963,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,162,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock and stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,162,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtNTYzMw_51d7984f-68ae-4abc-9802-127249d759bf"
      unitRef="usd">-6625779</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNC0xLTEtNTYxNw_329e68fc-7063-49d6-9b26-f30b2b97b406"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNi0xLTEtNTYxNw_99754632-ce1a-4981-8986-36a9cae24f38"
      unitRef="usd">-10820996</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtMi0xLTEtNTYzMw_838de442-e0e0-4536-ae45-99d0b72560e6"
      unitRef="usd">3206875</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtNC0xLTEtNTYxNw_ca1363ad-1ec7-4927-a944-6a1125291895"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzQtNi0xLTEtNTYxNw_b1adc3a4-2a33-4b61-97aa-32edcd4657be"
      unitRef="usd">3782224</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtODg_5937637c-8070-4b7b-b0b8-bedbae675822"
      unitRef="usd">-3418904</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtMi0xLTEtMA_5ca4855e-3371-44b7-83d8-39988a99719b"
      unitRef="usd">-3546511</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzMtNC0xLTEtMA_b0508f4a-5635-4332-952a-18fd554f5ce4"
      unitRef="usd">-7038772</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtNTYzMw_bdd3461b-c51d-494d-9409-55c8528e905b"
      unitRef="usd">-79496</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNC0xLTEtNTYxNw_a8130032-0ce0-431d-bf61-664987595763"
      unitRef="usd">-8752</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNi0xLTEtNTYxNw_5920a68b-7443-4cbc-bdfd-dd416a886443"
      unitRef="usd">-75704</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtNTYxMQ_5a12e5ec-2b4c-4ce0-9e9e-c8893f35be9d"
      unitRef="usd">-3339408</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNC0xLTEtNTYxMQ_53e79cb7-b1fb-414e-bad0-7dc76fefcd9c"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNi0xLTEtNTYxMQ_c241d0d7-e755-4582-baf9-bf9c8d837305"
      unitRef="usd">-6963068</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtODQ_1ea249d1-52dd-42ab-b826-8c6d2c5516c3"
      unitRef="shares">15162184</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtMi0xLTEtMA_a3e5bce1-d53a-4d84-b75e-f9a960e59641"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzYtNC0xLTEtMA_a5ef40f5-9c7c-48ea-96ff-02d96b893240"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtODQ_97ac3961-dd2c-4247-ba19-49b4c94dcbc1"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctMi0xLTEtMA_50802797-1f83-4c1a-ae08-5a4c0a27bd53"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzctNC0xLTEtMA_de2f35d1-c10c-475c-8a8e-1cc3238fad5f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtMi0xLTEtODQ_be14cf47-950c-450f-af55-9b2c5b9cb945"
      unitRef="shares">15162184</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtMi0xLTEtMA_cde171bf-648f-472c-9348-1ab429252670"
      unitRef="shares">15396098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1NjBmNzczOThkMWY0NDk0YmJjNmU2ZWMzNWVlMjkzMi90YWJsZXJhbmdlOjU2MGY3NzM5OGQxZjQ0OTRiYmM2ZTZlYzM1ZWUyOTMyXzgtNC0xLTEtMA_7543989e-2320-4fe3-96d1-1b22b8b68b25"
      unitRef="shares">15614052</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90ZXh0cmVnaW9uOmJiODIxNjg4ZDQ4NDQ2MTZhNTJjMGRkMDk2ODdjNzRjXzMyOQ_d8bcb149-dc6d-4f2a-a459-204b61a427bb">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.019%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItMi0xLTEtOTk_72ee05c2-9997-4a9b-90db-b86202b4a95b"
      unitRef="shares">197610</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItMi0xLTEtMA_77b1d132-2aa4-4b9c-bd9b-e2e95d59b654"
      unitRef="shares">4000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjYvZnJhZzpiYjgyMTY4OGQ0ODQ0NjE2YTUyYzBkZDA5Njg3Yzc0Yy90YWJsZTo1MTdkNDdjMWNiN2Q0NTgwODUzMjI0OGFlYzgyMjg3OS90YWJsZXJhbmdlOjUxN2Q0N2MxY2I3ZDQ1ODA4NTMyMjQ4YWVjODIyODc5XzItNC0xLTEtMA_1bcb5781-1df0-4a7a-8ac4-d9235dc6fe4d"
      unitRef="shares">41650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1ODA_3586facb-1d44-40f1-b44c-173c2d33d2db">Income Taxes&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,961,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,858,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,846,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(662,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,196,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,532,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,196,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,511,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,045,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,153,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 - 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,534,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,829,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,796,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,484,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,939,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2020, 2019 and 2018 reconciles with the federal statutory tax rate as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it is not more likely than not that its net deferred tax assets will be realized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As such, the net deferred tax assets, with the exception of one noted below, are fully offset with a valuation allowance as of the periods ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019, and December 31, 2018.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The only deferred tax asset not offset with a valuation allowance as of the periods ended December 31, 2019 and December 31, 2018 was the Company&#x2019;s AMT Credit Carryforward, which became refundable under the Tax Cuts and Jobs Act passed in 2017.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the balance of the refund related to this credit during the period ended December 31, 2020, and as such, the deferred tax asset has been realized and all remaining deferred tax assets are fully offset with a valuation allowance as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company has general business credit carryforwards of $1.7&#160;million.  These credit carryforwards will expire in years 2021 through 2041.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022-2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company is no longer subject to U.S. federal tax examinations for tax years before 2017, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2017.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2017 remain subject to examination and adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no unrecognized tax benefits in 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzM_6ff5303c-03a6-4fc8-a0be-e6b8d79b8328">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,961,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,858,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,846,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(662,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,313,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,196,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,532,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,196,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,511,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzMtMi0xLTEtMA_9ddcf490-0d21-455c-b932-aa2a66fc07f1"
      unitRef="usd">16961650</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzMtNC0xLTEtMA_7f384338-22b1-46f7-aae1-70972552f2f4"
      unitRef="usd">16964685</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzQtMi0xLTEtMA_1d2877a9-b4e0-4f53-b4cc-f3fae86e619b"
      unitRef="usd">227056</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzQtNC0xLTEtMA_174e9e7d-c02b-4e6a-ad96-7b7faee54489"
      unitRef="usd">227072</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzUtMi0xLTEtMA_3d999990-7036-43cb-a416-2982c6fc1899"
      unitRef="usd">249483</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzUtNC0xLTEtMA_87c984cb-c35e-44ef-9898-0aca8eac4238"
      unitRef="usd">257564</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzYtMi0xLTEtMA_97f57283-eff2-4b31-a161-fa20f91ee6c0"
      unitRef="usd">438235</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzYtNC0xLTEtMA_b06aca5c-181b-438e-9c4f-6aa7bef52710"
      unitRef="usd">469466</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzctMi0xLTEtMA_76eaa6dd-e52b-4f14-981b-a7e2e0017665"
      unitRef="usd">100362</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzctNC0xLTEtMA_cccdbb6e-c1b5-484d-b8c5-8b3b9a01609a"
      unitRef="usd">35227</us-gaap:DeferredTaxAssetsInventory>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzgtMi0xLTEtMA_14aacd4e-834c-4764-ac90-4f1a608c1560"
      unitRef="usd">952711</cpix:DeferredTaxAssetsDeferredCharges>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzgtNC0xLTEtMA_db9d1a11-ccf8-48c1-8329-c4f8f11565f1"
      unitRef="usd">845765</cpix:DeferredTaxAssetsDeferredCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzktMi0xLTEtMA_1c4cac5b-e858-4af1-9e65-7a19361d02d5"
      unitRef="usd">928638</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzktNC0xLTEtMA_49554eb2-e291-4d9c-adb6-60177b075ef3"
      unitRef="usd">1047149</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEwLTItMS0xLTA_b22e48a6-c65c-4d76-8821-36f109b9767a"
      unitRef="usd">19858135</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEwLTQtMS0xLTA_b209e9a9-2fbe-4c40-8874-c2f8806063fe"
      unitRef="usd">19846928</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEzLTItMS0xLTA_41f2cbbd-011a-4c5f-b7d3-2f715893783e"
      unitRef="usd">662014</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzEzLTQtMS0xLTA_be93f4b8-de4a-4635-8fb7-8e251c4d89c0"
      unitRef="usd">1313965</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE0LTItMS0xLTA_0ca6d0bd-9fb5-459a-b697-bb8517a6e94c"
      unitRef="usd">19196121</cpix:NetDeferredTaxAssetsGross>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE0LTQtMS0xLTA_ca383436-254b-408b-862f-c7e10146da90"
      unitRef="usd">18532963</cpix:NetDeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE1LTItMS0xLTA_28bf5cbe-5c77-4009-908f-75b042deafb2"
      unitRef="usd">19196121</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE1LTQtMS0xLTA_bf265110-78c8-46f4-bba0-d15192c9b3a5"
      unitRef="usd">18511161</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE2LTItMS0xLTA_ef735654-a95e-4a37-892c-bdaea9df34ea"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo4ZjNlYTlmOTdmMGM0YTgwOWNkZDY1YmU1Y2JhMTBjYy90YWJsZXJhbmdlOjhmM2VhOWY5N2YwYzRhODA5Y2RkNjViZTVjYmExMGNjXzE2LTQtMS0xLTA_c32e1456-ae1a-4275-85af-38539af4b485"
      unitRef="usd">21802</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzU_7aeff244-ebac-4974-83cd-90ec5f3a4873">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,045,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,153,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 - 2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,534,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,829,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,796,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,484,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,939,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idfc74587ea6e4b529a03805961c2bd04_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzItMi0xLTEtMA_df37de93-5b35-4d3a-bd84-6925f2ddd505"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i445b6f509473418eb2c8a5237c3bfefd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzItNC0xLTEtMA_94cf9ffb-7b2f-44d4-b6eb-8d8a3266c609"
      unitRef="usd">4342464</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie4313b14cb3a4d8f99fd5c8f9db1107d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzMtMi0xLTEtMA_9bb54211-93f5-4fca-9ed8-cd91beb8e040"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6847c5f2fcc44c1580a9549a452c791d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzMtNC0xLTEtMA_040e0b5a-c89c-4df9-a63c-951ee5ee523a"
      unitRef="usd">45045442</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9043384394c24481b001b6c237c321ee_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzQtMi0xLTEtMA_2335833c-92b8-48c1-8618-bdccf3f3afd0"
      unitRef="usd">44153819</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1fe6d71cfdbe4024a8518ad7bd357ab3_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzQtNC0xLTEtMA_142af6ac-3fee-4614-ab7e-89242caacc7a"
      unitRef="usd">458802</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iac92a1fad73b426db25cdc60a91363c0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzUtMi0xLTEtMA_dcdb2160-5bbe-457d-bfe5-197afc89f88f"
      unitRef="usd">7534351</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i361f3e2163a24e0599504b3aaa2131ea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzUtNC0xLTEtMA_936f77f6-29a0-4ef1-86df-46f66790c813"
      unitRef="usd">9829212</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9a8201ead17c4f4c9fab01031ebfa723_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzYtMi0xLTEtMA_e1563e00-e304-49cd-b0fa-e0fed2fb2292"
      unitRef="usd">4796324</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic3c2aba4cd314aabbe1faee299611416_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzYtNC0xLTEtMA_219a4a58-1f46-478a-b981-1b47ff131090"
      unitRef="usd">263861</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9d8a2a14899b4ec1a64b4b7a8ed1abda_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzgtMi0xLTEtMA_3ad089f2-5d87-4d4f-b917-cf2fe497df08"
      unitRef="usd">56484494</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i236e3d373ccf4b22afd608a82ed75788_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTpjZjljYjVmMzI0MWI0OWExODhiNWJkZmM5ZDVhNDIxNS90YWJsZXJhbmdlOmNmOWNiNWYzMjQxYjQ5YTE4OGI1YmRmYzlkNWE0MjE1XzgtNC0xLTEtMA_be3e5535-983f-4007-818e-cdae79fb17cd"
      unitRef="usd">59939781</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzY_365490eb-5053-4066-bf75-6eb115a5e58b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtMi0xLTEtMA_ae473c09-155a-46c4-aedd-a777ecbbc98c"
      unitRef="usd">-21802</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtNC0xLTEtMA_8c28bbe4-a757-48ce-92c5-b519659a655d"
      unitRef="usd">-65408</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzMtNi0xLTEtMA_06adb68d-cbc4-408f-8887-00d3257d6c44"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtMi0xLTEtMA_348cd3bb-eb71-4c39-b6e8-fe6115e226f3"
      unitRef="usd">55902</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtNC0xLTEtMA_8e5ac50a-009c-41e3-8fd5-b50130a57e70"
      unitRef="usd">-79316</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzQtNi0xLTEtMA_1bc65029-fcb0-4088-8eb7-829b49bd9e2b"
      unitRef="usd">16636</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtMi0xLTEtMA_1cdf0e41-b2ee-41b5-998f-4c18efaf3dac"
      unitRef="usd">34100</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtNC0xLTEtMA_7fddf1fe-c88e-47f5-a730-248e9d6d5cc1"
      unitRef="usd">-144724</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzUtNi0xLTEtMA_b3eda7db-9c0d-4818-a64f-f3c5bcbb2ff7"
      unitRef="usd">16636</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtMi0xLTEtMA_ff5d724f-e670-4a3e-93db-392a62404b5e"
      unitRef="usd">21802</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtNC0xLTEtMA_eef80a69-ef3a-4c68-b170-7acd3393a6ea"
      unitRef="usd">65408</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzgtNi0xLTEtMA_b5185362-7670-44b7-80aa-ada871e74779"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktMi0xLTEtMA_1efb999b-b741-42df-a7b1-a123c18f49d6"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktNC0xLTEtMA_ba25438c-550c-409a-822a-e29d6abe85fe"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzktNi0xLTEtMA_f5312c2f-d0ef-4075-af27-45939ec62d2c"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTItMS0xLTA_a934a7f6-07bc-4941-aadf-535fe0938115"
      unitRef="usd">21802</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTQtMS0xLTA_c378bb45-462c-46ae-a267-d55b6090c45e"
      unitRef="usd">65408</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzEwLTYtMS0xLTA_5bb118a5-e59b-4433-a2e6-ff08a72f0f11"
      unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTItMS0xLTA_68810260-753b-4320-b664-e0ffe8d6cdf4"
      unitRef="usd">55902</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTQtMS0xLTA_5287e737-1841-4eff-8abf-463f627ef64e"
      unitRef="usd">-79316</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTphZWUxMjIwOTgyYjU0NzIwOWJiMjMxN2QxMjMwM2YyNi90YWJsZXJhbmdlOmFlZTEyMjA5ODJiNTQ3MjA5YmIyMzE3ZDEyMzAzZjI2XzExLTYtMS0xLTA_c0323787-d3dd-449c-a00e-d9cee722c823"
      unitRef="usd">16636</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzI1NzE_b776115f-1244-46b8-a44b-f769b7e8d802">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2020, 2019 and 2018 reconciles with the federal statutory tax rate as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItMi0xLTEtMA_5ebd3864-6400-41fd-8d94-b8ce9c8f2dbb"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItNC0xLTEtMA_d10ceb49-81bc-47ad-845e-ea070adbf380"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzItNi0xLTEtMA_3aa31965-d01d-4358-bdf6-0ed8cc382417"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtMi0xLTEtMA_3699b77a-b766-4689-a3e6-a152fa1817ca"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtNC0xLTEtMA_fc786a51-c975-45d1-a937-78ff31a9bb2e"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzMtNi0xLTEtMA_bec523d6-5bff-405e-a3c9-5b6525323e57"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtMi0xLTEtMA_25f335c5-7e40-4850-b3e8-b88a39a83801"
      unitRef="number">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtNC0xLTEtMA_fd11cf33-0b97-4fc7-943d-db6bfb877d2e"
      unitRef="number">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzQtNi0xLTEtMA_1fbc3df1-7f91-4dca-b499-6c562aaad7a8"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtMi0xLTEtMA_7f987e89-1972-4403-9627-257dffe35005"
      unitRef="number">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtNC0xLTEtMA_adeff1c7-a69f-478d-b80d-b811e192ac93"
      unitRef="number">-0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzUtNi0xLTEtMA_9f62475b-22b5-4a36-b44f-12a9ea2e96f0"
      unitRef="number">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctMi0xLTEtMA_d2809e33-4651-462e-89f7-12fe7d7dea99"
      unitRef="number">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctNC0xLTEtMA_b734db82-89fc-44b2-b683-2eb29b860c83"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzctNi0xLTEtMA_f008bb9b-b7e1-426b-aa73-a82252db43fd"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtMi0xLTEtMA_e00bc70a-3934-4021-bcd5-978b70c013f3"
      unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtNC0xLTEtMA_038fdd95-b6ef-45df-a9c7-4707c7d28c3e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzgtNi0xLTEtMA_fe26eec9-226c-4a6c-aa39-19f661255289"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktMi0xLTEtMA_0a6dff25-5146-4232-8344-7c2b2335d555"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktNC0xLTEtMA_5d20861b-de56-46d3-bd2c-e06a754b0598"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo5MTkxOTliYmZiYzQ0NDYzYWI5OWE5M2Q1ODcwYWZlZS90YWJsZXJhbmdlOjkxOTE5OWJiZmJjNDQ0NjNhYjk5YTkzZDU4NzBhZmVlXzktNi0xLTEtMA_1b311e6d-a42a-4b0d-aa16-92441c99e5c7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzIxOTkwMjMyNjIxNzg_f740a14a-682c-4611-961d-c2ee536185c4">&lt;div style="margin-top:8pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company has general business credit carryforwards of $1.7&#160;million.  These credit carryforwards will expire in years 2021 through 2041.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022-2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie9167ce1de284dc593328aff87ed8bcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90ZXh0cmVnaW9uOmI2ZThhMmMzYzkwZDRhNzA5ZDc4M2E1Y2ZjYzUwNWRjXzIxOTkwMjMyNjIxNjU_dd1e5c37-30b2-499e-8e48-d44c8a44d0a7"
      unitRef="usd">1700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia5562813807040e1a0e26ee6bf76c4b6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzEtMi0xLTEtMzg5MA_3e1ee6f2-5fec-4cc7-bdde-62ee75ff0af4"
      unitRef="usd">173475</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie4051af70f9c4b60b1d310d19369cccb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzItMi0xLTEtMzg5MA_0b6b75b0-cf26-469c-b33f-ab07abfff167"
      unitRef="usd">622276</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9db379efa0bc4679a685f33d31ca995f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzMtMi0xLTEtMzg5MA_16d1c849-17fc-488d-b81f-f79d147f550c"
      unitRef="usd">836129</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4f1831e9cb7e4498bb1e5fac039825fa_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzQtMi0xLTEtMzg5MA_566f332a-4117-43c6-b497-95460f058904"
      unitRef="usd">97244</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie9167ce1de284dc593328aff87ed8bcc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMjkvZnJhZzpiNmU4YTJjM2M5MGQ0YTcwOWQ3ODNhNWNmY2M1MDVkYy90YWJsZTo0YjI3MjZjOTZlZjU0MjhlODg3Y2ZjMWY3MzRiZTg2YS90YWJsZXJhbmdlOjRiMjcyNmM5NmVmNTQyOGU4ODdjZmMxZjczNGJlODZhXzUtMi0xLTEtMzg5MA_7ac00299-26af-4cb2-9052-684d6f9dcbd8"
      unitRef="usd">1729124</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDk_14d479e9-bcb2-4981-a9eb-88c22760c1e9">Stock-Based Compensation Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under three equity compensation plans, with two of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#x2019; Incentive Plan (the "Directors&#x2019; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#x2019; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#x2019; Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was approximately $1.7 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 2.28 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any stock options and there were no options exercised during 2020, 2019 and 2018.    As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of restricted stock granted was based on the closing market price of the Company&#x2019;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzgy_f6820fca-5cb0-426e-a4a4-ccf245e4da01"
      unitRef="plan">3</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzExNw_5671ca67-1699-487a-b132-9e175c8e2e5f"
      unitRef="plan">2</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia24d0d8e81234fb38c59ac70536998b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzczMg_36608d6b-4348-44a2-a9d1-c2e0a75c5382"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4d13571f70a74cbea8cc3c2e111cf699_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzc5NQ_1fb2ab28-fcd7-4cfc-8630-7dff76b4168e"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue
      contextRef="i5b054a3338614ef4a60b55fb3e0f0983_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0Xzg5NA_9fc90c03-a837-4148-a22a-536ece1f2ddf"
      unitRef="number">1</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i39407155449e4cd7b91cf9a0ea955c04_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzEwMjE_f16f0258-7896-472e-b3cc-b8e96ccd1641">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifdf5204bce4e4cf08f3110023af611f2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzExMjA_2dd1e185-0469-4060-8397-2a205d84c34e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iaa1083c517cc425bada8b162234c0222_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzEzOTQ_4c7231be-89d3-42d0-87a2-e323dc739c88">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDU_4bbd152a-1533-484a-a8e8-4429f9e935ba">Stock compensation expense consisted of the following for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2f2761c3aa61481e9ce768736d55283b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItMi0xLTEtMA_6e2a1283-a505-4f15-9f3a-6db62f600a45"
      unitRef="usd">1050179</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if048f68b276d4efaaa2f710dc15c58ed_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItNC0xLTEtMA_988a811f-86e4-4de1-a132-3db4a69f8507"
      unitRef="usd">1481016</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i75bc44001e5247da87aaaa6fe49004cd_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzItNi0xLTEtMA_41343da2-a398-4b44-bf89-4f9d08cfd5de"
      unitRef="usd">1244606</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i436eb42902d244599c0bc8375f08440b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtMi0xLTEtMA_3ae0f9a3-3feb-4213-87e7-082fae0d02dd"
      unitRef="usd">-3663</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i55c8902a15624a57913ab5e23c482d70_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtNC0xLTEtMA_d84e1d7a-e314-47ac-8bb2-aad4f62e28e9"
      unitRef="usd">4882</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3d39a8afd7a4f5485dc0d057ab6de51_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzMtNi0xLTEtMA_31b74ea4-0e61-428e-8232-4b43fec5b5e1"
      unitRef="usd">120092</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9cfd07629518431490765805546dcdd3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtMi0xLTEtMA_3c27ab3e-ab65-4786-9e4a-98681e360bc4"
      unitRef="usd">1046516</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf145f8d53f142ea820e0fca8cf49972_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtNC0xLTEtMA_c0b1c058-88e0-484a-9ba4-3b81075d5b74"
      unitRef="usd">1485898</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifa6739e7f70b46089b224643faa80db4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZToyNWZjMjk3ZjJjMDY0ZmZkYTY4NWMxMTMzZjNiN2IwOC90YWJsZXJhbmdlOjI1ZmMyOTdmMmMwNjRmZmRhNjg1YzExMzNmM2I3YjA4XzUtNi0xLTEtMA_411619da-d7d3-4946-ba70-df6f399966d7"
      unitRef="usd">1364698</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzE2OTE_e7aec74c-01aa-4a81-bfb9-32176928ac2f"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzE4MzA_0012718f-570d-4ca4-bea0-7de5a7fc8655">P2Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MTE_670a9d31-4298-49a6-9817-d130b05254fc">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItMi0xLTEtMA_0c6486ec-5430-44ad-a1c4-44690be2fea1"
      unitRef="shares">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItNC0xLTEtMA_fcaa4aab-f80b-47c7-8328-c69a82ea4257"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItNi0xLTEtMA_d6f330cb-3bc7-4744-b4b5-b739d75cef2a">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia9902b1e772a4972957eb8992b200e37_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzItOC0xLTEtMA_00eaa2cb-28f7-46ae-ad5c-90fe0200094c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzMtMi0xLTEtMA_d93c71d7-f723-4c92-a037-19b0d0c3e6d6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzMtNC0xLTEtMA_86da7ffa-3c27-4349-ad71-b53e4aa3fadc"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzQtMi0xLTEtMA_6721cfa6-ed26-421e-84ca-69864c23d094"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzQtNC0xLTEtMA_67b0818e-b253-4f64-be9c-f5c03ddb39b7"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzUtMi0xLTEtMA_4348cbcb-b119-4382-8df3-db4bacf3a2bf"
      unitRef="shares">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzUtNC0xLTEtMA_cb498b98-3299-4c31-bbc4-04b95808f263"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtMi0xLTEtMA_41968597-08f1-4bea-b066-e7799fc85bb2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtNC0xLTEtMA_54328507-5df7-4549-aa84-58d3c3b8364c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzYtOC0xLTEtMA_35bbcdec-df05-4632-868c-6363b0dd42d0"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzctMi0xLTEtMA_a767dc8d-b698-4f42-aa01-6727e124ca32"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzctNC0xLTEtMA_0177ca75-619a-473e-a2ed-f0a2e2cb1c41"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzgtMi0xLTEtMA_676c62f6-e541-4325-bdf3-e401bff9a52b"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzgtNC0xLTEtMA_72261aef-5031-4ad4-82f4-e4637e02d6ff"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzktMi0xLTEtMA_b4647b36-2408-4120-aa05-b032f985d814"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzktNC0xLTEtMA_b7ca40c5-1041-4ed5-b0ea-49f2d4e1d028"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTItMS0xLTA_8b37f7cc-ae25-4941-9f8c-2f4f9e34732b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTQtMS0xLTA_a36fcc22-27d6-4d5c-9548-fdfe362b3125"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzEwLTgtMS0xLTA_e26e59dc-a795-4d4b-b5b9-1bf30a608d33"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTItMS0xLTA_b86cd9a8-69b2-4e80-9daa-959676566304"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTQtMS0xLTA_8189ae41-97a6-43c5-a284-0394e0887822"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTozNmZiMzZiNDVmMWM0YjY4OTMxZDNkOTI0ZmQwYjE2NC90YWJsZXJhbmdlOjM2ZmIzNmI0NWYxYzRiNjg5MzFkM2Q5MjRmZDBiMTY0XzExLTgtMS0xLTA_e01b89c5-951e-49e8-a987-5e6069bbd588"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90ZXh0cmVnaW9uOjAzZGU1MWJjZWM1NTQ4NGZhYjI3YzYyZjI3NjlkMTc0XzI2MDg_50e8d566-cb1a-427e-917a-6519d26c9772">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i18c4af7e297f4bdb9156fe284ac15e52_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzItMi0xLTEtMA_81e44482-ed40-4bf5-aa9c-d31c356bd8bb"
      unitRef="shares">833741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i18c4af7e297f4bdb9156fe284ac15e52_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzItNC0xLTEtMA_5c0d81f4-01e3-45ac-a01f-3a24ffb99557"
      unitRef="usdPerShare">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzMtMi0xLTEtMA_9f02ba0d-4d52-4735-9066-86e2ca360d91"
      unitRef="shares">229669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzMtNC0xLTEtMA_517041af-ef80-42b6-a103-f8a5353052f3"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzQtMi0xLTEtMA_b0ad7179-8732-4ebf-a609-1db0b445ab54"
      unitRef="shares">225536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzQtNC0xLTEtMA_7f9583fe-a3de-4cad-9b8a-e315016db5d2"
      unitRef="usdPerShare">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzUtMi0xLTEtMA_97d0e043-3a1b-4db4-9bd2-2ffc7aebb777"
      unitRef="shares">22925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5126864d4086482f8ca3437664a5be84_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzUtNC0xLTEtMA_68223aae-c858-4190-b154-3480d827ec6f"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i622af044beba4bd281a739b794311672_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzYtMi0xLTEtMA_8bf43363-6a9d-4dfa-8098-ddd9fb617bb7"
      unitRef="shares">814949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i622af044beba4bd281a739b794311672_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzYtNC0xLTEtMA_b6b050d1-8ba9-4cd4-9865-e4f750393178"
      unitRef="usdPerShare">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzctMi0xLTEtMA_d8f1abb9-0ec7-42bb-81d1-0a4daf6c0381"
      unitRef="shares">231091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzctNC0xLTEtMA_b025fb3a-3a55-41e8-a667-ce37b4dfdad3"
      unitRef="usdPerShare">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzgtMi0xLTEtMA_15890b4a-61d3-4170-b2f9-f886a67a1bda"
      unitRef="shares">228500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzgtNC0xLTEtMA_5e828a00-a8b3-4f43-897e-9345c84d0031"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzktMi0xLTEtMA_7735417f-96ee-4dc9-a8f4-a45958b28381"
      unitRef="shares">38125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic61129d8d63543738b86732ebf66f7c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzktNC0xLTEtMA_abf49b51-a58b-46b5-8d3f-bb8c76298807"
      unitRef="usdPerShare">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzEwLTItMS0xLTA_5483fcd2-5a19-49c0-9911-4c796346be2d"
      unitRef="shares">779415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie3845c3472b14a1fa15a1392ae5fb2c3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yMzIvZnJhZzowM2RlNTFiY2VjNTU0ODRmYWIyN2M2MmYyNzY5ZDE3NC90YWJsZTpmNDk0NzBkZjkyM2E0MTEyYTE1NTRlMDg1NWQ4MzYxMS90YWJsZXJhbmdlOmY0OTQ3MGRmOTIzYTQxMTJhMTU1NGUwODU1ZDgzNjExXzEwLTQtMS0xLTA_7a40aa7d-b8c5-48b6-8932-772f7606dbeb"
      unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8yMTk5MDIzMjU2ODk2_2c2209a7-ad0a-4725-b4f8-b46c191125d2">Employee Benefit Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2020, 2019 and 2018, the Company contributed approximately $50,000 in each year to the Plan as an employer match of participant contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $2.7 million and $2.3 million as of December&#160;31, 2020 and 2019, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.9 million and $3.1 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4MDcz_a3b834a4-951b-4ca5-8fd7-c199dd40bd90">P21Y</cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4MTI3_67b834dd-94d6-4f3b-b3d8-842c9fe6a7cc">six months</cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_162befc8-307c-4fd6-83dc-62bad86ac4f1"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_40749508-5126-41d6-91da-977d1a33c377"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4NDU4_dea2ee73-00d7-4df7-a335-7416fe5a1904"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4ODE5_7597f305-342b-436b-beaa-741a96a33f41"
      unitRef="usd">2700000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI4ODI3_283994af-c37a-4380-a6df-eb8fefffd69f"
      unitRef="usd">2300000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI5MDc2_d0b11d3e-ab04-4214-b6f7-e04b355813b5"
      unitRef="usd">2900000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18xMjY4L2ZyYWc6NTg2ZDA5Mjc5ZjJmNDMwOWJjOGNkY2VlNDg3NTc5M2EvdGV4dHJlZ2lvbjo1ODZkMDkyNzlmMmY0MzA5YmM4Y2RjZWU0ODc1NzkzYV8xMDk5NTExNjI5MDg0_f5274362-1fc5-433c-821b-7ef54c2c788d"
      unitRef="usd">3100000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTI_c93d526e-e933-4ea2-9750-4a66158ab382">Leases&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 2.0 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company recorded the following on the Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.4 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTU_9de57fbb-d08c-49b2-b7cf-a936bd994a47">Rent expense and sublease income  as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItMi0xLTEtMA_a495c07b-85ad-4bd6-be55-4b7682601b55"
      unitRef="usd">1166411</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItNC0xLTEtMA_ce601580-bdb9-4d48-9471-34ed73081890"
      unitRef="usd">1246143</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzItNi0xLTEtMA_b39f3280-3fc1-448d-bd30-6ae65f4049ad"
      unitRef="usd">1136610</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtMi0xLTEtMA_ed0baa1e-b77b-4a06-a3c9-bff257219353"
      unitRef="usd">680627</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtNC0xLTEtMA_0a57d9e0-5cd1-4c07-900d-f5c152dff071"
      unitRef="usd">688020</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyZWViNTE1MmQ1MDA0NWZmOTRmMmU1MWUyY2RmMzk4Yy90YWJsZXJhbmdlOjJlZWI1MTUyZDUwMDQ1ZmY5NGYyZTUxZTJjZGYzOThjXzQtNi0xLTEtMA_f4477892-9d03-45aa-b367-837a4c878657"
      unitRef="usd">662358</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3NjY_ece1f622-0e63-4f99-a6eb-68353715a017"
      unitRef="usd">3.6</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i48050618fd9d4e7e8a09489e02bf5f0a_I20190101"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3NzU_e19012c2-bc93-4260-bef6-bbb8e3f04428"
      unitRef="usd">3.8</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzMzOTg_1aec31e2-4a56-4fdf-810f-1d1c9c5cbcda">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzE2NDkyNjc0NDU3ODQ_d9beaf12-5f58-47bc-acee-47fd08160bfc"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTA_ca786b5e-e601-42f2-98a5-ea18e3b880bc">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company recorded the following on the Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo3NjZjZGQ0NzI3YjE0NjdhYTg3Nzg4ZDM1OWY1Y2E4Zi90YWJsZXJhbmdlOjc2NmNkZDQ3MjdiMTQ2N2FhODc3ODhkMzU5ZjVjYThmXzEtNC0xLTEtMA_47d5e4a3-1618-43f4-8125-53e508e4c057"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo3NjZjZGQ0NzI3YjE0NjdhYTg3Nzg4ZDM1OWY1Y2E4Zi90YWJsZXJhbmdlOjc2NmNkZDQ3MjdiMTQ2N2FhODc3ODhkMzU5ZjVjYThmXzEtNC0xLTEtNDM3NA_a594d16b-9733-4962-a6e9-6feb0e16e671"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzEtMi0xLTEtNjAwNA_f648d6d7-26d2-4ded-9f8a-189034c10f4e"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzItNC0xLTEtMA_b98f97ba-9f3c-44ce-a0ba-c463e1631f50"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzItMi0xLTEtNjAwNA_bf7b082a-7cc9-4e53-971a-de52ea6b162a"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzQtNC0xLTEtMA_6fd74cb0-1ed5-4135-a3fa-7c1b7ae0013c"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzMtMi0xLTEtNjAwNA_b77a299c-5d25-4063-bbce-294141ef9d12"
      unitRef="usd">2076472</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZToyOTQ4ZTFlN2VjY2U0NjRiYmVlMTljMGQ4ODZhODI4Mi90YWJsZXJhbmdlOjI5NDhlMWU3ZWNjZTQ2NGJiZWUxOWMwZDg4NmE4MjgyXzUtNC0xLTEtMA_66290cc7-895e-4ab7-9554-81bef6a35c7a"
      unitRef="usd">2996903</cpix:LeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzM3NTU_93d4f5a9-6027-4f52-b850-016b1aa17e30"
      unitRef="usd">400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90ZXh0cmVnaW9uOjMyYzRjZmEwMWMzZTRmNzE5OGM1ZTdhZmIzMjI3ODNjXzQwOTc_eb2ab916-68c2-4f29-afca-325c7cbe336f">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzItMi0xLTEtMA_2e7e2083-e05f-4492-8108-aaa22881cada"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzMtMi0xLTEtMA_fbc11469-eb06-491a-9b21-2c9b0f8b4ef6"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzQtMi0xLTEtMA_8501c0a9-5fb3-4c7f-b6c4-2f0388040ec5"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzUtMi0xLTEtMA_e63726a0-020f-4c41-8da5-69aaaa01dc2a"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzYtMi0xLTEtMA_5a05e705-388a-4e7c-9470-216a8971fa1e"
      unitRef="usd">2256680</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzctMi0xLTEtMA_c3eb6d28-92a7-499c-a719-54f01f867139"
      unitRef="usd">180208</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDQvZnJhZzozMmM0Y2ZhMDFjM2U0ZjcxOThjNWU3YWZiMzIyNzgzYy90YWJsZTo5N2E0NDQwZjcyZjU0MmJkODQyNDdiNjA2ZGYxZDdkMy90YWJsZXJhbmdlOjk3YTQ0NDBmNzJmNTQyYmQ4NDI0N2I2MDZkZjFkN2QzXzgtMi0xLTEtMA_79db6fb9-0a79-417b-9846-75913f9d1fbe"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90ZXh0cmVnaW9uOmRjNjFjZGE5N2MzYTQxNzdhNjAzOGJjNmJkYTQxZTdmXzY4OA_dc6169db-d119-4e8b-9eef-90c4cb955ad0">Fair Value of Financial InstrumentsThe Company owns marketable securities that had a maturity date of less than ninety days and are classified as cash and cash equivalents at December&#160;31, 2020 and December 31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The fair values of all other financial instruments outstanding as of December&#160;31, 2020 and 2019 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2020 or 2019.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90ZXh0cmVnaW9uOmRjNjFjZGE5N2MzYTQxNzdhNjAzOGJjNmJkYTQxZTdmXzY5MA_79fdfce5-305d-426d-bbfe-fb40efe2afce">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i7c6d1b5895064141892cc9e1fa697991_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMi0xLTEtMA_2d8d4a24-93e1-46a6-9c25-a25e01199dc0"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9f6a5312e3d74395bd3c1db13869d99c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktNC0xLTEtMA_6e1a491c-70fc-4e02-8194-f92450792ad9"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iaa7aeecc41504677b76f853c9fa184a6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktNi0xLTEtMA_4585cc64-a7e2-4493-9504-a2e0659bc567"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iffbd7aad4f8a44158c186bd69006fa50_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktOC0xLTEtMA_3f8e6ee3-f01d-459a-b6d2-960331838a0f"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4b530f82b6fe471b9506787cb064425d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMTAtMS0xLTA_05b05fe5-6f01-4a8e-aec9-50c0a41ea7e4"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i48a19579f22c4af496dcb8ed57b17e7f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzktMTItMS0xLTA_5aabcde2-ff7e-41ce-b3fa-cf84d372a2e3"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i035fe245e98f4edc8662280dfb190881_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTItMS0xLTA_14387580-63da-435e-9311-66fc1d6e4241"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iafad14dcd0734e159d5dc98d6debe999_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTQtMS0xLTA_18de4198-c614-4a6b-8421-34023324d9ad"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTYtMS0xLTA_6a303e57-ef33-4aa5-b506-d970c726d237"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idb72fd4e685045b9b3f14ba16be19e8f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTgtMS0xLTA_19f00706-e348-4ad9-928a-feed4f9b60b8"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id995a6b3c61f46a2916306ecd8f86ea5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTEwLTEtMS0w_269d8d92-9b3c-499d-a8b6-ae660e9a6bfe"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNDcvZnJhZzpkYzYxY2RhOTdjM2E0MTc3YTYwMzhiYzZiZGE0MWU3Zi90YWJsZTo4Yzc1NDRiYTc3NmQ0ZTllYjNmN2JhY2NiZDM2NDg1Yy90YWJsZXJhbmdlOjhjNzU0NGJhNzc2ZDRlOWViM2Y3YmFjY2JkMzY0ODVjXzEwLTEyLTEtMS0w_56db1940-17b8-4203-94d6-7489a02a03f9"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3XzkwMg_bd8aab4c-d7f4-463f-b850-848a65b7eeb3">Market Concentrations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#x2019;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#x2019;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;*: less than 10% of total&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 60% and 59% at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3XzkwNA_17f7931f-c752-4dc7-bcf9-447a21ebc523">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;*: less than 10% of total&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0806af42e92d434b8380cece41bef2f1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItMi0xLTEtMA_91f638a1-15bf-4fb4-8fdb-7f45e22341ae"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idca38735f6bf48f89c09c2c85125ba89_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItNC0xLTEtMA_04e1c939-1a6a-4c2d-8532-4f561ef0eceb"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib1aaf67bebf341cea9c892fb47997567_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzItNi0xLTEtMA_930a868e-1feb-4038-8d75-9e5d4b60a257"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i187575b302fb41bd9ee6b605b4f68a30_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtMi0xLTEtMA_4f041eb8-0639-4306-abc2-cfbc6a72326d"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i419ec7ac9d4f423c8c8f73bf9a5da296_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtNC0xLTEtMA_d9935c0c-d9b0-4961-a5ee-dc7af20079a5"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i78ce3c4a1d02440f8d5624232436389b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzMtNi0xLTEtMA_055eb7de-d723-464c-b4db-5b6d8f2f4f0c"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4d8fefbac99d4eafb16b2bf8a3836ae2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtMi0xLTEtMA_14f92925-e1c5-41d1-b39d-7944816c97ee"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if8c14abd94304867b117e4fea7e033be_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtNC0xLTEtMA_9c55cbc7-05f7-4acb-9966-4c3e72beb535"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i010aee2814cf4f14bce2ff9dacf24d5f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90YWJsZTpmMjM1ZWEyNzliMDE0MDcyYTIwMGM2ZmRjMmY4MWQ3Mi90YWJsZXJhbmdlOmYyMzVlYTI3OWIwMTQwNzJhMjAwYzZmZGMyZjgxZDcyXzQtNi0xLTEtMA_5059b973-96cc-4ecb-893f-9a699e7e4569"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6777a90bade44e95aedf63f8638b5d8f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3Xzg2Ng_def5e0a8-7675-4fa7-80d5-bd134936a3a8"
      unitRef="number">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i053e86b30f9f453cb231c55d294c07a9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTAvZnJhZzowNTc0NTE2MTFkNzc0MjU4YmM3Y2NhMTAyYmQ0MzlmNy90ZXh0cmVnaW9uOjA1NzQ1MTYxMWQ3NzQyNThiYzdjY2ExMDJiZDQzOWY3Xzg3Mw_32cfe51e-774e-46e9-8fed-3cd21dda8f2e"
      unitRef="number">0.59</us-gaap:ConcentrationRiskPercentage1>
    <cpix:ManufacturingAndSupplyAgreementsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzYzOQ_a349fa0c-80b9-436a-b65d-291f7dc3d4e1">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</cpix:ManufacturingAndSupplyAgreementsTextBlock>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="ie52ad4b1821b40aeaa322dea12dec215_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzY3_b6e93957-9215-4864-b0f1-34b098c7af90"
      unitRef="supplier">1</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="ic3a82fe51f4445d5a9623b513f48b606_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTYvZnJhZzpmYWZiMTUyNDdkM2M0OWJkYmFhYmI3ZDMzMjZmMmNmMy90ZXh0cmVnaW9uOmZhZmIxNTI0N2QzYzQ5YmRiYWFiYjdkMzMyNmYyY2YzXzcz_590eca5e-cc47-4991-a0cc-b3557cdae893"
      unitRef="supplier">2</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:EmploymentAgreementsTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNTkvZnJhZzpkZWJhYTUwOWQ5MmM0YjA5YTEyOTY0NTFhOGY0N2NhZC90ZXh0cmVnaW9uOmRlYmFhNTA5ZDkyYzRiMDlhMTI5NjQ1MWE4ZjQ3Y2FkXzMxMA_aaf77e16-60e5-4425-ac89-8fcd444f47b8">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.</cpix:EmploymentAgreementsTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzIzMzk_bf3ec397-023d-482b-9c5a-a1d453cb7c41">Discontinued Operations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#x201c;the Products&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgzNDA_72c8f2e7-a907-47b1-a9cd-8d46f8f9cdb2"&gt;two&lt;/span&gt;-years following the transition date.  Cumberland recorded the first four quarterly installments totaling $3.0 million during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Subsequent to the transaction date, th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,145,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,396,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,149,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2019 current assets associated with discontinued operations included $0.5&#160;million in the remaining &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inventory for the Products sold and returned to Clinigen as part of the transaction.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgyNjk_f1b9a849-0e6b-4960-a28e-30691f3bafc6"
      unitRef="usd">5000000</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NTExNzU_efb95933-6e5b-443e-87e5-b22761644e33"
      unitRef="usd">3000000.0</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzkzNDU4NDg4NDY2NjU_f4e19211-f66f-48cd-afaf-58ee822adfb1">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Subsequent to the transaction date, th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,145,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,396,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,149,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   &lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities associated with discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItMi0xLTEtNjExNw_52226e24-55a9-4522-af2f-4c3216ad85ec"
      unitRef="usd">3206875</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItNC0xLTEtNjExNw_b28138d3-bdc4-41c8-8d27-1eb6609d941e"
      unitRef="usd">13145344</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzItNi0xLTEtNjExNw_f123d5b3-9335-4ad8-800b-b7166d9bf76e"
      unitRef="usd">11396871</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtMi0xLTEtNjExNw_9dcf7010-2fd2-4f1a-ab8b-ea93481811fe"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtNC0xLTEtNjExNw_db801180-9123-44a3-9669-602acd387d4f"
      unitRef="usd">1330704</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzMtNi0xLTEtNjExNw_2068df5f-0452-45e8-9647-94406d0a2d66"
      unitRef="usd">1361273</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtMi0xLTEtNjExNw_62ed0155-c736-448c-ad86-d6282e0f3208"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtNC0xLTEtNjExNw_57ef8a7e-e566-4e64-936a-15f9fab68652"
      unitRef="usd">6149463</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzQtNi0xLTEtNjExNw_4ed3c2c9-da2d-4eb1-bbd3-87b3411c9187"
      unitRef="usd">6253374</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtMi0xLTEtNjExNw_da161a98-759e-4623-a161-2ba8a77ff2db"
      unitRef="usd">3206875</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtNC0xLTEtNjExNw_67eb95eb-cc59-4258-8a48-29f568c3f97e"
      unitRef="usd">5665177</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="icb38ed17fae340ce933596e5d361e981_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpjYTUzMmY1ZmVkMmE0NTBkYjI5YTg3MmYyNzU0YmViNC90YWJsZXJhbmdlOmNhNTMyZjVmZWQyYTQ1MGRiMjlhODcyZjI3NTRiZWI0XzUtNi0xLTEtNjExNw_efdad49f-f778-42df-af7d-14748c1327f1"
      unitRef="usd">3782224</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i60aad94f2f4f44b1a7b8ae65743e96b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzM4NDgyOTA3MDAyODY_2aae81fb-5038-44a8-b5d0-007bbcfbc9ce"
      unitRef="usd">500000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzItMi0xLTEtNjA3MA_7619c2bb-0006-4983-a964-946aafdcebad"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzItNC0xLTEtNjA3MA_542321e1-8baa-457a-9672-3098e2c7803a"
      unitRef="usd">1922457</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzMtMi0xLTEtNjA3MA_a8283ed6-1e6a-441c-9432-be46f8b61f7e"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzMtNC0xLTEtNjA3MA_b1a562c0-fad7-4293-87ab-afb3adb62b51"
      unitRef="usd">540267</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzQtMi0xLTEtNjA3MA_fa58723a-44fc-4a2e-a1d8-6ec20a37cb7a"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZToxYmYxYjZhZDc2MDc0YmY1YTY4OTdlYzVkZmYzNWVlMi90YWJsZXJhbmdlOjFiZjFiNmFkNzYwNzRiZjVhNjg5N2VjNWRmZjM1ZWUyXzQtNC0xLTEtNjA3MA_c87be2e0-9816-4b73-bc64-6f5b6723ceed"
      unitRef="usd">2462724</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzItMi0xLTEtNjExNQ_fc0faf4e-b69f-4b54-a37f-b9722a6ad5fe"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzItNC0xLTEtNjExNQ_9cf958b9-ec80-4c20-84de-0a471ceeac36"
      unitRef="usd">1918868</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzMtMi0xLTEtNjExNQ_77016481-57cd-4fa8-9398-e506227faec8"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzMtNC0xLTEtNjExNQ_24f8cbd2-01f1-420f-9434-6f1ea3b19981"
      unitRef="usd">232489</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1ac17932a25340aca07bdc1d4e8a3a20_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzQtMi0xLTEtNjExNQ_ed0edae1-b250-4f08-9119-b79d468a9ea1"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90YWJsZTpkNTEzMGIyNTZlZjA0ODdiYmY0N2NmZjQwZmQ0MjMwNi90YWJsZXJhbmdlOmQ1MTMwYjI1NmVmMDQ4N2JiZjQ3Y2ZmNDBmZDQyMzA2XzQtNC0xLTEtNjExNQ_5c85c22e-1dbe-46df-aae4-5c824ed05fa3"
      unitRef="usd">2151357</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjUvZnJhZzo2NzdlYTRkMGEwOGY0YmJjOGM1YjdkNDE4NzFjMWQwNS90ZXh0cmVnaW9uOjY3N2VhNGQwYTA4ZjRiYmM4YzViN2Q0MTg3MWMxZDA1XzI1MDY_10b4c6b3-1bc9-40fc-8b5c-2257a650027d">Commitments and Contingencies&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#x201c;USPTO&#x201d;) including U.S. Patent number 8,148,356 (the &#x201c;356 Acetadote Patent&#x201d;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. &lt;/span&gt;&lt;/div&gt;The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90ZXh0cmVnaW9uOjVhM2FjOTcxNzg2ODRkODI5MTA3ZjFiOTNiY2E3MTcyXzM1Mw_fb149a0c-bcba-471f-bb26-9006f6cb0f71">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,261,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,441,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,580,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,208,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,745,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,381,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,787,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,625,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(883,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,339,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,305,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,388,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,323,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,196,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,394,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,288,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,187,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,369,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,396,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90ZXh0cmVnaW9uOjVhM2FjOTcxNzg2ODRkODI5MTA3ZjFiOTNiY2E3MTcyXzM1NA_9ed9fea0-466c-4a38-8de2-b57a1076b8b8">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,261,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,441,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,580,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,208,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,745,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,381,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,275,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,787,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,625,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,206,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(481,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(883,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,339,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,935,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,305,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,388,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,323,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,196,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,394,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,288,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,187,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,316,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,369,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,211,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,349,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,396,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,665,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,953,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,537,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtMi0xLTEtMA_07773581-67e9-4db4-9b98-41ceb8ab47f8"
      unitRef="usd">8330734</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtNC0xLTEtMA_025485b3-0883-47ee-a677-63659bf7d523"
      unitRef="usd">9598177</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtNi0xLTEtMA_dbac73af-1e0e-42ab-acfa-9ae4b9ad9aff"
      unitRef="usd">9250689</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtOC0xLTEtMA_47205b6b-644a-44a7-8a2b-f97fe0d1386b"
      unitRef="usd">10261534</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzMtMTAtMS0xLTA_667df3da-9c40-4d0f-b42d-56497aa738bf"
      unitRef="usd">37441134</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtMi0xLTEtMA_f2facdd3-3fc3-4409-9a9a-451d8023a7b4"
      unitRef="usd">-1846001</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtNC0xLTEtMA_6c0baff2-7f42-40ae-9877-9de7258f318d"
      unitRef="usd">-1580962</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtNi0xLTEtMA_24b3ab70-cbd0-4cc1-9d6e-9ebddc7ed079"
      unitRef="usd">-1208686</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtOC0xLTEtMA_fba9c219-e768-4be6-aac3-f538c91960a9"
      unitRef="usd">-1745946</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzQtMTAtMS0xLTA_9ca2ce0d-5454-4ed1-84b1-0a9b23f260c2"
      unitRef="usd">-6381595</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMi0xLTEtMjEzMg_e2cd01ed-4db3-4b6a-a62b-ffc780156c65"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNC0xLTEtMjEzMg_3cfa0451-c2ee-4391-82ae-33b371926deb"
      unitRef="usd">-1679211</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNi0xLTEtMjEzMg_93577245-b282-435c-89a6-bd4414bf0d66"
      unitRef="usd">-1275620</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtOC0xLTEtMjEzMg_1ee8cfcb-176d-4b95-ace2-a91873b1e2fc"
      unitRef="usd">-1787530</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMTAtMS0xLTIxMzI_d0e21d43-5ee2-40b9-9066-8a2fe5ffd543"
      unitRef="usd">-6625779</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtMi0xLTEtMjEzMg_2aacf664-9cbe-4b5d-9e29-5937e2e9dad6"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtNC0xLTEtMjEzMg_993fdd35-1f62-4521-9258-3aadeeb85a7b"
      unitRef="usd">738622</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtNi0xLTEtMjEzMg_3932804d-26f4-42a9-ab36-441c44b5fc39"
      unitRef="usd">777916</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtOC0xLTEtMjEzMg_be8cf7b9-2a2e-4daa-97c9-71d6ea1eb8ab"
      unitRef="usd">872064</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzYtMTAtMS0xLTIxMzI_176fe447-24d0-42e9-8865-5b8f281a67eb"
      unitRef="usd">3206875</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMi0xLTEtMA_4535b5af-12c3-4f6e-b9b0-e952610f6fbb"
      unitRef="usd">-1055620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNC0xLTEtMA_9aa30c86-edea-4b7e-8403-c0e133f3d4c3"
      unitRef="usd">-918275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtNi0xLTEtMA_c6881792-9048-4230-bb7c-ef7d5386f499"
      unitRef="usd">-481737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtOC0xLTEtMA_d4380c0a-82cf-46e5-a88b-a7dfffe00375"
      unitRef="usd">-883776</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzUtMTAtMS0xLTA_91ae942d-2ae2-4fb7-a9e0-1672e505d671"
      unitRef="usd">-3339408</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktMi0xLTEtMjEzOQ_3aa17cb5-ac14-4bbf-be40-855b3e9e79e0"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktNC0xLTEtMjEzOQ_e869e343-393c-4704-903d-e115b759676e"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktNi0xLTEtMjEzOQ_53057a9e-345f-40d2-8e25-c48ef857a2be"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktOC0xLTEtMjEzOQ_bc1bb264-e015-4636-9779-797286145151"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzktMTAtMS0xLTIxMzk_ff6693d6-6780-4075-a7b8-2d333f6c83d3"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTItMS0xLTIxMzk_2d3213a2-bb69-4ad9-b6f0-e07213bbc9ad"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTQtMS0xLTIxMzk_97fc5539-2189-47b0-870d-bd6d6e32a6c4"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTYtMS0xLTIxMzk_435133a9-024a-4983-85e9-65b9c379d5c7"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTgtMS0xLTIxMzk_19ae1a95-f65f-44aa-a55c-516877a9015a"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEwLTEwLTEtMS0yMTM5_7aef39cf-e1ce-4efa-b938-bcbebc48ddab"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctMi0xLTEtMA_00236362-8d99-4cd3-b0f3-4ef1ae7946f8"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctNC0xLTEtMA_fe157292-900d-4086-a475-e5b7548e35ac"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctNi0xLTEtMA_bd632353-4b5f-4ebd-99e9-2b58bcab1177"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctOC0xLTEtMA_26132c2d-842f-4b9c-924b-0d50c9bdf9ac"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzctMTAtMS0xLTA_e59d002d-4baa-4ebf-bb39-caa3701583b2"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTItMS0xLTIxNjM_e2678847-e043-4668-b257-53bf1b1e56f1"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTQtMS0xLTIxNjM_cfa747e1-0d2f-4024-ac32-050cef3239d5"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTYtMS0xLTIxNjM_7da412cd-386b-4515-b4be-00e96e5aec24"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTgtMS0xLTIxNjM_443876e8-e7f0-44c7-8128-528021fd3cb9"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTEwLTEtMS0yMTYz_aef18dbf-13f1-4259-a18e-9165d93df969"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTItMS0xLTIxNjM_98db4efe-a656-49bf-bba8-504f154e8cb7"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTQtMS0xLTIxNjM_9fc9a2af-0b36-4858-89d8-efff737c143c"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTYtMS0xLTIxNjM_359e989a-1f26-46a3-ac3f-6064c2c3ef46"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTgtMS0xLTIxNjM_b1d90923-b5c0-48e0-b716-19041079f158"
      unitRef="usdPerShare">0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE0LTEwLTEtMS0yMTYz_4a622a28-56ff-49b2-81de-4306e0659bbc"
      unitRef="usdPerShare">0.21</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie1cde27885114d2e8ac70468a301b196_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtMi0xLTEtMA_138f18c3-1042-46eb-bbda-c95d0301b0ab"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i53c90f6095704e879f61efb25ca906f9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtNC0xLTEtMA_30b5f984-3163-40fd-a305-8fb09c371c56"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iefa6949f898f4ca0b49a215e83d05b1c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtNi0xLTEtMA_8d5ddee0-a6d2-469e-b5bd-dafa4de97af0"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtOC0xLTEtMA_45ddbf8f-3db1-4576-af1e-6adb46395484"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzgtMTAtMS0xLTA_1388733e-3610-42fc-85ea-e251f6a55c31"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTItMS0xLTA_9aba2786-6963-4a5f-a894-5e4e233337dc"
      unitRef="usd">8729860</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTQtMS0xLTA_39c4acce-9447-4657-a55c-5aa929131c16"
      unitRef="usd">9417443</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTYtMS0xLTA_c757080d-92ab-4dcf-ae71-eadfc30130ac"
      unitRef="usd">6935439</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTgtMS0xLTA_8f02a879-2fd0-4a4e-978c-036facc51f4e"
      unitRef="usd">9305553</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzExLTEwLTEtMS0w_29772dea-58fa-41d8-8fc6-433b639ec241"
      unitRef="usd">34388295</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTItMS0xLTA_d171ea52-ef09-46e4-b219-7449c0290bc3"
      unitRef="usd">-1323932</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTQtMS0xLTA_a999d888-2ddf-4b68-803c-3050a383cc82"
      unitRef="usd">-1373424</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTYtMS0xLTA_83552b47-f9f4-43c1-9501-a4c97139bacc"
      unitRef="usd">-3196436</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTgtMS0xLTA_123f0ab2-5b24-4154-90d5-ba3d6b876450"
      unitRef="usd">-3394390</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEyLTEwLTEtMS0w_989dc212-4cbf-4544-a521-50f3155149d9"
      unitRef="usd">-9288182</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTItMS0xLTIwMzc_9a8259fa-0356-4cb1-b8e2-2574e2a81aac"
      unitRef="usd">-1187553</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTQtMS0xLTIwMzc_19626109-a97d-4476-a653-02b4f8afa94b"
      unitRef="usd">-1338521</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTYtMS0xLTIwMzc_aa0f9cc6-29b8-4140-9d70-2098a6b08b5d"
      unitRef="usd">-3316286</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTgtMS0xLTIwMzc_9f4b51f2-3ff2-4c56-b32a-bd727ebecfbf"
      unitRef="usd">-3369329</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIwLTEwLTEtMS0yMDM3_01f29bd2-ac49-4d64-8573-cb80449aefbe"
      unitRef="usd">-9211688</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTItMS0xLTIwMzc_dccb5489-b1f1-4684-b3ed-cd0eee008668"
      unitRef="usd">1147136</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTQtMS0xLTIwMzc_dc8e93a9-43c9-42e4-a90b-f9245aa0aa1a"
      unitRef="usd">771709</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTYtMS0xLTIwMzc_96470ad6-add8-4288-a588-ab300aa9d7bf"
      unitRef="usd">1349351</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTgtMS0xLTIwMzc_9bfa1464-54dd-4e9c-812c-6452f9091b54"
      unitRef="usd">2396981</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzIxLTEwLTEtMS0yMDM3_ebcefb6f-1c12-4a52-9f4e-1fe4667c2660"
      unitRef="usd">5665177</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTItMS0xLTA_bb153a1b-eb9d-4036-98dd-68150ae9194e"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTQtMS0xLTA_eeeabf47-38b3-4a3c-bc15-554f1dd28b7e"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTYtMS0xLTA_ab39bc22-be19-4d0f-8a6f-40bf77488e57"
      unitRef="usd">-1953668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTgtMS0xLTA_7925f2de-eeea-46ed-be85-b48190daeced"
      unitRef="usd">-960706</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzEzLTEwLTEtMS0w_d452f52d-6546-433a-b0c5-99d09dbe35df"
      unitRef="usd">-3537759</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTItMS0xLTIwNDM_21484649-f15d-4739-8edf-aaa6ea15f675"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTQtMS0xLTIwNDM_209376a5-d33c-40e1-9348-89bf786fca2a"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTYtMS0xLTIwNDM_ba4e3c41-801e-4f25-af04-3705f108095c"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTgtMS0xLTIwNDM_33c5d6aa-8816-4bd4-b94e-a5962cc525c8"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI0LTEwLTEtMS0yMDQz_8a278cf7-b48e-4df7-90fe-04272d46944e"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTItMS0xLTIwNDM_2ba9715b-982e-4d4e-b2f6-82fbe0eecbf2"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTQtMS0xLTIwNDM_1628a0e6-c7c7-4955-a583-9566aa04430a"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTYtMS0xLTIwNDM_e28e64ef-4d1d-4ef1-80a0-c11619a9584c"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTgtMS0xLTIwNDM_45509dca-64e7-47a2-a4e0-966b58c3f4a7"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI1LTEwLTEtMS0yMDQz_bb1c9f28-1316-4abd-a76b-d6216ce966f1"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTItMS0xLTA_340d1ff6-11df-4959-81f7-8a8e8c8bdb25"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTQtMS0xLTA_bff68dfa-ea22-4115-b082-082030263841"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTYtMS0xLTA_66dc55f0-ec67-4a9e-8b44-a64e1142d4b7"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTgtMS0xLTA_7d11c31f-9a31-4cb5-9ada-2eb776cfb103"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE1LTEwLTEtMS0w_3d57dea5-538d-4d95-85d5-44cc19f773f3"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTItMS0xLTIwNDM_013ae205-1877-43a6-b2a2-cc7f9db5a0f6"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTQtMS0xLTIwNDM_83694200-8c0b-4cf2-b2bb-283eb61edbbc"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTYtMS0xLTIwNDM_b336e8a6-0975-422a-abeb-f46e6b750809"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTgtMS0xLTIwNDM_ffd9d97c-64ce-4e3e-b859-d41ae3a15cd4"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI4LTEwLTEtMS0yMDQz_abb14499-f222-4153-94ac-2a9104cf82c1"
      unitRef="usdPerShare">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTItMS0xLTIwNDM_e956e48a-baa6-4c2d-84ac-0a8c86b8cc18"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTQtMS0xLTIwNDM_963204e6-6d29-478f-a990-5ddae4d55491"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTYtMS0xLTIwNDM_ea67c7d7-cd49-4b2d-90d3-2099cb2d0b27"
      unitRef="usdPerShare">0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTgtMS0xLTIwNDM_b804a348-fee2-4f8d-a854-8720f9b08734"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzI5LTEwLTEtMS0yMDQz_d9b46059-8c49-46b5-a291-48f2bde5a7ff"
      unitRef="usdPerShare">0.37</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i33a485953ea94c868adbce3538277f6b_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTItMS0xLTA_4af1926d-9fd0-4684-a71d-03dcb8461640"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i645eda684ef34e4eb42dfbb6458add1e_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTQtMS0xLTA_ab4a6e92-d115-416f-b42b-0c6ad24f8dc3"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic0d5bc795ef04002a154c0d0a495300d_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTYtMS0xLTA_294db78e-09ff-4335-8cd7-ea37828c3b55"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6f59f556735e4376bc0aea179f8edc7f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTgtMS0xLTA_9286c71e-cc92-4e07-845e-f45a9d179b58"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i80ad86a15cb140888dbf4cf827ccff64_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjgvZnJhZzo1YTNhYzk3MTc4Njg0ZDgyOTEwN2YxYjkzYmNhNzE3Mi90YWJsZTpmZDQwMzY2OWM5ZDY0MTk1OWM5YmI0YzkyNDBlNDE0Ny90YWJsZXJhbmdlOmZkNDAzNjY5YzlkNjQxOTU5YzliYjRjOTI0MGU0MTQ3XzE2LTEwLTEtMS0w_15ca88fb-df2b-481e-8dad-235e6497a9ef"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90ZXh0cmVnaW9uOmIyODNhYjZhNTUzMDQ1NDRiZGQ1MjdkMTAyYzlkM2VmXzQwMw_c65f37e0-a9c4-4ab1-bc4f-ba3f7d691f6e">&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Years ended December&#160;31, 2020, 2019 and 2018&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;beginning&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;costs and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;end&#160;of&#160;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,610,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,133,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,927,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,747,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,632,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,382,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,382,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,511,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,511,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,196,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Composed of actual returns and credits for chargebacks and cash discounts.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifc1855e705644eb19c43b7bb2e117b81_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtMi0xLTEtMA_07bab6ae-2f78-4d3f-8b98-687a462c7085"
      unitRef="usd">326697</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtNC0xLTEtMA_f8bfef08-4f79-452b-b008-fa793ca5b75a"
      unitRef="usd">4610899</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtNi0xLTEtMA_f69f7070-3e03-49db-9a88-ac25c2a0f8ce"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8b6f8684f5d3492488e63de55c715ea0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtOC0xLTEtMA_907f7092-b70e-4136-9648-34fa9f2aaf22"
      unitRef="usd">4133176</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i40627ef8322d435c8f66224735bfa7b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzQtMTAtMS0xLTA_9c906de6-5946-4eee-b38d-77558373eea7"
      unitRef="usd">804420</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i40627ef8322d435c8f66224735bfa7b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtMi0xLTEtMA_e240a066-6b9b-48ef-bcfe-d2d598810174"
      unitRef="usd">804420</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtNC0xLTEtMA_7c981df7-d959-4dc6-b178-7ffc83f74bbd"
      unitRef="usd">5915066</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtNi0xLTEtMA_c3a519e3-0d07-48b2-b5ab-c65bb7433c09"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie842cee4508e41469e30fc3cd8c9046b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtOC0xLTEtMA_3ba9f514-cad4-49d0-b843-2c6adff116e0"
      unitRef="usd">5927435</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if3fbba7dd4a6485ea115af1a74515fea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzUtMTAtMS0xLTA_9c8f1fd2-1731-4361-84a1-3b0103cbf6cc"
      unitRef="usd">792051</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if3fbba7dd4a6485ea115af1a74515fea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtMi0xLTEtMA_dda4f9b0-e354-4683-a61e-cfe31c890029"
      unitRef="usd">792051</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtNC0xLTEtMA_db8d09b2-24ca-41f5-8974-8378df242e56"
      unitRef="usd">4940313</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtNi0xLTEtMA_a90ea692-8bec-4072-9de9-9ecd7d1b9de6"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6b3e68fd0c2d47169e68c25f337cccdc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtOC0xLTEtMA_2603e2da-668d-4258-b034-60b7fadc571e"
      unitRef="usd">4747687</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i053b532230724366b6e9f1045a453663_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzYtMTAtMS0xLTA_4e19f175-81c8-4053-b101-addba013f18c"
      unitRef="usd">984677</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idbf0cdcda3874fbf81f9d06a24caa475_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTItMS0xLTA_b2b959c4-366b-4e25-85ac-89bd0c751481"
      unitRef="usd">15632235</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTQtMS0xLTA_a1a109ac-c9d9-42bb-a478-308c9518c7ad"
      unitRef="usd">1749817</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTYtMS0xLTA_d75f1ff1-8c77-49c4-b87d-a99160a58361"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2e9427dd6968457e9d7c60903ddaec24_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTgtMS0xLTA_779e4c89-407a-4269-b390-b18949443dde"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i61d578da0f6f43cc8eb4610cda5b0867_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEwLTEwLTEtMS0w_70adbb0b-64dc-4678-b27b-a144f197515d"
      unitRef="usd">17382052</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i61d578da0f6f43cc8eb4610cda5b0867_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTItMS0xLTA_bbdaff61-528b-4c63-bce2-93240a72a7f9"
      unitRef="usd">17382052</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTQtMS0xLTA_8a31a254-3ce4-4ef6-b819-057b2121c6c5"
      unitRef="usd">1129109</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTYtMS0xLTA_1fa5ddda-aae9-4075-8915-848cacf2b6bc"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i51705b26178b42d5b32143f96e30e91b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTgtMS0xLTA_1ee8c2ec-c690-4f9a-9a66-4d4f4c8015a5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzExLTEwLTEtMS0w_87625c3e-4901-4067-b054-4460dd7d31d1"
      unitRef="usd">18511161</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibf1c8bb76b9a4e8e95347dc64b036b09_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTItMS0xLTA_ebe39d25-6ff6-44cd-90de-71a5f3424ca0"
      unitRef="usd">18511161</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTQtMS0xLTA_017d68fa-5235-45e6-9c77-6dbdfbda696f"
      unitRef="usd">684960</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTYtMS0xLTA_155ee872-66a2-44f3-ae2b-3fd5101bfcbb"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if01631ad013d47f5afd180f56a3d1bfc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTgtMS0xLTA_b5fb5e67-0970-4c71-bcd6-97471d25d98c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id9e5f707de404e5784e8284dcb422b96_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNzQvZnJhZzpiMjgzYWI2YTU1MzA0NTQ0YmRkNTI3ZDEwMmM5ZDNlZi90YWJsZTpmNDY2MTlkZTQwOTc0ZmU0OTg1NDU5MTAyODkzYzliNS90YWJsZXJhbmdlOmY0NjYxOWRlNDA5NzRmZTQ5ODU0NTkxMDI4OTNjOWI1XzEyLTEwLTEtMS0w_032a6f28-292d-4aba-971f-bf7a662cb03e"
      unitRef="usd">19196121</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260514060520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,639,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,920,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2021 annual meeting of shareholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490593080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,753,796<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
<td class="nump">12,377,713<span></span>
</td>
<td class="nump">7,859,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">10,638,157<span></span>
</td>
<td class="nump">8,871,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,199,926<span></span>
</td>
<td class="nump">2,757,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets associated with discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,462,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">49,969,592<span></span>
</td>
<td class="nump">50,163,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">11,656,742<span></span>
</td>
<td class="nump">15,554,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">574,169<span></span>
</td>
<td class="nump">747,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">28,118,316<span></span>
</td>
<td class="nump">30,920,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,028,148<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,234,338<span></span>
</td>
<td class="nump">3,298,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">96,463,305<span></span>
</td>
<td class="nump">104,549,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,396,286<span></span>
</td>
<td class="nump">9,993,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,016,779<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,254,381<span></span>
</td>
<td class="nump">11,084,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities associated with discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,151,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,667,446<span></span>
</td>
<td class="nump">24,150,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">1,059,693<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,862,772<span></span>
</td>
<td class="nump">8,737,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,589,911<span></span>
</td>
<td class="nump">53,464,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,988,429 and 15,263,555 shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">49,121,523<span></span>
</td>
<td class="nump">49,914,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">46,990,510<span></span>
</td>
<td class="nump">51,122,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(117,116)<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">46,873,394<span></span>
</td>
<td class="nump">51,085,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 96,463,305<span></span>
</td>
<td class="nump">$ 104,549,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411293000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value (dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, number of shares issued</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, number of shares outstanding</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406780200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 10,261,534<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">$ 37,441,134<span></span>
</td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,653,020<span></span>
</td>
<td class="nump">7,421,316<span></span>
</td>
<td class="nump">6,016,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,765,465<span></span>
</td>
<td class="nump">15,277,740<span></span>
</td>
<td class="nump">14,004,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,773,825<span></span>
</td>
<td class="nump">6,868,480<span></span>
</td>
<td class="nump">7,575,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,196,299<span></span>
</td>
<td class="nump">9,974,384<span></span>
</td>
<td class="nump">10,150,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434,120<span></span>
</td>
<td class="nump">4,134,557<span></span>
</td>
<td class="nump">2,769,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,822,729<span></span>
</td>
<td class="nump">43,676,477<span></span>
</td>
<td class="nump">40,517,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,745,946)<span></span>
</td>
<td class="num">(1,208,686)<span></span>
</td>
<td class="num">(1,580,962)<span></span>
</td>
<td class="num">(1,846,001)<span></span>
</td>
<td class="num">(3,394,390)<span></span>
</td>
<td class="num">(3,196,436)<span></span>
</td>
<td class="num">(1,373,424)<span></span>
</td>
<td class="num">(1,323,932)<span></span>
</td>
<td class="num">(6,381,595)<span></span>
</td>
<td class="num">(9,288,182)<span></span>
</td>
<td class="num">(11,172,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,345<span></span>
</td>
<td class="nump">243,364<span></span>
</td>
<td class="nump">564,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263,627)<span></span>
</td>
<td class="num">(246,186)<span></span>
</td>
<td class="num">(195,848)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,569,877)<span></span>
</td>
<td class="num">(9,291,004)<span></span>
</td>
<td class="num">(10,804,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,902)<span></span>
</td>
<td class="nump">79,316<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(1,787,530)<span></span>
</td>
<td class="num">(1,275,620)<span></span>
</td>
<td class="num">(1,679,211)<span></span>
</td>
<td class="num">(1,883,418)<span></span>
</td>
<td class="num">(3,369,329)<span></span>
</td>
<td class="num">(3,316,286)<span></span>
</td>
<td class="num">(1,338,521)<span></span>
</td>
<td class="num">(1,187,553)<span></span>
</td>
<td class="num">(6,625,779)<span></span>
</td>
<td class="num">(9,211,688)<span></span>
</td>
<td class="num">(10,820,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">872,064<span></span>
</td>
<td class="nump">777,916<span></span>
</td>
<td class="nump">738,622<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
<td class="nump">2,396,981<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
<td class="nump">3,206,875<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,418,904)<span></span>
</td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="num">(7,038,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,496<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
<td class="nump">75,704<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (883,776)<span></span>
</td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (960,706)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (3,339,408)<span></span>
</td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">-Continuing operations-basic</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">-Discontinued operations-basic</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.23)<span></span>
</td>
<td class="num">(0.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">-Continuing operations-diluted</a></td>
<td class="num">(0.12)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.12)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
<td class="num">(0.60)<span></span>
</td>
<td class="num">(0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">-Discontinued operations-diluted</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,162,184<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,162,184<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,840,673<span></span>
</td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,461<span></span>
</td>
<td class="nump">$ 1,980,450<span></span>
</td>
<td class="nump">$ 540,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406530024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,418,904)<span></span>
</td>
<td class="num">$ (3,546,511)<span></span>
</td>
<td class="num">$ (7,038,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">$ 872,064<span></span>
</td>
<td class="nump">$ 818,273<span></span>
</td>
<td class="nump">$ 2,396,981<span></span>
</td>
<td class="nump">$ 1,147,136<span></span>
</td>
<td class="nump">3,206,875<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(1,787,530)<span></span>
</td>
<td class="num">(1,883,418)<span></span>
</td>
<td class="num">(3,369,329)<span></span>
</td>
<td class="num">(1,187,553)<span></span>
</td>
<td class="num">(6,625,779)<span></span>
</td>
<td class="num">(9,211,688)<span></span>
</td>
<td class="num">(10,820,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,748,565<span></span>
</td>
<td class="nump">4,404,175<span></span>
</td>
<td class="nump">2,982,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
<td class="nump">65,408<span></span>
</td>
<td class="nump">81,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046,516<span></span>
</td>
<td class="nump">1,485,898<span></span>
</td>
<td class="nump">1,364,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess tax (benefit) expense derived from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(81,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,160,202)<span></span>
</td>
<td class="num">(804,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Increase in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,636<span></span>
</td>
<td class="nump">47,525<span></span>
</td>
<td class="nump">99,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Noncash investment gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,315)<span></span>
</td>
<td class="num">(168,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,518,707)<span></span>
</td>
<td class="num">(1,399,012)<span></span>
</td>
<td class="num">(47,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,131,347<span></span>
</td>
<td class="nump">1,106,175<span></span>
</td>
<td class="nump">528,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid, other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,489<span></span>
</td>
<td class="num">(615,199)<span></span>
</td>
<td class="nump">676,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,569,002<span></span>
</td>
<td class="nump">3,221,780<span></span>
</td>
<td class="nump">4,153,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,859,330)<span></span>
</td>
<td class="num">(729,820)<span></span>
</td>
<td class="num">(159,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,896,819<span></span>
</td>
<td class="num">(2,455,240)<span></span>
</td>
<td class="num">(1,390,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,518,242<span></span>
</td>
<td class="nump">5,511,596<span></span>
</td>
<td class="nump">4,503,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,415,061<span></span>
</td>
<td class="nump">3,056,356<span></span>
</td>
<td class="nump">3,112,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,817)<span></span>
</td>
<td class="num">(246,202)<span></span>
</td>
<td class="num">(455,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,973,110)<span></span>
</td>
<td class="num">(772,944)<span></span>
</td>
<td class="num">(3,819,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Proceeds from Life Insurance Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,888<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy', window );">Increase (Decrease) In Proceeds from Life Insurance Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,062,132<span></span>
</td>
<td class="nump">16,122,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,745,138)<span></span>
</td>
<td class="num">(19,572,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,757,789)<span></span>
</td>
<td class="nump">2,297,848<span></span>
</td>
<td class="num">(27,724,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,500,000)<span></span>
</td>
<td class="num">(77,500,000)<span></span>
</td>
<td class="num">(45,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,851,526)<span></span>
</td>
<td class="num">(3,494,921)<span></span>
</td>
<td class="num">(2,879,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred equity offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(383,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(52,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for Contingent Consideration Liability, Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(819,180)<span></span>
</td>
<td class="num">(1,033,108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Payments for Repurchase of Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,116,111)<span></span>
</td>
<td class="num">(5,080,529)<span></span>
</td>
<td class="nump">7,138,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,458,839)<span></span>
</td>
<td class="nump">273,675<span></span>
</td>
<td class="num">(17,473,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,938,960<span></span>
</td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">45,412,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</a></td>
<td class="nump">$ 24,753,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,753,796<span></span>
</td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">$ 45,412,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CashPaidDuringYearForAbstract', window );"><strong>Net cash paid (refunded) during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,991<span></span>
</td>
<td class="nump">198,661<span></span>
</td>
<td class="nump">95,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,486)<span></span>
</td>
<td class="nump">16,694<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid', window );">Change in unpaid invoices for purchases of intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340,997)<span></span>
</td>
<td class="num">(576,837)<span></span>
</td>
<td class="num">(539,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses', window );">Deferred offering costs included in accounts payable and other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Noncash increase in liabilities related to acquisition (see Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,629,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NoncashOrPartNoncashTransactionVestingOfShares', window );">Vesting of shares related to RediTrex approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">862,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Additions to intangible assets from final purchase price allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Year For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Proceeds from Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NoncashOrPartNoncashTransactionVestingOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Transaction, Vesting of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NoncashOrPartNoncashTransactionVestingOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases of Intangible Assets Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21C<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080552-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407317784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2017</a></td>
<td class="nump">$ 63,921,601<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">$ 11,709,222<span></span>
</td>
<td class="num">$ (198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(6,963,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,963,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(75,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(7,038,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,364,698<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">200,909<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(2,877,935)<span></span>
</td>
<td class="num">$ (2,877,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(443,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2018</a></td>
<td class="nump">55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(3,537,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,537,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(8,752)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">$ (685,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Sale of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">640,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="nump">862,200<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,485,898<span></span>
</td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(3,486,835)<span></span>
</td>
<td class="num">$ (3,486,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(623,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2019</a></td>
<td class="nump">15,263,555<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (3,339,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,339,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(79,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,418,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">1,046,516<span></span>
</td>
<td class="nump">$ 1,046,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(1,839,471)<span></span>
</td>
<td class="num">$ (1,839,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(503,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">$ (2,131,013)<span></span>
</td>
<td class="num">$ (117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404311320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,610,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,133,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,927,435)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,747,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,632,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,382,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,382,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,511,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,511,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Composed of actual returns and credits for chargebacks and cash discounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411629272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.8 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that was funded during 2020.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now 85%.  As noted above, the ownership interests of CET includes WinHealth and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $79,496, $8,752 and $75,704 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404316008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $2.4 million, $1.5 million and $2.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2020 and 2019, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2020 and 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $1.0 million at December&#160;31, 2020 and $0.8 million at December 31, 2019. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories. </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2020 and declared effective in January 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2020, the Company has expensed $0.4&#160;million in deferred offering costs associated with the Shelf Registration that was declared effective in January 2018. </span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. As a result, the Vibativ component of the Company is the reporting unit evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting unit through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2020, 2019 and 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,637&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379,424&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 20, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 20, for additional information.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404003032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174; and Vibativ&#174;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">RediTrex&#174; and Vibativ&#174;</a></td>
<td class="text">RediTrex<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and was recorded as an other current liability at December 31, 2019.  During December 2020 Cumberland launched RediTrex and the launch also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.8 million in net intangible assets related to RediTrex at December&#160;31, 2020.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, Cumberland recognized $0.5 million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.         </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million at closing and a $5.0 million cash payment during early 2019. In addition, </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is remeasured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $3.3&#160;million and the non-current portion is $4.9&#160;million, as of December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404349192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,567,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,870,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,336,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,840,673&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,407,845&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,803,961&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during 2019. There were no payments received in 2020.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The international agreements provide for $1.0 million in non-refundable up-front payments, milestone payments of up to $2.2 million related to regulatory approvals and up to $4.8 million in payments related to product sales.  From 2012 through December&#160;31, 2020, the Company has recognized a cumulative $1.2 million in upfront payments as other revenue and has recognized $0.1&#160;million in revenue related to the milestone payments associated with these international agreements.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2020, 2019 and 2018 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.8 million, $1.3 million, and $0.1 million for the years ending December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405862504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.  The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At December&#160;31, 2020 and 2019 the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.2 million and $0.1&#160;million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2020 and 2019. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million  that were classified as non-current inventories.  At December&#160;31, 2020, the Vibativ non-current inventory was $11.2 million and $15.3 million at December&#160;31, 2019.  The Company had Vibativ finished goods included in the non-current inventories at December&#160;31, 2020 of $2.1 million and we did not have any Vibativ finished goods included at December&#160;31, 2019.  At  December&#160;31, 2020 and December&#160;31, 2019, Cumberland had $0.4 million and $0.3 million, respectively, in non-current inventory for API related to its ifetroban clinical initiatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404264440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,906&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,557,087)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,394,329)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405862504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,543,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,400,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,709,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,499,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,833,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,901,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,306,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,882,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,312,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex and Vibativ. In November 2016, the Company acquired the U.S. rights to Nordic Group B.V.&#8217;s injectable methotrexate product line as an asset purchase. The agreement requires the Company to provide unvested restricted shares of Cumberland common stock and make a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. The payments are being treated as consideration for the assets acquired and are being capitalized and amortized over the expected useful life of the acquired asset. To date, the intangible assets related to the product include the $100,000 deposit paid at closing, the 180,000 restricted shares valued at $0.9 million that vested upon the November 2019 FDA approval, the additional $1.0&#160;million paid to Nordic during 2020 based on the 2019 FDA approval and the $1.0&#160;million owed to Nordic based on the 2020 product launch.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of  $11.8 million and goodwill of $0.9 million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.  The $0.1&#160;million increase in goodwill during 2019 was a result of changes in the purchase price allocation during the measurement period. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company recorded an additional $0.5 million and $0.7 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"/><td style="width:38.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118,316&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405864200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current and Other Long-term Liabilities</a></td>
<td class="text">Other Current and Other Long-term Liabilities<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,787,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,254,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,862,772&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737,323&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405703032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million, which was also the maximum aggregate principal available for borrowing under the previously amended Pinnacle Agreement. The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in compliance with the Tangible Capital Ratio financial covenant as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $15.0 million in borrowings under the Pinnacle Agreement at December&#160;31, 2020 and $18.5 million at December&#160;31, 2019.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90% (representing an interest rate of 3.65% at December&#160;31, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div>Borrowings under the line of credit are collateralized by substantially all of our assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404257704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into two million shares of common stock.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2020 and 2019, there was no preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, the Company issued 228,500 shares,  225,536 shares and 170,759 shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2020,  2019 and 2018.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities.  The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2020 or 2019.  The Company issued 30,704 shares for proceeds of  0.2 million during the year end December 31, 2018.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Warrants</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to 7,500 shares of common stock at $17.00 per share that expired in July 2019.  As of December&#160;31, 2020, there were no outstanding warrants.  </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 503,626 shares, 623,478 shares and 443,041 shares of common stock for approximately $1.8 million, $3.5 million, and $2.9 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. There remains $6.2 million available under the current repurchase program available for share repurchases at December&#160;31, 2020.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Cumberland Emerging Technologies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1 million investment in CET.  Cumberland </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchased additional CET shares through contribution of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.3 million in cash and a conversion of $0.7 million in intercompany loans payable.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for consideration of  $0.8&#160;million that was funded during 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the additional investment, the Company&#8217;s ownership in CET is 85%.  As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners.  </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)  &#160;&#160;&#160;&#160;Cumberland Foundation </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions that were paid to the Foundation during 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic Group B.V.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received approval from the FDA for the pre-filled syringe of the Methotrexate product.  With this approval, Nordic's 180,000 shares of Cumberland's common stock became vested.  The value of these shares at the date of approval was $0.9&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407245096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per Share</a></td>
<td class="text">Earnings (Loss) Per Share <div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.012%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,625,779)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,418,904)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,546,511)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038,772)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339,408)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,162,184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,162,184&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.019%"><tr><td style="width:1.0%"/><td style="width:39.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.321%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404258536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,961,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,362&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928,638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,858,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(662,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,532,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,196,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,511,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,045,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,153,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,829,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,484,494&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,939,781&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,802)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,802)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2020, 2019 and 2018 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets, with the exception of one noted below, are fully offset with a valuation allowance as of the periods ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019, and December 31, 2018.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only deferred tax asset not offset with a valuation allowance as of the periods ended December 31, 2019 and December 31, 2018 was the Company&#8217;s AMT Credit Carryforward, which became refundable under the Tax Cuts and Jobs Act passed in 2017.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the balance of the refund related to this credit during the period ended December 31, 2020, and as such, the deferred tax asset has been realized and all remaining deferred tax assets are fully offset with a valuation allowance as of December 31, 2020. </span></div><div style="margin-top:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company has general business credit carryforwards of $1.7&#160;million.  These credit carryforwards will expire in years 2021 through 2041.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.807%"><tr><td style="width:1.0%"/><td style="width:73.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022-2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,244&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2017, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2017.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2017 remain subject to examination and adjustment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits in 2020, 2019 and 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404246984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under three equity compensation plans, with two of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,663)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was approximately $1.7 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 2.28 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2020 and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"/><td style="width:34.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options and there were no options exercised during 2020, 2019 and 2018.    As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,091&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405857272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2020, 2019 and 2018, the Company contributed approximately $50,000 in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $2.7 million and $2.3 million as of December&#160;31, 2020 and 2019, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.9 million and $3.1 million as of December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404307736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015.  Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 2.0 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company recorded the following on the Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.4 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405579928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsThe Company owns marketable securities that had a maturity date of less than ninety days and are classified as cash and cash equivalents at December&#160;31, 2020 and December 31, 2019.  There were no transfers of assets between levels within the fair value hierarchy. The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The fair values of all other financial instruments outstanding as of December&#160;31, 2020 and 2019 approximate their carrying values.  There were no changes to the valuation techniques for the Level 2 marketable securities during 2020 or 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407904152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Market Concentrations</a></td>
<td class="text">Market Concentrations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the acquisition, development and commercialization of branded prescription products.  The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"/><td style="width:39.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 60% and 59% at December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405723576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsAbstract', window );"><strong>Manufacturing and Supply Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsTextBlock', window );">Manufacturing and Supply Agreements</a></td>
<td class="text">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404249848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EmploymentAgreementsAbstract', window );"><strong>Employment Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EmploymentAgreementsTextBlock', window );">Employment Agreements</a></td>
<td class="text">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406303768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxMGY4YzRkYzY1YTQwMWY5Njg5MDg4ZDE3ZTM2OTRjL3NlYzo1MTBmOGM0ZGM2NWE0MDFmOTY4OTA4OGQxN2UzNjk0Y18yNjIvZnJhZzo0OGFiYzcxOWYyMzA0ZTExOWUxZGZjNDk2Zjc3ZTJhYy90ZXh0cmVnaW9uOjQ4YWJjNzE5ZjIzMDRlMTE5ZTFkZmM0OTZmNzdlMmFjXzE2NDkyNjc0NDgzNDA_72c8f2e7-a907-47b1-a9cd-8d46f8f9cdb2">two</span>-years following the transition date.  Cumberland recorded the first four quarterly installments totaling $3.0 million during the year ended December 31, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect Products meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the Products. Cumberland was responsible for the Products through December 31, 2019 and beginning on January 1, 2020, the Products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:49.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,145,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,149,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 current assets associated with discontinued operations included $0.5&#160;million in the remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory for the Products sold and returned to Clinigen as part of the transaction.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for the Products' inventory as of December 31, 2019, no other operating assets and no liabilities were transferred to Clinigen, as such t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he accounts receivable and accounts payable associated with discontinued operations were not sold or disposed of as part of the Dissolution Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407838168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments were treated as consideration for the assets acquired and were capitalized.  They are being amortized over the remaining expected useful life of the acquired asset, currently through 2026. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Ethyol and Totect, the Company was required to pay royalties based on net sales.  The royalty expense was recognized as a component of selling and marketing expense in the period the associated revenue was recognized through the end of the licensing period, December 31, 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of  Patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div>The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405592040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,261,534&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,441,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,580,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,208,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,745,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,381,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,883,418)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,679,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,787,530)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,625,779)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,055,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(918,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(883,776)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,339,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,729,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,417,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,305,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,323,932)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373,424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,196,436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,394,390)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,187,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,369,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,396,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260410888072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.  Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  During this pandemic, less patients sought care, some patients postponed elective surgeries and Cumberland's access to medical facilities was substantially limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).</span></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2020 and 2019, cash equivalents consist primarily of money market funds as well as trading securities with original maturities of less than ninety days.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesThe Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of December&#160;31, 2020 and 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  At December&#160;31, 2020 and December&#160;31, 2019 , all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $1.0 million at December&#160;31, 2020 and $0.8 million at December 31, 2019. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net </span></div>realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div>Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 20, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 20, for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaids and Other Current Assets, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405630776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock', window );">Schedule of intangible assets, useful lives</a></td>
<td class="text">Amortization expense is recognized ratably over the following periods:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405681848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174; and Vibativ&#174; (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment during early 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,182,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability that is remeasured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 12, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,502,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,633,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.743%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - unlabeled vials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process - validation vials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,550,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property amortizable intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles and goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405861064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net product revenues by product</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.698%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,567,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,895,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,055,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,870,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,075,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,336,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,001,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284,111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,840,673&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,407,845&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,803,961&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407858728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories, current</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,345,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,554,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406104360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,906&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,557,087)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,394,329)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofDepreciationExpenseTableTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text">Depreciation expense was as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Depreciation Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406117272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,543,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,400,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,709,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,499,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,833,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,901,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,306,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,882,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,312,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,920,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of expected amortization expense of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.730%"><tr><td style="width:1.0%"/><td style="width:38.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118,316&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404025400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,787,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payment for asset purchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,254,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of other long-term liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,862,772&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,737,323&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405580936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of numerator and denominator in earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.012%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,625,779)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,820,996)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,418,904)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,546,511)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,038,772)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339,408)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963,068)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,162,184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock and stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,162,184&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396,098&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614,052&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.019%"><tr><td style="width:1.0%"/><td style="width:39.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.321%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407804504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,961,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,362&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928,638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,858,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,846,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(662,014)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,532,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,196,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,511,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of federal and state net operating loss carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,045,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,153,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 - 2039</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,829,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,484,494&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,939,781&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,802)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,802)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,408)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2020, 2019 and 2018 reconciles with the federal statutory tax rate as follows:&#160;</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of tax credit carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company has general business credit carryforwards of $1.7&#160;million.  These credit carryforwards will expire in years 2021 through 2041.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.807%"><tr><td style="width:1.0%"/><td style="width:73.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022-2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,244&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404305608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text">Stock compensation expense consisted of the following for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%"><tr><td style="width:1.0%"/><td style="width:40.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,663)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for 2020 and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"/><td style="width:34.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term&#160;(years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,091&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405869400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of rent expense and sublease income</a></td>
<td class="text">Rent expense and sublease income  as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.897%"><tr><td style="width:1.0%"/><td style="width:41.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of balance sheet classification</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company recorded the following on the Consolidated Balance Sheet: </span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease liability maturities</a></td>
<td class="text">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260403975928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value of financial instruments by level in hierarchy</a></td>
<td class="text">The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260410864968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of revenues concentration from major customers</a></td>
<td class="text">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.602%"><tr><td style="width:1.0%"/><td style="width:39.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*: less than 10% of total</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260403991208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:49.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,145,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,396,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,149,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782,224&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities have been presented as assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets.   </span><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.384%"><tr><td style="width:1.0%"/><td style="width:61.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities associated with discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405516792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,598,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,261,534&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,441,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,580,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,208,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,745,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,381,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,883,418)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,679,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,275,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,787,530)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,625,779)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,206,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,055,620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(918,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(481,737)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(883,776)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,339,408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,729,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,417,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,935,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,305,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,388,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,323,932)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373,424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,196,436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,394,390)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,288,182)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,187,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,316,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,369,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,211,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,396,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,665,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,953,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,537,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407961336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,496<span></span>
</td>
<td class="nump">$ 8,752<span></span>
</td>
<td class="nump">$ 75,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ContributionOfCashAdditionalSharesPurchased', window );">Contribution of cash</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IntercompanyLoansPayableConvertedAmount', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Exchange for consideration, amount</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET) | Harbin Gloria Pharmaceuticals Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ContributionOfCashAdditionalSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contribution of Cash, Additional Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ContributionOfCashAdditionalSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IntercompanyLoansPayableConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intercompany Loans Payable, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IntercompanyLoansPayableConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406984952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="nump">$ 10,261,534<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">$ 37,441,134<span></span>
</td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,028,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,028,148<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionAndDistributionCosts', window );">Distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,686<span></span>
</td>
<td class="nump">613,637<span></span>
</td>
<td class="nump">457,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,424<span></span>
</td>
<td class="nump">2,594,630<span></span>
</td>
<td class="nump">2,005,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain', window );">WinHealth Investment (Singapore) Ltd [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember', window );">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances, current</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionAndDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to the production and distribution of goods or services to customers and clients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionAndDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260410926136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember', window );">Product Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Estimated economic life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Term of license agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Life of patent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Useful Lives, (Textual)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490127192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174; and Vibativ&#174; - Narrative (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,840,673<span></span>
</td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,261,534<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">37,441,134<span></span>
</td>
<td class="nump">34,388,295<span></span>
</td>
<td class="nump">29,344,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,088<span></span>
</td>
<td class="nump">$ 837,829<span></span>
</td>
<td class="nump">$ 623,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (in shares)</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411000360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,855,363<span></span>
</td>
<td class="nump">$ 6,258,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Additional payments to acquire businesses</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407698888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174; and Vibativ&#174; - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at November 12, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,633,589<span></span>
</td>
<td class="nump">9,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,000)<span></span>
</td>
<td class="num">(1,160,202)<span></span>
</td>
<td class="num">(804,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="nump">1,546,346<span></span>
</td>
<td class="nump">820,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment', window );">Adjustment to initial fair value of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,180<span></span>
</td>
<td class="nump">1,033,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 8,200,553<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411429816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Schedule of Net Product Revenues by Product) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 35,840,673<span></span>
</td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">15,567,562<span></span>
</td>
<td class="nump">12,895,120<span></span>
</td>
<td class="nump">12,055,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,336,943<span></span>
</td>
<td class="nump">5,222,282<span></span>
</td>
<td class="nump">5,001,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,870,990<span></span>
</td>
<td class="nump">8,691,550<span></span>
</td>
<td class="nump">5,075,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,874,206<span></span>
</td>
<td class="nump">3,824,449<span></span>
</td>
<td class="nump">4,284,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">257,088<span></span>
</td>
<td class="nump">837,829<span></span>
</td>
<td class="nump">623,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,077,227<span></span>
</td>
<td class="nump">$ 936,615<span></span>
</td>
<td class="nump">$ 1,763,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 856,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411765624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 35,840,673<span></span>
</td>
<td class="nump">$ 32,407,845<span></span>
</td>
<td class="nump">$ 28,803,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherRevenuesAbstract', window );"><strong>Other Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionUpfrontPayment', window );">Other revenue, upfront payment</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval', window );">Other revenue, potential upfront payments related to regulatory approval</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionCumulativeUpfrontPayment', window );">Cumulative upfront payment</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionMilestonePayments', window );">Milestone payments associated with international agreements</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember', window );">Collaborative Arrangement, Federal Small Business Grant Programs | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember', window );">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionCumulativeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Cumulative Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionCumulativeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404077416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 16,223,162<span></span>
</td>
<td class="nump">$ 19,345,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">128,005<span></span>
</td>
<td class="nump">416,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">5,943,732<span></span>
</td>
<td class="nump">4,664,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">22,294,899<span></span>
</td>
<td class="nump">24,426,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(11,656,742)<span></span>
</td>
<td class="num">(15,554,992)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 10,638,157<span></span>
</td>
<td class="nump">$ 8,871,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260520731256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves, obsolescence and discontinuance</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">11,656,742<span></span>
</td>
<td class="nump">15,554,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">11,200,000<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV | Finished Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407497144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,131,256<span></span>
</td>
<td class="nump">$ 4,142,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,557,087)<span></span>
</td>
<td class="num">(3,394,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">574,169<span></span>
</td>
<td class="nump">747,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,275,703<span></span>
</td>
<td class="nump">1,260,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 806,906<span></span>
</td>
<td class="nump">878,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 638,903<span></span>
</td>
<td class="nump">646,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,409,744<span></span>
</td>
<td class="nump">$ 1,356,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405771320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Depreciation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements', window );">Depreciation, including amortization related to leasehold improvements</a></td>
<td class="nump">$ 314,444<span></span>
</td>
<td class="nump">$ 269,619<span></span>
</td>
<td class="nump">$ 213,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Including Amortization Related to Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260410909608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 28,118,316<span></span>
</td>
<td class="nump">$ 30,920,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">38,543,542<span></span>
</td>
<td class="nump">37,400,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(14,709,824)<span></span>
</td>
<td class="num">(11,499,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">23,833,718<span></span>
</td>
<td class="nump">25,901,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,306,922<span></span>
</td>
<td class="nump">9,882,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(6,312,460)<span></span>
</td>
<td class="num">(5,127,878)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">3,994,462<span></span>
</td>
<td class="nump">4,754,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">338,011<span></span>
</td>
<td class="nump">273,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(47,875)<span></span>
</td>
<td class="num">(9,020)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 290,136<span></span>
</td>
<td class="nump">$ 264,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411739048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973,110<span></span>
</td>
<td class="nump">772,944<span></span>
</td>
<td class="nump">3,819,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434,120<span></span>
</td>
<td class="nump">4,134,557<span></span>
</td>
<td class="nump">$ 2,769,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,543,542<span></span>
</td>
<td class="nump">37,400,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,306,922<span></span>
</td>
<td class="nump">9,882,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="nump">$ 11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411379880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets Future Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 4,338,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">3,691,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">3,629,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">3,629,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter', window );">2025 and thereafter</a></td>
<td class="nump">12,830,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 28,118,316<span></span>
</td>
<td class="nump">$ 30,920,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411628904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductSalesRelatedLiabilitiesCurrent', window );">Rebates, product returns, administrative fees and service fees</a></td>
<td class="nump">$ 4,072,151<span></span>
</td>
<td class="nump">$ 4,593,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">998,064<span></span>
</td>
<td class="nump">1,295,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="nump">2,787,741<span></span>
</td>
<td class="nump">2,374,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredAcquisitionLiabilityCurrent', window );">Deferred acquisition liability</a></td>
<td class="nump">2,187,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccruedLiabilitiesInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">294,000<span></span>
</td>
<td class="nump">829,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AccruedPaymentForAssetPurchaseCurrent', window );">Accrued payment for asset purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">915,285<span></span>
</td>
<td class="nump">991,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">11,254,381<span></span>
</td>
<td class="nump">11,084,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="nump">4,855,363<span></span>
</td>
<td class="nump">6,258,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">2,702,772<span></span>
</td>
<td class="nump">2,278,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">304,637<span></span>
</td>
<td class="nump">200,346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent, Total</a></td>
<td class="nump">$ 7,862,772<span></span>
</td>
<td class="nump">$ 8,737,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedPaymentForAssetPurchaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payment For Asset Purchase, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedPaymentForAssetPurchaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Accrued, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredAcquisitionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Acquisition Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredAcquisitionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductSalesRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Sales-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductSalesRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260406354008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Line of Credit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit, current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Maximum increase to line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate with minimum LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_ThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_ThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407212136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2009 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,405<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 383,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PreferredStockAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Initial public offering, effective date</a></td>
<td class="text">Aug. 10,  2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues', window );">Initial public offering, price per share | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering', window );">Initial public offering, gross proceeds</a></td>
<td class="nump">$ 85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts', window );">Initial public offering, underwriting discounts</a></td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, net proceeds</a></td>
<td class="nump">$ 74,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering', window );">Initial public offering, number of shares common stock received in exchange for preferred stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,500<span></span>
</td>
<td class="nump">225,536<span></span>
</td>
<td class="nump">170,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Gross Proceeds from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Shares, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Price Per Share, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodPricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260405498424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Warrants, Narrative) (Details) - Warrants, Issued in Consideration of 2009 Credit Facility Amendment<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2009 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants, number of shares called by warrants | shares</a></td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490201256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,839,471<span></span>
</td>
<td class="nump">$ 3,486,835<span></span>
</td>
<td class="nump">$ 2,877,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available under current repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LoansForgiveninExchangeForShareIssuedAmount', window );">Loans Forgiven in Exchange For Share Issued, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SharebasedCompensationCharitableContributionofSharesShares', window );">Charitable contribution of shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions', window );">Committed cash contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Exchange for consideration, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicMember', window );">Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,626<span></span>
</td>
<td class="nump">623,478<span></span>
</td>
<td class="nump">443,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,839,471<span></span>
</td>
<td class="nump">$ 3,486,835<span></span>
</td>
<td class="nump">$ 2,877,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember', window );">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,626<span></span>
</td>
<td class="nump">623,478<span></span>
</td>
<td class="nump">443,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member', window );">Share Repurchase Program Authorized in 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, number of shares authorized to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LoansForgiveninExchangeForShareIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loans Forgiven in Exchange For Share Issued, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LoansForgiveninExchangeForShareIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharebasedCompensationCharitableContributionofSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharebasedCompensationCharitableContributionofSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490251224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,787,530)<span></span>
</td>
<td class="num">$ (1,275,620)<span></span>
</td>
<td class="num">$ (1,679,211)<span></span>
</td>
<td class="num">$ (1,883,418)<span></span>
</td>
<td class="num">$ (3,369,329)<span></span>
</td>
<td class="num">$ (3,316,286)<span></span>
</td>
<td class="num">$ (1,338,521)<span></span>
</td>
<td class="num">$ (1,187,553)<span></span>
</td>
<td class="num">$ (6,625,779)<span></span>
</td>
<td class="num">$ (9,211,688)<span></span>
</td>
<td class="num">$ (10,820,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">872,064<span></span>
</td>
<td class="nump">777,916<span></span>
</td>
<td class="nump">738,622<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
<td class="nump">2,396,981<span></span>
</td>
<td class="nump">1,349,351<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
<td class="nump">3,206,875<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">3,782,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,418,904)<span></span>
</td>
<td class="num">(3,546,511)<span></span>
</td>
<td class="num">(7,038,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,496<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
<td class="nump">75,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (883,776)<span></span>
</td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (960,706)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (3,339,408)<span></span>
</td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,162,184<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of restricted stock and stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,162,184<span></span>
</td>
<td class="nump">15,396,098<span></span>
</td>
<td class="nump">15,614,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404309960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">197,610<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">41,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411634824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Operating Loss Carryforwards, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 19,196,121<span></span>
</td>
<td class="nump">$ 18,511,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">684,960<span></span>
</td>
<td class="nump">1,129,109<span></span>
</td>
<td class="nump">$ 1,749,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 56,484,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,939,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260493592120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss and tax credits</a></td>
<td class="nump">$ 16,961,650<span></span>
</td>
<td class="nump">$ 16,964,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles', window );">Property and equipment and intangibles</a></td>
<td class="nump">227,056<span></span>
</td>
<td class="nump">227,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for accounts receivable</a></td>
<td class="nump">249,483<span></span>
</td>
<td class="nump">257,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct', window );">Reserve for expired product</a></td>
<td class="nump">438,235<span></span>
</td>
<td class="nump">469,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">100,362<span></span>
</td>
<td class="nump">35,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DeferredTaxAssetsDeferredCharges', window );">Deferred charges</a></td>
<td class="nump">952,711<span></span>
</td>
<td class="nump">845,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Cumulative compensation costs incurred on deductible equity awards</a></td>
<td class="nump">928,638<span></span>
</td>
<td class="nump">1,047,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">19,858,135<span></span>
</td>
<td class="nump">19,846,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(662,014)<span></span>
</td>
<td class="num">(1,313,965)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NetDeferredTaxAssetsGross', window );">Net deferred tax assets, before valuation allowance</a></td>
<td class="nump">19,196,121<span></span>
</td>
<td class="nump">18,532,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: deferred tax asset valuation allowance</a></td>
<td class="num">(19,196,121)<span></span>
</td>
<td class="num">(18,511,161)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property and Equipment and Intangibles</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NetDeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NetDeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490133816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 56,484,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,939,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2021 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2021 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,342,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2022 - 2029 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2022 - 2029 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,045,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember', window );">2030 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">44,153,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember', window );">2030 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember', window );">2031 - 2039 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">7,534,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember', window );">2031 - 2039 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,829,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 4,796,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411233336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 21,802<span></span>
</td>
<td class="nump">$ 65,408<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="num">(55,902)<span></span>
</td>
<td class="nump">79,316<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (expense) benefit</a></td>
<td class="num">(34,100)<span></span>
</td>
<td class="nump">144,724<span></span>
</td>
<td class="num">(16,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(21,802)<span></span>
</td>
<td class="num">(65,408)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Deferred income tax (expense) benefit</a></td>
<td class="num">(21,802)<span></span>
</td>
<td class="num">(65,408)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="num">$ (55,902)<span></span>
</td>
<td class="nump">$ 79,316<span></span>
</td>
<td class="num">$ (16,636)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260600780360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (net of federal income tax benefit)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Permanent differences associated with general business credits</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax expense</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407710632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of tax credit carryforwards) (Details) - Federal And State<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,729,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">173,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2022 - 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">622,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember', window );">2030-2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">836,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember', window );">2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 97,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490259736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans', window );">Number of equity compensation plans | plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants', window );">Number of equity compensation plans available for future grants | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to share-based payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to share-based payments, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember', window );">NonPrincipal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue', window );">Stock options, exercise price as percent of weighted-average grant date fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member', window );">Long-Term Incentive Compensation Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans | shares</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member', window );">Directors&#8217; Incentive Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Principal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | NonPrincipal Owner | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260504117048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,046,516<span></span>
</td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,050,179<span></span>
</td>
<td class="nump">1,481,016<span></span>
</td>
<td class="nump">1,244,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(3,663)<span></span>
</td>
<td class="nump">4,882<span></span>
</td>
<td class="nump">120,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember', window );">Employee, Nonemployee and Foundation Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,046,516<span></span>
</td>
<td class="nump">$ 1,485,898<span></span>
</td>
<td class="nump">$ 1,364,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260500119336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited or expired, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exerciseable, end of period, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited or expired, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, end of period, weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, end of period, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, end of period, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490804216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">814,949<span></span>
</td>
<td class="nump">833,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted, shares</a></td>
<td class="nump">231,091<span></span>
</td>
<td class="nump">229,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested, shares</a></td>
<td class="num">(228,500)<span></span>
</td>
<td class="num">(225,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited, shares</a></td>
<td class="num">(38,125)<span></span>
</td>
<td class="num">(22,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">779,415<span></span>
</td>
<td class="nump">814,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted, weighted-average grant-date fair value</a></td>
<td class="nump">3.56<span></span>
</td>
<td class="nump">5.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Shares vested, weighted-average grant-date fair value</a></td>
<td class="nump">4.62<span></span>
</td>
<td class="nump">6.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Shares forfeited, weighted-average grant-date fair value</a></td>
<td class="nump">5.87<span></span>
</td>
<td class="nump">6.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404144552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge', window );">Defined contribution plan, eligibiilty, minimum employee age</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility', window );">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</a></td>
<td class="text">six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404151816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,028,148<span></span>
</td>
<td class="nump">$ 2,960,569<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260411112136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule of Rent Expense and Sublease Income) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 1,166,411<span></span>
</td>
<td class="nump">$ 1,246,143<span></span>
</td>
<td class="nump">$ 1,136,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="nump">680,627<span></span>
</td>
<td class="nump">$ 688,020<span></span>
</td>
<td class="nump">$ 662,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future minimum sublease income under noncancelable operating subleases</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407662952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,028,148<span></span>
</td>
<td class="nump">$ 2,960,569<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,016,779<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">1,059,693<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,076,472<span></span>
</td>
<td class="nump">$ 2,996,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404202616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">$ 1,144,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,256,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(180,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,076,472<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490126344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Fair value of marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407771176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260532444152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>supplier</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing agreements, number of primary suppliers for each product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingandSupplyAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Manufacturing and Supply Agreement [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingandSupplyAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260404047880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset', window );">Financial consideration</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FinancialConsiderationPaymentPeriod', window );">Financial consideration, payment period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets associated with discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,462,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_ClinigenMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets associated with discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_ClinigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_ClinigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260490781672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Discontinued Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 3,206,875<span></span>
</td>
<td class="nump">$ 13,145,344<span></span>
</td>
<td class="nump">$ 11,396,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Costs of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,330,704<span></span>
</td>
<td class="nump">1,361,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,149,463<span></span>
</td>
<td class="nump">6,253,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Income from discontinued operations</a></td>
<td class="nump">3,206,875<span></span>
</td>
<td class="nump">5,665,177<span></span>
</td>
<td class="nump">$ 3,782,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,922,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">540,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets associated with discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,462,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,918,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">232,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities associated with discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,151,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407013544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 10,261,534<span></span>
</td>
<td class="nump">$ 9,250,689<span></span>
</td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 9,305,553<span></span>
</td>
<td class="nump">$ 6,935,439<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
<td class="nump">$ 37,441,134<span></span>
</td>
<td class="nump">$ 34,388,295<span></span>
</td>
<td class="nump">$ 29,344,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,745,946)<span></span>
</td>
<td class="num">(1,208,686)<span></span>
</td>
<td class="num">(1,580,962)<span></span>
</td>
<td class="num">(1,846,001)<span></span>
</td>
<td class="num">(3,394,390)<span></span>
</td>
<td class="num">(3,196,436)<span></span>
</td>
<td class="num">(1,373,424)<span></span>
</td>
<td class="num">(1,323,932)<span></span>
</td>
<td class="num">(6,381,595)<span></span>
</td>
<td class="num">(9,288,182)<span></span>
</td>
<td class="num">(11,172,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (883,776)<span></span>
</td>
<td class="num">$ (481,737)<span></span>
</td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (960,706)<span></span>
</td>
<td class="num">$ (1,953,668)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (3,339,408)<span></span>
</td>
<td class="num">$ (3,537,759)<span></span>
</td>
<td class="num">$ (6,963,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260497968504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 792,051<span></span>
</td>
<td class="nump">$ 804,420<span></span>
</td>
<td class="nump">$ 326,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">4,940,313<span></span>
</td>
<td class="nump">5,915,066<span></span>
</td>
<td class="nump">4,610,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(4,747,687)<span></span>
</td>
<td class="num">(5,927,435)<span></span>
</td>
<td class="num">(4,133,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">984,677<span></span>
</td>
<td class="nump">792,051<span></span>
</td>
<td class="nump">804,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">18,511,161<span></span>
</td>
<td class="nump">17,382,052<span></span>
</td>
<td class="nump">15,632,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">684,960<span></span>
</td>
<td class="nump">1,129,109<span></span>
</td>
<td class="nump">1,749,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 19,196,121<span></span>
</td>
<td class="nump">$ 18,511,161<span></span>
</td>
<td class="nump">$ 17,382,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140260407770616">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
<td class="nump">$ 9,034,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>110
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPS5G@&8>@/LK(?3^Q+R@_)'E\C]02P,$%     @ -XIL4IA;\AF9!@  VQD
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M.B@N/Z=-T[GH^SI#> K=".OG>0C),$_(T,*%=)I$XIKTH#:ZVK2)#G?<@J4
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M+,LQ5'OB3?H0,L>,#343M--D&M?D!V4E7(+UGFQJ<"Z\B>4K[ 7!%-J'/M,
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M"E?,,Q*%,_Z<UC7$<7U'*^(=[>=VKY-W>=&]T=TE*/)@:JO*HE (]I^&2>P
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MVN;%^HQH/+5N&65!_-+B!H9)V58U& GE@DD*1AAWJ+A 0D+I2B0$*&A,Q,3
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MC?>[&:6,U&A@DD&@M2DC19I02"8<R@B0$!JQJ5EKE B5[ZI ]HID_X69&HE
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M*?M@63^"L]< +V1L@:WCS?L>>#%'?[;/4=2JZ%ZV:*OM FYPV"BMQT%],/2
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M2XO]E[9ZZEY/NZ_:MEIU'Q]5NE"U!L#ORPJ"XO!%WV#SZNC9_P!02P,$%
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M3*/4DK:WH]-VXVP,Y6 8<^-LY(8_)Z.@_LC)3"WX4U,;&B#!,)'&\VO$):_
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M!P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U5VV[C-A#]%4)=%%F
M&XF4K$MJ&["3+=J'!=(-ND51](&6QA81251)JD[^OD/*5F1TDZ)H7Z09<LZ9
M,\/;\JCTHZD!+'EJF\ZL@MK:_B8,35E#*\RUZJ'#F;W2K;#HZD-H>@VB\J"V
M"7D4I6$K9!>LEW[L7J^7:K"-[.!>$S.TK=#/6VC4<16PX#SP61YJZP;"];(7
M!W@ ^W-_K]$+)Y9*MM 9J3JB8;\*-NQFF[AX'_!%PM',;.(JV2GUZ)P?JU40
M.4'00&D=@\#?GW +3>.(4,8?)\Y@2NF <_O,_KVO'6O9"0.WJOE%5K9>!7E
M*MB+H;&?U?$'.-6S<'RE:HS_DN,8FZ8!*0=C57L"HX)6=N-?/)WZ, /DT2L
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MB<0.,C4%UM<# @.707,J*E!4+()I9+T)OFP+L)=Z!Z6=P\\BU@U3D4HZK$&
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M4O'^2HL85:0/9@^"M4 A,+9-=8LI(';&B)CT6=G+7%9YVQYPDR>MX/V?''%
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MD+ $2S8R),B%PMI4K? 8-"W>C(T%5V19/5T@QEK2"SN#YN!R25.Q(5-@C_%
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M?N -MQX(H''1B\)\,=HH*Y@:%(^)3%W;<Y>^309S D$%^)0"_7C[!H=S]]6
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MD'J_\,RT!H SKWSPRUZV-I*MJ;79#UJ!(5/O#WN( #(>P,ZR3D_/\=;S<RE
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M%4"JQ@/[Z+3&,S%SXYP"#%:Y+XL;5BAZ=3P)>GS<'J72RN]ZH!8CV;T CQB
MYO&LYA!;YI3?#0\IKASY7<6)#%HC%,IKA,R;CE"<JT?DCIZQFQ"RD/T8)1MG
M[A,8XO?EMVVN>4OLIQ'JC6\"U9K",Y]C0+QBSX-7+QC6;?[60.Q"&(Z)&,K4
MWB,=+QE.5\Y"MK0DKRN.2<>>?K* $Q3(WN6RX"E6<>4[P=0#!J&B2,RCY5."
M%&+7  ,Q3\7(FAT:#WA%[-7:U\B51F*715VVLBY!(%/IUI(IAAK,AUQ=5;HG
M)L(4AKGZT-2#'.]ZT=?L/I67T3-; ZB736@2?U^(75]#@_--EM76RC(#,SE(
M'K: @H&,H9KXIW60MJ )(L)!9Y2P=HT80\+^0*?BP=0Z1P;XIB;<HQ(U%4U
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M- VP6WA3A;<2*^.]*<+E5@H0D#?@_[7!4TB[8 7]:ZK+_P%02P,$%     @
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MVPX6\)IVBV[BUF* &UE\ I^)[0$T*!BX4&J:BBNP".IH8AVE<]+L"#P7_."
MQC:=@&)OTR7Q[3XZI;4@Z$ HR$\D@@J:.*;8(8?^98B[ 93*%?*5:M@I6W_P
M"B&I&V#8;_?>OOUFG:4G/R!(Z:BRK2<_/< *LD945L.7;XNJ=XM.N^^>U@2E
M18E&=FK3=K0,Q#I88,L_BGI<1_@5/D@>@CXT3 #CL\5X^)@)MQ_.)JV^R V0
M0!8M=:A&B9(P"6!16&@]STZ'D_/AA3))_X2C2]04*EL>YH<1#,JT4J,3B"TC
M$C]*C@O<V( 59@VA>2 DRC;6@S[SK"7";KS5"()C]8C^16UO.(XNV0T[@3/'
M6PR*%Q6P8N.QL9S]JSO,_%#C>^^ LH+05/S.9: ;59(I6*!410PT5#UH!>I[
MQQXZ=&IYARD+8D- KK WY!BZ1$A15-*ACY6/S678IZ.RA=5#U]A7X7ZPCM5@
M*B[#F*(Z@H]919H:=W4ERQC)SJ@O7&K(\-=%D+%N15NW6O)1?KS87=#^034Z
MW'T1,6&+Z,&AGKS55XN;OP',GQ5S)NK\;#[-<.QJ/;0J-M)A(V&::RA^5^B[
MJ7ACN$=,_[VQGV59_-TJK^(FMRHY3H6K"2R1 7\W>)C2L;/[PO[J4'C)O",V
M((CR</"5CZZ9GSESSI5?-ZU#^IZ&,Z+[Y!$-(*EE01BX(E+C#F547*KO)Y?7
M;R;/HX&1QS'D_D&Q!ZY@%GS!+'BW)R?PP64G#JL<(Q]:;1W/CR'="!N+=-7J
M ^WE<2@;OR6T42FVSM;"'9Q>@.:0':91<<C^_O#\*!LD@V^I"!U;ACJ:U!2Z
M+;MP6.'0^KB?0\=^3S?L].CAZ*CA@X^9_+(%@;C8P#^3@8MB),<CC1>Q0ZZ1
MKMK9GAH'5HY(,KH#0A_5AIM^W$R)>-5R=)J#BOMLE!$Y=LR/B10VGZ7+Z6K?
MV9$;0*7TX*Q\XO0]/LW)0:#'5'%BP>BS-'TX5 AF<;_SR#;C_>$!0PQ^'IT7
MAS5^ZOOA:'49E^Q^OCL<"5Q11H:LY W/QMV_^CZ>P9,,^$CVH+*<+%@G?TA#
MB^,TE'#FQ\'G0>'V&%$-\[;:4G!V(\%>^#[M*0(=%DG63X]](\]&%XZ:P+=\
MK>)Y1Q=W=X_][O[F=ME=6.[%NVO?6] ULXRF+53GTY/EI*/$81%L$Z\O&QMP
M&8J/%6Z?Y%@ [[<6+-\OV,'^/GOQ#U!+ P04    "  WBFQ25AZTNXT#  #;
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RE56UOVS80_BL'+1A6
M@(C>)3NS#21IBPY842/MM@_#/M#2R28JD2I)Q<E^_8Z4K3BHDWX8((A'\NYY
M[H['XV*O]%>S0[3PT+72+(.=M?U5&)IJAQTWEZI'23N-TAVW--7;T/0:>>V-
MNC9,HJ@(.RYDL%KXM;5>+=1@6R%QK<$,7<?UXPVV:K\,XN"X<">V.^L6PM6B
MYUO\C/:/?JUI%DXHM>A0&J$D:&R6P75\=9,Y?:_PI\"].9'!1;)1ZJN;_%8O
M@\@YA"U6UB%P&N[Q%MO6 9$;WPZ8P43I#$_E(_I['SO%LN$&;U7[EZCM;AG,
M JBQX4-K[]3^ Q[BR1U>I5KC_[ ?=3-BK 9C57<PIGDGY#CRAT,>3@QFT0L&
MR<$@\7Z/1-[+M]SRU4*K/6BG36A.\*%Z:W).2'<HGZVF74%V=K76=+[:/@*7
M-;S[-HB>,FX7H25LIQ%6!YR;$2=Y 2=.X*.2=F?@G:RQ?@X0DE.39\G1LYOD
M5<2W6%U"&C-(HB1Z!2^=(DT]7OJ#2!FL6R[M\X#A[^N-L9IJY)]7J+*)*O-4
MV?].ZJLX[D)>F9Y7N SHQAG4]QB\  [/EG%:KA3='V.Q!M6 W2$TJJ6+*.06
MN 7*,78;U)3G*[CC<HM.;3#8#"VT=%V,SS[]XCG<JJX?+"D_H:?P\T^S)(Y_
MA1P>D6L#%Q"SI,Q9&:6C7$2L2"/XU#2BPK.F\=%V%A5L'A4P*V<LS2-X/V@I
M[*#1Q]2(!R<;HOK.LDAG9)E"D14LCW+X'>FB[E1;@^AZK>[149HSG R4IM[B
MNI=+2>OL@&+LR/4LFK,RRTA*\X(5601?E.4M]&<SS6"KE3&0L9B*-LD+)V4)
MBQ/GCC%7U("JH1M:[@ZC1CK02O"Q,Q$.[Y2VXM]QX9>4Y7G)HEGYQLGI/&-I
M,G_S WY)+?P"\I)XBSE)95:R<E[0(9]PX0.U<X,,A*S:H?9U<$I]V*><C(Y:
M-2;ENV02@CF D)J0L$6)FMSST=34JH2[4*[G3J"DY4K0U:1J1>T)C*5A/!XJ
M/1>9=\1<GO4;]MP ?6,5NU%[R+$,T+6>YT7]5+[TFYW'O"#-C&5TU!>0%'-6
MQ"Y]29RR)"WA7#\(3QINAWKKGQ5#@0W2CKUW6IU>KNNQ83^IC\_>1ZZW0AK*
M<D.FT669!Z#'IV2<6-7[]KU1EAX#+^[H]47M%&B_4<H>)XY@>L]7_P%02P,$
M%     @ -XIL4IFZ.<* !@  N \  !D   !X;"]W;W)K<VAE971S+W-H965T
M,30N>&ULI5=K;]LV%/TKA&=L*R#8>OF5)0'R6+L"ZQ"T:8=AV =:HBTNDJB2
ME)WTU^]<ZF&[=M(-^Q!'?)W[.O?R\GRK](/)A+#LL<A+<S'(K*W.QF.39*+@
M9J0J46)EI73!+89Z/3:5%CQUAXI\'/K^=%QP60XNS]W<G;X\5[7-92GN-#-U
M47#]="URM;T8!(-NXKU<9Y8FQI?G%5^+#\)^K.XT1N,>)96%*(U4)=-B=3&X
M"LZN8]KO-GR28FOVOAE9LE3J@09OTXN!3PJ)7"26$#C^;<2-R',"@AJ?6\Q!
M+Y(.[G]WZ*^=[;!ER8VX4?GO,K79Q6 ^8*E8\3JW[]7V%]':,R&\1.7&_;)M
MLW<2#5A2&ZN*]C T*&39_.>/K1_V#LS]9PZ$[8'0Z=T(<EK><LLOS[7:,DV[
M@48?SE1W&LK)DH+RP6JL2IRSEV]+R\NU7.:"71DCK#D?6\#2XCAI(:X;B/ 9
MB"!D[U1I,\-^+E.1'@*,H4^O5-@I=1V^B'@KDA&+ H^%?NB_@!?U1D8.+WH&
M[XU2Z5;F.>-ERHXL9K?2)+DRM1;LSZNEL1I4^>L%L7$O-G9BX__CVQ<A*"7/
M3,43<3% SAFA-V)PC.OLZHW<6^8GEA.%C#)6I$RMF,T$6ZD<J2G+->.6P?6B
M6 H-]Y\Y]^,G6+ [K=(ZL0XIEPF24C!-A#=LR**Y-XDC_(4TF'FQ[WLS#'X5
MQIPA[Y*ZJ'-.$GFAM)5?N$O('X/8F_D+;Q[&KS (O'BQ\((X>,7NE>4YJYZ7
M&4;>/(J\63!GX<1;^($W]0-V!QDE5@/?B_RIMPA#!O1YZ$V"X)O*3+TH"+UX
MZD.7B1>$,V\^F_>JM,B1MUC$V!0RJ#Z)O6D4L7O-4Q1*%%$6P1,^9(6SR L"
M_YLR8Q(R@<"%!T]WPNP.,%SX7A!-63B-/7_AMQOD48"'+)Q#XAPV3"D&/HR'
M$\)X%_8A(T_XOK_W]4)499GD=;ICD#$JD<Z$K;29X\V-*BI>/OV U>1S+376
MVI 9KSU/I+*9 FR*'*N!E6*%_::L@"_9>Y'*>RT>G0*?Y!)NV8S 7VS8-"P$
M^:;>OK2=+)K\./HPZC2V"L=T*A/V1JNZ8M>C3Z/OOYN'P>PG,N=O7 .<7%8(
M:&0A%=;T'*.\@Y%0I+&85;5.,E3[$;N''+[60N JLKB'G'ASH!-$ V@CX:^Z
MW B77-ACM4SHTV2<3B#=;FJR*B=S$U44X  *?/+@["_X P0QY+AL-E?\J7"L
MLY+,54YDY^'6,O;Z]HKQBJ3SW&,YK\LD<W \R:38-$H#+!':XHIFAN= +R1^
MK2J%:>SK14%1MA0N;+CB'6--4S%2H1O6HA%PFG3,Z.+AA/;'$UY)<%5^Z58:
MXE/5V8@&0#Q6POFG-F)5YXC!2G0U:8=*4J"D8BG4::APS'\MFO0Z=%)/8IH;
M!JA*1/I45,I(1)C+E"H>E7YHW$ '\V;3<?3@WUJX T-_M" /YN0-FV&F#7E=
MN0EQ0-_%5R%RUJ6I)%\BEX?!R._!G$H['J>U)E>Z*DR=!WS7X!_!.A<W5N[!
MJ:W8A_L* J ]^QUM1KA-3N=IJ\B^6?-GLK+-8K;2JB!J:;[A9>+22%*<#+JE
M!KPKA13&?QW1-M?!DF$0C.:]J63_NBMUM+H7HX;BQR)V9-V1TV:H'>MLW]2P
M-?4_T95"X8^"7C\P$?ED2(V=GGU\$<TM%9_6/RY?,V@KJ' U]K?E"(Y G68<
M-W;2I&,+0IL*2$ 3XU*^0AE1Z8C=[G&(G$3"#D.G10)^N#0](*8_FARX%Q.S
M;L(C3<D=Z*CS)ZKV)_Q+A:*].+W]2\U5O[WRT.Q!E3&'%P>B4I?-551KW9"F
MY8)M>_K6_;N;"%J@P<=JW300<(-]<O& [YP$YER_%*<J$GR'&DFR7PSV[BYL
MS4/F[-_K=-A=I3L./]_+'+FFZS6V0KLKJ6G/3%]WGP37A@EJM9_KUB@_3ZLT
M1.,21S'Z&]]]!_B>3&;40'BSZ0*MS=21M[>?GT+I5-GYW44(05SRG-*=7'4Z
MX78&G;$_8 D90@[_VI+ J4<-51C/:")$(9HN B]<1#2,:!BB;T+?AV%\.)QT
M!1%)M[) 16LW1U<TF\6'O=*I+G^\]YHJA%Z[-R/=@F!C\[#J9_MGZ57S&MMM
M;]ZT[[A>R]*P7*QP% DT&31A[P965>YMME06+SWWF>%I+31MP/I*@>OM@ 3T
MC_7+?P!02P,$%     @ -XIL4B:RQ#IW P  TP<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,34N>&ULM57;;N,V$/V5@1KTB1O=;UG;0)+=H@7V8F1[>5CT
M@99&-A&)5$DJ7O]]AY*B>H'$0 OTP?*0G'-X9H8<KHY*/YH#HH5O72O-VCM8
MV]_XOJD.V'%SK7J4M-(HW7%+0[WW3:^1UR.H:_TH"#*_XT)ZF]4XM]6;E1IL
M*R1N-9BAZ[@^W6&KCFLO])XG'L3^8-V$OUGU?(]?T/[6;S6-_(6E%AU*(Y0$
MC<W:NPUO[A+G/SK\+O!HSFQPD>R4>G2#7^JU%SA!V&)E'0.GOR>\Q[9U1"3C
MKYG36[9TP'/[F?VG,7:*9<<-WJOV#U';P]HK/*BQX4-K']3Q9YSC21U?I5HS
M?N$X^2:9!]5@K.IF,"GHA)S^^;<Y#V> (G@%$,V :-0];32J?,<MWZRT.H)V
MWL3FC#'4$4WBA'1%^6(UK0K"V<UG>T -]X/6*"UP6<,T\T')_1N+NH,/@N]$
M*ZQ L_(M;>F ?C73WTWTT2OT800?E;0' ^]EC?7W!#YI701'SX+OHHN,[["Z
MACAD$ 51<($O7A(0CWSQQ02<!<F6;'R]W1FKZ=S\>6&?9-DG&?=)_J]$7Z1W
M=_?&]+S"M4>7TZ!^0N_?[3FO5;-W>[92*;J$QF(-J@'R@D:U=)N%W .W0!7!
M;D?0.+RY0.+J19^PA ?<<>L2W6M5#Y6ERVT'+6F"UW3$A4NZNZO0(.&<;!>/
MJ.:)*TA8D$<L3,/13LN8A5D.[[N^52=$.%(WF7 [E-@(:Z L"Q9D"80L*E-6
M!NF2E5[IL3U09+RJ]$!!4KB68G.K8^0U.CWD$[&\R%F>A&3%><+R/(/;&23D
M$P&4/D$_Z.I C8)"+DEI$$ 1E2Q(\L6WYZ?.L5-/!6X,M=YG#/SX0Q&%T5L2
M2L 1O.4GZL35(VRULG,O(W.O>;?D]T2"0I(6)L'",%6B#%,6%2DE(&1EGL"O
MRO(6U*M5NH*0<I0F+"[":1 4"2NR<N9KEZ/S<FT_*?FF^@^I=84LTI3%64QV
M1A(*5H0Q':X&B<TA.WJ(S%*(@'YY1%:4%U3^9-87!PG+XIS$!"Q.LN_B?5G[
M%>04W\1V!07+XYS%40POW7G_K-%VJ/?C<^+NQR#MU'.7V>7%NIT:]3_NTW/W
MD>N]D 9:; @:7.>I!WIZ0J:!5?W8MG?*TB,PF@=Z=5$[!UIO%!V'>> V6-[Q
MS=]02P,$%     @ -XIL4C ?E[S9!0  MP\  !D   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&ULK5=M;]LV$/XKA)8.&1#(EI(V:9L$R,N"96C7('W9AV$?
M*.EL<:5(E:3L^-_OCI1DQ9:];MB'Q!1Y]_#NN1>2YTMMOMH2P+&G2BI[$97.
MU6\F$YN74'$;ZQH4KLRTJ;C#3S.?V-H +[Q2)2?I=/IJ4G&AHLMS/_=@+L]U
MXZ10\&"8;:J*F]4U2+V\B)*HFW@4\]+1Q.3RO.9S^ CN<_U@\&O2HQ2B F6%
M5LS ["*Z2MY<GY"\%_@B8&D'8T:>9%I_I8_[XB*:DD$@(7>$P/%G 3<@)0&A
M&=]:S*C?DA2'XP[]SON.OF3<PHV6OXO"E1?16<0*F/%&ND>]_ 5:?UX27JZE
M]?_9,LBFIQ'+&^MTU2JC!950X9<_M3P,%,ZF.Q325B'U=H>-O)6WW/'+<Z.7
MS) THM' N^JUT3BA*"@?G<%5@7KN\A8R=SYQB$3?D[S5N@Y:Z0ZM)&7OM7*E
M93^K HKG !,TH;<C[>RX3O<BWD(>L^/DB*73=+H'[[CWZ]CC'>_QB]T*FTMM
M&P/LCZO,.H,Y\.<>\),>_,2#G_Q+TO9J47F]L37/X2+"^K%@%A %.S\H]B%W
M.@/#3@,#1\R5P&YT57.U8J <&"B84$XSSCZ5PA3L"DNCP#_'<)*D'V&AY4*H
M.;M!8>'8;]H!XZI@=[HQKAQH'/[XPUF:3M]N+OCIY.U/.R'?::[8U=P >)RE
M0.T'H13/);!KKKZR0])KX?N57J/;($8G@&DCYD)QR;8%V9);5G"'7O_:R!62
MDIP&I2UG:J,7H@#+L$4A.[41*A<UHO(%%Y)G"$LKF3889O)%SUA3DXL'R4NL
M*2E]>T">;IH*8R!I6.+VY G/A!1N1=(&OC5@'4IB('+L@!;64#C)"V0(H7#G
M@Q[W"-<1G: L=\+.>.A&J)B#<=@U6:Y54+3>"%Z30PB2K9Y3&[/[&9LU$MF
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M#A]Z?EAB8,"0 *[/-%[AVP_:H'^K7_X-4$L#!!0    ( #>*;%+DWZ&ZQPH
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M#VZ?<036@%6A5F -)K-DQ(S_B.4?;+UQ'XZ6M;5UZ6[72B*(1(#WJQK[;O=
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MC+^D_- %TVL4@*&!8N$\.?E(=:S1:10RQM-8LY,EMHAB-<(B9@E?%$8M#E3
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M+K;! .L;8_SP$388WW&K?P!02P,$%     @ -XIL4GJ? [?(!P  )!,  !D
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M0#3NGY[T0I6V-]ZL^3O(W'AO2KZDL4Y9VH#G"V-\>T,';#^,7?X74$L#!!0
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M3P/034=N%E:5O@O.E:6>ZJ<Y/6*HG0/M9TK9]<(EZ)[%R2]02P,$%     @
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MOARG9@^4E K4HS-YS1INSX 3X0D!Z\/;*E_;DD""1?6<Y(CY4P=@2.]#4YV
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M7%V(7.-Z;([O;,L>T%;N'IE5*R<M4'.6MC5*&G=<$\:"3TL\I3D I_*0+MT
MT//D_99;L[I"PZ@H+"I:8H"T#"5V\&IV'+7@.")B]8P[=BDF8Q:A<DF#%J=X
MZ^QX[&(<NG@58XY-*O> RFM?^.'-L/A\$H;ADF@@^1P5:&FAW@7G:5W%XH#E
MA'@QPI6Y!,Z9"?.CW!%ZARZ/]_N\JCKRM-A=/R(N/W,-/LE?2?:PH3&5@2W"
M*U&IS<I>B<1GA"E%2!06, 4E=3H9<)0TX R(T+03-N-D"4)JHTWJ12>M*7KG
MOQ9D&A=W9&L3$[>%-.3X4Q2M% %XWA#WP1+)C541(@!)U,GI%[(>BM;25*P
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MM&A>7)QIUY=Y*]IFL';*A?;: L>%*"CV':%/JU4[[AT<10O"F89A&XY):#!
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M<R*1'ONCJ[?\H\"$3#*/^9_X\4#7X 'Z'J$ ^P,;^)^)_OE_ %!+ P04
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M^<>+I%>Z-\BV<0:VEGBBXK+F)PQ=".#]TEK:&R'!^"@N_P)02P,$%     @
M-XIL4GPJD:;I!   I T  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MM5=;<^(V%/XK&IIIDQEOL TV)@5F8'?39F:WDTG2W8=.'V3[ .K*$I%D"/OK
M>R0;8]*%IFWZD*#+N7[GHN/11JHO>@E@R%/!A1YWEL:LKKI=G2VAH/I2KD#@
MS5RJ@AK<JD57KQ30W#$5O!OZ?MPM*!.=R<B=W:K)2):&,P&WBNBR**C:SH#+
MS;@3='8'=VRQ-/:@.QFMZ +NP?RZNE6XZS92<E: T$P*HF ^[DR#JUELZ1W!
M)P8;W5H3ZTDJY1>[N<G''=\:!!PR8R50_%G#6^#<"D(S'FN9G4:E96RO=]*O
MG>_H2THUO)7\,\O-<MQ).B2'.2VYN9.;GZ'V)[+R,LFU^T\V%>T@ZI"LU$86
M-3-:4#!1_=*G&H<60^(?80AKAM#972ER5KZCADY&2FZ(LM0HS2Z<JXX;C6/"
M!N7>*+QER&<F=Y"S!P5/WW\7#/H_$BIR\HFE%*&J3\X?:,I!7XRZ!M59IFY6
MBYY5HL,CHH.0?)3"+#5Y+W+(#P5TT<[&V'!G["P\*?$=9)>D%W@D]$/_A+Q>
MXWS/R>L=D3<K-9YH3=[*(F6"VCS1Y+=IJHW"=/G]A(I^HZ+O5/2/J+C'*LI+
M#D3.2:-NFCV63#.GSB/IMGWP+9Q/JK!E>Z57-(-Q!^M2@UI#9_*P!#*7'&N.
MB04Q-H9UX;&OH(G!:R90(>5D1;=894:[X&=H$LM!.2Q0@G*DZ<[R; _4%:+6
MHL4MU4L4QG)"#<FXU%;S&<;*\WWWMZ-PZDA>*DL 5/$M$@5#$C6$UY0ILJ:\
M=+BA309)+=.A>6^(P+:E*>8G47)+N=F2H1<DH1/R( UZ=\AQ1GK]AN!$>*,F
MO-%_"^^SZ'H6M)TS!_A]*^XG=;\\[N[6!MB&,EM2U*XQ^FZ+F;^B8ON#)A]@
M#9STCJ/-&4T99XBQ66*$&6(.!5!=*G AG[>"ANT6;[-2N1ACVV3ZDEC;CDK'
M/!!6#N8@S3)5XAI-Q,?'WML\><)W2%O#=95D1CH'L,%S4.2QI,H IM)E&^%C
M#LPHIR(#:_4O<@U%BA*"T/:5(,$<&7H^IHG+6(>6M63^LI1D(N-E?M3X\[Y+
M\(OC1KX8A\A/G(DM7[ _5KY4/;+V)?*K=)_F?^![XFH/L=M5_Z%?YE2(]O@%
M_>2O!8WLNR*L:]M*0\.9S,EY@)CVO,!/+EX?U,3'HHX'KX%J@NTJB?NG4!TB
MJHD7HS=1,OPG$"2!;4[^_P! @.[['KZ*KP%!X$7]V.OUXQ,@A+X# 4<_+XIZ
MISIIW'32^,6=] XRN1#X4.7D)D=/V)SA<JHUF+J[JMJ3#W5*,K0;[\OB^9Q1
M-=*3JO_U TKQ-JO K4MG'TZ].Z*5U;2Q>G^S?Q9(3@VXU[8>OJ[(-18HCG4Y
M64B9VW:]1B"DVB+NL1>'57OZC!.OC>)*R<R^/&](*3A-<>;-R1JK6Y.>-QSX
M1VC14)97]E?$@9>$ T=\1S<X96)#=>>8MN&P]::VC0DQ7:)*PXTPMAEGIK13
MA;*IA85 "ZD,^^H 9,)@YC.[K'$Y(T'@#6H!/Z&K&\8Y20Z>\#U7-:,L=F38
MLN->F_(YV'_[W'=;DW,!:N&^#^R84PI3#='-:?,),JTF[SUY]?WRD:H%PP>?
MPQQ9_4L[\:OJFZ#:&+ER<W@J#4[U;KG$SRA0E@#OYU*:W<8J:#[,)G\"4$L#
M!!0    ( #>*;%)WHYCA' ,  #H&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;(5576_K-@S]*X1W,6R 5DOR=VX2H.W=L&&X6-!VW<.P!\5F$J.R
MY4E*T_[[47;J=4#;/=@6*?+PD!+IY<G8!W= ]/#4Z=ZMHH/WPR*.77W 3KD+
M,V!/.SMC.^5)M/O8#195,SIU.I:<YW&GVCY:+T?=QJZ7YNAUV^/&@CMVG;+/
M5ZC-:16)Z$5QT^X//BCB]7)0>[Q%__NPL23%,TK3=MB[UO1@<;>*+L7B*@WV
MH\%]BR?W:@TADZTQ#T'XI5E%/!!"C;4/"(H^CWB-6@<@HO'W&3.:0P;'U^L7
M])_&W"F7K7)X;?0?;>,/JZB,H,&=.FI_8TX_XSF?+.#51KOQ#:?)-DTCJ(_.
MF^[L3 RZMI^^ZNE<AU<.)7_'09X=Y,A["C2R_**\6B^M.8$-UH06%F.JHS>1
M:_MP*+?>TFY+?GY]@X_8']'!=W=JJ]%]OXP]P8;-N#Y#7$T0\AT((>&KZ?W!
MP8]]@\U_ 6+B,Y.2+Z2NY(>(7["^@$0PD%SR#_"2.<EDQ$O^+\D_+[?.6[H)
M?WV FLZHZ8B:OH-Z2PW2'#6"V4%/[3-8TQQK3U?U'&W[_*)[JZ@?@H=>7+A!
MU;B*J-D<VD>,UG<'A&O3#:I__O:;4HKBLWL[<FVH:YS')G#SY+4SFMJO[?>T
MLJ/F&95U@.'$@.J-W18MU7PQUIQ>H@JO$C83MEO KY8@E38.X1.(C&5Y08\,
M@F1EE3%!CJ/ LXSE,H/[=JNHZ4!P5A:<516'DN658%G&(6.\H"<KX%KIQFCB
ME;$DR5F5)K224C)9RF#&!;D6<%FC5XWQ"(+@4B9Y#@DK9<K2M *2RY0)(>"W
M#FNM.O/TPT8]@,P*QLL2RJ0@VPIRF3!):/=JH'RHWP3Q*"A< 14%ST5&FB)/
M0@BXP::]L_@$949;1'4LN_P\?^\,5>3M,_@$2<;*E+.\2((@6<J)0IJ1($M6
M\H15N8"W+F+\JI\[M/MQ:H53/?9^:NU9.P_&RVD>_&L^3=6ORN[;WH'&';GR
MBR*+P$Z3:A*\&<;IL#6>9LVX/-!P1QL,:']GJ.)G(028?Q?K?P!02P,$%
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M_ 087VGM#H8G&"](\_\!4$L#!!0    ( #>*;%*1Q&0:H ,  %$(   9
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)U6VV[C-A#]E8$:%"W C>Z6E-H&
MDNP6+; 7(]FV#T4?:&ED$Y%(E:3B]=]W*"E:+Q"[11\L#:F9,V=NI)<'I9_,
M'M'"E[:19N7MK>UN?-^4>VRYN58=2OI2*]UR2TN]\TVGD5>#4=OX41 L_)8+
MZ:V7P]Y&KY>JMXV0N-%@^K;E^GB'C3JLO-![V7@0N[UU&_YZV?$=/J+]K=MH
M6ODS2B5:E$8H"1KKE7<;WMRE3G]0^%W@P9S(X"+9*O7D%K]6*R]PA+#!TCH$
M3J]GO,>F<4!$X^\)TYM=.L-3^07]YR%VBF7+#=ZKY@]1V?W*RSVHL.9]8Q_4
MX1><XAD(EJHQPQ,.HVZ:>E#VQJIV,B8&K9#CFW^9\G!BD =G#*+)(!IXCXX&
MEF^YY>NE5@?03IO0G#"$.E@3.2%=41ZMIJ^"[.SZD]VCAOM>:Y06N*Q@W'FO
MY.Z-1=W">\&WHA%6H($?/O-M@^;'I6_)MT/PR\G/W>@G.N,GC."#DG9OX)VL
ML/H6P"?2,_/HA?E==!'Q+9;7$(<,HB *+N#%<R;B 2^^F(F3:-F<EC]OM\9J
M:J"_+OA)9C_)X"<YX^>1YJKJ&P154T^6NL<*FJ]>7TOM14 WMC>FXR6N/)I+
M@_H9O2F:<@K@!!]*11-E+'DE J0%M6IH-(7< ;= 6<5V2Z9Q> /G05S.Z1$6
M\(!;;EVR.JVJOK0TJ;;7DC9X1?TJ7.+<X$&-9.<:S#$4Y;1Q!0D+LHB%:3C(
M:1&S<)'!N[9KU!$1#G0TC'9;E%@+:Z H<A8L$@A95*2L"-*Y4)W2PZR?I);"
MM12;^SI$7J'C0SH1R_*,94E(4IPE+,L6<#L9"?E,!DH?H>MUN:>IIY +8AH$
MD$<%"Y)LUNWXL77H=$ "-X;.T1<;^/Z[/ JCGX@H&0[&&WZD\I=/L-'*3@<3
MB3O-VSF_1R(4$K4P"6:$L1)%F+(H3RD!(2NR!#XKRQM09ZMT!2'E*$U8G(?C
M(L@3EB\*N-#'Z=S'Z7_NXY%",Y\9_]+/%X$O]?.K'DZ:\:.2;\K_T0NN\_(T
M9?$B)GE!.<M9'L8T#342FK-LZ1HT<^<$],LBDJ(LIWY-I@+%0<(6<49D A8G
MBV\*]#KW*\BH("/:%>0LBS,61_&K!?)/COD6]6ZXS-Q ]]*.)_Z\.]^7M^,U
M\55]O&P_<+T3TD"#-9D&UQF51(\7V+BPJALNC:VR= 4-XI[N?-1.@;[7BOIW
M6C@'\[^(]3]02P,$%     @ -XIL4AAJ$!$"!   >0D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&ULE59;;]LV%/XKA%9L-L!&-^OFV@9RZ; !;1$T
MW?HP[(&6CFPB$NF15)S\^QU2EN*TB9N^2#SDX7>^<^$A%WNI;O46P)#[MA%Z
MZ6V-V<U]7Y=;:)D^DSL0N%)+U3*#HMKX>J> 56Y3V_A1$*1^R[CP5@LW=ZU6
M"]F9A@NX5D1W;<O4PP4T<K_T0F^8^,PW6V,G_-5BQS9P ^:OW;5"R1]1*MZ"
MT%P*HJ!>>N?A_"*Q^D[A;PY[?30FUI.UE+=6^+-:>H$E! V4QB(P_-W!)32-
M!4(:_QTPO=&DW7@\'M!_=[ZC+VNFX5(V7WEEMDLO]T@%->L:\UGN_X"#/XY@
M*1OMOF1_T T\4G;:R/:P&1FT7/1_=G^(PVLV1(<-D>/=&W(LKYAAJX62>Z*L
M-J+9@7/5[49R7-BDW!B%JQSWF=5[I@07&TTF'Z364W(-BMQLF0(R^<+6#>CI
MPC=HQVK[Y0'SHL>,7L ,(_)1"K/5Y+VHH'H*X"/!D64TL+R(3B)>07E&XI"2
M*(B"$WCQZ'7L\.(?>?WH[C_G:VT4%LF_)_!G(_[,X<]>P+_!LU-U#1!9DY(U
M9=<P5X,HBJX%Q8Q4A(D*ZT=(S*J3N2 P\-HA+VUY/1?]D[;M*9[K'2MAZ>$Q
MU:#NP%M]V0*I98-'$.&)L9E%?+G7Q.!**=M=9T:*=NHI33MS3+73@)-R] U7
M>=,9G!P]F#2NGD9'T+QR. ^HH@G8RB"85VC7J!*'<Y=;_(2%_>3DT\!@3CYA
M<^("6<( 6RO9(FUAN.BL1]BDE..OR1LR26D:)33+BJF5"AJ%(4WSW$EA0/,H
MH$613LD5UP<,Y'($$=,H2&F>)22A:9K0,,MP+LLC&D6S9]A,8CH+<UH$,S=.
M9BE-PA#'&0WB'(E$4[?+:A-FL .N-:\X-D&4C.+KKL\(1E1(82DIS)7UBPL#
MF$2C25;069$21$LBDJ%WP7-,OH7#M1:3ZC*PE4T%R@4HIG&,>$$?$F0<9XC;
MARNE11K3(,6UJ\>4S\E7U^"@>LON,% ;Z$$UP4ZO#1:)I?OK+SG&^IWMD[PD
M(48NC6B8S^PP+E(:%+D=IN&,!NC&E2T:;,H$ZAJ[M*T]ZZSBI2TE['WEK2N_
M?B1W?7:<D>C==_^?(3B4ZP\IGF@&R=@,DE<W X;5]K8:W-90=HH;CB3AOFPZ
M>R0.E?WD0+ZN+9QD\7);N$1;3#S\IK\A=YR)/I#?I^(XM'LL5,+TH<WHGS[O
MYT]#\VAR,!86&:8E()B8 +]XI)/@V?SX1]<A]I"-N_0U!K43IK\9Q]GQ77'>
M7Z>/ZOVCY"-3&XZV&ZAQ:W"689!5?]'W@I$[=[FNI<&KV@VW^#8"915PO9;2
M#((U,+ZV5O\#4$L#!!0    ( #>*;%+W>%\Q=08   81   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;)U8:V_;-A3]*X27;3; QB+USI( :;IB!;HM
M:+,-P[ /M$S'PF31):DXV:_?(27+:J)XW3[$>O&>^SKW7C+G.Z7_,FLI+7G8
M5+6YF*RMW9[-YZ98RXTPIVHK:WQ9*;T1%H_Z;FZV6HJE%]I4<QX$R7PCRGIR
M>>[?W>C+<]78JJSEC2:FV6R$?GPM*[6[F+#)_L6'\FYMW8OYY?E6W,F/TOZR
MO=%XFO<HRW(C:U.JFFBYNIA<L;/7F5OO%_Q:RIT9W!/GR4*IO]S#N^7%)' &
MR4H6UB$(7.[EM:PJ!P0S/G68DUZE$QS>[]'?>M_ART(8>:VJW\JE75],L@E9
MRI5H*OM![7Z0G3^QPRM49?POV;5KDW!"BL98M>F$8<&FK-NK>.CB,!#(@A<$
M>"? O=VM(F_E&V'%Y;E6.Z+=:J"Y&^^JEX9Q9>V2\M%J?"TA9R_?U87:2'(K
M'J0ATUNQJ*29G<\MH-V">='!O&YA^ LPC),?56W7AGQ?+^7R<X Y;.H-XWO#
M7O.CB&]D<4I"1@D/>' $+^P=#3U>^*^.DC>E*2IE&BW)'U<+8S6H\><1%5&O
M(O(JHA=4?$3%+)M*$K5RQ)!:RR6Q4"B,D=8042])58I%696VE(:26MJQ4!_5
MXJKTS&Q%(2\F*$,C];V<7-ZN)8%_6U7+&II@@,6;:[P1]>.WQFD:-\D2!%IN
M%E(CV$0@),*0E:I0K.;,QQX_+,>J3M@%\*H5_@F@Z Y:V+*^(XAHZZ*#+["T
MQ)(3PA*:)XPF<;!_B&B2Q>1&.U'[Z$7DIZ;<HM2M?RIK*^J[TE&1<)[2($[:
M:\K)E;-,U(6$D1HU7:C&.:SA1'GOV$MXE-,H"PF/4QHG$?G0QLBOEP_;TCFQ
MU6K9%)9$849Y&),H@4R2D'?U/8Q0^I&P(*!APDD84Z@^N%^LA;Z#77G,:<H8
MR:*8IDE,KIM-4PG787P>T+6$[SJ%,C"OK(O&B^,-R@.JG7?>;1>!G=!+0/*,
M)F%&& VBE+(H)[?*BFHT;RRG69Q1!MO=;82X\NSS)+T_, U^[2.Z!Y@F":<!
MBV9DRFC(0N0EGOF,CJBC9"$1/DGN1=6T?HD^#]#/\H0RS@C+:!QR0(7DO33@
MSW.L48CI </9 Q3&*$O8BP:!2M]\E7'&O\,=9S0+.#E2P'%?P/$7%_!*+L'L
MRA/26&&EKZ$G="^$UH^(C$_@6"D?U?=R*;<%Z-18S^EV9)9_(Y6NKL7&L=Z;
M]BB%=N9Z9K=Q?5;\_]T5UP0 ,V@-;1\^([]#GWFB\&V'_]%C8QW[+#\1#2..
M\HK<)TY>N4O>?T?]!/B+(H[W84"BB+(XI!EZ3@2&N\SB/?-B84Y0TR$ 8T9
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M,H(:5V3J3Z9T!<ON_=8MM-C8-]-2:'J!67%-3UZ41H'.5T+H_<(X&![1B[\
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M1X>709A8M?&W\5Q9O-O]<(V/*=#N .XOE;+[B5-P>)Y-_@-02P,$%     @
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M/YKW&&UE38O 5R#J ]<80M.Y2)1QG- L J82K*8#*9,"IXP,1)D$XTDD2IG
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MM T'X/W*&#\M L'\?^CD;U!+ P04    "  WBFQ2UOP$??\#  #=#0  &0
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M3BYH3( *$?B2TMS[,ZF"H#-UZG<2!%K(@Z[M[%IRVB4,D6MY0;A+=Z:A<\,
M^OXNW?LN76#;EM^6^T'#S[9<UVV5Q,<NG1?:KF.W]#O7\'/4JN*T^%UH]/-1
M&'BM"%_ZG0C;BAN$;4.N-(2.'00H;-=LEQ"%MN,$H://F:#.F<"<,XS'- (?
M.,O68'+X]=#0 ,.:9_AJ319:S99I_3_97LGIUJW>LW!K#X9&#:^)7#*I-F$E
MV60R:ABBUW-L,R*A_6M;XZ1BN-LP#!YL)BDTC](KBN<T4786GP-1QKEV%9_
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MI]5%D:*XH10;Q7-SHDZYPO/9+!=XJP.A'?#YC'/UO-&'='5/'/P%4$L#!!0
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M:[IUH7* >;Z6YHU1W>03U/W_[']02P,$%     @ -XIL4F*F'4VC P  Z0L
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M- %POA-@G\W"O*"=[I?_ 5!+ P04    "  WBFQ2:(1,NM("  #1!P  &0
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MBZPZG#.:,%D&F.^G0NC7DW* YE\"X_\!4$L#!!0    ( #>*;%*X1>%8= (
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M1_%H1T!7GX9'YSO@Q>?A9Q]DDPPE23Q?\I^2')$9IUB+MY7Y?3DW5N.X_/G
M53JX2KVK=&_HKU4^(DR6O*V87!(JE+;LI:N^!DXM5,0JP@%'K%:\(DPT6JW
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M7] _-(=WAWGB1MRH\K,L['(:I $JQ)RO2_M1;?X4W8$BCY>KTC2_:-/&)CA
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M1\ANK1E.>_/?FA=NIG/SWJGFVIHQO(8;P]:.X7Q^#",^2U,\Z-!.[,,XDE
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MBLLEP1'AN8%Z/V=JDU_=Y /41\6C?P%02P,$%     @ -XIL4IY\Z/!_ @
MRP8  !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULE951;YLP$,>_BH7V
MT$I= 9L J0A2FZQ;'R95K;H]3'MPX!*L&IS93FGWZ6<;BK*%--U+\-G^W^_N
M<AQ9*^2CJ@ T>JYYHV9>I?7FPO=544%-U;G80&-.5D+65!M3KGVUD4!+)ZJY
MCX,@]FO*&B_/W-ZMS#.QU9PU<"N1VM8UE2]7P$4[\T+O=>..K2MM-_P\V] U
MW(-^V-Q*8_F#EY+5T"@F&B1A-?,NPXMY:N^["]\8M&IGC6PF2R$>K7%3SKS
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MQI2 1&H#>+_F7.UN]-FV^7ME_B]02P,$%     @ -XIL4KR4;/=+ @  V00
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M^U_O1R@KS]K:3R]$VB5#JJZ[J-C@YRO/<++A&%OE<>=\49]HOR?Z_$^BA&X
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M8DO^EPX<P?[^"G/E,LBQP):#URZ#H<\XMUKMC0/H>Z&/K4AN'3AH6\(R-W/
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M#0!^7RBE7U_, -W5XN0_4$L#!!0    ( #>*;%+K'8+6;0(  /H%   9
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;(U4R6[;,!#]E8%.#M!$BQ5G@2W
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MSJB<@;U?26FV@G/0K?OL+U!+ P04    "  WBFQ2<YF > \#  #7"0  &0
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M8PNZ*=17OOW(FH)"@S?GA:Q_P;89&WA@OI&*ETVPSJ#,J]V3/C=$= (@Z0E
M30 Z-P W ;@N=)=97=8M570R$GP+A!FMT4RCYJ:.UM7DE?D;9TKHK[F.4Y.[
M:LY+!OZFSTR"JYE62;8I&. +\$5KZ*\U$U3EU1)\XE*"*17BEY;.EHI,O@57
MMTS1O-"M=^!A=@NNWKP=^4HG9:#]>9/ ^UT"J">!6S:_!AC^ 5" @B/AT[/#
M8;H?[FLJ6CY0RP>J\4@/W@>6Z9(+!Q)ND7"-A'N07-R!;Y_T:'"G6"F_.^8B
M[5S$F;6=JS!SS;MS'?M+=FAAC686^M,DC$A"2$I&_M.1/,(VC]"9QTQ1Q1SU
M1"U.-#AW<3M7?$GNIO$A=VF*TSB!Q[E+VCP29QY:_Q#\!J<%F+: Z> DPL#Z
M2'!1"39P48?'X#B!L.-E\!P*3ZD06C. :'@*K6% ?%$E-G!="@DFB$0]JQA:
M.X%N/]%$(FWJ^I&>)4EH#0*&PS-J;01&EQ5E=+8HK;U M[_L<WE2F]8N8#(\
MD]9+8'I9;::'V@P#$A*"CA.*K-,@M].@  =GJ1)9XT!P<"Y19XOAWF.\5I4-
MW!Z7!(8X,3N>HUQ:RT%NRVFX/*5*9)T#D>&9M&Z"W/N-UZJR@=M799($?9JT
M1H/<1J-YA/4BQ^<9)K+V@>+A";6F@MR;D%=+,SD@- XQP6'/9@A9PT%NP]EG
M])1 L74/' S.)[;&@MT[DM<*M('K\IDF*$6P1Z'8F@YVF\Y=I0^W>94K!NZ9
MR'EVEDYQY[0S_'$'6YO!ESWPX,,3#XG3"*.>K1*V%H3=%G2,UY-JM;Z"AS\(
M8>LU^+)'(7QX%D(13J+_+WZ_<S]A+H<^4[',*PD*MM"!P76L$<3NOF7747Q=
M7UD\<J5X63=7C&JQF@'Z^X)S]=(QMR#MK=?D/U!+ P04    "  WBFQ2,E/+
MR!P#  "Y"@  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6R=5EUOVC 4
M_2M6M <JK<TG 2I *J35]E"I*NWV;)(;$C6QF6T*^_>SG9 ",2G="\3..<?G
MQ-?)'6\I>^,9@$"[LB!\8F5"K&]MF\<9E)C?T#40>2>EK,1"#MG*YFL&.-&D
MLK ]QPGM$N?$FH[UW!.;CNE&%#F!)X;XIBPQ^SN#@FXGEFOM)Y[S52;4A#T=
MK_$*%B!>UT],CNQ&)<E+(#RG!#%()]:=>QNYFJ 1OW+8\H-KI*(L*7U3@Y_)
MQ'*4(R@@%DH"R[]WF$-1*"7IXT\M:C5K*N+A]5[]08>789:8PYP6O_-$9!-K
M:*$$4KPIQ#/=_H Z4%_IQ;3@^A=M:ZQCH7C#!2UKLG10YJ3ZQ[OZ01P0W/ ,
MP:L)WBDA.$/P:X)_*2&H"8%^,E44_1PB+/!TS.@6,866:NI"/TS-EO%SHO9]
M(9B\FTN>F/XD,2T!O> =<-1;R+)*-@4@FB*1 9K3<DT)$,'5S <6S8! F@O4
MN]_)"N1PA7H1")P7_ I=H]=%A'K?KL:VD [5.G9<NYE5;KPS;EP//5(B,H[N
M20+)L8 MHS7YO'V^F=>I&$%\@WSW._(<SS$8FE],=T<&>G0Y?=B1QF]VR]=Z
M_AF]^88QN1NW'5)!(Q5HJ>",U ,DP'!AVJ.*V-=$]=YXGWKNT/'&]OOA@VNC
MPG[@#(]141OE-(@CW_W&=[_3]T)@ 0B3!%%9H<SDOQ((#]:\[O='K0!MV&#D
MN^%) (.8&X9^:$X1-BG"SA0O5.!"GF^]G2BO#I:0!ZL'^P.UK(Z8*6#8]N0'
MKN.<!&S#W" 8>,%)0H-:1\)!DW#06:H1I"#3)5VU.FRTAO];J\.V>5.Q&F"F
M:FW#SE3KJ'$^^KQ:3;Y''2M5EC]%1%V(([>N\_$U<#K][G?MRR59ZWZZ$2:<
M:2<,N'/A#CYU[@6'[LO)W-8KS/@Z,>!,[Q.3G.FXV0??]!+82O=&',5T0T3U
M^6MFF_[K3G<=)_,SU9?I7N%#IFKJ'C%;Y82C E(IZ=P,I"E6]4G50-"U[AR6
M5,@^1%]FLK<$I@#R?DJIV _4 DVW.OT'4$L#!!0    ( #>*;%(X32!#50,
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M&MQIN\,E<+1N>P->GTMIGD_L!-7GE=%?4$L#!!0    ( #>*;%)WU)V>' ,
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M9IBJ7A>X+E#/YXS)[41O4'?/PW]02P,$%     @ -XIL4J%T>I/4 P  \A
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M2('(VEYI>W;& <K*=_1PB&+RYGH)Q8W,X_^N\R1)!"1$ :(:/=7C9H1>2%I
M:[(G_?V^UV3E-#FFV&@_=HN_J^3.HSCM!><?#(,9B,0.U5(??\%4.3S5J_7@
M_F#'U0_K2S/0VR&S"5/^&_"-""W?$J6PU2&#NWN-1Y0#=GFC>&Y'S@U7>H"U
MESL@,0ACH)]O.5?O-V:#^F^.Q;]02P,$%     @ -XIL4HFE#UEZ P  70P
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M#3R^N65_FML!DA&B1^#JNBO7["BA$M"&IAP=:7: &SL9NY<#VGUH+Y_.+.]
MJ<[=<N"HD9S CN-6!GNL0ML=2"!NW#OX77O] 1GE0'$#T+.#L"VC:Q78XX&%
MB\E%!GG/6?" "M+A\^V0M%5TK4([&CAV\>4&PMX[3XH'A'@]B8ZCMI"N56B3
M 1V7:P_??>^U#I(']/@]NZ2[O/JL&GNI%.0T"K4<^-;4KP*MV:&09?U2]]8U
M\I.I#%O]<UT[FP+P$J8LO+]1K@X)@3+8J)"N':D[D)>U;-F0;&_*P163JK@T
MKSM5_P/7!NK[AC%Y;N@!ZG\4LS]02P,$%     @ -XIL4J61$[KP @  P0@
M !D   !X;"]W;W)K<VAE971S+W-H965T-S@N>&ULI59=3]LP%/TK5K0'D!CY
MZA>HK40IT_: 5,'8'J8]N,EM8V''F>U0^N]W[:19H6E [*6-[7O./<<W]LUX
M(]6CS@ ,>18\UQ,O,Z:X]'V=9""H/I<%Y+BRDDI0@T.U]G6A@*8.)+@?!<'
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M&*!L *ZOI#2[@4W0?+5,_P)02P,$%     @ -XIL4H^UYU^+ @  Z 8  !D
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MWT"')M&%;=&<2V(^QR6Z*$!A0N4E&J&'18$N/EQFKM(;&II;MN*WC7AP0KR
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MS4<.2!M@[D^%T.N)/4:7GTW]?U!+ P04    "  WBFQ2Q;<ARP0#  #B"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6RU5EUOVC 4_2M6I$F=U)$X
MX;,"I +[J+1.%6C;P[0'D]Q AF,SVX%.VH^?[80 +0F=1%]([-QSSKWW).;V
MMURLY!) H<>4,CEPEDJM;UQ7ADM(B6SP-3#]).8B)4HOQ<*5:P$DLJ"4NK[G
MM=V4),P9]NW>@QCV>:9HPN!!()FE*1%_1D#Y=N!@9[<Q319+93;<87]-%C #
M]77](/3*+5FB) 4F$\Z0@'C@W.*;"6X:@(WXEL!6'MPC4\J<\Y59W$4#QS,9
M 850&0JB+QL8 Z6&2>?QNR!U2DT#/+S?L7^PQ>MBYD3"F-/O2:26 Z?KH AB
MDE$UY=M/4!34,GPAI]+^HFT1ZSDHS*3B:0'6&:0)RZ_DL6C$ 0"W*P!^ ?"?
M IH5@*  !"\%- N ;;6;EV+[,"&*#/N";Y$PT9K-W-AF6K0N/V'&]YD2^FFB
M<6IX3\1*OUUCSD)@2A!CAD17,_U^11D%Q&,TA0VP#.1Q$(H%3]$]^<4%&ML\
M04A$6(2^$&%"-O 674U D83*M^A=&?2$9IK(5=]5NA23D!L6:8_RM/V*M+&/
M[CE32XG>LPBB8P)7]Z!LA+]KQ,BO99Q V$ !OD:^YWLG$AJ_&(Y[)^"3E\.[
M-=4$I:V!Y6M6\,T(U885SEVCCYQ'4E\$EQ+]W5N!:Z2:I5332@454L_M1#\^
MZQATIR"5/VL46J5"J[:88P6A%:[1&H39TT?3J9>GGL]O-3SOS2F/ZW$!KL!-
MSNAUG^..&M$N&]&^A*M^C52GE.J\DJO=4J%[85?K^:I=/8,[X4[NZO_K'36B
M5S:B=PE7@QHI[.V/>^^5?,4'?RGXPLZ>(?2K/KSQ&2#N5'E[3K%]QESL[[OA
MUU+=AB'/F#(.AY!LR)Q"'>_^A,?!:SFY/]IQ\]).UA.VO4HGZX&M7I4A[L'P
MH[^3A1TB);)-S__^R]UR4+VUX]F3_9$98.U0M:?)IU\])"T2/191B#6EU^CH
M\U[D V6^4'QM1ZPY5_ICM;=+/82#, 'Z><RYVBV,0#G6#_\!4$L#!!0    (
M #>*;%(^CTXQ+ (  / %   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM
M;,54RV[;,!#\E85."1!8LOPJ EE '*-H@*8(8K0]%#W0TDHBPH=*4I;S]R4I
M67#:V"EZ:"\BE]R9G1V!F[12/>D*T<">,Z&7065,?1V&.JN0$SV2-0I[4TC%
MB;&A*D-=*R2Y!W$6QE$T#SFA(D@3?_:@TD0VAE&!#PITPSE1SRMDLET&X^!P
M\$C+RKB#,$UJ4N(&S>?Z0=DH'%ARRE%H*@4H+);!S?AZM7#Y/N$+Q58?[<%U
MLI7RR05W^3*(G"!DF!G'0.RRPUMDS!%9&3]ZSF HZ8#'^P/[>]^[[65+--Y*
M]I7FIEH&[P+(L2 -,X^R_8!]/S/'ETFF_1?:/C<*(&NTD;P'6P6<BFXE^]Z'
M(T <GP#$/2#VNKM"7N6:&)(F2K:@7+9E<QO?JD=;<52XG[(QRMY2BS/I/1%-
M8:UI%!4E$)'#IJEK]@PWI4*T[AL-?Y)S\8DH19S#EW"Q1D,HTY=):*Q$5RC,
M>CFK3DY\0LX:LQ%,QE<01W&D716*ZB5-:#L<VHR'-F//.SW5)A64-_P,TV1@
MFGBFR5\;!M\^6@S<&>3Z^YF*TZ'B]+SVEQ4'SZ] -'R+"F0!M:+N3<'!,@WV
MO0*2K+)7,F\R\]J_Z.K.?5WW>G?I. EWKTB=#5)G;TC=OV'S?&":_R.;%T/%
MQ7^R>?&;S?$O-H='#]C-PGNB2BHT,"PL)AHMK.VJFR]=8&3MW_16&CLA_+:R
M(QF52[#WA93F$+@Q,0SY]"=02P,$%     @ -XIL4HD'IL7C @  D0@  !D
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MO:M(LQ)M ]M.%*]M2[?C2C>(=ICKII\* ]#O]YRKYXD)T/^-V/P$4$L#!!0
M   ( #>*;%)B0SW7S@0  .D3   9    >&PO=V]R:W-H965T<R]S:&5E=#@X
M+GAM;*5877/B-A3]*QJF#\E,-Y8M6Y8RA)DD$ )AVS29M ^=/A@0X%G;HK8<
M=O_]RA]X05P<MYN'X(]SSKU7.KJVW-_)]$NV$4*AKW&49#>]C5+;:\O*%AL1
M!]F5W(I$WUG)- Z4/DW75K9-1; L27%D.1A3*P["I#?HE]>>TT%?YBH*$_&<
MHBR/XR#]=B<BN;OIV;W]A9=PO5'%!6O0WP9K\2K4V_8YU6=6H[(,8Y%DH4Q0
M*E8WO5O[>L8+? GX,Q2[[. 8%97,I?Q2G$R6-SU<)"0BL5"%0J!_WL6]B*)"
M2*?Q;ZW9:T(6Q,/CO?I#6;NN91YDXEY&?X5+M;GIL1Y:BE601^I%[AY%78]7
MZ"UDE)7_T:[&XAY:Y)F2<4W6&<1A4OT&7^MQ."!H'9C@U 3')+AG"*0FD*X$
MMR:X70E>3?"Z$FA-H%T)?DWPNQ)836!=";PF<)- STT<WL\<[AK#;B;[9+;/
M4O;3;9?S;57&*ETY#%0PZ*=RA]("K_6*@]+:)5^;,4R*1?BJ4GTWU#PU^",/
M4B72Z!MZ"),@681!A"9)M;B+57+QJI?],H\$DBOT(?@M"?)EJ,3R\A)=#(4*
MPBB[1)_0V^L07?QRV;>43KD(;"WJ].ZJ])PSZ1'T629JDZ%1LA1+@#]MY]M.
MBX"EQZH9,&<_8'=.J^)0+*X0L7]%#G8PD-!]._U5;#4=GZ4/V^G3/&FEC]KI
MGX.T-?F'SK7;'*"/.]<.TA\[UP[2)YUK!^G3GYOWIY\;NEEW.FMQ,6F6/2GU
MR/]<]L,P6T0RRU.!_KZ=9RK53\M_6N*Z35RWC.N>B?LBWD62BPSJ!!73*YG%
MN\/[P,8.M3WB]JWWPQ5V"N2.ARGCQ[@A@/,XLWW_&#<ZQ3%"L&_&?0#T"/8\
MCQSCQJ<XRHGG$B._1T#/M7W7-?0F0'Z^PQG%Q[CI*8YH-=LV"WD"@"YAS.'>
M,7!V"G0X<5W&?R@>V<!K;."UVN#WK4BUT9(U"I.%C 6ZT&;+P.=#)40/4OBD
MQ\CC+C5< 0$=S"@S@$,(Z#',J6/X @(REV)L&\8 @(1P/>'&#(TAH,VI2XP<
M'Z'01#O2,:9R @(=PHE1S!0 4L)LSYSS)P#('<9L9BC.H-"VK9W)*>P.VKB#
MMKKC-[WW./(%"I1*PWFN@KE^$5$2Z7NQ[E+9)DC%1D9+D8(=A9[8]Q-CQ/=-
MZP X5_<)8C2*(8#C>EQ\8PA' ,[6C8(ZAA\>($&*?6PD.(8$N4<H989O *#G
M<@\;E4P G$^8;\A- 1@IG(T-X!,$]/1(>T;/FP% RBG!!Y4<><9O/..W/M!&
M09KH?I(AW5DJ7_QWTQP%9DU@UFK6NR +%^@B3,J7W"8ZV,LJ)?^P>'QE3O8]
MC#(>"L-.6B,8Y>.C/[.==9(>@RC;2/,1UC*[&#MQA?EL W4<HR4]P2@CIQF(
M<CW8@+SQ 6_UP3",<KWQZ>@$WLD),,IT0B>M$8SZP F=I,<@ZL0)L);I!/ZA
M$T"=$R? *-,)(.K$"=;!]CH6Z;K\:)3I?I(GJGKE;JXVWZ5NR^VY<?W.OI[8
MP/6I?3VK/CO]D*\^@NE-RSI,,A2)E0Z%KWP],FGU8:DZ47);;N[G4BD9EX<;
M$>C>5@#T_964:G]2!&B^[@V^ U!+ P04    "  WBFQ2M:S45R4$  #?#@
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M<9TG+M\G[!CT9F8'KI-"J4?G;*I5&+F"@$-I'0/%UP%RX-P181E_1\YPDG3
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  WBFQ2B6'5;+4&   '.P
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M_U/6[^-X^,?QRS/MJW9XR<^6/]C<_@102P$"% ,4    "  WBFQ2!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( #>*;%*-X#/\[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #>*;%*97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M-XIL4I7$[C4[!@  <!D  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #>*;%*86_(9F08  -L9   8
M          " @7X.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    "  WBFQ27D- X'L"  # !@  &               @(%-%0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ -XIL4N'Y2$"H"0  SR\
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M965T."YX;6Q02P$"% ,4    "  WBFQ218$H'4TI  #6@   &
M    @($<00  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M-XIL4AMG\X/T"0   QL  !D              ("!GVH  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    "  WBFQ2/$/BD\,'  "R$@  &0
M            @('*=   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( #>*;%*"N,\)/08  -L.   9              " @<1\  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ -XIL4E8>M+N- P
MVP<  !D              ("!.(,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    "  WBFQ2F;HYPH &  "X#P  &0              @('\
MA@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #>*;%(F
MLL0Z=P,  -,'   9              " @;.-  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ -XIL4C ?E[S9!0  MP\  !D
M     ("!89$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>*;%*BE<JL1 0  -,)   9              "
M@>JU  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ -XIL
M4GJ? [?(!P  )!,  !D              ("!9;H  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    "  WBFQ20V)G6.\"   B!P  &0
M        @(%DP@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( #>*;%)X8@ ,S@,  & (   9              " @8K%  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ -XIL4J,Z,40& P  [08
M !D              ("!C\D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    "  WBFQ2<NK&^6<"  !X!0  &0              @(',S
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #>*;%*]*%Y2
MN@<  +D4   9              " @6K/  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ -XIL4I#*7QTY!0  (PT  !D
M ("!6]<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  W
MBFQ21ZWDK-($   ^#0  &0              @('+W   >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #>*;%*9Z,Y ("8  #)Z   9
M          " @=3A  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ -XIL4EU M'1J @  ( 4  !D              ("!*P@! 'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  WBFQ2?"J1IND$  "D
M#0  &0              @(',"@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( #>*;%)WHYCA' ,  #H&   9              " @>P/
M 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -XIL4OV,
M96_H @  \P4  !D              ("!/Q,! 'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    "  WBFQ2\"P_!FD#  #+!P  &0
M    @(%>%@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M #>*;%(?5REEV0,  "P)   9              " @?X9 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ -XIL4I'$9!J@ P  40@  !D
M             ("!#AX! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    "  WBFQ2&&H0$0($  !Y"0  &0              @('E(0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #>*;%+W>%\Q=08
M  81   9              " @1XF 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ -XIL4B@)'3 G!   4 L  !D              ("!
MRBP! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  WBFQ2
ML=7R(O<#  "J"0  &0              @($H,0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #>*;%(D]R)NG@(  ",&   9
M      " @58U 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ -XIL4JW6?EB- @  >P4  !D              ("!*S@! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  WBFQ2@@;SZ$D$   Z"@
M&0              @('O.@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( #>*;%+[M#PLZ 0  !L-   9              " @6\_ 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ -XIL4M;\!'W_
M P  W0T  !D              ("!CD0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    "  WBFQ2,KTU'GT%   I%@  &0
M@('$2 $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #>*
M;%+BA_U[F0(  -8'   9              " @7A. 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ -XIL4NDI$->A!0  BA<  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( #>*;%)HA$RZT@(  -$'   9
M  " @>-G 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M-XIL4I\6C*>\ @  " D  !D              ("![&H! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    "  WBFQ2<%@N,XX$   >&   &0
M            @('?;0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( #>*;%*X1>%8= (  .P%   9              " @:1R 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ -XIL4D$^L;5G P
MZ0P  !D              ("!3W4! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    "  WBFQ2+^,_-!D%   V%@  &0              @('M
M> $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #>*;%*>
M?.CP?P(  ,L&   9              " @3U^ 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ -XIL4NH7MJ;B P  =0P  !D
M     ("!\X ! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>*;%*]>U.S3P4  &84   9              "
M@9&6 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ -XIL
M4NL=@M9M @  ^@4  !D              ("!%YP! 'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    "  WBFQ2<YF > \#  #7"0  &0
M        @(&[G@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( #>*;%*YG:5#WP,  *8,   9              " @0&B 0!X;"]W;W)K
M<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ -XIL4I'5=DJY P   1,
M !D              ("!%Z8! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q0
M2P$"% ,4    "  WBFQ2,E/+R!P#  "Y"@  &0              @($'J@$
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( #>*;%(X32!#
M50,  %8,   9              " @5JM 0!X;"]W;W)K<VAE971S+W-H965T
M-S(N>&UL4$L! A0#%     @ -XIL4N<$M%.= @  _ @  !D
M ("!YK ! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  W
MBFQ2Q \&MT\$  !J$0  &0              @(&ZLP$ >&PO=V]R:W-H965T
M<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( #>*;%)WU)V>' ,  $D+   9
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M970W.2YX;6Q02P$"% ,4    "  WBFQ2>9#FU[$"   =!P  &0
M    @($XR0$ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    (
M #>*;%).WD"IAP(   $'   9              " @2#, 0!X;"]W;W)K<VAE
M971S+W-H965T.#$N>&UL4$L! A0#%     @ -XIL4I)IG_V[ @  9@<  !D
M             ("!WLX! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"
M% ,4    "  WBFQ2!CH9TP@#  !"#0  &0              @('0T0$ >&PO
M=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( #>*;%+%MR'+! ,
M .(+   9              " @0_5 0!X;"]W;W)K<VAE971S+W-H965T.#0N
M>&UL4$L! A0#%     @ -XIL4CZ/3C$L @  \ 4  !D              ("!
M2M@! 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    "  WBFQ2
MB0>FQ>,"  "1"   &0              @(&MV@$ >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;%!+ 0(4 Q0    ( #>*;%**+/VDH ,  %(,   9
M      " @<?= 0!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%
M  @ -XIL4F)#/=?.!   Z1,  !D              ("!GN$! 'AL+W=O<FMS
M:&5E=',O<VAE970X."YX;6Q02P$"% ,4    "  WBFQ2M:S45R4$  #?#@
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M+G)E;'-02P$"% ,4    "  WBFQ2B6'5;+4&   '.P  #P
M@ %[\ $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -XIL4N;BI-"@ @
M!34  !H              ( !7?<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ -XIL4L* #&LZ @  :#,  !,              ( !
M-?H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &( 8@#E&@  H/P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>466</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1106123 - Statement - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts</Role>
      <ShortName>Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - RediTrex?? and Vibativ??</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexandVibativ</Role>
      <ShortName>RediTrex?? and Vibativ??</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Other Current and Other Long-term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</Role>
      <ShortName>Other Current and Other Long-term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2165116 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168117 - Disclosure - Market Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrations</Role>
      <ShortName>Market Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2171118 - Disclosure - Manufacturing and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements</Role>
      <ShortName>Manufacturing and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2173119 - Disclosure - Employment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmploymentAgreements</Role>
      <ShortName>Employment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2174120 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2178121 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2179122 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - RediTrex?? and Vibativ?? (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexandVibativTables</Role>
      <ShortName>RediTrex?? and Vibativ?? (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RediTrexandVibativ</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2366312 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2369313 - Disclosure - Market Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</Role>
      <ShortName>Market Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrations</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2375314 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/DiscontinuedOperations</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2380315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Organization</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - RediTrex?? and Vibativ?? - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails</Role>
      <ShortName>RediTrex?? and Vibativ?? - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - RediTrex?? and Vibativ?? - Vibativ Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails</Role>
      <ShortName>RediTrex?? and Vibativ?? - Vibativ Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - RediTrex?? and Vibativ?? - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails</Role>
      <ShortName>RediTrex?? and Vibativ?? - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails</Role>
      <ShortName>Revenues (Schedule of Net Product Revenues by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Revenues (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Debt (Line of Credit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DebtLineofCreditDetails</Role>
      <ShortName>Debt (Line of Credit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Debt</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Warrants, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails</Role>
      <ShortName>Income Taxes (Operating Loss Carryforwards, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails</Role>
      <ShortName>Income Taxes (Schedule of tax credit carryforwards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails</Role>
      <ShortName>Leases (Schedule of Rent Expense and Sublease Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails</Role>
      <ShortName>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails</Role>
      <ShortName>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2476441 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2477442 - Disclosure - Discontinued Operations - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations - Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2481443 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2482444 - Disclosure - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails</Role>
      <ShortName>Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="cpix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - cpix-20201231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - cpix-20201231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="cpix-20201231.htm">cpix-20201231.htm</File>
    <File>a2020-10kxex1011ajkazimi.htm</File>
    <File>a2020-10kxex1013leopavliv.htm</File>
    <File>a2020-10kxex1015jimherman.htm</File>
    <File>a2020-10kxexhibit311.htm</File>
    <File>a2020-10kxexhibit312.htm</File>
    <File>a2020-10kxexhibit321.htm</File>
    <File>a2020-xex1012martincearnal.htm</File>
    <File>a2020-xex1014michaelbonner.htm</File>
    <File>a2020-xex231consentofbdollp.htm</File>
    <File>a2020-xex232consentofbkdllp.htm</File>
    <File>a2020q4exhibit411.htm</File>
    <File>cpix-20201231.xsd</File>
    <File>cpix-20201231_cal.xml</File>
    <File>cpix-20201231_def.xml</File>
    <File>cpix-20201231_lab.xml</File>
    <File>cpix-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cpix-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20201231.htm": {
   "axisCustom": 3,
   "axisStandard": 30,
   "contextCount": 222,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 656,
   "entityCount": 1,
   "hidden": {
    "http://www.cumberlandpharma.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 16,
    "total": 17
   },
   "keyCustom": 62,
   "keyStandard": 404,
   "memberCustom": 46,
   "memberStandard": 33,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - RediTrex\u00ae and Vibativ\u00ae",
     "role": "http://www.cumberlandpharma.com/role/RediTrexandVibativ",
     "shortName": "RediTrex\u00ae and Vibativ\u00ae",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Property and Equipment",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Intangible Assets",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Other Current and Other Long-term Liabilities",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities",
     "shortName": "Other Current and Other Long-term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Debt",
     "role": "http://www.cumberlandpharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - Stock-Based Compensation Plans",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Employee Benefit Plans",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165116 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168117 - Disclosure - Market Concentrations",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrations",
     "shortName": "Market Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171118 - Disclosure - Manufacturing and Supply Agreements",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements",
     "shortName": "Manufacturing and Supply Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173119 - Disclosure - Employment Agreements",
     "role": "http://www.cumberlandpharma.com/role/EmploymentAgreements",
     "shortName": "Employment Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174120 - Disclosure - Discontinued Operations",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2178121 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179122 - Disclosure - Quarterly Financial Information (Unaudited)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - RediTrex\u00ae and Vibativ\u00ae (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RediTrexandVibativTables",
     "shortName": "RediTrex\u00ae and Vibativ\u00ae (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables",
     "shortName": "Other Current and Other Long-term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2366312 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369313 - Disclosure - Market Concentrations (Tables)",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsTables",
     "shortName": "Market Concentrations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2375314 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380315 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iec44f4c9886f4156832890687e6122d3_D20190401-20190430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "if2a2c29316304015acd330ba1069f0e5_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails",
     "shortName": "Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iaf2794b9547f4580a1f58f9127f37880_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
     "shortName": "RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1f0edc4849df4c21910d604bb57d2325_D20201001-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
     "shortName": "RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails",
     "shortName": "RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i23f33e7c9b22442bb753954859fb791f_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
     "shortName": "Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i8b8106a20e864d28bd6d0ef776efb119_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Revenues (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cpix:RevenueRecognitionUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ie005a45bb43941a58835f78c97251e65_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Intangible Assets (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ibdd73cbe73864cc2887a9612a508bf31_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ib61e32dba4b0475d984dfadd6379821d_I20171231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ib61e32dba4b0475d984dfadd6379821d_I20171231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Debt (Line of Credit) (Details)",
     "role": "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
     "shortName": "Debt (Line of Credit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i11f6eeba1e7d4e4db73754009484a0f6_D20200420-20200420",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
     "shortName": "Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i367d84ececcc49f0bfbb68634cd626f4_I20091231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails",
     "shortName": "Shareholders' Equity (Warrants, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i367d84ececcc49f0bfbb68634cd626f4_I20091231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails",
     "shortName": "Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
     "shortName": "Income Taxes (Operating Loss Carryforwards, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1106123 - Statement - Valuation and Qualifying Accounts",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts",
     "shortName": "Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i9d8a2a14899b4ec1a64b4b7a8ed1abda_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "idfc74587ea6e4b529a03805961c2bd04_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails",
     "shortName": "Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ie9167ce1de284dc593328aff87ed8bcc_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails",
     "shortName": "Income Taxes (Schedule of tax credit carryforwards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ie9167ce1de284dc593328aff87ed8bcc_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
     "shortName": "Stock-Based Compensation Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i2f2761c3aa61481e9ce768736d55283b_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i5a2a5d00643c4cf980b2671abc0ae2a9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i622af044beba4bd281a739b794311672_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i18c4af7e297f4bdb9156fe284ac15e52_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.cumberlandpharma.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails",
     "shortName": "Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
     "shortName": "Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails",
     "shortName": "Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i1ac17932a25340aca07bdc1d4e8a3a20_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i0806af42e92d434b8380cece41bef2f1_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails",
     "shortName": "Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "i0806af42e92d434b8380cece41bef2f1_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ie52ad4b1821b40aeaa322dea12dec215_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
     "shortName": "Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ie52ad4b1821b40aeaa322dea12dec215_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476441 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477442 - Disclosure - Discontinued Operations - Discontinued Operations (Details)",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations - Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ieb8b8fca28114aee8584ae7f0c55023c_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481443 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "if3fbba7dd4a6485ea115af1a74515fea_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482444 - Disclosure - Valuation and Qualifying Accounts (Details)",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails",
     "shortName": "Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "ifc1855e705644eb19c43b7bb2e117b81_I20171231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "iff5d882e978f4b1091a8bbb1b4c80860_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20201231.htm",
      "contextRef": "icf84cc8aa13a4c4e9c2848f65593a987_I20181112",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - cpix-20201231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - cpix-20201231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 81,
   "tag": {
    "cpix_AccountsReceivableAllowancesByComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Axis]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Axis]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_AccountsReceivableAllowancesByComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Domain]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Domain]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AccruedLiabilitiesInventoryPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Inventory Purchases",
        "label": "Accrued Liabilities, Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedLiabilitiesInventoryPurchases",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AccruedPaymentForAssetPurchaseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Payment For Asset Purchase, Current",
        "label": "Accrued Payment For Asset Purchase, Current",
        "terseLabel": "Accrued payment for asset purchase"
       }
      }
     },
     "localname": "AccruedPaymentForAssetPurchaseCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote.",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of balance sheet classification"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "terseLabel": "Adjustment to initial fair value of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Accrued, Current",
        "label": "Business Combination, Contingent Consideration, Liability, Accrued, Current",
        "terseLabel": "Current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityAccruedCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "totalLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor.",
        "label": "Caldolor [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CashPaidDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During Year For [Abstract]",
        "label": "Cash Paid During Year For [Abstract]",
        "terseLabel": "Net cash paid (refunded) during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearForAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ChargebacksCashDiscountsAndDamagedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "label": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "terseLabel": "Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods"
       }
      }
     },
     "localname": "ChargebacksCashDiscountsAndDamagedGoodsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen",
        "label": "Clinigen [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "label": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "terseLabel": "Collaborative Arrangement, Federal Small Business Grant Programs"
       }
      }
     },
     "localname": "CollaborativeArrangementFederalSmallBusinessGrantProgramsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Abstract]",
        "label": "Common Stock [Abstract]",
        "terseLabel": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ContributionOfCashAdditionalSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution of Cash, Additional Shares Purchased",
        "label": "Contribution of Cash, Additional Shares Purchased",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "ContributionOfCashAdditionalSharesPurchased",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CumberlandEmergingTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumberland Emerging Technologies, Inc [Member]",
        "label": "Cumberland Emerging Technologies, Inc [Member]",
        "terseLabel": "Cumberland Emerging Technologies, Inc (CET)"
       }
      }
     },
     "localname": "CumberlandEmergingTechnologiesIncMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One [Member]",
        "terseLabel": "Customer 1"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Three [Member]",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer 3"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Two [Member]",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer 2"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DeferredAcquisitionLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Acquisition Liability, Current",
        "label": "Deferred Acquisition Liability, Current",
        "terseLabel": "Deferred acquisition liability"
       }
      }
     },
     "localname": "DeferredAcquisitionLiabilityCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses",
        "label": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and other accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsDeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Deferred Charges",
        "label": "Deferred Tax Assets, Deferred Charges",
        "terseLabel": "Deferred charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredCharges",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "terseLabel": "Net operating loss and tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "label": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "terseLabel": "Property and equipment and intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyAndEquipmentAndIntangibles",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "terseLabel": "Reserve for expired product"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "terseLabel": "Defined contribution plan, eligibiilty, minimum employee age"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeAge",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "terseLabel": "Defined contribution plan, eligibility, minimum employee service time for participation eligibility"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "label": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "terseLabel": "Depreciation, including amortization related to leasehold improvements"
       }
      }
     },
     "localname": "DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DirectorsIncentivePlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors\u2019 Incentive Plan 2007 [Member]",
        "label": "Directors\u2019 Incentive Plan 2007 [Member]",
        "terseLabel": "Directors\u2019 Incentive Plan 2007"
       }
      }
     },
     "localname": "DirectorsIncentivePlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmployeeNonemployeeandFoundationContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee, Nonemployee and Foundation Contribution [Member]",
        "label": "Employee, Nonemployee and Foundation Contribution [Member]",
        "terseLabel": "Employee, Nonemployee and Foundation Contribution"
       }
      }
     },
     "localname": "EmployeeNonemployeeandFoundationContributionMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmploymentAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements [Abstract]",
        "label": "Employment Agreements [Abstract]"
       }
      }
     },
     "localname": "EmploymentAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cpix_EmploymentAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements",
        "label": "Employment Agreements [Text Block]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "localname": "EmploymentAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmploymentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ExpirationTermFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term Four [Member]",
        "label": "Expiration, Term Four [Member]",
        "terseLabel": "2031 - 2039",
        "verboseLabel": "2040"
       }
      }
     },
     "localname": "ExpirationTermFourMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term One [Member]",
        "label": "Expiration, Term One [Member]",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "ExpirationTermOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term Three [Member]",
        "label": "Expiration, Term Three [Member]",
        "terseLabel": "2030",
        "verboseLabel": "2030-2039"
       }
      }
     },
     "localname": "ExpirationTermThreeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term Two [Member]",
        "label": "Expiration, Term Two [Member]",
        "terseLabel": "2022 - 2029"
       }
      }
     },
     "localname": "ExpirationTermTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTimePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Axis]",
        "terseLabel": "Expiration Time Period [Axis]"
       }
      }
     },
     "localname": "ExpirationTimePeriodAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ExpirationTimePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Domain]",
        "terseLabel": "Expiration Time Period [Domain]"
       }
      }
     },
     "localname": "ExpirationTimePeriodDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal And State",
        "label": "Federal And State [Member]",
        "terseLabel": "Federal And State"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FinancialConsiderationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Payment Period",
        "label": "Financial Consideration, Payment Period",
        "terseLabel": "Financial consideration, payment period"
       }
      }
     },
     "localname": "FinancialConsiderationPaymentPeriod",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_FinishedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finished Goods",
        "label": "Finished Goods [Member]",
        "terseLabel": "Finished Goods"
       }
      }
     },
     "localname": "FinishedGoodsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "label": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "terseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsUsefulLivesTextual",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HarbinGloriaPharmaceuticalsCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harbin Gloria Pharmaceuticals Co [Member]",
        "label": "Harbin Gloria Pharmaceuticals Co [Member]",
        "terseLabel": "Harbin Gloria Pharmaceuticals Co"
       }
      }
     },
     "localname": "HarbinGloriaPharmaceuticalsCoMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.",
        "label": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]",
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd."
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Increase in cash surrender value of life insurance policies over premiums paid"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Proceeds from Life Insurance Policy",
        "label": "Increase (Decrease) In Proceeds from Life Insurance Policy",
        "negatedTerseLabel": "Increase (Decrease) In Proceeds from Life Insurance Policy"
       }
      }
     },
     "localname": "IncreaseDecreaseInProceedsFromLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite Period"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering [Abstract]",
        "label": "Initial Public Offering [Abstract]",
        "terseLabel": "Initial Public Offering [Abstract]"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_IntercompanyLoansPayableConvertedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intercompany Loans Payable, Converted Amount",
        "label": "Intercompany Loans Payable, Converted Amount",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "IntercompanyLoansPayableConvertedAmount",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose.",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "terseLabel": "Maximum increase to line of credit"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LoansForgiveninExchangeForShareIssuedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans Forgiven in Exchange For Share Issued, Amount",
        "label": "Loans Forgiven in Exchange For Share Issued, Amount",
        "terseLabel": "Loans Forgiven in Exchange For Share Issued, Amount"
       }
      }
     },
     "localname": "LoansForgiveninExchangeForShareIssuedAmount",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LongTermIncentiveCompensationPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "label": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "terseLabel": "Long-Term Incentive Compensation Plan 2007"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing agreements, number of primary suppliers for each product",
        "label": "Manufacturing agreements, number of primary suppliers for each product",
        "terseLabel": "Manufacturing agreements, number of primary suppliers for each product"
       }
      }
     },
     "localname": "ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements [Abstract]",
        "label": "Manufacturing and Supply Agreements [Abstract]"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements",
        "label": "Manufacturing and Supply Agreements [Text Block]",
        "terseLabel": "Manufacturing and Supply Agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ManufacturingandSupplyAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Line Items]",
        "terseLabel": "Manufacturing and Supply Agreement [Line Items]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementLineItems",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingandSupplyAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Table]",
        "terseLabel": "Manufacturing and Supply Agreement [Table]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementTable",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NetDeferredTaxAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Deferred Tax Assets, Gross",
        "label": "Net Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred tax assets, before valuation allowance"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsGross",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NoncashOrPartNoncashTransactionVestingOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Transaction, Vesting of Shares",
        "label": "Noncash or Part Noncash Transaction, Vesting of Shares",
        "terseLabel": "Vesting of shares related to RediTrex approval"
       }
      }
     },
     "localname": "NoncashOrPartNoncashTransactionVestingOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee [Member]",
        "label": "Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "NonemployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NonprincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonPrincipal Owner [Member]",
        "label": "NonPrincipal Owner [Member]",
        "terseLabel": "NonPrincipal Owner"
       }
      }
     },
     "localname": "NonprincipalOwnerMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic Group B.V."
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic",
        "label": "Nordic [Member]",
        "terseLabel": "Nordic"
       }
      }
     },
     "localname": "NordicMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak [Member]",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak",
        "verboseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Abstract]",
        "label": "Other Revenues [Abstract]",
        "terseLabel": "Other Revenues"
       }
      }
     },
     "localname": "OtherRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank [Member]",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock [Abstract]",
        "label": "Preferred Stock [Abstract]",
        "terseLabel": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "label": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "terseLabel": "Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ProductAndLicenseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product and License Rights [Member]",
        "label": "Product and License Rights [Member]",
        "terseLabel": "Product and License Rights"
       }
      }
     },
     "localname": "ProductAndLicenseRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Revenues [Abstract]",
        "label": "Product Revenues [Abstract]",
        "terseLabel": "Product Revenues"
       }
      }
     },
     "localname": "ProductRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "verboseLabel": "Product Rights"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductSalesRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales-Related Liabilities, Current",
        "label": "Product Sales-Related Liabilities, Current",
        "terseLabel": "Rebates, product returns, administrative fees and service fees"
       }
      }
     },
     "localname": "ProductSalesRelatedLiabilitiesCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductVibativMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Vibativ",
        "label": "Product, Vibativ [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "ProductVibativMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "label": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "terseLabel": "Change in unpaid invoices for purchases of intangibles"
       }
      }
     },
     "localname": "PurchasesOfIntangibleAssetsIncurredButNotYetPaid",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_RevenueRecognitionCumulativeUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Cumulative Upfront Payment",
        "label": "Revenue Recognition, Cumulative Upfront Payment",
        "terseLabel": "Cumulative upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionCumulativeUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Payments",
        "label": "Revenue Recognition, Milestone Payments",
        "terseLabel": "Milestone payments associated with international agreements"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePayments",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "label": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "terseLabel": "Other revenue, potential upfront payment related to product sales"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "label": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "terseLabel": "Other revenue, potential upfront payments related to regulatory approval"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Upfront Payment",
        "label": "Revenue Recognition, Upfront Payment",
        "terseLabel": "Other revenue, upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SalesRevenueGoodsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Goods, Gross [Member] [Member]",
        "label": "Sales Revenue, Goods, Gross [Member]",
        "terseLabel": "Sales Revenue, Goods, Gross"
       }
      }
     },
     "localname": "SalesRevenueGoodsGrossMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "label": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "terseLabel": "Schedule of intangible assets, useful lives"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofDepreciationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Depreciation Expense [Table Text Block]",
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "terseLabel": "Schedule of depreciation expense"
       }
      }
     },
     "localname": "ScheduleofDepreciationExpenseTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of rent expense and sublease income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans",
        "terseLabel": "Number of equity compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "terseLabel": "Number of equity compensation plans available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options, exercise price as percent of weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "terseLabel": "Committed cash contributions"
       }
      }
     },
     "localname": "ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ShareRepurchaseProgramAuthorizedIn2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program Authorized in 2010 [Member]",
        "label": "Share Repurchase Program Authorized in 2010 [Member]",
        "terseLabel": "Share Repurchase Program Authorized in 2010"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAuthorizedIn2010Member",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharebasedCompensationCharitableContributionofSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "terseLabel": "Charitable contribution of shares, shares"
       }
      }
     },
     "localname": "SharebasedCompensationCharitableContributionofSharesShares",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_SharesRepurchaseActivityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Axis]",
        "terseLabel": "Shares Repurchase Activity, Type [Axis]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeAxis",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SharesRepurchaseActivityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Domain]",
        "terseLabel": "Shares Repurchase Activity, Type [Domain]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "label": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "terseLabel": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options"
       }
      }
     },
     "localname": "SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "label": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "terseLabel": "Initial public offering, gross proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "label": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "terseLabel": "Initial public offering, underwriting discounts"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewSharesUnderwritingDiscounts",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodPricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Price Per Share, New Issues",
        "label": "Stock Issued During Period, Price Per Share, New Issues",
        "terseLabel": "Initial public offering, price per share"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPricePerShareNewIssues",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering",
        "label": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering",
        "terseLabel": "Initial public offering, number of shares common stock received in exchange for preferred stock"
       }
      }
     },
     "localname": "StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Exchange for consideration, amount"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment in CET"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ThirdAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Amendment",
        "label": "Third Amendment [Member]",
        "terseLabel": "Third Amendment"
       }
      }
     },
     "localname": "ThirdAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Tiered royalty payments (percentage)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "VIBATIV"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol [Member]",
        "label": "Vaprisol [Member]",
        "verboseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]",
        "label": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]",
        "terseLabel": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment"
       }
      }
     },
     "localname": "WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Domain]",
        "terseLabel": "WinHealth Investment (Singapore) Ltd [Domain]"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20201231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r77",
      "r126",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r219",
      "r298",
      "r301",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r323",
      "r325",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r323",
      "r325",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r219",
      "r298",
      "r301",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r216",
      "r298",
      "r299",
      "r493",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r216",
      "r298",
      "r299",
      "r493",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r323",
      "r325",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r323",
      "r325",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r298",
      "r300",
      "r527",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "verboseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r298",
      "r300",
      "r527",
      "r536",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r220",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r139",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r26",
      "r41",
      "r221",
      "r222"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AirlineProductsAndServicesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.",
        "label": "Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "AirlineProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r46",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r87",
      "r111",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r111",
      "r243",
      "r248"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r199",
      "r208",
      "r214",
      "r232",
      "r431",
      "r438",
      "r457",
      "r497",
      "r512"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r76",
      "r124",
      "r232",
      "r431",
      "r438",
      "r457"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r21",
      "r253",
      "r257"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets associated with discontinued operations",
        "totalLabel": "Current assets associated with discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r330",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r322",
      "r324",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r414",
      "r415",
      "r418"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r412",
      "r414",
      "r415",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r110",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r110",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r413",
      "r416",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Balance at December 31, 2018",
        "periodStartLabel": "Balance at November 12, 2018",
        "terseLabel": "Liability to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "RediTrex\u00ae and Vibativ\u00ae"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativ"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r54",
      "r113"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r114",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r113",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r458"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r14",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r122",
      "r124",
      "r156",
      "r160",
      "r161",
      "r163",
      "r165",
      "r176",
      "r177",
      "r178",
      "r232",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r287",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants, number of shares called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r287",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r69",
      "r265",
      "r502",
      "r517"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, no par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, number of shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, number of shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Equity, common shares outstanding",
        "periodStartLabel": "Equity, common shares outstanding",
        "verboseLabel": "Common stock, number of shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock \u2013 no par value; 100,000,000 shares authorized; 14,988,429 and 15,263,555 shares issued and outstanding as of December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r219",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r219",
      "r454",
      "r455",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r219",
      "r454",
      "r455",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Market Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r185",
      "r186",
      "r219",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r187",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r219",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.",
        "label": "Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset",
        "terseLabel": "Financial consideration"
       }
      }
     },
     "localname": "ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r89",
      "r493"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r386",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r386",
      "r394",
      "r396"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current income tax (expense) benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r386",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "State and other"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r184",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r498",
      "r499",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate with minimum LIBOR"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred Compensation Plan Assets",
        "terseLabel": "Deferred compensation assets"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r387",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r125",
      "r387",
      "r394",
      "r395",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r388",
      "r393"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "negatedTotalLabel": "Deferred income tax (expense) benefit"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r387",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Cumulative compensation costs incurred on deductible equity awards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for accounts receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: deferred tax asset valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r111",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r257"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r13",
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Costs of products sold"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, Marketing and other"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r257"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r13",
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r22",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share attributable to common shareholders",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r156",
      "r163",
      "r164",
      "r165",
      "r169",
      "r170",
      "r507",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r156",
      "r163",
      "r164",
      "r165",
      "r169",
      "r170",
      "r507",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Net income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax expense (net of federal income tax benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r372",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Permanent differences associated with general business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee wages and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to share-based payments"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost related to share-based payments, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r175",
      "r233",
      "r274",
      "r281",
      "r357",
      "r358",
      "r359",
      "r390",
      "r391",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Excess tax (benefit) expense derived from exercise of stock options"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial instruments by level in hierarchy"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r445",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r318",
      "r446",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r306",
      "r311",
      "r318",
      "r446",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r306",
      "r311",
      "r318",
      "r446",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r318",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r120",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r247",
      "r250",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r247",
      "r495"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r247",
      "r494"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r240",
      "r241",
      "r496"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Increase in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r252",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r128",
      "r199",
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r124",
      "r144",
      "r199",
      "r207",
      "r210",
      "r213",
      "r215",
      "r232",
      "r428",
      "r457"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r163",
      "r164",
      "r504",
      "r505",
      "r507",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "-Continuing operations-basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r163",
      "r164",
      "r165",
      "r507",
      "r518",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "-Continuing operations-diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r18",
      "r21",
      "r400",
      "r519"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r84",
      "r86",
      "r160",
      "r163",
      "r164",
      "r507",
      "r519",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "-Discontinued operations-basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r160",
      "r163",
      "r164",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "-Discontinued operations-diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r19",
      "r20",
      "r21",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r373",
      "r375",
      "r381",
      "r392",
      "r398",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r198",
      "r371",
      "r393",
      "r399",
      "r523"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Total income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r120",
      "r367",
      "r368",
      "r375",
      "r376",
      "r380",
      "r389",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Prepaid, other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of restricted stock and stock options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r120",
      "r246",
      "r490",
      "r491",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r82",
      "r196",
      "r466",
      "r467",
      "r508"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r103",
      "r107",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r47",
      "r238"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods, net of reserve"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r25",
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r74",
      "r120",
      "r172",
      "r235",
      "r236",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r48",
      "r238"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r73",
      "r139",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves, obsolescence and discontinuance"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r91",
      "r195"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment amount"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of operating lease liability maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r62",
      "r124",
      "r209",
      "r232",
      "r432",
      "r438",
      "r439",
      "r457"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r45",
      "r124",
      "r232",
      "r457",
      "r501",
      "r515"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r65",
      "r124",
      "r232",
      "r432",
      "r438",
      "r439",
      "r457"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r21",
      "r253",
      "r257"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities associated with discontinued operations",
        "totalLabel": "Current liabilities associated with discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r61",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of credit, current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r61",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r67",
      "r268",
      "r269"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by labor or machinery, classified as other.",
        "label": "Manufactured Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ManufacturedProductOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r72",
      "r124",
      "r232",
      "r457",
      "r500",
      "r514"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r281",
      "r429",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Repurchase of subsidiary shares to noncontrolling interest",
        "negatedTerseLabel": "Repurchase of subsidiary shares from noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r106",
      "r109",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "terseLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r78",
      "r79",
      "r85",
      "r112",
      "r124",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r162",
      "r199",
      "r207",
      "r210",
      "r213",
      "r215",
      "r232",
      "r457",
      "r506",
      "r520"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to common shareholders",
        "verboseLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r79",
      "r152",
      "r153",
      "r435",
      "r441"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests",
        "negatedTerseLabel": "Net loss at subsidiary allocated to noncontrolling interests",
        "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Additions to intangible assets from final purchase price allocation"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "terseLabel": "Noncash increase in liabilities related to acquisition (see Note 3)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r282",
      "r429",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Exercise of options and related tax benefit"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r282",
      "r429",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Sale of subsidiary shares to noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r281",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r199",
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": 1.0,
       "parentTag": "cpix_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities",
        "verboseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": 2.0,
       "parentTag": "cpix_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.",
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r63"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current and Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Gains (Losses)",
        "negatedTerseLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during early 2019",
        "verboseLabel": "Additional payments to acquire businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment for Contingent Consideration Liability, Financing Activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedTerseLabel": "Payments for Repurchase of Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments of Financing Costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred equity offering costs",
        "terseLabel": "Initial public offering, issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r95",
      "r419"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Cash paid for acquisition",
        "terseLabel": "Cash paid at closing",
        "verboseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets",
        "terseLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r330",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r27",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Principal Owner"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Initial public offering, net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "auth_ref": [
      "r94",
      "r105"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.",
        "label": "Proceeds from Life Insurance Policy",
        "terseLabel": "Proceeds from Life Insurance Policy"
       }
      }
     },
     "localname": "ProceedsFromLifeInsurancePolicies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Proceeds from Noncontrolling Interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "verboseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r97",
      "r356"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from Stock Options Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductionAndDistributionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients.",
        "label": "Production and Distribution Costs",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "ProductionAndDistributionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r21",
      "r78",
      "r79",
      "r104",
      "r124",
      "r144",
      "r152",
      "r153",
      "r199",
      "r207",
      "r210",
      "r213",
      "r215",
      "r232",
      "r428",
      "r434",
      "r436",
      "r441",
      "r442",
      "r457",
      "r509"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r261",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r57",
      "r254"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r33",
      "r34",
      "r256",
      "r516"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r120",
      "r256",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r33",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r33",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r366",
      "r550"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r120",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r281",
      "r360",
      "r513",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r233",
      "r357",
      "r358",
      "r359",
      "r390",
      "r391",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r193",
      "r194",
      "r206",
      "r211",
      "r212",
      "r216",
      "r217",
      "r219",
      "r297",
      "r298",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r83",
      "r124",
      "r193",
      "r194",
      "r206",
      "r211",
      "r212",
      "r216",
      "r217",
      "r219",
      "r232",
      "r457",
      "r509"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenues from customers outside the United States",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r473",
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in CCYY-MM-DD format.",
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Initial public offering, effective date"
       }
      }
     },
     "localname": "SaleOfStockTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of the components of income tax benefit (expense)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities, net"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r19",
      "r20",
      "r21",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of numerator and denominator in earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r328",
      "r353",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "verboseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of net product revenues by product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r244",
      "r246",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r31",
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories, current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of quarterly financial information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r330",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r337",
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r70",
      "r122",
      "r176",
      "r177",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of expected amortization expense of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r187",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of revenues concentration from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Shares forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares forfeited, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares granted, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, end of period, shares",
        "periodStartLabel": "Nonvested, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant-date fair value",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Shares vested, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares vested, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance under equity compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Options, exerciseable, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, end of period, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options forfeited or expired, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited or expired, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r339",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period, shares",
        "periodStartLabel": "Outstanding, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in USD per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r120",
      "r330",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vesting of common stock, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r122",
      "r124",
      "r156",
      "r160",
      "r161",
      "r163",
      "r165",
      "r176",
      "r177",
      "r178",
      "r232",
      "r274",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r71",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r175",
      "r233",
      "r274",
      "r281",
      "r357",
      "r358",
      "r359",
      "r390",
      "r391",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r175",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r39",
      "r40",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, shares issued",
        "verboseLabel": "Proceeds from the sale of common stock, net of offering costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r71",
      "r274",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r281",
      "r329",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, amount",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, number of shares authorized to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available under current repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common shares, shares",
        "terseLabel": "Repurchase of common shares, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r39",
      "r40",
      "r274",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "terseLabel": "Repurchase of common shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r124",
      "r229",
      "r232",
      "r457"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r124",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r232",
      "r233",
      "r281",
      "r357",
      "r358",
      "r359",
      "r390",
      "r391",
      "r426",
      "r427",
      "r440",
      "r457",
      "r459",
      "r460",
      "r464",
      "r531",
      "r532"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, balance",
        "periodStartLabel": "Equity, balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r281",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r465",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r465",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r465",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "terseLabel": "Summary of tax credit carryforwards"
       }
      }
     },
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Fair value of marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets:"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r131",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write off of deferred offering costs"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080552-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r554": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r555": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r556": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r557": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r558": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r559": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r561": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r562": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r563": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001628280-21-004654-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-004654-xbrl.zip
M4$L#!!0    ( #>*;%(J,01\%!L  ,./   <    83(P,C M,3!K>&5X,3 Q
M,6%J:V%Z:6UI+FAT;>U=Z7,;-Y;_OG\%1MG-V%441>JP)=GC*D7R;)QQG)3M
ME&L^;8'=((FHN\$!ND4S?_V^ T"CFY0L)W)$N9)R;*D/' _O^+T#Z.=_N_CI
M_/V_?WXIYG59B)]_^>[UJW.QL[NW]^'@?&_OXOV%^/[]CZ_%X7 T%N^MK)RN
MM:EDL;?W\LV.V)G7]>)T;V^Y7 Z7!T-C9WOOW^YA4X=[A3%.#?,ZWWGQ'*_
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M!ZKB)E'%_3N%/3 TC6J$E!S*GUX@AZ%6@;7R; 6$S"-$4O!>I:;(9D! @#7
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MK=NRERGE/93-J)+RZ'](@HK$34''(FQQ\,65")"Y%G/*."!4*G+*ZY%^#(B
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MRLWRW#84O'3+!BB$X7SX8V-U'&W,X> "9NLG3=R<0V"2]-E:D>;UU9PQ3#W
M&CJ)[(Z7=N=FZ<O40W4F90(U1:_Z9=>;ZN'3B5FLP*3(8#SY*ZEK]\&(!RY<
M^]LN7!SIV@*/,SD\C;&#U^+D$Z&(M9&PKH?G7: !QB[Q5(Q<EF 7UX*$89<Z
MN%2FW<H 2"W#O2.J4VL7 _,Q$H@Q8+EL&ZE"O>F@?_0&/X,GQ6&4W8*_*2V5
MZB(\9,1B%1[*PTHA+;ZK8O4@ED17$J7$RU<2!VXG[H^^P.TS>HJ@$_,Y*']4
MO\NU@/#:KTW%IP("Y-!JRMJA+2?AL&[OH00D(8)"M=*9)$$5MI*11@P+P\DP
MZ;XB7?M%#K4XR:S=G)Q?*I>#5Y+JWD@-+)W5F%%("[;7R#$(B4YTDZ^TX?*H
MWB/I'*[;<8SEZ*2$2U-IRF,D,-"%[;OTM,,M2&G=CJP!K55JY3P+B:E"?4QP
MC18F3*ASZLY7M%-O?+#=&N\[.AYXBCX"V]80@:.E>.4K:>]3'[+CS3K1$HI-
M_4"_G38>\ 42E)Q=HATC$<H6QEP?WHFY'W]F&?IR35'L\H96!,"*B#+LU>^K
M*\/G$UH2$]Z/,56T!PG/!JG:'0Z[T5'&-ND.$EMY8M???G.R_XR5<MQP'X7)
M%\MY!T]]Q"A=W-[!OF)R5E!/J+G19'\[5ODY],P\/$M)E)SGQB>90ONJ3I.K
MP,$OT;GR>2.?$Z.$4%O22#0C^O/Y^$#0&(?$3)3G)-)*N>( (9]-1&>7^I.Z
ML*B8HWG^.M7\ 3W^RKYL>?8%MZUB()H6TI>#XT%=?FN?K^:9&3Q"B$I_V\.Z
M2)A;EJ0Z%(ER!:Q;^FTM*\PYYV$+C081X*.TF*6;1=AKGY2,=CV2UAD!=G[E
MI0MM^U5OP]?"U RYZ7A+J@K@30,".*5)LJ\9&>H;N9U34+2K?XW/ V(J5EV6
M_]5,UBG"_A)UR!Z%)RO%0P"\+%"!.,.ZK7TQ K?O&UA@\58Y> OUS 7",#XJ
M.'' ON*3A,:'PVTUP>_0>H4CI;X+ 4"PPU1OA0OZ$C1\YN[YT-X-7(7)4EW'
MY(X UR&<A(D2,+,4WU4T^M:XZ.YA,NA':*X;M;I3X$&'Q/1/U0IGC(8])=)U
M=J<D!W&OAR&&;6$^A1^Y5@XWJC65ETH\!8"W?#=Q#W) &.FP?)4L3CO#[=T$
M=C$0 *Q.=A)LZFL^7QR/I/]:T.S1=J/9"S4!KY(^KG/O#OPG,JO$@'PF#*8M
M<. V;L[<7-+>JTZ/6US\N]W#^%PS<>&TV=$3S/P N^)/D\=!5OZI<(-6(?YI
M#+Q\89O9P+L K@3@EXFS[*$SK!B'[5G;R;!OZ(2<^TZ0 F_Q43V)_V'Y<(4Z
MUL**&8"U*CVKN8V\Q-!!_") C1R:)HD0FTTIZ81.C54S+%GP/65X+C>=5EKZ
MD =O[%3.?VRAW:*UOL,<$)]>X.FO5"0:3UV1:V=K/'A6?KK5NO>#!/ZP]\S*
MF/]<TD"0RWRU*^*#5<A[Q5C3ALAI&^3#S<MTFKY%KJ;]OK9!]8R>B>_ -TB*
M]C\-,3:%9!]\ME&,C[=::;[DP$M<MWOGN0X3^0@UQTE]C*@]"3>$<,.'4+QS
MZP^'XXIKU(GH?G)DVE1X&-&*3G)K3YIK-:L/D(0#S(G7PQ:OY=R4(=(:NN>0
ML*;3^4.%-Y\6G<6]H. !NY#712P\EQ93ZQ@F:F#N#UZ3GFPU?_\O'4J/7M)V
M<7:T\OU3\\&%BQ49X,WR5TC>JXJ.&%$>80 ?+6B',5>-8^SP6A5,IXLY"KW<
M?%0S'S4]P('@85(8R 3(X@.5Z>?CPF &;?17TKG.5,[XJT?*H5J%/I7WT+E\
M?[357/Z2U9*/B-TSI[]*DZLQ^_AIK ",.E<%;_ME#O1@N:E4F!_R'W\J(C87
M/XX1LY.,;DOY49=-R1JXCL>;41,AK\J'K""+8^!B<](LGJQ+Y[' '\QM"$ZX
M83N*0I(/G,'WM[Q2YQT=5RKO^Y#:_D=PJ,CKQFJ=P69N"L>O)B?]X/>@.+J]
MX:1H#(%1CNKZ#REV3S??>+CY[_B(YY:U,QX>86[*7[*\.G3MN@\0_XE<0M^#
M_ 9D*/Y_UY^#W(X$77[K[VH?QN]JWUM2[P^RS^?J[\[W ^[QZ[;O-WZ4,U3U
ML)NC*^&/)2P-E=LU.''T>MQ A((HSA@D1Y/!\WJF0X*>3EN<IGF%Y$ O;#V8
M6B?IRTWH^V\.WO]!T>BL\_YX\]<=?D=+1_NAI?5%O;F=$AP]8&,O?;T!A<^=
M\U&+45 M6+Q=/,!1+IPZ#3\\0[Q?R-6IKFBEZ:7^%_AJL_!B<G0R/#Q"B_6\
MAN'5>6C>"]&0A&BOSM?O'9X,CP\/KKT]&HZOO7=CLT^')T=/;]7L'@V9APW3
M=^"F_&/G8*>W-J?[BX]BW*4H+M?:5PF)]G<N@I_\NC/IJ7?X%1J+"0;$!&X0
M&<73X(;IC7!R/9+T;, )/? 9S7Q^C]UWGFS9(GQ2#](BG/_RXW<OW[X^>W,A
M?O[^[.V/9^<O?WG_ZOSL]3OQZLWYL+,FFPD]/OJS*;VU[$XMGNH:>LMN0?ON
MA\T/GSYS]+?X 3<7?QB*'Z6E4Z':2/<=D\_K4_QJ*;Q$NSMR$2BQ';2]'1=_
MM_*5>]=],?YWD?16Y/D#["KPWX,MX-N;-83?>Z/P,QJ63OK\0^RX1];Y#NI^
M[A: _CGMK&&>+P1QGHR'QT?'OP?B/'DR/!H_N7.(<S >[A\??CT0YW9ZZ8SJ
M=3B7YP\!YDI:+E *Y4-?2+T_)$K)&-0_YB]1@Z;.Y@/Z('7WF^QW@@[_ BUW
M#5K.AC\,Q;_D;[K4#PFM]'7\O48F6&=L("2';NX<J:R9XD^0XE;!MX.#X=.C
M>XV_[4U,OH)_YG59O/A_4$L#!!0    ( #>*;%((I7KA$QL  #J0   =
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M<]@7X<\=:5<8!MN^7&6&E^R4.!?OVGF&"ZY*1]?[=S?$G6="O&_XCUG!B<H
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MK>CR&2PH\/^#;>?%:XX[^2Q>W".K^P4J>?X0=OB3H,+C8?_DZ.2/0(7'C_L
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M:8O6"RPN+ H0 X9.-Z@I">N*(X01U5:M&A$HK%P!C?00WH5N0@^[;'*AY8A
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MT8NTN7)A.TF,90#636N$%T'L*C,]WFY>D4/HOJZ67[DA$\)_3VP3'QRKS2'
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MA-7KA'.%"Z4/6?AZ *X-RKP"'8*<356/51I*UF6LA)!+7NOR1'WV$P,&F*[
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M!Y6;W1J:? '_3*II\>+_ %!+ P04    "  WBFQ2CF?/S+,(  !5/0  &
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MMRO>PYV+T7D,_O.K=U8VRP-V;.$^G#(%.P60,G+];KR7L9+P:::V'X*2?L@
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M -UWD9+.]OJHLR4X?IR.:GC->^DHUSEL'MQ+2-W65G/J[LV+WE>>@3KS6C_
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MMNM9;M;@VY"A(' 'F,^"5:[PW*-Y^'2BV76:Z\&\-;2NQ?3VH+QU:$,Z3'B
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MURS*#TMOR9?_[RUZ.-IWG?NKZ=R;N\[=OL\,"GPJ+\H$5JUEC%A4#,SR[Z"
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MWF;YRH>!\K?X3)%_,!G]"U!+ P04    "  WBFQ2;>#'MA ;  #PCP  '@
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MNW9)5EKE^_2H*:C?9A1S6+% S0V'ZWOK'L",DD1@OG\%,_NPXHMN9^S"8Z0
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MNX+Y)/ 641M3S"6$W9)0TPT]52Y21-'W=@-@ONN$=19HV)"=R/%^=&]F9(*
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M'Y8Z&T9U]FL*BF!H&M4(*324/SU##D.M FOEV0H(F4< I>"]4HV0S8"  'J
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M#&[N3,-_F.!;(J^T(-9"%XZ!;PW!4R7] LM_,'@E&=J!*@AM*XF,U4&U;]:
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M&*)4G[ +RT4N!:;ZH4KGV I/O4286A1IU415980&R).VR\G,CN'TO-K QD,
M9"!Q0^'!EOU&#YT61!#8Q:A8H[W$BIQFF:*/K'#5C!$V@O\UM<!H&[M6J%0
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M8-W6A"^IL@H'1=L!RP"]I=EMY1*=C,,H,)%0BM4Z%3#:]U%]P!$]MT,##.S
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M0&="N0H9KX3!W%G,D%+*VP@ABR+2N1@%FX&&+H8B@-0'CV4T 8)<%S2E7(O
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M1\Q"$U<B]O#KI[]5B+Z&9-D]_3?\_TW1_3V83O^L@?-%50YZ6^7+XKSH!__
M825BW[W$^[;A!)_&804H1<\L05IK"UH?@0"P]1P/!T+9<"!TA=;W#HFR>P^)
MWH+V1_1/@'4E!OP@*YD.:?9=4QE0C%YCXM'B0WLGF2X)E.,EX]ULM[Y0B*$'
M'T<WN'<9!A *X@B8=4$3^MPX3RFR!B.A(PIS[(PE>3BX[(:J/BMZ4[3M,W3
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M[ZJ WNF4]5(.W6N##6*,"<0B(TQ;9:)R,4) ) /2?@&\A3G!;T85HS3UUM%
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MVRXLF=5^1)"F:+,%MA1Q'CS6BA$9%<%!*J( )AXB(0M O]^%UO-!U2WZ@RK
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M>V!W^)3JM 23=C5P 0Q-VA_&LDBY%7E@Q##A%R!8O &EOD%ET_6+"VC=S6J
MNT_K=':N7.CUCT*_W\E6ZR >FZN7$ 8.*^H=A@[0F3\N=ZY"Y8HZ#"W:02_I
M[%(NY0'70TFK(TD)T8IY+:PEB@84" K.+T(BT3(+Q6Q2D+@4 4L3<=#@R%AC
M14H=99HBCH-!9@$*)2^U4,RDQ'%P:5]&I\':1X:Y4)0HC82206!"/!TR!1LR
M!6+TP<.6[U F=F]E@E/I=,(]+"CVFHE@&(1^2GIC'(DZI(+1N-E3EHWZC<UC
MO['[]QN;6K])AH,3QC'));,N*B(1]89*AV,(S8 '&"1,9'OT8=Y(:!H)T3]N
M0# (EKRG 9D\]8?V G62<: &(P*SG*1->!7B6F!'K$<+4 A[M^O*\P"D/W3V
M/QWLS-,#7=,Y#!>A.PC#4OR[AT<_.MR9)6/GJE<T@>(Q''F5.WY"<"8.A^K\
MH/L *>X/,EW%6(HW.-(ILQ2K8(E3AA-0:6ICB'[^\UN^)A9Y0"RMC2R=Z?QK
M4!4U:'@":NG$8IH+GQG%U&+F+#7,JYB*!'$'_WJ+,9)^?MGBVU$YOBRG-2'R
M4!0U+VPA%)..1Q(=>)X.<X6,YDP;QHF3&L\Q6\RU6'PO1<T+6Z3(@J9"[\P1
MQA2V !T$J-F*$#S/"T^_0RS.JO U%E_QQ6@J)@:1MB&,W@:&"#.*8V6\M)YR
M:>P"5&-8(._B/I(Y+XQAG"8&1Q %:AD1WA+NO!-@3C 5U,UQX<%OQ^5Y.:A6
MA''?.4@<:2!84$-8@/!4<\3 !S6&8(J#F5_"F&^Y6'@/PZ2=08+Q6+H\Y!F-
M!?1 )&PTDM#%YHO=K@\QK[E>\<1]R]TY8JQASE/,C+$V@#$)@6@M,&:+4$-M
MKAV+>PODW/"#5X:D5 >M+0L.&\$LL]*HX+&Q?@'*'RZ[QA(J O544N<BLX28
MZ 520.O!2RZ5^GDU=EYT*&@LI O8!Z+2'IF:4J),C$H&KZQ;@"VXOH10LU5J
MLPDN )2!6A"U,3RE,6*J4-JX*6"# A$A"!NE<,R*GPJ4!W#"%V>F)C#$L8D2
M19V 1Q:#[X,\UE1HY]P<+X2?R['7!>8$[2V5.D2#K&-":B,4CQ2,*W8& N:X
M5)+P&,.M"RP++&(%4;!V5@;&M+(6!QZ-0U0K A^6218>8\!DL41A "%:EH->
MQW3' )\'4P^JT+Q+.C*Z>G1@]#U=?K?709A'7H641\BBI0J\0>,DXF!K0,86
M8'5V*DW^26[/R[)[FL0(H$_WOPAI=T^X+LM7.I\@).<7Z]MJ[S'E$H,W8"1S
M-ACETI!(P!B["!@M)$#;115<OZSJ,4(+A@JWB#-#*54"LQ"9 2^-<]"?@"+2
MBBY .G_*CSLN^IUP$'>[OK@H_ "(<#)!KMNKBJXK>J9S<-D-7R/D[X!F#C+P
M-4,2IX*/.C#GI=6@51I"+Z,Y=X@M"(X/4S5BVA)R;\;8O#25_WQ_B9WS7J>\
M#F$BV7L993+ZR EBUH6T8"@B%2G&"!%JHL X+LK>0%^0G)N=15:2,VW),08P
MI(YCZ1PCW!IO5*J@!ZZ=0V2A-A;] I"'H>Y7A>L'?Y]%S3\BI^G0R$U91EDA
MD:2M0ZDQX,&H%%<&*92DPG-.%+4+("M?LT\CK5]&^")B*@IE 40/#FA*FX@2
M(^\P=UP%OP!+!^<#OAG5&>?6,0;=&3AA$FA: H)&Q+3E"@)'= $6^<T)?#-9
MCL>H")81C8@GC'&M';).4<G!6P-8EX$\P;D/2\R?$-TI@,]@+@@S7&I,C>6!
M4,<4\1(M 7\^&H*SH5!+/=5&F>BE89$SQ;U#'J5L8^$#QTM H8^'X$Q85+OH
MD11$<ZP8Q6#ZI. *<<Z$=]XOPR#:R A.(&FZ_GDYZ/H\&+T%_5$5=K"T$6G$
MC$?E.84/)*3<SH"B,\I%IK4D2T"S\P/Q;'@X&B&I#C)*9)E 2EM"F& 48A*%
MO&5+P,-S!/%,B!HKQTR4@6@9F?56@]<44^Z8@7 3(ICAQB!SB.Q4AY-^:/+I
M4SA^9/()$Z$$\PS!7T5BJJ7-J!0"'%D;%%L 4ITU+K.G39$28Q%C-E@#.D44
M-D"C5FKPA+"09/ZS9.= IZ:7$NL$QD1[Y07EH$M4605FC00;A8C2_71#YPOI
M;0:J&'>426(Q2XL.,3>8:F("CY:X.5X[-&OL'B9U!6(Y)+"*7GL69% F%4Q.
M^^K8R",:+O%+.C4'-9=NL<HMV?V!'I!.>&RYTM /##.L-'%.IQ5,0LN%V/OB
MN2FJ/TUG$'Z['G_\'>YH*G=V_3)<A$^F=<<G[79[@WZ=S\#3FMV=:$S>H_2.
MO4E3Q>-4%,YT7IG>0^2L/$R>;Q2&4TP"]9)1S:VG#GN+J1+::[T "S*F(2=D
M)2=?&TXQTH3@',,<,2&EE2(J3M,B60S1V *L$5E::&*T7AKC652& 3[*826L
M%QHA$0U?@.WC5E3_&($&LYRBJ(A-D[T2V^0:2"6=!0^!$3['A9565/^H<J(,
MUESJ2$@:?&-:I%W3@N?28AED7"@Y62YH$.4Q$);V_HHL>*>$($0A'RU$,TJM
MO/JY,LPF&H^9=QY)R@+FVG/OM/+"!QOT(BR@> S"G1>TO)4D>A:$ @^76VW3
MQ*$U6-B =5"+17OSJ5M39$*(3;D1ECJ!(Q.&:"PH$L%Y%94(AO\<:#VH;DW3
M;BDDP),@01//*+.*ILTJ76#8AD@B7J Q[JTR+QQK5HP>%O6'WZY_"UUW=FZJ
M#Y.;"YA.VBX@UU%Y49:^?E&5]=<V"/B11GP^=+LUJ/LE.#F?G3R-W/4]\[ZL
M1D^H)UY\]-N#%#V8_4"_=X8J"6Z8L)$!UVB'M"-.<9Q6/2B]0#.@*TF>$TF>
M418C-B8*:8.-E&$7C'9*DVB9U%IR\>D6=BM)7DGRUR5Y1DE"DDMN*4K2BZW7
MJ7:10-RR*)2A: &\BWO!-\6*-<NO,0OI73"(-)TT3GL&WC)URJDHJ8W:< \Q
MCE@ [V(ER7,FR3-:9J9<H(X9[!%A#*5$;$% I FC@BIM%\"[6$GRO$GR;%;<
M>15#M$#**9?(1(N%)3:"8Z&H,&&1\O.67\*FI-0/L\O![/V+J!QF!CQD1A%3
M$/QA+ .+P<B *+5A ?R+E2S/G2S/QL, H4K5V!5F+K(T5>,"B5%[XR)AGL<%
M\#!6LCQ_LCP3'T-(*8U&UOC 6-#<!!\%C0I<9<O!_U@J'V.<<>Y<VB05)-J%
MXL+8SM1JL,ZS$SL;PX\X#4I8BJ*.C%-G08(<YQ[ =PA$;ZD,_\\M8(]FC<>%
M8>M!#]X@5'<7AQT='=WEW@5B R?&,XL5P9:!K3>&$N*#P?#'$<SG-WWFKL*(
M1?<>A1%_:+Y^JEO?&$5BX#@RQKCG1@M"+<<T,F4%FN-L[^^N23DO72^0,1"?
M10).+0/I-](J$P27C 8M%F$[PU<#"V>\[A>=HE^$>K<+#FN_K":+7V]U0!U.
MP\+L6H*=#T0JQ3%FG@25ZE2S/+>$+6Z&Y2?<,PBEYV%=V?=['8A.J=01=1I%
M@32'[@I*ZBAPB&D?1G!V1=3#?F.C?A,4S6&_L?OWFVA3-(5^"VF5'M-1I31?
M9Y!EVH#!"XIZQ"UVPWZ3HW[3<]EO\O[]IJ?4;U99%9TA"O34A*"X@G]D1.#J
M(D*'_8;1(X91W]YO&#U^+6IJF.(:8@0#\8 "8O/6!<JI(E)&83^)#N:0W[[-
MZ9T6OPG&@S="L1 I"RP5YO/16O@9>M#CT7 J&_7;_/%;ZHQ[\ELZ=4K\YI#G
MUDG-0X3.R;7P6*J@9AC(($*C$J)RU&_SQV^I,^[);^G4*?&;B%Q'SH6D/*2R
M*]:EL B#757!.]D,>>HAOSV.D_CM_79??IMFH2B'%>=!(BX8:"G6CE$KK4U[
M68![G9?-8#G//G5*_,[C!YN=3GEINB[4FUU_&.I0783Z\[&'\6G/RVJK"K[H
MO_SZ4/&/N=MR:NXVA)@1C!"+W%.F"5,J".H#YTZ"$V30 HWLSRMNLQ_R9D@0
M&:)*8SJ,<J=B6LO&@-K2;LMV 2I[S2NV#U+Y*RA&7 B,(Q489D('BJ*CSBL(
M\=AG+N(*MQ_4R=D45*3@O1KI/3," @)P+3 W$1O)..8QF/D?>YI7;!]D6$I8
M&H2*'CF@4(E!)X5R)&W3*)USWBW0K.&\XC87,W>6@Y&D2*;<26%%T!$CQ@WC
M\'4!*HO-*[8/M(HX(E ]GU:)L6BCPE%[) QASA@F^?*%&I^??Q"W0PP50)?V
MODP%&!8E\B!!,P+V3V@(/[@,VDLGD$;4>Q,<682*P@L&X^P#$8$]E\H;%$5D
MU#D5+!,8E-APBY20RQ>(S%YCIUF16")NB<!2I=%7;BG!C$8M(#X)&B]S7#(/
M&CN;E:L1.V6M%%8;%E30G#+IG6 646&17KXP9?8:.[VH)2(L*#8>80I12X0
MTX-)C5P8ZK&-RQRUS('&SJAJ@@X\2B1]8(@%,+>@MD0Q[X"SB=5SG$^T8%#_
M>$SSM+C:J$)=#BIXQ>;K63 ^M\<7%\]^A3\CTXNB<@"B@%@409PC5"I"YK$,
M5&CFWB4P;ZZI^]<=@.V\Z+;/0G%ZUM\@9)WW^K]<%KY_MH$1^O_7\IG/?JU[
MIOOL5UL]A>N;S\UM/KM9:G+;=(K3[D9*L<PIB.F"T7%7=LIJXW]0_N^7"._8
MCN:\Z%QO_.T8,*Y;^^&R=5B>F^[?GM2F6[<!SB(V)];%QP"M@@;FKY=-FQG<
MIU-TP^@=,$G-?O=8_]WNCT?M"?Y)3\@[>^+U_N[QSG;KZ'CS>.>H=;2S]?IP
M]W@7/F[N;[=V_K/U^^;^BYW6UL'>WN[1T>[!_MR_T)O-H]]W]U\<'^P_:6UO
MM0CB3']SH^\2YHG+>L;[HGO:[H38W]#0K-$/56Y(^N7!NX-\*NEW=\?SLCK_
M/_^#!?KE5V"&;MG='YS#G5QK2""'(>:2M-PK!=&T5)%9C#0VX+!9;)E3$%/=
M69&AU36)UGTH-K9+-TB4EVAU;6A!Z)_7=KN\>$D.+T[HWL"_W[EX^T*_/WC_
M^FKOQ0D[^7CXX>3C"3XY_N-R[\T)WW]_RO>V3]G;[1WZ]GB/'!P?OG])]SLG
M'TN\=_S;^<&+/?3VQ1[9?[.#]K:?GQ\<G["#XTUV\.*/JWWR^N/^^P_H!*NK
ME^3M]<D;)]Z^W[QZ>^P[^^_]A[?;FY?[+Y[#O4ZO]HY/R?[Q\P][Y/#LY/V'
MJY/SW0O_XD_F?_]7YRWI7-CWO7.X?P?N2?;)X8>][4UT\N;/]P?;.U<'VR=X
M[\T?']^^>%X<'#\O3CH*?G/OTCYR@CO7ILGO8MRQM@HHM*4-&H+2E"?!UIYA
MU/YWIN<;$.XI85CU^O<3S(=70G(OJ=O<WW^]^;)UN//JX/"X]>KUX='KS?WC
MUO%!8IACH)%&)#%M'1RV,/^[_T?KX'GK^/>=UMR_V@1%CNEQ<^LXM1]KRJ9-
M-?/RVL CK?Y9:,6B=J;3N@ZF:H&#&7QKZKP2@;),'ZZ^ZF]X<&#/X8YGWERG
M9X;N7;SS*OM&.XV_^W,1T/7>]N[5.^TE1\;'=D#6M)DGL:V],VVKM7/$@1]O
MR-JS[> :?YGB)ZW4W_>FH^\4WG-3G8+[V"][&^0Q;"+&]Y+E,G[6XOG012+N
MU?X'M.0[.58Y#*=%W:\@_-B'(S^70GW<>^_>*:G E%/73FONVPPST"?E79L(
MPFGP03*-UIYMO=[[;>?P9?*47_V^>;BWN;7S^GAW:_/E46MW?^M3Y5J_CYJ(
M1U&3>QKQ!Z5V:)5+HQG]T*O*BR2!M[F]D<3=KBNK7MFLQ3M*9V^E)8+5]5;I
M?S+!!*;?0>\T"T(;K]LZ"M%.V?)M2VEH*\# $D*"\W+MV7'H=D-=A_"I$+:V
M;KIS[GV.W4/PL9I=-*O6[G!0R.6VM_;+]=;TY?-3\3LV5[>?"X\" _K3"=[N
M]3L:M>4J@*1Q I1HJ6PK3TT[./C5@J,A9%Q[)D@;2\$IT3_L6SRVM*4=!HHZ
MC2*"D]L)K6Z&^L%CYT;0GL,3?U;9^OA.8H\4T:0M@W9M!IW6-D*2MJ;4>4)5
ME":F@6+<IE10^=!NZX][NW2.S/B#R^ZF]Q48F^$_+Z$!^.<38O3.*FX,TK%-
MF8(8S%'>-AQ",FFH4%(P):E=>T8XX:TWH>ZW(%QM;>;:,)_*\Y.'-VR?8T9^
M.LQV^+O@5!!<F#9V2(-1 _2,IZQ-?)JQID$"@&O/C@9%/[0T__%X>5EU?PL^
M'E3'Y67WIY.BW<MW06,-^@VR$RCXY!*<(*-!B@RA1@C+"(IT[=F^J<\NBD[G
M,=3]F^.L(8XYPCJH7L&91=?]A $6?L="B,#=JBV '-J,8=\V!C[%8%"TPBK'
MZ%\%6(^E<J]* +7SMNC]G)$P>><CMLI8VR;:!= ZC=H:,]%&T:<-4J.,"JT]
MHY(@>F_>GE,7[N\/*%2)NC>K8'Y.,:+O$'&6$FXAV$AB9+EL@X[CMF<6I66G
MU*<!%8'YIT+TCX=4]9>E,YU79V7W9XT*=]@[I+D@#HFVY *003&T#>*^'04E
M8%(958@GAYJW$1)JVCH^Z[F KV>R8)ZF(X,;5+EN3ZO*H_:A"K[5&U3UP'3[
MK7[9@C/RB!DF?[?_:)4Q3^-MNO[&'9,@_51T;?0*MJQ\J-KP)AW3J\/&Z,,O
MOJA['7.]471S>_)%OUR$JE^ T X[!;IWF"BDZ3IG*CFC_0K^[T>W'Z81K6<_
M]6G??WZ,RG4BR!</HW7\Q6-_=5NRKLGT[XKE.D+TNV[[5\?(NI#?=]>_[%D.
MF'SY\.1MGV;4&N1  I+(_'.-KGV2J+!!>E<M?%N=4N["'6*Q-I=Z=%ST0?)!
M.X)Q9RV7-B#]))=MV%%_T0<H]<#:O4Y=^.ZJ3'J/UM'UN2T[?Z__L>JL+W=6
MFD0=BU:X<F>IWET+*/GRK(!?;GC[CD[\BOH-.3H9,^BA5EUV"M\:O=&R]-\#
M^EE#\WF-B<T,L)!^UO/"OG@M]M[OP3UWZ=[Q_OG>\6N^OWUVMO]BYWKOS1X[
M>;/?V7NQ1T_(_MG>\1_#:_Z$9_'NV^/R>N\CM/^]N]HC)U?[QQ_0P8L=='*\
M>W7R\>SLA+R^//GHWY^0G:O]Y]#&X\W^WA%*_[X+E 4D=&C[(&.;"<K:%BO5
MEI9Q%J3P$L=F9@6D_:A?N@]/6O\;@:%L]4S5NDB[8[9Z*4?\S%2?A=(/02DK
M??DQ?1GR?D/[*V6YA[+LCI5%,4,<9[B=-G& >(:CMLY#%X8[AP5#0B1E>;7[
MGY4FS*LF?#JPFJSYYV.J(ZNR,[3U"YM%]=C*\L=862@B8#V<:;.(X8^TO&V5
M16VG' F&:!JLRF/JWORW]:)36M.!2+<#L6YKSU0?0O\>.I1]JZ<Y?%V6"/_T
MS@C_8<<L[VYVJ_4P3[]/IS5\Y8,;9CIM#+K =>DL$)FR&^XY-O3]T_Y%-V4-
M;5 QOLECKW#:RL.&'=/UK5?@7)T;%P:9LNO6;M>MMXJZU2W[+=.Z#)U.^T.W
MO(0F!E-#[W@X6 ]"]:1EZI8/L<@_=5N'@TYHTF' =HW$;$(Z0>+66U].X)_/
M?FHU;_3YWP5[CWO@787_#HK$'4 9.<.I"KVRZM=W<<EX?499??)37JQQPS&
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MG ?7,>?EU8H?OGT L/W*?)BE*CZ9-X(JST.O,A_+#F@^B%55I$&7\VM7)(H
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MXA,X3%-&7N2DF+G8BO:BO,A)B9BR2$?([Y,JI4,RSN+I5""<.,9]L/'A9.^
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M<6FFN#O^O) O#I_(Z40[O^5FC!'1AHUF]I;N4BL1_K_MK 69C6&<61^Q)0@
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M6Z4BP(Y;/\2_V=F]DGRL0J@.&7=@F3HPZ! N>0?;.)+IV-1E,8Q="21 %H:
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M?@IA3QPN#]@X6L-UKO48&@730TM[N#U*=1L8RD)22_FLE"%C^\@"DM($Y!S
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M G:59,AJ[SZ,3KB5G.YQ0K\J"ZZWD0KC'VA!IC$>:F0X+:1PD4U=I--I0Z]
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M';TZ_?O'D^V=OS_>??[BL9]=%^=:;&OX?7VT8+(7[1CZ $%_*ST67;IU.YY
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MGH>:]=7A?V_N8LA,3!\:.=@9;?N@=$I>QLTH_A*]3 L="D?Q8T&X@^K'"E2
M%,S7882WDH-10HN=CIB.HMV Z=EQ@I2AST5T_7[2'SFM7>;S%NA0"4%_A9LB
M=6S9&.?0-@5N9$-UA>P/.N7IEZ:BCY 2DRFQ(9D<P[-G^68>EPF0S+T+52W)
MJB)/AGRI#'EPCE51C27!.J>/U"HO8?DSQ&R]__M_T&Y1\KP,_7YH97FGZ<;S
ML(^I-.VQFM;B6WH(3/:X$3P[#C%-S\K8YJIRTY3%+*XGN"6G+E$L=B*P:44
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MB'EM=EK3G%,X.M52WF0^,Z7]!?U04&Q0T@^QC1WDC$#V=6I)M7]ISBPB)6R
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MK_7C^]EK_1.UUC4+#L=FE)Z6YL>T$0=.T7>I.-P%-^F:Z[L"ILZ*B Z;U%R
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M-K@+A !9%A5#;OJJF@2?'C<9O7DSFL,19<!&!(\F:909(3<&?3:6XUV'Q<4
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M[!C3/IZ3@P7TD:! & 9#$IJ7V)Q=I)CE+ ]S/KJ=N2::1D&6L%;7DENUG1/
M)P(>^WPHJYQXY)@<HJE7#75-@P"ZIW"F:<&+)(SDH"7;,"Y&:S4*ZQ2_<]03
M0B8I]3(V1K<G50IIBE!*?8*\6%#8=+3.7GO2"9%Z.C0\!VOT[0$Q\!;#%7:Q
MB#EWLMRB6AIJV>ZB\T1D70P>:X8>_4*VBJ6A.J6YW#81+VV\JP,!#G?FCJQ
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M)CTO6'RO^'-1;+A*#3(Z2+GV151C)$![C**C1L6PP/(FZ9IW7C8'DW&+UH_
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MX:T;-Q SG36N<47^&>0)ER0DBJ :F00F@6+UDYN_!>F9[-X,DX(\/0>".;A
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MM&6<2EC:V[YQN5"?&^5T<VIZE8#L9-)O'FB$TG'T9Z-*<V])"!B&.ZG2EQB
M<FKJ,$ABW!ITP2,C*(E,,=RS!FVTBO;SW(V0')_807RNHB:T#A"^87<N+L!G
MY0]DM@8_/?Y%2NB,1AKU8W^;TC>8YBX7*6_8CA#IZH$=#<"LE<#)6/9$]Z'5
M6B:Y"O+TLE+<@2LY<N&OE6PUQ9MX1D&^X/FN*$(=U@5%OAMPQLG*5Z=BUQ-'
M:S)YI&;+Q:Z4.N#RB#.ZC6QC<YVV!1K%PUJIYN\O19P&1&ZR#<PM@=9NW=0
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M=O2;2=-?A0&$4[!4"1PBNX*P2Y%.-+.XAK<'"_#9:!)@J;A?M/7=K\)\H&+
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MJ.M)CJZV\A31=RF[6C:6UV""&YD\^(*@-;"-R3*34[*L=P:.QYR X/\](57
M?L8$9H9Y?W3+E-KA@F'>0+:CMI!\R^(&V&EQ"<I;U(A;T S5'DHWFE16C"<N
MP_$W]1DHEF[JZ"TBL$U5K,I.&.:*FC7WX * )O&WX[-C!H%T+"6+@"SUJO5!
M A6P)%8R9-?$4(S!!:5@CGAXO&#1:K(#H#3CGE\:LK*8VHZH.\:O']I,S[M"
MT#+" KR@AVL'(?/SA)5*B!11HATG/WG&5'%*W+*ZQ#H]X$\\_N2;SQ-_\HF&
MRRCM;+(M'%;N^UF[G8'KL(,DM&@D,#UK^A4>#B/%21'X^=/-TT4;_+ES] 'Q
MUH8G2E-TRIZ&3WX&TOWH5?:G>]'D!%MI8CC'!X@8FG.*":KLJAM*;FL3T)Q&
M!ADI(DK76[;*L!&G5MAME8+:%3;:Z=>3G.*F]#J9DR=09 [?PAF;\Z$'UQ>@
M^B);389";S:A%VT(6CEY%N[+(OY6@/M67I\2J1]6*S5'0(!"I],Q"H>SD6F.
MS3_$FOG $><Q;D]XJX.E$"JY !.*VC]XH*+'?W9#/PULA!0?+F#IS?6M0TUF
M=68QXF?90 E*Z?.J*1>Y0?D)Y'Z;H&%'9*PL*AX?<3L>[HH#@M3?@[Q&7G3F
MLK22.(%X_1>%3RYT1X#0K&TRZNN6I8T3:_<)&C,]Q9$T2;4SQ1UME3\Y1.$]
M.3<<&;ZL8NO3Y25A"].IAN2VX.@%JRP:XU)\MG?A.&=-+K@00IS>9#ZG?*_*
MVQJMY&OC@(ZCO7")T(XT(7ERF\!%F[2AA;M)NPW=X%9%,!'9&GSN^KX\WG53
M'X4>\,F5E!9N(C(ZRQ&H[S:KWYI>H[H=9%WW(1:$DJ%*1I]O"3-/3:Q:M0GT
M>A+?*]?:A-Z^L\:$R,UYT/8@JGN,\5"X6B"EG+*<!=H";U4E%VL'!&UQW)G0
ML0YT5]B_\P*6@GKN*=QIU3]'*Z"8JM^%KE3V^RNV5MJ%K&>4UCU&%&F>(G/^
MPAKD=?V0HP3EEP'E?+ UJ.';F9446]6W.WN:!]^BC61>VTBB1VAZCY,SG,GR
M:&R#='?&]!#<3HUF:^@[H!2ME(3,(5[XF:'N#J+4'UV"_9JQ/A WS=/CN)?;
M*/1W#Q;K^ AC6F9DWH$647JBN7P!T7'0PI[C"HW2!\?)4Y01JLHW$( +OX-\
M-BUAIA]'4$:G6$\DAD3#/)G(Z%ZYEC?+!3'+FNI&:I_9:X?(@J,]I7MM]I',
M6)0+A*ULW\B=-6^N'LMXO8P03R]GRK1SW4A=4;P.J?:R5G[EN>'WG!#QP)=T
MN&ZD$A"]TW&R"_P^5T:.Y="[H17^9,,/:1]E-FGGUX^J](25P<9#E\<>'(W/
M I/PJFVN^HMKV))+['KW\*R,Q V;AB DY.JXFTS*<,&E1%KL9I=@X)P\4+R;
MY/0A*[@7V=17IODUC,2D8<S*&X>F,2[A>G#"J)9KP133P79G[M%$*XKQBVX?
MH)E^-HBQ+6MB-8D-ID-.D G.3?XQ"2R_2M8+!Q37 9/2(F0N69_"'\JSY1[H
MKVSZ$&_WD==M*T:GCU]2XR^AO5K6/>'*++<7>QJOT4LR.HQ0A<&4TE*S!;XP
MG!97$5:O3H@8I%"+*CRI:K'25/*:.6ZH!"D=?V,<))4IH^[I:$^P E011;?L
ML)!0"-[2>[A*M=!J=Q\G1-YB9(Q LRUIDIGEL(1YV-T[36NF\U725\9;,Z\9
MB(C="5B,*J\^8A$ ##_74,L!R4?8JUD>XZ)>L4"<WM-GI*-[<W@ &ARV9MKK
M;2]Y[N)-A-[L60QA2R@EPAY8J(C8.6:WQ^O:4)[KVDKZ;+3PA',X\"NY$W]4
M90'Z8COS&_*#63B,1'CT_*;CVNB;":PJ9H*.0'05A 78 VD,%_0^A+AO<X['
M)[(W1?X4TMT@9-7>.H4<P;5'_+M<\.]VX.<YB0C^.2-\J8>_&X)E4Y6-SR6[
M0:+\&>'AE8O-C6 "J@QD%-WK"_N4YV=[&"7=JLR9QPM<T#, R(8T2H9S5 #6
MD? J(7C*J/JMY.;M] ([5DA(,WB)C5B"1Q-ER,6PX0D'63!!UYZ>PFE)H"'5
M?YA']HS.IL:Y2L""4XG8G8$ETJ]Y?"0=*FR^PO;MH<+V%L/U#K[,W,;<97G5
M783U5>-!/.2Z1[@K@MD[(F6$R =Z.T]G7^+AGXL-LA80.OZA^3,[SVI(QG9@
MF:W9*WP.4D+W^5Q,Y#D'B78R$L/R]HV&%:YY7'-A>*ZO@^S-:>>MIP=8H.[1
M>/!N+&6D;L 5RT6M"Z[L1$?->TW1<?AY<A<52S=C-52:RV71MXW[T3UBVNVL
M_N:%_@0)XVV=MWBPNW=^?G$&ZA5YB.0N*;!==YVLVY0M!$W_=.='>YY)9$F5
M8V3*W-%'E:F[=TX>OWB$:^M[S5Y\5N*MVW8]M0MTBZIHW5'2N<N=G2WNW!N-
MC7O[/[1T!S-TP^MC^B#;M868FK13CW/OHJ;*;W.<!(!X#>=EJL<2I*W]EC$T
M-LNFM8Y"-M8[M1L0%I*UQDR)0JSJZ"$Y#HGR%9__CGMII'[=_%/V WOFR=-'
M_P@3ZJ=Y=@BYB14R-#Y)D75A$?C+=(6A"3].'GF)&,K/4$W$EG@1/IL*TZ0"
M(^C;R#OC)GW#925>+&40(PFF<;Z(087'R:]NVS:T]K3@Z1%5DR<P!]XRNW0;
M L7SSW]-J&J?9Q2#J864-@TPC9B@6F=V7QH0]WQH 183H4*,DO=4T<Y+<K+2
MI%R"1!K[B/W<'P"-*FKQ.AO<'#X/RH!XCKR QP&4-)TH'C/"'08$U<V=KT^+
MMT&XA4X07YK[!XDC"JA4LH@0W26<]$Z[HN4!+SGNQXB0AD:WO(EY= 1"50J*
M*E!M#O7KNKFJ]V!]S5 L8K)7C>9A1I73D#O "-ALKI^'^82W>@6URI1*[!?E
M/O8AH3/G[6MQ+0719%E+"W-9,6VN;Z0)2I4A%Q;'Q*G7$QUE1B/WDRZ!$;T1
M?9UU8_=C15_Q>MJMAK? DN/1=IY0AY9>ZEUJVE56"Z[']#MYDX2.%M&J;AG&
MT*-#=!S/2;66>@W&RGO2J$J=GUX, V885KUG^8A JQKE:S- GWQM4YN?)"Y<
M-HNADZ]TI-,:TCR$)NM,_Y_'B*GYI=_-1ZH"MPE7B]<G5!LY0ZF+>W3?L+ZK
M;>(I, N3&O*7P#E>%QA' ,<FJ_H&B]GLCX*==Z]1*'ZCK3F'POJ.J7HE"KCA
MQ0KG"C7;@DDF '.C]),OEP?V-J,YS(A1+$*M2/5-FE 'OML(F7-DS[,*OZ&/
M'GP?NA=G&2AQYAZ]+A>OSY%<!R1VQ\1U(/\LNXNHON\?D5_:+^UKYU;+:C.;
M*6JEU@D1?R"E'WB/0;^:AT9KC:D-)&AV-*6DL"?GP\KB_N=]#BV]ZF;1:?(^
MC)?0B 4V#7A0MPBA,SJEGPW-8ON7H'\6T?&HK+344ZAM V.<:F_/6$-BUR!S
MS!&F: *R%\38G.LH/*S1C//O/34$0\"=V?Z5),5%5I3_H\Q3KR'#-]36_ZA?
M1*Y8UAV!SNF,&3\*?BT[$")9))Q2546]\KHI#&L*TNA5;'<ZS]+"R/7P3MV8
M_6%#"DUX0!>X1[T^>2$L_J0V0BV-%,ZA[\?=. PM.G ;+VK"*'ES'0XXEUS@
M%&C==&^,H,![L,2?U,FOA+KXXOZ#^ZD/8AC>9"(9#+R*\+@C@K[X7!"%SPWN
MV\W1"6&_R9Z?8I%07\;=.\^?GYR>W+GG0I]&106HA8.7VJFNT\=>4_T%E'5
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M"(4^A";O%)IPLZI0SSK_F 'KL.R@+X*_+)\=\F@?<U;8F"S*RY(R:8NV7)?
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M"L(B3;!S>;#Q8@T'WQY,SV\WVHF>;,*>O6 +1O:.OHA3P)W>3)02KJ53I!A
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M99I0"F,F369D K+)>?BV95Z0&:JBJ2I,XV) "AUVLG.T>JD)HU5+Q[0M0R"
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M>.MH,4JW  DB2[\J&U=?)PEFWJ+&"EOE ;)TVHI2R% E)ID.@U?O@J["U1)
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M+9M5BS#R(CBL6)UCR4JQ/*SG&,K;/]>K.S7*P<5^&G3T9)DJEY\JY:IEF-B
MCH-&[CK4%4LLK9&;I)T-UC67JP$)E2>F@ CTM\ ;E<"<*CHF.QF4X[2ZPG6
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MP+N?KX0S2Z(HN<$\<E FE6^1*BE29Z;)I2XI?2PUU+*&$69721$%SD3 W_W
MR9-+00GIFS"_HJ?Y!5!<H*"+"7W)QQ_,*[(<?H$'F<F71/2!.,F!'OYB(?P4
MERRB3-S <X5#,$BPV'=).G>\]LF_6LYG_'G=IN;^$M^-,5L@07KCI\%)E"34
MO&"]/+_R<WCV=1)=PU;"[ NOIXBG(,#AN]C3J <P+2+A9[CC&>PT3^#+U/I(
MI(*GA7DD I<^W6F_OE@(VNE[V!*PW"4L -_]3J[E5[F6"[T6E[X(KY'+!G+
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M\M].ASV?HM'P\Y'P<\_MCD9N9[P%Z;3AYX:?#X*?W7:_XXZZFT<E'#P[/TE
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MT>>I/DI U5U >+^M9'L77KJ'</)S6^31A<K_E899[D?):K'DK@6Z!Q-@.:!
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M\_CO2+L;#&B1\: #VRM<=0&?XY;SB"3O>$9#<+@&"6W;NN4U#*#!1O3X=_G
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MB&.QE+WXN'FWC)N_-B@TO%5ZWTK5\6XAQWLJZ$V'S%7 X(C?EO3Z\ 3_TFP
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M@36F?8+RV12L_CIC*QC3L'";Z#\-W%L.NW^!X8$DRL%/><B JM@<9GE4)XV
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MX-60'?3=*?C-0V9QM8("R$6PA%X=I,7Y51R#S^7,4)W$BS#-:A8B'%##$P@
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M&JNUSUV)8<N3]%='A\T&(M-532M0+<^=C44KH\?+!'DD.[].=K95W795XY&
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M.JB/[OCLX075AY6QA2_/6II"Z]YKS6]XN):4XH2O&@+DAAWR5A#-UYXPM)N
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MV%>K,TZF=1]\MXYNW#'@JM\#NQOH2@2>;@.*H#QR/"8%].G5&0(M=F#!K&J
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MDLZ3X8L]FQGWS],D99W3'$LR?AFEN&GYV'N_?&QN$X\D7"^>_CP6=IF5FRW
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M66.P9)J&K9LS8.DC#2G"+EAWB$S&LR'3DRRM+:N;L'D@9DD0>Z4@9CF!;4T
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M3""<9EFNY<U$3""]POM0&)8$S=T$37,1T%P4"5>Z*'^N-;7O5ZY^9=*ZW2B
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MS(92#CO* 1].@OMK!?>.84ELWWYLKTU#*Z5YG]RDR<VN0OO4I6X?LD]=RK+
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M,=;ZN:@=M4#E(1@#%0W372*2(5)K+/1G#.=--&_P4Q6#5JS*6"C"<H<A&9;
M1HS9"IY0#%/H B?!9L('P*3) %7K-4EC9%,<B#$H?X"-7%!@^9P/2(:#Z[R
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MVZ1$M]?3'V@\DS=\Z%#(#)KMMK1&4P"_B(V]EPBW%,*-E%&A;NQ[<:QKU""
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M"!PO46M4'"\4QQ=:(Q G$O,)J%81A)0:G P(:Z:ME2PKDDNO564:(4@W@/R
M0AME&FQ;>#4N65VN%%>-V[F:AWWG^X=MZXJ>R\C#[6#8.B)V73]CD=J9ZR[O
MZ9T02@7AN$Q"3OT_R\CP*IO7/==P:G3\E3R%\^5^]6.UZW$]VW%-ID6T%21R
M0C4D8CT(+A)820+0[(0TSFC!7!D>*:EI-*F%XAL*Z24JZ KI>X'TA9+.,<OL
M<ZGW)@;EM&!@E+&0O*,TY2A-C&UW96L;).<*Z<V$]!+%=(7TO4#Z0E1[PR)1
M&=%LK05A/ &3.0<3;4PZ)1T+I(5NF+G>+7WM-76W]<?NX,\TF Q'*(UKAF"W
MPW5CO-W_NP5S,=O4<E=*FXW2Z+3P<)E8JV5Q]?LVOXB!UPI-%28UR=QS7EIW
MLX9RM%3$=>%14XPV!MCSBX\*[%4#^T)^>,62)XJ#+WE&@I=A:TX(P#7EV64I
MG3IM14E40W7-'=Q@8,\O02JP5PWL"Q&2A6(Y10,\E,FPQ"4P3I+67VA0E_!@
MP]:V9*:A<E/3"+LM1=J@=B^T57R3Z>C>L'WA]!LU.++Y(J7="!=3"=IUK]PW
M&_>Q:;4B&'.990;<N-)#TS*PD0D0V>J02%8RM!/K&"6-,+9F&ZX9PM<F5E*1
MO1!D7\B5*$-V5@I@-*!<2<Z!(QXQ[AE%XY5;7F;**BH;:J_CNL9*.@OIM=,I
M%=H+@?94V1--))998225$D;#4:L00X%*J@4BVG%C$-I:-5I>3T7<C%8+W18L
M/W*WCMVW$B2<$BOG*F8J,;&&5[JM7!80+WYQN@]V!A&_,SI)\?>+Y:]<.!L7
M\FD!HU52.GD+UH<$0M  Q@6T=3)QA''-HF?(A8U4MB$W# BJ7MF- 7HG<KTJ
MT!<*] L]HW.B/+, C@4!B/,,UOH,AHK,F>:4%:#SAC'::#.WV5.!WEV@=R(#
MK )]H4"?+K02WB7E0:.4 8$<#I[+C/],4@:2G(JV9&Y3B6 W74J@>&@!F</A
MX -,TNAH;C'SL#TZRZU169A+IS3W.!6SE?KN3'UB6LPD;D@FO#AIDP6A4LD=
M$QR8I-)11GA4N41CC+0-YQVI,JT8[UX@IF*\8QB?FE]*HG->9U $U0LNKP(T
M9B6$4D0NO:/1(<8ULXUA%>$;BO .!68JPA>#\*FYI$DP7_P3@@A6_DK@66D9
M:XW007HK33G%\0R7<@.K6H3MLG)I.T64EG3'H^&?_9ABSW_K_>-DC%_T!_]U
M8V.(7AX-CUK\]@<G4]TCAG?L8[= /X\?CF(: 3[.Q^7QCX>'_=@K#W$=";2;
M,1W<,&6$P(NS[?++M[>X5Y [?\2S?^R3)S]VR/,?&Z02Z6Q$*J?E$%-"Z90Y
M1*1.$"A^3AOA915S%%(RZETKAZQJ#)T[.6TF3*V1,WBC2*+K.JK2Q9+IXD)9
M)1.89<J YP[I(B@+AG +N.#2&BLEFF.E\@Z9HV%S]>BJ3+%A3+$*/5:98LE,
M<:'04E:.6RTA*HLR+4@.)A$!/A+-I5<N97+:280T:$]VG2D6&7?JMGI[VA^?
MZ3#4:W/*L(?MK>JFV+HE(4YO@TJ)=Z3$W:FFXWMTK_BM+ \I4] ^E99IF8#3
M$;_"#1",U-HP4C)L2LLT)N9.I:L.ZNY"?HFI=!7RRX7\RVG(4Z^HEE9 <#8@
MY&F13-*#X0PQGZ/*.6UM2X0\;= @KI#?7,@O,:FN0GZYD'\W#7EEC%8R1["6
M"A!M!Q/K.%@IJ$W.<RUBVQB5X$DOYFYC4H-4BPI2W12:JO&GC9=$MW<356:<
MC1F_3^F?KWM?#KCW%BW=",F622VA)![;9" QR;-,PO.@BC$DJ&R(HC7<5#EA
M19JI<L(]<L++:4X0A=T)X2"SB2"LBB4C5P#+-D@J?$J&%I\(D:KA<E'#GRLG
M; @G+%%454ZX1TYX-\T)3BF1)?.@36E:K8, QY(#Y;2S7CF?;2R<0"EK-%]4
M@=):A)"Z*ZD*-GKY</CE+)WO="+M(B9 W=;#=(O/^/LUGN?3ZQ4N8I[47S@5
M*.\R G;P@EL/6F\R+(X%/!@FW]K&).E_3_K'93CSJMT):V@,='2^U OWK2SH
M^,UP)^#JCM*+LP5_<>@&DYU!?':^YM4:F,T:^#J=H2JIU-1+"U*1 $(Q"JX,
ML5!$9&>SH+&X#% .-H;.,V.J=B/H,*R7*/PKK.\1UA>9I-;Z8#WGI:U:F4V3
M?6DOY,O,*?Q/9CK)DDDJ5,-N:"E48;T1L%ZB=J^POD=87Z1]2HV6ETJAI(4S
M$)(R\%*%<G@+(;53SIFM[9(>+M4\+5$[VE)DC>1)?S!Q@P_]MG-B;>Z^V<ID
M]\=:U]:P<Z9Q[AS$3+P3+((T&05)3 (<L0XD=]F3X"+:I"6SW>KBGZS]!384
MSZN4)!7/"\O11#PKZ8V7!J@YC3^6+NZN] :R!.G:^TQ+MQ#-&BM$1?-FHGF5
M2J2B>6'IEZ6'*0TVX'%L$B>ER5<$RUD&X3B5SBB>N"^10T-M(\SU;(*U[PW2
M;0F"JCND%,\BA..V*TY,H]XP]P[[.:$JP>^Y04B]X^%A/W0@_W(-B:^CJN1L
MZ7_%E?\=UWKW?*E?G*UTY;W9>&^J2?MGMO_E('E!I"AYYB6'2D3#P$7E0>7D
MR_ *&;/<VA:*-.:&4=^U>?/&@'JQTN1[&@VC&W^L>+Y_/+^<QK.51'/N-01+
M$H@0,UAG)4@GB16!L%Q:E?[__W^&4?:OBN?-Q?-BQ4G%\_+P_&X:SX+$H'U$
M*,ND02A-P"EF(-"<4]"9.TV[B.>'$R Y[]^),N2T..Q"H/SI#D_2HF5*]<]T
M2*>$8[R<ZQU<_YH6OU52G(T4I[H/OOV^]^;#@0]46^LR),]#*0F+R(J$0?:"
M2R>"0.&RM4V)N''27G6_+A+>.Z.^.]P0F5+AO"0XO[P$9Z&4<80ZH,SH,NU:
M@#$A@9?<Z"AXX$PLS,BIF.X:IN]7JE1,+PG3[RX?T9(1Y22'G!'.HHVN!"7
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M\%G,['Q1VOV(#_+0'8_3X_,O_A7[X^-#]^UQ?] ^CO9--ZCNLZNWZA'1IMS
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M@4>E8TY&0I3@ 4TJ:XAG2E/G W&).7NPNU*+JI+@;"3X[:I>BDD&K7@ 2ED
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M##%S#8)'!4X+#M1KY9SC#HW.,C%:,=MP5B.47</H_<8^*CQ7*!+>O/R^]_*
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M4KB45RFU=<';;%5,@N;LG38A.*&L\UE:?K!;UNAJ.N7N_J\S9$Z?Q@!>EQ#
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M/_;>M+EM)%D7_BL(Q;TQ=@1+@Z6P=9_7$6HO/>K;DMVVW'WL+XK:(,$F"0Y
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M)&7<#](4!#K-,J&RH%!^$<H\#]6W1&%[:1=W@ZJ"?[1PW8>?]X[S+(H"CD7
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M689J[G'MX)O@.8[Y[CT].'H/_SX]IB(*PR+D).!I1"A+0Y(IQDG(>! 7J2S
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MI$X%WH>=+6O<NG4QA0-9,=7R0JUF(%D;L'/4P@L=@9^XP<IV,+!U&K!FC//
M>O>0]4[/%^C*LXYTF[F OG$8')3=2MBZ &\/G[:)6FT0_H.6BFXV$WABVZOU
M[]QD$YCJ"I1:9BJL%\I'CD>2<I48)AL /=\*LY+1X&F3!"::;]!%JC_>5L*!
MTW33,=LVA]-O:?X,<4DM,\!T^BZ="[G!I'<UNGJA- VG7=V',_F^BE<NU7UN
M*+-\H3)TD1+D$;2)O#>J59ANZ;Y<*D16<[3\@N2S$B0A0=1*D"[0OC]OP";0
M&T8>F[(G3&A5S<1)#L-BIH[%6-H]KIQ54DVU[)GI-*=VW%Y-C-,B*NL2;5^X
MZSW#H%K-I!H4RZ)''A-&FXEWJJ823H',,,T)4X&DXDNO46)ERD<FWK1B\WZM
M;6_\B;UP\<9SXJ,?DUAA+WO-S[;(BTRK2N?[VVUJ:XTP#=3MAUFROGE-:<14
M<RT,;P6;=08H5@-[UWU]3&LBZ&UANOH!MVVJ-]OL!/O RBDNG, G1'<57UNN
MD0Z8#FIJ/.S7-Q9J,Y]<(9MY"B?&L.QDCNFL)1 CTYZ#,QM#/,>@T[*2['QB
M(X5=L8\=H=O%-AT5!5FW)%!8C"[%YD;#L]U#VK")K2*SQ=#N$NA6N&M%7;L4
M[7&!6:(_9(HY8=M]&_V>Z[T_FW7A0:,.!'K->[<G_UTQ79X#4AOKQ'2TIBY/
M7,'2.DFWH2)-F!NSM)5HL!1@N5Z97IOMIO&KQ_RR:^6796-^V9A?=C/SRZZ6
M+[8%)/\R3]W7ZB4_:;_%:K8RLHC8(EDF<48F_%$6&'R8&!>W+1%M:RQ8&SSA
M"M8VMP44QI]>-\N---UA_+*U8LI6$_^AUN)/#U:][*S]-76O%Y!F'"P\O"-[
M\>=MRB)^0OQXXNU<047T'AAO6!0F#W_QCF G%4[D"+T91M^!N96JV+''U6($
M++LG:OV$OF[M^_7,N4NH,G7ARY[V@YK%%"3+G+65/348D6!D<KB"%090G&'<
M3U!?M-<ZO/$$:TTWM=4V81R]*D-%19?#:OKJI4^AZCA4L9QA" J"U7K-VTPI
ML%4^C=R9 7VA+C6SB A:9]2SAQ>X#YV-J$ON>[HMX>>D^PVA DJ;*-8.49J$
M^5:I-&LWX<$MFB9\>)FR?6/"@5;GPM/P@)=/!Z2#>]DC9=RZH04>V62KWF%^
M[OO.O=8''M!**6L1?+8;ZQVFSC7=6YN*X';54-\H<> 7F:!2)#%<0$&1)UGN
M9YD,4A4E.17'09[O7!X'^0DWR78-YD'TT #";?[W.T<H78HF'!^W9L 38W2
M3+@Y<<GW-BX)WYL]C0X_[4>'3Z;EV]F!?_C[ZPB[%1Z^$Q_?'OW][C \^/3V
MZ/3T[7I<\MWK\S='(CIX)_SG__PQ>_/I+__MD2P/GYR$AY^>30__.8C>?#J<
M/O_]V?O__?2:'AS]=>SG19##UA(19#ZAE/HDXYD@(?.%SV6>I"E=#TOZ65KP
M("[22&:44<DDCR(N"AJ'BD4Y6P]+O@1)>E2KCQ=U3-JJ45W^DN&D:)C2R(^H
MBE5.PRCD 7PQ\GD:J31-\N!;D_U/RJ'Y4>RJQ>7?)<<Y?Y=YW/7]:T7_IM"_
MV/RXE(C7B)ZQ3 A1B"CW*95YQ)!ETIAG0<!#Q8/;6"MQD3;L9,CWRC3]20%O
MZ]UMD?CFQM4MM3[<YHBV"6.'52WACOP=+).%]]ONW[O>@QWSMYV'.O@IM"JZ
MENWY>O?5;B_ETWRAU6/*.4*I:%U2XW,M89\Q&]V53N :;)*Z#?+J_+A:L>7,
M-FUC)B12GZH5*$]5B5W>EJ>H7C83[]WJ@YJ7B,TBRVK!EF T]#_6]2#PMJ:J
M$9-J\)G&HS*?@]$#4]3FHGY2:\:WGQSVFA8/I_-0:M=L*71N?B_VM&"XL0CF
M@U(1]_W_7 >(.<E!ETQX$N:4LI0QQ5,:!A$522&+.-1 S$E@@9CAA\CO S&3
M^#K]I6T-]%&U9PC2*6&J =)M;E*'Z1^M=^U_/'@BCEG.@R(N!$E#OR"@S.:$
M<RE(D.4II4D8"W0:!;X_ ?+;@%9&0Q856(V8,:@C:LN5;BIE;-'&'_?I7WL9
M#(;5GQWHVKXM'6GI)KF'='-X='#,BX QO\A)KO7U+&4D2Y5/.*-<2+_P6>#O
M//)W\TV: >$UM=AP0XGC*MN8K4\#N7(A\1C(EC7ZB40.R@IC0$4^+8"*0EE$
M+$N%#"-?^?EE]$.O03^O$(=@7WNVGNC*BQ?:>:AQ*!HM;(S">+]%S/,GKX_#
M) 9;25"2^F&,^-<!R92*B!_$(H(S2GD@0,1D%XB8/KZ$Q>DI^I?1 !?")&1;
M:)P68N[9DST# _J!38>^7ZO&6 UCF(,T;2JC^6B7C!5H[AL,@80M"F,+M+$L
M.V1,ET)MM9O!'";>E(%R94K(F#@M0;-P&HR+9IO,*N 56$LU1^?8!24![*(R
M (150_YROKG>K."SDZY&U.VBJ[YA#KI1URB@RF87O650-R#H'ZL"CLP4(;6
MTUAW=_MUH^=]53F=;-97M55^ TISFSX@-:/DZOUS>Z>IP$!6VKT'&C(U& ;%
MKBNK=.:'QVO\%HHDXVT<!>6M%I0AS/MK!64G'7LB\R)!N<"\N&K5#"K+G44V
M$* M.>N\,K2 +$8.Z'[74>[B5$8%\Z4(%:=)JGB0@::7^Z#TQ4P&E_7:NY9R
M=P'-_8T3WTIR]U"-"Y\_V3^.!6<\9Y($A4H)99$B&0\34.,R4001MD*1EZAQ
M]HYU"$P8A3 B:2 +]6UJ$IA,/1.[%O$H/U2Q"$+*LX(JGC&:<Q7ZF4@CRE@J
MCO>!9H*OHIGM!@&N"6Z?@6G@[('S^TP^T>&[_>,DXT64<D9DE"BP'F5!>%%D
M< OG:986<<)I"A)K]Z)69(Z&6C6GPXA8J4X>:=NR;+8\=J8!7DM-47^LIN?#
M#-A^C3US"8+:@)LO^PCQRVVEB9Z1'-U'>NB>/#4Z'(S>7LHNS.JTNY'F[Q3-
MOPF>8U7>N_?1\R=[,3QS ^C?)DQJ'K ( $@57\\"H7]E2(F;J[CWN/749,37
MU4>-5PZBXCJ\&!2%C 1+(^:G-$A]S@6/,\[B)"GR.(LU+WZ=SK*%%U^V:;#[
M!FJH1.?XGDXFL?Y,N3?O^Z?V$"X6'I\OV5PGH=QG%>=I>/CD_3F,Z1\>[9\?
M'!T<QT4:!VF1$YXE :$%I80Q8%_..:C><+8)PU9RN]EGO58&AMCML$ONZ55%
M=1="QU:&X5O>N@MF\9-6WOCKUK#+WKX>C_E*"IK17!94A$$>^#+Q*1Q-"F9I
M&!L#(?"_A8'PTJ+MC-QAN /FBID\"E2,(B LH))0%7&21UR1-!8Q\V.A8I6A
M,1!_QA@HVBH+4_.G&\ TEZ(9#<&,3 'G1>AAKI+0W8UH:_3UP=898^_#5B\$
MIK/_NQ:RW4TL3EK+B+B]"'U6AFPIO7:1)%V5X3(4UR+1</0U^Z#3<W\K*X.X
MYSW8Z?Z\&8P^F5:<33L_IM%_D.#LGO8*/?#Y%@MEL@&2LN[QK-4))BEC8Z%>
MY[SU3CDZ$QF]=T".[2L-,.%2(W5,>I:SMAO:J#A"SL.9N<*_K1'PUG^,'H\5
M=LX3+HG0?-$4R[@EGE;- JF.V#V2>B78HJG42R&]Z7=#+>9J-:OF)7.^XP60
MK>'H]Z7MWH0_8 *IT #2W<MWO?UEKU:<>;KV&*?^>\UFQ"3:( I*]S:V/*W
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M 5\?'7K8K/WG#%A-K"?*,&JI8!Q;;[%RP9/ H[;,4CS]J#D2+WO6_'/_\:]
M62XH*#_AU!R#Z^UKX0.E7"*BA$?<VWQJCC#D0PR8D:!")("LR[<=%@?U;V8!
MR&YPEA_X!)H4K7<A,/76J2]EAM?6UO==U#3:9)"P2B#.#$-:Z(2\$$QY @89
M"4LK?/FV]J0#F:D.#B$.NY[TWQRV/EF^N;U5;IY&+.9?$)RTY\%+83.OJI':
M8*T#49%)P_T^7&_I[C.,ZK83BV]Q4/P7_FM_+F[^?.&3R*M@).2IMLVKX]@;
MIWVM@E?7&AW?;.4M:4[.&E_4UC:&&G"Q^V.#[QZMD_K7^LG>UPV\]V.=;*[!
MOT_ U+S<RW\:>U]W?N:F&^,:\/OA[M%AH[:]@W?I'IBR6\W=[7RF>(?N_EC/
MC3?@S^_'8.9FOFI6WU[=Y\998G1$WEN%..8"V21SE1FF@5F'>923Q\RUU-Q8
M[H4UGH./8C2UP3$M*4E6&C5Y-GD+# +X<N>FV3>J!%--I?MO-3XT 9K#H@.@
MY?!%0YRR&COK4E(L)9)N/2BM'G[T]X44J;CB;XTNW,X_0+7^;+="SW<KUY,[
M,9FO<LQ_'2:_>_$#-ID1[1H,Z4N[=;+^LQO;H(2?8?9:,)C.IXO!P'.T\3O8
M<0T?.Q];"3?VG>5!<\M1TB0S3"D,_J E"'8 #-Y;Q$G(!Q[XGP[_\^(/C?@U
M__4?FA+UST[E-'9S64HAS.V!,/<M]D[AI0P: 5QU#LB'^O,K%]&V.Y5XFIN_
M3FZ\]Y[V'SC"$D8]K5O"1&^1%SGL+Y>ET8\Y[,_QLA;F48?][W[/X,==]:[!
M$GA,SA=EL&J9Z84:K'R.Y@PSE-T]XJ-3@MA]Q7J=D*VYSU M(K;36A1^J,>_
M2<_RL1Y?CSW^>^DE/+2U?GO>Q;TU7GQKE>W'N.7'J1[YWS989Q9<Z/@ R;KW
MN2<7HZPW?J?93NTTP3+WK].2!ZI=D ''I)2,R1%BGI$S9<0)S0'1/+@?C>[A
MT!%=_YEY(V"&<TH3_A^V[<]YR6L^V@\=Y#4O-M? !Z6_-VLG]<.]DQT,?Q]O
MPO=W<\[RQSH%'Y36CW8N:I\G\YH;O';RY6CW9.=BEWXYV=O^!G]_X^#'@D][
M#,^Y2_,?\%G/B\/5C4%><]N3S=5]$[B5.CK$I;"(*Q605LX@;B*AT0CM4UI:
M(:(JI((_-WD#WJZPN 2N$KCN+-.PQ&+.N<0\<<J-TS9E<=9)JHA->$;Z]A*X
M7AZXZI_'@,L*'*.5"@5!,EQIB1S3 H7D2<!.T4!Q4;&GC:@2.D\G(DK@*H'K
M+N *AN7V=)$ZQ[EPR@@EO,E<FV!Y:>T+X-)#X-(E<,TY<(U;7)A)KQG %262
M(BZ41<8FAK@CRB?'DHNI "XL1%52,4? -5N(90%<XD&CX>>(M'P4HB9.$H;M
M53O"!#=*&QVY$5S"KDL33\])H5F"TTN#4VW4':2U\WVOI0M.*.1A[P%W$'Y8
M90,2G"HO/<>$9Q8Y7-4*5V%+>GU&IE(][U1/\'2DB3AP)B(/ 5P>*;B.F,=H
M>**Z='H62CU'G)ZLGB'Q"*L&ZJD"01P;BVRV(HA@G@<6O?:D(.@V14.24COG
M3#L-HUJ1:$+2B@LO-+,^19J(CD["XI:6_6)IY^3F&1TX:12!)03:2;Q!%OY#
M/C@*^VJ23NNE%5'%"OX(M;!LA@M@V'^VS9!O]1*9KK)3[Q#.E/0A*4%)L(X[
MP#8O->6,,:ED$LF5OL "P=FW,5\@!RJDMBQ@CCRG.34D;;^]..7Y+V6IDS+#
M&2QWU?#GXO.;HP!KJ>A7A)TF<$(-=H(RT.]DA2=>:2Z=E<D157H5"Z7HHUX%
M*#IUSN:@#A)$9AX!8I!65"##>! XB"29RXI.*:U2_0Y3P*6B#Q6=*:93](Y%
M:[DG1EOO =L%M9ELPI0.RH(I^OB.;KCUF54=<482XCA$Y"QS2 ?'A3!!*>8+
M!P63JC$S.BAEYF$6G5SUL6M!.1Y2BU>&3P;HY'%@F;LK!JZYTMI&*;2QF''L
M##C7I;^Q0.@T4HH&OH9F#&L=$?B2*=.G"I2/T*)<?R:9U\1%6_!\*%ZE6):!
MS7G33)[ &Y1*<)YX@KTD$4JQ2#ZZZ+7PI8.P4)IYY2"L[C-#O&7:(6P%1^ 0
M6&2]T"@HDJ1@QA&K,LF8IKS*^6V'[DO-?+-BHJ1DPI8Z#+LF#MI1Q[F-SB<;
M%9A\I46_6)IYO6?Z1(7 E*#D*.R9'E/D6 C(&"LD./$D,KVT ONEYE5"2)EN
M>#E]W#R)OFE/6C_1G_:XS#F\))X1JC6%K4>#9<%]P$;%H%(R0G.<,"]]@$7"
ML]JH#P#>G54D:F2Y!SS3E"'- T4FP.X520@^LV51H:K@*<Q1;*)4\>>N84I4
M\F2HE": 21FU\TYRST+V\0.GI3.Q4"H^XDS@!"8HQJ#=3D9P)I)#.C=]T]1Y
MCBTV,8+)HID"=V)&5Z)4\452<4Q(,$S39*7G@1L76-2,8.8PB43%TBM9+!6_
MWL63=MQ8+1!)!"-NB$4:C#-$J<&<.<&(HTLKDK(J+3,,+WJVP9ZU&YW6[;00
M9;#D9IT#$91ZY7/O.:Z,-P*#@^&IT8H:<4N?M1*6YA.6=D:="V*=$L%S%)5@
MB.=8IL;4(66=M2((137-"0:L5)72-ZC-+#7SGL($8UTPFK#,>P9>@0=GGTEE
MF+#P=WFN8;$T<\0G2%$JCKU'WC&).#$F%R5X9).(D9D$6BN75@R354EF/ Q9
MZN6+ZR58[=(:XV4TED<K')A_D4F:J$J2.%P:\HNEE]<[)K=><\(UN.E@S7,C
M#*BDUP@6VUI"%#CL^9QR54F6T_)E>N'E]'$KAL9V._XL,PLO>K+9"";!XB?9
M3@3P,E12'5G$4N?Z(E8:_PL$90<CIQEJI'ZPKZ,AFB>'A(@6<<<8<IY89*5(
MUJ@4DHU+*UJ F3'KT:PR]/CF:EYTIJ;_+)>I7*;GCO(M O/AM'[L3XC[S=),
M]1UTEWKP8\ZW<LV487T$GT1IZLRGJ;-^_L?VQH"O<'5?.R.2S <VA<IY5BR0
MHUZ@8!2X<,8X9OG2"A-5,&JK4LUZ;/.ANO(ZX982J-XY4&EL@Y:6".\(QUKK
MX!+W25/E?4J2EV'?!0.J;U= Y5/N3X0EPDD%!!M/1(Y0B:AV-A*>A'8!@(I6
M.58 5K/VP2N!J@2JUSP XYB.@:AD(^/81\.8,#**P"2)1I,R#KY@0+5[!51$
M>:HTQ@A'[Q!/VB*CF4)!1>)MPLY$L*BHKFK,JD;.6&C_XD U<'F']QL(>)]/
M[#6YA48>=(++>O1)/^0]'\"V/9TYCLBWIHXKKOAP!L3-S"-]@__P9;%]^DBF
MT+G>G-]Y8>:[YQ%&;WXKG?PK;)K%J-9Z!35Y-L>KE<^]3/'7S/S,\6?TO<P.
M:"M_-'P\[<2"MGFMT>FV&ZY7;+#VH!W[Q.<%*_F_6J<'_PM_*C\:I_^*M@DO
M_7EH89NL?(4G/*M\;BW#M4X:^:J_Y-@BQ?^\^FCQ;_+/7PORP5:O71GV!"MN
M>^/\_>O,H5P6#YC$?YZU.@43[F_MV,P-BN,_LS0B5GQ[$NUM)^8+S*L\N#;,
M=Z?2.*U\/FR<VF+V\\)6\LHN5RH;I]F2.NJ=]FVL8N$!)4 \3F$ M@U?/QAA
MH1]R45:ZL7V2V;,+B3IKQ[\;K5[GP:+U%1Z^80?BY&.OF-$.7+SRR]+T]Y9^
MO:*Q[)ZW*OW'ZH_?#HB+JY5SN'.STZIT8&6*@>5G>.B8UC[U[PDSTXXV2W>U
M\D<W+%_)]O #8Z(]Z&&=)_A[JP>7*;Z]7%GMP.W;L=-K=@>$G'D(PSMVQG2S
M'7WKX!06%89\=M9N_02[LQN;%S,QI_N@B*?,)XDCM]K U%%'I,(B*F:EO2>H
M.!.%^E-LX#<F3G\#QEJ/ZP?[,F&!L1?(D@1F+%$Z]WTA*#!A'34B>>F75O#R
M;1'! 6]ZEB5X$[5C DPI2%9[9RBU814J9_:BD*V"6KW8Z0?)B"R<67$R16PV
M< NM[73AKT+ZX9*MLP'E?:<2KC>0Y<HV7"6"6L&/T];U#4!@(\!BR!<>\+6/
M[N8WR-M']_<!.BF:Z:-O .V J+/O_XU\:\ ^BZ^_8AT\"^QHMWYE&BWM*[NQ
M!0)_091,S,_(S\/VM9%[$)$#\#A&-L%P?[/-<WO16?K'N'D$MM&5EYS9=V=]
M_)7_<6VXY&WFU^O/VG3KZO-.[=/ZUA^K];7*G_]:W:JM?E[?V=[XO/K']\I&
M_3/@*[SQ?>?3]XVUC=6MC?7O,S_0W,W#=.FI@Y'4J71;L!^-*.\7V'I/?<,V
M*]^':MRI5'[YW!HPN_\Z3>"FTL4_B?Y]'HSSZ=-6&>'-KAP"(%YOO?W=OG%:
MT*SGB8!9/+/M[FEL=XHMW;=.8!/+L]NX[,_4@%%[<+W_[@RSO8-KV4ZG!1_/
M"W,%D8W3O ?V(7(,C#L955MCQD"^W-^- );-H>U6HO6'PSM>C<L" H,U<99)
MOC/HYW%V8CS.4-V.!SV SU;[HF\^_)U-J:&Q-!AIM3!_KBG!AQ^L]F\WN \\
M3K-9<3=OE:\$]F(K?S6,V5!PU0[LZYWA'I._&7W&\HDIAM_;#1ADHS\#UZLS
M>/AL+X56I]. 8>1;7B?4#_(-[=7M3BQ<&/YTKD?9:#:Z%U<#A<TD_FUA8\L#
M:#9A-+V\Q.V\R74OED<MKP:HUL59-C#!VH*E:'2;L&2@;8,=+IN08[MM]<9V
M6X$E*ZQ2$-_^9%[;E7#Y:[]K0-$>!COMY I=/7Q_H0:/DD6Z4/_\KSSS(%>W
M/-CPPP]=B(MB&<8%L;">KV=D*)=Y.$,KN]"6@9#WSO*:#*7GBI\>)J$!PCXT
M+F!=8VID@WR*I(Y($,! ! /R=%) 3NQ%?V @F-/6J-VZ (\3Y*J29[77[8&N
M]*\XU**AMN9[V0H(TVDGQ2QBX!KD+W5Z9V?-0C"+&_N!3=L;?=81)1\Z2?<]
M^#3%K-YXV&)4MS]#7_.O'83.E557S'[+^UZ['4\]B&9>I2X\#,A@(8T%G'0G
M@;!R"'("2Y)7/8\2GC;!(L,5KK\PO,5YJ]<,H +=/BB []OI0YJ%V[A._+]>
M?E00OT8K+"]22&?ZKI$7?UQ9IH!T5H99'+,G5GL\R#'S9S">@5>VU1>6/*R=
MLP*J_NS+\ =VP=9Y_7)W7P<=!)<:@>5L\B'XA)RA%GRP1'!D%+9KL[1"EF\R
M=U2&[A>(_GWN5_5:MZ_1 _2L=Y9!:T$DYT\P.P%J;7-<A#I;V5&+H=O:NL*V
MU0&T?63Q$O6U;_O*$TMUB A,ZHAX=+D9%.$(6T.#XQ*GW-^5+M]LX7PE7NW^
M]/9WMRE67=XJWH,<78G1G_VM^7O>ZCZT &VN'>\7?38I,2AAB1$/1B =0("X
M3\HK$RSG($!\^6;[G5%\&HG27 G3T,8L3 JP<G+D+H=X*.SV[58/[($U,*:R
M6=R/-C%2+0([U1OFPZ@I4O&]DUX_<+,H\OCY:L3EWCB0O8WSS>W:/E8I\S,'
MA)7,Y\V\1(X*@2187#0I0I7))[3O B^0O=[9?:'(C& 3<K0@HE,;[NK#O? C
MR\S/^O;&/N.6XR05<CCSH?$0D!8@0D%Q$L&P2M'*'-.^K29C1'"&XC&"61EY
MIEA24_RPSNU6^SMP2C;'HD?7\?F,SCE*7ZA4KFKJ.\F#P%,E&ZCY@RE#?8HY
M[-"L'+1S7 1V _CE9!BDRI_J%B&I3@1G$B;6750^KV]?[0UY);Z#@C0KGWH=
M&%^G4UD-)XW3D;A,IW(>X7WXNQEML1Z^!1[H03S-X8ZK2UYYRG\T$ES3-[+;
MV:E\+B*L?:]_VCLYD%)DTZ)M@W/;#\CVO=6KZ%$G?Z4+0QH&Y;S/ P5!2LWX
MLXAD-:VKP KZ/@H-<:G3ZK5]/\8:8)*;K;.*:\#@0PZ"7,4.EBM?B[D;"FHQ
MK7W9NYK.;CX-\J0D'A:B3_8@7>".>L,DMRPY\$XT(>(^>M<RB?=RB$<WUW;W
M36**T2B1YC@@SK1&SMJ$@G?4$5@BG<O[\1T66G4F>2!$416\%1I'+@P#<] %
M:AE.ECG"[FOL7<K#2\K#]OI^, E[IBR*(5C8 36X?$YY9'P$>T301#7.5M/-
MK.ZU/&0LFD4F.!76JIB\9X$3P[7AC"M"9*:#5D[<4^M:RL2+RD3VXC(9GU6(
M6 H88;!'3@2:SP%)L+*#X-1-MXJN+.EA^/\"]KM.)?8W\ML\M#$;H#H2]V]>
M/"@OWT\#$@S6/P]>"K#I2#)2&YPY(%1DTG"_3[%8NMN*TE.MJ#=*'_\B?NW/
MT\V?_S-6V_D,[L6XRFR<@LKDL,U:H^.;K0X85-MP_4_-EC]^<XW8&6C$V3%\
MA]:^KHN];<]V+[_A^M&G0T"TG[LG7T[JEULG>_#O^M==7/L^H1$GWV!\N^>[
MV\UF_3(<U=>^%=>I;7]I[/[89?6O>R?P;[QW].WGOR_76?UH8Y^ZZ"@&C])0
MX1!W@2$MC4/"1FM#) "@J0]R1?)Z-2.3Q8K*$"@WPG,; 5D92R"<5!!..8%I
MCX S9SE3W^[%I97AM#=R7>M$]>Z8$DS-@M]_M_'184M-RDS"TF,N2=1:1@:O
M^2"LDIF8\86E[+L_C*'7C)OI2MX^%WF@[G:.2G]LB:OMYRX3SB6.!. 7XA$L
M-NM(0-A(RD)DQG@\*4$+Z1QNCY4EY(/HC6M%Z"><.]G]&F1"1PH BIS$<$^I
M,/+;?9[RH 0KU[S?/CU7M3)%.?U$43Y,2M.>=>)OPU_^&1J=LZ:]^*UQ6CQ:
M\:4II_L'14Y:+3-F<IW3H(? X/*#$JCEH@1JXH!'_SV)ES&^_6W8C!_YGGGD
M5>\:+%'+E.L%&JR@#[KL [L_/.]YD(DS/#=E]76.O)G[K)9B:3+:/T?#V(5]
M?&+&'G_ZX2GSEH>G;C\E]M:W?*:&;//;;&7+GE=R3*W=&*9"SUOMXR+EU6[E
M8-]+-&A[<AN@Q3DV_*!'?#='AHGU1!EPU*E@'%L/+H +G@0>M053'N]O/+7W
MRI5E#H);&\IM/78WTU:$Y_M[)./]]@>#'V>G#PX&B\VUU8O:]NK%WMH!O ;O
M7?KSS;6]YN[V[R>UM3S.6K['Q5YC\F#P,:^M;?RLK?U^O+FV=0@V_&7]<I77
M3_XZK)WLGL/X:.URX[P.UYG@K*1,>NH41L9[A3A7!ND8,<)!!V.)95'DA*6L
M4LJJ1+Y#WNP2FMXI- E+K0@82\X\]\EH[*A4Q#J/;:369&AZ6K>5$IJ>'9I&
M>FIKI43BD2%)&48\4W[KZ"DBR3FM$[$!1X F4V5<5!6=M0G4&W;HN_4XZ\(8
MD?D83?]TZ#!0<O$HLW'BN1_527+*W"U()\FYLK.* HDK1+N"L^^#HO[5TU"+
M;7\(#D.C$W=.P:T:",%8X5>)<P_!N3'*0.Z2=6!T(8T%X)P/!EE/&0K.4F.Q
ML-@XP#FJJQC/VD#J@4#SHO97J>-S8["4.OZ:.C[*&2BT=S@7@AK,$)?4(4=D
M1(D*QX-5DA&[M,+!S^+RR;2@SZCC[SX:]B77WQV"'7/0:H5.M<C]%&?."ON]
MY"I8;)OF"NJ&R_PUKW+IH3T>U;Z-6BY6,_#(@D5*:XYXPF##*!61!4-%.*L5
MMV"YB*KAK*K8.XP=E;K\!L&64I>?39='+!1.3 I:<F0+NB18*>0" 0N%!Y/K
MV*1SV4*I2LFKH-USI,O/%&Q9  JE/D]"8[1&ZVUC+D]K!;S0@/>*QLO7=JM3
M8MMLV#;.FRH]-UP3Q#3+1XJ%18:Q@&AP%/:L7%"<CQ33*C6\JLV32=MGU8X%
MBL!\8(U_11.GU/C':/R(-6,-\\9DHK04/>)""^28\V#<Y.5R@9&4VUWS*J>R
M2KE<%(W_.'21S7SL,#<)Z3?FZ3[9[/G8KMPO\VG:U%NG@_4MT6XFM-L=M6\$
ML]AQ2Q"VN>.%= 99'"7R6'.<F6X3R>?G2%4*657\9B#FUS(&\QX4]Q4ME%)Q
M'ZVX(V8*"8EYF@*R)A^PD98BISA#H- )$T\!=L%,(:(J!*\:,R>*^^ZK6V[$
M62J^:3N=1FH,.E#V)?\EHB\/M# 'IX@FN#ENMS_?=17C<T[-?&\&<VK$Q7(3
MF&T3\*/6&^962V(5DI$*Q)E)R#GC48I1>$Z=QL4F@*N2Z2IY.J_W,ZK+&P>N
M2K LP7+10GLE6,X.EB,6,U/!BA@< E ,B,.*(,<C18DS!\CI",V!/5W5BE2I
MX.\ *Q_/JX;G^LS]6'/R? 0Q6]FM3N[U->A(UVB'HC=XH]]6#.[82[F?>+O?
M>>P,5LL>Q$H:*^'J]_0']5JN5#[9W&>[U>_D/DK"=-U[?.2B[=SY>W#1]GC+
MSJ*A?VP4K<ZZ]CBWJ>_"Z@_:ZTT,8+23?2M5.H>-LWXK\_;D6S"D1M&\?:R_
M^%5WMW/;CH>M7N>JH_H5:]1A/*T<MIIPLZ)->?^^C=/K8GP NVZC.9UD8-BP
M?F+8H^Y.[I9>,-N$X=B:K?,\0;G/>:=XE%PHUXX%N4-6!'B,W.@\3VOQB1#[
MU%9PA=SL[F P4>U.%KWJX+=6KULYB=W#!W8]?W.>P(?VD!BV.>GS(>2IL=W8
M&5F=@IEAV-,7YC;W?:J$7B%1\6<^A%NMM#(S#\QBGNP.3#\Z:?V=)[*_6B[?
M!&Y6=#'LM[@_A,4N^AQGW6BWCJ+O4Q$-I/3Z[B +N<1WN?(CRU'\>]"V'J80
M0*C@21DVL/<@H1?Y#OWES10"5UWL?0M@JT_F8"O^$)8I%D00H!ZG_<[+H5<T
MPQ^]-;S>Z%XYT%.%"&1]M7M+FZ9A@R8ST5!WG/QKA-T"_CG277>JS/:'WIE8
MD_[L=WPQ,_F*H$K#5<TO#=8L*_&CVQ0^SD6;J?/8E=GQ5R&$,* ;M5)OWV#L
MM9O;[)+-;9^-#%:_A,\<[>PS1J*4@B*7I,D% A0901,R25*)64A2XMQL[(ZV
MO;/VGWN<R5DN_G,N_L9E;=OO$Q*3ROUW<2"9PQT;6'?"01:LE=3;R$EX0/_=
MB9YQE<I#NL9]8#8W6K*YS=J.KV1S>QTVMP?TI5O$+F=]DMK3.,Y16['^_WJ-
M/H 4!CXXH[;?#:;/'-;GPYIH*?Z_;; V;?;7^B2RX_Y28X15;(3[[*R7#Y=U
MXK"/FNT3:YV-<=2"M7@ MF-N0UWY96GUSXT!9^W('<?YR\8MS*&+E;U'E+W'
MBRN?+KM1J_W/PV7S('-G-W"B0^7Z>0LDSQ_I6X>#D0X^/^2\RMV]B];5[;%F
M.KE+]IA3E6\(WQP^_W6+N;_L&3Q.J]F?O*(Q]TC7\7#%/C9V^5$SNMMW&^\Q
MDY<K4PYJP]*<Y?--63U6>^!]M0NS^6MN,M[P(Y_+[L2P/_R?F>[LH#7P*X<^
M[8U=[J'][N;;E0,AR9(S7/PA.?&(HHP1#Q>OYYG*:SVEH=*8:PW7G%<S<4I.
M_^/9A^N7FVOK^\8KPAA7B!,'#@',,=)>"10-]UJZ*%-,.3&_?+-R\,HCZ+O1
M!>OO>/KXEJJVNQS?ZI@@3KO 1>4<+CV+:%'A$HL^&*HU3\X:KIS3*8#WH[F3
M[&7+O#Z@9.'-M9U]04@"=Q.#/&6&&.H(<C%:1&TB1CG/,;6Y5NLY?4TC#3;*
M!"X$YCHJ+;6FP:M %!%!Z9>M"_J *TWK:\<7]2./X7.\MEW;]S1RD3Q!E#&)
M>*(4&1<%RBK(J?!8%*LN[FAQ?]MVGW?Y"9[><(44-V*\X_;%+4ATAV4QX_;%
MN55)!R)38!R0QH#4&V%A*JA*CHCG#'&5HC<I>@6Y D_&@15!D,%6YXR91AK;
M@+PG"O-D">! YM.[HY%^8=-DXMP^B>FAS92^(&GW2=E=$@M;W5W6Z_3OC9E=
M6<YGD45KL!*6I4B"Y"$D#:H7O%"><P'_XZ4LOJ@LUHX.]AUC6/'$4>[2CKAU
M#FD)6"BYL)HK[HAF.=1V,V_[^+T/8VLYXU(JR2D%T-$ 0BIWC@<)\*XTH%]P
MU7?.:]L[^PJ3:#7VR(/Q@WA4"EDF%6(TFIB#[1J;O.IWT;N,QE:K0_[8FS9P
M]K2S%S82K<CYID:*W7;+@2?IP=L;1!G D2OBJY/L9D_C]]#W\WN\%9F'?"LR
MCS\'W.I_ FYW5T_#.OC+1?Q@'LD]#H;ZTMS[NG4([X,<;S5K:S7X>_T\4]=L
M;N\UX3MT\T>]N7=T0.J-27WYZWCOZSJ,!;[[%70 = W&T(#?1?UD!\:W*W;I
M7R?@#M!_7]9(_6#?1T)3"!B!90XJXIU FH2$4J(^189C2N8&>X91)("?YJ(&
MY(Q$:Z<Q4\&!.2F%<Y/,#,-5*"#T:@D>0?-Q[XU?FK;C5GGZR%*TN;KOI3,J
M!HZ8\R&G,3F8>AA^>*P95YX2+Q[(UY&S*(/J)92K'8MPW!R'[,:$.P[EX4[J
MCIO&Z2/).R9FYJ7).XS&CR'O8'S92/$"?!C:/(RX8I;!4K9,Z*(,EJAE0O@"
M#98^C,!DWIA&[JRZ?LTTY<-X.+9RN2'@SMNE4Q\VSEXGIEZSTLRF\(0E_!')
M4TKNF)([9G%N^4H-.M_T($<.;/<R576\=EI>L '$"\[>?-72C)Z2F>JJ>9F"
MLHF;$"DWT3MJ:&#88NU=X"%.==5&PF8P)O];Z+4S >N#?;B=8CO*_.4+ZL3U
M3\><'>UNA\.]KU^.:_0;W5SS>/=D]^<F.'.[1[L7M1];Q[4?W\CFVJ?C^O>)
MTS$G]<,Z_7*\^^/;Y=[:+J]?;C7VCM8YW+M1/]KXN0?CW%O;X;6OW\@8F\OG
M2=;=C?/ZC_I1_>0;A:=MP/Q<[FT?\]T?ZZ1.ZS /.W07G,S:D0<'<N/GYO;Q
M>>VH=E'?WB$PA_N14X5CI"@*G! /N6N6% EARH+G5+O@P7]DDP&$85Q)4T(>
M$%Y2W!G)J>3:<<[A+\Y,P1AJHU,LBE+&WJV,76[L<Y+COR$@2Y-"7&&&-$D:
M29K9;CGWE*:E%3%=Q@I>YP=;K"4Q4$D,-*BIDLIR%32@">$X8BNMR\U/7:+<
M"^V?7OAR*_#,6V.WQ4"?T3:U!G.*+4&<4@ ,:G(V&RL$TDJ3X39II9=62)4J
M404TF:,VM24JE:AT%RHEH2QE(,721XZUU,DZKPR,+QGK_3.<02]1Z7E1Z;J%
M1^Z"SRTQR$15G!\SR 4FD.2)*HVUIL(6J"1S%P\\1ZCTP!CO(N#(9DH-'V<*
M$KRSN/0SN/R4$O#VO!=)*HZEL=(YY3$1,5>+85VZ8V\//;7;W;&3=;YW\HW!
M\US63G8NX/O'FS^^'-9/\E''3S!G&Q>UHR8\@[^XZ?(?[^M N+<.''U%,+AC
M7",'2(-LDEA*+ 3S^.DN/V=)*:4MH4YPH9(E24K)LUVG!&>JE+%W*V.7W_:3
MYH2(S&]GB[/6)"+#0=!T2BH1X4TH&(>?Q>>?H6?H K8&G:75@'"<8\&4$X$3
M\'T#P]0'XH)B(3!7NKQSIGTC+J]/UCMB. *TI(CS '@LC$=2<&5"")0RL;2B
ML:P:/&,C\Y?S:TO-&P:;1,!*A:09QCP:9X*WC& M(O4J^%BZ=?.F>==N7<!,
M*8PMXC;SFS&2D ' 1"KYR*0#;YW!5J65KC(QHU,W1V0 <^W4?>FU0;>&+;\2
M* /\_K($ &7^=XA=DC@&1G\,Q&A.50+[/BI--:"7B(G2TE!_>\#Z=D=N[IC5
MUVJ\MK9Z43]:O=A<VSJJT=\;FS_V3N#WD_K1E\;N=KU9/]F]G.8,*J&E)X$B
M*BE H+(4&>HCRNX;]4XS2=VMN;D'.X->2$:%%3+9Q&7@#@LEB=<R, GX2TH9
M>[<R!LZ@H<F$A"EB- C$ V?(*>R12=%[B;G324]S!BLOG/M]YZ02L]BOU%%C
M4H@\>NX"=3)(FE**@G-%U#/T$2_MUV=5U1'/45C" N<<86I NTB(R$F64(#=
M/ 1XSU*\M)+;BIOWF"HME7BHQ)&8A'4PQ%+)<7#6&"R5T\%%[;GDI1,Z;TI\
M[80FKX61&(/7B0,H<6)(>R:1 9O<6863Q0J4F,NJP M$R[M(3N@?T79B[K=<
M:9R<M5M_]WO+E?G%1[B41% =)?=@T$M.K-0N"DK  0!O@U%7FOMS #\[=YC[
M!Y=[/]8O]K9_A_'_WJSE>?JQ \_JX1D_'=>VO_'Z4?-D;^WX1NYG<_O;ON#,
M:RTT\APS<"G!K[26>D1C<HXH1;"U3\\OLI2D(\'YE'NFZ6A KGR(R3-KE1-E
MV.(=R]CQOF%4.RLBHCE3PBD5R%"9D$Y,I^B,,(K=DU^L]G]OM2OMF/M, B[W
M7VGFC:#_:VYO7^8A9S5$/7,14Q(UT8(KJXQ(3((GHI0WT7);>I-SIJ4CWF1,
M$EN.*4I,&,2M<2CW[$'6!$^3P]KD; BI<FRJBL](O5)F(E^^P-1Q!3Z_5)HH
M'FTP)E'8CPV-GHM 9.D$SIONC60B+1<D@1,8G<CG9!)'VNJ$4F 1;&GKDQ!9
M]YB05?#PWW\N<M+M&78@H6_1@62$-/1LM _)W2?_WW[(5Z6RU<I!UM!7B*?/
MRS4>$!)\T&'L][E5O#QY:+E5/.-6,<8I'15CSEH&#D\^(16)RJ%"A2A(M518
M4T?)T@JO$I89\F8L&'NZLBQ03N # \#+$V*6 /"\ '!M*]+D(R'*(1Q21!Q<
M,P  B9$*E($+P&W(038  $ZKA#Y7RN#% >"%\@F%J?,V285.Y[>*]0-^NAA
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M@NW#=!4_/7!=ENV\1P!P3&FMN562>HZELI%D=IKHK?(.IJ?,7<T= (S:/L0
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M>&(1Q"EX)AAF,O' 2AEZ;1G:7#O8=RXYJH1#ECB"N*(:6<,%PI&GZ&G"@3'
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M=8890JW VB5&GE/E;@0>)TOX/K#6K=/ZVO%%_<AC@'OX_.J^B$H0&1@2PD2
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M$= [IF,@*MG(./;1,":,C"(P2:+1_0R<'B*@+A%P?A#PV@:,7E!'24(1]BA
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M$V!O "1=4G&S5]%,R2Z5"CBFX_P4(>;#RN^SUEC\W\!VX1-X(F=[S=XKWDB
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MFI/=S4]GNR=?6KN@V^P<?\4'%^\O#HZ]V+EX<[1[\8GN[A\(N [;.;^LUQR
M#K1.OYQ\HJ#;G.]M?CC>W=QM[EY\N\ASPN$\T)6^Y=:'%_][\>EB;__3H:8R
M4<D#"AHGQ*FT2$M-D3+1"ANU2E1=[DQ$&& ,=X(3FA,[E:'!:IV<U\8:8JX,
M$O]X! )FN ?9T434OXMJ+V[11NG7-Y]]6"XD]L)*.)!R$80!#2U34V1!D8##
MM6V4U V[%#Z!N_T:+K/7,MGVL"KMW<#!M8J]E$H9?Q.QII9:K.VUBY\!"/.6
MYIY?QGC&)8W.,$],T,);(HDG&4 PH"TVJ/J%7#*ILO9<NLV"/<_.M-B^ C!@
M%NVE$F;V)P7NFW#>JT.4@_-#RJBQS@GD:(B()^F0558C%Z-T)$2I!)A&5=UT
M19I5"P=L+D/!)4TA%]S&2N2.R^*+TXJ<.T-R_FG.2B^#4&_E'NCCMCDK)8UL
M@W$1P^8@/^\[>.I.*-&Q!_Q0?M5;(DO[L>EGZ\?>^T/L@] 1>T09XXAC89"V
M42+,/)C55FGF@8)$ W E_W?5N*XVNLR+Z)P [P(DP;I7#O*<EQU_&4V#?2DW
MY2F(I7377$,I[_+3CQZN)IBRWF']4 D@%"F!8'P>0T:40H9PB[Q6DF@'N@(#
M@B%J=1ZQY"!)23"-HFN;N>%"CD/T>C-^XD4\>G<DDAM5O_R,1O[,3S_RWF67
M^U#T5Y)_)/B7J$;FL6EF^VSG_2$GP8,9X1$.S.3$[#RU#FA&NB2B<CP!V*RL
MZ9_55*T6ZZ7S),0P\/UQL<=9MUG^$<#"&(=K2AOP!VQA/X*M^YS("5"FDD^?
MIEYN<_1NKYF,Z,[7PY0P#RP7[KN0'<&6(LO@MY"T%)Z#]<K4RIK\665>Z:H:
MZ2]E8"V[1@>ECW3I*6>DV;P;!O^&>G FH^S^V<BO\XII9.<'0$TB3@NE%8I)
MYGZ=.B"M/<U3,D%"!4PY!1N4KUX=<#(INL^:<#OV)T)IZ)L?.\YSUZUG0BK3
MHFE()[6(ND0W=/?LD!(;H\ :&2H$XB9AI(T,".,4I/(^46E6UA1?U3\143FI
M,)Z<=L PC57?P7''D!'H-(IH_5$.G6:?;1G]+!6BC#ZGW5&XIM*A2V?IH-_)
M7G=OAP&#/#5BU,%AL8J!>U:H42_Z3'QGG6[H30SUR^)MNSV7WG;+)P0$*\7=
M1FDZE&>-0J!O.]UWH_4HOY@L;C<O[F=8V2O$^_IT\O=\Y^Q086X"<1$DH=2(
M9PK6)A)$HA2",$>M >+MGW5&I'I3,^Y&0;GGY[ESUWKNQB17E#3W_#UV,Z'G
M$DZ..MVR6"'W+LH<NJ /YW;SWQ9SW<PR?@41Z^,G?\7<#M=Y?^BE"(%9CJ(P
M#/$@:&ZU"S\$&.(R81==V5[E6I]-1>H3CK\D=ZJ(W9M.3F^";S>;W>C[G6[O
M*OT 0^3VSU4T>7B]4C#Y//8]7QS,?:#;.,Q3Z^?^?#]F&UV6TG%4U%*4DY'@
MZ.J1(F@K\$<551XW/<VGMYHGP.[5W\. X^1]2@]F?H+)_8M>IXB]/$ZIV3N*
M :S)G_;=&#>Y!<&<I?!3L,@U\O5G/+(WT2I>,9-\Q;M?#X5V3$?,D(F!(,YB
M1$X;BW(L2K $JA[6/YD0-W=?;S<DKM[7^]Q7!4ILM)H@07+9=E(66:L$(H$Z
M[!T+3O&5M7;G"NC-<49>4K>G=/(7JO?X:_6>2@%_*4I/Y5(;YJ]DGAR!^J5V
M>*7^$Q9$=R5TC%XI@;,/,SBP&V/PDNCH#4!\N->V#C\-8I4_W^0\H/Q"L=TK
M!>(K1HCI!@_^;/?"'X(MA*4#N/")*\1="D@K3Y'STE"2FW(P![H2U0UQ?7"K
M42Q((D&K&*04E 3%(Q<F%^5+B3F)%BC$E[7Y9D@BOY88-8G<'XE\NP ADKM$
M2A<%BMJ#O9SGAQH.DD0+;"W1S"@2,E6(AF!7Y]>/-,V,*8O1A2:<1Z (XUGD
M- DC<&+2"D*D ]VBS#\G>D07NJ:+1Z0+G)V G$OC1$*8YG:5+D1DD@HH,: .
M1BE7TN;8)FXH86[J0VGD?,Z<H0WV3>N\<3G%,Y>3=9ME_O;P_.^QFC\Q-<%B
MF'T^O&KI+VP.O;F]JH(M&RKY1[M3=$Y+4HP_8M<W<V/B29Y,KPC3HG%6-B[6
M ^(U-B=0=7."NCG!DS<GF)NG^<N\RTMYFMC98'!@UG##I0IP(*.1)\Y3--JP
MG^9I+J_FO]TN=CO?2[=..==Q5M]/S=8PI>WC46REXD/\.BD(AO^_!=E:?$1L
M$K;YN+61$^P[L$=YO\:?]T!,WFZ4&0E122:-D%1SYZ(SDEJ#%=?4>4S5)1T
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MD5$$)@EH&.07!'+K+)>25O9*$ZBW-32!PBL67]L_]O:_G<%]SW?S>(;]K<.
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M;6_]V'E_*"RA442/*&P9P#+H82::B+S6AB4F7#0A>XT9 Y,+WSP/?YF\QC4
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M>H%4Y!AQ+3!R+&KDM+;,6,U 3*ZLW5?QQK.'WAI.EM%<J^'D2>%DVF(+A'A
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M)+7\,CX5W_;72Z<%V!S+DPKSY)#D+^J'!TQ*K(-TB#.N$>>6@I(:2$[OPA9
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M"NJ6T1JL)/QMJV95F.YC L2$=J8HE<3&A 3.5/TV<*1IX@ 0DJF(:9 IO06
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MFJVE[V#5C [XQA![9,'JZ8,QUR\@J0F[ Z 6/-27%Z#N&2@6@& IFVC]8:\
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MP"OK'P4ER 33B.U SUHUU^T,"VA<K353)GMJP?Y3^.QL[;!G2R %V!O M&8
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M/-@$SDA/GT_EW&><X[2\.IW$\R5V.1#CJW6OJGT_6\M5<,TV\4?/%\'B[OV
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M.3+=3P<N]_"!1M$"?SK(:DF);0O?&+9<3;A-/L+2@S!+T/;IP/+\9<B!YGB
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M"H#&Q1J86W%]^\S?P_ZZG'(6.>)<618#ME> I:S3=JO&1?6;S3A!][(ZP\2
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MV;86S9&XR/Z6;G(XU6-B_'Y\>E[OABS\E8;IE<Z.092. !M@,8B:FB$W,BM
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MU]B!RVY FPZXKMS <_/N[/>+2;07J-&*!-= A-]%,^0:L4D_[)KS88BZR_I
M5CZ8"TB!(CHDEI113(<0V$*'T!6M(D)"Q#X!Q%.D_I84VZ,POXUQ&P232V _
M+T*ED0XB+_9@5+(U!U>:Q2(IT,U%FPQH16J2B]Q"<;A <$!F[I8B[6C6!@HS
M/\/DO%#\>C[%?.G5\X\X7:(# ,U=I-&I8"F^$8KY"!1I.FM+1,6%DRU(OQ_6
M,7C!@(;?^-'_]^]6#$0QZ^^M=-->P>SCCZ?='X,*I%T_] !*:!M&L")Y9FT
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M!L&Y2UHW"2CNAW54^<6 ##0(+5_D>NMS/*.A__"EMFW $0VHMKLT+$!MA&F
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M98;UDOX3V%YL'7;-NP9ZHVU9'[@MBPZWQ/LX!8C-^._O9X.1]P1\K@B1'93
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M(5%JN[T #&4V2N22^L;7>T,Y!F]Z!%(:2#FOL\M%=9D(QJG((P.(=6&V@4$
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MR--92>6LT@;PN!>UX>+8D6[QY6C21EEAN%;2&>N1*)=35DQX28T>'??*TVZ
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M1I# +"-H8:"]P9"?X*GAE"8)1G0RX1X\>KAMNJ*\I]6$5=%"NX?FX]_3-1I
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M>YS1O#@>$4U8.NH^BA9R/V%B=GOP8"QTF3K2JN"200(82,E8<2*LXF \$\F
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M)K)^;VM"_NK=N$$@5NS<!S$.S@1#!7)VV:-6UW#7,?>/=>\$; *.L''$$6.
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M!:1 VF%,/_X@96MUB](Q>XT0BM9Y[ZYI<#EHEKDAI[7Q\SM"QL#W_%CHY%Z
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MN]DEZ'D>@HQGH#"-DSE-*$.0MO4@C%.GV@SB/I6""12EOB5*0*1XZXY<:YP
M)V:R^N$^:R,'V=D+2=W!AR%"^1@\0+N &9DN__:8'$B$A$41<JH@FN0?2RLD
M!9ZKBI@Z5I$I #^U[/K<X*=@[Y4MKPB%=W /B+)+0@!R4A/N63(F2;W29PC0
M+1@1]!O!;]W2TDKDUL)G>P3-!?IZ?)7G#+T+9-79]UT^9/9%\,&GGWBQ%IHG
MVIE11S(\2/=E9"V0N5M*>,&C5E7DRN*.Z(J5[35_V9?%U_)?V"/V"?:^#A$0
M-WKBK?(-\R8W1-I7XZE#IX%USU%%"=O;!Z4_P_R\%9Q_S8?^-,%88[[#/K(
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M_<,I>#+U;W. /SS#[%]F?]W,XD]. LQ_VU26]C44NZW3YGV'0JY&)$J^[OT
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MI=U .S#.^\ 7X*6[RA=DX;/$K\-+CHQJJWR;&0Y0#%]X\4!E\>?64/)^Q2^
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M_=UMR&I_)6'R[^AJ%OC+\,:557_5.-^JA2B)$4.K6R+$49V]XSY[&5+(J<Y
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M,)A$S.BY^"NUC\1JK[RZAFU3-6DA](DVH^(;AJS%BF#X;U4'2F\&9D_I=7.
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MO3R-6(>K33BB]CSRX@!-=77PG_D&'"#N'EX4VR"#(>$%,=A0#@#E ,5')CF
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M,"]=RF>76ZPA!TB/OZY%+/&;7W? PREVN8YLU*B)//MAV,/3.R*7 KI&$?3
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M_^(*!:8^)IS]*(;U-&5)5F;>"[:.4VV)J.5>? [A'S^F^XYV\-8LP85/%&@
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M_TZR0,7_6@FD6W)$BZG%$0;-Q'!#A4X#'7WGF]LH=XK0H&"L(G0*948#:,9
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M-4X1J=*D$, %"!U"]>X*'[:[\AN)L*7HQJH'(3!W4;_C'?".KX8==;G/"#O
MZ$IRF'/%KXP[+]0H/\,-TZ7'&5LW> &,3SR$NV4(KA+T'-[5I0T29M.TPOB
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M^-7DV]'\4?3=4"NYZ>:TE$K+H@G\"P,1^&96A>USP+=@/0Z2V)9#OU:\8_*
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M&T_LHJ6(,>L.T&__FLA<9:FA+K0ON1]9DE&!I-X&V/A<ZF^2D7X8)BW)U(A
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M21E'Y R\VKYRY+D1%48RH\41A+WH*^MC$JX4%"J<'_\L&MN ZMU-]N[A;CR
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M/?OG95J2>4BB(!.L8^98^J+CD9[V YZ\V:FU.G^[:<-FZ3@-CCB#.!!5,1S
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MQYT.8<\+< 5#&U@@(A=-'3F,/%?P;Q:8TW4^(C\ZF#,BN^=8>U]Q5*907.9
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MHU=;F:X^*3YT81SSV@ZYC-G[3__6<\JMAB[L0A5HI!S<[Z)+YU3^*K).(&\
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MB.V"/0UP24S]SF4 ^GXG^LR@!+49H_H*#O<F1;M/AVTBQZ_!4D/W_TFH;;-
MV4;D)$8/] \^V%U"$HADEGL]ZXOQP0;;7)Q_U=IW=7<U;QL[M?%IBPQ[@MM
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M$)>O:%><X3ZF5FKP6(M=?5++*N2;KXO"&"3SK?QNM-1SLNSH:O@)&#I,HE$
M_-BJ\),Q\C83\F%G0AI%=F,N_9'<=4CZ)+^>DHQ*BM>A=4B65SZMIRVF#<*:
MGJN(^ ^:EPNYRHO:,I0+J?+524]9EH@T# B##"4*(AD+2#*50B:Y2%268,FX
MDY764Y"IV6^O'Q[GRR<I02,S^*!_[6K#]9T42^MN!*@')LR/&WE;G,N!?);7
M@N75(.PKR[BFXI6('1F1USZO'S.:D_IZJSR?+[^9\BO&H?I1EK+X*LOFM%(E
M84R25,)$,;U7Y5D**<(A5#P.!0LCFHG(A05M!IT:XWUZ_1*80C5B/9<W((Q@
M0&[ 1A&PU:0R7UI='(^/G6;%C@9]8SVT'W$@F)T9T04WG^QG->ZH3.>"Q"&K
M.=T[M=3[WV2YDJ+U"?Y=FOI<4MSJ;2J]EY7#\!5=R3<T+^I01Z%WW'&0A3 D
MD8 H#")(26 .=G"0QBQCR,VE-QG-)L?%=4#)UTJ+&_"MD1_26H'ZA @*$Q6K
MM ZC!L1Z?ZL&/EUZSG=E^F=2EM4!:HQV3ZQ:G$ #5'VH!0Q4P& UF5#=H>9_
M$@=AWI7[<QR?#36GXQ4JZ"M@CU#CEVN3-:.)0[Q^D,5]OKC_+/F7Q7*^O,]E
M>;?@31I6C D5/!.0(Z8@2E0&,4\Q3+"2"8T%0:E]#3/+0:>V\&[%!JW<8%=P
MDXO P8\O7W_^R2%>UG8&NE?"H7 =.EC-"M(>Z82VJ#J$(@^ [DCQR)Y0=HM$
M=H2K,QS9]EGCQ20[:K<7F.QZ;Y_,[:-SAI>T_/*I.N'3CZB6C??J;:[T;\IU
M8;:F'Y;SG#_-XEAOY+@,8)PD*40JRR"3B0E59GICAR634>A0E>8Z::R^I><H
M1=,<Y6F3EVM-0-FJ4F^V3(KB7&NC?]^H QZ-/B8 =ZE7<?!8R(=\_6!.8?/S
MQ;1\3JO%ZC'L+#W?(>O= AA%P$:3>O<!WBM@E $;;4"MSBCSX9+6/L:\C)7X
M/N3\.*;*7PMK=S)][Z>/F&Y_+0+["?E7/ZVG!W2UY']LLWS$JW6A5]2F5GSE
M*IO%0JHPEA$,$TPARBB&!'$*L=0K6LHI%3*>[9:]ONQPNCAHCZ5KX%5K)P--
MKT]\^?"P7#11Y#VCR2\C+_764"F!81R:&G<R))"2F$/$XXPK*N*$.)V=><)]
MQ$WC<Z!NZ33UBN70WDPC[$X2I0"UN!N7XZ=N*-U=BM;H>/7U71YU7"><-0I'
MWC'[.WOL;]YI8Z4P,[@I?9ZF62 RDD$9*,WQ88HAQ8K#@&-$DX JDF"[D,_3
M TPOE',CXE\=+-9CX"QV!E>!,3 Q;&3K5TG_& \'R_PJ7$:RN#<R_L63W7Q6
MZ4Y[^/BN\>S<LQ+OV:_GK^IGE[[-N0EJ6MS?WA>R.@\H&Y]C)N,TQ$I!1FFB
M32$E( M%!GDD.(H3'(2Q5>V.BR--S1;:" H^FB,-1\/G/*!V]HX7F 9FLRU"
M6R$].F:MH?!ITYP?;%13YJ+.AQ;,Y1O<B*$L5K./YFRP>6LQS20+-0T0_<5#
ME*828HJP9H5898P@%-O1P,%SI_;15Z(Y1@(>0M7]@5\!P."[%KVZEZNJ)N;?
M)#6AJU5\A;^ O3.Z=WR_^HZ=;U?_[?"[/7SD*%_I&3W:;_+<K_LNS9O4BMN%
MJ'8J7Y9S?7]9'\UO;$$N R$D2V#"X\14)P@AX8A!)I 23/\OCJA;'IGMT-/;
M;KR]NWUQ]_;N\]WK3^#VW2OP^G_]>O?Y'ZY+N"7PMBNZ?S '7^ W(E<QO$V(
ME<^65GW1\;OF6XX]L@G@ALBQ1>!X?U]Z6LCWZF4A1;YJ%D 9TE3%.(8LE<S4
MC-5F A<!I(@%.,9A%""K\)OS0TS-;# 2&H]I+:,KS1P!:$LHU\ R.'7L(C+(
MKN"<]GZIX6B4D4G@G);'G_O9*_M]V!_S\@_#'+]J08N5-@ K)G%;\SJ?,:&W
MM9*S6N+V)!UDI;/"Q.<[W#W@J*^SE>Z';[;=32-GI)C/[6XE'\H90S$WJQKD
MH9(0$15 0A," QP$.(L#@:63@^QZD::V.EX=W ]^KY:32CG']#P/$VQY0#GJ
MM WM"AAGQL9+G3@">1(Y#UNI_AS)"D<H>LLR.'YRS^H1]3/+S\M;KG<YA;Q;
M:(:3Y>IN\6G-RESDM*@W1+=*Z=T17<EREB@9X4PHF"4!-W$?"#*"E)[N.!5"
ML90GJ5/EB!Y"3(VS6QW :@EHK85I6U&I82))RQU%'&M)])DB.PX>&OB!67<7
M\T8!<+>#^:X.=>6=C18>RTM<@:'7TA)]Y!BWK,052!V5E+CF6;ZJE5697>^T
M\G5MK=VR5P1+'*=40IP&"40HH9 P3J'(I) \(RR.G$+C7 :?&C766:7SY>(>
MZN$>?)8@ZY@!.P8<"M>!F>],N;$:Z:WP8Y48NXS9L(7%.L9_YG)BEY&Y7$3,
MXAGN_58_2?VX?/7T^CO_8HS-=_IMFZ4IRFB($\AI9D[$,(9$! $4D50!$3P@
MV*J)P;D!IL9,K8R@%1(8*>T;L9X$L9MX?$ S]&;6#16G#JU=JE_1J?7D8T?K
MV-JEU&[GUL[K>L3)OEB7>AM8EGKOR/(%K<NR-NT"5OI/V@PR06_ZQRUG/#7E
M!U_65#+#.$P0T9NXA/$8HK R4Y)8?_^!HHG>TP6Q?>+WU>),C1X:L<#CLJB<
M.4NEMW9U[4Z^4<S\<:N90W#J];/7S33CS\G O-3J G:4N=EV0%F!/7UN-L;/
MTTU;<E5?76LUZC0YQ!R/.ETCQ2B/,6UN0<[>4.X,BKY^E/&"J+TALA=T[>^I
M?=HLF@".N[)<[V>GO)/?Z@257TW>XC>]'.M?F=J359W>&0\%CD6FM,EKPC9)
MA""+0PG#5"5)J%?%A%/[SHM]1)C:(GBWT/+1.7A<LWG.]1JH9%&U9EWO2 ]$
M*[Y++\%>,V2QZ V.^] &>)4.5RMPF FGE6BRX6[ KA[@U6@SX-+@<>B9&&D-
M&VA&'+L_7@-F=T/(7D\>L4?D-9KOMXV\ZDF]N^5P*47Y1BMUG"%O?)6!8"%-
M4P:ER1C0NRX)<4P3*/6VS*2P1U&6.3;,Z1YQ:HM,*S P$W]-X0Y[S"U/R'PB
M.?1QV!4@]FFF8P>,YWXZ%P8=NZ6.'08GNNI8WMB/<=X_5G:UZ5K.EP_RK>GD
MAU'$N%#:GE5A!I%6%^(L#F$@)2<T82*FVK)=KNC<CF-.C.'$*IN1!CQX:D4$
M>24C^'&NI;0LW]>)I4I1$'*-((LE1%P(B!%E$$M,L"*28[>B\==B.4J'RH&P
MM./A*Q$:F'FWX-PUX+SM!,>9;3O4]\FOIX89E5$[]#SDT*Y+>[@+_D87:T7Y
MJC(*MSFA[ZIJ?N_5AR)_H,73I_7CXSS7G]N;9?&:\B]->[09#BA):1+ ),#&
M;1 K<]RO:9;& 19Q@B2U]Z-?)<K4>&-/&4 WVMR 1:6/<:H_UAJ!LE4)J&4!
MI%9*_ZK2RF%/>]U$6G@71IN>@4GK3S8S#EZ'T69H)._#P#/EYH7P FZG-^*Z
M$<;S2GA!8L\[X>>)/;T4RW(EJ]9GNUV9'/.7NA\R(?+;%Q1L6Y -D,!D!XK7
M?7+WB.-NDJVT/]HAV]W5P]![)1\+R?.*LK7I.%\+\ZT]F"/^?U8__"CG5:GA
MY5L3?F52@.\>-(5^K;_%610*G$6<0H)8H$T]),T)$8>*846%2G!DM_?S(<S4
MC+U==6[,1K%6"- =C4!1JV2"MN>M4B#?T<K!I+AV,BW,O1&G:&#.VY^=C2Y@
M5QGP<3L[&WW W?/,CH/)-^(LC63T#3Q;;D:?)W@[S;YKQQC/\/.$QI[IY^N9
M5]?,::.64!PB_4\ (Q8*B *I(&9!!'E$%9=)0"*2N/B+CX>8FKOXLQGC^D;I
M)["T,YZO0VC@Q6-'.(_A6)=5'ZANS:@A5I>U[*A%XR$4ZC^7B_O_TO_\/5_\
MIZ3SU9</7VCQ0'\IENO'E\NW^4-N&E MQ*L7U2_^:UE(JG^^$FT;G92@)%$8
MTB#5)B_-,DT%800C3F+&,_U_G%B;O%<*,S63MU4';/0!M4*@T@B\7/X%-$H!
MK15X]:+^/:@4,[^^ 5JY\_5;_4^GA=$[XB0-S%N^YJ=/FZJKOSM[^W?$"1O)
M_AW\PW*S@#T!W&D!7SO&>!:P)S3V+&!?S^QG 7\NJ)!MA_I;7@=^?91<YE\I
MF[>-?2).F4"(0AZ&#.I%D4%"TA1R%" E*4TD=JI\8#7JU):\5DZP%=3-0K;#
MVLYH]H[@P.O1"?# [[64X+/\O@(O]$?VAT?OLQ- /JUMNX%'-<"=L#BTR=UN
M[F&FO][XN[='/RZ-'+KNG] 7L!5SKPQZG_X.G8@Y6$^^D!O)-.J-H)O)8X-*
MISW3^8#QC!4;/?8L$:L;_.3K:OY8WB_R?TIQ)_0PN<H-E]R6I=1#UI5-C,VS
M6YNV+/4[)M[DB[S\(L4ORZ4H[Q9?]<W+XFE&@Q!%&0MARK,8(D4B2%B60IP0
MQ@C6/PVM(LE'DG=JIDTK);@W8H*\E?.Z?%'?DVRQ%DQKZ@9>44YGF&[U!;L*
M@UKCMF"4J I#[1;N;K2^ 9N7H5(<W$WS9;@NN_@97XIG33\>_^6X.D5YH*ER
MS6'V+<:S)CD/A.FE+.BAANV;GR9-I^K7WTT!RNT.IY*F/<%*(A*%619!E84<
MHL"4?%0TABP(5:*-"I71R*U7AL6H+FPR3IN,1NB*%I95L:WVN)!6@KLFJ5T&
MWLX+XAG,@=?K%L5&W K-NG19+?$ !XP. /E-6+L\[,@I:]8X'">MV=\Z<G'Q
MND''W4)OT2J3HJQ$^_R%+MX_FD>4[Y::*\N5%'^7IC>=9E?-%_1>_J(?O7I%
M5_(-S>LFUC/,@B0),P5)R&)3N9% &C,,XRQ&02ICDH1X]EAW.EW18F7'=E-0
MS84!#A4<C@PV\M\ )N_SQ<($.9F ]B:]_ENC%J2U7N#>* :%U@PHK1KX:G0;
MJ<BYSQ<MCGE(5$PAHE+JK7K(($O2%*J$41D$28 CV;QHKQ>VG<LGH)C[:]:J
M-\I+)LW2_?^#U\O.<)B"J!.R3*ZNXW_3]OS:0::Q;58:&]" <P-VWL@6(- @
M!"J(@,$(&)# ;YVOX'A- 0:8\TFT%?"IUY^C,<$ ,^FMM<$0LO6S1W^C1;4Q
M_ZB?6??TG$5(B3"+&,P":EJUJ1 RP@+(,!4D3&A*X\0E .!XB*FYQ%L)@1'1
ML=-K!Y!VR]-U\ R\6#@BX\S3YY7WR9HG1AF5P\YK><@H'5?V^[[?R=5+6IK\
MR:^YD.+%TZ^:BNX6F\H"MWR5?ZV#<*NRA6O]L^:7FH9F61;SC&M0TY!K*UXB
M!&DF0PTTHPD* YY$3L% UXDS-=[0V@"NU3'IQY4^QF[Z<6TLIGSQ$UAN2F;0
MC5IUX2*^4:Z]2&OGQC=73JP=-XTW70/SF)DIHPGXL#M3O[8SM2UNLM6HK=]:
MS=+[R[/DS'U^P/7)DU=*-"JG^D'OD'\]/;5'X,3+Y5S_>6F>]%7NF)!OI"D@
M.__T0.?S]IBEL@*UC'H?_U"V#7:%0!S3#%(5:J8. PRI$/I?81*0.):A2.QS
M=J\49FH\O:?.[C[W!C0:@4HEL#E(K;>GK58.I^'73J-%W,.(DS,P*U\[+WT2
M%JZ=((=8A!$G:J1 @^$GS"V$P!/"G?$!UXXQWN&_)S3V3O9]/?-Z[\3M][R<
M!2C!:1PAF*E,0)2J!.(84QC%D:!9)BG&O*]OP@PPM97K8/]M1+S"+U%!Z.Z5
M< 5F7)]$-R97>21V%1_*'U&-\6S>B%T-NWP1>]?U//GF7Z18S^5[U?)%%094
MYI7I_.)IYV^?S;"S.&"12C&#4J8)1$E&($ZX@A)%$0T#'DFDG)IH.PHP-2YH
MY3='>YOU=5>%&[.IW?D!^+W2P[4[MNL\69["#8C^T"=FWH%W/\_JB9[7LR=7
M&<8])^J)T-&93M_G]&/%E\N'AWQ5IU\LQ*9U3%6^G2HB4B$S&*I(;^F9GA5*
M> Q%E 0!8R@DG+H%)':,-KU Q!UAJ_ YOBNN&Z=UH6Q'7YZ0&WQ#O0_92RO(
MG-G( @R?Q-,UW*@<8Z'W(9W8W-*/.5XK)8TW4M;%H3_3[\90,V'7^NGSNLK2
MRZH'X]WBE52R**30%]7!C.;HN#ZLGL^7WTQ9_AE6'"&L) RXT.96&A)(A$AA
M$B6(A RC*+-JC#J0?%.SQFK134?BKZVL@+;"NK&3[YFT8[1GG)^!67"C65NJ
M7HM=;Q;WM;L!VTEL-:RN;3)D-DJ"C98WIB42]QJV/= \^"1@WR*.2MH#X7M(
M]$,-TS/?I0XV,N63/\I'_6%]H:4V:<UJM%Q4#:)F88B02-( <H&(WEYC"4E&
M"0P9(T&J5X)0IK.%O#<5^>P8__*@5B1!:I+8'7HXKM@*:G9WO!(5E%6?+,=$
ME\N(V_&R)Q1'2G-IA*TJL>]C60L,*HD])KE8H^,UQ^7RJ..FN%BC<)3A8G]G
M/^9I,OS:"A584H9%C$TU(0Z1PBG$ <50$16GE$5(I<QM#[L_P/2VK;>?/KW^
M_,F-/ Y LR.*_D ,3 J-^31$G?G3.OO\U ]&&/6S/JW=X2=\YJIKO?(?"A.*
MMGKZH.=RI?>J)D;YT7!%[>5%D8A4:J*"HP#K#UDED$29A%E,&$&4A2R1_;SQ
MW0-/;=^WZPQN)=>[ B-[Y7+92'^M]_W"?+AZW?VA/+1)<16H5WC6[1 :QJ-^
M8>QG\J3;(7+>@VYY_\B9M-6_?I/E:M,:-YPEC"8L"QGD06:ZTTH"61P@F$8A
M#Q5),,ZL>J(/(=S4&+ 2$7RM96R2#$=*'CPU=99$^$P3,O31Y/7)?/5T-AHV
M';\GD(C7@?LD$NI.R??G2(SK0-9;@EO7&#WWE74U2O.\IH&PZW;I[ ,F]#UO
MA02ME,/LHRZ"X75/=7ZT<?=7%[4^VFM=OJ-G-Q*I=W%RDU=0-3QI:R$]M4Z:
M5VMYJ_22_@])BS?Y5SF+4R;C2& 8<"(ARF0*J6G/3)5,DRP+$<6!BYG22XK)
MV2-&.*!?O=BQB4FO*; CF\&!'9B':OEO=A*C*A5N-H7B]/9LM01,:FLBUT8$
MK>; * *,)AZ[IEP#I-?&*KT$&;?WRC58';5GN>IA_4CQS;I8Y*MU82HOO<F_
MFS^U:1=1*%5,,P09$P%$F'/])R9AAG":2J5"$L4NS'=^J*G1VT;2RA/2RNI&
M=1W VO&9'[@&)JW32'G,.;%'PR?S=(PV*KU<UOJ00RSNZ.G[,0=5=V6YEN)5
MU4BXWF-4!3%.[UEF 8TC'%$%8Q$D)IA20DPEA_KG*N8XXH0Y98ZXBS U8MGU
M"? =.6],+]-U1XB+KRDA2F9IDII$U5B8LT$.*8E3R+!BDD24B#1T.QL<=E+&
M.3\\-RV#3X>E(VU0B,=PEY6@%O^F+CIU<]HYMIO;6%NW;Y:%DA6=>72/]4;3
MJQ/,78IQ75V]43IR:/5_DMM*)60^>[U8:5OY5@C]SI6?5G0EWQ=590$3I"F2
M0/(T#B!A0I.?$"9S7T0PS3CA2M(($:OLIDL#36W5J64%C;#ZXS/B:DA!*[ =
MSUW$MYO-?*(V,&?U!\R:C6S1V').V9).*?E?[I=??]:/J/E&_^&09BX^?A0R
ML56RI0SKZZ=6"/BWJG#<W:*FMAEA"0DS2F' <0B1-JH@YB&"D8R31*A$9@EN
MXSP_CW#"Z2B_U9>X'S+Z>2SCN01M?<L^$:.CO0$#GY .,:%_FM-3RU*H-00F
MT6 R!ZP]IVT2AZ^NLO\Y#F9[SLAX54G/C'_5@6ZI)3#10&TS"!7&&<MBDX86
M*XAP%D,LTE"_/9%4*,L2E1#'@.&3 TUOX[]IF_E8"^H80GP:3J>S\2L@&N=<
MO 2-A .TS^C&8(#C\,.1GN,H_(RV9X[!SUW=H]S=W4)O-HU[BRZ>WB[I8O-H
M4_BX, 6/*Q_D3#$5T(!SF 6,0!20$-(XSF#*,A3$)-.OBWVS/\M!I[9EKL4K
MC6&R5-J&V"H!YD8+-\)P@K^;/H8"=6 RV9485"+OT$HK-;AU<(([8>I006X
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M44!@$$M*]3\ASIA;B/G)<2;WK3=B@HV<KA'EI^&T_-:O!VGH#_X(GP%Z2EZ
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MC544"2A0HC2O1 @2'"H8,L+"2$:IBIPV$RZ#3XUG-K*#2GBP(_U-F]9> JU
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MK1([KKO6%5.7B_A[+N3=0BV+A\8F_RH7:_E&B_OZN^:6!9VW[1K+%T\?FDZ
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M&>,1)22 (M6-_5 00<II !F*$A2P)*7"JIYQ#UGF9JNU$R*W/X0NP5XK5+6
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MQ$NC6+ H)7:)R$YR.'QX1O[F:#7^$S19I)9^=:>E,/3 CP;O1+[Z4OX%V&L
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MM-/GUZ571RMIZ<Z9>.G-MA/S7="1/Y#7'$/M(TO-SQ?+J51U4RH(0 L#4((
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M,&N:UD^,N7T=U+.([/C'$7XS4AH?U)&9JE( EAJ @PI5NORBC"4N$W_;VBR
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M'0=Q!#&.0QC& A.1QBF75N>XIA//[<O>;M.<U9)GVG?.*NE=VV/?@-^,V\8
M=612:^.Y%WJQ#VV:IL&U&5KC-+.^,?<K-:XV0^1ZDVK#^QT[!M;>J]\W^>YI
M'UZ@N;$Z-1!\?VC0=)OZE&_+SE0?<[(NONR[VGT2VR6C >:I""#R< (1Q0'$
M ?>A3!.4<!F&2!BE+HPBW=SH[ZYW9\!!U\Z,%E]M14;FSKTKOU2L'6G3UNUP
M(+S8-_K31[W;NCM@J2(XZ*C^)@8\\AT%_$&;  XJX+3]_\; ]JSUWRB3N#'_
MMPW1DW\5RMHJXSV73' O\",?^D)ZBKUI!"G& K(X9D'D!81**T?3V0QS8^#?
M]F7IM<GT2#;_$E4@7;$7V8Z1SS$U8]5>2(W-C()NP4&R!:B%/73=V;X<_?VW
MO^"G#\.1WE5LAB2N\TDF)9^K.IX2R/4+!\EXX^]*9W=50K(J6)\2&>!4;U$I
M\2&2G@=I&BJ[+J:<QR3!L4_MFGS=G-/HX9^TMU<KW4H1!<L?'_-UG=K6*WOM
M MZ1)Q3I1C%$B"@23@,,J> II'%*$0Y3B5'8([?0$>T)2;D#ZX5-#Q%SR T=
M D,".;8GX"1)D(-*VKKR[F*H+@;6V(R8&7AATM?,";R.P8ULP(X;'3G^8E>!
MI8Q(2&,OT74%%-OPD,(4A\KXBX+$8RSU$CMK[_(T<V.7=H,0UI+3DE,N0VI(
M)+V!&IL]+C51.32AJ&*;2?$#U-W*!^213F@&)8_+,TW+&)W:GM%$]]4.465O
MR8KGJWTQ#5\(7Q#.H1?H]#(2!S -.8*1,C\8)C3UL%$+Y@MCSXT%_LJH0N_9
M(D[I!*ON-[TG B._WHU@+O6X3V"PB,ERAV.BP*M&P'\,%%YU6>'.&*J36Z8+
ME+HLZU$TU)5+'$V2W>,CV;S<RV_DY]N-X-GV..)A?U8G@XB&F"@C)>9J]TEP
M"M4>*(%IK&P50M16B5@=*)A./#?"JN76.Z(M^0E8*3I@;=DM+1C3%3"T:4;
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M6UV?($)B1&!9I00Q[$&L:V_IN Y._- / L]XHV$TY=RH=2]TJT02^&4O]Z]
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MR 1*(0JPU*FL$22"Q3P.$:;(/)5U:NGG1L 'R706;%:7"Y>Z2=)STV%J^T,
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M:2T6T#:LWC3H5'+&-COU\E]K&C%65XBS53.CW&G68F3&M>O=<)0N.GB&>G]
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M3%B2<Q%)KY/YWI),S2J&!T;8:BL\Y%9D/_KM/SUNO#L*Z ,3;G.\]HO5XB_
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M)I:&4\'I@Z+U!W6DR,";DJH;7"WNK#G\#YPJ&O!5<#-?IC:S_V/<#K7^8 \
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MBL7F>08>:DV :E0![,[1Q=A_LAPLZ*&G8.CCE0;] UOI<X7^G@HST"@!6BW
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MH,@IBM*<RP@YE32>G&938[IF5W-G!;7;FA^- I#5&M3_ J4---=&B=XQYE,
MWR<D?0KR3HGYKX]@;Y:+/7A A0_8&(!V\>TU1F;-!9^;5(<6)]  55\"+%3
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MY;VR'IPF>D5X!(;Y38"#-WL(6 <FG)N=N^M@IU2+;:BG.K=R(: KH/5I$SL
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MB*_S\+HMYF% &Y@&=GA9*<%;)[S\([\N0A$T^.O\:./&?UW4^B@$[/(=00-
M/3>5%YXRI=?Z;#CC(#M/1V!&B'!\G;VIH_Z.$8^!=J]'C:7;EQU%*HY51"'6
MQAK&E!MK6%!;'RNAG$9)++1G2L>YH7R^B'$2.+:=VIL$54,X=3:J2ZJJ9^;&
MV0G(I=(B0PI2D<<09[DTV%,-4Y[)2"DAB?0R3T+ /TH1PQ9\+]0#@>Y&\2&@
M')C;MR@:&4$EY""<?@F)H-WTSHTU;D.]"QH?]=2[='T_WF[CEF[U4?.F0__[
MB\ 8$5.11-* J[F$6$8Y)"K7,$HS16W[;<2]8MA[RC$UTMD/ SMN!W>4O->C
M0T??"7-CI!&F86#"VI^!$TWDCDX_/>+(O%GM2C1#DEY?44;EQ"OQ>DF9USZN
M1XS5NV*MA'DIRH]&X>6F^*YLQ2N#1=YDGR#-F$X1@P1A##$F'%*9,"AIRM-4
M(*9R)VO,:;2IL>-6WC__B21Q_C>PE;LJ# :LY![Q*1?![N:\X! .S&PNZ/6I
M!'$11H_(G)!PCA1,$P96O^@75Y@Z U8N/F2\&!-7?0["0IQOZNF1J.LB?%=U
M#1Y#_3:9R@:>+(7A_>JM^FI>+F77 C-=B^UUJISG@E(E$P0SG")CWFH)29X*
ML[#*G&=I2FBJO#;-5P@S-1:OY&Q+;UG;5M4-&< OQIBU9I=69I:JD-7M)5PM
ME2XVG@F=5TVAXQ9\I(D9>IO>JM'6^+(6;Y7Z>:C*#-2S5UG!5IV]Z^UVQ.PN
M1="8@Q#X!MW\7R//N Z" ,@=.1%"/+.'6?PK6SYI)C9/ZV)Y9]Z]KT^/CXOG
MF[NUJFJ2?BJ6ZN-&/93S""6YRAF'&4H5Q"+!AG>I-C\QQ$D:RSA+G,UCUU&G
M1K '<E>?:BTYV(H.?K?"@TIZ'U//>1X<+.<AT!V8)2< K(<M/03 (]G4^R@"
MO5H#%^2K77@H"]L7O$Y+V_EAXUG<OOH=6-[>-_>@_-]6RT?S>%$\LL7MCZ5:
M-YO)F'!%%$^@(-+P>HPDI.9_$*<)-59U&HLH<V;X,X-,C="-F)];,4$EIP>U
MG /2@:(#P#,P(Q\CT\>#<0XB#[(- -5(W-H',C_NO(!%)U6>NW<\9KP@_0$1
M7KJV9]ES(Z7MW+-:F(ONJI(NJMRT]>=L8Y^O3[PL9,'6S[:Y]>;Y8UD^V9(!
M\P@G2K!<P"@AAA-9%D.&D-G%L%RFG+"$$*\B+/U%F1J'?F7UF4ZYE;<^MR_M
M0?[R0$V;*UOIZ5GMN_^TN?D:QIF,X1E['^I6BQG8%LVLNI/M- &U*J#5)6"!
M\:OQ#%J-O+\TXY8NOQJUHSKGUS^Q9_"";3/3!.[4#]Y%/:4)3W64PIB:V<(I
ME9#SW%"J)"(3+$V4YGYA9^<'FU[@V=>]B*;V6$-5,GM&E74@[!A0$ 2UH6,&
M]H3\CY:O3K='&"3ZZ3)(04,!SH\V[FG_1:V/#O0OW]&/2*H.8[?Z7\SV2=K<
MKK\4=_>;NGWLK?ZJA-DH5R&S;+%0\LUS<UW97%C.291*3$0*J50(8HX$9$EJ
MV0910C*JN<Y]S+8KY9F:[=;*-P/+2H?*CJN--U&I /@S^-%<Y$=0U\Z<&XN-
M.!\#4UVEB<6_D=%\)J 2<M9TJK;_MM,(O-W.3ZO4]HZ *2N!\ W)DM>*-"J5
M!L+O)=^&>FQ/ZV[;EVR_<]E>*[LWST>MRVYL_L[MH[VPO'W:E!NVE,8F_6),
MTP]U<L\\91%6'%,8XYP9ADX09%55=H+B+-9,1YE7&?9AQ)P:A?_V@K@]S<AA
MIM+1!'WU"1K:?-WK^'C0;7._[:-A\).=(:TN,]"H:G[8*0M^M^J"1M^0YNZ@
M$Q+45!Y&TG'-[$'1/C+1AQVMWTKR>;T22LFR<D4P&Q#\]7ZUWGQ3ZP=;/;?<
M5%TOYUHKJFT-6T1CLS(((B#/.8=9JA2.:"Z)]LJ4<AMV:DS?2EW[\<K&[?K
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M"4D3J%)MRWJPV-B#F89(*T(ETXQBIP:K[D-.S9QK)9Y5U<GK.,6MU#W*5WJ
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MA[?%OT6^.38;9 +<5H[PL Z]=Z@2(&J)02UR4QI\5O>!L:78U(_ZBH -!_R
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M9R3CDB>2*/?S/X<!I[8 U"*#6F;P0FAC;7E0D0O<#BP?&,2!V?T2?GT.'EV
M].#RP(".Q.'7 ^O'W!XH=3*VRW/&8VH/K0X8VN>^OD4CRE*IV\>J(.SRKDHV
M_U0P;FOX/O_*-D]K\V=5G6*WN1684JRI@&DJL[K=#$FQ@GE"29HK1KCVRG?J
M(</4^'N_I.*J500L*I?GHE4%/-2Z%+X'IGTFR<T#,3#T0]OTE?3VW+-%O%)@
M!K8JS$"KQ* 5&:^ ,6R9"W\Q1BY_T1NGX[(8_1_5CRK?/SPN5L]*[1VY-E8
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M);<6?RT[V!-^!BKQ ]92Z(-:T+(*7@*,6V&A#S9'Q19Z/21$F3O[Q/+KH]F
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MTJ@%[./6:6#S<.SX@S&>:^<2#OV<.X<:!W/O-(\=W\%SJ,])%\^+2_K9&+8
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M$4::JX')O]("KC0T>H!*$=!J<M"^U>8 OVBZM>NY%8[E X :DM"O$6=4[@Z
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MDVUHT8H9S+_M'I7\UWKS[_>K4H.I*/8U*7^P1OSSCP5;%G/.J-8DTI"GR#!
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MN,PECK3BG$"D4&1WSCGD2&"81BQ*TDCE"GMQ6V]+ID9TUA&[[Q6E*S.P*YT
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MT["Z!72.EG47D+G@8.(3N>VQMD%TAO9<GQPXS1E$$:/7*3H3&V9HQNE;W>R
M?B]I=I",>3D-<3J;KJ>XHBAO4UKY?C$CH:]JQ+?^?"4:$XPVPGJ(5J=:RB_
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M^%QM=RUK2&EY3L^;ACB=71QN.*5RR<R#X5*!BHQ<X:0L:!U0<VTDEZV:)1U
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M[T+Q*%R3XLG=R.LR07.*77<@C760G+FWLGX.RS]PTYOE5TSGR^VM/AM]8B(
MLGK G^,FL66A-II&+R1FW6:4XB[4C7L/8FQ+>+2^^MF+=Q?E) ?R;"FT!Y\R
M@SI9!F*,M,I"X<PRKU6S^8P[DCCNA8<3H[*1YCH8R/<(9U<W-AX2I+$RF<A
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MUJ$.3DD0F$,(TEGEK"0Q-;EB=DW"N(5GI\35@6+O #"[%B&Y0G^KM*/]ODX
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M(>D^6ISANYI<>8,?:J^7K7 ^WX6_#D4JIP+XE&R]?&GI.T.1+I%MF5?9VR8
MVHFZ<?/SC7 UO%XZ,$M7K==O7/5],2=IG6\2?!?<34)MOAY]!G2I#H"1&F)*
M'$+V=7*0,KPT:>:Q$W7CIO$;@6UXO70 MLV1UCS7+_54_6.87?-RO8)2Y(IS
MRT%$7>O<78 @.:_G6UY+GI@)3=KH[43=N#G^5G[6X'KI &P_A^4?N,G)_8KI
M?+FIC]LNFVAMI!5#EIE< %"U>T&404"6AA5GC'>VB3E[G*1Q\_:-8#60!CK
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M![N*BR<%,2<'1D7NC)&8^2XMFO<O!;Q)12\E1RT4?O<>Q<'2[P Z#T\NOC%
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M7GO\P[Q#Y-#'>5Z!G)MB'6A16#W8;L'%6( %Z;2O45!LTE?T4J95&G(RJ+0
M;CR9.OT3L' /OJ!EPHG4Z#ST_TRK'(K>=M,JAV"@@_#HDG+ZY<TP/,6\2242
MM3XE6D)3K4,H!D)&GNL'Z)N<%[Q#Q4N95CD("<NQU-(!IO87W W;BU17TU_Q
M2]Z.RI(A(PLI@TEU(\@3^YY;#M%*KX/T%-UUUO'S.#/3(OP ;(VVL3^2HCL
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M+NI0T-7FL7OMB#[XG%$W+I^G=*3]Q=_FZW]5P/U!;UJ=TP)>E7Z]S8.9UNZ
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M=FQI=BYH=&U02P$"% ,4    "  WBFQ2?9^ ]",;  "RC@  '0
M    @ &<-@  83(P,C M,3!K>&5X,3 Q-6II;6AE<FUA;BYH=&U02P$"% ,4
M    "  WBFQ2CF?/S+,(  !5/0  &               @ 'Z40  83(P,C M
M,3!K>&5X:&EB:70S,3$N:'1M4$L! A0#%     @ -XIL4KTYU_NV"   BCT
M !@              ( !XUH  &$R,#(P+3$P:WAE>&AI8FET,S$R+FAT;5!+
M 0(4 Q0    ( #>*;%(D;3!)*04  (L9   8              "  <]C  !A
M,C R,"TQ,&MX97AH:6)I=#,R,2YH=&U02P$"% ,4    "  WBFQ2;>#'MA ;
M  #PCP  '@              @ $N:0  83(P,C M>&5X,3 Q,FUA<G1I;F-E
M87)N86PN:'1M4$L! A0#%     @ -XIL4MBJ3.D!&P  \X\  !X
M     ( !>H0  &$R,#(P+7AE>#$P,31M:6-H865L8F]N;F5R+FAT;5!+ 0(4
M Q0    ( #>*;%+?B9!;%0,  . )   ?              "  ;>?  !A,C R
M,"UX97@R,S%C;VYS96YT;V9B9&]L;' N:'1M4$L! A0#%     @ -XIL4OCO
M.'?L @  S0D  !\              ( !":,  &$R,#(P+7AE>#(S,F-O;G-E
M;G1O9F)K9&QL<"YH=&U02P$"% ,4    "  WBFQ2]HF"^ \4   C<0  %0
M            @ $RI@  83(P,C!Q-&5X:&EB:70T,3$N:'1M4$L! A0#%
M  @ -XIL4A>*_Y69X0, 1EPF !$              ( !=+H  &-P:7@M,C R
M,#$R,S$N:'1M4$L! A0#%     @ -XIL4LP)ZYS)&@  02D! !$
M     ( !/)P$ &-P:7@M,C R,#$R,S$N>'-D4$L! A0#%     @ -XIL4C(.
M5@')*0  I<0! !4              ( !-+<$ &-P:7@M,C R,#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( #>*;%)EUW$2>($  )]Y!0 5              "
M 3#A! !C<&EX+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  WBFQ2?'U?
M7J4[ 0#ZJ0$ %               @ ';8@4 8W!I>"TR,#(P,3(S,5]G,2YJ
M<&=02P$"% ,4    "  WBFQ2>"+20)XT 0 @^0P %0              @ &R
MG@8 8W!I>"TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ -XIL4@S;Z6O
MQ0  P/D( !4              ( !@],' &-P:7@M,C R,#$R,S%?<')E+GAM
7;%!+!08     $@ 2 /,$  !VF0@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
